<SEC-DOCUMENT>0001439222-20-000069.txt : 20201105
<SEC-HEADER>0001439222-20-000069.hdr.sgml : 20201105
<ACCEPTANCE-DATETIME>20201105121818
ACCESSION NUMBER:		0001439222-20-000069
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		77
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201105
DATE AS OF CHANGE:		20201105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AGIOS PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001439222
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36014
		FILM NUMBER:		201289461

	BUSINESS ADDRESS:	
		STREET 1:		88 SIDNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-649-8600

	MAIL ADDRESS:	
		STREET 1:		88 SIDNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AGIOS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20080703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>agio-20200930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:deac00a5-3ebc-4b82-b8fc-c0af8bd8bb5e,g:0b2f6d2b-1088-4e3a-817f-9f8454765406,d:4174004101c4483bbd134be7ce58ff32--><html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:agio="http://agios.com/20200930" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>agio-20200930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80L2ZyYWc6NGVmMTVjMmI1ZmEyNDc0NTgwZDExNjUwYjk2MmY4YzIvdGFibGU6MjQ1NjFkNWM1ZGEwNDdhYmIyMzU2ZTY1ODc2ZmE0ZmIvdGFibGVyYW5nZToyNDU2MWQ1YzVkYTA0N2FiYjIzNTZlNjU4NzZmYTRmYl8zLTEtMS0xLTA_0521348b-5543-4901-adf2-c77897bc9df3">2020</ix:nonNumeric><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80L2ZyYWc6NGVmMTVjMmI1ZmEyNDc0NTgwZDExNjUwYjk2MmY4YzIvdGFibGU6MjQ1NjFkNWM1ZGEwNDdhYmIyMzU2ZTY1ODc2ZmE0ZmIvdGFibGVyYW5nZToyNDU2MWQ1YzVkYTA0N2FiYjIzNTZlNjU4NzZmYTRmYl80LTEtMS0xLTA_66d79948-331b-4e46-a12f-b92ab73e730e">Q3</ix:nonNumeric><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80L2ZyYWc6NGVmMTVjMmI1ZmEyNDc0NTgwZDExNjUwYjk2MmY4YzIvdGFibGU6MjQ1NjFkNWM1ZGEwNDdhYmIyMzU2ZTY1ODc2ZmE0ZmIvdGFibGVyYW5nZToyNDU2MWQ1YzVkYTA0N2FiYjIzNTZlNjU4NzZmYTRmYl81LTEtMS0xLTA_1052cdf1-bdf1-4e26-9ec0-cd1fe80f2fdc">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80L2ZyYWc6NGVmMTVjMmI1ZmEyNDc0NTgwZDExNjUwYjk2MmY4YzIvdGV4dHJlZ2lvbjo0ZWYxNWMyYjVmYTI0NzQ1ODBkMTE2NTBiOTYyZjhjMl85MQ_65603b69-f1b5-4c8c-98de-2f2f40632098">0001439222</ix:nonNumeric><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80L2ZyYWc6NGVmMTVjMmI1ZmEyNDc0NTgwZDExNjUwYjk2MmY4YzIvdGV4dHJlZ2lvbjo0ZWYxNWMyYjVmYTI0NzQ1ODBkMTE2NTBiOTYyZjhjMl84OQ_bef15f09-1694-43fa-8bdb-b66565a95bf3">--12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="agio-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ifed18f9e51ed48aeb5b773bd6fa0af3f_I20201030"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1370538e8004f039f21787ab6a847b3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i902ffdd5069945e4a1e2d8259b7aa937_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9bd25f418764e27874e4887f9629cba_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac48a829910e4ec2be6c0709f8ab5d04_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15c6da9822264b9abd38a7580c17d5b2_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6645fba9caf44b8b8bcb42c98bf2278_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia038c518019748b78ce08495d4f16d87_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6be33be9efa74778b57706d8c1dc08f4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5a1fdf43a234d5c9fb4b6957bdd5c72_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ad876aa13d343ee93185f8c0c654899_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if80b6528409e4dfebe89f52e9c71dd73_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib30ef62521f14a1a8085c15b3b924dcb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib271d15ecd62424c99f55144e625afde_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d4b033413e949bdb33308f291e151d7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib72090a087094a15a97bb50cce1d461f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5e859f8f93d478cbc47d931bf3d4f16_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bd62d81b9224846bad804af424c7c55_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic73499b256364473912a51549d885406_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3d4f0ce49ea478683a5e066d98b9657_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83a0c267e8c14a0b8cb5af9dc8889826_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie94a42df3bd64de59963733402e60f0b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14d2deb841a8484bbb9f4d6e7db83773_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia39f990b1b954fd4b7055ed175a61da7_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84f838015f2c4600ab21342b2ab257bb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie226d1a9de1e4a689a12ba5ade263cbf_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e3117ca1e3d475081f74ed85067fdd9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74af35b6091d4e40bc61c88695b202c8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i633904fd4bf04f1db95a04a559e03ad2_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id355d6bb2f5148079147b0cb69a30e3a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78340b4431bb4f3cb0c67e9c396fe87c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bda0d5bb34046e6976dbdd780aa978b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e478fecc462477aa454e3d9436e4752_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6ddd43f0d1749b3b53381bd19850103_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id32fe94f97e84076b84beaff756aa3fa_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dac01400f8a441eaf95cdb7f2c88e1e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc5c534cd84f4787a526c269ef4c6151_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie481c63be9664fed98e565204a85caf1_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if50f19fc8ffb45ec878303df8a922a99_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f336477ca834d10a759110a6b168a44_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c742c6a37f940b1b7230f3dad49ebc6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaea355a6eee4c84b610bb5a3998cb0a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if74da64f69904adba74c4a3593889ebc_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icafe5156f770497288825e054150807e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e51e0bf32b84c06bc802cf158d85892_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic794988e2ef64d2d903b700cc61ab8ac_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5e2bd57c0864b8ca52c0dbc9e5247eb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie77331352e8e487ab5aaa801714a9478_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f5eb666df1f4354b1d4dcf993b7fd72_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfb43edba9e24d7aa4bc0b84a542b1a4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic221521f25684d8291dde2458b8fd56d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddbd8fd3a9234d15a8eda0993f4f1137_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccd377f04511411f8b9b576f6daddde7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7a7de9468d1492cb68a6b85d84c50e3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i958a5eaaa1994c0e8785e2290bffb78c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ee3f08f37a94847b4581c44661b6945_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if10cfda3b1ae42dd94275ef357f4b6ab_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23e8641cdf9d4a0ba36b18e83e1f74f5_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09874c19ef114cc9a325361e8c04db94_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0aee4cc470d44c5e99067c41afb5f002_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44c7bfd7973b423691bd63d2af7d57aa_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic76020b398604ca1bf1af8adacc2ffce_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c08cf4ec15f402aadb383d3cf0aac8d_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia32695c6f95b4eecbd80e2ba29818b2d_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bf3fa70c71d4e65bfa404b0233a7d5e_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac1252d10b6040f4876c7756be3e4a76_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99487a9075154d1481319c8e1e5c20c8_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2989a9b9047443f9a4e2a2c0bb1625f4_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f6dcdda42cf4c478aff8535b767c4c4_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8b377237524434a885c88b184553ef7_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7159c55a54a64257836b127ebdbe79ca_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc3e62b98968494bba8bee317e04525f_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14619843617f40c7a9cf1f66f71c1c27_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4f71ec0a74244a898c7f64d6f7c861d_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9327aef1d4d84255b2eb04bc36f39536_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33d12dc0073b41d0b953c2cd4414bb09_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1053b3953d9d41a4b58d1f9f40168930_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96e9cac9a5b245e1ab992da2a4f3b707_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c451a043eeb4e1c90f9351c338a270c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie090a495a771498fa103545475845412_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i711e80bbc9f74ab3b7066dfb0f019bfb_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i382fc23536884c45afe5acfaef266947_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53f5dfe3b6464427a8673fa0c75cf825_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c8d5ed345084b43bbf0c55a4d2ee227_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c9f7f3cb6d047899b09ad580b69156b_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife55cfc6e645489a9aa97a13da6dfe00_I20200611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:Agreement2010Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CelgeneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied54aa2a3f7e42998c98d6f9afe5e255_D20200611-20200611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-11</xbrli:startDate><xbrli:endDate>2020-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf22f68ca84c40088ac574f70d88d77d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:Agreement2010Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i543ea632249a45b4b913803db254e6d2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71a231d7d6a8434383ad19d455d7141a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie11b847113844524904871ec37728936_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i039327938bac4cc0a80cd5dc934f1d1d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7218efcd2284c88a1600bcc960ede96_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2e5aaad6c904909a156e5d4b4f185fe_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if555a5ee5cf0408a86be0d8a8d59801f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i821a817349064dcc8e6938597d3db79e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaed01c1b899c4709b5accd32d8312191_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08437c72c35449abacdc997fcf6867a2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b4d1304c21246dc941d6150f7c3972e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideab8d3cd8824f7ebaadb03c9812b1b1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i744b349803e74e989804d827439ae1f4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f2d69b28ccb4f61b622f3b366b4804b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedf6f8c98e70432c9500860ae91e2b2d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6132c63023e4bc0bb7db5e06ab568fd_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie484602594fc4892b37a19ce7a0605b8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a819345c25a47a78c1b9247bebd1445_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12994fbfaa05455592901db5a2d7fb86_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7596257a08c149ec9fafbb992990cc54_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bf8521cd905445da506519413d478f2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ee1c71ed01b4620aa8b7c580a5c2c35_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff55f01694f94e28b5c7fd66fab94514_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib489bc944aa14ea39dfa0ea27a8ccdda_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68f2b8cd5ee04a16971376df19807a05_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8ead45948574c9f9ee622f88491ada5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8047261250f94d8eb8d6c0f98068c56e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bbfc1e3bc29413aba5926d90622f3d0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafa6f804a3734443b6af52bbcd7cda22_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadc513dfb0aa455792b1559bd9ff0b07_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i204de70f9ce54574b913c7c1a1f5bec6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ac3885e5cc24c1a9b936fd11ed191f3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b8e02d6bad0479cb0dd2303c690ac0b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i015ac4920a1c4c3a9611d7a7be258105_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c2c48c0358445ac84d1add069e26cb6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23d92d9ecc2b4415b962d6feb4c7a44a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>agio:security</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ib2575fe6eebf402cbdb0a3e5509d729d_D20200611-20200611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:RPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-11</xbrli:startDate><xbrli:endDate>2020-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e16d3756d704760a00e78beb3a53457_D20160501-20160531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CelgeneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:MasterResearchAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-05-01</xbrli:startDate><xbrli:endDate>2016-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="extension"><xbrli:measure>agio:extension</xbrli:measure></xbrli:unit><xbrli:context id="ic19c9efe1bc441b28792cb1fb430006c_I20160531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CelgeneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:MasterResearchAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bbc2d1419c542459a401e63c7eca48e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03d3c6ff3eaa4f96a6b43c3884afbdd5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i635a87f89b85400aa10e6ca171a7869f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a9429c5ed7c4eafa27ec8b3c0962e9c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i231960ca9c014f48bb976e41d6c6d505_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CommercializationActivityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i332309b5d2244ef5b9ecb08809dcbd9f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CommercializationActivityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85fcfba1e36545e493bcf708b4e9df68_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CommercializationActivityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b78993cbec4481bbc686cda5de776b1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CommercializationActivityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21cd91eb1d2842528666b7c51b692515_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CollaborationReceivableDuefromRelatedPartiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i822eacbd7a3140f7a5ad55739d7525b2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CollaborationReceivableDuefromRelatedPartiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60e99bcf39eb4a1198ea4cb7a6f6bc0c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CollaborationReceivableDuefromRelatedPartiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11fc8fb499ea4d2cb1eb548dd4ca43db_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:UnbilledReceivableDueFromRelatedPartiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f99babce6584b2ba9dc951305e2fc7b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:UnbilledReceivableDueFromRelatedPartiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id771f4009bfa4c4bbdedf06974f817e1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:UnbilledReceivableDueFromRelatedPartiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id866c85fcea34845a31e92f2f2b956a9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:RoyaltyReceivableDuefromRelatedPartiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ed0f7fca6824f939606850129df11d9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:RoyaltyReceivableDuefromRelatedPartiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b35d322903843578f6a68da48ebf6bb_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:RoyaltyReceivableDuefromRelatedPartiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib908b1f10858485dad4c2ae0e63c92ea_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:DeferredRevenueCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99f701a2e0cb4e8b8665c215666a581f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:DeferredRevenueCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29d069dedee94effb0e3fe4e2557d773_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:DeferredRevenueCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18ae39e61005422296a6185b1b3642ac_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if60bb09a8e0d4226ba3167b23f5cb3a4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f0956f37ec44b6bb6d0f4fa5248bef0_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54571e1728c5451ab4e07db6c9467aee_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08ba0b22d8f3450e8b229803691aa936_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7c63d1760f04d71aa4c373f08d1f88e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddeab0bd8cc74b7db5aebf3e35be317a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i107aa1a97aea4de79780fd1a3849f4c9_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7731b8f59ba649e78547d1a6207a646b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6c5708e816d4a5a9da9fda8e44e426a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84dcb1f3e8204171af357b73d909bde3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47b3d55b232f4b37b1ce3de5d1256c7a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fa5e00c5e3b4d8a94adfcd4dc578cea_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bf86b21d1ec42508367f7984e0d709b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i313f3bed2b4d41b1b3befbd3ba0eb04d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i461b9941feeb4551aaa603496fbf1cbf_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63a35d727f94435cb7df160054110884_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CollaborationReceivableDueFromRelatedPartiesCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01071852f46a4d4dadbc5092fae50573_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CollaborationReceivableDueFromRelatedPartiesCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fc858c76d804b0094142147dcd5fabf_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CollaborationReceivableDueFromRelatedPartiesCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9648064ef4d46a89718d0c2f677340c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc55bcf17208425a91152e001413e76a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf00db5bcb514269bb6f8b107e6bda6d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87a76a2d90d94c09897329e40592f335_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb29efd46e8a49fcac140e1509cd977e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1af4d73a6f24932b9251f45c0dc1886_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic35eee998d714c1eb9833f09bbeecf44_I20200611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i921c8ef362934a03b834f05fd487675a_I20200611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:RPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a10fdb988c14ed4b148d6aab1625976_D20200612-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:RPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-12</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6317ec5824324379aa89da98e74f17b5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:RPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf7298c7e23d4bc79ec2339352a2c49b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:RPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21d7d92ef32c4570af111a2c6296175e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:RPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d699758856a480db8a54b5c63108b48_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f9615d7d1de4efaa136793d0d91cefc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42fd0d585d7e44eb875c04c73f32f4f3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d04844a7e1741f4b543721609a357af_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieaba62f70942436b9630689bd74a2d35_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91da41946dd44926b3eb2a6c70cedcec_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic195c0c995c94bb99b62faec4ada3a82_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceBasedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16638a665f8b48bda553a1b68fe9582c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceBasedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie97254b0a3bd414a957ad2f9c5b213a2_D20180101-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceBasedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd2bc890754e428c838e48a9739bb6ca_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceBasedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i174a0833a8f7445eab78db94209d6095_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i511c756fbbb74474b18ddbc87da9898f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:MarketBasedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b990092bc0c49da82be729ba6370e53_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:MarketBasedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c31701e76ca45a499b9de7eb21dcc8c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:MarketBasedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88427bac77074d34bf85fa93670c9058_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3878b4c8c3294913aa799ef8147b4a81_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d8671ea0b684937a1904b1b3c85413c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf949780f933480e95db1152a36fe193_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03bf9b8187f0451d9f3b63e3cf6178da_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09fde5e4560a422a85918a18e444182d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bd07546e3954875b0cf85d146e836c1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8a5352cdcf54a3dbc6e981a9f2d988e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice9aeab243b54c76ba9666c481969a67_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i357045d6181740eeae955e96b15cf9ae_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie651fcd18fce4247ae0c8601b611a96b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceBasedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic805411b96ea4c5f9301de6e30503f1f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceBasedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i798423a51884438da4abc925685536ec_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceBasedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5e015813aa04cc5b172ca860a6d9adb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49a46c45215d41c8aa7526c20b7d66b5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbd22adb7da84d4385fef484796aface_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6718bfa0a37a457e90f8816b0655456b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i454184cf989649608cb48e499349776d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:OtherStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03016330feec4c92b5f1d60dc4e263e1_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:OtherStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic370bb45afd5438bade9612c8288612a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:OtherStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f25d07cfaa34641ae0ed3f419c27b42_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:OtherStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27fa78f0171d419fbd8f33e0452c4ae6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b35ca8234b946a59c38dcb3c34529b6_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03be922ff7cb4cf492b6d47edf9144c9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia14da64b4d914e7ca355088908976d71_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94a210d561984f12a0afc697ddbaea44_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4effbc54b019404fbb07e9b964ce6494_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf1c03f73f434b93ac3f9ad188cac55e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64b9b9df1ff7448d85c07ee71a10ce67_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i158dfd79c688479084d989c430f722ec_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idefd32a8ce2246baa8ff2d8323b75046_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7607646d4b3b4f108a7e2b95056780a1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98274e1aae044562a57287ce093c0a26_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02527e9e8cad486f90f2ce345b3c2608_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7f3d9262b9a4930b2cf048450740cd9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1179a5820c534eac932533d105b3c232_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i824f503805804c518c65ccdbfb63cb4c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i086f8600af974684a490cec7619bf25c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d2dbb49a82349ac86136605ab26307a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4d9eaf7cb8641d0852c0cdf98b22872_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85f451c88a3e4c928e436beab4f05862_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a52ff240e81427b90c795cee938d4b5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4879e95ef7744941b0e26ca90bfc6605_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d57d7b84fb04a96892f11a0576100dd_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic96c925a7d99431399902b60bcb6babb_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i4174004101c4483bbd134be7ce58ff32_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:21.345%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGV4dHJlZ2lvbjphMDkzZGE0N2M2OWQ0NTExYjQyYmYyMThkOTgwNDFmMF84Mg_8128f591-7222-4c20-ad83-5f63a47dfa87">10-Q</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:21.345%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Mark One)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6MzQ2ZjJlOWFkMzEzNDVlYzhjMDc1NDg2MzlkZjk5YTEvdGFibGVyYW5nZTozNDZmMmU5YWQzMTM0NWVjOGMwNzU0ODYzOWRmOTlhMV8wLTAtMS0xLTA_7d8a4437-331b-410e-b7ad-e6fab3a6e093">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGV4dHJlZ2lvbjphMDkzZGE0N2M2OWQ0NTExYjQyYmYyMThkOTgwNDFmMF8xMzE_6793fc5c-a22d-4b51-927a-80af24332274">September&#160;30, 2020</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6MTkyYjUzOWEyNDAxNDIzN2E5OTRkNTU4ZDY5NjNkNDUvdGFibGVyYW5nZToxOTJiNTM5YTI0MDE0MjM3YTk5NGQ1NThkNjk2M2Q0NV8wLTAtMS0xLTA_9d748bc3-0705-4313-8ccc-c8198e88d548">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGV4dHJlZ2lvbjphMDkzZGE0N2M2OWQ0NTExYjQyYmYyMThkOTgwNDFmMF8xNjM_5da110b2-c904-42bd-a3c7-a119d5fb01bc">001-36014</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:21.345%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGV4dHJlZ2lvbjphMDkzZGE0N2M2OWQ0NTExYjQyYmYyMThkOTgwNDFmMF8xNjg_1299a76b-0d33-4e5c-93e1-bd206781898b">AGIOS PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:21.345%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:20.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6OTY1OGNmNTU3ZGI3NDlkNGJkNTFhM2ZiYTA5ZDczZDEvdGFibGVyYW5nZTo5NjU4Y2Y1NTdkYjc0OWQ0YmQ1MWEzZmJhMDlkNzNkMV8wLTAtMS0xLTA_e7f1e855-475c-4160-b3be-b66166291d50">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6OTY1OGNmNTU3ZGI3NDlkNGJkNTFhM2ZiYTA5ZDczZDEvdGFibGVyYW5nZTo5NjU4Y2Y1NTdkYjc0OWQ0YmQ1MWEzZmJhMDlkNzNkMV8wLTMtMS0xLTA_5e86b0cb-4cda-467f-88e9-01585c15a133">26-0662915</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of<br/> Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S.&#160;Employer<br/> Identification&#160;No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6OTY1OGNmNTU3ZGI3NDlkNGJkNTFhM2ZiYTA5ZDczZDEvdGFibGVyYW5nZTo5NjU4Y2Y1NTdkYjc0OWQ0YmQ1MWEzZmJhMDlkNzNkMV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjphZGVkNjQzMTE1MGU0MTc5YWNmZmQ4YmY4NmNmZjdkNl80_73552abc-9537-4464-9fd6-f84fc61bae23">88 Sidney Street</ix:nonNumeric>, <ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6OTY1OGNmNTU3ZGI3NDlkNGJkNTFhM2ZiYTA5ZDczZDEvdGFibGVyYW5nZTo5NjU4Y2Y1NTdkYjc0OWQ0YmQ1MWEzZmJhMDlkNzNkMV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjphZGVkNjQzMTE1MGU0MTc5YWNmZmQ4YmY4NmNmZjdkNl84_b90e793b-9a45-4d30-a622-67ad7b452e79">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6OTY1OGNmNTU3ZGI3NDlkNGJkNTFhM2ZiYTA5ZDczZDEvdGFibGVyYW5nZTo5NjU4Y2Y1NTdkYjc0OWQ0YmQ1MWEzZmJhMDlkNzNkMV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjphZGVkNjQzMTE1MGU0MTc5YWNmZmQ4YmY4NmNmZjdkNl8xMg_2cb5b2d5-96cf-44ba-9154-6b904e43a2a6">Massachusetts</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6OTY1OGNmNTU3ZGI3NDlkNGJkNTFhM2ZiYTA5ZDczZDEvdGFibGVyYW5nZTo5NjU4Y2Y1NTdkYjc0OWQ0YmQ1MWEzZmJhMDlkNzNkMV8zLTMtMS0xLTA_b5d200a0-3fb7-42e5-b90d-cf387f5ed73e">02139</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGV4dHJlZ2lvbjphMDkzZGE0N2M2OWQ0NTExYjQyYmYyMThkOTgwNDFmMF8yMzI_a863effc-6cc8-4883-9e08-9d45af30c4e9">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGV4dHJlZ2lvbjphMDkzZGE0N2M2OWQ0NTExYjQyYmYyMThkOTgwNDFmMF8yMzY_7b911cc6-d9fe-4c4a-9f65-2d51dc1d4e75">649-8600</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-bottom:2pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:21.345%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6NGZjMWE0NjJlM2U1NDRkOTlmZjMzZWFiMGUyZTM2YTYvdGFibGVyYW5nZTo0ZmMxYTQ2MmUzZTU0NGQ5OWZmMzNlYWIwZTJlMzZhNl8xLTAtMS0xLTA_e00a7c1e-8890-4597-a0be-a413b4318d1b">Common Stock, Par Value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6NGZjMWE0NjJlM2U1NDRkOTlmZjMzZWFiMGUyZTM2YTYvdGFibGVyYW5nZTo0ZmMxYTQ2MmUzZTU0NGQ5OWZmMzNlYWIwZTJlMzZhNl8xLTEtMS0xLTA_c5d2e63d-d035-4bfa-b8f0-38004919bd2e">AGIO</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6NGZjMWE0NjJlM2U1NDRkOTlmZjMzZWFiMGUyZTM2YTYvdGFibGVyYW5nZTo0ZmMxYTQ2MmUzZTU0NGQ5OWZmMzNlYWIwZTJlMzZhNl8xLTItMS0xLTA_355d5835-815d-4455-ae74-a035319346ee">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGV4dHJlZ2lvbjphMDkzZGE0N2M2OWQ0NTExYjQyYmYyMThkOTgwNDFmMF83ODk_b996f177-9fe1-4bfd-ba2d-f2a0b4f54447">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGV4dHJlZ2lvbjphMDkzZGE0N2M2OWQ0NTExYjQyYmYyMThkOTgwNDFmMF8xMTE2_c45279f9-9155-4817-8781-27ed9b70e53e">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-bottom:7pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:27.828%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6YmQ1NWM4ZGQ1ZWQzNDQwMzlhMDliNzhjN2E0ZjVhOGIvdGFibGVyYW5nZTpiZDU1YzhkZDVlZDM0NDAzOWEwOWI3OGM3YTRmNWE4Yl8wLTAtMS0xLTA_312643a0-3664-43ac-bf33-9df8257088cf">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6YmQ1NWM4ZGQ1ZWQzNDQwMzlhMDliNzhjN2E0ZjVhOGIvdGFibGVyYW5nZTpiZDU1YzhkZDVlZDM0NDAzOWEwOWI3OGM3YTRmNWE4Yl8xLTMtMS0xLTA_080f0a7f-eead-4f05-a02f-5f27dab038cd">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging&#160;growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6YmQ1NWM4ZGQ1ZWQzNDQwMzlhMDliNzhjN2E0ZjVhOGIvdGFibGVyYW5nZTpiZDU1YzhkZDVlZDM0NDAzOWEwOWI3OGM3YTRmNWE4Yl8yLTMtMS0xLTA_878b35f0-ffbe-402c-8d89-24e0ac249889">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-bottom:7pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;&#9744;</span></div><div style="margin-bottom:7pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGV4dHJlZ2lvbjphMDkzZGE0N2M2OWQ0NTExYjQyYmYyMThkOTgwNDFmMF8xODU4_11ab709e-e8c6-4a50-b4b8-2c33296454b2">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;&#160;&#160;&#9746;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Number of shares of the registrant&#8217;s Common Stock, $0.001 par value, outstanding on October&#160;30, 2020: <ix:nonFraction unitRef="shares" contextRef="ifed18f9e51ed48aeb5b773bd6fa0af3f_I20201030" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGV4dHJlZ2lvbjphMDkzZGE0N2M2OWQ0NTExYjQyYmYyMThkOTgwNDFmMF8xOTYw_eed584f7-e8f1-43ab-b600-aeb5332e82b6">69,259,817</ix:nonFraction> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i4174004101c4483bbd134be7ce58ff32_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AGIOS PHARMACEUTICALS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2020 </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">No.</span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_10">PART&#160;I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_13">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_16">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_16">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_16"> 30, 2020 and December&#160;31, 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_19">Condensed Consolidated Statements of Operations for the Three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_19">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_19"> Months Ended </a>September 30<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_19">, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_19">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_22">Condensed Consolidated Statements of Comprehensive Loss for the Three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_22">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_22"> Months Ended </a>September<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_22"> 30, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_22">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_25">Condensed Consolidated Statements of Stockholders' Equity for the Three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_25">Ni</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_25">ne</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_25"> Months Ended </a>September<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_25"> 30, 2020 and 201</a>9</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_25">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_28">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_28">N</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_28">ine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_28"> Months Ended </a>September<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_28"> 30, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_31">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_70">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_70">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_91">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_91">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_94">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_94">30</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_97">PART&#160;II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_97">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_100">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_100">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_103">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_103">66</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_106">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_106">67</a></span></div></td></tr></table></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i4174004101c4483bbd134be7ce58ff32_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i4174004101c4483bbd134be7ce58ff32_13"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements (Unaudited)</span></div><div id="i4174004101c4483bbd134be7ce58ff32_16"></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AGIOS PHARMACEUTICALS, INC.</span></div><div style="margin-top:9pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets </span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands, except share and per share data)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMy0xLTEtMS0w_acef6189-e151-4a51-8716-4228dcf0fe5e">104,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMy0zLTEtMS0w_33737f48-812b-44c0-9271-40513e6414ed">80,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfNC0xLTEtMS0w_502804bf-ef8b-494a-bb6d-177727a30b95">500,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfNC0zLTEtMS0w_79215eaf-4c1b-4551-ac48-66d9dccc05f6">483,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfNS0xLTEtMS0w_c7907154-4e5e-44d6-baca-148aeb58474c">18,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfNS0zLTEtMS0w_bde645e8-834c-46cf-8c3a-a8364f6de770">8,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration receivable &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:CollaborationReceivableDueFromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfNi0xLTEtMS0w_eb2a501d-9837-4a11-ae84-72d71a67e3bf">2,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="agio:CollaborationReceivableDueFromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfNi0zLTEtMS0w_25100598-ef62-43d2-ab87-4f3ad0476173">1,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration receivable &#8211; other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:CollaborationReceivableOtherCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfNy0xLTEtMS0w_6b76f16b-ba02-4511-bd2b-16cfd7c064fd">1,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="agio:CollaborationReceivableOtherCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfNy0zLTEtMS0w_31050125-67d0-4833-8f90-326c28216546">1,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty receivable &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:zerodash" name="agio:RoyaltyReceivableDuefromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfOC0xLTEtMS0w_05a6804f-8bc3-4682-b192-77bacc6232f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="agio:RoyaltyReceivableDuefromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfOC0zLTEtMS0w_ff5363b6-f7a2-40e1-b5b5-16d389330e6d">2,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfOS0xLTEtMS0w_90f80dcb-8702-4c8b-96ee-20527700aa2e">11,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfOS0zLTEtMS0w_c6618734-63f2-4552-8fdf-60c8c41593fe">7,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTAtMS0xLTEtMA_82e7c1b0-3e86-4099-815f-ffd2ae5d6fff">28,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTAtMy0xLTEtMA_baba7f37-10e1-4fe2-b3fc-ef991e76a008">24,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTEtMS0xLTEtMA_06cb70e2-db9c-4ccb-9d81-8a2621c17214">669,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTEtMy0xLTEtMA_844f82ae-2509-42f6-860c-5204dd17bcc9">611,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTItMS0xLTEtMA_4d2c4d64-2cfc-44fe-913c-b94d67df15cb">116,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTItMy0xLTEtMA_3416c1a6-7068-4381-83a2-a55d4e2528ad">152,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTMtMS0xLTEtMA_eb0260c2-8da6-4cb2-ad56-7b9ed2c469e3">86,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTMtMy0xLTEtMA_b7a97f27-3b0f-46f7-9451-706a18533c8a">93,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTQtMS0xLTEtMA_3c66a5b8-45fa-44bc-916f-021f7e30c623">33,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTQtMy0xLTEtMA_50a54c4a-bde3-411e-9155-07df776296d0">31,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTUtMS0xLTEtMA_115abaf5-cbc8-483c-bfcf-dea0f33012cb">677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTUtMy0xLTEtMA_653fdac8-a83b-4b3f-a8a9-2e4726955b14">993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTYtMS0xLTEtMA_b2060fc8-3a96-4d06-bdbf-2bdf21b18bf9">1,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTYtMy0xLTEtMA_b7f00b07-2e85-4b54-bdb7-51173d263614">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTctMS0xLTEtMA_ac9d036a-2102-4720-8c46-7b9c96f22873">908,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTctMy0xLTEtMA_93ef8396-552a-49b7-b79c-6fb10b6124d6">890,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjAtMS0xLTEtMA_6a1c5d78-0c99-4ac9-800f-1abd34a80730">12,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjAtMy0xLTEtMA_aab145f6-9cb8-4c3b-a6b1-7fded3a0c52c">21,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjEtMS0xLTEtMA_69cb1942-c1ba-4dec-9560-6be33520e786">49,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjEtMy0xLTEtMA_ee8ab8a4-e458-403c-8f84-02ef48454abd">53,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjItMS0xLTEtMA_014cb380-cc7f-466f-8011-1e58d01da207">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjItMy0xLTEtMA_4c85c8e4-431d-4b8d-9bdf-e375b045ec99">10,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjMtMS0xLTEtMA_f05eb028-2f81-4202-8837-33d8a4615f20">6,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjMtMy0xLTEtMA_08ad91c8-2638-404f-9764-04a046faa314">6,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjQtMS0xLTEtMA_7648b369-a85d-4539-9da8-b40de75a34ae">313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjQtMy0xLTEtMA_ae124fc8-550c-434d-818b-27b3a3e00d09">273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjYtMS0xLTEtMA_1fc721e7-d5e9-4fd8-ad9d-f4fa67efb497">69,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjYtMy0xLTEtMA_2470fc9c-d177-40bb-bddb-d94878a1f72e">92,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjctMS0xLTEtMA_8480dd82-e97a-4660-addc-f63ab10d146f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjctMy0xLTEtMA_8d14fa78-06af-41ca-91d8-3c9e60e3d3ee">50,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjgtMS0xLTEtMA_70f4f0af-9198-475b-8e8f-59cc1e98acba">99,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjgtMy0xLTEtMA_70abef6f-e401-48b8-a16f-3a3231602bf2">106,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjktMS0xLTEtMA_4150fda2-ed03-430f-b617-f5e0281247c7">412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjktMy0xLTEtMA_0960d6e8-862a-4c62-b333-cbfd2af60f39">673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to the sale of future revenue, net of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:SaleOfFutureRevenueLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzAtMS0xLTEtMA_da928817-0a5e-4adc-8e50-2ff01a4fe2fe">258,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:zerodash" name="agio:SaleOfFutureRevenueLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzAtMy0xLTEtMA_de19f45e-462c-472a-882f-5e7c872c6def">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzEtMS0xLTEtMA_ae4dd551-a218-4471-99d8-3947fc160dc3">427,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzEtMy0xLTEtMA_3393bf5b-eb0f-4a5d-b72f-7e3b6ad07729">250,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjE5ZjUxZTYzMTBjZTRkZGViYjFiNjZiZWQ2ZDY1MGY5XzIx_5593368c-223e-4712-9978-40bf440d3d22"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjE5ZjUxZTYzMTBjZTRkZGViYjFiNjZiZWQ2ZDY1MGY5XzIx_994e6cfa-ec8c-4abe-bebc-7427cc82b46e">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjE5ZjUxZTYzMTBjZTRkZGViYjFiNjZiZWQ2ZDY1MGY5XzM1_35128c0c-1647-444f-949d-0b49690a7427"><ix:nonFraction unitRef="shares" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjE5ZjUxZTYzMTBjZTRkZGViYjFiNjZiZWQ2ZDY1MGY5XzM1_aaf081fd-ebda-4e6b-9771-23464f0bbdec">25,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjE5ZjUxZTYzMTBjZTRkZGViYjFiNjZiZWQ2ZDY1MGY5XzU3_0156d3f3-27f8-4e5a-98ce-e80d2b9bcfb0"><ix:nonFraction unitRef="shares" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjE5ZjUxZTYzMTBjZTRkZGViYjFiNjZiZWQ2ZDY1MGY5XzU3_a9ea175c-0fd5-4694-9521-50ab0fd7c193"><ix:nonFraction unitRef="shares" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjE5ZjUxZTYzMTBjZTRkZGViYjFiNjZiZWQ2ZDY1MGY5XzU3_ae2f2a14-beb1-4789-8b44-6fbf00858c26"><ix:nonFraction unitRef="shares" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjE5ZjUxZTYzMTBjZTRkZGViYjFiNjZiZWQ2ZDY1MGY5XzU3_b9adec17-da34-41e6-add2-0623a20c8b6c">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding at September 30, 2020 and December 31, 2019</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzMtMS0xLTEtMA_5bde958b-f726-4b4e-9a81-aa75b80b9c73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzMtMy0xLTEtMA_a4beed46-defe-40a2-8612-5db1898bf2be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjhkMGIxM2I3YjdiYTRiNzdhOWZkMTJmYzMyYTRlOGY2XzE4_22904584-9016-4c06-bdb6-d96300d08e66"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjhkMGIxM2I3YjdiYTRiNzdhOWZkMTJmYzMyYTRlOGY2XzE4_36912072-4c28-408c-80bb-d9c764995116">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjhkMGIxM2I3YjdiYTRiNzdhOWZkMTJmYzMyYTRlOGY2XzMy_2025ed91-e39f-4e44-9a01-eea78fddc392"><ix:nonFraction unitRef="shares" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjhkMGIxM2I3YjdiYTRiNzdhOWZkMTJmYzMyYTRlOGY2XzMy_d7309e58-0d64-498c-b32a-f0edf4c278d4">125,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjhkMGIxM2I3YjdiYTRiNzdhOWZkMTJmYzMyYTRlOGY2XzU0_1d232e69-20cd-4da8-a4f7-514aba94d78b"><ix:nonFraction unitRef="shares" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjhkMGIxM2I3YjdiYTRiNzdhOWZkMTJmYzMyYTRlOGY2XzU0_71e9995b-222d-465a-9911-4e973935df97">69,198,063</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjhkMGIxM2I3YjdiYTRiNzdhOWZkMTJmYzMyYTRlOGY2XzYx_2ce13757-da7e-4d2d-a3b0-50904e5e49b5"><ix:nonFraction unitRef="shares" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjhkMGIxM2I3YjdiYTRiNzdhOWZkMTJmYzMyYTRlOGY2XzYx_d2f2588c-d116-4d6e-be81-2ec41e837e2c">68,401,105</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzQtMS0xLTEtMA_332b3ad0-78d3-4d78-96de-341d5da09ba4">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzQtMy0xLTEtMA_11c479db-174f-4738-ae43-585ddc429578">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzUtMS0xLTEtMA_ece7a9b1-3b62-4836-82c4-5411ebd261c4">2,225,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzUtMy0xLTEtMA_a0c2f24f-31d7-45e6-91ae-603c740d6425">2,156,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzYtMS0xLTEtMA_ec368694-ded0-471b-a203-7bb01eb5d967">663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzYtMy0xLTEtMA_f468567d-3b98-4221-8189-1d63525b0a6f">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzctMS0xLTEtMA_6a875194-ca48-4093-a3f7-016cbf0d7c63">1,745,818</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzctMy0xLTEtMA_f11406fd-3416-4ee4-94bd-be9b0faeb454">1,516,105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzgtMS0xLTEtMA_1b59e105-c253-44f5-b531-63fcc2654684">480,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzgtMy0xLTEtMA_84070512-47ef-4940-b8a5-893e6162e76d">640,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzktMS0xLTEtMA_548095a1-3c32-45ad-80b6-99c2f3c2cf0d">908,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzktMy0xLTEtMA_58123956-56af-4d7f-a4b6-a957c967f8e3">890,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i4174004101c4483bbd134be7ce58ff32_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AGIOS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands, except share and per share data)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i902ffdd5069945e4a1e2d8259b7aa937_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMy0xLTEtMS0w_ee75e748-f734-4627-b83a-624196f28132">31,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9bd25f418764e27874e4887f9629cba_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMy0zLTEtMS0w_14f0e384-07e2-4865-a7b3-c9c8d7b102a4">17,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac48a829910e4ec2be6c0709f8ab5d04_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMy01LTEtMS0w_00904f98-d794-47ac-ae6d-0f542ee12268">81,971</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c6da9822264b9abd38a7580c17d5b2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMy03LTEtMS0w_54910873-1abf-40b4-a474-7e0a93f29cef">40,287</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6645fba9caf44b8b8bcb42c98bf2278_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNC0xLTEtMS0w_db608ef0-67aa-4956-a556-c24f590ec93a">1,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia038c518019748b78ce08495d4f16d87_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNC0zLTEtMS0w_57e63c24-d532-4ac7-898c-0bd564f41c2a">5,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6be33be9efa74778b57706d8c1dc08f4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNC01LTEtMS0w_99483f8b-7b0a-4c47-a24d-2e4502e20fa2">67,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5a1fdf43a234d5c9fb4b6957bdd5c72_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNC03LTEtMS0w_8b6029ba-5286-432b-a5c2-261113679bfb">32,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue &#8211; other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad876aa13d343ee93185f8c0c654899_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNS0xLTEtMS0w_fa6bc8d7-fd0a-4540-9e2e-5fd24b9e367b">1,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if80b6528409e4dfebe89f52e9c71dd73_D20190701-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNS0zLTEtMS0w_a7335076-db98-4786-ba71-11422610642e">420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ef62521f14a1a8085c15b3b924dcb_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNS01LTEtMS0w_68641d46-1c02-4d8b-ba42-68a9ecaa1a51">2,786</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib271d15ecd62424c99f55144e625afde_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNS03LTEtMS0w_bfe05a0c-e0f2-46d0-9486-051cad7328ba">2,202</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d4b033413e949bdb33308f291e151d7_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNi0xLTEtMS0w_fb1fb438-0e56-41bf-a105-b6e21db07cbe">683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib72090a087094a15a97bb50cce1d461f_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNi0zLTEtMS0w_20251276-e588-4100-86e3-535656016d19">2,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e859f8f93d478cbc47d931bf3d4f16_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNi01LTEtMS0w_4b5dacb2-ebbb-4330-b16d-1680e9263b33">7,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bd62d81b9224846bad804af424c7c55_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNi03LTEtMS0w_66ca3e60-865e-48f1-8d2f-bc560b4c8531">7,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNy0xLTEtMS0w_af5ab40c-7893-4d8e-aa2b-2b697dd64fc5">34,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNy0zLTEtMS0w_51b8ac2f-d5f8-4b0a-b6c3-ccb6cc3ac8fc">26,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNy01LTEtMS0w_a665c1f6-7541-4e48-9ec5-323cd953f86f">159,151</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNy03LTEtMS0w_5c5357b9-fcca-45e7-a790-9b16693f1dfd">82,472</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost and expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfOS0xLTEtMS0w_9540a9a7-e9bf-4a1b-ad8a-1360a0b363a5">638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfOS0zLTEtMS0w_83119fb5-bab2-4334-bf55-fe958e7e7eb7">393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfOS01LTEtMS0w_f1dad492-25ec-4535-9b02-7887e1f11299">1,846</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfOS03LTEtMS0w_e07c77d6-da8e-41b1-bb66-68e58645870b">1,030</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTAtMS0xLTEtMA_20a8bff9-fbd4-4200-b686-e1f86f320254">89,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTAtMy0xLTEtMA_85fb8a7d-1ed9-4d77-92af-52b225b8b133">101,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTAtNS0xLTEtMA_553d6eac-dba2-4ab4-be17-77f45e360e8b">271,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTAtNy0xLTEtMA_f64da5c8-6337-4cd1-bfb7-fab0155f13d0">304,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTEtMS0xLTEtMA_3137ab6b-439d-40ab-bd1e-526aea7f2190">34,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTEtMy0xLTEtMA_377af897-d547-4a93-a67b-85a9c69cfaf1">33,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTEtNS0xLTEtMA_7640cb6f-c04c-466f-9adc-98226477f5c2">109,292</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTEtNy0xLTEtMA_67da7177-e011-4aa6-8e95-15181f4317e7">97,200</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTItMS0xLTEtMA_41a76af9-060a-4b58-98ae-e02650c0a5f9">125,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTItMy0xLTEtMA_3c8bb676-e6a5-4481-ad4b-b124be17f1e8">135,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTItNS0xLTEtMA_2c6caf04-d204-4368-97eb-aa8c996d941f">382,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTItNy0xLTEtMA_86334f77-7c40-4e52-8e57-c380302edd89">402,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTMtMS0xLTEtMA_0c0bf784-930e-4986-94d9-dac299ca8184">90,327</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTMtMy0xLTEtMA_d3536e69-86f2-4d90-a4e8-ca176c6f61ae">109,060</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTMtNS0xLTEtMA_f4e6253d-8d70-40f2-8ff4-1e218c0aa27c">223,715</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTMtNy0xLTEtMA_61d825ee-e938-443c-96c2-a2f009d41933">320,404</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTQtMS0xLTEtMA_389d09a1-18b2-44af-8642-a6162278e2a8">1,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTQtMy0xLTEtMA_da8ab768-7cba-4c17-a553-b62203e08ad5">2,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTQtNS0xLTEtMA_d51e9f35-265e-4efa-95c3-ff51ef3e8383">5,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTQtNy0xLTEtMA_bc45a1ef-bb33-42d9-a54d-8088f79dc217">11,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense for the sale of future revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:InterestExpenseNonCashSaleOfFutureRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTUtMS0xLTEtMA_d82fec9a-fc28-4974-b7e6-eb9b5176b5ee">9,767</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="agio:InterestExpenseNonCashSaleOfFutureRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTUtMy0xLTEtMA_8d90002d-4bd7-4aac-92bd-357524afa6f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:InterestExpenseNonCashSaleOfFutureRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTUtNS0xLTEtMA_a6e31a27-787e-44f8-a0f4-5d0e3e3e84eb">11,818</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="agio:InterestExpenseNonCashSaleOfFutureRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTUtNy0xLTEtMA_43a0567f-80a9-4b71-8793-aa75d73ae9c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTYtMS0xLTEtMA_79770292-3c3c-4578-8289-6840fec6f199">98,979</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTYtMy0xLTEtMA_547c9ffc-3019-4925-ad61-6ba3d6067f66">106,173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTYtNS0xLTEtMA_3417b3e6-90d6-4306-aa96-68fd34d7d8c0">229,713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTYtNy0xLTEtMA_8162c3e0-e812-4302-b890-728eea32cc26">309,122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share &#8211; basic and diluted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTctMS0xLTEtMA_359cb9bc-c61e-485e-a6e3-cef12bafe764">1.43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTctMy0xLTEtMA_c2b07eb9-7cc1-4e88-ac90-ceabc89e6ada">1.81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTctNS0xLTEtMA_fed957cd-748f-46a0-a8c1-c6081fc268e6">3.33</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTctNy0xLTEtMA_95cbd11c-f3ae-46aa-9683-aca69f25e481">5.27</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares used in computing net loss per share &#8211; basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTgtMS0xLTEtMA_18425d8d-4cf9-4fff-85b4-e83c8411e5e4">69,144,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTgtMy0xLTEtMA_3717325c-eafe-4a36-85a8-c4fab21b7d65">58,803,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTgtNS0xLTEtMA_38014f0f-9b53-41f0-bf17-311db4bc9e08">68,905,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTgtNy0xLTEtMA_2a7e1da3-a3ce-4f74-b740-bd9d0923e2cb">58,661,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i4174004101c4483bbd134be7ce58ff32_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AGIOS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yMi9mcmFnOjhmMGIzMDk5NTRhNTQ2NmE4NWNhMTAwNTIyMzUzMjM0L3RhYmxlOjlkZDk1MDk2MjNhYTQyNzI4ZWRjMDViMGM3NDRmMmNlL3RhYmxlcmFuZ2U6OWRkOTUwOTYyM2FhNDI3MjhlZGMwNWIwYzc0NGYyY2VfMi0xLTEtMS0w_79770292-3c3c-4578-8289-6840fec6f199">98,979</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yMi9mcmFnOjhmMGIzMDk5NTRhNTQ2NmE4NWNhMTAwNTIyMzUzMjM0L3RhYmxlOjlkZDk1MDk2MjNhYTQyNzI4ZWRjMDViMGM3NDRmMmNlL3RhYmxlcmFuZ2U6OWRkOTUwOTYyM2FhNDI3MjhlZGMwNWIwYzc0NGYyY2VfMi0zLTEtMS0w_547c9ffc-3019-4925-ad61-6ba3d6067f66">106,173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yMi9mcmFnOjhmMGIzMDk5NTRhNTQ2NmE4NWNhMTAwNTIyMzUzMjM0L3RhYmxlOjlkZDk1MDk2MjNhYTQyNzI4ZWRjMDViMGM3NDRmMmNlL3RhYmxlcmFuZ2U6OWRkOTUwOTYyM2FhNDI3MjhlZGMwNWIwYzc0NGYyY2VfMi01LTEtMS0w_aeb05931-d16a-41fa-abe6-ad0c6da1f727">229,713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yMi9mcmFnOjhmMGIzMDk5NTRhNTQ2NmE4NWNhMTAwNTIyMzUzMjM0L3RhYmxlOjlkZDk1MDk2MjNhYTQyNzI4ZWRjMDViMGM3NDRmMmNlL3RhYmxlcmFuZ2U6OWRkOTUwOTYyM2FhNDI3MjhlZGMwNWIwYzc0NGYyY2VfMi03LTEtMS0w_4d39a752-acbe-4d8e-8e61-391d058f6bdd">309,122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (loss) gain on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yMi9mcmFnOjhmMGIzMDk5NTRhNTQ2NmE4NWNhMTAwNTIyMzUzMjM0L3RhYmxlOjlkZDk1MDk2MjNhYTQyNzI4ZWRjMDViMGM3NDRmMmNlL3RhYmxlcmFuZ2U6OWRkOTUwOTYyM2FhNDI3MjhlZGMwNWIwYzc0NGYyY2VfNC0xLTEtMS0w_b9462cc3-d924-4f08-ad5b-f2df9e2cb681">973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yMi9mcmFnOjhmMGIzMDk5NTRhNTQ2NmE4NWNhMTAwNTIyMzUzMjM0L3RhYmxlOjlkZDk1MDk2MjNhYTQyNzI4ZWRjMDViMGM3NDRmMmNlL3RhYmxlcmFuZ2U6OWRkOTUwOTYyM2FhNDI3MjhlZGMwNWIwYzc0NGYyY2VfNC0zLTEtMS0w_840d9023-1ea9-4e32-a10c-07fcb3e8b9d2">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yMi9mcmFnOjhmMGIzMDk5NTRhNTQ2NmE4NWNhMTAwNTIyMzUzMjM0L3RhYmxlOjlkZDk1MDk2MjNhYTQyNzI4ZWRjMDViMGM3NDRmMmNlL3RhYmxlcmFuZ2U6OWRkOTUwOTYyM2FhNDI3MjhlZGMwNWIwYzc0NGYyY2VfNC01LTEtMS0w_9d078113-3ad8-4974-85e8-cdce68619970">461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yMi9mcmFnOjhmMGIzMDk5NTRhNTQ2NmE4NWNhMTAwNTIyMzUzMjM0L3RhYmxlOjlkZDk1MDk2MjNhYTQyNzI4ZWRjMDViMGM3NDRmMmNlL3RhYmxlcmFuZ2U6OWRkOTUwOTYyM2FhNDI3MjhlZGMwNWIwYzc0NGYyY2VfNC03LTEtMS0w_efc19c07-d4ef-4988-8ebc-90270c890bb4">2,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yMi9mcmFnOjhmMGIzMDk5NTRhNTQ2NmE4NWNhMTAwNTIyMzUzMjM0L3RhYmxlOjlkZDk1MDk2MjNhYTQyNzI4ZWRjMDViMGM3NDRmMmNlL3RhYmxlcmFuZ2U6OWRkOTUwOTYyM2FhNDI3MjhlZGMwNWIwYzc0NGYyY2VfNS0xLTEtMS0w_dccadc2c-12e3-46a1-b17a-e30d7f94b02d">99,952</ix:nonFraction>)</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yMi9mcmFnOjhmMGIzMDk5NTRhNTQ2NmE4NWNhMTAwNTIyMzUzMjM0L3RhYmxlOjlkZDk1MDk2MjNhYTQyNzI4ZWRjMDViMGM3NDRmMmNlL3RhYmxlcmFuZ2U6OWRkOTUwOTYyM2FhNDI3MjhlZGMwNWIwYzc0NGYyY2VfNS0zLTEtMS0w_90f33741-3c71-4c74-af6c-1970be613742">106,199</ix:nonFraction>)</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yMi9mcmFnOjhmMGIzMDk5NTRhNTQ2NmE4NWNhMTAwNTIyMzUzMjM0L3RhYmxlOjlkZDk1MDk2MjNhYTQyNzI4ZWRjMDViMGM3NDRmMmNlL3RhYmxlcmFuZ2U6OWRkOTUwOTYyM2FhNDI3MjhlZGMwNWIwYzc0NGYyY2VfNS01LTEtMS0w_54a915dd-a2ce-4bc4-9820-299b3c28e3b9">229,252</ix:nonFraction>)</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yMi9mcmFnOjhmMGIzMDk5NTRhNTQ2NmE4NWNhMTAwNTIyMzUzMjM0L3RhYmxlOjlkZDk1MDk2MjNhYTQyNzI4ZWRjMDViMGM3NDRmMmNlL3RhYmxlcmFuZ2U6OWRkOTUwOTYyM2FhNDI3MjhlZGMwNWIwYzc0NGYyY2VfNS03LTEtMS0w_f7bd315a-c4b0-4792-b0d2-c615d69260ea">306,487</ix:nonFraction>)</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i4174004101c4483bbd134be7ce58ff32_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AGIOS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders' Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.288%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>(Loss) Income</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3d4f0ce49ea478683a5e066d98b9657_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMi0xLTEtMS0w_e3f31e59-82e6-4aba-ae22-1c4e8a23fbf5">68,401,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3d4f0ce49ea478683a5e066d98b9657_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMi0zLTEtMS0w_a66e645f-476a-426b-a295-0c8006884870">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83a0c267e8c14a0b8cb5af9dc8889826_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMi01LTEtMS0w_765b0323-0fc9-4954-a3f7-3076000b267c">2,156,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie94a42df3bd64de59963733402e60f0b_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMi03LTEtMS0w_9d39fb91-bf3c-4cd0-805a-e65360372a84">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d2deb841a8484bbb9f4d6e7db83773_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMi05LTEtMS0w_6e9b30a0-27f9-415b-afcf-8db0af56fc8b">1,516,105</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMi0xMS0xLTEtMA_7dd86ec2-4bf1-484f-8159-12e6dc818b2f">640,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issued under stock incentive plan and ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia39f990b1b954fd4b7055ed175a61da7_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfNC0xLTEtMS0w_0f8eee1a-848c-419e-9c3a-f0dc87bd6204">388,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39f990b1b954fd4b7055ed175a61da7_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfNC0zLTEtMS0w_a16bde61-0b21-4fe1-9f10-da8f34491f2a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f838015f2c4600ab21342b2ab257bb_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfNC01LTEtMS0w_63fd3b1d-728b-4248-9b1f-48f81aa1b9dc">5,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226d1a9de1e4a689a12ba5ade263cbf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfNC0xMS0xLTEtMA_ea21c8ef-d1f1-4f59-9029-efd1edcb7679">5,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84f838015f2c4600ab21342b2ab257bb_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfNS01LTEtMS0w_0c910561-0c56-41f9-b93a-66049959c91c">19,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie226d1a9de1e4a689a12ba5ade263cbf_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfNS0xMS0xLTEtMA_4565fa93-f909-4839-b91d-8dddfb608b87">19,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e3117ca1e3d475081f74ed85067fdd9_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfNi03LTEtMS0w_a41c185d-f533-4ec8-81d1-04567ffd3d1a">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie226d1a9de1e4a689a12ba5ade263cbf_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfNi0xMS0xLTEtMA_29c6c5ec-8129-42e8-a70c-ba7233121d39">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74af35b6091d4e40bc61c88695b202c8_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfNy05LTEtMS0w_bca6fb9f-2a59-47be-bd51-d18d74d84c1f">40,256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie226d1a9de1e4a689a12ba5ade263cbf_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfNy0xMS0xLTEtMA_7f5beccb-3b33-4219-98f2-d12b34ee40e4">40,256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i633904fd4bf04f1db95a04a559e03ad2_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfOS0xLTEtMS0w_ce4c4db0-63c3-4359-97b7-952ab3c9a77c">68,789,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i633904fd4bf04f1db95a04a559e03ad2_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfOS0zLTEtMS0w_d238d604-4702-415a-891d-acd0624cbdae">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id355d6bb2f5148079147b0cb69a30e3a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfOS01LTEtMS0w_5f499657-0e4c-45cb-8518-b47fb60b2b21">2,181,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78340b4431bb4f3cb0c67e9c396fe87c_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfOS03LTEtMS0w_81d0b63b-ff88-44c0-87c8-6647deeb0d84">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7bda0d5bb34046e6976dbdd780aa978b_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfOS05LTEtMS0w_8e58b8fb-d818-4382-a934-518df6663b7e">1,556,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e478fecc462477aa454e3d9436e4752_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfOS0xMS0xLTEtMA_379e4bdc-bb7b-455e-8c39-53ac89c19e74">625,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issued under stock incentive plan and ESPP</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6ddd43f0d1749b3b53381bd19850103_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTEtMS0xLTEtMA_9be7db46-5713-498f-8884-8b49b2ec70fe">268,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id32fe94f97e84076b84beaff756aa3fa_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTEtNS0xLTEtMA_8949ec87-c083-48fb-a9b7-43fbe167920b">1,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dac01400f8a441eaf95cdb7f2c88e1e_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTEtMTEtMS0xLTA_18e31f6f-51b8-43dd-a4e6-1b250990bc32">1,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id32fe94f97e84076b84beaff756aa3fa_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTItNS0xLTEtMA_48f6ec36-22b7-466d-82b6-08c870507c8c">20,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dac01400f8a441eaf95cdb7f2c88e1e_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTItMTEtMS0xLTA_e90e6e12-8a21-4a7b-905a-0025da70a7a1">20,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc5c534cd84f4787a526c269ef4c6151_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTMtNy0xLTEtMA_ae57c622-957b-45ed-afea-c41c2ae23554">1,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dac01400f8a441eaf95cdb7f2c88e1e_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTMtMTEtMS0xLTA_d4a6f6e5-e200-40b3-a011-824efcff571f">1,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie481c63be9664fed98e565204a85caf1_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTQtOS0xLTEtMA_ebf159cc-c291-4970-b2e5-fdad38e89d5c">90,478</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dac01400f8a441eaf95cdb7f2c88e1e_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTQtMTEtMS0xLTA_6f8c417d-3137-4880-8f6c-6aea780f966c">90,478</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if50f19fc8ffb45ec878303df8a922a99_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTYtMS0xLTEtMA_b43ada67-7a2b-4531-b5f1-a3e554f48df5">69,058,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if50f19fc8ffb45ec878303df8a922a99_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTYtMy0xLTEtMA_774a0077-4317-40c6-8c5c-c30a6fbebc8a">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f336477ca834d10a759110a6b168a44_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTYtNS0xLTEtMA_5258df9f-3ac5-483a-bb2e-d32e5c298e12">2,203,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c742c6a37f940b1b7230f3dad49ebc6_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTYtNy0xLTEtMA_b517ce34-230d-4521-add9-c3dd235a7f3c">1,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idaea355a6eee4c84b610bb5a3998cb0a_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTYtOS0xLTEtMA_20c4689b-db94-4666-b495-37fd1e1a1b17">1,646,839</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if74da64f69904adba74c4a3593889ebc_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTYtMTEtMS0xLTA_d972580d-db60-442c-939b-28b6fd35b891">558,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issued under stock incentive plan and ESPP</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icafe5156f770497288825e054150807e_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTctMS0xLTEtNDQ_4a26d513-8085-446b-b8d4-9801fd9c50eb">139,367</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e51e0bf32b84c06bc802cf158d85892_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTctNS0xLTEtNDQ_ebfcf74e-6b47-41e9-872d-3c885f7b2459">3,532</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTctMTEtMS0xLTQ0_e7a17bd3-ccfa-4a3f-8e24-5ab8bee7a74c">3,532</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e51e0bf32b84c06bc802cf158d85892_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTgtNS0xLTEtNDQ_274f5d8b-56ec-40d8-86d4-6773127b58a3">18,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTgtMTEtMS0xLTQ0_073348de-fdea-40ab-bfc8-7a5c594a5424">18,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic794988e2ef64d2d903b700cc61ab8ac_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTktNy0xLTEtNDQ_0ce3e6b5-8e63-4c3e-939c-709eb4585734">973</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTktMTEtMS0xLTQ0_32758415-1fca-414d-b1f4-715a828b010c">973</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5e2bd57c0864b8ca52c0dbc9e5247eb_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMjAtOS0xLTEtNDQ_33df12ba-18e5-4bff-80d9-6f37c213c880">98,979</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMjAtMTEtMS0xLTQ0_ef60c08f-a484-4d47-a4b3-ec298aab78f3">98,979</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie77331352e8e487ab5aaa801714a9478_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMjEtMS0xLTEtMTAx_d878ef75-60c5-4671-9f64-fd1f1130d252">69,198,063</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie77331352e8e487ab5aaa801714a9478_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMjEtMy0xLTEtMTAx_ce324f92-0a87-4b46-834b-a98b7abfc5d2">69</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f5eb666df1f4354b1d4dcf993b7fd72_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMjEtNS0xLTEtMTAx_82a80add-1569-4b83-b267-3fecbd963a8c">2,225,538</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfb43edba9e24d7aa4bc0b84a542b1a4_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMjEtNy0xLTEtMTAx_db333cec-6c62-45bc-9e26-a15c51215b11">663</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic221521f25684d8291dde2458b8fd56d_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMjEtOS0xLTEtMTAx_2e2f465b-a38e-420a-a585-052ce650613c">1,745,818</ix:nonFraction>)</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMjEtMTEtMS0xLTEwMQ_b0ad303e-cb19-4a67-9caf-c2b3732dec00">480,452</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AGIOS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders' Equity (Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.288%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>(Loss) Income</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands, except share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iddbd8fd3a9234d15a8eda0993f4f1137_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMi0xLTEtMS0w_56871918-6682-4e6c-83b7-e98ca625194f">58,218,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddbd8fd3a9234d15a8eda0993f4f1137_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMi0zLTEtMS0w_d6f80a33-24b5-440d-b235-378085b9e0bf">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccd377f04511411f8b9b576f6daddde7_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMi01LTEtMS0w_f669d26d-c23e-4b3a-a790-1b187bdee0f5">1,794,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7a7de9468d1492cb68a6b85d84c50e3_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMi03LTEtMS0w_6541a5f2-8b7f-444d-acc4-f4614c25e3b8">2,171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i958a5eaaa1994c0e8785e2290bffb78c_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMi05LTEtMS0w_b71e4ed7-df43-441c-8cfd-8fbb4fdf3d4b">1,104,633</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ee3f08f37a94847b4581c44661b6945_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMi0xMS0xLTEtMA_ee6b07e4-ac20-4084-965f-2c6c477ab495">687,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issued under stock incentive plan and ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if10cfda3b1ae42dd94275ef357f4b6ab_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMy0xLTEtMS0w_cd742a75-3710-4c7f-b302-b950da888039">441,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if10cfda3b1ae42dd94275ef357f4b6ab_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMy0zLTEtMS0w_ec9f9dc8-ece6-4642-9fd9-4968cc122f5c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23e8641cdf9d4a0ba36b18e83e1f74f5_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMy01LTEtMS0w_f2fcb045-66a9-4048-ae9f-a1b4fa86f9e7">6,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09874c19ef114cc9a325361e8c04db94_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMy0xMS0xLTEtMA_7d670df8-686a-483b-a8dd-aef2aea7c789">6,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23e8641cdf9d4a0ba36b18e83e1f74f5_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfNC01LTEtMS0w_2a919db0-baed-4c04-b9c8-d7d9ad7a0638">18,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09874c19ef114cc9a325361e8c04db94_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfNC0xMS0xLTEtMA_1e2bb72d-a48c-48cf-8531-9231762cc4eb">18,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aee4cc470d44c5e99067c41afb5f002_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfNS03LTEtMS0w_d2e5abea-097c-4baf-b658-4c90af81aa42">1,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09874c19ef114cc9a325361e8c04db94_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfNS0xMS0xLTEtMA_2d2d056c-2a64-42aa-aa89-bd608931008b">1,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44c7bfd7973b423691bd63d2af7d57aa_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfNy05LTEtMS0w_560522cf-4a1a-42f5-b495-e3d2bd2f04a5">93,078</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09874c19ef114cc9a325361e8c04db94_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfNy0xMS0xLTEtMA_c11ed887-c506-42f3-8c77-e30cff888b11">93,078</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic76020b398604ca1bf1af8adacc2ffce_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfOC0xLTEtMS0w_1dcb5557-0e38-4834-90bf-a25dc5da8516">58,659,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic76020b398604ca1bf1af8adacc2ffce_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfOC0zLTEtMS0w_6ce3ba46-eb36-481c-80aa-aabd552d987c">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c08cf4ec15f402aadb383d3cf0aac8d_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfOC01LTEtMS0w_7eb91963-ac97-4f0d-99eb-79d4345acbaa">1,818,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia32695c6f95b4eecbd80e2ba29818b2d_I20190331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfOC03LTEtMS0w_eaac4daf-184c-4177-869c-97fc02f7f280">484</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bf3fa70c71d4e65bfa404b0233a7d5e_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfOC05LTEtMS0w_ed40b5a5-1412-4bc3-aa4d-9740e24401d5">1,197,711</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac1252d10b6040f4876c7756be3e4a76_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfOC0xMS0xLTEtMA_483171be-9a65-40ea-b415-95e2e050b5f6">620,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issued under stock incentive plan and ESPP</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99487a9075154d1481319c8e1e5c20c8_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTAtMS0xLTEtMA_6576ea78-ce9a-4d18-9253-e069c43b9809">89,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2989a9b9047443f9a4e2a2c0bb1625f4_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTAtNS0xLTEtMA_bfdebf7e-3d79-4f92-9789-756d46ac662f">2,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f6dcdda42cf4c478aff8535b767c4c4_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTAtMTEtMS0xLTA_82a36378-e991-4f02-a7fa-ab7fe7ab6647">2,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2989a9b9047443f9a4e2a2c0bb1625f4_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTEtNS0xLTEtMA_11fb47b0-eee2-4807-aea0-0abd65532044">18,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f6dcdda42cf4c478aff8535b767c4c4_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTEtMTEtMS0xLTA_b791b832-2e3f-4567-a7a1-62b48d102033">18,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b377237524434a885c88b184553ef7_D20190401-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTItNy0xLTEtMA_13d0b462-c487-4cc2-a788-9f58aad786c7">974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f6dcdda42cf4c478aff8535b767c4c4_D20190401-20190630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTItMTEtMS0xLTA_b2046752-c977-42f1-b58d-7a1905bf083c">974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7159c55a54a64257836b127ebdbe79ca_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTMtOS0xLTEtMA_336a0c08-8cbd-44b6-a6c4-3c17aefe4d15">109,871</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f6dcdda42cf4c478aff8535b767c4c4_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTMtMTEtMS0xLTA_80ca9f1b-8b82-4ce3-bfbf-ae9972669b06">109,871</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at June 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc3e62b98968494bba8bee317e04525f_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTUtMS0xLTEtMA_cebb243d-2aeb-4134-b94e-adb588f6a64e">58,749,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc3e62b98968494bba8bee317e04525f_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTUtMy0xLTEtMA_1f0d97d6-41af-499c-818a-72d9bab9c63e">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14619843617f40c7a9cf1f66f71c1c27_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTUtNS0xLTEtMA_c08966ee-3390-4603-a6db-820fdfc6e445">1,839,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4f71ec0a74244a898c7f64d6f7c861d_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTUtNy0xLTEtMA_abe0cdac-b712-4ce6-ab4a-fed4204d1755">490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9327aef1d4d84255b2eb04bc36f39536_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTUtOS0xLTEtMA_e8bb908d-387e-49f2-8240-c8a9993bf8a3">1,307,582</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33d12dc0073b41d0b953c2cd4414bb09_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTUtMTEtMS0xLTA_81dba3a3-55c0-4c1d-afd0-86c876aa8dfd">532,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock issued under stock incentive plan and ESPP</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1053b3953d9d41a4b58d1f9f40168930_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTYtMS0xLTEtNTk_92b610fc-6570-4ffd-9aae-3fd2fd150821">128,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96e9cac9a5b245e1ab992da2a4f3b707_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTYtNS0xLTEtNTk_c03af969-3533-4b63-9f79-02ec403b97a3">3,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTYtMTEtMS0xLTU5_73f3e322-1373-4383-9008-8284b440a105">3,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96e9cac9a5b245e1ab992da2a4f3b707_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTctNS0xLTEtNTk_19625df2-aca2-49b9-bc10-a5968e4896d7">18,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTctMTEtMS0xLTU5_d2745d10-6885-4a19-9af4-e65fa8f50eaa">18,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c451a043eeb4e1c90f9351c338a270c_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTgtNy0xLTEtNTk_ecf55ae8-e1bd-4f90-8583-817f3d67b515">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTgtMTEtMS0xLTU5_b82bb911-28d0-49e4-9249-594ff89dab42">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie090a495a771498fa103545475845412_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTktOS0xLTEtNTk_f207851c-f42d-441e-8989-04c03d44f1f8">106,173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTktMTEtMS0xLTU5_37c678f0-97d3-4490-b069-e54a592888e1">106,173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at September 30, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i711e80bbc9f74ab3b7066dfb0f019bfb_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMjAtMS0xLTEtNzE_fcaa487b-1302-4a01-9caa-a2e051018f59">58,877,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i711e80bbc9f74ab3b7066dfb0f019bfb_I20190930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMjAtMy0xLTEtNzE_7c55d546-a45b-4ad2-9396-6e51bf471fcf">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382fc23536884c45afe5acfaef266947_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMjAtNS0xLTEtNzE_476b3508-5384-400f-aecf-fb1ed7be5c11">1,861,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53f5dfe3b6464427a8673fa0c75cf825_I20190930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMjAtNy0xLTEtNzE_3c97d777-07f5-44eb-89af-ead3b5d462cb">464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c8d5ed345084b43bbf0c55a4d2ee227_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMjAtOS0xLTEtNzE_685759a3-174d-4bc2-8fa6-30c6aac62ddd">1,413,755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9f7f3cb6d047899b09ad580b69156b_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMjAtMTEtMS0xLTcx_96068c68-26b1-4adb-86a9-565b8368431e">448,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i4174004101c4483bbd134be7ce58ff32_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AGIOS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:6pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMy0xLTEtMS0w_f21e3901-c477-44f1-8968-93334b060c7f">229,713</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMy0zLTEtMS0w_384dfb64-12d9-4eb6-ab36-758643397b15">309,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNS0xLTEtMS0w_5f73f522-9cff-47f9-a235-45237f356b40">7,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNS0zLTEtMS0w_2d87bc34-5af1-4209-bf3d-45e8fc437d6a">6,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNi0xLTEtMS0w_26b3f1d5-4a75-49af-8d34-d29b1197cf06">58,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNi0zLTEtMS0w_a5aad2f3-8e9b-499b-9449-2c98e445ea83">55,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net accretion of premium and discounts on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNy0xLTEtMS0w_d47b1cc6-2ea5-4cec-952e-220a295d4f88">1,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNy0zLTEtMS0w_0b663d05-dd48-4a96-a9f3-b8f71b2c2596">2,772</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on disposal of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfOC0xLTEtMS0w_90d10d8a-6073-4a82-b704-3ff649e81d55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfOC0zLTEtMS0w_b7c2614c-998e-4250-a4c5-be8744c3b499">466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:OperatingLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfOS0xLTEtMS0w_a862d1e2-42f7-44b3-a526-418a74b15e2f">6,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="agio:OperatingLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfOS0zLTEtMS0w_b5fe704c-cc0b-49c1-b690-c2d899f277d7">6,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense associated with the sale of future revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:InterestExpenseNonCashSaleOfFutureRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTAtMS0xLTEtMA_2659fa23-c065-4728-8d59-e7ef20667ba1">11,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="agio:InterestExpenseNonCashSaleOfFutureRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTAtMy0xLTEtMA_5a41e659-f011-4934-bc6c-65d30f0dafbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:RoyaltyRevenueNonCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTEtMS0xLTEtMA_837e1ef3-ffac-4e71-9ac5-6929b9a73523">4,341</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="agio:RoyaltyRevenueNonCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTEtMy0xLTEtMA_9838ae27-274c-43f7-b4dc-bfc9685d9e67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTMtMS0xLTEtMA_38204963-1517-4c90-a302-153ab901f35a">10,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTMtMy0xLTEtMA_01784a60-c700-4907-946f-d318b086cb7d">2,030</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration receivable &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" name="agio:IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTQtMS0xLTEtMA_67e13102-fe28-4d87-925f-6e4fc66c753e">795</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" sign="-" name="agio:IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTQtMy0xLTEtMA_3cd71bad-6f88-4241-8d00-bbe1c8085901">624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration receivable &#8211; other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" name="agio:IncreaseDecreaseInCollaborationReceivableOtherCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTUtMS0xLTEtMA_3f66a606-0201-4e7d-ad11-a596fa0a8172">64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" name="agio:IncreaseDecreaseInCollaborationReceivableOtherCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTUtMy0xLTEtMA_60dfefc3-fa65-4a34-a08b-a3113befe8e5">199</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty receivable &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="agio:IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTYtMS0xLTEtMA_359b8b6f-a3e4-43d4-a2a8-b5a1432e2a5c">2,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" name="agio:IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTYtMy0xLTEtMA_0d01ca14-d9a9-4957-9ad6-2e4674738137">366</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTctMS0xLTEtMA_e9766720-2db5-4df1-ad96-f94e5654107e">4,040</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTctMy0xLTEtMA_4df9b6b5-ec0a-44f5-9d2c-5718c57590ef">4,980</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current and non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTktMS0xLTEtMA_12688003-071c-4ec5-a0ca-ec19180c87e9">6,033</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTktMy0xLTEtMA_e3500ae5-a987-4daf-89bc-6d56e46d8249">3,552</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjAtMS0xLTEtMA_9f0c2e1b-1667-45eb-8f60-128f52e05853">7,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjAtMy0xLTEtMA_a02e6824-9966-4ec0-9985-f1fff0a87a8a">2,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjEtMS0xLTEtMA_6e3c64d0-9394-44a1-8423-8580fe777587">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjEtMy0xLTEtMA_8e9ab893-f6ef-45b7-a6c0-2339e26a6f7b">4,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="agio:IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjItMS0xLTEtMA_53f44d8f-7de2-4a56-9878-acff2a55d167">61,513</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="agio:IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjItMy0xLTEtMA_3d54e6ec-8590-4f73-978e-7760bed71d24">25,849</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="agio:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjMtMS0xLTEtMA_a029582e-e411-4553-b554-ea00cb1ab822">6,112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="agio:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjMtMy0xLTEtMA_3062fd6b-7d99-4d7a-9dec-69019c689dfd">4,190</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 42pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjUtMS0xLTEtMA_78d9628e-d897-4380-873f-e4b875d0cc45">241,362</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjUtMy0xLTEtMA_ca76f2e4-a7c3-4626-b63b-3d85f542eaa0">277,011</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjctMS0xLTEtMA_c9ceb9f2-cd24-49cd-8389-d7534b6a4554">430,624</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjctMy0xLTEtMA_00bf22a9-5295-4550-a886-54d4acf48933">194,822</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities and sales of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjgtMS0xLTEtMA_3ad491e4-79fa-41ba-a522-1eaa99a8753d">448,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjgtMy0xLTEtMA_1a93eef5-ce6d-4992-bad1-f334172b0aae">476,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjktMS0xLTEtMA_43025246-3e80-48b7-827f-d5b64957ee87">13,892</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjktMy0xLTEtMA_d1dc3014-5222-40a6-abeb-4315537033a5">5,347</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 42pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMzAtMS0xLTEtMA_fe2b0fce-9626-4bcd-868b-f255f40acb49">4,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMzAtMy0xLTEtMA_7beb904e-0bea-42dc-a6f6-7e039bdae678">276,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments on financing lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMzItMS0xLTEtMA_901f60a5-bfc2-4d4f-8980-12b2656f41be">250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMzItMy0xLTEtMA_edb60e42-3db7-45cd-94d4-363f75a0a017">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from stock option exercises and employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMzUtMS0xLTEtMA_cbc7271f-dae4-4f26-bf5f-ab23f6e17f93">10,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMzUtMy0xLTEtMA_a325bb20-f083-4648-8689-1916e453c051">12,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the sale of future revenue, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMzYtMS0xLTEtMA_9e33df90-b359-46e4-9393-40960df55e36">250,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="agio:ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMzYtMy0xLTEtMA_5778acfd-6338-46c6-a32c-10a9ee95ebfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 42pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMzgtMS0xLTEtMA_9b6adbca-dd7b-4fa4-820a-9bd1d3f9711a">260,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMzgtMy0xLTEtMA_00c8ef4f-6d4a-46ba-bd0b-d6a619e5aaf4">12,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMzktMS0xLTEtMA_add52332-bbac-4483-ab7a-a5a4e73695b7">23,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMzktMy0xLTEtMA_552c0df4-0249-414c-ad7a-aea1519524eb">11,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNDAtMS0xLTEtMA_9c150023-49aa-4d0e-8497-04006426422e">80,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ee3f08f37a94847b4581c44661b6945_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNDAtMy0xLTEtMA_48c4a1f4-a7d4-44be-a1ec-6959dcac4e3d">70,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNDEtMS0xLTEtMA_18942250-65ce-46d6-b3a4-16e94414b47f">104,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c9f7f3cb6d047899b09ad580b69156b_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNDEtMy0xLTEtMA_adf09229-0a4f-455c-a3f2-40bc2b9bcf7b">81,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash investing and financing transactions</span></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property and equipment in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNDMtMS0xLTEtMA_25d8d7fe-9293-4b97-81f4-77cf6e481662">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNDMtMy0xLTEtMA_bc19ad3e-a38e-4122-8ea6-c63db382854c">2,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities arising from obtaining operating lease assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNDYtMS0xLTEtMA_e66ad4e7-4f26-4389-9251-7fd3dfb017bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNDYtMy0xLTEtMA_094add9a-2b1a-4ade-9276-d59ab3092f45">42,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i4174004101c4483bbd134be7ce58ff32_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AGIOS PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i4174004101c4483bbd134be7ce58ff32_34"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8zNC9mcmFnOjg5NDU1Y2U3NzY0ODRmYzlhMThkNjEzMDMzMGNjMGVmL3RleHRyZWdpb246ODk0NTVjZTc3NjQ4NGZjOWExOGQ2MTMwMzMwY2MwZWZfNDY5Nw_40959fe0-66ba-4748-b063-8ea86b220bdd" continuedAt="i8aab2c3c377e4ee99b3d97b42583af25" escape="true">Overview and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="i8aab2c3c377e4ee99b3d97b42583af25" continuedAt="ic2ce5930026e4199864972100c57f4b4"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">References to Agios</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout this Quarterly Report on Form&#160;10-Q,&#160;&#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; and similar expressions, except where the context requires otherwise, refer to Agios Pharmaceuticals, Inc. and its consolidated subsidiaries, and &#8220;our Board of Directors&#8221; refers to the board of directors of Agios Pharmaceuticals, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company committed to transforming patients&#8217; lives through scientific leadership in the field of cellular metabolism and adjacent areas of biology, with the goal of creating differentiated, small molecule medicines for patients in the areas of hematologic malignancies, solid tumors and rare genetic diseases, or RGDs. To address these focus areas, we take a systems biology approach to deeply understand disease states, drive the discovery and validation of novel therapeutic targets, and define patient selection strategies, thereby increasing the probability that our experimental medicines will have the desired therapeutic effect. We are located in Cambridge, Massachusetts.</span></div><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8zNC9mcmFnOjg5NDU1Y2U3NzY0ODRmYzlhMThkNjEzMDMzMGNjMGVmL3RleHRyZWdpb246ODk0NTVjZTc3NjQ4NGZjOWExOGQ2MTMwMzMwY2MwZWZfNDY5OA_51236d8b-e2ad-4607-9f54-d799602c81af" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of September&#160;30, 2020, the condensed consolidated statements of operations, comprehensive loss and stockholders' equity for the three and nine months ended September 30, 2020 and 2019, and the condensed consolidated statements of cash flows for the nine months ended September 30, 2020 and 2019 are unaudited. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of our management, reflect all adjustments, which include only normal recurring adjustments, necessary to fairly state our financial position as of September&#160;30, 2020, our results of operations and stockholders' equity for the three and nine months ended September 30, 2020 and 2019, and cash flows for the nine months ended September 30, 2020 and 2019. The financial data and the other financial information disclosed in these notes to the condensed consolidated financial statements related to the three and nine-month periods are also unaudited. The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2020 or for any other future annual or interim period. The condensed consolidated balance sheet data as of December&#160;31, 2019 was derived from our audited financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles, or U.S. GAAP. The condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019 that was filed with the Securities and Exchange Commission, or the SEC, on February&#160;19, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include our accounts and the accounts of our wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared in conformity with U.S. GAAP.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8zNC9mcmFnOjg5NDU1Y2U3NzY0ODRmYzlhMThkNjEzMDMzMGNjMGVmL3RleHRyZWdpb246ODk0NTVjZTc3NjQ4NGZjOWExOGQ2MTMwMzMwY2MwZWZfNDY5NQ_75bceb17-708e-4558-92e3-2ba6f0ea80bd" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain the pandemic or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 11, 2020, we sold our tiered, sales-based royalty rights on worldwide net sales of IDHIFA&#174; (enasidenib), as well as our rights to receive up to $<ix:nonFraction unitRef="usd" contextRef="ife55cfc6e645489a9aa97a13da6dfe00_I20200611" decimals="-5" format="ixt:numdotdecimal" name="agio:RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8zNC9mcmFnOjg5NDU1Y2U3NzY0ODRmYzlhMThkNjEzMDMzMGNjMGVmL3RleHRyZWdpb246ODk0NTVjZTc3NjQ4NGZjOWExOGQ2MTMwMzMwY2MwZWZfMzgyNA_58ca2c90-30c3-4b25-a64f-a07725cac0ef">55.0</ix:nonFraction>&#160;million in outstanding regulatory milestone payments from Bristol Myers Squibb, or BMS, to Royalty Pharma, or RPI, for $<ix:nonFraction unitRef="usd" contextRef="ied54aa2a3f7e42998c98d6f9afe5e255_D20200611-20200611" decimals="-5" format="ixt:numdotdecimal" name="agio:ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8zNC9mcmFnOjg5NDU1Y2U3NzY0ODRmYzlhMThkNjEzMDMzMGNjMGVmL3RleHRyZWdpb246ODk0NTVjZTc3NjQ4NGZjOWExOGQ2MTMwMzMwY2MwZWZfMzkzOA_8287a6bc-d453-40d1-a316-2096f60b9a79">255.0</ix:nonFraction>&#160;million. Under the 2010 Agreement, we remain eligible to receive a $<ix:nonFraction unitRef="usd" contextRef="idf22f68ca84c40088ac574f70d88d77d_I20200930" decimals="-5" format="ixt:numdotdecimal" name="agio:RevenueRecognitionMilestoneMethodEligibleReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8zNC9mcmFnOjg5NDU1Y2U3NzY0ODRmYzlhMThkNjEzMDMzMGNjMGVmL3RleHRyZWdpb246ODk0NTVjZTc3NjQ4NGZjOWExOGQ2MTMwMzMwY2MwZWZfNDAwMA_25b26e4b-7bc3-4c17-93cd-5200be855d81">25.0</ix:nonFraction>&#160;million potential </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><ix:continuation id="ic2ce5930026e4199864972100c57f4b4"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">milestone payment for the enasidenib program upon achievement of a specified ex-U.S. commercial milestone event, as well as reimbursement for costs incurred for our co-commercialization efforts and development activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, we had cash, cash equivalents and marketable securities of $<ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8zNC9mcmFnOjg5NDU1Y2U3NzY0ODRmYzlhMThkNjEzMDMzMGNjMGVmL3RleHRyZWdpb246ODk0NTVjZTc3NjQ4NGZjOWExOGQ2MTMwMzMwY2MwZWZfNDMwNA_00506c18-3a90-4a5f-8819-d0aaf6703097">722.4</ix:nonFraction> million. Although we have incurred recurring losses and expect to continue to incur losses for the foreseeable future, we expect our cash, cash equivalents and marketable securities will be sufficient to fund current operations for at least the next twelve months from the issuance date of these financial statements.</span></div></ix:continuation><div id="i4174004101c4483bbd134be7ce58ff32_37"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8zNy9mcmFnOjZjZjBmNjk5NTU1ZTQxMjZiMzc3ZTBkZTE1OGVlMmQzL3RleHRyZWdpb246NmNmMGY2OTk1NTVlNDEyNmIzNzdlMGRlMTU4ZWUyZDNfMzMzNg_1a9afa69-a1fe-4b23-80be-cfc3bab37346" continuedAt="ic4099e6f8c4c4545ad682dc20b0923dd" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ic4099e6f8c4c4545ad682dc20b0923dd"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant accounting policies</span></div><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8zNy9mcmFnOjZjZjBmNjk5NTU1ZTQxMjZiMzc3ZTBkZTE1OGVlMmQzL3RleHRyZWdpb246NmNmMGY2OTk1NTVlNDEyNmIzNzdlMGRlMTU4ZWUyZDNfMjc0ODc3OTA3Mjc4MQ_9cd717a5-6b66-46b6-bbbc-7675c8608c6a" continuedAt="ic1811dfcdf3f48c69fb15529948e5ce5" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board, or FASB issued Accounting Standards Update, or ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which introduces new guidance for the accounting for credit losses on instruments within its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. Credit losses relating to available-for-sale debt securities will also be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. The guidance is effective for fiscal years beginning after December 31, 2019, including interim periods within those years. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the quarter ended March 31, 2020, we adopted ASU 2016-13, which eliminated the concept of other-than-temporary impairments and required credit losses on debt securities to be recorded through an allowance for credit losses instead of as a reduction in the amortized cost basis of the securities. Application of the amendments is through a cumulative-effect adjustment to retained earnings as of the effective date. Based upon our analysis, the adoption of this final rule did not have a material impact on the financial statements. </span></div></ix:nonNumeric><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="agio:SaleOfFutureRevenuePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8zNy9mcmFnOjZjZjBmNjk5NTU1ZTQxMjZiMzc3ZTBkZTE1OGVlMmQzL3RleHRyZWdpb246NmNmMGY2OTk1NTVlNDEyNmIzNzdlMGRlMTU4ZWUyZDNfMjc0ODc3OTA3Mjc4MA_166f0bd7-14b5-4bab-a4a0-a95c92a07d26" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability related to sale of future revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We treat the sale of future revenue to RPI as a debt financing, as we have significant continuing involvement in the generation of the cash flows. As result, we recorded the proceeds from this transaction as a liability related to the sale of future revenue to be amortized to interest expense using the effective interest rate method over the life of the arrangement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liability related to sale of future revenue and the related interest expense are based on our current estimates of future royalties expected to be paid over the life of the arrangement. We will periodically assess the expected royalty payments using a combination of internal projections and forecasts from external sources. To the extent our future estimates of royalty payments are greater or less than previous estimates or the estimated timing of such payments is materially different than its previous estimates, we will prospectively recognize related non-cash interest expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further discussion of the sale of future revenue, refer to Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale of Future Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization of issuance costs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We treated the liability related to sale of future revenue as a debt financing. As such, the long-term liability is initially recorded at its proceeds, net of deferred costs. Issuance costs, fees directly related to the sale of future revenue, are offset against initial carrying value of the long-term liability and are amortized on a straight-line basis over the remaining patent life of the product to an operating expense.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes to the significant accounting policies previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019.</span></div><ix:continuation id="ic1811dfcdf3f48c69fb15529948e5ce5"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.</span></div></ix:continuation></ix:continuation><div id="i4174004101c4483bbd134be7ce58ff32_40"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RleHRyZWdpb246YjExODg3NjJlN2IxNDVhNzhmZDU2YjkzMmNlNDczMTdfMTkzMA_04648071-13b9-4830-a331-bccc729bf527" continuedAt="i514b66466a4844ba91f0fabfc965a4f9" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i514b66466a4844ba91f0fabfc965a4f9" continuedAt="i2f2598244acf4da298a3e13dfbf85624"><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RleHRyZWdpb246YjExODg3NjJlN2IxNDVhNzhmZDU2YjkzMmNlNDczMTdfMTkzMQ_311af4b9-dc8a-46fe-8b38-2a66170cb0c7" continuedAt="i2c2296276ee2483892e929d13f8b1462" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record cash equivalents and marketable securities at fair value. Accounting Standards Codification, or ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><ix:continuation id="i2f2598244acf4da298a3e13dfbf85624"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><ix:continuation id="i2c2296276ee2483892e929d13f8b1462"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</span></ix:continuation></div><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RleHRyZWdpb246YjExODg3NjJlN2IxNDVhNzhmZDU2YjkzMmNlNDczMTdfMTkzMw_1d642415-ff4e-46fb-8656-a9b14f553dbb" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash equivalents and marketable securities measured at fair value on a recurring basis as of September&#160;30, 2020:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i543ea632249a45b4b913803db254e6d2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfMS0xLTEtMS0w_183ae7ef-7b24-4f0d-87cc-083ed7001f4c">54,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a231d7d6a8434383ad19d455d7141a_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfMS0zLTEtMS0w_544c9442-4221-49b4-9000-1318908884de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie11b847113844524904871ec37728936_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfMS01LTEtMS0w_23bb58bc-19ad-4131-a27a-cd975fd5c3b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i039327938bac4cc0a80cd5dc934f1d1d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfMS03LTEtMS0w_0f02b69f-3cb7-451a-898b-987215e4789b">54,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7218efcd2284c88a1600bcc960ede96_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfMi0xLTEtMS0w_01faf268-8293-4f61-bef8-cbf3b31bf951">54,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2e5aaad6c904909a156e5d4b4f185fe_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfMi0zLTEtMS0w_6b431e1c-e2dd-4edc-90c2-89534e6f0663">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if555a5ee5cf0408a86be0d8a8d59801f_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfMi01LTEtMS0w_31c6f475-ad34-4cce-8c61-1cebabed2cdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i821a817349064dcc8e6938597d3db79e_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfMi03LTEtMS0w_76f6deb6-24e9-4a7e-9102-fa72d718e039">54,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaed01c1b899c4709b5accd32d8312191_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfNi0xLTEtMS0w_d348441b-e22c-4597-941a-bc7d54d8de0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08437c72c35449abacdc997fcf6867a2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfNi0zLTEtMS0w_744e4f41-0def-4ac2-a6ad-6b23ed484e00">145,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b4d1304c21246dc941d6150f7c3972e_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfNi01LTEtMS0w_de206ab4-ae0d-4578-8a19-2b5991e30b5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideab8d3cd8824f7ebaadb03c9812b1b1_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfNi03LTEtMS0w_a9cad327-acc3-4735-9bab-ab079f90a674">145,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744b349803e74e989804d827439ae1f4_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfNy0xLTEtMS0w_ce73a5d7-4dba-48d0-a9eb-d9cedeaacc40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f2d69b28ccb4f61b622f3b366b4804b_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfNy0zLTEtMS0w_f1dee12c-6347-40a7-9093-115fbf21d228">155,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedf6f8c98e70432c9500860ae91e2b2d_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfNy01LTEtMS0w_c6020f54-7c09-4c36-bbe1-ed8f8d7418ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6132c63023e4bc0bb7db5e06ab568fd_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfNy03LTEtMS0w_3a329d8a-f44e-4de5-b326-c782f76cb6b6">155,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484602594fc4892b37a19ce7a0605b8_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfOC0xLTEtMS0w_bdd776f3-3906-461d-bd31-d228582b1111">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a819345c25a47a78c1b9247bebd1445_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfOC0zLTEtMS0w_8d002365-1da7-4777-b685-aa28991bbb81">316,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12994fbfaa05455592901db5a2d7fb86_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfOC01LTEtMS0w_f8a5abbd-e666-4c87-b03b-06a400c08923">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7596257a08c149ec9fafbb992990cc54_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfOC03LTEtMS0w_1b9fd941-f4e5-4235-99af-fc600a325c7e">316,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7218efcd2284c88a1600bcc960ede96_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfOS0xLTEtMS0w_28495d79-e4a5-4a5e-b6bf-4fd90a71fbbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2e5aaad6c904909a156e5d4b4f185fe_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfOS0zLTEtMS0w_b8cef74e-ceed-4697-bff0-c1ba45189ddf">617,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if555a5ee5cf0408a86be0d8a8d59801f_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfOS01LTEtMS0w_1e315ba7-0193-4d77-8b28-47fbdd9a1fbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i821a817349064dcc8e6938597d3db79e_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfOS03LTEtMS0w_2a87ef7b-0300-4cf1-934d-53f5bc155aa1">617,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7218efcd2284c88a1600bcc960ede96_I20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:CashEquivalentsAndAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfMTAtMS0xLTEtMA_3f4f6692-7365-4c41-a385-6ddbfdb474ab">54,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2e5aaad6c904909a156e5d4b4f185fe_I20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:CashEquivalentsAndAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfMTAtMy0xLTEtMA_9a550e86-1afd-400d-a200-0c78042e9607">617,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if555a5ee5cf0408a86be0d8a8d59801f_I20200930" decimals="-3" format="ixt:zerodash" name="agio:CashEquivalentsAndAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfMTAtNS0xLTEtMA_affe695f-1cc4-4e9e-86dc-c71a732cff56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i821a817349064dcc8e6938597d3db79e_I20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:CashEquivalentsAndAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfMTAtNy0xLTEtMA_614917bb-72f8-4b20-b90f-a9c87ba033d8">672,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and marketable securities have been initially valued at the transaction price and subsequently, at the end of each reporting period, valued utilizing third-party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches, and observable market inputs to determine value. After completing our validation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of September&#160;30, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to the valuation methods during the nine months ended September 30, 2020. We evaluate transfers between levels at the end of each reporting period. We have <ix:nonFraction unitRef="usd" contextRef="if555a5ee5cf0408a86be0d8a8d59801f_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:FairValueNetAssetLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RleHRyZWdpb246YjExODg3NjJlN2IxNDVhNzhmZDU2YjkzMmNlNDczMTdfMTgzNw_0552fc51-4ce9-4884-93db-c8ad83931fb9">no</ix:nonFraction> financial assets or liabilities that were classified as Level 3 at any point during the nine months ended September 30, 2020.</span></div></ix:continuation><div id="i4174004101c4483bbd134be7ce58ff32_43"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfMjE3OQ_eb6635c2-d627-4054-806c-221f5c962bf4" continuedAt="ib9914535595b4476b8142209dba1913a" escape="true">Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="ib9914535595b4476b8142209dba1913a" continuedAt="i65483c2a592249da8b0287c05b756734"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfMjE3NA_6b43b5e5-df8b-4554-a3d0-d87483d26e50" continuedAt="i8c17dc79bdfb41539bf7393553be4590" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable securities are classified as available-for-sale pursuant to ASC 320, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments &#8211; Debt and Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and are recorded at fair value. Unrealized gains are included as a component of accumulated other comprehensive income in the condensed consolidated balance sheets and statements of stockholders&#8217; equity and a component of total comprehensive loss in the condensed consolidated statements of comprehensive loss, until realized. Unrealized losses are evaluated for impairment under ASC 326, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8c17dc79bdfb41539bf7393553be4590">, to determine if the impairment is credit-related or noncredit-related. Credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings, and noncredit-related impairment is recognized in other comprehensive income, net of taxes. Realized gains and losses are included in investment income on a specific-identification basis.</ix:continuation> There were <ix:nonFraction unitRef="usd" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:MarketableSecuritiesRealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfOTI0_257d3681-625f-4449-8c0e-8f750a652c4d"><ix:nonFraction unitRef="usd" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:MarketableSecuritiesRealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfOTI0_3e8832bf-f506-41ce-ab0c-3f45f39baf50"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:MarketableSecuritiesRealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfOTI0_b557d037-b8de-4f84-bfca-7720dc57d63a"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:MarketableSecuritiesRealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfOTI0_c3964a53-67c4-43b8-9ac9-50264b44214a">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> material realized gains or losses on marketable securities for the three and nine months ended September 30, 2020 or 2019.</span></div><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfMjE3Ng_cb2131af-d033-4844-88bd-49533c8a3381" continuedAt="if3362adbde0f4ac89b70f29a5cedeed6" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities at September&#160;30, 2020 consisted of the following:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf8521cd905445da506519413d478f2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMy0xLTEtMS0w_d5220954-6faf-4cea-a4b4-f2bd843e9220">139,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf8521cd905445da506519413d478f2_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMy0zLTEtMS0w_bdb0623c-e5f8-47b5-acd3-2d8e33a75cc4">380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bf8521cd905445da506519413d478f2_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMy01LTEtMS0w_e27cde85-bdbf-4d54-9fef-4f61e92fb591">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf8521cd905445da506519413d478f2_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMy03LTEtMS0w_1c7b2f43-c4bf-49f0-b5cd-5276a345a6ea">139,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ee1c71ed01b4620aa8b7c580a5c2c35_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfNC0xLTEtMS0w_3d83897f-bb03-4f94-8dbd-9ea9d4cca52b">94,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ee1c71ed01b4620aa8b7c580a5c2c35_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfNC0zLTEtMS0w_bd3339ca-ace4-4cd2-8f53-7edddbe0902e">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ee1c71ed01b4620aa8b7c580a5c2c35_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfNC01LTEtMS0w_e4e7282d-8366-4dc3-84c2-604f3cab6a07">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ee1c71ed01b4620aa8b7c580a5c2c35_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfNC03LTEtMS0w_9160e84a-896b-46f2-8381-d622d5baa257">94,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff55f01694f94e28b5c7fd66fab94514_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfNS0xLTEtMS0w_866cc900-cbbe-4784-8ef7-6669fb057e9a">265,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff55f01694f94e28b5c7fd66fab94514_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfNS0zLTEtMS0w_b0f0d2a5-40a2-4d78-81b5-56c25ecdee5f">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff55f01694f94e28b5c7fd66fab94514_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfNS01LTEtMS0w_9d2dfa31-1313-4f9a-a22a-1eedff27726a">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff55f01694f94e28b5c7fd66fab94514_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfNS03LTEtMS0w_e82db871-722e-4379-adc8-c89141ec8d19">266,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib489bc944aa14ea39dfa0ea27a8ccdda_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfNi0xLTEtMS0w_842c80cb-2bec-4a3c-b0f3-b0ceba76ea75">499,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib489bc944aa14ea39dfa0ea27a8ccdda_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfNi0zLTEtMS0w_941cbcea-63f9-4502-a9db-15126a05aab6">824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib489bc944aa14ea39dfa0ea27a8ccdda_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfNi01LTEtMS0w_5a756fe9-cd11-462e-8bcd-59d14bf4c3b0">58</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib489bc944aa14ea39dfa0ea27a8ccdda_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfNi03LTEtMS0w_5ec5f7ef-5649-43f9-8f3c-866a75be6ee9">500,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68f2b8cd5ee04a16971376df19807a05_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTEtMS0xLTEtMA_84a21553-7ab8-4f73-b134-215e3ecad65a">5,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68f2b8cd5ee04a16971376df19807a05_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTEtMy0xLTEtMA_36b90968-b262-4349-a8ad-df3df76b5fae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68f2b8cd5ee04a16971376df19807a05_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTEtNS0xLTEtMA_baca65ae-697f-4f5b-8a63-51071081cf1c">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68f2b8cd5ee04a16971376df19807a05_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTEtNy0xLTEtMA_6963837b-201c-4f20-8de9-ba2cfffe43e0">5,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ead45948574c9f9ee622f88491ada5_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTItMS0xLTEtMA_12c51fbc-01cf-48a0-b427-dc70c8ac17f9">61,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ead45948574c9f9ee622f88491ada5_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTItMy0xLTEtMA_9c7da279-9d3e-420b-95d4-a0b89f3b97a8">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ead45948574c9f9ee622f88491ada5_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTItNS0xLTEtMA_5800f711-4b4c-456e-b4b0-4c9e5d691a56">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ead45948574c9f9ee622f88491ada5_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTItNy0xLTEtMA_7f008347-d6fa-473a-8195-f965d5de3f40">61,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8047261250f94d8eb8d6c0f98068c56e_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTMtMS0xLTEtMA_c5c0ddcd-c7af-44ff-85a8-fc791e6bd421">50,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8047261250f94d8eb8d6c0f98068c56e_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTMtMy0xLTEtMA_fb4d893e-d8b1-47a3-acba-7df1b57ac823">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8047261250f94d8eb8d6c0f98068c56e_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTMtNS0xLTEtMA_04d5026e-082e-4118-955c-7897e7c6bf63">103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8047261250f94d8eb8d6c0f98068c56e_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTMtNy0xLTEtMA_423b2cf3-ba0b-4b5a-af47-38d0c48955d1">50,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bbfc1e3bc29413aba5926d90622f3d0_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTQtMS0xLTEtMA_496b9b74-66fb-43cc-903a-e6cc6d805878">116,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bbfc1e3bc29413aba5926d90622f3d0_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTQtMy0xLTEtMA_3dc9699c-bb15-4493-b4ab-f3395b6aed47">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7bbfc1e3bc29413aba5926d90622f3d0_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTQtNS0xLTEtMA_36958802-2f45-4353-bf12-5a98d3e361f2">113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bbfc1e3bc29413aba5926d90622f3d0_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTQtNy0xLTEtMA_f59c35b2-f96b-4528-b045-0764ae98400c">116,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTUtMS0xLTEtMA_fb70ac88-5ed3-413a-a62b-44a3a6910be0">616,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTUtMy0xLTEtMA_7e2c92eb-1585-4548-8910-249a3e2d09ac">834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTUtNS0xLTEtMA_46670ad7-f0c7-4dfb-be9a-c94d7bc58c6f">171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTUtNy0xLTEtMA_80cbe29f-01df-4581-9397-c82025af2e3f">617,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><ix:continuation id="i65483c2a592249da8b0287c05b756734"><ix:continuation id="if3362adbde0f4ac89b70f29a5cedeed6"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities at December&#160;31, 2019 consisted of the following:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafa6f804a3734443b6af52bbcd7cda22_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMi0xLTEtMS0w_b911027a-a039-4e61-9bc1-622a135c19a6">178,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafa6f804a3734443b6af52bbcd7cda22_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMi0zLTEtMS0w_7538bd29-f4a6-421b-9a79-095e7aec00b6">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iafa6f804a3734443b6af52bbcd7cda22_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMi01LTEtMS0w_e9099212-6507-4482-a797-031e091ec9d1">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafa6f804a3734443b6af52bbcd7cda22_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMi03LTEtMS0w_3ab69457-feef-4687-bce6-01b8d85f6ecf">178,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadc513dfb0aa455792b1559bd9ff0b07_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMy0xLTEtMS0w_61fc061f-460f-4635-9148-9f60ea7d2ba8">80,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadc513dfb0aa455792b1559bd9ff0b07_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMy0zLTEtMS0w_4d4f22f3-5889-42c2-987f-a3b658f0ccc1">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadc513dfb0aa455792b1559bd9ff0b07_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMy01LTEtMS0w_dcff74b2-0283-4d20-beba-35a87da1c8f6">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadc513dfb0aa455792b1559bd9ff0b07_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMy03LTEtMS0w_bc4ab5c6-7134-460a-8af3-9f32743a6d14">80,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i204de70f9ce54574b913c7c1a1f5bec6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfNC0xLTEtMS0w_80576af6-2274-402b-b10c-fc9fb9a77bea">224,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i204de70f9ce54574b913c7c1a1f5bec6_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfNC0zLTEtMS0w_00cb2552-c41c-4297-b041-ee718cf328c1">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i204de70f9ce54574b913c7c1a1f5bec6_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfNC01LTEtMS0w_5dd55f32-ece4-49f4-a4e5-b7e34fb08e98">91</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i204de70f9ce54574b913c7c1a1f5bec6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfNC03LTEtMS0w_ea754307-e6a8-4268-b445-ddd1a4b30c89">224,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ac3885e5cc24c1a9b936fd11ed191f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfNS0xLTEtMS0w_a080799b-eea7-437a-922b-6e01b8bbe32f">483,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ac3885e5cc24c1a9b936fd11ed191f3_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfNS0zLTEtMS0w_3981f6ef-154f-4f8a-8f4d-0d5ec46db791">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ac3885e5cc24c1a9b936fd11ed191f3_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfNS01LTEtMS0w_b4befbdd-fa54-4474-9109-5ee9a445457f">145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ac3885e5cc24c1a9b936fd11ed191f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfNS03LTEtMS0w_7c1d631a-f7de-4d91-811d-9ce1fda32b56">483,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8e02d6bad0479cb0dd2303c690ac0b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfOS0xLTEtMS0w_fdc4f57f-c9cb-4148-9592-f432186d0707">35,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8e02d6bad0479cb0dd2303c690ac0b_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfOS0zLTEtMS0w_47901377-ab19-48a3-abd1-11740bb5ce91">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b8e02d6bad0479cb0dd2303c690ac0b_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfOS01LTEtMS0w_6ad43d3e-2623-4f3c-982e-e63cde0fd814">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8e02d6bad0479cb0dd2303c690ac0b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfOS03LTEtMS0w_824a3435-75ba-47d0-814d-e232f87ae558">35,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015ac4920a1c4c3a9611d7a7be258105_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTAtMS0xLTEtMA_178f02d3-b592-4340-914e-d5b976b1a5cc">17,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015ac4920a1c4c3a9611d7a7be258105_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTAtMy0xLTEtMA_aec19473-e6ac-43ba-9db5-a77a7c5c3d37">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i015ac4920a1c4c3a9611d7a7be258105_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTAtNS0xLTEtMA_47e30803-69a0-4e48-ba30-dd0f6848c85e">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015ac4920a1c4c3a9611d7a7be258105_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTAtNy0xLTEtMA_1fdd8169-e644-487a-b95c-0f97fd1e1beb">17,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c2c48c0358445ac84d1add069e26cb6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTEtMS0xLTEtMA_eface8b0-acc6-49ea-9d8b-365c77fa94fe">99,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c2c48c0358445ac84d1add069e26cb6_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTEtMy0xLTEtMA_d3e278d6-20b4-4a03-9ca9-012dfac244dd">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c2c48c0358445ac84d1add069e26cb6_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTEtNS0xLTEtMA_f322867b-c109-4eb7-a5ad-b7f3a9358ddc">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c2c48c0358445ac84d1add069e26cb6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTEtNy0xLTEtMA_54175bb7-178b-4690-96d3-12dc83242ab2">100,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d92d9ecc2b4415b962d6feb4c7a44a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTItMS0xLTEtMA_540e21f3-95bb-45d5-866b-e19f576595d0">152,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d92d9ecc2b4415b962d6feb4c7a44a_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTItMy0xLTEtMA_fa7df1ef-eb06-4f2c-ad21-ca1ae0da486c">256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23d92d9ecc2b4415b962d6feb4c7a44a_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTItNS0xLTEtMA_277b9440-765b-4701-a7bb-59aa6a3fdbdf">123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d92d9ecc2b4415b962d6feb4c7a44a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTItNy0xLTEtMA_077a9626-6b5f-4b29-8c43-ed130d6d32b5">152,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTMtMS0xLTEtMA_96021050-86ba-4da0-9800-4ee8e1100290">636,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTMtMy0xLTEtMA_9a7d7223-0378-4deb-ba97-b50db3b00fb0">470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTMtNS0xLTEtMA_587a5cba-c777-48d8-8d0b-71738d69397b">268</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTMtNy0xLTEtMA_fb9c0fe8-a7c2-4ce0-a67f-ea25a204afd1">636,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020 and December&#160;31, 2019, we held both current and non-current investments. Investments classified as current have maturities of less than one year. Investments classified as non-current are those that: (i)&#160;have a maturity of greater than one year, and (ii)&#160;we do not intend to liquidate within the next twelve months, although these funds are available for use and, therefore, are classified as available-for-sale.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020 and December&#160;31, 2019, we held <ix:nonFraction unitRef="security" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfMTUzMA_e7a052cb-6525-43d4-abc9-d91ad4c7ad81">74</ix:nonFraction> and <ix:nonFraction unitRef="security" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfMTUzNw_a0dd9427-6cfc-421a-86b1-5d18f49c1253">113</ix:nonFraction> debt securities, respectively, that were in an unrealized loss position for less than one year. We did <ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfMTY0Mw_3b2d765f-223e-45ae-8907-08d82317925f"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:FinancingReceivableAllowanceForCreditLosses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfMTY0Mw_c149330c-7afd-45ea-9447-7b762377d58d">no</ix:nonFraction></ix:nonFraction>t record an allowance for credit losses as of September&#160;30, 2020 and December&#160;31, 2019 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at September&#160;30, 2020 and December&#160;31, 2019 was $<ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfMTgyMg_dbdb2bc1-c76f-4bd9-b1a9-03b2cd9532a6">247.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfMTgyOQ_3ef5dc6d-66af-462d-9809-50715681cc7e">345.7</ix:nonFraction> million, respectively. There were <ix:nonFraction unitRef="security" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfMTg1OA_0216e6b3-9349-4f15-a867-6efb03e88505"><ix:nonFraction unitRef="security" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfMTg1OA_87ab21aa-d9b2-4e85-b9c8-2c1eeaed5246">no</ix:nonFraction></ix:nonFraction> individual securities that were in a significant unrealized loss position as of September&#160;30, 2020 and December&#160;31, 2019. Given our intent and ability to hold such securities until recovery, and the lack of significant change in the credit risk of these investments, we do not consider these marketable securities to be impaired as of September&#160;30, 2020 and December&#160;31, 2019.</span></div></ix:continuation><div id="i4174004101c4483bbd134be7ce58ff32_46"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80Ni9mcmFnOmE0OTYzZjE3ZjlhNDQxZjA4ZThhMjBmNTk5ZWYyYmIxL3RleHRyZWdpb246YTQ5NjNmMTdmOWE0NDFmMDhlOGEyMGY1OTllZjJiYjFfMTA3_5fc38e43-9918-4641-96ff-2fbc96585de3" continuedAt="i29498ca6cb104edb8e3b5b49c6461751" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="i29498ca6cb104edb8e3b5b49c6461751"><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80Ni9mcmFnOmE0OTYzZjE3ZjlhNDQxZjA4ZThhMjBmNTk5ZWYyYmIxL3RleHRyZWdpb246YTQ5NjNmMTdmOWE0NDFmMDhlOGEyMGY1OTllZjJiYjFfMTA4_a383f5b8-8126-478e-897c-73c7d1fcdf74" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, which consists of commercial supply of TIBSOVO&#174;, consists of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80Ni9mcmFnOmE0OTYzZjE3ZjlhNDQxZjA4ZThhMjBmNTk5ZWYyYmIxL3RhYmxlOjgwMmViNjc0Nzc3NTQ5NDFhNWJiODdmNGMzNDI4N2FmL3RhYmxlcmFuZ2U6ODAyZWI2NzQ3Nzc1NDk0MWE1YmI4N2Y0YzM0Mjg3YWZfMS0xLTEtMS0w_e778d392-5a2d-4703-ac00-55959cd346ea">1,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80Ni9mcmFnOmE0OTYzZjE3ZjlhNDQxZjA4ZThhMjBmNTk5ZWYyYmIxL3RhYmxlOjgwMmViNjc0Nzc3NTQ5NDFhNWJiODdmNGMzNDI4N2FmL3RhYmxlcmFuZ2U6ODAyZWI2NzQ3Nzc1NDk0MWE1YmI4N2Y0YzM0Mjg3YWZfMS0zLTEtMS0w_625d2909-c889-4d36-879d-74424966c2c2">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80Ni9mcmFnOmE0OTYzZjE3ZjlhNDQxZjA4ZThhMjBmNTk5ZWYyYmIxL3RhYmxlOjgwMmViNjc0Nzc3NTQ5NDFhNWJiODdmNGMzNDI4N2FmL3RhYmxlcmFuZ2U6ODAyZWI2NzQ3Nzc1NDk0MWE1YmI4N2Y0YzM0Mjg3YWZfMi0xLTEtMS0w_556dda90-7b21-4a40-900b-0a6caadf65da">9,166</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80Ni9mcmFnOmE0OTYzZjE3ZjlhNDQxZjA4ZThhMjBmNTk5ZWYyYmIxL3RhYmxlOjgwMmViNjc0Nzc3NTQ5NDFhNWJiODdmNGMzNDI4N2FmL3RhYmxlcmFuZ2U6ODAyZWI2NzQ3Nzc1NDk0MWE1YmI4N2Y0YzM0Mjg3YWZfMi0zLTEtMS0w_03e8d3fb-fcab-465c-9df7-a979b8c2b7ee">6,808</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80Ni9mcmFnOmE0OTYzZjE3ZjlhNDQxZjA4ZThhMjBmNTk5ZWYyYmIxL3RhYmxlOjgwMmViNjc0Nzc3NTQ5NDFhNWJiODdmNGMzNDI4N2FmL3RhYmxlcmFuZ2U6ODAyZWI2NzQ3Nzc1NDk0MWE1YmI4N2Y0YzM0Mjg3YWZfMy0xLTEtMS0w_0b2c1dda-0b01-4f83-a364-b08b4502f943">799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80Ni9mcmFnOmE0OTYzZjE3ZjlhNDQxZjA4ZThhMjBmNTk5ZWYyYmIxL3RhYmxlOjgwMmViNjc0Nzc3NTQ5NDFhNWJiODdmNGMzNDI4N2FmL3RhYmxlcmFuZ2U6ODAyZWI2NzQ3Nzc1NDk0MWE1YmI4N2Y0YzM0Mjg3YWZfMy0zLTEtMS0w_0480a7df-2624-4e4d-b1a2-0a99dd6e908d">343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80Ni9mcmFnOmE0OTYzZjE3ZjlhNDQxZjA4ZThhMjBmNTk5ZWYyYmIxL3RhYmxlOjgwMmViNjc0Nzc3NTQ5NDFhNWJiODdmNGMzNDI4N2FmL3RhYmxlcmFuZ2U6ODAyZWI2NzQ3Nzc1NDk0MWE1YmI4N2Y0YzM0Mjg3YWZfNC0xLTEtMS0w_712d26f1-6dd7-4426-b809-df0aacdbf822">11,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80Ni9mcmFnOmE0OTYzZjE3ZjlhNDQxZjA4ZThhMjBmNTk5ZWYyYmIxL3RhYmxlOjgwMmViNjc0Nzc3NTQ5NDFhNWJiODdmNGMzNDI4N2FmL3RhYmxlcmFuZ2U6ODAyZWI2NzQ3Nzc1NDk0MWE1YmI4N2Y0YzM0Mjg3YWZfNC0zLTEtMS0w_7b67bd16-1080-4857-8585-23e533a54b3e">7,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i4174004101c4483bbd134be7ce58ff32_49"></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfMTM5NA_5a3838c8-069c-4758-b768-0d2d54f8ccc7" continuedAt="i0a396333f4a94c29aa23240cb332f2f3" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i0a396333f4a94c29aa23240cb332f2f3" continuedAt="ifd2eaeb84b474bccbe8a41518c7f61a4"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our building leases are comprised of office and laboratory space under non-cancelable operating leases. These lease agreements have remaining lease terms of <ix:nonNumeric contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfMTcy_ba70f1b5-67da-4b55-83f0-f59dfa44df0c">seven years</ix:nonNumeric> and contain various clauses for renewal at our option. The renewal options were not included in the calculation of the operating lease assets and the operating lease liabilities as the renewal options are not reasonably certain of being exercised. The lease agreements do not contain residual value guarantees. Operating lease costs for the three and nine months ended September 30, 2020 were $<ix:nonFraction unitRef="usd" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfNTIy_576672f1-8f55-4388-83fd-9d7a72336e8c">3.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfNTI5_163e1b43-4418-4c38-97d8-434cd519a74a">11.4</ix:nonFraction>&#160;million, respectively, and cash paid for amounts included in the measurement of operating lease liabilities for the three and nine months ended September 30, 2020 were $<ix:nonFraction unitRef="usd" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfNjQ4_aaab4d64-6fcf-40ea-96a1-d46e858fb4ff">3.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfNjU1_ae8595de-a632-46e3-a100-d1e262a2519f">10.9</ix:nonFraction>&#160;million, respectively. Operating lease costs for the three and nine months ended September 30, 2019 were $<ix:nonFraction unitRef="usd" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfMTA5OTUxMTYyOTE5NQ_b0be073f-3ea2-40ec-93a9-fe32a4a68e53">3.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfMTA5OTUxMTYyOTIwMg_dcb8121f-965a-4c4e-bb04-5032e775187e">10.6</ix:nonFraction>&#160;million, respectively, and cash paid for amounts included in the measurement of operating lease liabilities for the three and nine months ended September 30, 2019 were $<ix:nonFraction unitRef="usd" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfMTA5OTUxMTYyOTIyOQ_4a45d367-86d4-4d48-91be-c33eedc1f762">2.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfMTA5OTUxMTYyOTIzNw_a5d44e70-6b06-42d7-8519-4ec27e675f0a">8.5</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not entered into any material short-term leases or financing leases as of September&#160;30, 2020.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><ix:continuation id="ifd2eaeb84b474bccbe8a41518c7f61a4" continuedAt="i0e6d19984a7d4921a5b513f32d402866"><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfMTM5Ng_3fab3faf-d7ae-44f5-b4ab-ff3a686c84c3" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, undiscounted minimum rental commitments under non-cancelable leases, for each of the next five years and total thereafter were as follows:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RhYmxlOjI0ZDVhYzYzMmI4NTQzYzlhNTExNjM5YTBjNzgxMGJhL3RhYmxlcmFuZ2U6MjRkNWFjNjMyYjg1NDNjOWE1MTE2MzlhMGM3ODEwYmFfMS0xLTEtMS0w_86114459-db9d-47ec-88bc-b3130f250582">2,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RhYmxlOjI0ZDVhYzYzMmI4NTQzYzlhNTExNjM5YTBjNzgxMGJhL3RhYmxlcmFuZ2U6MjRkNWFjNjMyYjg1NDNjOWE1MTE2MzlhMGM3ODEwYmFfMi0xLTEtMS0w_5cb011ae-c94e-40d1-936d-dcbe7472d11a">14,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RhYmxlOjI0ZDVhYzYzMmI4NTQzYzlhNTExNjM5YTBjNzgxMGJhL3RhYmxlcmFuZ2U6MjRkNWFjNjMyYjg1NDNjOWE1MTE2MzlhMGM3ODEwYmFfMy0xLTEtMS0w_4bae0d89-04a7-4d36-8815-b721dcc75b30">16,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RhYmxlOjI0ZDVhYzYzMmI4NTQzYzlhNTExNjM5YTBjNzgxMGJhL3RhYmxlcmFuZ2U6MjRkNWFjNjMyYjg1NDNjOWE1MTE2MzlhMGM3ODEwYmFfNC0xLTEtMS0w_5c716656-000f-4265-8d48-3a1954797f65">18,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RhYmxlOjI0ZDVhYzYzMmI4NTQzYzlhNTExNjM5YTBjNzgxMGJhL3RhYmxlcmFuZ2U6MjRkNWFjNjMyYjg1NDNjOWE1MTE2MzlhMGM3ODEwYmFfNS0xLTEtMS0w_283ed00a-fb32-4cca-ba69-971f95d701bb">18,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RhYmxlOjI0ZDVhYzYzMmI4NTQzYzlhNTExNjM5YTBjNzgxMGJhL3RhYmxlcmFuZ2U6MjRkNWFjNjMyYjg1NDNjOWE1MTE2MzlhMGM3ODEwYmFfNi0xLTEtMS0w_031db82e-6f98-43a9-9567-badac4b22a44">19,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RhYmxlOjI0ZDVhYzYzMmI4NTQzYzlhNTExNjM5YTBjNzgxMGJhL3RhYmxlcmFuZ2U6MjRkNWFjNjMyYjg1NDNjOWE1MTE2MzlhMGM3ODEwYmFfNy0xLTEtMS0w_3cd99c30-2372-4757-9d0d-5eecc2446b3f">44,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undiscounted minimum rental commitments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RhYmxlOjI0ZDVhYzYzMmI4NTQzYzlhNTExNjM5YTBjNzgxMGJhL3RhYmxlcmFuZ2U6MjRkNWFjNjMyYjg1NDNjOWE1MTE2MzlhMGM3ODEwYmFfOC0xLTEtMS0w_67fda882-5f77-470f-b00f-e8acf55e3b69">134,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RhYmxlOjI0ZDVhYzYzMmI4NTQzYzlhNTExNjM5YTBjNzgxMGJhL3RhYmxlcmFuZ2U6MjRkNWFjNjMyYjg1NDNjOWE1MTE2MzlhMGM3ODEwYmFfOS0xLTEtMS0w_01e896d8-b5e1-45fe-82e7-8b00b283411e">27,621</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RhYmxlOjI0ZDVhYzYzMmI4NTQzYzlhNTExNjM5YTBjNzgxMGJhL3RhYmxlcmFuZ2U6MjRkNWFjNjMyYjg1NDNjOWE1MTE2MzlhMGM3ODEwYmFfMTAtMS0xLTEtMA_074c0072-50ab-4ed5-827f-94d093bda10f">106,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0e6d19984a7d4921a5b513f32d402866">In arriving at the operating lease liabilities as of September&#160;30, 2020 and December&#160;31, 2019, we applied the weighted-average incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfMTMwMQ_81d50b24-d28d-4645-8699-e305da5b9e05"><ix:nonFraction unitRef="number" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfMTMwMQ_b0a1ae7c-0e6b-4401-901f-65357a2a4c69">5.7</ix:nonFraction></ix:nonFraction>% for both periods over a weighted-average remaining lease term of <ix:nonNumeric contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfMTM2OQ_117e71b4-1bd2-4be7-84ac-83d15d0fcf0d">7.4</ix:nonNumeric> years and <ix:nonNumeric contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfMTM3Ng_4195e7a1-f3db-4cf0-b592-534f242d0a44">8.2</ix:nonNumeric> years, respectively.</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div id="i4174004101c4483bbd134be7ce58ff32_52"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81Mi9mcmFnOjYwODkxZTQ4ZmEwMjQwZjE5Njk3OThiYTRhYTY2ODE5L3RleHRyZWdpb246NjA4OTFlNDhmYTAyNDBmMTk2OTc5OGJhNGFhNjY4MTlfNzI_e09148e1-b819-4ef0-9b31-c74eae3b7c94" continuedAt="i0657de34b9ea4bcfa788c190c4b84d20" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="i0657de34b9ea4bcfa788c190c4b84d20"><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81Mi9mcmFnOjYwODkxZTQ4ZmEwMjQwZjE5Njk3OThiYTRhYTY2ODE5L3RleHRyZWdpb246NjA4OTFlNDhmYTAyNDBmMTk2OTc5OGJhNGFhNjY4MTlfNzE_55c6e1bd-3c5a-4fb5-b4e2-a62af07538d0" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81Mi9mcmFnOjYwODkxZTQ4ZmEwMjQwZjE5Njk3OThiYTRhYTY2ODE5L3RhYmxlOmMyYzg3Y2YxMjU0ZjQwODRiZTJjZjdmMjkxNDViMzMwL3RhYmxlcmFuZ2U6YzJjODdjZjEyNTRmNDA4NGJlMmNmN2YyOTE0NWIzMzBfMS0xLTEtMS0w_1bc50cf9-0a70-44f0-adc1-6a867a09cbd2">19,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81Mi9mcmFnOjYwODkxZTQ4ZmEwMjQwZjE5Njk3OThiYTRhYTY2ODE5L3RhYmxlOmMyYzg3Y2YxMjU0ZjQwODRiZTJjZjdmMjkxNDViMzMwL3RhYmxlcmFuZ2U6YzJjODdjZjEyNTRmNDA4NGJlMmNmN2YyOTE0NWIzMzBfMS0zLTEtMS0w_3fcbc25f-8d90-4155-83da-02913094fc87">18,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:AccruedResearchAndDevelopmentCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81Mi9mcmFnOjYwODkxZTQ4ZmEwMjQwZjE5Njk3OThiYTRhYTY2ODE5L3RhYmxlOmMyYzg3Y2YxMjU0ZjQwODRiZTJjZjdmMjkxNDViMzMwL3RhYmxlcmFuZ2U6YzJjODdjZjEyNTRmNDA4NGJlMmNmN2YyOTE0NWIzMzBfMi0xLTEtMS0w_dd3856f3-fdba-4f17-af79-0e5d62055cef">16,188</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="agio:AccruedResearchAndDevelopmentCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81Mi9mcmFnOjYwODkxZTQ4ZmEwMjQwZjE5Njk3OThiYTRhYTY2ODE5L3RhYmxlOmMyYzg3Y2YxMjU0ZjQwODRiZTJjZjdmMjkxNDViMzMwL3RhYmxlcmFuZ2U6YzJjODdjZjEyNTRmNDA4NGJlMmNmN2YyOTE0NWIzMzBfMi0zLTEtMS0w_b00181ac-f4b0-4231-a0f5-a837013f12f2">21,777</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81Mi9mcmFnOjYwODkxZTQ4ZmEwMjQwZjE5Njk3OThiYTRhYTY2ODE5L3RhYmxlOmMyYzg3Y2YxMjU0ZjQwODRiZTJjZjdmMjkxNDViMzMwL3RhYmxlcmFuZ2U6YzJjODdjZjEyNTRmNDA4NGJlMmNmN2YyOTE0NWIzMzBfMy0xLTEtMS0w_5d81fce3-cbb7-403d-9484-9c58ea6af02d">3,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81Mi9mcmFnOjYwODkxZTQ4ZmEwMjQwZjE5Njk3OThiYTRhYTY2ODE5L3RhYmxlOmMyYzg3Y2YxMjU0ZjQwODRiZTJjZjdmMjkxNDViMzMwL3RhYmxlcmFuZ2U6YzJjODdjZjEyNTRmNDA4NGJlMmNmN2YyOTE0NWIzMzBfMy0zLTEtMS0w_5a413d24-8627-4973-98fa-f51f000592bf">8,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued revenue-related reserves and other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81Mi9mcmFnOjYwODkxZTQ4ZmEwMjQwZjE5Njk3OThiYTRhYTY2ODE5L3RhYmxlOmMyYzg3Y2YxMjU0ZjQwODRiZTJjZjdmMjkxNDViMzMwL3RhYmxlcmFuZ2U6YzJjODdjZjEyNTRmNDA4NGJlMmNmN2YyOTE0NWIzMzBfNC0xLTEtMS0w_b9701d52-e6fe-4a8b-ae51-11ec72b9b25b">11,018</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81Mi9mcmFnOjYwODkxZTQ4ZmEwMjQwZjE5Njk3OThiYTRhYTY2ODE5L3RhYmxlOmMyYzg3Y2YxMjU0ZjQwODRiZTJjZjdmMjkxNDViMzMwL3RhYmxlcmFuZ2U6YzJjODdjZjEyNTRmNDA4NGJlMmNmN2YyOTE0NWIzMzBfNC0zLTEtMS0w_da175105-0473-410d-82a7-c0dedea3d2a8">4,048</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81Mi9mcmFnOjYwODkxZTQ4ZmEwMjQwZjE5Njk3OThiYTRhYTY2ODE5L3RhYmxlOmMyYzg3Y2YxMjU0ZjQwODRiZTJjZjdmMjkxNDViMzMwL3RhYmxlcmFuZ2U6YzJjODdjZjEyNTRmNDA4NGJlMmNmN2YyOTE0NWIzMzBfNS0xLTEtMS0w_017e514b-fbc1-4a61-a0da-94e9b7b0e71f">49,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81Mi9mcmFnOjYwODkxZTQ4ZmEwMjQwZjE5Njk3OThiYTRhYTY2ODE5L3RhYmxlOmMyYzg3Y2YxMjU0ZjQwODRiZTJjZjdmMjkxNDViMzMwL3RhYmxlcmFuZ2U6YzJjODdjZjEyNTRmNDA4NGJlMmNmN2YyOTE0NWIzMzBfNS0zLTEtMS0w_c8552609-d816-410f-a83d-7b8fc8996ec6">53,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i4174004101c4483bbd134be7ce58ff32_55"></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RleHRyZWdpb246ZDMzYjRkYmEwYmUzNDY3Yzk0ZGE1NjU4MGRhMzRjYmNfNzcy_ac6db41e-8b48-47a0-b716-f4d72c0f8baa" continuedAt="ie6a8d6d40feb4408af03be063ed06870" escape="true">Product Revenue</ix:nonNumeric></span></div><ix:continuation id="ie6a8d6d40feb4408af03be063ed06870" continuedAt="i54c619d6ef96411695f964aadde08c4b"><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RleHRyZWdpb246ZDMzYjRkYmEwYmUzNDY3Yzk0ZGE1NjU4MGRhMzRjYmNfMjQ_08f12fa4-d653-4885-a051-3f6bd78dd194" continuedAt="i102e723e215146bb89b44abaf901d223" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell TIBSOVO&#174;, our wholly owned product, to a limited number of specialty distributors and specialty pharmacy providers, or collectively, the Customers. The Customers subsequently resell TIBSOVO&#174; to pharmacies or dispense directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of TIBSOVO&#174;.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation related to the sale of TIBSOVO&#174; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer. </span></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:6pt"><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RleHRyZWdpb246ZDMzYjRkYmEwYmUzNDY3Yzk0ZGE1NjU4MGRhMzRjYmNfNzYz_75b30aaf-3c53-4361-aa1a-0dc08f15a89f" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i902ffdd5069945e4a1e2d8259b7aa937_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmJlZWNhZTBiMTlmNzRlNzA5YzQ0NGFmMjI1MWY3ZGNjL3RhYmxlcmFuZ2U6YmVlY2FlMGIxOWY3NGU3MDljNDQ0YWYyMjUxZjdkY2NfMi0xLTEtMS0w_ee75e748-f734-4627-b83a-624196f28132">31,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9bd25f418764e27874e4887f9629cba_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmJlZWNhZTBiMTlmNzRlNzA5YzQ0NGFmMjI1MWY3ZGNjL3RhYmxlcmFuZ2U6YmVlY2FlMGIxOWY3NGU3MDljNDQ0YWYyMjUxZjdkY2NfMi0zLTEtMS0w_14f0e384-07e2-4865-a7b3-c9c8d7b102a4">17,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac48a829910e4ec2be6c0709f8ab5d04_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmJlZWNhZTBiMTlmNzRlNzA5YzQ0NGFmMjI1MWY3ZGNjL3RhYmxlcmFuZ2U6YmVlY2FlMGIxOWY3NGU3MDljNDQ0YWYyMjUxZjdkY2NfMi01LTEtMS0w_1e2d87c1-f509-41fb-8b6f-b9d35f67093c">81,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c6da9822264b9abd38a7580c17d5b2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmJlZWNhZTBiMTlmNzRlNzA5YzQ0NGFmMjI1MWY3ZGNjL3RhYmxlcmFuZ2U6YmVlY2FlMGIxOWY3NGU3MDljNDQ0YWYyMjUxZjdkY2NfMi03LTEtMS0w_a2e8e31f-217a-49ae-94d6-f72935291d35">40,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><ix:continuation id="i102e723e215146bb89b44abaf901d223" continuedAt="i15cd19a4955a472d89dd594f28f58ef8"><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reserves for Variable Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><ix:continuation id="i54c619d6ef96411695f964aadde08c4b" continuedAt="iad84686f0d6b43b981ac0ce78d40b938"><ix:continuation id="i15cd19a4955a472d89dd594f28f58ef8"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Adjustments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally provide Customers with discounts, including prompt pay discounts, and allowances that are explicitly stated in the contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from certain Customers.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are estimated using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated channel mix and are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government rebates include Medicare, TriCare, and Medicaid rebates, which we estimate using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Returns</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the amount of product sales that may be returned by Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate product return liabilities using the expected value method, based on available industry data, including our visibility into the inventory remaining in the distribution channel.</span></div></ix:continuation><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RleHRyZWdpb246ZDMzYjRkYmEwYmUzNDY3Yzk0ZGE1NjU4MGRhMzRjYmNfNzY0_4e59fdb3-2899-46a6-adfa-70b0679b2a9d" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government Rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" name="agio:ContractWithCustomerContractualAdjustmentReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfMS0xLTEtMS0w_dc5dc261-5516-4844-b04b-4231802a9b70">874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerRebateReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfMS0zLTEtMS0w_fcd61b56-59e8-45e9-986a-32b6394ffdf6">1,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerRightToRecoverProductReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfMS01LTEtMS0w_6259d6b5-e269-4813-982c-055d66c9068e">1,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerTotalAllowancesAndReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfMS03LTEtMS0w_ff45e6a0-5adc-44d5-b5ed-23556f27353e">3,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provisions relating to sales in the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:CurrentYearProvisionForContractualAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfMi0xLTEtMS0w_522eddaa-4ed6-4ecf-b2a4-0a12c44eacab">10,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:CurrentYearProvisionsForRebateReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfMi0zLTEtMS0w_e5b9ed9f-3554-4630-aa5f-acc8110c9ee1">9,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:ProvisionForRightToRecoverProductInCurrentYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfMi01LTEtMS0w_ef5b15eb-8d98-404a-aca3-42f78aae54a9">1,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerCurrentYearReserveProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfMi03LTEtMS0w_4bf4b870-b705-4264-b941-fdfee0a3c6b9">20,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" sign="-" name="agio:PriorYearProvisionForContractualAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfMy0xLTEtMS0w_7fe1617d-8768-4659-a5d5-6d48db0c9060">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" name="agio:PriorYearProvisionsForRebateReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfMy0zLTEtMS0w_f4d954d0-24a6-44c8-bb6a-be9585b3dd45">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" sign="-" name="agio:ProvisionForRightToRecoverProductInPriorYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfMy01LTEtMS0w_2fe219b1-8484-4517-9dba-c4d77342869d">476</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" sign="-" name="agio:ContractWithCustomerPriorYearsReserveProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfMy03LTEtMS0w_07e63720-addb-4ed8-a14c-5bdaf5a74032">357</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/returns relating to sales in the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfNC0xLTEtMS0w_fe45262c-2f44-4213-a194-87d96ea5eb6d">8,966</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerRebateReserveRecoveriesInCurrentYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfNC0zLTEtMS0w_e9032865-2812-493c-84a8-b1f7e546dd90">2,260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="agio:ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfNC01LTEtMS0w_0fdeb7e5-f8f9-4c9a-971f-40485d0e5adf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerCurrentYearReserveRecoveries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfNC03LTEtMS0w_a679110c-dbd9-4a73-b733-3762678c536e">11,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/returns relating to sales in the prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" name="agio:ContractWithCustomerContractAdjustmentRecoveriesPriorYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfNS0xLTEtMS0w_60ef4c40-2f8c-4c2c-b611-4bff47c7ab78">653</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" name="agio:ContractWithCustomerRebateReserveRecoveriesInPriorYears" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfNS0zLTEtMS0w_0db31c74-4807-4397-a9ad-243913b46d50">677</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="agio:ContractWithCustomerRightToRecoverProductPriorYearRecoveries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfNS01LTEtMS0w_f66842f2-4bbf-43a8-a6e8-4ff2e71019aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerPriorYearsReserveRecoveries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfNS03LTEtMS0w_9716a988-d2a0-430a-81bc-2b94d8fce31a">1,330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerContractualAdjustmentReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfNi0xLTEtMS0w_1c1d55a2-4d33-49bc-96f0-19703f0ad5c3">1,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerRebateReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfNi0zLTEtMS0w_c437dcf7-6800-4afa-8dab-fbb04c511ba0">7,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerRightToRecoverProductReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfNi01LTEtMS0w_b3760b61-62a3-438f-9a68-f6a8ff0a561a">2,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerTotalAllowancesAndReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfNi03LTEtMS0w_598151ce-8a0f-4301-83e0-ade6dcacd597">11,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="agio:ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RleHRyZWdpb246ZDMzYjRkYmEwYmUzNDY3Yzk0ZGE1NjU4MGRhMzRjYmNfNzcw_b08a1ab5-9a7f-4596-941e-dc0b72caa89f" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue-related reserves above, included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOjNkNGQ2ODg4MzQwMjRlMGVhNTRiMGJmMTE4NzNmOGYzL3RhYmxlcmFuZ2U6M2Q0ZDY4ODgzNDAyNGUwZWE1NGIwYmYxMTg3M2Y4ZjNfMS0xLTEtMS0w_ccfa7bdb-29c2-4891-a630-0a2d2e3159dc">732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOjNkNGQ2ODg4MzQwMjRlMGVhNTRiMGJmMTE4NzNmOGYzL3RhYmxlcmFuZ2U6M2Q0ZDY4ODgzNDAyNGUwZWE1NGIwYmYxMTg3M2Y4ZjNfMS0zLTEtMS0w_2a1c73a8-c682-4471-a30f-25c92c3961b6">540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Component of accrued expenses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerAllowanceAndReservesLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOjNkNGQ2ODg4MzQwMjRlMGVhNTRiMGJmMTE4NzNmOGYzL3RhYmxlcmFuZ2U6M2Q0ZDY4ODgzNDAyNGUwZWE1NGIwYmYxMTg3M2Y4ZjNfMi0xLTEtMS0w_a9f5c00c-4c4e-4087-bf69-5aaa372b87db">11,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerAllowanceAndReservesLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOjNkNGQ2ODg4MzQwMjRlMGVhNTRiMGJmMTE4NzNmOGYzL3RhYmxlcmFuZ2U6M2Q0ZDY4ODgzNDAyNGUwZWE1NGIwYmYxMTg3M2Y4ZjNfMi0zLTEtMS0w_231819f4-c222-4f92-9470-2a15541ecb76">3,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerTotalAllowancesAndReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOjNkNGQ2ODg4MzQwMjRlMGVhNTRiMGJmMTE4NzNmOGYzL3RhYmxlcmFuZ2U6M2Q0ZDY4ODgzNDAyNGUwZWE1NGIwYmYxMTg3M2Y4ZjNfMy0xLTEtMS0w_d3a0ccc4-b6ed-4110-b025-9288c94d1dd7">11,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerTotalAllowancesAndReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOjNkNGQ2ODg4MzQwMjRlMGVhNTRiMGJmMTE4NzNmOGYzL3RhYmxlcmFuZ2U6M2Q0ZDY4ODgzNDAyNGUwZWE1NGIwYmYxMTg3M2Y4ZjNfMy0zLTEtMS0w_dd704dba-c113-4768-9a6d-a77637fb0db1">3,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="agio:ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RleHRyZWdpb246ZDMzYjRkYmEwYmUzNDY3Yzk0ZGE1NjU4MGRhMzRjYmNfNzYy_10875acd-7e0a-4bf4-b1fa-a73cb7a27e58" continuedAt="ia41152f20872453f99982b876ede31b2" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in our contract assets during the nine months ended September 30, 2020:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOjJkMDYyNWYzNDdkOTRlZWQ5ZjBmNjIyODBhMGQ3YzdkL3RhYmxlcmFuZ2U6MmQwNjI1ZjM0N2Q5NGVlZDlmMGY2MjI4MGEwZDdjN2RfMi0xLTEtMS0w_2c82a61d-4cb2-4e26-95d7-f907929e8a3a">8,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerAssetRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOjJkMDYyNWYzNDdkOTRlZWQ5ZjBmNjIyODBhMGQ3YzdkL3RhYmxlcmFuZ2U6MmQwNjI1ZjM0N2Q5NGVlZDlmMGY2MjI4MGEwZDdjN2RfMi0zLTEtMS0w_f4f0a6f6-5803-4b53-9d96-5afc597a692d">102,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOjJkMDYyNWYzNDdkOTRlZWQ5ZjBmNjIyODBhMGQ3YzdkL3RhYmxlcmFuZ2U6MmQwNjI1ZjM0N2Q5NGVlZDlmMGY2MjI4MGEwZDdjN2RfMi01LTEtMS0w_2752d308-0af7-4e31-a344-e0e3be98626f">92,467</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOjJkMDYyNWYzNDdkOTRlZWQ5ZjBmNjIyODBhMGQ3YzdkL3RhYmxlcmFuZ2U6MmQwNjI1ZjM0N2Q5NGVlZDlmMGY2MjI4MGEwZDdjN2RfMi03LTEtMS0w_755c6338-bb8c-4cb9-8ecd-125c5b61cde0">18,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="iad84686f0d6b43b981ac0ce78d40b938"><ix:continuation id="ia41152f20872453f99982b876ede31b2">(1)  Additions to contract assets relate to amounts billed to Customers for product sales and deductions to contract assets primarily relate to collection of receivables during the reporting period.</ix:continuation></ix:continuation> </span></div><div id="i4174004101c4483bbd134be7ce58ff32_58"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTEyMjA_3eee5f2b-1897-4d50-8b10-09fda6b1942b" continuedAt="ib3571edc233843569c37d4be3938be66" escape="true">Collaboration and License Agreements </ix:nonNumeric></span></div><ix:continuation id="ib3571edc233843569c37d4be3938be66" continuedAt="i572d792315c14e5ab0d0cf83df359d94"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting analysis and revenue recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration and license agreements typically involve us granting licenses of our intellectual property and performing research and development services in exchange of upfront fees, milestone payments and royalty payments. Since December 31, </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><ix:continuation id="i572d792315c14e5ab0d0cf83df359d94" continuedAt="i3a0e9b3a96b04df291e777144bdc212e"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019, there have been no material changes to the key terms of our collaboration or license agreements. For further information on the terms and conditions of our existing collaboration and license agreements, please see the notes to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized, we performed the following steps: (i) identified the promised goods or services in the contract; (ii) determined whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measured the transaction price, including the constraint on variable consideration; (iv) allocated the transaction price to the performance obligations; and (v) recognized revenue when (or as) we satisfied each performance obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties and sales-based milestones and in which the license is deemed to be the predominant item to which the royalties relate, we recognize royalty revenue upon the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestone revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting period we evaluate whether milestones are considered probable of being reached and, to the extent that a significant reversal would not occur in future periods, estimate the amount to be included in the transaction price using the most likely amount method.&#160;Milestone payments that are not within our control, such as regulatory approvals, are considered constrained and are excluded from the transaction price until those approvals are received.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Celgene Corporation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into the following collaboration agreements, or collectively, the Collaboration Agreements, with Celgene, a wholly owned subsidiary of BMS, which is a related party through ownership of our common stock: </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2010, we entered into a discovery and development collaboration and license agreement focused on cancer metabolism, or the 2010 Agreement, which was amended in October 2011 and July 2014. The discovery phase of the 2010 Agreement expired in April 2016. On August 15, 2016, we terminated the 2010 Agreement as to the program directed to the isocitrate dehydrogenase 1, or IDH1, target, for which ivosidenib was the lead development candidate. Accordingly, the sole program remaining under the 2010 Agreement is IDHIFA&#174; (enasidenib), a co-commercialized licensed program for which Celgene leads and funds global development and commercialization activities. On June 11, 2020, we sold our tiered, sales-based royalty rights on worldwide net sales of IDHIFA&#174; (enasidenib), as well as our rights to receive up to $<ix:nonFraction unitRef="usd" contextRef="ife55cfc6e645489a9aa97a13da6dfe00_I20200611" decimals="INF" format="ixt:numdotdecimal" name="agio:RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMzM4MQ_ff89900f-bfc8-49e4-b3c4-a7c4dd117e27">55.0</ix:nonFraction>&#160;million in outstanding regulatory milestone payments from BMS, to RPI for $<ix:nonFraction unitRef="usd" contextRef="ib2575fe6eebf402cbdb0a3e5509d729d_D20200611-20200611" decimals="-5" format="ixt:numdotdecimal" name="agio:ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMzQ1MA_2266f1d8-2597-41af-b0ed-e4262f399fbf">255.0</ix:nonFraction>&#160;million. Under the 2010 Agreement, we remain eligible to receive a $<ix:nonFraction unitRef="usd" contextRef="idf22f68ca84c40088ac574f70d88d77d_I20200930" decimals="-5" format="ixt:numdotdecimal" name="agio:RevenueRecognitionMilestoneMethodEligibleReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMzUxMg_25b26e4b-7bc3-4c17-93cd-5200be855d81">25.0</ix:nonFraction>&#160;million potential milestone payment for the enasidenib program upon achievement of a specified ex-U.S. commercial milestone event, as well as reimbursement for costs incurred for our co-commercialization efforts and development activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April&#160;2015, we entered into a joint worldwide development and profit share collaboration and license agreement with Celgene, and our wholly owned subsidiary, Agios International Sarl, entered into a collaboration and license agreement with Celgene International II Sarl, or collectively, the AG-881 Agreements, to establish a worldwide collaboration focused on the development and commercialization of vorasidenib products. Under the AG-881 Agreements, we and Celgene split all worldwide development costs for vorasidenib, subject to specified exceptions. The AG-881 Agreements were terminated effective September 4, 2018, upon which we received sole global rights to vorasidenib. In connection with the termination of the AG-881 Agreements, Celgene will be eligible to receive royalties from us at a low single-digit percentage rate on worldwide net sales of products containing vorasidenib.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">In May&#160;2016, we entered into a master research and collaboration agreement with Celgene, or the 2016 Agreement, focused on metabolic immuno-oncology, or MIO, a developing field which aims to modulate the activity of relevant immune cells by targeting critical metabolic nodes, thereby enhancing the immune mediated anti-tumor response. The initial <ix:nonNumeric contextRef="i5e16d3756d704760a00e78beb3a53457_D20160501-20160531" format="ixt-sec:durwordsen" name="agio:RevenueRecognitionMultipleDeliverableArrangementsTermOfAgreement" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTEyMTQ_db325fa4-46ad-4635-8a40-2937a43513a2">four-year</ix:nonNumeric> research term of the 2016 Agreement ended May 2020. On March 25, 2020 Celgene declined the option to extend the research agreement for up to <ix:nonFraction unitRef="extension" contextRef="i5e16d3756d704760a00e78beb3a53457_D20160501-20160531" decimals="INF" format="ixt-sec:numwordsen" name="agio:RevenueRecognitionMultipleDeliverableArrangementsNumberOfExtensions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfNTEzMQ_c903b800-0b60-43ef-b224-1103c5506871">two</ix:nonFraction>, or in specified cases, up to <ix:nonFraction unitRef="extension" contextRef="i5e16d3756d704760a00e78beb3a53457_D20160501-20160531" decimals="INF" format="ixt-sec:numwordsen" name="agio:RevenueRecognitionMultipleDeliverableArrangementsNumberOfSpecialCaseExtensions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfNTE2NA_7ed16c67-87fb-49dc-bc61-a2774a177ceb">four</ix:nonFraction> additional <ix:nonNumeric contextRef="i5e16d3756d704760a00e78beb3a53457_D20160501-20160531" format="ixt-sec:durwordsen" name="agio:RevenueRecognitionMultipleDeliverableArrangementsSpecialCaseExtensionTerm" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTEyMjM_42a5f61c-0aef-42ca-8936-a21cbc6726e1">one-year</ix:nonNumeric> terms which would have required the payment of a $<ix:nonFraction unitRef="usd" contextRef="i5e16d3756d704760a00e78beb3a53457_D20160501-20160531" decimals="INF" format="ixt:numdotdecimal" name="agio:UpfrontPaymentAgreementExtensionFeeReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfNTIzNQ_e4c0f41f-16dd-411c-b855-5926621c6ce7">40.0</ix:nonFraction>&#160;million extension fee. Further, on April 10, 2020 Celgene notified us that they will be declining to elect any program as a continuation program under the 2016 agreement. Celgene had designated AG-270, our inhibitor of methionine adenosyltransferase 2a, or MAT2A, as a development candidate under the 2016 Agreement. On March 25, 2020, Celgene notified us of their decision to decline their option to enter into a Development &amp; Commercialization Agreement with respect to the MAT2A program under the 2016 Agreement which </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><ix:continuation id="i3a0e9b3a96b04df291e777144bdc212e" continuedAt="i3a652bde11ab4a30bd84b4547bfeebbf"><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">would have required the payment of a $<ix:nonFraction unitRef="usd" contextRef="ic19c9efe1bc441b28792cb1fb430006c_I20160531" decimals="INF" format="ixt:numdotdecimal" name="agio:OptionExerciseFeeReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfNTc4OA_929b3e08-4a51-42d4-8eca-4741c5571b73">30.0</ix:nonFraction>&#160;million fee. As a result of the decisions, the research services were fully satisfied as of May 17, 2020, no additional performance obligations remain under the 2016 Agreement and we are no longer eligible for any milestone payments for the 2016 Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration revenue</span></div><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="agio:RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfNTQ5NzU1ODE1MDExNg_5a448beb-c813-4a06-a5c0-1806d96c4a2b" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2020 and 2019, we recognized the following collaboration revenue:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Services performed that were considered performance obligations as of the modification dates</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On-going research and development services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bbc2d1419c542459a401e63c7eca48e_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjYwYjBkYjFmZmU4ZTQ3NDRhMDIwNTQ4ODBlZjU4ZmQ3L3RhYmxlcmFuZ2U6NjBiMGRiMWZmZThlNDc0NGEwMjA1NDg4MGVmNThmZDdfNC0xLTEtMS0w_b1f5b22b-61fd-4ce0-8281-bd5f608adc67">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d3c6ff3eaa4f96a6b43c3884afbdd5_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjYwYjBkYjFmZmU4ZTQ3NDRhMDIwNTQ4ODBlZjU4ZmQ3L3RhYmxlcmFuZ2U6NjBiMGRiMWZmZThlNDc0NGEwMjA1NDg4MGVmNThmZDdfNC0zLTEtMS0w_c808cfea-fc22-4331-848f-26446731789a">4,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i635a87f89b85400aa10e6ca171a7869f_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjYwYjBkYjFmZmU4ZTQ3NDRhMDIwNTQ4ODBlZjU4ZmQ3L3RhYmxlcmFuZ2U6NjBiMGRiMWZmZThlNDc0NGEwMjA1NDg4MGVmNThmZDdfNC01LTEtMS0w_bfee0931-a9f2-4f96-805f-8c1db021c773">64,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a9429c5ed7c4eafa27ec8b3c0962e9c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjYwYjBkYjFmZmU4ZTQ3NDRhMDIwNTQ4ODBlZjU4ZmQ3L3RhYmxlcmFuZ2U6NjBiMGRiMWZmZThlNDc0NGEwMjA1NDg4MGVmNThmZDdfNC03LTEtMS0w_f05eef96-2172-4c54-9223-5f9332b570d1">29,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Services performed that were not considered performance obligations as of the modification dates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercialization activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i231960ca9c014f48bb976e41d6c6d505_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjYwYjBkYjFmZmU4ZTQ3NDRhMDIwNTQ4ODBlZjU4ZmQ3L3RhYmxlcmFuZ2U6NjBiMGRiMWZmZThlNDc0NGEwMjA1NDg4MGVmNThmZDdfOC0xLTEtMS0w_c5128e62-5cbb-43bc-94fe-a680e2e50444">1,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i332309b5d2244ef5b9ecb08809dcbd9f_D20190701-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjYwYjBkYjFmZmU4ZTQ3NDRhMDIwNTQ4ODBlZjU4ZmQ3L3RhYmxlcmFuZ2U6NjBiMGRiMWZmZThlNDc0NGEwMjA1NDg4MGVmNThmZDdfOC0zLTEtMS0w_88c341bb-f09b-40b8-8035-00e00db691b9">821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85fcfba1e36545e493bcf708b4e9df68_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjYwYjBkYjFmZmU4ZTQ3NDRhMDIwNTQ4ODBlZjU4ZmQ3L3RhYmxlcmFuZ2U6NjBiMGRiMWZmZThlNDc0NGEwMjA1NDg4MGVmNThmZDdfOC01LTEtMS0w_a88cfbf4-add9-4d67-8c22-a9459bafd59b">2,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b78993cbec4481bbc686cda5de776b1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjYwYjBkYjFmZmU4ZTQ3NDRhMDIwNTQ4ODBlZjU4ZmQ3L3RhYmxlcmFuZ2U6NjBiMGRiMWZmZThlNDc0NGEwMjA1NDg4MGVmNThmZDdfOC03LTEtMS0w_f479db40-6285-4444-8ffa-6707fcb8d3a3">2,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue - related party</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6645fba9caf44b8b8bcb42c98bf2278_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjYwYjBkYjFmZmU4ZTQ3NDRhMDIwNTQ4ODBlZjU4ZmQ3L3RhYmxlcmFuZ2U6NjBiMGRiMWZmZThlNDc0NGEwMjA1NDg4MGVmNThmZDdfOS0xLTEtMS0w_16dcb823-d09c-4ee0-9b5c-318e1b6e6d80">1,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia038c518019748b78ce08495d4f16d87_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjYwYjBkYjFmZmU4ZTQ3NDRhMDIwNTQ4ODBlZjU4ZmQ3L3RhYmxlcmFuZ2U6NjBiMGRiMWZmZThlNDc0NGEwMjA1NDg4MGVmNThmZDdfOS0zLTEtMS0w_c1207584-61fc-4f30-b862-99ee9a37266b">5,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6be33be9efa74778b57706d8c1dc08f4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjYwYjBkYjFmZmU4ZTQ3NDRhMDIwNTQ4ODBlZjU4ZmQ3L3RhYmxlcmFuZ2U6NjBiMGRiMWZmZThlNDc0NGEwMjA1NDg4MGVmNThmZDdfOS01LTEtMS0w_c456af71-3e88-4c08-a7b1-a1362d250c2f">67,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5a1fdf43a234d5c9fb4b6957bdd5c72_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjYwYjBkYjFmZmU4ZTQ3NDRhMDIwNTQ4ODBlZjU4ZmQ3L3RhYmxlcmFuZ2U6NjBiMGRiMWZmZThlNDc0NGEwMjA1NDg4MGVmNThmZDdfOS03LTEtMS0w_de937e21-308c-4e8f-b5f9-5d2dee30eff5">32,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfNTQ5NzU1ODE1MDExNw_ec0afbfe-6aff-4962-92f3-f16319417288" continuedAt="i157e1321137d4d829c36b7400ce21394" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in our contract assets and liabilities during the nine months ended September 30, 2020:</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration receivable &#8211; related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21cd91eb1d2842528666b7c51b692515_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfMi0xLTEtMS0w_b68bd2b2-f843-4481-8f3d-92d602234c4b">1,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i822eacbd7a3140f7a5ad55739d7525b2_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerAssetRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfMi0zLTEtMS0w_38aaba32-2320-40c0-8ad9-8e0c2cd15caa">4,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i822eacbd7a3140f7a5ad55739d7525b2_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfMi01LTEtMS0w_829fae80-6c8c-4af8-82f2-7836d56d4ab2">4,693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60e99bcf39eb4a1198ea4cb7a6f6bc0c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfMi03LTEtMS0w_79bdc941-2faa-490d-98d8-1c99dbccca9e">1,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unbilled receivable - related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11fc8fb499ea4d2cb1eb548dd4ca43db_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfMy0xLTEtMS0w_e80684a0-fd1a-4d9f-be43-3b770cbf8749">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f99babce6584b2ba9dc951305e2fc7b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerAssetRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfMy0zLTEtMS0w_64a5d84f-ed02-4a5c-b57c-eaef7416283d">1,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f99babce6584b2ba9dc951305e2fc7b_D20200101-20200930" decimals="-3" name="agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfMy01LTEtMS0w_8af1b3bb-c37e-4688-8805-b36b8822661c">346</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id771f4009bfa4c4bbdedf06974f817e1_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfMy03LTEtMS0w_29aa65fe-c902-4b0a-a6c1-1afb456a09fa">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty receivable &#8211; related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id866c85fcea34845a31e92f2f2b956a9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfNC0xLTEtMS0w_93141477-2af3-463f-baba-a28ae4952fa7">2,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ed0f7fca6824f939606850129df11d9_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerAssetRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfNC0zLTEtMS0w_e2f6a3aa-a8ca-400a-8b4b-39df9e809f61">5,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ed0f7fca6824f939606850129df11d9_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfNC01LTEtMS0w_2a9761a6-f568-482d-92c5-92db8a79dc7f">7,915</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b35d322903843578f6a68da48ebf6bb_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfNC03LTEtMS0w_87f87218-85e7-4b80-bc4a-dfbdad1e2ecc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue &#8211; related party, current and net of current portions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib908b1f10858485dad4c2ae0e63c92ea_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfNi0xLTEtMS0w_7c0a5273-7798-4ac0-9a3f-7904593d3832">61,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f701a2e0cb4e8b8665c215666a581f_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfNi0zLTEtMS0w_07828c32-9f11-41f1-9199-44803c73763d">2,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99f701a2e0cb4e8b8665c215666a581f_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfNi01LTEtMS0w_0b0786ea-d82a-46b6-84f2-02ffe38bf51e">63,934</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d069dedee94effb0e3fe4e2557d773_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfNi03LTEtMS0w_d146bcb2-0138-4a68-87b6-ed0751ae61fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1)  Additions to collaboration receivables - related party relate to amounts billed to Celgene for reimbursable costs incurred by us during the reporting period. Deductions to receivables relate to collection of receivables during the reporting period.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(2)  Unbilled receivables - related party amounts relate to future reimbursable costs to Celgene.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)  Additions to royalty receivables - related party relate to amounts billed to Celgene during the reporting period. Deductions to receivables relate to collection of receivables during the reporting period. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)  Additions to deferred revenue - related party relate to consideration from Celgene during the reporting period. Deductions relate to deferred revenue recognized as revenue during the reporting period.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in collaboration revenue from on-going research and development services during the three and nine months ended September&#160;30, 2020 is primarily due to our updated estimate of the future costs that would be incurred from on-going research and development services to complete one of our performance obligations under the 2016 Agreement that is recognized over time using an input method, due to Celgene&#8217;s decision to decline extending the research term in the first quarter of 2020.</span></div><ix:continuation id="i157e1321137d4d829c36b7400ce21394"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2020 and 2019, we recognized the following as revenue due to changes in the contract liability balances:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts included in the contract liability at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmNjMWIwZmI0ZDNlNzQ0YTA4YWY5NjIwYjA5YWJmZDlkL3RhYmxlcmFuZ2U6Y2MxYjBmYjRkM2U3NDRhMDhhZjk2MjBiMDlhYmZkOWRfMi0xLTEtMS0w_b9f271b4-3c82-4ffb-937f-21ad4c41e48e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmNjMWIwZmI0ZDNlNzQ0YTA4YWY5NjIwYjA5YWJmZDlkL3RhYmxlcmFuZ2U6Y2MxYjBmYjRkM2U3NDRhMDhhZjk2MjBiMDlhYmZkOWRfMi0zLTEtMS0w_59f6fe5a-0275-4f76-b6a1-6b16c80e4f13">4,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmNjMWIwZmI0ZDNlNzQ0YTA4YWY5NjIwYjA5YWJmZDlkL3RhYmxlcmFuZ2U6Y2MxYjBmYjRkM2U3NDRhMDhhZjk2MjBiMDlhYmZkOWRfMi01LTEtMS0w_4d5fd732-dff4-421e-8bcf-a74433b759d3">61,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmNjMWIwZmI0ZDNlNzQ0YTA4YWY5NjIwYjA5YWJmZDlkL3RhYmxlcmFuZ2U6Y2MxYjBmYjRkM2U3NDRhMDhhZjk2MjBiMDlhYmZkOWRfMi03LTEtMS0w_9a616567-adbc-4102-991a-a47936d1fe15">28,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance obligations satisfied in previous periods</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmNjMWIwZmI0ZDNlNzQ0YTA4YWY5NjIwYjA5YWJmZDlkL3RhYmxlcmFuZ2U6Y2MxYjBmYjRkM2U3NDRhMDhhZjk2MjBiMDlhYmZkOWRfMy0xLTEtMS0w_965331ea-76c0-4635-91f4-b60f7ce10d68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmNjMWIwZmI0ZDNlNzQ0YTA4YWY5NjIwYjA5YWJmZDlkL3RhYmxlcmFuZ2U6Y2MxYjBmYjRkM2U3NDRhMDhhZjk2MjBiMDlhYmZkOWRfMy0zLTEtMS0w_778a0fe1-8996-434c-a339-9f579988285e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmNjMWIwZmI0ZDNlNzQ0YTA4YWY5NjIwYjA5YWJmZDlkL3RhYmxlcmFuZ2U6Y2MxYjBmYjRkM2U3NDRhMDhhZjk2MjBiMDlhYmZkOWRfMy01LTEtMS0w_008b106f-d93c-4a68-a1df-cae1381294b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmNjMWIwZmI0ZDNlNzQ0YTA4YWY5NjIwYjA5YWJmZDlkL3RhYmxlcmFuZ2U6Y2MxYjBmYjRkM2U3NDRhMDhhZjk2MjBiMDlhYmZkOWRfMy03LTEtMS0w_e4e593a8-e8f8-415f-aca3-071a1ac6a75e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the aggregate amount of the transaction price allocated to performance obligations that are partially unsatisfied was $<ix:nonFraction unitRef="usd" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfNzcxMw_7ee0162e-2b96-4199-8ef9-bfb6980ffdaa">4.5</ix:nonFraction> million. This amount is expected to be recognized as performance obligations are satisfied through September 2023. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><ix:continuation id="i3a652bde11ab4a30bd84b4547bfeebbf" continuedAt="i0e4c533135a44ed0b7f422683fa1401b"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the underlying performance obligation, or delivery of the enasidenib license, had been satisfied as of June 2014, royalty revenue is recognized as the related sales occur. <ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="agio:RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTEyMjE_9ea2e0c0-892d-4034-9e07-72ef023454bd" continuedAt="i3ecce35148f74bcdaf9dafdf8e5ab2bd" escape="true">During the three and nine months ended September 30, 2020 and 2019, we recognized the following as royalty revenue:</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:6pt"><ix:continuation id="i3ecce35148f74bcdaf9dafdf8e5ab2bd"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.332%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue &#8211; related party</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d4b033413e949bdb33308f291e151d7_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjIwMTc2ZjIxNjk5NjQyYzU5NjdjMDhmMmY3M2M3YTlkL3RhYmxlcmFuZ2U6MjAxNzZmMjE2OTk2NDJjNTk2N2MwOGYyZjczYzdhOWRfMi0xLTEtMS0w_c0696796-b1c3-426c-9b5c-a407b2aec183">683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib72090a087094a15a97bb50cce1d461f_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjIwMTc2ZjIxNjk5NjQyYzU5NjdjMDhmMmY3M2M3YTlkL3RhYmxlcmFuZ2U6MjAxNzZmMjE2OTk2NDJjNTk2N2MwOGYyZjczYzdhOWRfMi0zLTEtMS0w_36f5e9eb-0298-4180-ad79-b57ed7bbde91">2,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5e859f8f93d478cbc47d931bf3d4f16_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjIwMTc2ZjIxNjk5NjQyYzU5NjdjMDhmMmY3M2M3YTlkL3RhYmxlcmFuZ2U6MjAxNzZmMjE2OTk2NDJjNTk2N2MwOGYyZjczYzdhOWRfMi01LTEtMS0w_30ea6617-a7ae-4443-bcac-ca355502895b">7,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bd62d81b9224846bad804af424c7c55_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjIwMTc2ZjIxNjk5NjQyYzU5NjdjMDhmMmY3M2M3YTlkL3RhYmxlcmFuZ2U6MjAxNzZmMjE2OTk2NDJjNTk2N2MwOGYyZjczYzdhOWRfMi03LTEtMS0w_684ea507-5f25-43cb-99aa-e8ff135d38ea">7,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 11, 2020, we sold our tiered, sales-based royalty rights on worldwide net sales of IDHIFA&#174; (enasidenib), as well as our rights to receive up to $<ix:nonFraction unitRef="usd" contextRef="ife55cfc6e645489a9aa97a13da6dfe00_I20200611" decimals="INF" format="ixt:numdotdecimal" name="agio:RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfODIzOQ_ff89900f-bfc8-49e4-b3c4-a7c4dd117e27">55.0</ix:nonFraction>&#160;million in outstanding regulatory milestone payments from BMS, to RPI for $<ix:nonFraction unitRef="usd" contextRef="ib2575fe6eebf402cbdb0a3e5509d729d_D20200611-20200611" decimals="-5" format="ixt:numdotdecimal" name="agio:ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfODMwOA_2266f1d8-2597-41af-b0ed-e4262f399fbf">255.0</ix:nonFraction>&#160;million. For further discussion of the sale of future revenue, refer to Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale of Future Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestone revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfODQyNg_22674662-13dc-4b2f-bc11-7d1dfe24d5e4"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="INF" format="ixt-sec:numwordsen" name="agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfODQyNg_8fdd646f-2b36-47bb-8538-97e1ecb86777"><ix:nonFraction unitRef="usd" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="INF" format="ixt-sec:numwordsen" name="agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfODQyNg_9aa1330d-a1e0-4df1-9b8c-ddb72048c47e"><ix:nonFraction unitRef="usd" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="INF" format="ixt-sec:numwordsen" name="agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfODQyNg_e23f7908-e845-46b3-911d-914c9506082e">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> milestones were achieved during the three and nine months ended September 30, 2020 or 2019. The next potential milestone expected to be achieved under the remaining terms of our Collaboration Agreements is the achievement of a specified ex-U.S. commercial milestone event, which would result in a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="idf22f68ca84c40088ac574f70d88d77d_I20200930" decimals="INF" format="ixt:numdotdecimal" name="agio:PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfODcwMQ_ffd8cccf-cd89-4f43-9a9c-ebead87cea01">25.0</ix:nonFraction> million under the 2010 Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CStone Pharmaceuticals </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, we and CStone Pharmaceuticals, or CStone, entered into an exclusive license agreement, or the CStone Agreement, to grant CStone specified intellectual property licenses to enable CStone to develop and commercialize certain products containing ivosidenib in mainland China, Hong Kong, Macau and Taiwan, or the CStone Territory. We retain development and commercialization rights for the rest of the world. On March 2, 2020, we amended the CStone Agreement to include Singapore as part of the CStone Territory. Pursuant to the CStone Agreement, CStone will initially be responsible for the development and commercialization of ivosidenib in acute myeloid leukemia, or AML, cholangiocarcinoma, and, at our discretion, brain cancer indications. CStone is responsible for all costs it incurs in developing, obtaining regulatory approval of, and commercializing ivosidenib in the CStone Territory, as well as certain costs incurred by us. Pursuant to the CStone Agreement, we received an initial upfront payment in the amount of $<ix:nonFraction unitRef="usd" contextRef="i18ae39e61005422296a6185b1b3642ac_D20180601-20180630" decimals="-5" format="ixt:numdotdecimal" name="agio:ContractWithCustomerLiabilityIncreaseFromCashReceipts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfOTc5MQ_7b0fb940-297a-49c0-8b2f-ee50f52d4ca6">12.0</ix:nonFraction> million and are entitled to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="if60bb09a8e0d4226ba3167b23f5cb3a4_I20200930" decimals="-5" format="ixt:numdotdecimal" name="agio:ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfOTg0Mg_11e2f3a4-ef18-4b97-841f-f05a7511148d">407.0</ix:nonFraction> million in milestone payments upon the achievement of certain development, regulatory and sales milestone events. We will also be entitled to receive tiered royalties, ranging from <ix:nonFraction unitRef="number" contextRef="i0f0956f37ec44b6bb6d0f4fa5248bef0_D20180601-20180630" decimals="INF" name="agio:RoyaltyPercentageRemitted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTAwMTg_a4ee81ef-1a26-4f3d-a0b3-02292b9077bf">15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i54571e1728c5451ab4e07db6c9467aee_D20180601-20180630" decimals="INF" name="agio:RoyaltyPercentageRemitted" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTAwMjQ_730200bc-ec41-4e1e-b612-91933c91148d">19</ix:nonFraction>% percent, on annual net sales, if any, of ivosidenib in the CStone Territory.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration revenue</span></div><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="agio:RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTEyMTc_0c51639e-e9b1-4d70-8d14-87acd1f2bbfa" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2020 and 2019, we recognized the following collaboration revenue -other:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Services performed that were considered performance obligations as of the inception date</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and other services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08ba0b22d8f3450e8b229803691aa936_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjM2YzVkODlhM2ViZDQ2YjJiMDc3ZGJjMGM2MDg2MTllL3RhYmxlcmFuZ2U6MzZjNWQ4OWEzZWJkNDZiMmIwNzdkYmMwYzYwODYxOWVfMy0xLTEtMS0w_7f0d67d0-62f7-405e-882b-41e8dfa26a83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7c63d1760f04d71aa4c373f08d1f88e_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjM2YzVkODlhM2ViZDQ2YjJiMDc3ZGJjMGM2MDg2MTllL3RhYmxlcmFuZ2U6MzZjNWQ4OWEzZWJkNDZiMmIwNzdkYmMwYzYwODYxOWVfMy0zLTEtMS0w_44649c67-0576-4494-ad36-77fa7434cf33">103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddeab0bd8cc74b7db5aebf3e35be317a_D20200101-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjM2YzVkODlhM2ViZDQ2YjJiMDc3ZGJjMGM2MDg2MTllL3RhYmxlcmFuZ2U6MzZjNWQ4OWEzZWJkNDZiMmIwNzdkYmMwYzYwODYxOWVfMy01LTEtMS0w_3c31b4ca-0188-43bc-a32b-d492f1413d9a">192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i107aa1a97aea4de79780fd1a3849f4c9_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjM2YzVkODlhM2ViZDQ2YjJiMDc3ZGJjMGM2MDg2MTllL3RhYmxlcmFuZ2U6MzZjNWQ4OWEzZWJkNDZiMmIwNzdkYmMwYzYwODYxOWVfMy03LTEtMS0w_3933efcf-7958-40bf-adfc-a90e252be1b1">103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Services performed that were not considered performance obligations as of the inception date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7731b8f59ba649e78547d1a6207a646b_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjM2YzVkODlhM2ViZDQ2YjJiMDc3ZGJjMGM2MDg2MTllL3RhYmxlcmFuZ2U6MzZjNWQ4OWEzZWJkNDZiMmIwNzdkYmMwYzYwODYxOWVfNS0xLTEtMS0w_635d1c2f-2b82-4989-922c-09d56a60a19d">1,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6c5708e816d4a5a9da9fda8e44e426a_D20190701-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjM2YzVkODlhM2ViZDQ2YjJiMDc3ZGJjMGM2MDg2MTllL3RhYmxlcmFuZ2U6MzZjNWQ4OWEzZWJkNDZiMmIwNzdkYmMwYzYwODYxOWVfNS0zLTEtMS0w_6924f813-b520-477e-babf-2b191536e40c">523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84dcb1f3e8204171af357b73d909bde3_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjM2YzVkODlhM2ViZDQ2YjJiMDc3ZGJjMGM2MDg2MTllL3RhYmxlcmFuZ2U6MzZjNWQ4OWEzZWJkNDZiMmIwNzdkYmMwYzYwODYxOWVfNS01LTEtMS0w_fe5b87d8-d081-464c-b676-f8a7579df659">2,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47b3d55b232f4b37b1ce3de5d1256c7a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjM2YzVkODlhM2ViZDQ2YjJiMDc3ZGJjMGM2MDg2MTllL3RhYmxlcmFuZ2U6MzZjNWQ4OWEzZWJkNDZiMmIwNzdkYmMwYzYwODYxOWVfNS03LTEtMS0w_e306ad43-ff83-4b9b-bc1a-223164445a80">2,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue - other</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa5e00c5e3b4d8a94adfcd4dc578cea_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjM2YzVkODlhM2ViZDQ2YjJiMDc3ZGJjMGM2MDg2MTllL3RhYmxlcmFuZ2U6MzZjNWQ4OWEzZWJkNDZiMmIwNzdkYmMwYzYwODYxOWVfNy0xLTEtMS0w_e88bf6d7-d2eb-4a96-9e71-bbb6c08f8f5f">1,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bf86b21d1ec42508367f7984e0d709b_D20190701-20190930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjM2YzVkODlhM2ViZDQ2YjJiMDc3ZGJjMGM2MDg2MTllL3RhYmxlcmFuZ2U6MzZjNWQ4OWEzZWJkNDZiMmIwNzdkYmMwYzYwODYxOWVfNy0zLTEtMS0w_4d74a1f1-dc87-4a71-8298-eae673e4b4f7">420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313f3bed2b4d41b1b3befbd3ba0eb04d_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjM2YzVkODlhM2ViZDQ2YjJiMDc3ZGJjMGM2MDg2MTllL3RhYmxlcmFuZ2U6MzZjNWQ4OWEzZWJkNDZiMmIwNzdkYmMwYzYwODYxOWVfNy01LTEtMS0w_614d596d-1380-46ec-ae07-415c6545145b">2,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461b9941feeb4551aaa603496fbf1cbf_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjM2YzVkODlhM2ViZDQ2YjJiMDc3ZGJjMGM2MDg2MTllL3RhYmxlcmFuZ2U6MzZjNWQ4OWEzZWJkNDZiMmIwNzdkYmMwYzYwODYxOWVfNy03LTEtMS0w_8d31b777-45cd-44ce-a99f-4a9d2fc7f6ad">2,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="agio:ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlockTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTEyMjc_a1ecb4bb-b7a8-4451-b20d-d82676652825" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents changes in our contract assets during the nine months ended September 30, 2020:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets (1)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration receivable - other</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63a35d727f94435cb7df160054110884_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjQxMDljZTNiODY3YjQ5MmI4MTM1YzNkMGE1NDExYmM0L3RhYmxlcmFuZ2U6NDEwOWNlM2I4NjdiNDkyYjgxMzVjM2QwYTU0MTFiYzRfMi0xLTEtMS0w_484125a5-e64f-41db-9e06-bbaa45136155">1,928</ix:nonFraction>&#160;</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"></td><td style="border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01071852f46a4d4dadbc5092fae50573_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerAssetRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjQxMDljZTNiODY3YjQ5MmI4MTM1YzNkMGE1NDExYmM0L3RhYmxlcmFuZ2U6NDEwOWNlM2I4NjdiNDkyYjgxMzVjM2QwYTU0MTFiYzRfMi0zLTEtMS0w_a602ef23-86f6-4ad4-b965-d3cd698ab95c">2,786</ix:nonFraction>&#160;</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"></td><td style="border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01071852f46a4d4dadbc5092fae50573_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjQxMDljZTNiODY3YjQ5MmI4MTM1YzNkMGE1NDExYmM0L3RhYmxlcmFuZ2U6NDEwOWNlM2I4NjdiNDkyYjgxMzVjM2QwYTU0MTFiYzRfMi01LTEtMS0w_024a83ee-5007-429c-8ab9-c32f706e6ca1">2,722</ix:nonFraction>)</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"></td><td style="border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fc858c76d804b0094142147dcd5fabf_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjQxMDljZTNiODY3YjQ5MmI4MTM1YzNkMGE1NDExYmM0L3RhYmxlcmFuZ2U6NDEwOWNlM2I4NjdiNDkyYjgxMzVjM2QwYTU0MTFiYzRfMi03LTEtMS0w_1dba9938-7dad-4cb0-945d-2cbf77c3f5ce">1,992</ix:nonFraction>&#160;</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    Additions to contract assets relate to amounts receivable from CStone. Deductions to contract assets relate to collection of receivables during the reporting period.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><ix:continuation id="i0e4c533135a44ed0b7f422683fa1401b"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the aggregate amount of the transaction price allocated to performance obligations that are partially unsatisfied was $<ix:nonFraction unitRef="usd" contextRef="ie9648064ef4d46a89718d0c2f677340c_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTA1ODc_6a1e6ea2-3b24-4b09-a4ac-b390d268e459">0.5</ix:nonFraction> million.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The license was determined to be the predominant item to which sales-based royalties and sales-based milestones relate. As the license was delivered in June 2018, we will recognize royalty revenue when the related sales occur. To date, <ix:nonFraction unitRef="usd" contextRef="ibc55bcf17208425a91152e001413e76a_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTA4NDM_fa4ba82a-6dee-4cd7-bb3c-0b83607b4196">no</ix:nonFraction> royalties have been received under the CStone Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestone revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iaf00db5bcb514269bb6f8b107e6bda6d_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTA5MjE_106aa9c1-ae31-44ee-b4fc-2127597003a9"><ix:nonFraction unitRef="usd" contextRef="i87a76a2d90d94c09897329e40592f335_D20200701-20200930" decimals="INF" format="ixt-sec:numwordsen" name="agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTA5MjE_c2b69d24-5470-4dd9-a5d9-458e8c0388ab"><ix:nonFraction unitRef="usd" contextRef="icb29efd46e8a49fcac140e1509cd977e_D20190101-20190930" decimals="INF" format="ixt-sec:numwordsen" name="agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTA5MjE_f1ca938e-caee-4a17-b325-fb867197bc8a"><ix:nonFraction unitRef="usd" contextRef="ib1af4d73a6f24932b9251f45c0dc1886_D20190701-20190930" decimals="INF" format="ixt-sec:numwordsen" name="agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTA5MjE_f3590eb8-443a-4dfb-8930-ec527e62f60c">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> milestones were earned during the three and nine months ended September 30, 2020 and 2019. The next potential milestone expected to be achieved under the CStone Agreement is the dosing of the first patient in a local study in a solid tumor indication in mainland China. Achievement of this event will result in a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="ie9648064ef4d46a89718d0c2f677340c_I20200930" decimals="-5" format="ixt:numdotdecimal" name="agio:ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTEyMTI_8e99cfbd-448e-4465-8c91-f8a2f06d58a6">5.0</ix:nonFraction> million.</span></div></ix:continuation><div id="i4174004101c4483bbd134be7ce58ff32_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="agio:SaleOfFutureRevenueRoyaltyObligationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RleHRyZWdpb246NDE1ZTUzNmU1Zjg2NDZjNmI2M2M0MDFjMDNlMjk3NDRfMzU2Mg_500de401-465d-4975-b6f2-7bda904a5fe1" continuedAt="i2e381a620a5645f9ab1937d4bcb35040" escape="true">Sale of Future Revenue</ix:nonNumeric></span></div><ix:continuation id="i2e381a620a5645f9ab1937d4bcb35040" continuedAt="i4b347703d90146af8e70e602cf401910"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 11, 2020, we sold our tiered, sales-based royalty rights on worldwide net sales of IDHIFA&#174; (enasidenib), as well as our rights to receive up to $<ix:nonFraction unitRef="usd" contextRef="ife55cfc6e645489a9aa97a13da6dfe00_I20200611" decimals="-5" format="ixt:numdotdecimal" name="agio:RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RleHRyZWdpb246NDE1ZTUzNmU1Zjg2NDZjNmI2M2M0MDFjMDNlMjk3NDRfMTg0_b31f9eab-a1d4-4027-8fc3-74edfeb1068b">55.0</ix:nonFraction>&#160;million in outstanding regulatory milestone payments from BMS, to RPI for $<ix:nonFraction unitRef="usd" contextRef="ib2575fe6eebf402cbdb0a3e5509d729d_D20200611-20200611" decimals="-5" format="ixt:numdotdecimal" name="agio:ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RleHRyZWdpb246NDE1ZTUzNmU1Zjg2NDZjNmI2M2M0MDFjMDNlMjk3NDRfMjUz_86d039c4-a88b-4a39-8ba3-3f9bbd7fb1aa">255.0</ix:nonFraction>&#160;million. The gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="ib2575fe6eebf402cbdb0a3e5509d729d_D20200611-20200611" decimals="-5" format="ixt:numdotdecimal" name="agio:ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RleHRyZWdpb246NDE1ZTUzNmU1Zjg2NDZjNmI2M2M0MDFjMDNlMjk3NDRfMjc5_c5ce1d45-6711-4a88-9569-0822c61bc045">255.0</ix:nonFraction>&#160;million approximate the fair value of the liability related to the sale of future revenue based on a discounted cash flow model. The fair value for the liability related to the sale of future revenue at the time of the transaction was based on our current estimates of future royalties expected to be paid to RPI over the remaining patent life of the product, which are considered level 3 inputs. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Purchase Agreement, although we sold all of our rights to receive royalties on worldwide net sales of IDHIFA&#174; and future regulatory milestone payments, we continue to co-promote IDHIFA&#174; and are therefore involved in the generation of these royalties. Due to our continuing involvement, we will continue to account for any royalties earned as revenue. We recorded the net proceeds from this transaction as a liability related to sale of future revenue, or Royalty Obligation, that will be amortized using the effective interest method over the remaining patent life. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As royalties are remitted to RPI from BMS, the balance of the Royalty Obligation will be effectively repaid over the life of the BMS license agreement. In order to determine the amortization of the Royalty Obligation, we are required to estimate the total amount of future royalty payments to RPI over the life of the BMS license agreement. The $<ix:nonFraction unitRef="usd" contextRef="ib2575fe6eebf402cbdb0a3e5509d729d_D20200611-20200611" decimals="-5" format="ixt:numdotdecimal" name="agio:ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RleHRyZWdpb246NDE1ZTUzNmU1Zjg2NDZjNmI2M2M0MDFjMDNlMjk3NDRfMTYwNw_e9a44b42-3372-45eb-b101-531c04a7102f">255.0</ix:nonFraction>&#160;million recorded will be accreted to the total of these royalty payments as interest expense over the life of the Royalty Obligation. At execution, our estimate of this total interest expense resulted in an effective annual interest rate of approximately <ix:nonFraction unitRef="number" contextRef="ic35eee998d714c1eb9833f09bbeecf44_I20200611" decimals="3" name="agio:PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RleHRyZWdpb246NDE1ZTUzNmU1Zjg2NDZjNmI2M2M0MDFjMDNlMjk3NDRfMTg1Nw_8b3af950-4a82-4fd1-9553-f0d83930d1e7">16.4</ix:nonFraction>%. This estimate contains significant assumptions that impact both the amount recorded at execution and the interest expense that will be recognized over the royalty period. We will periodically assess the estimated royalty payments to RPI from BMS and to the extent the amount or timing of such payments is materially different than the original estimates, an adjustment will be recorded prospectively to increase or decrease interest expense. There are a number of factors that could materially affect the amount and timing of royalty payments to RPI from BMS, and correspondingly, the amount of interest expense recorded by us, most of which are not within our control. Such factors include, but are not limited to, delays or discontinuation of development of enasidenib, regulatory approval, changing standards of care, the introduction of competing products, manufacturing or other delays, generic competition, intellectual property matters, adverse events that result in governmental health authority imposed restrictions on the use of the drug products, significant changes in foreign exchange rates as the royalties remitted to RPI are made in U.S. dollars (USD) while the underlying sales of enasidenib will be made in currencies other than USD, and other events or circumstances that are not currently foreseen. Changes to any of these factors could result in increases or decreases to both royalty revenues and interest expense. </span></div><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="agio:SaleOfFutureRevenueRoyaltyObligationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RleHRyZWdpb246NDE1ZTUzNmU1Zjg2NDZjNmI2M2M0MDFjMDNlMjk3NDRfMzU2Mw_d2629c43-5133-493c-af8a-c599dfa6b6b6" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity of the Royalty Obligation since the transaction inception through September 30, 2020:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the sale of future revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i921c8ef362934a03b834f05fd487675a_I20200611" decimals="-3" format="ixt:numdotdecimal" name="agio:SaleOfFutureRevenueLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RhYmxlOjliYWZiMTBjYjI3YzQxODhiOTdmNGIzMWY4NmJkMjQxL3RhYmxlcmFuZ2U6OWJhZmIxMGNiMjdjNDE4OGI5N2Y0YjMxZjg2YmQyNDFfMS0xLTEtMS0w_dd0c0061-0c71-4520-a1f5-ddb7c5caa2ba">255,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a10fdb988c14ed4b148d6aab1625976_D20200612-20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:SaleOfFutureRevenueIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RhYmxlOjliYWZiMTBjYjI3YzQxODhiOTdmNGIzMWY4NmJkMjQxL3RhYmxlcmFuZ2U6OWJhZmIxMGNiMjdjNDE4OGI5N2Y0YjMxZjg2YmQyNDFfMi0xLTEtMS0w_88d4dd26-008b-4ddc-9663-2fd7529241d9">4,463</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-cash royalty related to the sale of future revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a10fdb988c14ed4b148d6aab1625976_D20200612-20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:SaleOfFutureRevenuesNonCashRoyaltyRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RhYmxlOjliYWZiMTBjYjI3YzQxODhiOTdmNGIzMWY4NmJkMjQxL3RhYmxlcmFuZ2U6OWJhZmIxMGNiMjdjNDE4OGI5N2Y0YjMxZjg2YmQyNDFfMy0xLTEtMS0w_c1545d20-b244-4c85-b76e-e99837c78eae">4,341</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense associated with the sale of future revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a10fdb988c14ed4b148d6aab1625976_D20200612-20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:SaleOfFutureRevenueInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RhYmxlOjliYWZiMTBjYjI3YzQxODhiOTdmNGIzMWY4NmJkMjQxL3RhYmxlcmFuZ2U6OWJhZmIxMGNiMjdjNDE4OGI5N2Y0YjMxZjg2YmQyNDFfNC0xLTEtMS0w_a253b4c6-4d22-4ab1-910c-7d134a010ebc">11,818</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a10fdb988c14ed4b148d6aab1625976_D20200612-20200930" decimals="-3" name="agio:SaleOfFutureRevenueAmortizationOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RhYmxlOjliYWZiMTBjYjI3YzQxODhiOTdmNGIzMWY4NmJkMjQxL3RhYmxlcmFuZ2U6OWJhZmIxMGNiMjdjNDE4OGI5N2Y0YjMxZjg2YmQyNDFfNS0xLTEtMS0w_0fd7412d-ec34-443b-95c7-80fc7ab70290">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liability related to the sale of future revenue</span></div></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6317ec5824324379aa89da98e74f17b5_I20200930" decimals="-3" format="ixt:numdotdecimal" name="agio:SaleOfFutureRevenueLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RhYmxlOjliYWZiMTBjYjI3YzQxODhiOTdmNGIzMWY4NmJkMjQxL3RhYmxlcmFuZ2U6OWJhZmIxMGNiMjdjNDE4OGI5N2Y0YjMxZjg2YmQyNDFfNi0xLTEtMS0w_112174e5-f9e9-403f-85d0-ee0811cfd143">258,121</ix:nonFraction>&#160;</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4b347703d90146af8e70e602cf401910">During the three and nine months ended September 30, 2020, $<ix:nonFraction unitRef="usd" contextRef="ibf7298c7e23d4bc79ec2339352a2c49b_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="agio:SaleOfFutureRevenuesNonCashRoyaltyRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RleHRyZWdpb246NDE1ZTUzNmU1Zjg2NDZjNmI2M2M0MDFjMDNlMjk3NDRfMTA5OTUxMTYzMTUwNQ_a6b40393-27ec-43a9-a7bb-ff88e40267eb">2.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i21d7d92ef32c4570af111a2c6296175e_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="agio:SaleOfFutureRevenuesNonCashRoyaltyRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RleHRyZWdpb246NDE1ZTUzNmU1Zjg2NDZjNmI2M2M0MDFjMDNlMjk3NDRfMTA5OTUxMTYzMTUxMw_24dd667a-bc6a-4925-b331-c03db766fe73">4.3</ix:nonFraction> million of non-cash royalty revenue from net sales of IDHIFA&#174; were recognized, respectively</ix:continuation>.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i4174004101c4483bbd134be7ce58ff32_64"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMjczMQ_ecb77a30-46cb-4239-9126-99d4a38e866d" continuedAt="i0945bbc65b7a43eea43509f9a5d091d7" escape="true">Share-Based Payments</ix:nonNumeric></span></div><ix:continuation id="i0945bbc65b7a43eea43509f9a5d091d7" continuedAt="i9f5a7e2ecf024e84ab4a5a0cf3c478a0"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2013 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2013, our Board of Directors adopted and, in July 2013 our stockholders approved, the 2013 Stock Incentive Plan, or the 2013 Plan. The 2013 Plan became effective upon the closing of our initial public offering and provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock units, or RSUs, performance-based stock units, or PSUs, and other stock-based awards to employees, non-employees and non-employee directors. Following the adoption of the 2013 Plan, we granted no further stock options or other awards under the 2007 Stock Incentive Plan, or the 2007 Plan. Any options or awards outstanding under the 2007 Plan at the time of adoption of the 2013 Plan remain outstanding and effective. As of September&#160;30, 2020, the total number of shares reserved under the 2007 Plan and the 2013 Plan was <ix:nonFraction unitRef="shares" contextRef="i9d699758856a480db8a54b5c63108b48_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMTQ3_43cb3cee-0442-4484-82bf-f3e81495bfee">10,680,089</ix:nonFraction>, and we had <ix:nonFraction unitRef="shares" contextRef="i5f9615d7d1de4efaa136793d0d91cefc_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMTYy_166daba9-b7cb-445d-8061-29af58b806ee">2,919,442</ix:nonFraction> shares available for future issuance under the 2013 Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock options</span></div><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMjczMg_44953a4a-7bcf-4ec6-8fe3-d417d2bd8c0f" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents stock option activity for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfMS0xLTEtMS0w_3dd3672b-e7f0-4f0a-8bda-7d3895942930">6,201,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfMS0zLTEtMS0w_dfa89889-8241-45c4-8fe6-dc2e5ae52627">58.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfMi0xLTEtMS0w_98469100-8369-4670-a2b2-0de684df12fe">956,945</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfMi0zLTEtMS0w_c3e442a3-570f-4e17-93ef-fca71d01ff78">49.84</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfMy0xLTEtMS0w_6964b5d3-8e8e-4dcc-a199-b69b5c2915ab">339,284</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfMy0zLTEtMS0w_8b5b51d5-8867-4f68-8525-5c8bddb46249">19.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfNC0xLTEtMS0w_4ec4ea43-954e-4d9d-b908-67a9945c4949">448,901</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfNC0zLTEtMS0w_951612d5-4c4a-4df8-bfc3-05711a503953">65.98</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfNS0xLTEtMS0w_facff0f0-ffdc-4784-b94d-e7a29d38c405">6,370,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfNS0zLTEtMS0w_46cee2ed-b382-4ac3-a289-080205053fab">58.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfNi0xLTEtMS0w_ee40f17c-f04d-428b-96b8-15d48d61966d">4,067,553</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfNi0zLTEtMS0w_8e9518d5-325b-469b-bcb7-2b1ed7965ab3">61.23</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfNy0xLTEtMS0w_e1b01b48-4f6f-4048-925c-b0c4b7663266">6,370,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfNy0zLTEtMS0w_a19f70f3-03b8-479f-8c8d-f259dd61c2f0">58.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, there was approximately $<ix:nonFraction unitRef="usd" contextRef="i5f9615d7d1de4efaa136793d0d91cefc_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMzMz_5c4fa73e-9c6c-4f2e-ad4a-6c70f206bf23">77.4</ix:nonFraction> million of total unrecognized compensation expense related to unvested stock option awards, which we expect to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="i42fd0d585d7e44eb875c04c73f32f4f3_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfNDk3_0a099c19-cd48-41a3-8018-e6f2aa4d5e4e">2.4</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted stock units</span></div><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMjcyNg_f1772855-e989-443e-b06e-63f59d06b033" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents RSU activity for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant&#160;Date&#160;Fair&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d04844a7e1741f4b543721609a357af_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjJhOTJkYmQ1NWU1ODQxMmQ5ZjU2YmJmMzVkYzI5NmM4L3RhYmxlcmFuZ2U6MmE5MmRiZDU1ZTU4NDEyZDlmNTZiYmYzNWRjMjk2YzhfMS0xLTEtMS0w_b4843774-6a3c-416f-897d-e071eb3d8289">766,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3d04844a7e1741f4b543721609a357af_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjJhOTJkYmQ1NWU1ODQxMmQ5ZjU2YmJmMzVkYzI5NmM4L3RhYmxlcmFuZ2U6MmE5MmRiZDU1ZTU4NDEyZDlmNTZiYmYzNWRjMjk2YzhfMS0zLTEtMS0w_80f60b6c-b03b-409e-9e29-94c044f654a4">63.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieaba62f70942436b9630689bd74a2d35_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjJhOTJkYmQ1NWU1ODQxMmQ5ZjU2YmJmMzVkYzI5NmM4L3RhYmxlcmFuZ2U6MmE5MmRiZDU1ZTU4NDEyZDlmNTZiYmYzNWRjMjk2YzhfMi0xLTEtMS0w_c766712b-38fa-490a-ba36-cf47c40c9f07">829,791</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieaba62f70942436b9630689bd74a2d35_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjJhOTJkYmQ1NWU1ODQxMmQ5ZjU2YmJmMzVkYzI5NmM4L3RhYmxlcmFuZ2U6MmE5MmRiZDU1ZTU4NDEyZDlmNTZiYmYzNWRjMjk2YzhfMi0zLTEtMS0w_d2f507ab-a589-4af4-82c0-617f155be158">50.33</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ieaba62f70942436b9630689bd74a2d35_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjJhOTJkYmQ1NWU1ODQxMmQ5ZjU2YmJmMzVkYzI5NmM4L3RhYmxlcmFuZ2U6MmE5MmRiZDU1ZTU4NDEyZDlmNTZiYmYzNWRjMjk2YzhfMy0xLTEtMS0w_75f5e114-540c-4d32-b4ec-b480711a1a5b">258,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieaba62f70942436b9630689bd74a2d35_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjJhOTJkYmQ1NWU1ODQxMmQ5ZjU2YmJmMzVkYzI5NmM4L3RhYmxlcmFuZ2U6MmE5MmRiZDU1ZTU4NDEyZDlmNTZiYmYzNWRjMjk2YzhfMy0zLTEtMS0w_01afba6b-2f12-4535-8ac5-1cad2e71bf15">69.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ieaba62f70942436b9630689bd74a2d35_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjJhOTJkYmQ1NWU1ODQxMmQ5ZjU2YmJmMzVkYzI5NmM4L3RhYmxlcmFuZ2U6MmE5MmRiZDU1ZTU4NDEyZDlmNTZiYmYzNWRjMjk2YzhfNC0xLTEtMS0w_b8dd9de3-2d5f-4098-b528-dc79a1c865c1">132,805</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieaba62f70942436b9630689bd74a2d35_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjJhOTJkYmQ1NWU1ODQxMmQ5ZjU2YmJmMzVkYzI5NmM4L3RhYmxlcmFuZ2U6MmE5MmRiZDU1ZTU4NDEyZDlmNTZiYmYzNWRjMjk2YzhfNC0zLTEtMS0w_053835a8-cbcd-4146-a18c-873faf6e87bb">58.31</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91da41946dd44926b3eb2a6c70cedcec_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjJhOTJkYmQ1NWU1ODQxMmQ5ZjU2YmJmMzVkYzI5NmM4L3RhYmxlcmFuZ2U6MmE5MmRiZDU1ZTU4NDEyZDlmNTZiYmYzNWRjMjk2YzhfNS0xLTEtMS0w_32dc4e67-9d6a-4305-94f4-f75de981009d">1,205,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i91da41946dd44926b3eb2a6c70cedcec_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjJhOTJkYmQ1NWU1ODQxMmQ5ZjU2YmJmMzVkYzI5NmM4L3RhYmxlcmFuZ2U6MmE5MmRiZDU1ZTU4NDEyZDlmNTZiYmYzNWRjMjk2YzhfNS0zLTEtMS0w_03f7882d-c1bb-47fd-a408-638f4a3cf23e">53.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, there was approximately $<ix:nonFraction unitRef="usd" contextRef="i91da41946dd44926b3eb2a6c70cedcec_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfNjE0_59ebc908-6019-4144-80bc-5fc297960496">41.7</ix:nonFraction> million of total unrecognized compensation expense related to RSUs, which we expect to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="ieaba62f70942436b9630689bd74a2d35_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfNzU0_469bd65c-244b-475d-88ac-92a2748830b4">1.9</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-based stock units </span></div><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMjczNA_4abcc49f-6876-417f-aaad-3442aa3bfb8a" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents PSU activity for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant&#160;Date&#160;Fair&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic195c0c995c94bb99b62faec4ada3a82_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjk1MGM4YjkyYTEzYzQ1OGNhYzY1ZWZiMDE4ODYyZmZkL3RhYmxlcmFuZ2U6OTUwYzhiOTJhMTNjNDU4Y2FjNjVlZmIwMTg4NjJmZmRfMS0xLTEtMS0w_24151d09-00ab-4f4c-a591-121fb555a599">218,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic195c0c995c94bb99b62faec4ada3a82_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjk1MGM4YjkyYTEzYzQ1OGNhYzY1ZWZiMDE4ODYyZmZkL3RhYmxlcmFuZ2U6OTUwYzhiOTJhMTNjNDU4Y2FjNjVlZmIwMTg4NjJmZmRfMS0zLTEtMS0w_013a9989-1eb3-49d4-8623-190897327d7b">55.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16638a665f8b48bda553a1b68fe9582c_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjk1MGM4YjkyYTEzYzQ1OGNhYzY1ZWZiMDE4ODYyZmZkL3RhYmxlcmFuZ2U6OTUwYzhiOTJhMTNjNDU4Y2FjNjVlZmIwMTg4NjJmZmRfMi0xLTEtMS0w_4a0cc95c-f4be-4322-bd84-dc558ac8ef39">20,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i16638a665f8b48bda553a1b68fe9582c_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjk1MGM4YjkyYTEzYzQ1OGNhYzY1ZWZiMDE4ODYyZmZkL3RhYmxlcmFuZ2U6OTUwYzhiOTJhMTNjNDU4Y2FjNjVlZmIwMTg4NjJmZmRfMi0zLTEtMS0w_3c0cca62-1393-4067-8782-57fa3a4d229f">48.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i16638a665f8b48bda553a1b68fe9582c_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjk1MGM4YjkyYTEzYzQ1OGNhYzY1ZWZiMDE4ODYyZmZkL3RhYmxlcmFuZ2U6OTUwYzhiOTJhMTNjNDU4Y2FjNjVlZmIwMTg4NjJmZmRfMy0xLTEtMS0w_920fb205-be7c-4ddd-a8b5-30aec2b5a4d2">78,920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i16638a665f8b48bda553a1b68fe9582c_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjk1MGM4YjkyYTEzYzQ1OGNhYzY1ZWZiMDE4ODYyZmZkL3RhYmxlcmFuZ2U6OTUwYzhiOTJhMTNjNDU4Y2FjNjVlZmIwMTg4NjJmZmRfMy0zLTEtMS0w_f8a2f005-64d7-4663-80de-c856d8fa6400">54.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie97254b0a3bd414a957ad2f9c5b213a2_D20180101-20180930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjk1MGM4YjkyYTEzYzQ1OGNhYzY1ZWZiMDE4ODYyZmZkL3RhYmxlcmFuZ2U6OTUwYzhiOTJhMTNjNDU4Y2FjNjVlZmIwMTg4NjJmZmRfNC0xLTEtMS0w_a738d545-b8d7-48e8-b267-eeaff527a583">17,616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie97254b0a3bd414a957ad2f9c5b213a2_D20180101-20180930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjk1MGM4YjkyYTEzYzQ1OGNhYzY1ZWZiMDE4ODYyZmZkL3RhYmxlcmFuZ2U6OTUwYzhiOTJhMTNjNDU4Y2FjNjVlZmIwMTg4NjJmZmRfNC0zLTEtMS0w_550b8b4b-3d22-48fc-bb24-63a549cb2472">61.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd2bc890754e428c838e48a9739bb6ca_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjk1MGM4YjkyYTEzYzQ1OGNhYzY1ZWZiMDE4ODYyZmZkL3RhYmxlcmFuZ2U6OTUwYzhiOTJhMTNjNDU4Y2FjNjVlZmIwMTg4NjJmZmRfNS0xLTEtMS0w_3a31e5d9-c26c-478d-b4d4-8170c977879e">142,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idd2bc890754e428c838e48a9739bb6ca_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjk1MGM4YjkyYTEzYzQ1OGNhYzY1ZWZiMDE4ODYyZmZkL3RhYmxlcmFuZ2U6OTUwYzhiOTJhMTNjNDU4Y2FjNjVlZmIwMTg4NjJmZmRfNS0zLTEtMS0w_91ad98d6-9f73-4853-9c8a-894c4f63d8b4">54.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense associated with these PSUs is recognized if the underlying performance condition is considered probable of achievement using our management&#8217;s best estimates.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><ix:continuation id="i9f5a7e2ecf024e84ab4a5a0cf3c478a0"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, there was <ix:nonFraction unitRef="usd" contextRef="i174a0833a8f7445eab78db94209d6095_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMTA1Ng_a7d9ce2d-9482-4d4b-a9c0-6b7525eb9ce7">no</ix:nonFraction> unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered probable of achievement, and $<ix:nonFraction unitRef="usd" contextRef="i174a0833a8f7445eab78db94209d6095_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMTE5OA_20f8849f-2982-44fc-a15c-a4e57e0c6a8c">5.9</ix:nonFraction> million of total unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered not probable of achievement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Market-based stock units</span></div><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="agio:ScheduleOfMarketBasedUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMjcyNw_061b58ba-6357-4599-a760-37ceaf5c1d81" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents market-based stock unit, or MSU, activity for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:68.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i511c756fbbb74474b18ddbc87da9898f_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjBmZDRlZWVjYTIzZDQ2MDBiNjVlMmM4ZWVlN2E0YjFjL3RhYmxlcmFuZ2U6MGZkNGVlZWNhMjNkNDYwMGI2NWUyYzhlZWU3YTRiMWNfMS0xLTEtMS0w_aa39ee40-4192-4d39-8368-d7bf79dc3398">42,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i511c756fbbb74474b18ddbc87da9898f_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjBmZDRlZWVjYTIzZDQ2MDBiNjVlMmM4ZWVlN2E0YjFjL3RhYmxlcmFuZ2U6MGZkNGVlZWNhMjNkNDYwMGI2NWUyYzhlZWU3YTRiMWNfMS0zLTEtMS0w_bb65762c-7706-4a64-945a-50de69654d64">41.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b990092bc0c49da82be729ba6370e53_D20200101-20200930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjBmZDRlZWVjYTIzZDQ2MDBiNjVlMmM4ZWVlN2E0YjFjL3RhYmxlcmFuZ2U6MGZkNGVlZWNhMjNkNDYwMGI2NWUyYzhlZWU3YTRiMWNfMi0xLTEtMS0w_400e6f52-1b0a-42d4-afb5-504ba3111265">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b990092bc0c49da82be729ba6370e53_D20200101-20200930" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjBmZDRlZWVjYTIzZDQ2MDBiNjVlMmM4ZWVlN2E0YjFjL3RhYmxlcmFuZ2U6MGZkNGVlZWNhMjNkNDYwMGI2NWUyYzhlZWU3YTRiMWNfMi0zLTEtMS0w_ea691fe2-14e9-44c6-89fe-671d46fe895d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c31701e76ca45a499b9de7eb21dcc8c_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjBmZDRlZWVjYTIzZDQ2MDBiNjVlMmM4ZWVlN2E0YjFjL3RhYmxlcmFuZ2U6MGZkNGVlZWNhMjNkNDYwMGI2NWUyYzhlZWU3YTRiMWNfNS0xLTEtMS0w_9b78ab59-e94c-44e3-b652-935606d4b9b5">42,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2c31701e76ca45a499b9de7eb21dcc8c_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjBmZDRlZWVjYTIzZDQ2MDBiNjVlMmM4ZWVlN2E0YjFjL3RhYmxlcmFuZ2U6MGZkNGVlZWNhMjNkNDYwMGI2NWUyYzhlZWU3YTRiMWNfNS0zLTEtMS0w_077429e7-f7e6-4fa7-b07c-e4b848fa5563">41.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of MSUs are estimated using a Monte Carlo simulation model. Assumptions and estimates utilized in the model include the risk-free interest rate, dividend yield, expected stock volatility and the estimated period to achievement of the market condition. As of September&#160;30, 2020, there was <ix:nonFraction unitRef="usd" contextRef="i2c31701e76ca45a499b9de7eb21dcc8c_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMjc0ODc3OTA3MjI5Mg_cb5b37f6-6572-4275-bc8d-00444d58a2a3">no</ix:nonFraction> remaining unrecognized compensation expense related to MSUs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2013 Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 Employee Stock Purchase Plan, or the 2013 ESPP. We issued and sold <ix:nonFraction unitRef="shares" contextRef="i88427bac77074d34bf85fa93670c9058_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMjEwMQ_3ac6325a-756c-4cb6-976e-0b4629e9f29b">120,293</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i3878b4c8c3294913aa799ef8147b4a81_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMjEwOA_1ad5563e-b933-4af8-8f38-f81d624d0ea2">77,981</ix:nonFraction> shares of common stock during the nine months ended September 30, 2020 and 2019, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="i88427bac77074d34bf85fa93670c9058_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMjI5Mw_058f8c25-0a8b-4070-8d04-a4868e2c3465">836,363</ix:nonFraction> shares of our common stock. As of September&#160;30, 2020, we had <ix:nonFraction unitRef="shares" contextRef="i6d8671ea0b684937a1904b1b3c85413c_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMjM0MQ_410d1664-64e5-41a2-a29d-3b69ceba3514">471,353</ix:nonFraction> shares of common stock available for future issuance under the 2013 ESPP.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation expense</span></div><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMjcyOQ_b040c8bd-4503-4b38-b4bc-c1edf12bb971" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf949780f933480e95db1152a36fe193_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfMi0xLTEtMS0w_d6af0348-c032-4f9a-9f9f-bff82b15eb40">11,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bf9b8187f0451d9f3b63e3cf6178da_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfMi0zLTEtMS0w_2f85bf56-abb6-4f92-915c-5f5e8e73a87a">11,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09fde5e4560a422a85918a18e444182d_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfMi01LTEtMS0w_159f5891-f531-496f-8b4c-49a69eb98d44">34,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd07546e3954875b0cf85d146e836c1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfMi03LTEtMS0w_a1f264c5-3648-4317-b8cc-af3ac834bf24">37,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8a5352cdcf54a3dbc6e981a9f2d988e_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfMy0xLTEtMS0w_1e744758-4452-4d9e-a59c-99aeb0cd2c46">6,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice9aeab243b54c76ba9666c481969a67_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfMy0zLTEtMS0w_09267b09-746d-4b06-ab69-0314128a83d5">4,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaba62f70942436b9630689bd74a2d35_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfMy01LTEtMS0w_380a3bd0-1cee-4621-a0b3-cfcafa0fd58d">20,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i357045d6181740eeae955e96b15cf9ae_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfMy03LTEtMS0w_1d1a31f1-3359-4e84-9c17-fc86f9942477">14,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie651fcd18fce4247ae0c8601b611a96b_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNC0xLTEtMS0w_eb2def5b-ed6a-4a3c-bcf6-c6f60d822d8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic805411b96ea4c5f9301de6e30503f1f_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNC0zLTEtMS0w_bde55223-37ab-4d11-adce-aa7ae0c94ba7">1,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16638a665f8b48bda553a1b68fe9582c_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNC01LTEtMS0w_0613e83b-e531-4eca-b440-999986e60aef">1,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i798423a51884438da4abc925685536ec_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNC03LTEtMS0w_31744bc9-e64e-4db2-af44-dc7bbe6b5300">1,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5e015813aa04cc5b172ca860a6d9adb_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNS0xLTEtMS0w_12d5134c-2991-4c9a-9009-e1c9df671441">339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49a46c45215d41c8aa7526c20b7d66b5_D20190701-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNS0zLTEtMS0w_0aec7700-b83e-4568-bf0a-1632be9840c8">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbd22adb7da84d4385fef484796aface_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNS01LTEtMS0w_2c31d2af-5169-43cc-a767-64a52b4e9538">1,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6718bfa0a37a457e90f8816b0655456b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNS03LTEtMS0w_f9a6a35b-867f-41ee-a345-f7ff2210b8b6">1,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i454184cf989649608cb48e499349776d_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNi0xLTEtMS0w_2df29681-6ec6-445d-ae2e-8fa5d430f648">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03016330feec4c92b5f1d60dc4e263e1_D20190701-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNi0zLTEtMS0w_160b7382-702b-41e1-8d80-71c1aa3e3a4b">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic370bb45afd5438bade9612c8288612a_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNi01LTEtMS0w_32845598-9518-49e3-a1bc-82b75a56129b">781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f25d07cfaa34641ae0ed3f419c27b42_D20190101-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNi03LTEtMS0w_429814fd-3b8a-4385-a750-c4d0903839ba">719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNy0xLTEtMS0w_b3f742f0-cedc-4506-9f53-483fe2aa91a6">18,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNy0zLTEtMS0w_823a73c2-be33-4b02-9597-4355ae4ce6aa">18,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNy01LTEtMS0w_b5b46e83-762b-4a37-a9e4-16f809be4967">58,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNy03LTEtMS0w_5062a4ed-41f1-4812-9bc0-087cc6e71dc0">55,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMjcyMw_1b00c83e-fbfe-4a6c-87ad-8a342cceb6b7" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses related to stock options and stock-based awards were allocated as follows in the condensed consolidated statements of operations:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27fa78f0171d419fbd8f33e0452c4ae6_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjkwNWFmYzk3MDIzMTQwZDA4MWZiYzgzNjU2MGJiM2FhL3RhYmxlcmFuZ2U6OTA1YWZjOTcwMjMxNDBkMDgxZmJjODM2NTYwYmIzYWFfMi0xLTEtMS0w_e3df64e5-5400-4ab1-85d4-51520626e902">8,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b35ca8234b946a59c38dcb3c34529b6_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjkwNWFmYzk3MDIzMTQwZDA4MWZiYzgzNjU2MGJiM2FhL3RhYmxlcmFuZ2U6OTA1YWZjOTcwMjMxNDBkMDgxZmJjODM2NTYwYmIzYWFfMi0zLTEtMS0w_fabc37e0-fd59-4664-9a0b-2a5fe84a0132">9,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03be922ff7cb4cf492b6d47edf9144c9_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjkwNWFmYzk3MDIzMTQwZDA4MWZiYzgzNjU2MGJiM2FhL3RhYmxlcmFuZ2U6OTA1YWZjOTcwMjMxNDBkMDgxZmJjODM2NTYwYmIzYWFfMi01LTEtMS0w_e97adefc-0222-4a20-b3ee-b5765fb77a09">28,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia14da64b4d914e7ca355088908976d71_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjkwNWFmYzk3MDIzMTQwZDA4MWZiYzgzNjU2MGJiM2FhL3RhYmxlcmFuZ2U6OTA1YWZjOTcwMjMxNDBkMDgxZmJjODM2NTYwYmIzYWFfMi03LTEtMS0w_402fc0fe-3b3c-45af-a048-62cf13555a2a">29,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94a210d561984f12a0afc697ddbaea44_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjkwNWFmYzk3MDIzMTQwZDA4MWZiYzgzNjU2MGJiM2FhL3RhYmxlcmFuZ2U6OTA1YWZjOTcwMjMxNDBkMDgxZmJjODM2NTYwYmIzYWFfMy0xLTEtMS0w_1733824c-e06e-4c73-a60d-09ba636e3898">9,665</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4effbc54b019404fbb07e9b964ce6494_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjkwNWFmYzk3MDIzMTQwZDA4MWZiYzgzNjU2MGJiM2FhL3RhYmxlcmFuZ2U6OTA1YWZjOTcwMjMxNDBkMDgxZmJjODM2NTYwYmIzYWFfMy0zLTEtMS0w_b42ca46d-d344-4198-95d5-f4d2f8dfee84">8,728</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf1c03f73f434b93ac3f9ad188cac55e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjkwNWFmYzk3MDIzMTQwZDA4MWZiYzgzNjU2MGJiM2FhL3RhYmxlcmFuZ2U6OTA1YWZjOTcwMjMxNDBkMDgxZmJjODM2NTYwYmIzYWFfMy01LTEtMS0w_6b8d66ee-d209-47e2-af91-35c9a8b64a75">30,063</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64b9b9df1ff7448d85c07ee71a10ce67_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjkwNWFmYzk3MDIzMTQwZDA4MWZiYzgzNjU2MGJiM2FhL3RhYmxlcmFuZ2U6OTA1YWZjOTcwMjMxNDBkMDgxZmJjODM2NTYwYmIzYWFfMy03LTEtMS0w_60c93f81-daea-4040-adc7-45ed808c446d">25,274</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjkwNWFmYzk3MDIzMTQwZDA4MWZiYzgzNjU2MGJiM2FhL3RhYmxlcmFuZ2U6OTA1YWZjOTcwMjMxNDBkMDgxZmJjODM2NTYwYmIzYWFfNC0xLTEtMS0w_d3b671f5-c4cd-49bf-b367-3d97f8519118">18,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjkwNWFmYzk3MDIzMTQwZDA4MWZiYzgzNjU2MGJiM2FhL3RhYmxlcmFuZ2U6OTA1YWZjOTcwMjMxNDBkMDgxZmJjODM2NTYwYmIzYWFfNC0zLTEtMS0w_f5b0885a-13cd-4a8d-bc85-519b4eff77d8">18,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjkwNWFmYzk3MDIzMTQwZDA4MWZiYzgzNjU2MGJiM2FhL3RhYmxlcmFuZ2U6OTA1YWZjOTcwMjMxNDBkMDgxZmJjODM2NTYwYmIzYWFfNC01LTEtMS0w_9403b6f6-10be-40fc-a042-01aa27241794">58,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjkwNWFmYzk3MDIzMTQwZDA4MWZiYzgzNjU2MGJiM2FhL3RhYmxlcmFuZ2U6OTA1YWZjOTcwMjMxNDBkMDgxZmJjODM2NTYwYmIzYWFfNC03LTEtMS0w_eff42502-176d-4b74-935c-45490318a23d">55,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i4174004101c4483bbd134be7ce58ff32_67"></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RleHRyZWdpb246MDM1Yzc0NjYxZTU3NGM2NDg0ODg4MWY4MzZkN2NmODhfNDc0_5499c37b-5cdd-4001-89c8-454b72bb5439" continuedAt="i9d8bc22b735d4178abd61a3ae6f60d88" escape="true">Loss per Share</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9d8bc22b735d4178abd61a3ae6f60d88" continuedAt="i34a9d4ebc9b1485f91e2414ff2479e84"><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RleHRyZWdpb246MDM1Yzc0NjYxZTU3NGM2NDg0ODg4MWY4MzZkN2NmODhfMjc0ODc3OTA2OTkxNQ_24dbb68f-f5b8-4e0e-a44f-cd800965d7f2" continuedAt="i6627bffdf1594e23abd554bca5735227" escape="true">Basic net loss per share is calculated by dividing net loss by the weighted-average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury stock method. For purposes of the dilutive net loss per share calculation, stock options, RSUs, PSUs and MSUs for which the performance and market vesting conditions, respectively, have been deemed probable, and 2013 ESPP shares are considered to </ix:nonNumeric></ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><ix:continuation id="i34a9d4ebc9b1485f91e2414ff2479e84"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6627bffdf1594e23abd554bca5735227">be common stock equivalents, while PSUs and MSUs with performance and market vesting conditions, respectively, that were not deemed probable as of September&#160;30, 2020 are not considered to be common stock equivalents.</ix:continuation></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we had a net loss for all periods presented, the effect of all potentially dilutive securities is anti-dilutive. Accordingly, basic and diluted net loss per share was the same for all periods presented.</span></div><ix:nonNumeric contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RleHRyZWdpb246MDM1Yzc0NjYxZTU3NGM2NDg0ODg4MWY4MzZkN2NmODhfNDcx_d51e7db8-b718-47c4-ad20-a8056934e58c" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:71.734%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.117%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three and Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i158dfd79c688479084d989c430f722ec_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfMi0xLTEtMS0w_45704fad-954f-4f84-bd10-6b183f182a83"><ix:nonFraction unitRef="shares" contextRef="idefd32a8ce2246baa8ff2d8323b75046_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfMi0xLTEtMS0w_a4192fa3-a150-487c-9c95-6e4fc3680144">6,370,245</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7607646d4b3b4f108a7e2b95056780a1_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfMi0zLTEtMS0w_10ddaf80-60fb-49ca-9c71-b34762c59fed"><ix:nonFraction unitRef="shares" contextRef="i98274e1aae044562a57287ce093c0a26_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfMi0zLTEtMS0w_55462da0-2a0c-476f-85e0-bf5e4c53625f">6,185,935</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02527e9e8cad486f90f2ce345b3c2608_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfMy0xLTEtMS0w_06303ae3-08dd-4231-a166-737554f55cbe"><ix:nonFraction unitRef="shares" contextRef="ib7f3d9262b9a4930b2cf048450740cd9_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfMy0xLTEtMS0w_759c67ff-d9c1-4368-90e0-d94bf2adabe3">1,205,478</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1179a5820c534eac932533d105b3c232_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfMy0zLTEtMS0w_34d47764-b80d-41fa-9f08-bbff508b44a1"><ix:nonFraction unitRef="shares" contextRef="i824f503805804c518c65ccdbfb63cb4c_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfMy0zLTEtMS0w_d34b5208-ab28-4c74-aec7-a3e0424f7018">733,100</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i086f8600af974684a490cec7619bf25c_D20200701-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfNC0xLTEtMS0w_063e5ad8-c612-4d44-8317-b323773a64ca"><ix:nonFraction unitRef="shares" contextRef="i7d2dbb49a82349ac86136605ab26307a_D20200101-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfNC0xLTEtMS0w_120cd947-49d4-4dfc-91c2-a0a027b4b854">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4d9eaf7cb8641d0852c0cdf98b22872_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfNC0zLTEtMS0w_297bdd37-cee7-4164-aa82-b1f5767ab08b"><ix:nonFraction unitRef="shares" contextRef="i85f451c88a3e4c928e436beab4f05862_D20190701-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfNC0zLTEtMS0w_dbabda04-4121-4106-84b6-e1a51ed41475">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7a52ff240e81427b90c795cee938d4b5_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfNS0xLTEtMS0w_bc6b0602-945d-4724-ab53-9d7cd886d90f"><ix:nonFraction unitRef="shares" contextRef="i4879e95ef7744941b0e26ca90bfc6605_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfNS0xLTEtMS0w_e3292d77-99ff-45f4-99b0-d42b1208c41a">13,201</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d57d7b84fb04a96892f11a0576100dd_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfNS0zLTEtMS0w_472202f9-b1d5-4b23-9f49-ce6c9be83a68"><ix:nonFraction unitRef="shares" contextRef="ic96c925a7d99431399902b60bcb6babb_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfNS0zLTEtMS0w_d488a53d-0dea-4ffd-80c8-7bc245c512d4">13,754</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfNi0xLTEtMS0w_49f8bb56-a4b8-43ac-a707-83d380698f8e"><ix:nonFraction unitRef="shares" contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfNi0xLTEtMS0w_94799962-a2c3-4454-827d-d8f0dd58f0ff">7,588,924</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic73499b256364473912a51549d885406_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfNi0zLTEtMS0w_7af52342-c0e7-45a5-90b5-b7272054d8c9"><ix:nonFraction unitRef="shares" contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfNi0zLTEtMS0w_e4d4b535-18b7-45af-8848-b3779aab93a5">6,932,789</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i4174004101c4483bbd134be7ce58ff32_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-looking Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations should be read with our unaudited condensed consolidated financial statements as of September&#160;30, 2020 and for the three and nine months ended September 30, 2020 and 2019, and related notes included in Part I, Item&#160;1 of this Quarterly Report on Form 10-Q, as well as the audited consolidated financial statements and notes and Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019 filed with the SEC on February&#160;19, 2020. This Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations, estimates, forecasts and projections, and the beliefs and assumptions of our management, and include, without limitation, statements with respect to our expectations regarding our research, development and commercialization plans and prospects, results of operations, selling, general and administrative expenses, research and development expenses, the sufficiency of our cash for future operations and business activity disruption due to the COVID-19 pandemic. Words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;strategy,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; &#8220;vision&#8221; and similar statements or variation of these terms or the negative of those terms and similar expressions are intended to identify these forward-looking statements. Readers are cautioned that these forward-looking statements are predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by our forward-looking statements are those discussed under the heading &#8220;Risk Factors&#8221; in Part II, Item&#160;1A and elsewhere in this report, and in our Annual Report on Form 10-K for the year ended December&#160;31, 2019. We undertake no obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.</span></div><div id="i4174004101c4483bbd134be7ce58ff32_73"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company committed to transforming patients&#8217; lives through scientific leadership in the field of cellular metabolism and adjacent areas of biology, with the goal of creating differentiated, small molecule medicines for patients in the areas of hematologic malignancies, solid tumors and rare genetic diseases, or RGDs. To address these focus areas, we take a systems biology approach to deeply understand disease states, drive the discovery and validation of novel therapeutic targets, and define patient selection strategies, thereby increasing the probability that our experimental medicines will have the desired therapeutic effect.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hematologic malignancies and solid tumors</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing ivosidenib for the treatment of IDH1 mutant-positive cancers. Ivosidenib is an orally available, selective, potent inhibitor of the mutated IDH1 protein, making it a highly targeted therapy for the treatment of patients with cancers that harbor IDH1 mutations, including those with acute myeloid leukemia, or AML, myelodysplastic syndromes, or MDS, and cholangiocarcinoma. We hold worldwide development and commercial rights to ivosidenib and have licensed certain development and commercialization rights to ivosidenib to CStone in mainland China, Hong Kong, Macau, Taiwan, and Singapore. We will fund the future development and commercialization costs related to this program with the exception of development and commercialization activities of CStone under the CStone Agreement. The FDA has approved TIBSOVO&#174; (ivosidenib) for the treatment of adult patients with R/R AML and a susceptible IDH1 mutation and for the treatment of patients with newly diagnosed AML with a susceptible IDH1 mutation as detected by an FDA-approved test who are at least 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy. In December 2018, we submitted a marketing authorization application, or MAA to the European Medicines Agency, or EMA for TIBSOVO&#174; for the treatment of adult patients with IDH1 mutant-positive R/R AML. In October 2020, we announced the withdrawal of the MAA based on feedback from the EMA's Committee for Medicinal Products for Human Use (CHMP) that the available clinical data from our single arm, uncontrolled Phase 1 trial did not sufficiently support a positive benefit-risk balance for the proposed indication. The FDA granted orphan drug designation for ivosidenib for the treatment of cholangiocarcinoma, granted Breakthrough Therapy designation for ivosidenib in combination with azacitidine for the treatment of newly diagnosed AML with an IDH1 mutation in adult patients who are at least 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy, and granted Breakthrough Therapy designation for ivosidenib for the treatment of adult patients with relapsed or refractory MDS with a susceptible IDH1 mutation as detected by an FDA-approved test.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Celgene, in collaboration with us, is developing enasidenib for the treatment of IDH2 mutant-positive hematologic malignancies. Enasidenib is an orally available, selective, potent inhibitor of the mutated IDH2 protein, making it a highly targeted therapeutic candidate for the treatment of patients with cancers that harbor IDH2 mutations, including those with AML, who have a historically poor prognosis. The FDA has granted Celgene approval of IDHIFA&#174; (enasidenib) for the treatment of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adult patients with R/R AML and an IDH2 mutation. Celgene has worldwide development and commercialization rights for IDHIFA&#174;, and we are eligible to receive royalties at tiered low-double digit to mid-teen percentage rates on any net sales of IDHIFA&#174; and have exercised our rights to provide up to one-third of the field-based commercialization efforts in the United States. On June 11, 2020 we sold our tiered, sales-based royalty rights on worldwide net sales of IDHIFA&#174;, as well as our rights to receive up to $55.0 million in outstanding regulatory milestone payments from Bristol Myers Squibb, or BMS, to Royalty Pharma, or RPI, for $255.0 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pre-commercial clinical cancer product candidates are vorasidenib, AG-270, and AG-636.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing vorasidenib for the treatment of IDH mutant-positive low grade glioma. Vorasidenib is an orally available, selective, brain-penetrant, pan-IDH mutant inhibitor. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing AG-270 for the treatment of cancers carrying a methylthioadenosine phosphorylase, or MTAP, deletion, which is present in approximately 15 percent of all cancers. AG-270 is an orally available selective potent inhibitor of MAT2A. On March 25, 2020, Celgene declined to exercise its right to opt into co-development and co-commercialization for AG-270, our MAT2A inhibitor development program, under the 2016 Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, we made the decision to cease the internal development of AG-636 for the treatment of hematologic malignancies, including lymphoma due to limited enrollment in our phase 1 trial in lymphoma. AG-636 is an inhibitor of the metabolic enzyme dihydroorotate dehydrogenase, or DHODH, licensed by us from Aurigene Discovery Technologies Limited, or Aurigene. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RGDs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lead product candidate in our RGD portfolio, mitapivat, targets pyruvate kinase-R, or PKR, for the treatment of pyruvate kinase, or PK, deficiency and other hemolytic anemias. PK deficiency is a rare genetic disorder that often results in severe hemolytic anemia, jaundice and lifelong conditions associated with chronic anemia and secondary complications due to inherited mutations in the pyruvate kinase enzyme within red blood cells. Mitapivat is an orally available small molecule and a potent activator of the wild-type (normal) and mutated PKR enzymes, which has resulted in restoration of adenosine triphosphate levels and a decrease in 2,3-diphosphoglycerate levels in blood sampled from patients with PK deficiency and treated ex-vivo with mitapivat. We are also developing mitapivat for the treatment of patients with thalassemia and sickle cell disease, or SCD. We have worldwide development and commercial rights to mitapivat and expect to fund the future development and commercialization costs related to this program. The FDA and EMA granted orphan drug designations for mitapivat for the treatment of patients with PK deficiency, and the FDA granted orphan drug designation for mitapivat for the treatment of patients with thalassemia. We are also developing AG-946, a next-generation PKR activator, for the potential treatment of hemolytic anemias.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the aforementioned development programs, we are seeking to advance a number of early-stage discovery programs in the areas of hematological malignancies, solid tumors, and RGDs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration and license agreements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and License Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of the notes to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for a description of the key terms of our arrangements with Celgene and CStone.</span></div><div id="i4174004101c4483bbd134be7ce58ff32_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our condensed consolidated financial statements. We have determined that our most critical accounting policies are those relating to revenue recognition, accrued research and development expenses, stock-based compensation, and the liability related to the sale of future revenue. Except those that have been disclosed in Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the notes to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q, there have been no significant changes to our existing critical accounting policies discussed in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><div id="i4174004101c4483bbd134be7ce58ff32_79"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of COVID-19 on our Business</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of SARS-CoV-2 and the resulting disease COVID-19 has caused an economic downturn on a global scale, as well as significant volatility in the financial markets. In March 2020 the World Health Organization declared COVID-19 a pandemic. As of September 30, 2020, we have not experienced a significant financial or supply chain impact directly related to the pandemic but ha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ve</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> experienced some disruptions to clinical operations, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">timelines to complete </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patient enrollment </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">some of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our clinical trials</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as further described below</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In this time of uncertainty as a result of the C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OVID-19 pandemic, we are continuing to serve our customers while taking precautions to provide a safe work environment for our employees and customers. In March 2020, we established and implemented a work from home policy for our employees. In April 2020, we made internal resource allocation decisions in order to deliver on key business objectives and to increase our financial flexibility, including, pausing the development of certain preclinical research programs, delaying the start of certain longer-term clinical studies, limiting staff hiring, reducing the number of contract workers, and delaying or limiting information technology and facilities infrastructure projects. In June 2020, we implemented Phase 1 of our return to work program, which enabled all of our lab-based employees and related support personnel to return to our Cambridge office, and in September 2020 we began implementing Phase 2 of our return to work program by opening our Cambridge office to an additional, limited number of employees who prefer to work onsite. Our field-based employees engage with healthcare providers and other third parties remotely and, where local regulations allow, on a limited in-person basis. We are conducting our return to work program under strict guidelines as required by federal, state, and local authorities. We have been monitoring our supply chain network for disruptions due to the COVID-19 pandemic, and our third-party manufacturers remain largely unaffected, with any campaign delays experienced to date being limited to a few days in duration. Although global shipping continues to be disrupted due to the pandemic, we have not experienced a supply impact and have accrued additional safety stock of TIBSOVO&#174; in order to further mitigate risk.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the pandemic continues to unfold, the extent of the pandemic&#8217;s effect on our operational and financial performance will depend in large part on future developments, which cannot be predicted with confidence at this time. Future developments include changes in the duration, scope and severity of the pandemic, the actions taken to contain or mitigate its impact, the impact on governmental programs and budgets, the development of treatments or vaccines, and the resumption of widespread economic activity. Any prolonged material disruption of our employees, suppliers, manufacturing, or customers could negatively impact our consolidated financial position, consolidated results of operations and consolidated cash flows.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As a result, we may have to take further actions that we determine are in the best interests of our employees or as required by federal, state, or local authorities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, our operations have primarily focused on organizing and staffing our company, business planning, raising capital, assembling our core capabilities in cellular metabolism, identifying potential product candidates, undertaking preclinical studies, conducting clinical trials, establishing a commercial infrastructure and marketing our approved products. To date, we have financed our operations primarily through commercial sales of TIBSOVO&#174; funding received from our various collaboration agreements discussed above, private placements of our preferred stock, our initial public offering of our common stock and concurrent private placement of common stock to an affiliate of Celgene, and our follow-on public offerings.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, since inception, we have incurred significant operating losses. Our net losses were $229.7 million and $309.1 million for the nine months ended September 30, 2020 and 2019, respectively. As of September&#160;30, 2020, we had an accumulated deficit of $1.7 billion. We expect to continue to incur significant expenses and net losses until such time we are able to report profitable results. Our net losses may fluctuate significantly from year to year. We expect that we will continue to incur significant expenses as we continue to advance and expand clinical development activities for our lead programs: ivosidenib, vorasidenib, mitapivat, AG-270, and AG-946; continue to discover and validate novel targets and drug product candidates; expand and protect our intellectual property portfolio; and hire additional commercial, development and scientific personnel.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our wholly owned product, TIBSOVO&#174;, received approval from the FDA on July 20, 2018 for the treatment of adult patients with R/R AML with susceptible IDH1 mutation. Upon FDA approval of TIBSOVO&#174; in the U.S., we began generating product revenue from sales of TIBSOVO&#174;. We sell TIBSOVO&#174; to a limited number of specialty distributors and specialty pharmacy providers, or collectively, the Customers. These Customers subsequently resell TIBSOVO&#174; to pharmacies or dispense directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of TIBSOVO&#174;.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also recognize collaboration revenue from our agreements with Celgene and CStone, and royalty revenue from Celgene on sales of IDHIFA&#174;. On June 11, 2020, we sold our tiered, sales-based royalty rights on worldwide net sales of IDHIFA&#174; (enasidenib), as well as our rights to receive up to $55.0 million in outstanding regulatory milestone payments from Celgene, a wholly-owned subsidiary of BMS, to RPI for $255.0 million. Due to our continued involvement in the generation of these royalties through our co-promote right, we are treating the sale of these royalties as a liability and will continue to recognize royalty revenue on sales of IDHIFA&#174;.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we expect to continue to generate revenue from a combination of product sales, royalties on product sales, cost reimbursements, milestone payments, and upfront payments to the extent we enter into future collaborations or licensing agreements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of sales</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists primarily of manufacturing costs for sales of TIBSOVO&#174;. Based on our policy to expense costs associated with the manufacturing of our products prior to regulatory approval, certain of the manufacturing costs associated with product shipments of TIBSOVO&#174; recorded during the three and nine months ended September 30, 2020 and three and nine months ended September 30, 2019, respectively, were expensed prior to July 20, 2018 and, therefore, are not included in costs of sales during the three and nine months ended September 30, 2020 and three and nine months ended September 30, 2019, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect research and development costs to increase significantly for the foreseeable future as our product candidate development programs progress. However, the successful development of our product candidates is highly uncertain. As such, at this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the remainder of the development and to commercialize these product candidates. We are also unable to positively predict when future net cash inflows will commence from TIBSOVO&#174; (ivosidenib), vorasidenib, mitapivat, AG-270, AG-946 or any of our other product candidates. This is due to the numerous risks and uncertainties associated with developing medicines, including the uncertainty of:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establishing an appropriate safety profile with an investigational new drug application, or IND, and/or new drug application, or NDA, enabling toxicology and clinical trials;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the successful enrollment in, and completion of, clinical trials;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the receipt of marketing approvals from applicable regulatory authorities;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establishing compliant commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">launching commercial sales of the products, if and when approved, whether alone or in collaboration with others; and</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintaining an acceptable safety profile of the products following approval.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of any of our product candidates would significantly change the costs and timing associated with the development of that product candidate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts, and the development of our product candidates, which include:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">employee-related expenses, including salaries, benefits and stock-based compensation expense;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">expenses incurred under agreements with third parties, including contract research organizations, or CROs, that conduct research and development and both preclinical and clinical activities on our behalf, and the cost of consultants;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the cost of lab supplies and acquiring, developing and manufacturing preclinical and clinical study materials; and</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">facilities, depreciation, and other expenses, which include direct and allocated expenses for rent and the maintenance of facilities, insurance and other operating costs.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the clinical development activities related to our most advanced programs The timing of trial and site initiations, enrollment and data readouts </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may be impacted depending on the duration, scope and severity of the COVID-19 pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ivosidenib (mutant IDH1 inhibitor)</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">A phase 1b, multicenter, international, open-label clinical trial, to evaluate safety and clinical activity of ivosidenib or enasidenib in combination with induction and consolidation therapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation who are eligible for intensive chemotherapy. This trial has completed enrollment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">A phase 1/2 frontline combination clinical trial, conducted by Celgene, of either ivosidenib or enasidenib in combination with VIDAZA&#174; (azacitidine) in newly diagnosed AML patients not eligible for intensive chemotherapy. The trial has completed enrollment.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">AGILE, a global, registration-enabling phase 3 clinical trial, combining ivosidenib and VIDAZA&#174; (azacitidine) in newly diagnosed AML patients with an IDH1 mutation who are ineligible for intensive chemotherapy. The trial is enrolling patients. Although we experienced disruptions related to the COVID-19 pandemic, we expect to complete enrollment in 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">HO150/AMLSG29, an intergroup sponsored, global, registration-enabling phase 3 trial, supported in collaboration with Celgene, combining ivosidenib or enasidenib with standard induction and consolidation chemotherapy in frontline AML patients with an IDH1 or IDH2 mutation. The trial is currently enrolling patients, although we experienced disruptions related to the COVID-19 pandemic.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">A phase 1 multicenter, open-label, dose-escalation and expansion clinical trial, designed to assess its safety, clinical activity and tolerability as a single agent in patients with advanced hematologic malignancies with an IDH1 mutation. The trial recently reopened enrollment of its relapsed or refractory MDS arm. Although we experienced disruptions related to the COVID-19 pandemic, we expect to complete enrollment in 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">A phase 1 multicenter, open-label, dose-escalation and expansion clinical trial, designed to assess its safety, clinical activity and tolerability as a single agent in patients with advanced solid tumors with an IDH1 mutation, including glioma, cholangiocarcinoma, and chondrosarcoma. The trial has completed enrollment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ClarIDHy, a registration-enabling phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial of ivosidenib in previously-treated patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation. The trial has completed enrollment. The primary endpoint of the trial was met and, although we experienced disruptions related to the COVID-19 pandemic, we expect to file an sNDA with the FDA for TIBSOVO&#174; in cholangiocarcinoma in the first quarter of 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">A phase 1 multi-center, open-label clinical trial of ivosidenib in patients with advanced IDH1 mutant-positive solid tumors, including glioma. The trial has completed enrollment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">A perioperative study with ivosidenib and vorasidenib in low grade glioma to further investigate their effects on brain tumor tissue. The trial has completed enrollment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vorasidenib</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">A phase 1 multi-center, open-label clinical trial of vorasidenib in patients with advanced IDH1 or IDH2 mutant-positive solid tumors, including glioma. The trial has completed enrollment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The above mentioned perioperative study with ivosidenib and vorasidenib in low grade glioma to further investigate their effects on brain tumor tissue. The trial has completed enrollment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">INDIGO, a registration-enabling phase 3 clinical trial of vorasidenib in low-grade (grade 2) glioma with an IDH1 or IDH 2 mutation. The trial is enrolling patients, although we experienced disruptions related to the COVID-19 pandemic.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mitapivat: PK Activator</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">DRIVE PK, a global phase 2, first-in-patient, open-label safety and efficacy clinical trial of mitapivat in adult, transfusion-independent patients with PK deficiency. This trial has completed enrollment. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ACTIVATE-T, a single arm, global, pivotal trial of mitapivat in regularly-transfused patients with PK deficiency. The trial has completed enrollment. Although we experienced disruptions related to the COVID-19 pandemic, we expect to report topline data from the trial in the first quarter of 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ACTIVATE, a 1:1 randomized, placebo-controlled, global, pivotal trial of mitapivat in patients with PK deficiency who do not receive regular transfusions. The trial has completed enrollment. Although we experienced disruptions related to the COVID-19 pandemic, we expect to report topline data from the trial by the end of 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">A phase 2, open-label safety and efficacy clinical trial of mitapivat in adult patients with non-transfusion-dependent thalassemia. The trial has completed enrollment. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">In collaboration with the National Institutes of Health, or NIH, we are evaluating mitapivat in a phase 1 trial in patients with sickle cell disease pursuant to a cooperative research and development agreement. The trial is ongoing and enrolling patients, although the NIH experienced disruptions related to the COVID-19 pandemic.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AG-270: Targeting MAT2A for the treatment of MTAP-deleted cancers</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">A phase 1 trial in multiple tumor types carrying an MTAP deletion. The first part of the trial, is a dose-escalation of AG-270 and is complete. The next phase of development consists of two arms evaluating AG-270 in combination with taxanes. One arm of the study will test AG-270 in combination with docetaxel in MTAP-deleted non-small cell lung </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cancer and the other arm will test AG-270 in combination with nab-paclitaxel and gemcitabine in MTAP-deleted pancreatic ductal adenocarcinoma. Both combination arms are enrolling patients, although we experienced disruptions related to the COVID-19 pandemic.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AG-636: Targeting DHODH for the treatment of hematologic malignancies</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">A phase 1 dose-escalation trial of AG-636 in subjects with advanced lymphoma. In the first quarter of 2020, we made the decision to halt internal development of AG-636, due to limited enrollment in this trial, and will wind down the trial during 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AG-946: Next-generation PKR Activator</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">A phase 1 trial of AG-946 in healthy volunteers and in patients with SCD. The trial is currently enrolling healthy volunteers, although we experienced disruptions related to the COVID-19 pandemic.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other research and platform programs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other research and platform programs include activities related to exploratory efforts, target validation and lead optimization for our discovery and follow-on programs, and our proprietary metabolomics platform.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, general and administrative expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in executive, finance, business development, commercial, legal and human resources functions. Other significant costs include facility related costs not otherwise included in research and development expenses, legal fees relating to patent and corporate matters, and fees for accounting and consulting services.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our selling, general and administrative expenses will increase in the future to support continued research and development, and commercialization activities, including the potential commercialization of our product candidates. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, lawyers and accountants, among other expenses.</span></div><div id="i4174004101c4483bbd134be7ce58ff32_82"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior-year amounts have been reclassified to conform with current presentation. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the three and nine months ended September 30, 2020 and 2019</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Revenue</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue &#8211; related party</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue &#8211; other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue &#8211; related party</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,706&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,024&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,151&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,472&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Revenue - Third Quarter of 2020 vs. Third Quarter of 2019 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in total revenue of $8.7&#160;million for the three months ended September 30, 2020 compared to the three months ended September 30, 2019 was primarily due to an increase in product revenue of $14.3 million, partially offset by a decrease in collaboration revenue - related party of $4.3 million. The increase in product revenue was driven by increased sales volume of TIBSOVO&#174;. The decrease in collaboration revenue - related party was due to the completion of the performance obligation under the 2016 Agreement in the second quarter of 2020. </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Revenue - Nine Months ended September 30, 2020 vs. Nine Months ended September 30, 2019 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in total revenue of $76.7 million for the nine months ended September 30, 2020 compared to the nine months ended September 30, 2019 was primarily due to an increase in in product revenue of $41.7 million and an increase in collaboration revenue - related party of $34.6 million. The increase in collaboration revenue - related party for the nine months ended September 30, 2020 was primarily due to our updated estimate of the future costs that would be incurred from on-going research and development services to complete one of our performance obligations under the 2016 Agreement that is recognized over time using an input </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">method, due to Celgene&#8217;s decision to decline extending the research term in the first quarter of 2020. The increase in product revenue was primarily the result of increased sales volume of TIBSOVO&#174;. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Operating Expenses</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost and expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,033&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,084&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,866&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,876&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Operating Expenses - Third Quarter of 2020 vs. Third Quarter of 2019 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in total operating expenses of $10.1 million for the three months ended September 30, 2020 compared to the three months ended September 30, 2019 was primarily due a decrease in research and development expenses of $12.1 million which is described below under Research and Development Expenses. Cost of sales has increased moderately in 2020 as we have depleted our finished goods inventory that was expensed prior to receiving FDA approval of TIBSOVO&#174;.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Operating Expenses - Nine Months ended September 30, 2020 vs. Nine Months ended September 30, 2019 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in total operating expenses of $20.0 million for the nine months ended September 30, 2020 compared to the nine months ended September 30, 2019 was primarily due to a decrease in research and development expenses of $32.9 million which is described below under Research and Development Expenses partially offset by an increase in selling, general and administrative expense of $12.1 million due to higher personnel costs, including stock-based compensation expense, related to additional hiring for our workforce. Cost of sales has increased moderately in 2020 as we have depleted our finished goods inventory that was expensed prior to receiving FDA approval of TIBSOVO&#174;.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses, by major program, are outlined in the table below: </span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enasidenib (IDH2 inhibitor)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ivosidenib (IDH1 inhibitor)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vorasidenib (AG-881) (Pan IDH inhibitor)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mitapivat (PKR activator)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AG-270 (MAT2A inhibitor)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AG-636 (DHODH inhibitor) discontinued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AG-946 (Next-Gen PKR activator)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research and platform programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total direct research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,492&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Facilities and IT related expenses &amp; other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total indirect research and development expenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,191&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,513&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,236&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,999&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,555&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,672&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,728&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,646&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Research and Development Expenses - Third Quarter of 2020 vs. Third Quarter of 2019 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in total research and development expenses of $12.1 million for the three months ended September 30, 2020 compared to the three months ended September 30, 2019 was primarily due to a $6.6 million decrease in ivosidenib costs. The decrease in ivosidenib costs was primarily due to decreased trial activities for the ClarIDHy trial and decreased clinical costs driven by $1.1 million in milestones achieved by HOVON during the three months ended September 30, 2019 for the initiation of the HO150/AMLSG29 trial. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Research and Development Expenses - Nine Months ended September 30, 2020 vs. Nine Months ended September 30, 2019 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in total research and development expenses of $32.9 million for the nine months ended September 30, 2020 compared to the nine months ended September 30, 2019 was primarily due to a $20.3 million decrease in ivosidenib costs, a $5.8 million decrease in other research and platform programs, and a $4.6 million decrease in AG-636 costs. The decrease in ivosidenib costs was primarily due to decreased trial activities for the ClarIDHy trial and decreased clinical costs driven by $5.3 million in milestones achieved by HOVON during the nine months ended September 30, 2019 for the initiation of the HO150/AMLSG29 trial. The decrease in other research and platform programs was primarily driven by planned decreased activity on various exploratory and discovery activities and a $4.0 million upfront payment for exploratory efforts in the second quarter of 2019. The decrease in AG-636 costs was primarily due to the decision to halt internal development of AG-636 in the first quarter of 2020 due to limited enrollment, and a $2.0 million milestone due to Aurigene upon first patient dosing within the phase 1 lymphoma trial in in the second quarter of 2019. </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income and Expense</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,887&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,820&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense for the sale of future revenue</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,767)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,818)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income and Non-Cash Interest Expense for the Sale of Future Revenue- Third Quarter of 2020 vs. Third Quarter of 2019 -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The change in interest income, net is primarily attributable to the decrease in interest rates at the end of the first quarter of 2020, which reduced the interest rates earned by 0.50% to 1.50% from prior periods and the decrease in our outstanding marketable securities balance for the three months ended September 30, 2020. The change in non-cash interest expense for the sale of future revenue was due to the interest expense associated with the sale of future revenue recorded in the three months ended September 30, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income and Non-Cash Interest Expense for the Sale of Future Revenue- Nine Months ended September 30, 2020 vs. Nine Months ended September 30, 2019 -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The change in interest income, net is primarily attributable to the decrease in interest rates at the end of the first quarter of 2020, which reduced the interest rates earned by 0.50% to 1.50% from prior periods and the decrease in our outstanding marketable securities balance for the nine months ended September 30, 2020. The change in non-cash interest expense for the sale of future revenue was due to the interest expense associated with the sale of future revenue recorded in the nine months ended September 30, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss from Operations and Net Loss</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,327)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,060)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223,715)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320,404)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,979)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106,173)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229,713)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309,122)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss from Operations and Net Loss &#8211; Third Quarter of 2020 vs. Third Quarter of 2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; The decrease in loss from operations and net loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three months ended September 30, 2020 compared to the three months ended September 30, 2019 was primarily driven by higher total revenue as described above in Total Revenue and by lower total expenses as described above in Total Operating Expenses. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss from Operations and Net Loss &#8211; Nine Months ended September 30, 2020 vs. Nine Months ended September 30, 2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; The decrease in loss from operations and net loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the nine months ended September 30, 2020 compared to the nine months ended September 30, 2019 was primarily driven by higher total revenue as described above in Total Revenue and by lower total expenses as described above in Total Operating Expenses. </span></div><div id="i4174004101c4483bbd134be7ce58ff32_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of liquidity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, and through September&#160;30, 2020, we have funded our operations through commercial sales of TIBSOVO&#174;, upfront, milestone, extension, cost reimbursement and royalty payments related to our collaboration agreements, product sales, proceeds received from our issuance of preferred stock, our initial public offering and concurrent private placement of common stock to an affiliate of Celgene, and our follow-on public offerings.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 30, 2020, we entered into an at-the-market sales agreement, or the 2020 sales agreement, with Cowen &amp; Company LLC, or Cowen, pursuant to which we may offer and sell shares of our common stock having an aggregate offering price of up to $250.0 million through Cowen pursuant to a universal shelf registration statement on Form S-3 filed with the SEC on April 30, 2020. As of September 30, 2020, $250.0 million in common stock remained available for future issuance under the 2020 sales agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 11, 2020, we sold our tiered, sales-based royalty rights on worldwide net sales of IDHIFA&#174; (enasidenib), as well as our rights to receive up to $55.0 million in outstanding regulatory milestone payments from BMS, to RPI for $255.0 million. Under the 2010 Agreement, we remain eligible to receive a $25.0&#160;million potential milestone payment for the enasidenib program. The potential milestone payment is a $25.0 million milestone payment upon achievement of a specified ex-U.S. commercial milestone event, as well as reimbursement for costs incurred for our co-commercialization efforts and development activities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our existing cash, cash equivalents and marketable securities, we are eligible to earn milestone payments, cost reimbursements, and royalty payments under our collaboration agreements with Celgene and CStone. Our ability to earn the milestone payments, cost reimbursements and royalty payments, and the timing of earning these amounts are dependent upon the timing and outcome of our development, regulatory and commercial activities, and is uncertain at this time. Our right to payments under our collaboration agreements with Celgene and CStone are our only committed potential external source of funds.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash flows</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our cash flows for the nine months ended September 30, 2020 and 2019:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(241,362)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,011)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,350&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,213&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,924&#160;</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,207&#160;</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the nine months ended September 30, 2020, we received $83.3 million from sales of TIBSOVO&#174;, $7.9 million in royalty payments and $4.7 million in cost reimbursements related to our Collaboration Agreements with Celgene, $6.1 million in interest received, and $2.7 million in cost reimbursements related to our CStone Agreement. These amounts were offset by operating expenses driven by research and development costs described above in Research and Development Expenses and increased staffing needs due to our expanding operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2019, we received $41.3 million from sales of TIBSOVO&#174; and $14.3 million in cost reimbursements and royalty payments under our Collaboration Agreements with Celgene. These amounts were offset by increased operating expenses which relate to increases in clinical trial costs due to advancements in our most advanced product candidates, commercialization efforts, expanded facilities and increased staffing needs due to our expanding operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by investing activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Cash provided by investing activities for the nine months ended September 30, 2020 was primarily the result of higher proceeds from maturities and sales of marketable securities than purchases of marketable securities, offset by $13.9 million in purchases of property and equipment. Cash provided by investing activities for the nine months ended September 30, 2019 was primarily the result of higher proceeds from maturities and sales of marketable securities than purchases of marketable securities, offset by $5.3 million in purchases of property and equipment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by financing activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Cash provided by financing activities for the nine months ended September 30, 2020 was primarily the result of net proceeds of $250.5 million from the sale of our tiered, sales-based royalty rights on worldwide net sales of IDHIFA&#174; (enasidenib) and our ex-US regulatory milestones to RPI in June 2020, and the $10.6 million of proceeds received from stock option exercises and purchases made pursuant to our 2013 ESPP. Cash provided by financing activities for the nine months ended September 30, 2019 was primarily the result of the $12.0 million of proceeds received from stock option exercises and purchases made pursuant to our 2013 ESPP.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding requirements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue to commercialize TIBSOVO&#174;, and continue the research, development and clinical trials of, and seek additional marketing approvals for, our product candidates. If we obtain additional marketing approval for any of our other product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of Celgene, CStone or other partners. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our existing cash, cash equivalents and marketable securities as of&#160;September&#160;30, 2020, together with anticipated product revenue, anticipated interest income and anticipated expense reimbursements under our collaboration and license agreements, but excluding any additional program-specific milestone payments, will enable us to fund our operating expenses and capital expenditure requirements to the end of 2022. Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical trials for our product candidates;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the success of and developments regarding, our collaborations;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs, timing and outcome of regulatory review of our product candidates;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">commercialization expenses related to approved medicines such as TIBSOVO&#174; and IDHIFA&#174;;</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">levels of product revenue from sales of TIBSOVO&#174;;</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs associated with preparation for the potential commercial launch of one or more of our product candidates, including the build-out of a limited commercial infrastructure in the EU;</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to establish and maintain additional collaborations on favorable terms, if at all;</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to successfully execute on our strategic plans; </span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">operational delays due to the ongoing COVID-19 pandemic; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the extent to which we acquire or in-license, or monitor or out-license, other medicines and technologies. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other nondilutive strategic transactions. We do not have any committed potential external source of funds other than our collaborations. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed or on attractive terms, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div id="i4174004101c4483bbd134be7ce58ff32_88"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-balance Sheet Arrangements</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC rules. </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements in the normal course of business with CROs for clinical trials and contract manufacturing organization for supply manufacturing and with vendors for preclinical research studies and other services and products for operating purposes. These contractual obligations are cancelable at any time by us, generally upon prior written notice to the vendor.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2020, there were no significant changes to our contractual obligations and commitments described under Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><div id="i4174004101c4483bbd134be7ce58ff32_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk related to changes in interest rates. As of September&#160;30, 2020 and December&#160;31, 2019, we had cash, cash equivalents and marketable securities of $722.4 million and $717.8 million, respectively, consisting primarily of investments in U.S. Treasuries, government securities and corporate debt securities. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investments are primarily in short-term marketable securities. Our marketable securities are subject to interest rate risk and could fall in value if market interest rates increase. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, we do not believe an immediate and uniform 100 basis point change in interest rates would have a material effect on the fair market value of our investment portfolio.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also exposed to market risk related to changes in foreign currency exchange rates. We have contracts with CROs located in Asia and Europe that are denominated in foreign currencies, and we are subject to fluctuations in foreign currency rates in connection with these agreements. We do not currently hedge our foreign currency exchange rate risk. As of September&#160;30, 2020 and December&#160;31, 2019, liabilities denominated in foreign currencies were immaterial.</span></div><div id="i4174004101c4483bbd134be7ce58ff32_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures. Based on that evaluation of our disclosure controls and procedures as of September&#160;30, 2020, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date are effective at the reasonable assurance level. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports it files or submits under the Exchange Act is accumulated and communicated to its management, including its principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, that occurred during the fiscal quarter ended September&#160;30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i4174004101c4483bbd134be7ce58ff32_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div><span><br/></span></div><div id="i4174004101c4483bbd134be7ce58ff32_100"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained herein, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of our management are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;strategy,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; &#8220;vision&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. You should read this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. The risks described are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. These risk factors restate and supersede the risk factors set forth under the heading &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since inception, we have incurred significant operating losses. Our net losses were $411.5 million, $346.0 million and $314.7 million for the years ended December&#160;31, 2019, 2018 and 2017, respectively, and $229.7 million for the nine months ended September 30, 2020. As of September&#160;30, 2020, we had an accumulated deficit of $1.7 billion. To date, we have generated only modest revenue from sales of TIBSOVO&#174; and prior to our sale to RPI of our royalty rights to IDHIFA&#174; and any other product that contains the compound enasidenib as an active ingredient, which we refer to as the RPI Transaction, royalties on sales of IDHIFA&#174; . Other than the FDA approvals of TIBSOVO&#174; (for the treatment of IDH1 mutant-positive adult patients with R/R AML or newly diagnosed AML who are at least 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy) and IDHIFA&#174; (for the treatment of IDH2 mutant-positive adult patients with R/R AML), we have not obtained marketing approval for any of our product candidates, which are in preclinical or clinical development stages. We have financed our operations primarily through public offerings of our common stock and our collaboration agreements with Celgene and have devoted substantially all of our efforts to research and development. We expect to continue to incur significant expenses and net losses until such time as we are able to report profitable results. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that we will incur significant expenses if and as we:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">initiate and continue clinical trials for our products and product candidates, including: ivosidenib, enasidenib, vorasidenib, mitapivat, AG-270 and AG-946;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">continue our research and preclinical development of our product candidates;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">seek to identify additional product candidates;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">seek marketing approvals for our product candidates that successfully complete clinical trials;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establish and maintain a sales, marketing and distribution infrastructure to commercialize any medicines for which we have or may obtain marketing approval;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">require the manufacture of larger quantities of product candidates for clinical development and, potentially, commercialization;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">hire additional clinical, quality control and scientific personnel;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">add additional personnel to support our product development and planned future commercialization efforts and our operations;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">add equipment and physical infrastructure to support our research and development; and</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">acquire or in-license other medicines and technologies.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To become and remain profitable, we must develop and eventually commercialize one or more medicines with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those medicines for which we may obtain marketing approval and satisfying any post-marketing requirements. Notwithstanding the extent to which we may succeed in these activities, we may never generate revenues that are significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect to incur significant expenses as we continue to advance our ongoing activities, particularly as we continue the research and development of, initiate and continue clinical trials of, seek marketing approvals for, and potentially commercialize our product candidates, to the extent that such expenses are not the responsibility of Celgene or other collaborators. For example, we have incurred and expect to continue to incur expenses related to the commercialization of TIBSOVO&#174;, and expect to continue to incur expenses in connection with the build-out of a limited commercial infrastructure in the EU. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our existing cash, cash equivalents and marketable securities as of&#160;September&#160;30, 2020, together with anticipated product revenue, anticipated interest income and anticipated expense reimbursements under our collaboration and license agreements, but excluding any additional program-specific milestone payments, will enable us to fund our operating expenses and capital expenditure requirements to the end of 2022. Our estimate as to how long we expect our existing cash, cash equivalents, and marketable securities to be available to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical trials for our product candidates;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the success of, and developments regarding, our collaborations;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs, timing and outcome of regulatory review of our product candidates;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">commercialization expenses relating to approved medicines such as TIBSOVO&#174; and IDHIFA&#174;;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">levels of product revenue from sales of TIBSOVO&#174;;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the cost associated with preparation for the potential commercial launch of one or more of our product candidates, including the build-out of a limited commercial infrastructure in the EU;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to establish and maintain additional collaborations on favorable terms, if at all; </span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to successfully execute on our strategic plans;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">operational delays due to the COVID-19 pandemic; and</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the extent to which we acquire or in-license, or monitor or out-license, other medicines and technologies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain additional marketing approvals and achieve product sales. In addition, TIBSOVO&#174;, IDHIFA&#174;, or our current and any future product candidates, if approved, may not achieve or maintain commercial success. Even if we succeed in developing and commercializing one or more of our product candidates, we may never achieve sufficient product revenue to achieve or maintain profitability. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time as we can generate positive cash flow, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other nondilutive strategic transactions. We do not have any committed external source of funds, other than agreements with our collaborators, which are limited in scope and duration. To the extent that we raise additional capital from the issuances and sales of our common stock pursuant to the 2020 sales agreement or through the sale of equity or convertible debt securities, the ownership interests of our common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may require us to enter into agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. In addition, securing financing could require a substantial amount of time and attention from our management and may divert a disproportionate amount of their attention away from day-to-day activities, which may adversely affect our management&#8217;s ability to oversee the development of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. For example, in June 2020 we sold our tiered, sales-based royalty rights on worldwide net sales of IDHIFA&#174;, as well as our rights to receive up to $55.0 million in outstanding regulatory milestone payments from BMS to RPI for $255.0 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our short operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commenced operations in late 2008. Our operations to date have been primarily limited to organizing and staffing our company, business planning, raising capital, acquiring and developing our technology, identifying potential product candidates, undertaking preclinical studies and clinical trials of our product candidates, establishing a commercial infrastructure and undertaking commercialization efforts with respect to TIBSOVO&#174; and IDHIFA&#174;. All of our product candidates are still in preclinical and clinical development, with the exception of TIBSOVO&#174; and IDHIFA&#174;. Typically, it takes about 10 to 15 years to develop one new medicine from the time it is discovered to when it is available for treating patients, assuming that it successfully completes all stages of research and development and achieves marketing approval, all of which is highly uncertain. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors that may adversely affect our ability to successfully commercialize our products and product candidates. We are in the process of transitioning from a company with solely a research focus to a company capable of supporting commercial activities and we have not yet demonstrated our ability to conduct large-scale sales and marketing activities. We may not be successful in such a transition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition and operating results may continue to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in tax law may adversely affect our business or financial condition.  On December 22, 2017, the U.S. government enacted the Tax Cuts and Jobs Act, or the Tax Act, which significantly reformed the U.S. Internal Revenue Code of 1986, as amended, or the Code. The Tax Act, among other things, contained significant changes to corporate taxation, including a reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, the limitation of the tax deduction for net interest expense to 30% of adjusted taxable income (except for certain small businesses), the limitation of the deduction for net operating losses arising in taxable years beginning after December 31, 2017 to 80% of current year taxable income and elimination of net operating loss carrybacks for losses arising in taxable years ending after December 31, 2017 (though any such net operating losses may be carried forward indefinitely), the imposition of a one-time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, the elimination of U.S. tax on foreign earnings (subject to certain important exceptions), the allowance of immediate deductions for certain new investments instead of deductions for depreciation expense over time, and the modification or repeal of many business deductions and credits. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of Congress&#8217; response to the COVID-19 pandemic, the Families First Coronavirus Response Act, or FFCR Act, was enacted on March 18, 2020, and the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, was enacted on March 27, 2020. Both contain numerous tax provisions. In particular, the CARES Act retroactively and temporarily (for taxable years beginning before January 1, 2021) suspends application of the 80%-of-income limitation on the use of net operating losses, which was enacted as part of the Tax Act. It also provides that net operating losses arising in any taxable year beginning after December 31, 2017, and before January 1, 2021 are generally eligible to be carried back up to five years. The CARES Act </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">also temporarily (for taxable years beginning in 2019 or 2020) relaxes the limitation of the tax deductibility for net interest expense by increasing the limitation from 30 to 50% of adjusted taxable income.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory guidance under the Tax Act, the FFCR Act and the CARES Act is and continues to be forthcoming, and such guidance could ultimately increase or lessen impact of these laws on our business and financial condition. It is also possible that Congress will enact additional legislation in connection with the COVID-19 pandemic, some of which could have an impact on our company. In addition, it is uncertain if and to what extent various states will conform to the Tax Act, the FFCR Act or the CARES Act.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery, Development, and Commercialization of our Product Candidates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not successfully commercialize TIBSOVO&#174; in current and any additional indications for which it may be approved our prospects may be substantially harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the FDA approved TIBSOVO&#174; for the treatment of adult patients with R/R AML with a susceptible IDH1 mutation, and in May 2019, the FDA approved TIBSOVO&#174; for the treatment of adult patients with newly diagnosed AML with a susceptible IDH1 mutation who are at least 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy. In December 2019, the FDA granted Breakthrough Therapy designation for ivosidenib for the treatment of adult patients with relapsed or refractory MDS with a susceptible IDH1 mutation as detected by an FDA-approved test, and we recently reopened enrollment in the MDS arm of our Phase 1 clinical trial of ivosidenib with the goal of generating sufficient data to pursue a regulatory filing in this indication. We are also evaluating ivosidenib in other clinical trials for the treatment of IDH1 mutant-positive cancers. Our ability to generate product revenue from TIBSOVO&#174; will depend heavily on our successful development and commercialization of the product.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of TIBSOVO&#174; (ivosidenib) could be unsuccessful if:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the medical community and third-party payors no longer accept TIBSOVO&#174; as safe, efficacious, and cost-effective for the treatment of adult patients with R/R AML with a susceptible IDH1 mutation or newly diagnosed AML with a susceptible IDH1 mutation who are at least 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we fail to maintain the necessary financial resources and expertise to manufacture, market and sell TIBSOVO&#174;;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we fail to continue to develop and implement effective marketing, sales and distribution strategies and operations for the development and commercialization of TIBSOVO&#174;;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we fail to continue to develop, validate and maintain a commercially viable manufacturing process for TIBSOVO&#174; that is compliant with current good manufacturing practices;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we fail to successfully obtain third party reimbursement and generate commercial demand that results in sales of TIBSOVO&#174;;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our efforts to commercialize TIBSOVO&#174; are impeded by the effects of the COVID-19 pandemic;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we encounter any third-party patent interference, derivation, inter partes review, post-grant review, reexamination or patent infringement claims with respect to ivosidenib;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we fail to comply with regulatory and legal requirements applicable to the sale of TIBSOVO&#174;;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">competing drug products are approved for the same indications as TIBSOVO&#174;;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">new significant safety risks are identified;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we fail to gain and/or maintain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ivosidenib does not demonstrate acceptable safety and efficacy in current or future clinical trials, or otherwise does not meet applicable regulatory standards for approval in indications other than currently approved indications.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience significant delays or an inability to successfully develop and commercialize TIBSOVO&#174; (ivosidenib), our business would be materially harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to identify or discover potential product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A key element of our strategy is to identify and test compounds that target cellular metabolism and adjacent areas of biology in a variety of different types of hematologic malignancies, solid tumors and RGDs, as well as in immune cells for the treatment of cancer. A significant portion of the research that we are conducting involves new compounds and drug discovery methods, including our proprietary technology. The drug discovery that we are conducting using our proprietary technology may not be successful in identifying compounds that are useful in treating cancer or RGDs. In addition, our efforts in the emerging field of metabolic immuno-oncology may not be as successful as our efforts to date in cancer metabolism and RGDs. Furthermore, our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the research methodology used may not be successful in identifying appropriate biomarkers or potential product candidates; or</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be medicines that will receive marketing approval and achieve market acceptance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research programs to identify new product candidates require substantial technical, financial and human resources. We may choose to focus our efforts and resources on a potential product candidate that ultimately proves to be unsuccessful.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to identify suitable compounds for preclinical and clinical development, we will not be able to generate incremental product revenue in future periods, which likely would result in significant harm to our financial position and adversely impact our stock price.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The COVID-19 pandemic, which began in late 2019 and has spread worldwide, has and may continue to affect our ability to initiate or continue our planned, ongoing and future clinical trials, disrupt regulatory activities, disrupt our ability to maintain a commercial infrastructure for our products or have other adverse effects on our business and operations. In addition, this pandemic may continue to adversely impact economies worldwide, which could result in adverse effects on our business and operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic, which began in December 2019, has spread worldwide, causing many governments to implement measures to slow the spread of the outbreak through quarantines, strict travel restrictions, heightened border scrutiny, and other measures. The outbreak and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. The future progression of the pandemic and its effects on our business and operations are uncertain. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a continuation of shelter-in-place orders and/or other mandated local travel restrictions, our employees conducting research and development activities may not be able to access our research space, and our core activities may be significant limited or curtailed, possibly for an extended period of time. In light of the pandemic, we may choose to pause certain research programs, delay the start of certain longer-term clinical trials and limit hiring. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face disruptions that may affect our ability to initiate and complete clinical trials including disruptions in procuring items that are essential for our research and development activities, including, for example, raw materials used in the manufacturing of our product candidates and laboratory supplies for planned and ongoing clinical trials, in each case, for which there may be shortages because of ongoing efforts to address the outbreak. We have enrolled, and seek to enroll, patients in our clinical trials at sites located both in the United States and internationally. Site initiation, participant recruitment and enrollment, participant dosing, distribution of clinical trial materials, study monitoring and data analysis has been and may continue to be paused or delayed due to changes in hospital or university policies, federal, state or local regulations, prioritization of hospital resources toward pandemic efforts, or other reasons related to the pandemic. We have faced and expect to continue to face difficulties recruiting or retaining patients in our ongoing clinical trials because of the pandemic. Patients enrolled in our clinical trials may be unable or unwilling to visit clinical trial sites which may impact the collection of important clinical trial data and has, and may continue to, necessitate remote data verification. In addition limitations in the ability to visit sites has affected, and may continue to adversely affect, our enrollment timelines for our clinical trials, and may adversely affect the timing of completion of our clinical trials or our ability to complete clinical trials in a fully compliant manner. For example, due to disruptions related to the COVID-19 pandemic, we have delayed our expectations for completion of enrollment of our phase 3 AGILE clinical trial and the MDS arm of our phase 1 clinical trial of ivosidenib until 2021. Additionally, the potential suspension of clinical trial activity at clinical trial sites may have an adverse impact on our clinical trial plans and timelines.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have faced and may continue to face disruptions in our ability to prepare and submit applications to regulatory authorities for drug approvals and to build and maintain a commercial infrastructure for our products and product candidates. For example, we plan to submit to the FDA an sNDA for TIBSOVO&#174; for previously treated IDH1 mutant-positive cholangiocarcinoma in the first quarter of 2021, which we originally intended to submit in the fourth quarter of 2020. We may face manufacturing disruptions or disruptions related to the ability to obtain necessary institutional review board, or IRB, or other necessary site approvals, as well as other delays at clinical trial sites.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to the COVID-19 pandemic may redirect resources with respect to regulatory and intellectual property matters in a way that would adversely impact our ability to progress regulatory approvals and protect our intellectual property. In addition, we may face impediments to regulatory meetings and approvals due to measures intended to limit in-person interactions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic may continue to significantly impact economies and financial markets worldwide, which could result in adverse effects on our business and operations, impact our ability to raise additional funds through public offerings and impact the volatility of our stock price and trading in our stock. We cannot be certain what the overall impact of the COVID-19 pandemic will be on our business and it has the potential to adversely affect our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not know whether we will be able to develop any additional medicines of commercial value, based on our approach to the discovery and development of product candidates that target cellular metabolism.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our scientific approach focuses on using our proprietary technology to identify key metabolic enzymes in diseased cells in the laboratory and then using these key enzymes to screen for and identify product candidates targeting cellular metabolism and adjacent areas of biology. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our focus on using our proprietary technology to screen for and identify product candidates targeting cellular metabolism and adjacent areas of biology may not result in the discovery and development of commercially viable medicines to treat patients with hematologic malignancies, solid tumors or RGDs. Any medicines that we develop may not effectively correct metabolic pathways or alter the metabolic state of immune cells. If we are able to develop a product candidate that targets cellular metabolism and adjacent areas of biology in preclinical studies, we may not succeed in demonstrating safety and efficacy of the product candidate in human clinical trials. In addition, even if we obtain marketing approval for one of our product candidates, we can provide no assurance that commercialization of such product candidate will be successful.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend heavily on the success of our clinical product candidates. Clinical trials of our product candidates may not be successful. If we or our collaborators are unable to commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to generate product revenue will depend heavily on the successful development and eventual commercialization of our current and any future product candidates, including vorasidenib, mitapivat, AG-270 and AG-946.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of ivosidenib, vorasidenib, mitapivat, AG-270, and AG-946 and our other product candidates will depend on many factors, including the following:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">successful enrollment in, and completion of, clinical trials;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">safety, tolerability and efficacy profiles that are satisfactory to the FDA, the EMA or any comparable foreign regulatory authority for marketing approval;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">timely receipt of marketing approvals from applicable regulatory authorities;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establishing both clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the performance of any collaborators;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtaining and maintaining patent and trade secret protection and non-patent exclusivity for our medicines;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">launching commercial sales of the medicines, if and when approved, whether alone or in collaboration with others;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">acceptance of the medicines, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">effectively competing with other therapies;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">continuing acceptable safety profile for the medicines following approval;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">enforcing and defending intellectual property rights and claims; and</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">achieving desirable medicinal properties for the intended indications.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of these factors are beyond our control, including clinical development, the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing and sales efforts of any collaborator. If we or any collaborators do not achieve one or more of these factors in a timely manner or at all, we or such collaborators could experience significant delays or an inability to successfully commercialize our most advanced product candidates, which would materially harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If clinical trials of products or product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, and any collaborators, are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining marketing approval from the FDA. Foreign regulatory authorities, such as the EMA, impose similar requirements in foreign jurisdictions. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">safety and efficacy of our product candidates in humans. In June 2018 Celgene submitted an MAA to the EMA for IDHIFA&#174; for IDH2 mutant-positive AML, which it subsequently withdrew in December 2019. In December 2018, we submitted an MAA to the EMA for TIBSOVO&#174; for the treatment of adult patients with IDH1 mutant-positive R/R AML, which we subsequently withdrew in October 2020. We plan to submit an sNDA for TIBSOVO&#174; for previously treated IDH1 mutant-positive cholangiocarcinoma to the FDA in the first quarter of 2021. However, we can provide no assurance that we will successfully submit such sNDA, or any NDA for any of our other product candidates, or that any future MAA, NDA or sNDA submitted by us or Celgene will receive regulatory approval on the timeframe we expect, or at all. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. The clinical development of our product candidates is susceptible to the risk of failure inherent at any stage of product development, including failure to demonstrate efficacy in a clinical trial or across a broad population of patients, the occurrence of adverse events that are severe or medically or commercially unacceptable, failure to comply with protocols or applicable regulatory requirements and determination by the FDA or any comparable foreign regulatory authority that a product candidate may not continue development or is not approvable. For instance, in December 2016, we withdrew our IND for AG-519, our second PKR activator, following verbal notification of a clinical hold from the FDA relating to a previously disclosed case of drug-induced cholestatic hepatitis which occurred in our phase 1 clinical trial of AG-519 in healthy volunteers. Although these decisions and this hepatic adverse event finding do not affect our ongoing clinical trials for mitapivat, our first PKR activator, we cannot provide any assurances that there will not be similar or other treatment-related severe adverse events in our other clinical trials of mitapivat, that our other trials will not be placed on clinical hold in the future, or that patient recruitment for our other trials will not be adversely impacted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that even if one or more of our product candidates has a beneficial effect, that effect will not be detected during clinical evaluation as a result of one or more of a variety of factors, including the size, duration, design, measurements, conduct or analysis of our clinical trials. Conversely, as a result of the same factors, our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any. Similarly, in our clinical trials we may fail to detect toxicity of, or intolerability caused by our product candidates, or mistakenly believe that our product candidates are toxic or not well-tolerated when that is not in fact the case.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any inability to successfully complete preclinical and clinical development could result in additional costs to us, or any collaborators, and impair our ability to generate revenue from product sales, regulatory and commercialization milestones and royalties. Moreover, if we or our collaborators are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we or our collaborators are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we or our collaborators may:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">be delayed in obtaining marketing approval for our product candidates;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">not obtain marketing approval at all;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">be subject to additional post-marketing testing requirements; or</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">have the medicine removed from the market after obtaining marketing approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to successfully complete clinical trials of our product candidates and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market any of our product candidates would significantly harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we, or any collaborators, experience any of a number of possible unforeseen events in connection with clinical trials of our product candidates, potential clinical development, marketing approval or commercialization of our product candidates could be delayed or prevented.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaborators may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">regulators or institutional review boards may not authorize us, our collaborators or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we or our collaborators may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">clinical trials of our product candidates may produce negative or inconclusive results, and we or our collaborators may decide, or regulators may require us, to conduct additional clinical trials, including testing in more subjects, or abandon product development programs;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate; enrollment in these clinical trials, which may be particularly challenging for some of the orphan diseases we target in our RGD programs, may be slower than we anticipate; or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">third-party contractors used by us or our collaborators may fail to comply with regulatory requirements or meet their contractual obligations in a timely manner, or at all;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we or our collaborators might have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">regulators, institutional review boards, or the data safety monitoring board for such trials may require that we, our collaborators or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the cost of clinical trials of our product candidates may be greater than anticipated;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; and</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our product candidates may have undesirable side effects or other unexpected characteristics, causing us, our collaborators or our investigators, regulators or institutional review boards to suspend or terminate the trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should the COVID-19 pandemic persist and/or spread, our clinical development plans could be affected. Site initiation, participant recruitment and enrollment, participant dosing, distribution of clinical trial materials, study monitoring and data analysis may be paused or delayed due to changes in hospital or university policies, federal, state or local regulations, prioritization of hospital resources toward pandemic efforts, or other reasons related to the pandemic. Some participants and clinical investigators may not be able to comply with clinical trial protocols, for example if quarantines or other travel limitations continue to impede participant movement, affect sponsor access to study sites, or interrupt healthcare services, and we may be unable to conduct our clinical trials. For example, due to disruptions related to the COVID-19 pandemic, we have delayed our expectations for completion of enrollment of our phase 3 AGILE clinical trial and the MDS arm of our phase 1 clinical trial of ivosidenib until 2021. Furthermore, site initiations and patient enrollment may be delayed or suspended by local health authorities considering the COVID-19 outbreak.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product development costs for us, or any collaborators, will increase if we, or they, experience delays in testing or pursuing marketing approvals and we, or they, may be required to obtain additional funds to complete clinical trials and prepare for possible commercialization of our product candidates. We do not know whether any preclinical tests or clinical trials will begin as planned, will need to be restructured, or will be completed on schedule or at all. Significant preclinical study or clinical trial delays also could shorten any periods during which we, or any collaborators, may have the exclusive right to commercialize our product candidates or allow our competitors, or the competitors of any collaborators, to bring products to market before we, or any collaborators, do and impair our ability, or the ability of any collaborators, to successfully commercialize our product candidates and may harm our business and results of operations. In addition, many of the factors that lead to clinical trial delays may ultimately lead to the denial of marketing approval of any of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaborators may not be able to initiate or continue clinical trials for our product candidates if we or they are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or analogous regulatory authorities outside the United States. For example, in the first quarter of 2020, we made the decision to halt internal development of AG-636 for the treatment of hematologic malignancies, including lymphoma due to limited enrollment in our phase 1 trial in lymphoma. Furthermore, enrollment has been and may continue to be particularly challenging in light of the ongoing COVID-19 pandemic and even more so for some of the orphan diseases we target in our RGD programs. For example, due to disruptions related to the COVID-19 pandemic, we have delayed our expectations for completion of enrollment of our phase 3 AGILE clinical trial and the MDS arm of our phase 1 clinical trial of ivosidenib until 2021. </span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment is also affected by other factors including:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">prevalence and severity of the disease under investigation;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">availability and efficacy of approved medications for the disease under investigation;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">eligibility criteria for the study in question;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">perceived risks and benefits of the product candidate under study;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">efforts to facilitate timely enrollment in clinical trials;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">patient referral practices of physicians;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the ability to monitor patients adequately during and after treatment; and</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">proximity and availability of clinical trial sites for prospective patients.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilizing our precision medicine approach, we generally focus our development activities on genetically or biomarker defined patients most likely to respond to our therapies. As a result, the potential patient populations for our clinical trials are narrowed, and we may experience difficulties in identifying and enrolling a sufficient number of patients in our clinical trials. In particular, the successful completion of our clinical development program for mitapivat for the treatment of PK deficiency is dependent upon our ability to enroll a sufficient number of patients with PK deficiency. PK deficiency is a rare disease with a small patient population. Further, there are only a limited number of specialist physicians that regularly treat patients with PK deficiency and major clinical centers that support PK deficiency are concentrated in a few geographic regions. The small population of patients, the nature of the disease and limited trial sites may make it difficult for us to enroll enough patients to complete our clinical trials for mitapivat for PK deficiency in a timely and cost-effective manner.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, some of our competitors may have ongoing or planned clinical trials for product candidates that would treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. For example, Daiichi Sankyo Company, Ltd., or Daiichi Sankyo, with DS-1001b, Bayer AG, or Bayer, with BAY1436032, and Forma Therapeutics Holdings, LLC, or Forma, with FT-2102, are conducting clinical trials that are targeted specifically towards patients with IDH1 mutant positive-cancers and/or include IDH mutant positive populations; Rocket Pharma LTD, or Rocket Pharma, is conducting a clinical trial of a gene therapy targeting PK deficiency; Forma is developing a PKR activator for the treatment of hemolytic anemias, including PK deficiency and SCD; and IDEAYA Biosciences, Inc., or IDEAYA, is developing a MAT2A inhibitor for the treatment of MTAP-deleted cancers. As these companies and others initiate and conduct clinical trials, they may compete for eligible patients with our clinical trials of our product candidates. Competition for these patients may make it particularly difficult for us to enroll enough patients to complete our clinical trials for our product candidates in a timely and cost-effective manner.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on CROs, and clinical trial sites to ensure the proper and timely conduct of our clinical trials and while we have agreements governing their committed activities, we have limited influence over their actual performance. Our or our collaborators&#8217; inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If serious adverse side effects or unexpected characteristics are identified during the development of our product candidates, we may need to abandon or limit our development of some of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the exception of TIBSOVO&#174; and IDHIFA&#174;, our most advanced product candidates are still in clinical stage development and their risk of failure is high. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans or will receive marketing approval. Adverse events or undesirable side effects caused by, or other unexpected properties of, our product candidates could cause us or any collaborators, an institutional review board or regulatory authorities to interrupt, delay or halt clinical trials of one or more of our product candidates and could result in a more restrictive label, or the delay or denial of marketing approval by the FDA or comparable foreign regulatory authorities. If adverse effects were to arise in patients being treated with any of our product candidates, it could require us to halt, delay or interrupt clinical trials of such product candidate or adversely affect our ability to obtain requisite approvals to advance the development and commercialization of such product candidate. If any of our product candidates is associated with adverse events or undesirable side effects or has properties that are unexpected, we, or any collaborators, may need to abandon development or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds that initially showed promise in earlier stage testing for treating cancer, RGDs or other diseases have later been found to cause side effects that prevented further development of the compound. For instance, in December 2016, we withdrew our IND for AG-519, our second PKR activator, following verbal notification of a clinical hold from the FDA relating to a previously disclosed case of drug-induced cholestatic hepatitis which occurred in our phase 1 clinical trial of AG-519 in healthy volunteers. Although these decisions and this hepatic adverse event finding do not affect our ongoing clinical trials for mitapivat, we cannot provide any assurances that there will not be similar or other treatment-related severe adverse events in our other clinical trials for mitapivat, that our other trials will not be placed on clinical hold in the future, or that patient recruitment for our other trials will not be adversely impacted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of preclinical studies and early clinical trials may not be predictive of results of future clinical trials.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of clinical trials do not necessarily predict success in future clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in earlier development, and we could face similar setbacks. The design of a clinical trial can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. In addition, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for the product candidates. Even if we, or any collaborators, believe that the results of clinical trials for our product candidates warrant marketing approval, the FDA or comparable foreign regulatory authorities may disagree and may not grant marketing approval of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. If we fail to receive positive results in clinical trials of our product candidates, the development timeline and regulatory approval and commercialization prospects for our most advanced product candidates, and, correspondingly, our business and financial prospects would be negatively impacted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial medicines or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable medicines. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to successfully develop companion diagnostics for our product candidates, or experience significant delays in doing so, we may not realize the full commercial potential of our therapeutics.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we are focused on precision medicine, in which predictive biomarkers will be used to identify the right patients for our drug candidates, we believe that our success will depend, in part, on our ability to develop companion diagnostics, which are assays or tests to identify an appropriate patient population for these drug candidates. There has been limited success to date industry-wide in developing these types of companion diagnostics. To be successful, we need to address a number of scientific, technical and logistical challenges. We have little experience in the development of diagnostics and may not be successful in developing appropriate diagnostics to pair with any of our therapeutic product candidates that receive marketing approval. Companion diagnostics are subject to regulation by the FDA and similar regulatory authorities outside the United States as medical devices and require separate regulatory approval prior to commercialization. Given our limited experience in developing diagnostics, we rely and expect to continue to rely in part or in whole on third parties for their design and manufacture. We also depend on Abbott Laboratories for the development of the FDA approved diagnostic for TIBSOVO&#174;, and may in the future depend on other third parties for the development of other companion diagnostics for our cancer therapeutic product candidates. If any parties, including without limitation Celgene or us, or any third parties engaged by Celgene or us are unable to successfully develop companion diagnostics for our therapeutic product candidates, or experience delays in doing so:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the development of our therapeutic product candidates may be adversely affected if we are unable to appropriately select patients for enrollment in our clinical trials;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our therapeutic product candidates may not receive marketing approval if safe and effective use of a therapeutic product candidate depends on an in vitro diagnostic; and</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may not realize the full commercial potential of any therapeutics that receive marketing approval if, among other reasons, we are unable to appropriately select patients who are likely to benefit from therapy with our medicines.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of any of these events, our business would be harmed, possibly materially.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if any of our product candidates receives marketing approval, we or others may later discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, which could compromise our ability, or that of any collaborators, to market the product.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials of our product candidates are conducted in carefully defined sets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials, or those of any collaborators, may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If, following approval of a product candidate, we, or others, discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, any of the following adverse events could occur:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">regulatory authorities may withdraw their approval of the product or seize the product;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we, or any collaborators, may be required to recall the product, change the way the product is administered or conduct additional clinical trials;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular product;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may be subject to fines, injunctions or the imposition of civil or criminal penalties;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication, including, for example, the black box warning for differentiation syndrome on the labels for IDHIFA&#174; and TIBSOVO&#174;;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we, or any collaborators, may be required to create a Medication Guide outlining the risks of the previously unidentified side effects for distribution to patients;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we, or any collaborators, could be sued and held liable for harm caused to patients;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the product may become less competitive; and</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our reputation may suffer.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TIBSOVO&#174; and IDHIFA&#174;, or any of our product candidates that receive marketing approval in the future, may fail to gain and/or maintain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. For example, current cancer treatments like chemotherapy and radiation therapy are well established in the medical community, and doctors may continue to rely on these treatments. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenue and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">efficacy and potential advantages compared to alternative treatments;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the approval, availability, market acceptance and reimbursement for the companion diagnostic;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the ability to offer our medicines for sale at competitive prices;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">convenience and ease of administration compared to alternative treatments;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ensuring uninterrupted product supply;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the strength of marketing and distribution support;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">sufficient third-party coverage or reimbursement; and</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the prevalence and severity of any side effects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish and maintain sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates if and when they are approved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited experience in the sale, marketing or distribution of pharmaceutical products. To achieve commercial success for approved medicines for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to other third parties. Although we have established sales and marketing capabilities to support our co-promotion efforts for IDHIFA&#174; and our sales of TIBSOVO&#174;, we will need to further build our sales and marketing infrastructure to sell, or participate in sales activities with our collaborators for, our other product candidates if and when they are approved, including, for example, to support the potential approval of one or more product candidates in the EU.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may inhibit our efforts to commercialize our medicines on our own include:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future medicines;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the lack of complementary medicines to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability of product revenue to us are likely to be lower than if we were to market and sell any medicines that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our medicines effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new drug products is highly competitive. We face competition with respect to our current products and product candidates, and we and our collaborators will face competition with respect to any product candidates that we or they may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of the disease indications for which we are developing our product candidates, such as AML, high risk myelodysplasia, thalassemia and SCD. For example, Jazz Pharmaceuticals plc, AbbVie Inc. (in collaboration with Roche Holdings Inc.), Novartis International AG, or Novartis, Pfizer, Inc., or Pfizer, and Astellas Pharma Inc. are each marketing therapies to treat AML, Acceleron Pharma Inc. and bluebird bio, Inc., or bluebird, are each marketing therapies to treat beta thalassemia, Novartis and Global Blood Therapeutics are each marketing therapies to treat SCD, and a number of other biotechnology companies have product candidates in clinical development in similar indications as ours. Some competitive products and therapies are based on scientific approaches that are the same as or similar to our approach, and others are based on entirely different approaches, for example, in the area of RGDs. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing most of our initial product candidates for the treatment of cancer. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy, and cancer drugs are frequently prescribed off-label by healthcare professionals. Some of the currently approved drug therapies are branded and subject to patent protection, and others are available on a generic basis. Many of these approved drugs are well established therapies and are widely accepted by physicians, patients and third-party payors. Insurers and other third-party payors may also encourage the use of generic products. We expect that our product candidates, if approved, will be priced at a significant premium over competitive generic products, as is the case with TIBSOVO&#174; and IDHIFA&#174;. This may make it difficult for us to achieve our business strategy of using our product candidates in combination with existing therapies or replacing existing therapies with our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also pursuing product candidates to treat patients with RGDs. There are a variety of treatment options available, including a number of marketed enzyme replacement therapies, for treating patients with RGDs. In addition to currently marketed therapies, there are also a number of products that are either enzyme replacement therapies or gene therapies in various stages of clinical development to treat RGDs. These products in development may provide efficacy, safety, convenience and other benefits that are not provided by currently marketed therapies. As a result, they may provide significant competition for any of our product candidates for which we obtain marketing approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also a number of product candidates in preclinical or clinical development by third parties to treat hematologic malignancies, solid tumors and RGDs by targeting similar mechanisms of action as our product candidates. These companies include large pharmaceutical companies, such as AstraZeneca plc, Bayer, Daiichi Sankyo, Eli Lilly and Company, Roche and its subsidiary Genentech, Inc., GlaxoSmithKline plc, Merck, and Pfizer, as well as biotechnology companies of various sizes, such as bluebird, Forma, IDEAYA and Rocket Pharma. In addition, there are several companies developing immunotherapies, including metabolic immunotherapies, targeting cancer, including AstraZeneca plc; BeiGene, Ltd.; Bristol-Myers Squibb Company; GlaxoSmithKline plc; Genentech Inc.; and Merck. Our competitors may develop products that are more effective, safer, more convenient or less costly than any that we are developing or that would render our product candidates obsolete or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">non-competitive. In addition, our competitors may discover biomarkers that more efficiently measure metabolic pathways than our methods, which may give them a competitive advantage in developing potential products. Our competitors may also obtain marketing approval from the FDA or other regulatory authorities for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other clinical stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the FDA does not grant our products appropriate periods of data exclusivity before approving generic versions of our products, the sales of our products could be adversely affected. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With FDA approval of an NDA, the product covered by the application is specified as a &#8220;reference-listed drug&#8221; in the FDA&#8217;s publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; or the Orange Book. Manufacturers may seek approval of generic versions of reference-listed drugs through submission of abbreviated new drug applications, or ANDAs, in the United States. In support of an ANDA, a generic manufacturer need not conduct clinical trials. Rather, the applicant generally must show that its product has the same active ingredient(s), dosage form, strength, route of administration and conditions of use or labeling as the reference-listed drug and that the generic version is bioequivalent to the reference-listed drug, meaning it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring to market than the reference-listed drug and companies that produce generic products are generally able to offer them at lower prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any reference-listed drug may be typically lost to the generic product. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may not approve an ANDA for a generic product until any applicable period of non-patent exclusivity for the reference-listed drug has expired. The Federal Food, Drug, and Cosmetic Act, or FDCA, provides a period of five years of non-patent exclusivity for a new drug containing a new chemical entity. Specifically, in cases where such exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification that a patent covering the reference-listed drug is either invalid or will not be infringed by the generic product, in which case the applicant may submit its application four years following approval of the reference-listed drug. The FDCA also provides a period of three years of new clinical investigation data exclusivity in connection with the approval of a supplemental indication for the product for which a clinical trial is essential for approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that a generic manufacturer is somehow able to obtain FDA approval without adherence to these periods of data exclusivity, the competition that our approved products may face from generic versions could negatively impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on our investments in those product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us or our collaborators could cause us or our collaborators to incur substantial liabilities and could limit commercialization of any medicines that we or they may develop.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk as we or they commercially sell any medicines that we or they may develop. If we or our collaborators cannot successfully defend ourselves or themselves against claims that our product candidates or medicines caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">decreased demand for any product candidates or medicines that we may develop;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">injury to our reputation and significant negative media attention;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">significant costs to defend the related litigation;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">loss of revenue;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">reduced resources of our management to pursue our business strategy; and</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the inability to commercialize any medicines that we may develop.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain product liability insurance coverage, it may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage as we advance or expand our clinical trials and if we successfully commercialize any medicine. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. In addition, if one of our collaboration partners were to become subject to product liability claims or were unable to successfully defend themselves against such claims, any such collaboration partner could be more likely to terminate such relationship with us and therefore substantially limit the commercial potential of our products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, or those of any third parties with which we contract, may fail or suffer security breaches, which could result in a material disruption of our product development programs. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems and those of third parties with which we contract are vulnerable to damage from computer viruses, worms and other destructive or disruptive software, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such systems are also vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees, third-party vendors and/or business partners, or from cyber attacks by malicious third parties. Cyber incidents are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber incidents could include the deployment of harmful malware, ransomware, denial-of-service attacks, unauthorized access to or deletion of files, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. Cyber incidents also could include phishing attempts or e-mail fraud to cause payments or information to be transmitted to an unintended recipient. We could be subject to risks caused by misappropriation, misuse, leakage, falsification or intentional or accidental release or loss of information maintained in the information systems and networks of our company, including personal information of our employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">System failures, accidents, cyber attacks or security breaches could cause interruptions in our operations, and could result in a material disruption of our clinical and commercialization activities and business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions, in addition to possibly requiring substantial expenditures of resources to remedy. For example, the loss of clinical trial data from completed or future trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and our product research, development and commercialization efforts could be delayed. In addition, we may not have adequate insurance coverage to provide compensation for any losses associated with such events.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a material breach of our security or that of our vendors occurs, the market perception of the effectiveness of our security measures could be harmed, we could lose business and our reputation and credibility could be damaged. We could be required to expend significant amounts of money and other resources to repair or replace information systems or networks. Although we develop and maintain systems and controls designed to prevent these events from occurring, and we have a process to identify and mitigate threats, the development and maintenance of these systems, controls and processes is costly and requires ongoing monitoring and updating as technologies change and efforts to overcome security measures become more sophisticated. Moreover, despite our efforts, the possibility of these events occurring cannot be eliminated entirely.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which we must comply. For example, the collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the EU, including personal health data, is subject to EU General Data Protection Regulation, or the GDPR, which took effect across all member states of the European Economic Area, or EEA, in May 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to: processing health and other sensitive data; obtaining consent of individuals to whom the personal health data relates; providing information to individuals regarding data processing activities; implementing safeguards to protect the security and confidentiality of personal data; providing notification of data breaches; and taking certain measures when engaging third-party processors. The GDPR increases our obligations with respect to clinical trials conducted in the EEA by expanding the definition of personal data to include coded data and requiring changes to informed consent practices and more detailed notices for clinical trial subjects and investigators. In addition, the GDPR also imposes strict rules on the transfer of personal data to countries outside the EU, including the United States and, as a result, increases the scrutiny that clinical trial sites located in the EEA should apply to transfers of personal data from such sites to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">countries that are considered to lack an adequate level of data protection, such as the United States. The GDPR also permits data protection authorities to require destruction of improperly gathered or used personal information and/or impose substantial fines for violations of GDPR, which can be up to four percent of global revenues or 20 million Euros, whichever is greater, and it also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of GDPR. In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the breadth and depth of changes in data protection obligations, preparing for and complying with the GDPR&#8217;s requirements is rigorous and time intensive and requires significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data collected in the EU. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from our clinical trials, could require us to change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and increase our cost of doing business, and could lead to government enforcement actions, private litigation and significant fines and penalties against us and could have a material adverse effect on our business, financial condition or results of operations. Similarly, failure to comply with federal and state laws regarding privacy and security of personal information could expose us to fines and penalties under such laws. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar privacy and data security requirements are either in place or underway in the United States. There are a broad variety of data protection laws that are applicable to our activities, and a wide range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission and state Attorneys General all are aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered at both the state and federal levels. For example, the California Consumer Privacy Act, which went into effect on January 1, 2020, is creating similar risks and obligations as those created by GDPR, though the California Consumer Privacy Act does exempt certain information collected as part of a clinical trial subject to the Federal Policy for the Protection of Human Subjects (the Common Rule). Many other states are considering similar legislation. A broad range of legislative measures also have been introduced at the federal level. Accordingly, failure to comply with current and any future federal and state laws regarding privacy and security of personal information could expose us to fines and penalties. We also face a threat of consumer class actions related to these laws and the overall protection of personal data. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on our collaborations and may depend on collaborations with additional third parties for the development and commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to several collaboration agreements, including the 2010 Agreement with Celgene, pursuant to which we and Celgene are evaluating enasidenib in specified clinical trials, and the CStone Agreement, pursuant to which we have granted rights to CStone for the development and commercialization of ivosidenib, either as monotherapy or in combination with other therapies, in the CStone Territory. These collaborations involve complex allocations of rights.  Furthermore, in specified cases these collaborations provide for milestone payments to us based on the achievement of specified clinical development, regulatory and commercial milestones, provide us with royalty-based revenue if certain product candidates are successfully commercialized and provide for cost reimbursements of certain development activities. We cannot predict the success of these collaborations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek other third-party collaborators for the development and commercialization of our product candidates. Our likely collaborators for any collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. If we enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations involving our product candidates, including our collaborations with Celgene and CStone, pose the following risks to us:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations. Under the 2010 Agreement, and the CStone Agreement, development and commercialization plans and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">strategies for licensed programs, such as enasidenib, or in the CStone Territory, ivosidenib, will be conducted in accordance with a plan and budget approved by a joint committee comprised of equal numbers of representatives from each of us and Celgene or CStone, as to which Celgene or CStone, as applicable, may have final decision-making authority.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities. For example, in March 2020, Celgene notified us of its decision to decline its option to enter into a development and commercialization agreement with respect to MAT2A and provided notice of its decision to decline its right to extend the research term of the 2016 Agreement. Further, in April 2020, Celgene notified us that BMS has declined to elect any program for continued development and opt-in rights under the 2016 Agreement.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing, which may result in a need for additional capital to pursue further development or commercialization of the applicable product candidate. For example, under the 2010 Agreement, it is possible for Celgene to terminate the agreement, upon 90 days prior written notice, with respect to any product candidate at any point in the research, development and clinical trial process, without triggering a termination of the remainder of the collaboration arrangement.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our medicines or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Collaborators with marketing and distribution rights to one or more medicines may not commit sufficient resources to the marketing and distribution of such medicine or medicines.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation. For example, under specified circumstances Celgene has the first right to maintain or defend our intellectual property rights with respect to enasidenib under the 2010 Agreement and, although we may have the right to assume the maintenance and defense of our intellectual property rights if Celgene does not, our ability to do so may be compromised by Celgene&#8217;s actions.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our medicines or product candidates or that result in costly litigation or arbitration that diverts management attention and resources.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We may lose certain valuable rights under circumstances identified in our collaborations, including, in the case of our agreements with Celgene, if we undergo a change of control.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates. For example, in September 2018, we and Celgene agreed to terminate the AG-881 Agreements effective as of September 4, 2018, as a result of which we are responsible for future development costs of vorasidenib, other than certain agreed-up costs which we and Celgene had split until December 31, 2018. Celgene can terminate the 2010 Agreement upon 90 days&#8217; notice or upon a material breach of the agreement by us that remains uncured for a period ranging from 60 to 90 days. CStone has the right, under certain circumstances, to terminate the CStone Agreement upon advance notice to us, and may, subject to specified cure periods, terminate the CStone Agreement in the event of our uncured material breach or under specified circumstances relating to our insolvency. </span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">If present or future collaborators of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated. For example, BMS may not retain and motivate key personnel who are important to the continued development of the programs under our agreements with Celgene. In addition, BMS could determine to reprioritize Celgene&#8217;s development programs such that it ceases to diligently pursue the development of our programs, and/or cause the agreement between Celgene and us to terminate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The failure to maintain the CStone Agreement or the failure of CStone to perform its obligations under the CStone Agreement, could negatively impact our business prospects in the CStone Territory.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, we entered into the CStone Agreement, for the development and commercialization of ivosidenib, either as monotherapy or in combination with other therapies, in the CStone Territory. Pursuant to the CStone Agreement, CStone will </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be responsible for the development and commercialization of ivosidenib in the CStone Territory. Our ability to generate royalty and milestone revenue under the CStone Agreement is dependent on CStone&#8217;s performance of its obligations under the agreement. We cannot control the amount and timing of resources that CStone will dedicate to these efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a number of other risks associated with our dependence on the CStone Agreement with respect to ivosidenib in the CStone Territory, including:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">CStone may fail to comply with applicable regulatory guidelines with respect to developing, manufacturing or commercializing ivosidenib, which could adversely impact future development or potential sales of ivosidenib in the CStone Territory or elsewhere;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We and CStone could disagree as to future development plans and CStone may delay, fail to commence or stop future clinical trials or other development;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">There may be disputes between CStone and us, including disagreements regarding the CStone Agreement, that may result in the delay of or failure to achieve developmental, regulatory and sales objectives that would result in milestone or royalty payments, the delay or termination of any future development or commercialization of ivosidenib in the CStone Territory, and/or costly litigation or arbitration that diverts our management&#8217;s attention and resources;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">CStone may fail to provide us with timely and accurate information regarding development, sales and marketing activities or supply forecasts, which could adversely impact our ability to comply with our obligations to CStone, as well as our ability to generate accurate financial forecasts; and</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Business combinations, significant changes in CStone&#8217;s business strategy, or the impact of public health epidemics, such as the COVID-19 pandemic, may adversely affect CStone&#8217;s ability or resources available to perform its obligations under the CStone Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CStone Agreement is also subject to early termination, including through CStone&#8217;s right under certain circumstances to terminate upon advance notice to us. If the CStone Agreement is terminated early, we may not be able to find another collaborator for the further development and commercialization of ivosidenib in the CStone Territory on acceptable terms, or at all, and we may be unable to pursue continued development and commercialization of ivosidenib in the CStone Territory on our own.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely and expect to continue to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not independently conduct clinical trials of any of our product candidates. We rely and expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct our clinical trials. In addition, we currently rely and expect to continue to rely on third parties to conduct some aspects of our research and preclinical testing. Any of these third parties may terminate their engagements with us, some in the event of an uncured material breach and some at any time. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third-parties or to do so on commercially reasonable terms. Switching or adding additional third parties involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays may occur in our product development activities. Although we seek to carefully manage our relationships with our CROs, we could encounter similar challenges or delays in the future and these challenges or delays could have a material adverse impact on our business, financial condition and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, and legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our responsibility to comply with any such standards. We and these third parties are required to comply with current good clinical practices, or cGCP, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area and comparable foreign regulatory authorities for all of our products in clinical development. Regulatory authorities enforce these cGCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA, or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with cGCP regulations. In addition, our clinical trials must be conducted with product produced under current good manufacturing practices, or cGMP, regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a U.S. government-sponsored database, clinicaltrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, third parties on whom we rely may also have relationships with other entities, some of which may be our competitors. In addition, these third parties are not our employees, and except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our on-going clinical, nonclinical and preclinical programs. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our medicines. As a result, our results of operations and the commercial prospects for our medicines would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely and expect to continue to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our medicines, producing additional losses and depriving us of potential product revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We contract with third parties for the manufacture of our product candidates for preclinical and clinical testing and expect to continue to do so for late-stage clinical trials and for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or medicines or that such supply will not be available to us at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any manufacturing facilities. We currently rely, and expect to continue to rely, on third-party manufacturers for the manufacture of our product candidates for preclinical and clinical testing and for commercial supply of any of these product candidates for which we or our collaborators obtain marketing approval. To date, we have obtained materials for our product candidates for our ongoing preclinical and clinical testing from third-party manufacturers. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have long-term supply agreements in place for commercial supply of TIBSOVO&#174; with third-party manufacturers, we may be unable to establish any further long-term supply agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">reliance on the third party for regulatory compliance and quality assurance;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the possible breach of the manufacturing agreement by the third party;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us; and</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">reliance on the third party for regulatory compliance, quality assurance, environmental and safety and pharmacovigilance reporting.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements on a global basis. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or medicines, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our medicines and harm our business and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any medicines that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been monitoring our supply chain network for any disruptions due to the COVID-19 pandemic, and our CDMO manufacturers have remained largely unaffected, with any campaign delays experienced to date being limited to a few days in duration. Although global shipping continues to be disrupted due to the pandemic, we have not yet experienced a supply impact and we have accrued additional safety stock of TIBSOVO&#174; in order to further mitigate risk. While we have not yet experienced disruptions to our supply chain due to the COVID-19 pandemic, if either we or any third parties on which we rely are adversely impacted by restrictions resulting from the COVID-19 pandemic, our supply chain may be disrupted, limiting our ability to manufacture our product candidates for our clinical trials and research and development operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for redundant supply for bulk drug substance or drug product. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and anticipated future dependence upon others for the manufacture of our product candidates or medicines may adversely affect our future profit margins and our ability to commercialize any medicines that receive marketing approval on a timely and competitive basis.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek to establish additional collaborations, and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. For some of our product candidates, we may decide to collaborate with additional pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such collaboration could be more attractive than the one with us for our product candidate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential collaborators. Following the discovery phase until termination or expiration of the 2010 Agreement, either in its entirety or with respect to the relevant program, we may not directly or indirectly develop, manufacture or commercialize, outside of the collaboration, any medicine or product candidate with specified activity against any collaboration target that is within a licensed program or against any former collaboration target against which Celgene is conducting an independent program under the agreement. During the term of the CStone Agreement, we are prohibited from developing or commercializing, in the CStone Territory and in specified indications, other compounds or products that inhibit IDH1 mutations at specified levels of binding.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain patent or trade secret protection for our medicines and technology, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize medicines and technology similar or identical to ours, and our ability to successfully commercialize our medicines and technology may be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our proprietary medicines and technology. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and medicines that are important to our business. We do not yet have issued patents for all our most advanced product candidates in all markets in which we intend to commercialize but we continue to actively pursue patent protection for our assets around the world.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process is costly and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify and/or file patent applications on every aspect of our research and development output that is or may be eligible for patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who may have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties, any of these parties may </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. There is also the possibility that loss or theft of data or records may jeopardize the ability to seek patent protection or impede the progress or drafting of patent applications.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed patent rights, and in the future may license additional patent rights, from third parties. Such licenses may be accompanied by milestone and/or royalty payment obligations. These licensed patent rights may be valuable to our business, and we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology or medicines underlying such licenses. We cannot be certain that these patents and applications will be prosecuted and enforced in a manner consistent with the best interests of our business. If any such licensors fail to maintain such patents, or lose rights to those patents, the rights we have licensed may be reduced or eliminated and our right to develop and commercialize any of our products that are the subject of such licensed rights could be adversely affected. In addition to the foregoing, the risks associated with patent rights that we license from third parties also apply to patent rights we own.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect our technology or medicines or that effectively prevent others from commercializing competitive technologies and medicines. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore we cannot be certain that we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming the other requirements for patentability are met, prior to March 2013, in the United States, the first to make the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. Beginning in March 2013, the United States transitioned to a first inventor to file system in which, assuming the other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent. We may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant and inter partes review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize medicines without infringing third-party patent rights.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of the patent or in one or more patent claims being narrowed or invalidated, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and medicines. Given the significant amount of time required for the discovery, development, preclinical and clinical testing and regulatory review and approval of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. In such circumstances we would be relying primarily on regulatory or marketing exclusivity to exclude others from commercializing a generic version of our products. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents and other intellectual property rights. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may initiate legal proceedings alleging that we or our collaborators are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights. Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. We have in the past and may in the future become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our medicines and technology, including opposition, derivation, revocation, reexamination, post-grant and inter partes review or interference proceedings before the USPTO or other patent offices around the world. For example, in 2011, The Leonard and Madlyn Abramson Family Cancer Research Institute at the Abramson Cancer Center of the University of Pennsylvania initiated a lawsuit against us, one of our founders, Craig B. Thompson, M.D., and Celgene, alleging misappropriation of intellectual property and, in 2012, the Trustees of the University of Pennsylvania initiated a similar lawsuit against us and Dr.&#160;Thompson. Each of these lawsuits was settled in 2012. We are not aware of any other legal proceedings having been filed against us to date. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. If we or one of our collaborators are found to infringe a third party&#8217;s intellectual property rights, we or they could be required to obtain a license from such third party to continue developing and marketing our medicines and technology. However, we or our collaborators may not be able to obtain any required license on commercially reasonable terms or at all. Even if we or our collaborators were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us. We or our collaborators could be forced, including by court order, to cease developing and commercializing the infringing technology or medicine. In addition, we or our collaborators could be found liable for monetary damages. A finding of infringement could prevent us or our collaborators from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we or our collaborators have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees, consultants or advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our organization.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our confidential information related to our proprietary platforms and technology, our business and competitive position could be harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for some of our technology and medicines, we also rely on maintaining the confidentiality of unpatented know-how, technology and other proprietary information, to maintain our competitive position. For example, we consider the confidential information and know-how related to our cellular metabolism technology platform to be our primary intellectual property assets in this space. Unpatented proprietary technical information and know-how can be difficult to protect. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to protect this proprietary technical information and know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated proprietary information is difficult, expensive and time-consuming, and the outcome is unpredictable. If any of our proprietary technical information and know-how were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. Moreover, we anticipate that with respect to this platform, at least some of this technical information and know-how will, over time, be disseminated within the industry through independent development, the publication of journal articles describing the methodology, and the movement of personnel skilled in the art from academic to industry scientific positions.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we complete necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our product candidates. If we or our collaborators are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we or they will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, record keeping, labeling, storage, approval, advertising, promotion, sale and distribution, export and import, are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by the EMA and comparable regulatory authorities in other countries. With the exception of the FDA approvals of IDHIFA&#174; and TIBSOVO&#174;, we and our collaborators have not received approval to market any of our product candidates from regulatory authorities in any jurisdiction. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, it is possible that the FDA or EMA may refuse to accept for substantive review any NDA, sNDA or MAA that we and/or Celgene submit for our product candidates, or may conclude after review of our data that our marketing application is insufficient to obtain marketing approval of our product candidates. If the FDA or EMA does not accept or approve our applications for any of our product candidates, the applicable regulator may require that we conduct additional clinical trials, preclinical studies or manufacturing validation studies and submit that data before reconsidering our applications. Depending on the extent of these or any other FDA- or EMA-required trials or studies, approval of any marketing applications that we submit may be delayed by several years, or may require us to expend more resources than we planned. It is also possible that additional trials or studies, if performed and completed, may not be considered sufficient by the FDA or EMA to approve any marketing applications. For example, Celgene submitted an MAA to the EMA for IDHIFA&#174; for IDH2 mutant-positive AML which it subsequently withdrew in December 2019, and we submitted an MAA to the EMA for TIBSOVO&#174; for the treatment of adult patients with IDH1 mutant-positive R/R AML, which we subsequently withdrew in October 2020. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party contract research organizations to assist us in this process, and failure to obtain marketing approval for our products or product candidates will prevent us from commercializing the product or product candidate in the applicable jurisdictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application we submit, or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we or our collaborators ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved medicine not commercially viable.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the COVID-19 pandemic may continue to disrupt the U.S. and international healthcare and regulatory systems. These disruptions could materially delay the review of, and/or decision making with respect to, marketing approvals for our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidates. Any delay in regulatory review or decision making resulting from such disruptions could materially affect the development of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, if we or our collaborators experience delays in obtaining approval or if we or they fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenue will be materially impaired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain marketing approval in foreign jurisdictions would prevent our medicines from being marketed in such jurisdictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market and sell our medicines in the EU and many other jurisdictions, we or our collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, a product must be approved for reimbursement before the product can be approved for sale in that country. We or our collaborators may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Celgene submitted an MAA to the EMA for IDHIFA&#174; for IDH2 mutant-positive AML, which it subsequently withdrew in December 2019 and we submitted an MAA to the EMA for TIBSOVO&#174; for the treatment of adult patients with IDH1 mutant-positive R/R AML, which we subsequently withdrew in October 2020. Celgene or we may not be successful in obtaining EMA approval of IDHIFA&#174; or TIBSOVO&#174;, respectively, on a timely basis, or ever. Moreover, approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our medicines in any market.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on June&#160;23, 2016, the electorate in the United Kingdom voted in favor of leaving the EU, commonly referred to as Brexit. Following protracted negotiations, the United Kingdom left the EU on January 31, 2020. Under the withdrawal agreement, there is a transitional period until December 31, 2020 (extendable up to two years). The Prime Minister has indicated that the United Kingdom will not seek to extend the transitional period beyond the end of 2020. Negotiations between the United Kingdom and the EU towards a trade agreement have been progressing, but latterly have been subject to late negotiation brinkmanship. If no trade agreement has been reached before the end of the transitional period, there may be significant market and economic disruption. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the regulatory framework for pharmaceutical products in the United Kingdom covering quality, safety, and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales, and distribution of pharmaceutical products is derived from EU directives and regulations, Brexit could materially impact the future regulatory regime that applies to products and the approval of our product candidates in the United Kingdom. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the United Kingdom and/or the EU and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom and/or EU for our product candidates, which could significantly and materially harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, other European countries may seek to conduct referenda with respect to continuing membership with the EU. We do not know to what extent Brexit or other comparable initiatives, or any resulting changes, would affect our ability to conduct clinical trials or obtain marketing approval in these jurisdictions, and each could materially impact our ability to conduct clinical trials or obtain marketing approval on a timely basis, or at all. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A fast track designation by the FDA may not actually lead to a faster development or regulatory review or approval process, nor does it assure approval of the product candidate by FDA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, enasidenib and ivosidenib received fast track designation for treatment of patients with AML that harbor an IDH2 and IDH1 mutation, respectively. If a drug is intended for the treatment of a serious or life-threatening disease or condition and the drug demonstrates the potential to address unmet medical needs for this disease or condition, the drug sponsor may apply for FDA fast track designation. The FDA has broad discretion whether or not to grant fast track designation, so even if we believe a particular product candidate is eligible for such designation, the FDA may decide not to grant it. Even if our product candidates receive fast track designation, we may not experience a faster development process, review or approval, if at all, compared to conventional FDA procedures. The FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We, or any collaborators, may not be able to obtain orphan drug designation or orphan drug exclusivity for our drug candidates and, even if we do, that exclusivity may not prevent the FDA or the EMA from approving competing drugs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs and biologics for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another marketing application for the same product for that time period. The applicable period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a product no longer meets the criteria for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition. Moreover, even after an orphan drug is approved, the FDA can subsequently approve a different product for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2017, the Congress passed the FDA Reauthorization Act of 2017, or FDARA. FDARA, among other things, codified the FDA&#8217;s pre-existing regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. The new legislation reverses prior precedent holding that the Orphan Drug Act unambiguously requires that the FDA recognize the orphan exclusivity period regardless of a showing of clinical superiority. The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any product or product candidate for which we or our collaborators obtain marketing approval could be subject to restrictions or withdrawal from the market and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our medicines, when and if any of them are approved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product or product candidate for which we or our collaborators obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such medicine, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to quality control and manufacturing, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and record keeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the medicine may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine, including the requirement to implement a risk evaluation and mitigation strategy.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other agencies, including the Department of Justice, or the DOJ, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA and DOJ impose stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we market our medicines for uses other than their respective approved indications, we may be subject to enforcement action for off-label marketing. Violations of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations and enforcement actions alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws, which violations may result in the imposition of significant administrative, civil and criminal penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, later discovery of previously unknown adverse events or other problems with our medicines, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">restrictions on such medicine, manufacturers or manufacturing processes;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">restrictions on the labeling or marketing of a medicine;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">restrictions on distribution or use of a medicine;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">requirements to conduct post-marketing studies or clinical trials;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">warning letters or other notice of violation letters;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">withdrawal of the medicine from the market;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">recall of medicines;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">damage to relationships with any potential collaborators;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">unfavorable press coverage and damage to our reputation;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">fines, restitution or disgorgement of profits or revenue;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">suspension or withdrawal of marketing approvals;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">refusal to permit the import or export of our medicines;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">product seizure;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">injunctions or the imposition of civil or criminal penalties; and</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">litigation involving patients using our medicines.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-compliance with EU requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the EU requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with healthcare providers, physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which, in the event of a violation, could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with healthcare providers, physicians and third-party payors may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any medicines for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation or arranging of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal False Claims Act imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, false or fraudulent claims for payment by a federal healthcare program or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per-claim penalties;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs to report payments and other transfers of value to physicians and teaching hospitals; and</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws and transparency statutes, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of EU Member States, such as the U.K. Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Under the Trump Administration&#8217;s regulatory reform initiatives, the FDA&#8217;s policies, regulations and guidance may be revised or revoked and that could prevent, limit or delay regulatory approval of our product candidates, which would impact our ability to generate revenue. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the Trump Administration may impact our business and industry. Namely, the Trump Administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. An under-staffed FDA could result in delays in the FDA&#8217;s responsiveness or in its ability to review submissions or applications, issue regulations or guidance, or implement or enforce regulatory requirements in a timely fashion or at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, on January 30, 2017, President Trump issued an Executive Order, applicable to all executive agencies, including the FDA, which required that for each notice of proposed rulemaking or final regulation to be issued in fiscal year 2017, the agency shall identify at least two existing regulations to be repealed, unless prohibited by law. These requirements are referred to as the &#8220;two-for-one&#8221; provisions. This Executive Order includes a budget neutrality provision that required the total incremental cost of all new regulations in the 2017 fiscal year, including repealed regulations, to be no greater than zero, except in limited circumstances. For fiscal years 2018 and beyond, the Executive Order requires agencies to identify regulations to offset any incremental cost of a new regulation and approximate the total costs or savings associated with each new regulation or repealed regulation. In interim guidance issued by the Office of Information and Regulatory Affairs within OMB on February 2, 2017, the administration indicates that the &#8220;two-for-one&#8221; provisions may apply not only to agency regulations, but also to significant agency guidance documents. In addition, on February 24, 2017, President Trump issued an executive order directing each affected agency to designate an agency official as a &#8220;Regulatory Reform Officer&#8221; and establish a &#8220;Regulatory Reform Task Force&#8221; to implement the two-for-one provisions and other previously issued executive orders relating to the review of federal regulations, however it is difficult to predict how these requirements will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. More recently, on October 9, 2019, President Trump issued executive order (&#8220;Executive Order on Promoting the Rule of Law Through Improved Agency Guidance Documents&#8221;) meant to ensure that agency guidance documents do not establish legally binding requirements and it directs each agency to rescind guidance documents that it determines should no longer be in effect. If these executive actions impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we or any collaborators are able to commercialize any product candidates, such products may become subject to unfavorable pricing regulations and third-party reimbursement practices, which would harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by third-party payors, including government health administration authorities and private health coverage insurers. If coverage and reimbursement is not available, or reimbursement is available only to limited levels, we, or any collaborators, may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us, or any future collaborators, to establish or maintain pricing sufficient to realize a sufficient return on our or their investments. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved drugs. Marketing approvals, pricing and reimbursement for new drug products vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we, or any collaborators, might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay commercial launch of the product, possibly for lengthy time periods, which may negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability or the ability of any collaborators to recoup our or their investment in one or more product candidates, even if our product candidates obtain marketing approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Therefore, our ability, and the ability of any collaborators, to commercialize any of our product candidates will depend in part on the extent to which coverage and reimbursement for these products and related treatments will be available from third-party payors. Third-party payors decide which medications they will cover and establish reimbursement levels. The healthcare industry is acutely focused on cost containment, both in the United States and elsewhere. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability or that of any collaborators to sell our product candidates profitably. These payors may not view our products, if any, as cost-effective, and coverage and reimbursement may not be available to our customers, or those of any collaborators, or may not be sufficient to allow our products, if any, to be marketed on a competitive basis. Cost-control initiatives could cause us, or any collaborators, to decrease the price we, or they, might establish for products, which could result in lower than anticipated product revenue. If the prices for our products, if any, decrease or if governmental and other third-party payors do not provide coverage or adequate reimbursement, our prospects for revenue and profitability will suffer.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, increasingly, third-party payors are requiring higher levels of evidence of the benefits and clinical outcomes of new technologies and are challenging the prices charged. We cannot be sure that coverage will be available for any product candidate that we, or any collaborator, commercialize and, if available, that the reimbursement rates will be adequate. Further, the net reimbursement for drug products may be subject to additional reductions if there are changes to laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. An inability to promptly obtain coverage and adequate payment rates from both government-funded and private payors for any of our product candidates for which we, or any collaborator, obtain marketing approval could significantly harm our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current and future healthcare reform legislation may increase the difficulty and cost for us and any collaborators to obtain reimbursement and commercialize our drug candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, affect our ability, or the ability of any collaborators, to profitably sell any drugs for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any collaborators, may receive for any approved drugs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among the provisions of the Patient Protection and Affordable Care Act, or ACA, of potential importance to our business and our drug candidates are the following:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">an annual, non-deductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">expansion of healthcare fraud and abuse laws, including the civil False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">extension of manufacturers&#8217; Medicaid rebate liability;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">expansion of eligibility criteria for Medicaid programs;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">new requirements to report certain financial arrangements with physicians and teaching hospitals;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include the Budget Control Act of 2011, which, among other things, led to aggregate reductions to Medicare payments to providers of up to 2%&#160;per fiscal year that started in 2013 and will stay in effect through 2024 unless additional Congressional action is taken, and the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. Further, there have been several recent U.S. congressional inquiries and proposed state and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since January 2017, President Trump has signed two Executive Orders designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. One Executive Order directs federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. The second Executive Order terminates the cost-sharing subsidies that reimburse insurers under the ACA. Several state Attorneys General filed suit to stop the administration from terminating the subsidies, but their request for a restraining order was denied by a federal judge in California on October 25, 2017. The loss of the cost share reduction payments is expected to increase premiums on certain policies issued by qualified health plans under the ACA. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Centers for Medicare &amp; Medicaid Services, or CMS, has recently proposed regulations that would give states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. On November 30, 2018, CMS announced a proposed rule that would amend the Medicare Advantage and Medicare Part D prescription drug benefit regulations to reduce out of pocket costs for plan enrollees and allow Medicare plans to negotiate lower rates for certain drugs. Among other things, the proposed rule changes would allow Medicare Advantage plans to use pre authorization (PA) and step therapy (ST) for six protected classes of drugs, with certain exceptions, permit plans to implement PA and ST in Medicare Part B drugs; and change the definition of &#8220;negotiated prices&#8221; while a definition of &#8220;price concession&#8221; in the regulations. It is unclear whether these proposed changes we be accepted, and if so, what effect such changes will have on our business. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results. We continue to evaluate the effect that the ACA and its possible repeal and replacement has on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA. For example, with enactment of the Tax Cuts and Jobs Act of 2017 or TCJA, which was signed by the President on December 22, 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. According to the Congressional Budget Office, the repeal of the individual mandate will cause 13 million fewer Americans to be insured in 2027 and premiums in insurance markets may rise.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA, and therefore because the mandate was repealed as part of the TCJA, the remaining provisions of the ACA are invalid as well. The Trump Administration and CMS have both stated that the ruling will have no immediate effect, and on December 30, 2018 the same judge issued an order staying the judgment pending appeal. The Trump Administration thereafter represented to the Court of Appeals considering this judgment that it does not oppose the lower court's ruling. On July 10, 2019, the Court of Appeals for the Fifth Circuit heard oral argument in this case. In those arguments, the Trump Administration argued in support of upholding the lower court decision. On December 18, 2019, that court affirmed the lower court&#8217;s ruling that the individual mandate portion of the ACA is unconstitutional and remanded the case to the district court for reconsideration of the severability question and additional analysis of the provisions of the ACA. On January 21, 2020, the U.S. Supreme Court declined to review this decision on an expedited basis. On March 2, 2020, the Supreme Court agreed to hear this case and has scheduled oral arguments for November 10, 2020. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to evaluate the effect that the ACA and its possible repeal and replacement could have on our business. It is possible that repeal and replacement initiatives, if enacted into law, could ultimately result in fewer individuals having health insurance coverage or in individuals having insurance coverage with less generous benefits. While the timing and scope of any potential future legislation to repeal and replace ACA provisions is highly uncertain in many respects, it is also possible that some of the ACA provisions that generally are not favorable for the research-based pharmaceutical industry could also be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">repealed along with ACA coverage expansion provisions. Accordingly, such reforms, if enacted, could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition and ability to develop or commercialize product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The costs of prescription pharmaceuticals in the United States and foreign jurisdictions is subject to considerable legislative and executive actions and could impact the prices we obtain for our drug products, if and when approved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs of prescription pharmaceuticals in the United States has also been the subject of considerable discussion in the United States, and members of Congress and the Administration have stated that they will address such costs through new legislative and administrative measures. The pricing of prescription pharmaceuticals is also subject to governmental control outside the United States. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost effectiveness of our product candidates to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our ability to generate revenues and become profitable could be impaired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, there have been several recent U.S. congressional inquiries and proposed federal and proposed and enacted state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. At the federal level, Congress and the current administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. For example, on May 11, 2018, the current administration issued a plan to lower drug prices. Under this blueprint for action, the current administration indicated that the Department of Health and Human Services, or HHS, will take steps to end the gaming of regulatory and patent processes by drug makers to unfairly protect monopolies, advance biosimilars and generics to boost price competition, evaluate the inclusion of prices in drug makers&#8217; ads to enhance price competition, speed access to and lower the cost of new drugs by clarifying policies for sharing information between insurers and drug makers, avoid excessive pricing by relying more on value-based pricing by expanding outcome-based payments in Medicare and Medicaid, work to give Medicare Part D plan sponsors more negotiation power with drug makers, examine which Medicare Part B drug prices could be negotiated by Medicare Part D plans, improve the design of the Medicare Part B Competitive Acquisition Program, update Medicare&#8217;s drug-pricing dashboard to increase transparency, prohibit Medicare Part D contracts that include &#8220;gag rules&#8221; that prevent pharmacists from informing patients when they could pay less out-of-pocket by not using insurance, and require that Medicare Part D plan members be provided with an annual statement of plan payments, out-of-pocket spending, and drug price increases. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More recently, President Trump has issued five executive orders that are intended to lower the costs of prescription drug products. The first order would require all federally qualified health centers to pass on to patients the discounts the health centers receive on insulin and epinephrine through Medicare&#8217;s 340B Drug Discount Program. The second order would establish an international pricing index that would set the price Medicare Part B pays for the costliest medications covered under the program to the lowest price in other economically advanced countries. President Trump initially indicated that this order would be held back until August 24, 2020, but it has not been issued.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The third order is intended to reduce the costs of drugs by supporting the safe importation of prescription drugs. Specifically, the order calls upon the HHS to facilitate grants to individuals of waivers of the prohibition of importation of prescription drugs that would allow patients to import FDA approved drug products from abroad, so long as doing so would result in lower costs. In addition, the order would allow wholesalers and pharmacies to re-import both biological drugs and insulin that were originally manufactured in the United States and then exported for international sale. This action follows the publication of a proposed rulemaking on December 23, 2019, that, if finalized, would allow states or certain other non-federal government entities to submit importation program proposals to the FDA for review and approval. Applicants would be required to demonstrate that their importation plans pose no additional risk to public health and safety and will result in significant cost savings for consumers. At the same time, the FDA issued draft guidance that would allow manufacturers to import their own FDA-approved drugs that are authorized for sale in other countries (multi-market approved products).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fourth executive order would end drug rebates used by health plan sponsors, pharmacies or pharmacy benefit managers, or PBMs, in operating the Medicare Part D program. Specifically, the order directs HHS to exclude from safe harbor protections under the federal anti-kickback statute retroactive price reductions that are not applied at the point-of-sale. Instead, the order requires HHS to establish new safe harbors that would allow health plan sponsors, pharmacies, and PBMs to pass on those discounts to consumers at point-of-sale in order to lower patient&#8217;s out-of-pocket costs and permit the use of certain bona fide PBM service fees. Each of these orders directs the federal government to implement the initiatives outlined in the orders, meaning they will not have immediate effects.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, the fifth order instructs the federal government to develop a list of &#8220;essential&#8221; medicines and then buy them and other medical supplies from U.S. manufacturers instead of from companies around the world, including China. The order is meant to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reduce regulatory barriers to domestic pharmaceutical manufacturing and catalyze manufacturing technologies needed to keep drug prices low and the production of drug products in the United States. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, legislative and regulatory proposals have also been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical drugs. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our drug candidates, if any, may be. In addition, increased scrutiny by the United States Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us and any collaborators to more stringent drug labeling and post-marketing testing and other requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal and/or civil liability and harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and possibly other state and national anti-bribery and anti-money laundering laws in countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, third-party intermediaries, joint venture partners and collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or benefits to recipients in the public or private sector. We may have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. In addition, we may engage third party intermediaries to promote our clinical research activities abroad and/or to obtain necessary permits, licenses, and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of these third-party intermediaries, our employees, representatives, contractors, partners, and agents, even if we do not explicitly authorize or have actual knowledge of such activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncompliance with anti-corruption and anti-money laundering laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension and/or debarment from contracting with certain persons, the loss of export privileges, reputational harm, adverse media coverage, and other collateral consequences. If any subpoenas, investigations, or other enforcement actions are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of operations and financial condition could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of management&#8217;s attention and resources and significant defense and compliance costs and other professional fees. In certain cases, enforcement authorities may even cause us to appoint an independent compliance monitor which can result in added costs and administrative burdens.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we obtain approval to commercialize our product candidates outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that we will be subject to additional risks in commercializing our product candidates outside the United States, including:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">different regulatory requirements for approval of drugs in foreign countries; </span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">reduced protection for intellectual property rights; </span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">business interruptions resulting from geopolitical actions, including war and terrorism or natural disasters including earthquakes, typhoons, floods, fires and the impact of public health epidemics, such as the ongoing COVID-19 pandemic.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employee Matters and Managing Growth</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain our key executives and scientific leadership and to attract, retain and motivate qualified personnel.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the principal members of our management and scientific teams, each of whom is employed &#8220;at will,&#8221; meaning we or they may terminate the employment relationship at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives. We have had recent executive transitions, including of our chief executive officer, chief financial officer, and chief scientific officer. We cannot predict the likelihood, timing or effect of future transitions among our executive leadership. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors, including our scientific co-founders, may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, we were required to close our facilities except for a limited number of essential facilities and laboratory staff. We recently opened our Cambridge office to an additional, limited number of employees who prefer to work onsite, and our field-based employees engage with healthcare providers and other third parties remotely and, where local regulations allow, on a limited in-person basis. In the event of a continuation of shelter-in-place orders and other mandated local travel restrictions, our employees conducting research and development activities may not be able to access our research space, and our core activities may be significantly limited or curtailed, possibly for an extended period of time.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we have established, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately, disclose unauthorized activities to us, or comply with securities laws. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, including for illegal insider trading activities, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Business Conduct and Ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to expand our development, regulatory and future sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to experience growth in the number of our employees and the scope of our operations, including in the areas of drug development, regulatory affairs and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may enter into transactions to acquire other businesses, products or technologies. Because we have not made any acquisitions to date, our ability to do so successfully is unproven. If we do identify suitable candidates, we may not be able to make such acquisitions on favorable terms, or at all. Any acquisitions we make may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our existing business in an effective, timely and non-disruptive manner. Acquisitions may also divert management attention from day-to-day responsibilities, increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or the effect that any such transactions might have on our operating results.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock and Other Matters</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establish a classified board of directors such that not all members of the board are elected at one time;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">allow the authorized number of our directors to be changed only by resolution of our board of directors;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">limit the manner in which stockholders can remove directors from the board;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">limit who may call stockholder meetings;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a shareholder rights plan, or so-called &#8220;poison pill,&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities analysts do not publish research or reports about our business or if they publish negative, or inaccurate, evaluations of our stock, the price of our stock and trading volume could decline.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock relies in part on the research and reports that industry or financial analysts publish about us or our business. If one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price and trading volume to decline.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active trading market for our common stock may not be sustained.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our common stock is listed on the Nasdaq Global Select Market, an active trading market for our shares may not be sustained. If an active market for our common stock does not continue, it may be difficult for our stockholders to sell their shares without depressing the market price for the shares or to sell their shares at all. An inactive trading market for our common stock may also impair our ability to raise capital to continue to fund our operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock is likely to be volatile, which could result in substantial losses for purchasers of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock has been, and may continue to be, volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. For example, since January&#160;1, 2015 the price of our common stock on the Nasdaq Global Select Market has ranged from $27.77 per share to $138.85 per share. The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The COVID-19 pandemic, which has had a broad impact globally, including restrictions on travel and quarantine policies put into place by businesses and governments, may have a material effect on our business. While the full extent of the economic impact and the duration of the pandemic may be difficult to assess or predict, it has already caused, and is likely to result in further, significant disruption of global financial markets, which may reduce our ability to access capital either at all or on favorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the COVID-19 pandemic could materially and adversely affect our business and the value of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price for our common stock may be influenced by many factors, including:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">regulatory actions with respect to our product candidates or our competitors&#8217; products and product candidates;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing and results of clinical trials of product candidates;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">commencement or termination of collaborations for our development programs;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">failure or discontinuation of any of our development programs;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">results of clinical trials of product candidates of our competitors;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">regulatory or legal developments in the United States and other countries;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the recruitment or departure of key personnel;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the level of expenses related to any of our product candidates or clinical development programs;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the results of our efforts to develop additional product candidates or products;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">actual or anticipated changes in estimates as to financial results or development timelines;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">announcement or expectation of additional financing efforts;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">sales of our common stock by us, our insiders or other stockholders;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">variations in our financial results, including fluctuations in levels of sales of TIBSOVO&#174; or results of companies that are perceived to be similar to us;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in estimates or recommendations by securities analysts, if any, that cover our stock;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the societal and economic impact of public health epidemics, such as the ongoing COVID-19 pandemic;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">market conditions in the pharmaceutical and biotechnology sectors;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">general economic, industry and market conditions; and</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the other factors described in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of the forgoing matters were to occur, or if our operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. In the past, following periods of volatility in the market price of a company's securities, securities class-action litigation often has been instituted against that company. Such litigation, if instituted against us, could cause us to incur substantial costs to defend such claims and divert management's attention and resources, which could seriously harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain stockholders hold a substantial number of shares of our common stock. If such stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, shares of common stock that are either subject to outstanding options or reserved for future issuance under our stock incentive plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and Rule 144 and Rule 701 under the Securities Act of 1933, as amended, or the Securities Act, and, in any event, we have filed a registration statement permitting shares of common stock issued on exercise of options or upon vesting of restricted stock units, performance-based stock units or market-based stock units to be freely sold in the public market. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain holders of our common stock are entitled to rights with respect to the registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates. Any sales of securities by these stockholders who have exercised registration rights could have a material adverse effect on the trading price of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our executive officers, directors and principal stockholders maintain the ability to significantly influence all matters submitted to stockholders for approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, our executive officers, directors and a small group of stockholders, in the aggregate, beneficially owned shares representing a significant percentage of our capital stock. As a result, if these stockholders were to choose to act together, they would be able to significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, could significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of our company on terms that other stockholders may desire.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales and issuances of our common stock or rights to purchase common stock could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that significant additional capital will be needed in the future to continue our planned operations. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to those of holders of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section&#160;382 of the Code and corresponding provisions of state law, if a company undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership by certain stockholders over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change taxable income may be limited. Our prior equity offerings and other changes in our stock ownership, some of which are outside of our control, may have resulted or could in the future result in an ownership change. We completed a review of our changes in ownership through December&#160;31, 2019, and determined that we did not have a qualified ownership change since our last review as of December 31, 2018. Future ownership changes under Section 382 may limit the amount of net operating loss and tax credit carryforwards that we could potentially utilize to reduce future tax liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also a risk that due to regulatory changes, such as suspensions on the use of net operating losses, or other unforeseen reasons, our existing net operating losses could expire or otherwise become unavailable to offset future income tax liabilities. As described above in &#8220;Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition,&#8221; the Tax Act, as amended by the CARES Act, includes changes to U.S. federal tax rates and the rules </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">governing net operating loss carryforwards that may significantly impact our ability to utilize our net operating losses to offset taxable income in the future. In addition, state net operating losses generated in one state cannot be used to offset income generated in another state. For these reasons we may be unable to use a material portion of our net operating losses and other tax attributes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxation in numerous U.S. states and territories. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Nevertheless, our effective tax rate may be different than experienced in the past due to numerous factors, including as a result of changes in the mix of our profitability from state to state, the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives and corporate governance practices.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred and will continue to incur significant legal, accounting and other expenses as a public company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Global Select Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations. Our management and other personnel devote, and will need to continue to devote, a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be the sole source of gain for our stockholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders for the foreseeable future.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i4174004101c4483bbd134be7ce58ff32_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description of Exhibit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File&#160;Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date of Filing</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1439222/000119312513307909/d574969dex31.htm">Restated Certificate of Incorporation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 30, 2013</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000119312518353307/d653738dex31.htm">Second Amended and Restated By-Laws</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 19, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31-1x09x30x20.htm">Certification of principal executive officer pursuant to Rule&#160;13a 14(a)/15d 14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31-2x09x30x20.htm">Certification of principal financial officer pursuant to Rule&#160;13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32-1x09x30x20.htm">Certification of principal executive officer pursuant to 18&#160;U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32-2x09x30x20.htm">Certification of principal financial officer pursuant to 18&#160;U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are not embedded within the Inline XBRL document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Calculation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Label Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Presentation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101.INS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">* This certification will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.</span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i4174004101c4483bbd134be7ce58ff32_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4174004101c4483bbd134be7ce58ff32_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:50.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.898%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AGIOS PHARMACEUTICALS, INC.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 5, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jacqualyn A. Fouse</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jacqualyn A. Fouse, Ph.D.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal executive officer)</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 5, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jonathan Biller</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan Biller<br/>Chief Financial Officer and Head of Legal and Corporate Affairs<br/>(principal financial officer)</span></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit31-1x09x30x20.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i597219e26a024e489af257dff5327c41_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jacqualyn A. Fouse, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Quarterly Report on Form 10-Q of Agios Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;5, 2020 </font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:58.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.076%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jacqualyn A. Fouse, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jacqualyn A. Fouse, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal executive officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit31-2x09x30x20.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ifb9efc468a6247cb968664b191af6126_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jonathan Biller, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Quarterly Report on Form 10-Q of Agios Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;5, 2020</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.634%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jonathan Biller</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan Biller</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Chief Financial Officer and Head of Legal and Corporate Affairs</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal financial officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit32-1x09x30x20.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ia59eae75c4144117bac88a7f0c834d1e_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Agios Pharmaceuticals, Inc. (the &#8220;Company&#8221;) for the fiscal quarter ended September&#160;30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Jacqualyn A. Fouse, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that, to her knowledge on the date hereof&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;5, 2020</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:58.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.076%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jacqualyn A. Fouse, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jacqualyn A. Fouse, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal executive officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit32-2x09x30x20.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i4a436fd81851443d9879e5d5a3e5aa4c_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Agios Pharmaceuticals, Inc. (the &#8220;Company&#8221;) for the fiscal quarter ended September&#160;30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Jonathan Biller, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that, to his knowledge on the date hereof&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;5, 2020</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jonathan Biller</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan Biller</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Chief Financial Officer and Head of Legal and Corporate Affairs</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal financial officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>agio-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:deac00a5-3ebc-4b82-b8fc-c0af8bd8bb5e,g:0b2f6d2b-1088-4e3a-817f-9f8454765406-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:agio="http://agios.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://agios.com/20200930">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agio-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agio-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agio-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agio-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://agios.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://agios.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://agios.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://agios.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OverviewandBasisofPresentation" roleURI="http://agios.com/role/OverviewandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Overview and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OverviewandBasisofPresentationAdditionalInformationDetails" roleURI="http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails">
        <link:definition>2402401 - Disclosure - Overview and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://agios.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://agios.com/role/FairValueMeasurements">
        <link:definition>2105103 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://agios.com/role/FairValueMeasurementsTables">
        <link:definition>2306301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>2407402 - Disclosure - Fair Value Measurements - Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetails" roleURI="http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails">
        <link:definition>2408403 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://agios.com/role/MarketableSecurities">
        <link:definition>2109104 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://agios.com/role/MarketableSecuritiesTables">
        <link:definition>2310302 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesAdditionalInformationDetails" roleURI="http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails">
        <link:definition>2411404 - Disclosure - Marketable Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesSummaryofMarketableSecuritiesDetails" roleURI="http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails">
        <link:definition>2412405 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://agios.com/role/Inventory">
        <link:definition>2113105 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://agios.com/role/InventoryTables">
        <link:definition>2314303 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryScheduleofInventoryDetails" roleURI="http://agios.com/role/InventoryScheduleofInventoryDetails">
        <link:definition>2415406 - Disclosure - Inventory - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://agios.com/role/Leases">
        <link:definition>2116106 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://agios.com/role/LeasesTables">
        <link:definition>2317304 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://agios.com/role/LeasesAdditionalInformationDetails">
        <link:definition>2418407 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails" roleURI="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails">
        <link:definition>2419408 - Disclosure - Leases - Schedule of Undiscounted Minimum Rental Commitments Under Non-cancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1" roleURI="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1">
        <link:definition>2419408 - Disclosure - Leases - Schedule of Undiscounted Minimum Rental Commitments Under Non-cancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://agios.com/role/AccruedExpenses">
        <link:definition>2120107 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://agios.com/role/AccruedExpensesTables">
        <link:definition>2321305 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesSummaryofAccruedExpensesDetails" roleURI="http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails">
        <link:definition>2422409 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenue" roleURI="http://agios.com/role/ProductRevenue">
        <link:definition>2123108 - Disclosure - Product Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueTables" roleURI="http://agios.com/role/ProductRevenueTables">
        <link:definition>2324306 - Disclosure - Product Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueScheduleofProductRevenueDetails" roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails">
        <link:definition>2425410 - Disclosure - Product Revenue - Schedule of Product Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails" roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails">
        <link:definition>2426411 - Disclosure - Product Revenue - Schedule of Product Revenue Allowance and Reserves (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueScheduleofRevenueRelatedReservesDetails" roleURI="http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails">
        <link:definition>2427412 - Disclosure - Product Revenue - Schedule of Revenue-Related Reserves (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails" roleURI="http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails">
        <link:definition>2428413 - Disclosure - Product Revenue - Schedule of Changes in Contract Assets and Liabilities, Product Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreements" roleURI="http://agios.com/role/CollaborationandLicenseAgreements">
        <link:definition>2129109 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsTables" roleURI="http://agios.com/role/CollaborationandLicenseAgreementsTables">
        <link:definition>2330307 - Disclosure - Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails" roleURI="http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails">
        <link:definition>2431414 - Disclosure - Collaboration and License Agreements - Celgene Purchase Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsCollaborationRevenueDetails" roleURI="http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails">
        <link:definition>2432415 - Disclosure - Collaboration and License Agreements - Collaboration Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails" roleURI="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails">
        <link:definition>2433416 - Disclosure - Collaboration and License Agreements - Schedule of Changes in Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails" roleURI="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails">
        <link:definition>2434417 - Disclosure - Collaboration and License Agreements - Schedule of Revenues as a Result of Changes in Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsAdditionalInformationDetails" roleURI="http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails">
        <link:definition>2435418 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails" roleURI="http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails">
        <link:definition>2436419 - Disclosure - Collaboration and License Agreements - CStone Pharmaceuticals Purchase Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails" roleURI="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails">
        <link:definition>2437420 - Disclosure - Collaboration and License Agreements - Schedule of Collaboration Revenue from CStone Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails" roleURI="http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails">
        <link:definition>2438421 - Disclosure - Collaboration and License Agreements - Changes in Contract Assets and Liabilities Under CStone Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofFutureRevenue" roleURI="http://agios.com/role/SaleofFutureRevenue">
        <link:definition>2139110 - Disclosure - Sale of Future Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofFutureRevenueTables" roleURI="http://agios.com/role/SaleofFutureRevenueTables">
        <link:definition>2340308 - Disclosure - Sale of Future Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofFutureRevenueAdditionalInformationDetails" roleURI="http://agios.com/role/SaleofFutureRevenueAdditionalInformationDetails">
        <link:definition>2441422 - Disclosure - Sale of Future Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofFutureRevenueScheduleofRoyaltyObligationDetails" roleURI="http://agios.com/role/SaleofFutureRevenueScheduleofRoyaltyObligationDetails">
        <link:definition>2442423 - Disclosure - Sale of Future Revenue - Schedule of Royalty Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://agios.com/role/ShareBasedPayments">
        <link:definition>2143111 - Disclosure - Share-Based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://agios.com/role/ShareBasedPaymentsTables">
        <link:definition>2344309 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsAdditionalInformationDetails" roleURI="http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails">
        <link:definition>2445424 - Disclosure - Share-Based Payments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsSummaryofStockOptionActivityDetails" roleURI="http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails">
        <link:definition>2446425 - Disclosure - Share-Based Payments - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails" roleURI="http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails">
        <link:definition>2447426 - Disclosure - Share-Based Payments - Summary of Unvested RSUs Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails" roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails">
        <link:definition>2448427 - Disclosure - Share-Based Payments - Schedule of Performance-Based and Market- Based Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails" roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails">
        <link:definition>2449428 - Disclosure - Share-Based Payments - Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails" roleURI="http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails">
        <link:definition>2450429 - Disclosure - Share-Based Payments - Expenses Related to Equity-Based Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossperShare" roleURI="http://agios.com/role/LossperShare">
        <link:definition>2151112 - Disclosure - Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossperShareTables" roleURI="http://agios.com/role/LossperShareTables">
        <link:definition>2352310 - Disclosure - Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails" roleURI="http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails">
        <link:definition>2453430 - Disclosure - Loss per Share - Common Stock Excluded from Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="agio_CurrentYearProvisionsForRebateReserve" abstract="false" name="CurrentYearProvisionsForRebateReserve" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate" abstract="false" name="PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" abstract="false" name="ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock" abstract="false" name="RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="agio_CollaborationReceivableOtherCurrent" abstract="false" name="CollaborationReceivableOtherCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock" abstract="false" name="RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="agio_Agreement2010Member" abstract="true" name="Agreement2010Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_OperatingLeaseRightOfUseAssetAmortization" abstract="false" name="OperatingLeaseRightOfUseAssetAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" abstract="false" name="ContractWithCustomerContractAdjustmentRecoveriesPriorYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_DeferredRevenueCurrentMember" abstract="true" name="DeferredRevenueCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_PriorYearProvisionsForRebateReserve" abstract="false" name="PriorYearProvisionsForRebateReserve" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" abstract="false" name="ContractWithCustomerRebateReserveRecoveriesInPriorYears" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_RoyaltyPercentageRemitted" abstract="false" name="RoyaltyPercentageRemitted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="agio_ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts" abstract="false" name="ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_SaleOfFutureRevenueIssuanceCosts" abstract="false" name="SaleOfFutureRevenueIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_PerformanceBasedStockUnitMember" abstract="true" name="PerformanceBasedStockUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_ContractWithCustomerRightToRecoverProductReserve" abstract="false" name="ContractWithCustomerRightToRecoverProductReserve" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_InterestExpenseNonCashSaleOfFutureRevenue" abstract="false" name="InterestExpenseNonCashSaleOfFutureRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfSpecialCaseExtensions" abstract="false" name="RevenueRecognitionMultipleDeliverableArrangementsNumberOfSpecialCaseExtensions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="agio_AccruedResearchAndDevelopmentCostsCurrent" abstract="false" name="AccruedResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_IncreaseDecreaseInCollaborationReceivableOtherCurrent" abstract="false" name="IncreaseDecreaseInCollaborationReceivableOtherCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_CurrentYearProvisionForContractualAdjustments" abstract="false" name="CurrentYearProvisionForContractualAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_TwoThousandAndThirteenStockIncentivePlanMember" abstract="true" name="TwoThousandAndThirteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_ChangeInContractWithCustomerAssetRollForward" abstract="true" name="ChangeInContractWithCustomerAssetRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_CashEquivalentsAndAvailableForSaleSecurities" abstract="false" name="CashEquivalentsAndAvailableForSaleSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_SaleOfFutureRevenuePolicyPolicyTextBlock" abstract="false" name="SaleOfFutureRevenuePolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="agio_GovernmentRebatesRollForward" abstract="true" name="GovernmentRebatesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_ContractWithCustomerPriorYearsReserveRecoveries" abstract="false" name="ContractWithCustomerPriorYearsReserveRecoveries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_UnbilledReceivableDueFromRelatedPartiesCurrentMember" abstract="true" name="UnbilledReceivableDueFromRelatedPartiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_RevenueRecognitionMultipleDeliverableArrangementsTermOfAgreement" abstract="false" name="RevenueRecognitionMultipleDeliverableArrangementsTermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="agio_CollaborationReceivableDueFromRelatedPartiesCurrent" abstract="false" name="CollaborationReceivableDueFromRelatedPartiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold" abstract="false" name="ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerAssetAndLiabilityTable" abstract="true" name="ContractWithCustomerAssetAndLiabilityTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" abstract="false" name="ContractWithCustomerRebateReserveRecoveriesInCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfExtensions" abstract="false" name="RevenueRecognitionMultipleDeliverableArrangementsNumberOfExtensions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="agio_EmployeeStockPurchasePlan2013Member" abstract="true" name="EmployeeStockPurchasePlan2013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized" abstract="false" name="RevenueFromContractsWithCustomersMilestoneRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" abstract="false" name="ContractWithCustomerRightToRecoverProductPriorYearRecoveries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_RPIMember" abstract="true" name="RPIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_ContractWithCustomerPriorYearsReserveProvisions" abstract="false" name="ContractWithCustomerPriorYearsReserveProvisions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerAssetAndLiabilityLineItems" abstract="true" name="ContractWithCustomerAssetAndLiabilityLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock" abstract="false" name="ScheduleOfMarketBasedUnitsActivityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="agio_EmployeePurchasePlanMember" abstract="true" name="EmployeePurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_RevenueRecognitionMultipleDeliverableArrangementsSpecialCaseExtensionTerm" abstract="false" name="RevenueRecognitionMultipleDeliverableArrangementsSpecialCaseExtensionTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue" abstract="false" name="SaleOfFutureRevenuesNonCashRoyaltyRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_SaleOfFutureRevenueRoyaltyObligationAbstract" abstract="true" name="SaleOfFutureRevenueRoyaltyObligationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlockTableTextBlock" abstract="false" name="ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlockTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables" abstract="false" name="ContractWithCustomerAssetProceedsFromCollectionOfReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerRebateReserve" abstract="false" name="ContractWithCustomerRebateReserve" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractualAdjustmentsRollForward" abstract="true" name="ContractualAdjustmentsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_SaleOfFutureRevenueAmortizationOfIssuanceCosts" abstract="false" name="SaleOfFutureRevenueAmortizationOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_OtherStockAwardsMember" abstract="true" name="OtherStockAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_ProvisionForRightToRecoverProductInPriorYears" abstract="false" name="ProvisionForRightToRecoverProductInPriorYears" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts" abstract="false" name="ContractWithCustomerLiabilityIncreaseFromCashReceipts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_MarketBasedStockUnitsMember" abstract="true" name="MarketBasedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_ResearchServicesMember" abstract="true" name="ResearchServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_ContractWithCustomerCurrentYearReserveRecoveries" abstract="false" name="ContractWithCustomerCurrentYearReserveRecoveries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ChangeInContractWithCustomerLiabilityRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_PerformanceStockUnitMember" abstract="true" name="PerformanceStockUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_IncreaseDecreaseInOperatingLeaseLiability" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember" abstract="true" name="CollaborationReceivableDuefromRelatedPartiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" abstract="false" name="ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="agio_ProvisionForRightToRecoverProductInCurrentYear" abstract="false" name="ProvisionForRightToRecoverProductInCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_OptionExerciseFeeReceivable" abstract="false" name="OptionExerciseFeeReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" abstract="false" name="PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_CStonePharmaceuticalsMember" abstract="true" name="CStonePharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty" abstract="false" name="IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerAssetRevenueRecognized" abstract="false" name="ContractWithCustomerAssetRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_SaleOfFutureRevenueRoyaltyObligationTableTextBlock" abstract="false" name="SaleOfFutureRevenueRoyaltyObligationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="agio_NonCurrentAssetsMember" abstract="true" name="NonCurrentAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_RoyaltyRevenueNonCash" abstract="false" name="RoyaltyRevenueNonCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_RoyaltyReceivableDuefromRelatedPartiesCurrent" abstract="false" name="RoyaltyReceivableDuefromRelatedPartiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_SaleOfFutureRevenueLiabilityNoncurrent" abstract="false" name="SaleOfFutureRevenueLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember" abstract="true" name="PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_CStoneAgreementMember" abstract="true" name="CStoneAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_ContractWithCustomerAllowanceAndReservesLiability" abstract="false" name="ContractWithCustomerAllowanceAndReservesLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent" abstract="false" name="IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_MasterResearchAndCollaborationAgreementMember" abstract="true" name="MasterResearchAndCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_SaleOfFutureRevenueInterestExpense" abstract="false" name="SaleOfFutureRevenueInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember" abstract="true" name="RoyaltyReceivableDuefromRelatedPartiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_CollaborationRevenueOtherMember" abstract="true" name="CollaborationRevenueOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember" abstract="true" name="CollaborationReceivableDueFromRelatedPartiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" abstract="false" name="ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold" abstract="false" name="RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_RevenueRecognitionMilestoneMethodEligibleReceivable" abstract="false" name="RevenueRecognitionMilestoneMethodEligibleReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_CelgeneMember" abstract="true" name="CelgeneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_CollaborationRevenueRelatedPartyMember" abstract="true" name="CollaborationRevenueRelatedPartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent" abstract="false" name="IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_CurrentAssetMember" abstract="true" name="CurrentAssetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" abstract="true" name="TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_CommercializationActivityMember" abstract="true" name="CommercializationActivityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward" abstract="true" name="SaleOfFutureRevenueLiabilityNoncurrentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_SaleOfFutureRevenueRoyaltyObligationTextBlock" abstract="false" name="SaleOfFutureRevenueRoyaltyObligationTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="agio_ContractWithCustomerContractualAdjustmentReserve" abstract="false" name="ContractWithCustomerContractualAdjustmentReserve" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_PriorYearProvisionForContractualAdjustments" abstract="false" name="PriorYearProvisionForContractualAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ProductReturnsRollForward" abstract="true" name="ProductReturnsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_ContractWithCustomerTotalAllowancesAndReserves" abstract="false" name="ContractWithCustomerTotalAllowancesAndReserves" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" abstract="false" name="ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="agio_ContractWithCustomerCurrentYearReserveProvisions" abstract="false" name="ContractWithCustomerCurrentYearReserveProvisions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock" abstract="false" name="RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="agio_UpfrontPaymentAgreementExtensionFeeReceivable" abstract="false" name="UpfrontPaymentAgreementExtensionFeeReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>agio-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:deac00a5-3ebc-4b82-b8fc-c0af8bd8bb5e,g:0b2f6d2b-1088-4e3a-817f-9f8454765406-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://agios.com/role/CoverPage" xlink:type="simple" xlink:href="agio-20200930.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://agios.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="agio-20200930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://agios.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_14343f56-5218-4611-bfcd-abb3055a7536" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c682ed92-f57f-4f48-a506-beb8d43b719d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_14343f56-5218-4611-bfcd-abb3055a7536" xlink:to="loc_us-gaap_AssetsCurrent_c682ed92-f57f-4f48-a506-beb8d43b719d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_574ae623-1140-4ae5-94a0-c0bb42eef63c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_14343f56-5218-4611-bfcd-abb3055a7536" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_574ae623-1140-4ae5-94a0-c0bb42eef63c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_11441d50-1a34-4898-aa25-fb48b03003f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_14343f56-5218-4611-bfcd-abb3055a7536" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_11441d50-1a34-4898-aa25-fb48b03003f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b5e5d422-91ef-41ef-9b6c-17a3d5111c35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_14343f56-5218-4611-bfcd-abb3055a7536" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b5e5d422-91ef-41ef-9b6c-17a3d5111c35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_21a224a9-9884-411a-9e31-2c51312fb9b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_14343f56-5218-4611-bfcd-abb3055a7536" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_21a224a9-9884-411a-9e31-2c51312fb9b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2a6ecf40-8548-456f-b863-e7d13c8265fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_14343f56-5218-4611-bfcd-abb3055a7536" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2a6ecf40-8548-456f-b863-e7d13c8265fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_203b6016-5a2a-4020-be36-f9854f118375" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4b7e5d52-4cec-4994-9e45-6d40f7264642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_203b6016-5a2a-4020-be36-f9854f118375" xlink:to="loc_us-gaap_Liabilities_4b7e5d52-4cec-4994-9e45-6d40f7264642" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_672ef192-9324-4245-bc08-343168d1e43f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_203b6016-5a2a-4020-be36-f9854f118375" xlink:to="loc_us-gaap_StockholdersEquity_672ef192-9324-4245-bc08-343168d1e43f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bc35eb88-74d9-4036-a1de-9df24fb777e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7cd7e6c1-f0cf-4f0d-a67c-08b107f36fda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bc35eb88-74d9-4036-a1de-9df24fb777e6" xlink:to="loc_us-gaap_AccountsPayableCurrent_7cd7e6c1-f0cf-4f0d-a67c-08b107f36fda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a7513e99-322b-469f-9380-5f401b84cf00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bc35eb88-74d9-4036-a1de-9df24fb777e6" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a7513e99-322b-469f-9380-5f401b84cf00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4eb377cd-7490-4b89-af1d-26344cdc0eb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bc35eb88-74d9-4036-a1de-9df24fb777e6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_4eb377cd-7490-4b89-af1d-26344cdc0eb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9c96e928-e31f-41ad-b22c-66217aab2550" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bc35eb88-74d9-4036-a1de-9df24fb777e6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9c96e928-e31f-41ad-b22c-66217aab2550" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_6cc1b876-0d94-47ea-bf2a-2797b04fbe01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bc35eb88-74d9-4036-a1de-9df24fb777e6" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_6cc1b876-0d94-47ea-bf2a-2797b04fbe01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_de452df4-40db-46c6-96b6-2c4f9c6b754f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_bc599494-b186-4312-9e88-9267dd37944c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_de452df4-40db-46c6-96b6-2c4f9c6b754f" xlink:to="loc_us-gaap_PreferredStockValue_bc599494-b186-4312-9e88-9267dd37944c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e0a1f12e-532d-48b4-a579-4d6e9b28456d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_de452df4-40db-46c6-96b6-2c4f9c6b754f" xlink:to="loc_us-gaap_CommonStockValue_e0a1f12e-532d-48b4-a579-4d6e9b28456d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_298bfe22-60fa-4207-a79d-36310089367a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_de452df4-40db-46c6-96b6-2c4f9c6b754f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_298bfe22-60fa-4207-a79d-36310089367a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_62f3a2c9-d3c2-4c22-8ef8-0e51d33a0443" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_de452df4-40db-46c6-96b6-2c4f9c6b754f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_62f3a2c9-d3c2-4c22-8ef8-0e51d33a0443" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1f81a67f-7bf5-43a9-abc0-1eb9d77cceb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_de452df4-40db-46c6-96b6-2c4f9c6b754f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1f81a67f-7bf5-43a9-abc0-1eb9d77cceb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4e47b65b-e9b5-4def-9e11-94dc0d1c9785" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b2f6cc84-e7c0-42ba-bc09-a777e83054da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4e47b65b-e9b5-4def-9e11-94dc0d1c9785" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b2f6cc84-e7c0-42ba-bc09-a777e83054da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b9d29ceb-4230-4769-aee2-013c885ba778" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4e47b65b-e9b5-4def-9e11-94dc0d1c9785" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b9d29ceb-4230-4769-aee2-013c885ba778" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_3f885484-9294-4950-9847-6d7648f88732" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4e47b65b-e9b5-4def-9e11-94dc0d1c9785" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_3f885484-9294-4950-9847-6d7648f88732" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationReceivableDueFromRelatedPartiesCurrent_0719749c-cebc-44f6-822f-4a3743b2bfb6" xlink:href="agio-20200930.xsd#agio_CollaborationReceivableDueFromRelatedPartiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4e47b65b-e9b5-4def-9e11-94dc0d1c9785" xlink:to="loc_agio_CollaborationReceivableDueFromRelatedPartiesCurrent_0719749c-cebc-44f6-822f-4a3743b2bfb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationReceivableOtherCurrent_00f79afa-6d88-4c80-9852-f430843cf57c" xlink:href="agio-20200930.xsd#agio_CollaborationReceivableOtherCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4e47b65b-e9b5-4def-9e11-94dc0d1c9785" xlink:to="loc_agio_CollaborationReceivableOtherCurrent_00f79afa-6d88-4c80-9852-f430843cf57c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RoyaltyReceivableDuefromRelatedPartiesCurrent_e26f7e59-534c-42de-b102-a0de9c8d47df" xlink:href="agio-20200930.xsd#agio_RoyaltyReceivableDuefromRelatedPartiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4e47b65b-e9b5-4def-9e11-94dc0d1c9785" xlink:to="loc_agio_RoyaltyReceivableDuefromRelatedPartiesCurrent_e26f7e59-534c-42de-b102-a0de9c8d47df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_bda09a65-7332-473e-9b13-03d918366f06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4e47b65b-e9b5-4def-9e11-94dc0d1c9785" xlink:to="loc_us-gaap_InventoryNet_bda09a65-7332-473e-9b13-03d918366f06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1f27ee05-40cb-4c10-ad69-775b2baa9237" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4e47b65b-e9b5-4def-9e11-94dc0d1c9785" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1f27ee05-40cb-4c10-ad69-775b2baa9237" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_59363ee7-2ca5-4820-a9e6-61dd7c144782" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_c8d46eae-a79d-481c-a3a0-1f867fc7bd17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_59363ee7-2ca5-4820-a9e6-61dd7c144782" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_c8d46eae-a79d-481c-a3a0-1f867fc7bd17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4ae20b69-5644-48ee-9717-5c5609b285d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_59363ee7-2ca5-4820-a9e6-61dd7c144782" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4ae20b69-5644-48ee-9717-5c5609b285d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_17a605f3-8c43-457c-955b-c5166687a7ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_59363ee7-2ca5-4820-a9e6-61dd7c144782" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_17a605f3-8c43-457c-955b-c5166687a7ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_02e9eb45-4c41-41b2-8ff9-24dae8818795" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_59363ee7-2ca5-4820-a9e6-61dd7c144782" xlink:to="loc_us-gaap_LiabilitiesCurrent_02e9eb45-4c41-41b2-8ff9-24dae8818795" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueLiabilityNoncurrent_d4848709-9eaf-4af8-8eb8-d334862dd090" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_59363ee7-2ca5-4820-a9e6-61dd7c144782" xlink:to="loc_agio_SaleOfFutureRevenueLiabilityNoncurrent_d4848709-9eaf-4af8-8eb8-d334862dd090" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="agio-20200930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="agio-20200930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ff335c11-b414-44f9-86d0-eb6e12cb7a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dcf3cf45-118e-437f-b2d2-530abd6930d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ff335c11-b414-44f9-86d0-eb6e12cb7a2d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dcf3cf45-118e-437f-b2d2-530abd6930d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a419168e-50f4-4681-9bcc-8f5a3f96a88f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ff335c11-b414-44f9-86d0-eb6e12cb7a2d" xlink:to="loc_us-gaap_CostsAndExpenses_a419168e-50f4-4681-9bcc-8f5a3f96a88f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_50ea69d2-6a2c-4e57-bca2-426d384aebb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ace2a1ad-5973-483b-a53e-9a255f5adbf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_50ea69d2-6a2c-4e57-bca2-426d384aebb4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ace2a1ad-5973-483b-a53e-9a255f5adbf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a23e5514-ba56-4407-b0a2-2f52c8f495a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_50ea69d2-6a2c-4e57-bca2-426d384aebb4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a23e5514-ba56-4407-b0a2-2f52c8f495a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_660e24f6-b943-4121-9724-00dfd366c4c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_50ea69d2-6a2c-4e57-bca2-426d384aebb4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_660e24f6-b943-4121-9724-00dfd366c4c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_093ff0c3-f492-48c2-8c92-4d66282dd0a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_005200ad-3bab-495a-8f18-3a3a7badd862" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_093ff0c3-f492-48c2-8c92-4d66282dd0a5" xlink:to="loc_us-gaap_OperatingIncomeLoss_005200ad-3bab-495a-8f18-3a3a7badd862" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d79ad3ca-acfa-4e0d-943e-168fede04fb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_093ff0c3-f492-48c2-8c92-4d66282dd0a5" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d79ad3ca-acfa-4e0d-943e-168fede04fb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_InterestExpenseNonCashSaleOfFutureRevenue_03bf64eb-1ad7-4e41-a1ab-5301a283e52e" xlink:href="agio-20200930.xsd#agio_InterestExpenseNonCashSaleOfFutureRevenue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_093ff0c3-f492-48c2-8c92-4d66282dd0a5" xlink:to="loc_agio_InterestExpenseNonCashSaleOfFutureRevenue_03bf64eb-1ad7-4e41-a1ab-5301a283e52e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="agio-20200930.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b010e9a8-429f-435a-a027-dcb4c92e8c78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0b48131d-a601-4e04-b4a6-a8a96d7480f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b010e9a8-429f-435a-a027-dcb4c92e8c78" xlink:to="loc_us-gaap_NetIncomeLoss_0b48131d-a601-4e04-b4a6-a8a96d7480f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_fbb3998f-a083-44c0-934a-4bcf7493b0b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b010e9a8-429f-435a-a027-dcb4c92e8c78" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_fbb3998f-a083-44c0-934a-4bcf7493b0b2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="agio-20200930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="agio-20200930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0aa8c9c5-081c-49ad-b3c7-9f6b3a61c247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_85259b50-c41d-4454-bfa4-e9952ed08673" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0aa8c9c5-081c-49ad-b3c7-9f6b3a61c247" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_85259b50-c41d-4454-bfa4-e9952ed08673" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_6b4e40cf-b910-4b0d-a13f-3dab7428da16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0aa8c9c5-081c-49ad-b3c7-9f6b3a61c247" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_6b4e40cf-b910-4b0d-a13f-3dab7428da16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts_eff2cf2b-6bac-44c4-8ba6-fbc834d30e0b" xlink:href="agio-20200930.xsd#agio_ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0aa8c9c5-081c-49ad-b3c7-9f6b3a61c247" xlink:to="loc_agio_ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts_eff2cf2b-6bac-44c4-8ba6-fbc834d30e0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6eba88d5-7288-48ab-94fc-052b737f019d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_68c10b5a-dc4f-42c7-9322-a3dfd3bbe5bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6eba88d5-7288-48ab-94fc-052b737f019d" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_68c10b5a-dc4f-42c7-9322-a3dfd3bbe5bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_f2181e79-c091-426b-895e-27287bdc413b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6eba88d5-7288-48ab-94fc-052b737f019d" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_f2181e79-c091-426b-895e-27287bdc413b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b2154776-4d88-4c1f-941a-0155ea95f613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6eba88d5-7288-48ab-94fc-052b737f019d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b2154776-4d88-4c1f-941a-0155ea95f613" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d6804855-fb5d-4d6e-8f73-3e9e33d7c2d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_66297802-1d6e-429c-8290-6fd959c3f116" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d6804855-fb5d-4d6e-8f73-3e9e33d7c2d0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_66297802-1d6e-429c-8290-6fd959c3f116" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_39d11262-5227-4c1b-9ab3-0a241180d359" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d6804855-fb5d-4d6e-8f73-3e9e33d7c2d0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_39d11262-5227-4c1b-9ab3-0a241180d359" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dbea435c-ff86-46eb-bbe2-dfdc6293d18b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d6804855-fb5d-4d6e-8f73-3e9e33d7c2d0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dbea435c-ff86-46eb-bbe2-dfdc6293d18b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bd1e653d-8534-444b-8ba6-850a2dc6e9fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1f24c910-7f86-495b-a77c-1b975f883e67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bd1e653d-8534-444b-8ba6-850a2dc6e9fb" xlink:to="loc_us-gaap_NetIncomeLoss_1f24c910-7f86-495b-a77c-1b975f883e67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_218d7ab8-d2dc-42fc-9e39-f62853b647cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bd1e653d-8534-444b-8ba6-850a2dc6e9fb" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_218d7ab8-d2dc-42fc-9e39-f62853b647cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6cddf119-cd80-4a1b-925d-e96678a60ce9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bd1e653d-8534-444b-8ba6-850a2dc6e9fb" xlink:to="loc_us-gaap_ShareBasedCompensation_6cddf119-cd80-4a1b-925d-e96678a60ce9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3e80b373-3132-412b-80ca-dc45f3a8813f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bd1e653d-8534-444b-8ba6-850a2dc6e9fb" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3e80b373-3132-412b-80ca-dc45f3a8813f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ae142141-4ee4-46fd-bda3-3c1fdea44602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bd1e653d-8534-444b-8ba6-850a2dc6e9fb" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ae142141-4ee4-46fd-bda3-3c1fdea44602" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_OperatingLeaseRightOfUseAssetAmortization_e33b1515-4035-4cfd-93f7-963612bf42e4" xlink:href="agio-20200930.xsd#agio_OperatingLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bd1e653d-8534-444b-8ba6-850a2dc6e9fb" xlink:to="loc_agio_OperatingLeaseRightOfUseAssetAmortization_e33b1515-4035-4cfd-93f7-963612bf42e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_InterestExpenseNonCashSaleOfFutureRevenue_b70b5d95-0734-45a9-ab9b-bdfe4ead34c8" xlink:href="agio-20200930.xsd#agio_InterestExpenseNonCashSaleOfFutureRevenue"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bd1e653d-8534-444b-8ba6-850a2dc6e9fb" xlink:to="loc_agio_InterestExpenseNonCashSaleOfFutureRevenue_b70b5d95-0734-45a9-ab9b-bdfe4ead34c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RoyaltyRevenueNonCash_8ccaad03-5785-4205-b04f-02355a3fbe36" xlink:href="agio-20200930.xsd#agio_RoyaltyRevenueNonCash"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bd1e653d-8534-444b-8ba6-850a2dc6e9fb" xlink:to="loc_agio_RoyaltyRevenueNonCash_8ccaad03-5785-4205-b04f-02355a3fbe36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_ffcceb7c-1972-4c6a-89c8-70efee07985d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bd1e653d-8534-444b-8ba6-850a2dc6e9fb" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_ffcceb7c-1972-4c6a-89c8-70efee07985d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent_eb697668-1aef-4dfb-a60c-eac1ffac3d1f" xlink:href="agio-20200930.xsd#agio_IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bd1e653d-8534-444b-8ba6-850a2dc6e9fb" xlink:to="loc_agio_IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent_eb697668-1aef-4dfb-a60c-eac1ffac3d1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseInCollaborationReceivableOtherCurrent_2b0e3a45-366f-4181-bb48-e5332f6fd021" xlink:href="agio-20200930.xsd#agio_IncreaseDecreaseInCollaborationReceivableOtherCurrent"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bd1e653d-8534-444b-8ba6-850a2dc6e9fb" xlink:to="loc_agio_IncreaseDecreaseInCollaborationReceivableOtherCurrent_2b0e3a45-366f-4181-bb48-e5332f6fd021" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent_d86bdcc8-d737-45a5-bd48-1dd52abd32f0" xlink:href="agio-20200930.xsd#agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bd1e653d-8534-444b-8ba6-850a2dc6e9fb" xlink:to="loc_agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent_d86bdcc8-d737-45a5-bd48-1dd52abd32f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f92a5804-b233-4894-ba6c-f55345cb16b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bd1e653d-8534-444b-8ba6-850a2dc6e9fb" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f92a5804-b233-4894-ba6c-f55345cb16b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0016c3a4-8883-47a5-bc6b-5d15287fb22b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bd1e653d-8534-444b-8ba6-850a2dc6e9fb" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0016c3a4-8883-47a5-bc6b-5d15287fb22b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9fafa9e1-a5e7-4795-b6d3-98b1cf3fbd4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bd1e653d-8534-444b-8ba6-850a2dc6e9fb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9fafa9e1-a5e7-4795-b6d3-98b1cf3fbd4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_0c6897e8-116b-4dd6-80da-d5dfa17f6d93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bd1e653d-8534-444b-8ba6-850a2dc6e9fb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_0c6897e8-116b-4dd6-80da-d5dfa17f6d93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty_7b2ece39-700e-46b5-ba14-d86281549f24" xlink:href="agio-20200930.xsd#agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bd1e653d-8534-444b-8ba6-850a2dc6e9fb" xlink:to="loc_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty_7b2ece39-700e-46b5-ba14-d86281549f24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseInOperatingLeaseLiability_86fd0430-99f2-4be1-969b-8bf79d3268bc" xlink:href="agio-20200930.xsd#agio_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bd1e653d-8534-444b-8ba6-850a2dc6e9fb" xlink:to="loc_agio_IncreaseDecreaseInOperatingLeaseLiability_86fd0430-99f2-4be1-969b-8bf79d3268bc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/OverviewandBasisofPresentation" xlink:type="simple" xlink:href="agio-20200930.xsd#OverviewandBasisofPresentation"/>
  <link:calculationLink xlink:role="http://agios.com/role/OverviewandBasisofPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#OverviewandBasisofPresentationAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="agio-20200930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://agios.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="agio-20200930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="agio-20200930.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://agios.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="agio-20200930.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://agios.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_14d8b221-f32e-4d2e-b2f6-3aaea310dfdd" xlink:href="agio-20200930.xsd#agio_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9ac7a22c-295c-44e7-acc5-9c9c2973ccda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_14d8b221-f32e-4d2e-b2f6-3aaea310dfdd" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9ac7a22c-295c-44e7-acc5-9c9c2973ccda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bc3196c6-9f2c-46ba-9d59-fcbb59e5ba89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_14d8b221-f32e-4d2e-b2f6-3aaea310dfdd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bc3196c6-9f2c-46ba-9d59-fcbb59e5ba89" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecurities" xlink:type="simple" xlink:href="agio-20200930.xsd#MarketableSecurities"/>
  <link:calculationLink xlink:role="http://agios.com/role/MarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="agio-20200930.xsd#MarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://agios.com/role/MarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#MarketableSecuritiesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#MarketableSecuritiesSummaryofMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a49952d7-f4b9-4117-bafb-643458c280bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fd20f9de-439c-4280-9db8-dafbc277e2e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a49952d7-f4b9-4117-bafb-643458c280bd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fd20f9de-439c-4280-9db8-dafbc277e2e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_370d10ec-69f2-4f6c-9ebd-78fb90cb4ea6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a49952d7-f4b9-4117-bafb-643458c280bd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_370d10ec-69f2-4f6c-9ebd-78fb90cb4ea6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_50b238e7-38a2-46c1-ba48-94fbe2267801" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a49952d7-f4b9-4117-bafb-643458c280bd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_50b238e7-38a2-46c1-ba48-94fbe2267801" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/Inventory" xlink:type="simple" xlink:href="agio-20200930.xsd#Inventory"/>
  <link:calculationLink xlink:role="http://agios.com/role/Inventory" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/InventoryTables" xlink:type="simple" xlink:href="agio-20200930.xsd#InventoryTables"/>
  <link:calculationLink xlink:role="http://agios.com/role/InventoryTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/InventoryScheduleofInventoryDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#InventoryScheduleofInventoryDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/InventoryScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6481a21e-19f5-4751-9ebc-98216a49aa20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_b7847464-0009-41d8-b0d4-d535167f5680" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_6481a21e-19f5-4751-9ebc-98216a49aa20" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_b7847464-0009-41d8-b0d4-d535167f5680" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_37a06752-378e-481a-b91c-87c4eb07390c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_6481a21e-19f5-4751-9ebc-98216a49aa20" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_37a06752-378e-481a-b91c-87c4eb07390c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_12266133-3d72-4ffa-a4b8-c7d9081194d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_6481a21e-19f5-4751-9ebc-98216a49aa20" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_12266133-3d72-4ffa-a4b8-c7d9081194d2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/Leases" xlink:type="simple" xlink:href="agio-20200930.xsd#Leases"/>
  <link:calculationLink xlink:role="http://agios.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/LeasesTables" xlink:type="simple" xlink:href="agio-20200930.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://agios.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#LeasesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/LeasesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_84e54be5-bf98-43cb-b020-dc3c13e55613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0eb6c6aa-7e8c-4c9d-9f24-1e0f4dfd2dc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_84e54be5-bf98-43cb-b020-dc3c13e55613" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0eb6c6aa-7e8c-4c9d-9f24-1e0f4dfd2dc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4455c3c8-ea75-4612-b4c9-0dca605fe82a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_84e54be5-bf98-43cb-b020-dc3c13e55613" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4455c3c8-ea75-4612-b4c9-0dca605fe82a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e2abb949-c48d-4979-8b7b-022871f600b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_84e54be5-bf98-43cb-b020-dc3c13e55613" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e2abb949-c48d-4979-8b7b-022871f600b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2297a380-541c-4db2-892b-70e2f7cb7962" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_84e54be5-bf98-43cb-b020-dc3c13e55613" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2297a380-541c-4db2-892b-70e2f7cb7962" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4a55d9c1-5530-44e7-9c47-aa49b2e1be61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_84e54be5-bf98-43cb-b020-dc3c13e55613" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4a55d9c1-5530-44e7-9c47-aa49b2e1be61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a6e561c0-a851-4f16-b491-67daefe4d5f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_84e54be5-bf98-43cb-b020-dc3c13e55613" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_a6e561c0-a851-4f16-b491-67daefe4d5f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_cca66376-6909-4659-ba5c-232e0fc10883" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_84e54be5-bf98-43cb-b020-dc3c13e55613" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_cca66376-6909-4659-ba5c-232e0fc10883" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1" xlink:type="simple" xlink:href="agio-20200930.xsd#LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f37888b5-bc0f-4267-adfe-c8b34bc369fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3e49f039-9665-4d28-9858-4eea89e0127b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f37888b5-bc0f-4267-adfe-c8b34bc369fc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3e49f039-9665-4d28-9858-4eea89e0127b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9d82c564-9eb9-4ec5-b0a3-d373f17be8a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f37888b5-bc0f-4267-adfe-c8b34bc369fc" xlink:to="loc_us-gaap_OperatingLeaseLiability_9d82c564-9eb9-4ec5-b0a3-d373f17be8a0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/AccruedExpenses" xlink:type="simple" xlink:href="agio-20200930.xsd#AccruedExpenses"/>
  <link:calculationLink xlink:role="http://agios.com/role/AccruedExpenses" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="agio-20200930.xsd#AccruedExpensesTables"/>
  <link:calculationLink xlink:role="http://agios.com/role/AccruedExpensesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#AccruedExpensesSummaryofAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_44590938-3c8a-43d3-85bb-1f264a2c59c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c5dad013-4a84-4368-a1a0-5dfea8eb485c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_44590938-3c8a-43d3-85bb-1f264a2c59c0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c5dad013-4a84-4368-a1a0-5dfea8eb485c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AccruedResearchAndDevelopmentCostsCurrent_0790331b-6088-4ce3-858c-f9af0864dcd6" xlink:href="agio-20200930.xsd#agio_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_44590938-3c8a-43d3-85bb-1f264a2c59c0" xlink:to="loc_agio_AccruedResearchAndDevelopmentCostsCurrent_0790331b-6088-4ce3-858c-f9af0864dcd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_a89d6908-8bb5-4831-aa37-f27a95ebeda8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_44590938-3c8a-43d3-85bb-1f264a2c59c0" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_a89d6908-8bb5-4831-aa37-f27a95ebeda8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_5524abf8-4eba-4cd5-8b3b-997886c90276" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_44590938-3c8a-43d3-85bb-1f264a2c59c0" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_5524abf8-4eba-4cd5-8b3b-997886c90276" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenue" xlink:type="simple" xlink:href="agio-20200930.xsd#ProductRevenue"/>
  <link:calculationLink xlink:role="http://agios.com/role/ProductRevenue" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueTables" xlink:type="simple" xlink:href="agio-20200930.xsd#ProductRevenueTables"/>
  <link:calculationLink xlink:role="http://agios.com/role/ProductRevenueTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ProductRevenueScheduleofProductRevenueDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerCurrentYearReserveProvisions_849e5b2a-bf88-4828-a476-840e5ee9f346" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerCurrentYearReserveProvisions"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentYearProvisionForContractualAdjustments_883ead76-f8f1-46f1-a9c4-cc6e2484305c" xlink:href="agio-20200930.xsd#agio_CurrentYearProvisionForContractualAdjustments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveProvisions_849e5b2a-bf88-4828-a476-840e5ee9f346" xlink:to="loc_agio_CurrentYearProvisionForContractualAdjustments_883ead76-f8f1-46f1-a9c4-cc6e2484305c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentYearProvisionsForRebateReserve_8224b228-c6fb-40f5-a547-728376a7096e" xlink:href="agio-20200930.xsd#agio_CurrentYearProvisionsForRebateReserve"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveProvisions_849e5b2a-bf88-4828-a476-840e5ee9f346" xlink:to="loc_agio_CurrentYearProvisionsForRebateReserve_8224b228-c6fb-40f5-a547-728376a7096e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProvisionForRightToRecoverProductInCurrentYear_08a19706-409f-4d97-9bbe-c46808942f7c" xlink:href="agio-20200930.xsd#agio_ProvisionForRightToRecoverProductInCurrentYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveProvisions_849e5b2a-bf88-4828-a476-840e5ee9f346" xlink:to="loc_agio_ProvisionForRightToRecoverProductInCurrentYear_08a19706-409f-4d97-9bbe-c46808942f7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries_34954eb4-392e-4174-91a0-e83bd4a01d1e" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerCurrentYearReserveRecoveries"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_072f92b5-59f8-422a-a8f6-6a0b9662e39b" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries_34954eb4-392e-4174-91a0-e83bd4a01d1e" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_072f92b5-59f8-422a-a8f6-6a0b9662e39b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_b742ae64-ddd2-4825-86e2-41692dbc955c" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries_34954eb4-392e-4174-91a0-e83bd4a01d1e" xlink:to="loc_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_b742ae64-ddd2-4825-86e2-41692dbc955c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_4322bed5-770b-4dcb-9176-931dc45291b7" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries_34954eb4-392e-4174-91a0-e83bd4a01d1e" xlink:to="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_4322bed5-770b-4dcb-9176-931dc45291b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerPriorYearsReserveProvisions_0bafe678-b61e-48c5-b649-de8cfa0e65ec" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerPriorYearsReserveProvisions"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProvisionForRightToRecoverProductInPriorYears_10d5c634-ee68-412c-b957-f04767e7ad5f" xlink:href="agio-20200930.xsd#agio_ProvisionForRightToRecoverProductInPriorYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveProvisions_0bafe678-b61e-48c5-b649-de8cfa0e65ec" xlink:to="loc_agio_ProvisionForRightToRecoverProductInPriorYears_10d5c634-ee68-412c-b957-f04767e7ad5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PriorYearProvisionsForRebateReserve_3e4c1b7e-72ae-4d6d-89de-3de64199fcd5" xlink:href="agio-20200930.xsd#agio_PriorYearProvisionsForRebateReserve"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveProvisions_0bafe678-b61e-48c5-b649-de8cfa0e65ec" xlink:to="loc_agio_PriorYearProvisionsForRebateReserve_3e4c1b7e-72ae-4d6d-89de-3de64199fcd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PriorYearProvisionForContractualAdjustments_0400ff00-8696-41e9-b28f-1c42c0f4d9a8" xlink:href="agio-20200930.xsd#agio_PriorYearProvisionForContractualAdjustments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveProvisions_0bafe678-b61e-48c5-b649-de8cfa0e65ec" xlink:to="loc_agio_PriorYearProvisionForContractualAdjustments_0400ff00-8696-41e9-b28f-1c42c0f4d9a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_711a08ae-1254-4ee0-a615-3b5bffea6c8f" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerTotalAllowancesAndReserves"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractualAdjustmentReserve_024f80a3-e8f2-499f-b3bd-6f44cc5a0113" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerContractualAdjustmentReserve"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_711a08ae-1254-4ee0-a615-3b5bffea6c8f" xlink:to="loc_agio_ContractWithCustomerContractualAdjustmentReserve_024f80a3-e8f2-499f-b3bd-6f44cc5a0113" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserve_0ce1d9d3-108e-43b9-83be-5f135424821b" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerRebateReserve"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_711a08ae-1254-4ee0-a615-3b5bffea6c8f" xlink:to="loc_agio_ContractWithCustomerRebateReserve_0ce1d9d3-108e-43b9-83be-5f135424821b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductReserve_456450df-fe4d-486c-8aec-33e5d821d74d" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerRightToRecoverProductReserve"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_711a08ae-1254-4ee0-a615-3b5bffea6c8f" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductReserve_456450df-fe4d-486c-8aec-33e5d821d74d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries_b4a45dea-8066-4ed4-9c36-395358bbf41b" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerPriorYearsReserveRecoveries"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_3eb0c6a2-9f9b-4447-9c49-ab33f7cb78b0" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries_b4a45dea-8066-4ed4-9c36-395358bbf41b" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_3eb0c6a2-9f9b-4447-9c49-ab33f7cb78b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_983b54d3-8657-4b20-830c-4e798dcba7ac" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries_b4a45dea-8066-4ed4-9c36-395358bbf41b" xlink:to="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_983b54d3-8657-4b20-830c-4e798dcba7ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_5113ba6a-60ae-47ba-8d46-d3f3f51f1267" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries_b4a45dea-8066-4ed4-9c36-395358bbf41b" xlink:to="loc_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_5113ba6a-60ae-47ba-8d46-d3f3f51f1267" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ProductRevenueScheduleofRevenueRelatedReservesDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_133508e9-f025-47dd-a0e7-b4f40bd089f4" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerTotalAllowancesAndReserves"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_5aa09e4a-12d5-4559-959d-44590d86ba82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_133508e9-f025-47dd-a0e7-b4f40bd089f4" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_5aa09e4a-12d5-4559-959d-44590d86ba82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAllowanceAndReservesLiability_319c5ea9-45c3-4542-8ce0-842c0d693f45" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerAllowanceAndReservesLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_133508e9-f025-47dd-a0e7-b4f40bd089f4" xlink:to="loc_agio_ContractWithCustomerAllowanceAndReservesLiability_319c5ea9-45c3-4542-8ce0-842c0d693f45" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreements"/>
  <link:calculationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsTables"/>
  <link:calculationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsCollaborationRevenueDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/SaleofFutureRevenue" xlink:type="simple" xlink:href="agio-20200930.xsd#SaleofFutureRevenue"/>
  <link:calculationLink xlink:role="http://agios.com/role/SaleofFutureRevenue" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/SaleofFutureRevenueTables" xlink:type="simple" xlink:href="agio-20200930.xsd#SaleofFutureRevenueTables"/>
  <link:calculationLink xlink:role="http://agios.com/role/SaleofFutureRevenueTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/SaleofFutureRevenueAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#SaleofFutureRevenueAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/SaleofFutureRevenueAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/SaleofFutureRevenueScheduleofRoyaltyObligationDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#SaleofFutureRevenueScheduleofRoyaltyObligationDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/SaleofFutureRevenueScheduleofRoyaltyObligationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPayments" xlink:type="simple" xlink:href="agio-20200930.xsd#ShareBasedPayments"/>
  <link:calculationLink xlink:role="http://agios.com/role/ShareBasedPayments" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="agio-20200930.xsd#ShareBasedPaymentsTables"/>
  <link:calculationLink xlink:role="http://agios.com/role/ShareBasedPaymentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ShareBasedPaymentsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ShareBasedPaymentsSummaryofStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/LossperShare" xlink:type="simple" xlink:href="agio-20200930.xsd#LossperShare"/>
  <link:calculationLink xlink:role="http://agios.com/role/LossperShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/LossperShareTables" xlink:type="simple" xlink:href="agio-20200930.xsd#LossperShareTables"/>
  <link:calculationLink xlink:role="http://agios.com/role/LossperShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>agio-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:deac00a5-3ebc-4b82-b8fc-c0af8bd8bb5e,g:0b2f6d2b-1088-4e3a-817f-9f8454765406-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://agios.com/role/CoverPage" xlink:type="simple" xlink:href="agio-20200930.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://agios.com/role/CoverPage" xlink:type="extended" id="i98fe8256b76746e589d8dadc2dd475a4_CoverPage"/>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="agio-20200930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://agios.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i682ef9f712a549ad9d060ff60fa7f7e0_CondensedConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="agio-20200930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="icecb06824865411193cce9f2e338e548_CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="agio-20200930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended" id="i5b4c5d130e4a42b5b9be139876724ea3_CondensedConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_65d7b4da-906d-4636-8202-cda87795f700" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_5d76ee25-4c1e-4393-9a63-f3346d00207c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65d7b4da-906d-4636-8202-cda87795f700" xlink:to="loc_us-gaap_RevenuesAbstract_5d76ee25-4c1e-4393-9a63-f3346d00207c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a9670efe-86fb-4f54-8111-1642517f3ce3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_5d76ee25-4c1e-4393-9a63-f3346d00207c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a9670efe-86fb-4f54-8111-1642517f3ce3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_a765bba5-029b-407e-bf3c-d7da306c6ac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65d7b4da-906d-4636-8202-cda87795f700" xlink:to="loc_us-gaap_OperatingExpensesAbstract_a765bba5-029b-407e-bf3c-d7da306c6ac5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_85a74394-f5cd-4feb-bb03-ab32659039a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a765bba5-029b-407e-bf3c-d7da306c6ac5" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_85a74394-f5cd-4feb-bb03-ab32659039a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5a00141d-a52d-4690-a715-cd7def264b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a765bba5-029b-407e-bf3c-d7da306c6ac5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5a00141d-a52d-4690-a715-cd7def264b2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d5a44fe6-c657-4184-96cc-9e087150886f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a765bba5-029b-407e-bf3c-d7da306c6ac5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d5a44fe6-c657-4184-96cc-9e087150886f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_090d0a80-54e0-4727-804c-b57dfdc4753b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a765bba5-029b-407e-bf3c-d7da306c6ac5" xlink:to="loc_us-gaap_CostsAndExpenses_090d0a80-54e0-4727-804c-b57dfdc4753b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d6734760-3093-479d-be43-f14f50d7a9e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65d7b4da-906d-4636-8202-cda87795f700" xlink:to="loc_us-gaap_OperatingIncomeLoss_d6734760-3093-479d-be43-f14f50d7a9e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_35890c2a-77af-4300-9a86-7afffab342ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65d7b4da-906d-4636-8202-cda87795f700" xlink:to="loc_us-gaap_InvestmentIncomeInterest_35890c2a-77af-4300-9a86-7afffab342ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_InterestExpenseNonCashSaleOfFutureRevenue_b7b4865b-4fc3-416c-92e6-96b2b43c1ef4" xlink:href="agio-20200930.xsd#agio_InterestExpenseNonCashSaleOfFutureRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65d7b4da-906d-4636-8202-cda87795f700" xlink:to="loc_agio_InterestExpenseNonCashSaleOfFutureRevenue_b7b4865b-4fc3-416c-92e6-96b2b43c1ef4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_351b0b9e-1274-4743-978e-33eab3fe7e0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65d7b4da-906d-4636-8202-cda87795f700" xlink:to="loc_us-gaap_NetIncomeLoss_351b0b9e-1274-4743-978e-33eab3fe7e0a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_1f1308b0-0dc4-4511-9023-a64c9ec7f688" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65d7b4da-906d-4636-8202-cda87795f700" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_1f1308b0-0dc4-4511-9023-a64c9ec7f688" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_94398260-20ad-446a-ac35-1ed0e838fefa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_65d7b4da-906d-4636-8202-cda87795f700" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_94398260-20ad-446a-ac35-1ed0e838fefa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d70317fd-f0cf-46f0-b90f-6962e979cf7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_65d7b4da-906d-4636-8202-cda87795f700" xlink:to="loc_us-gaap_StatementTable_d70317fd-f0cf-46f0-b90f-6962e979cf7f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bd006f3c-fda2-4897-b2c9-a41261f63083" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d70317fd-f0cf-46f0-b90f-6962e979cf7f" xlink:to="loc_srt_ProductOrServiceAxis_bd006f3c-fda2-4897-b2c9-a41261f63083" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bd006f3c-fda2-4897-b2c9-a41261f63083_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_bd006f3c-fda2-4897-b2c9-a41261f63083" xlink:to="loc_srt_ProductsAndServicesDomain_bd006f3c-fda2-4897-b2c9-a41261f63083_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f2e28c15-81f3-4fbb-a08f-dffc4a190b6a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_bd006f3c-fda2-4897-b2c9-a41261f63083" xlink:to="loc_srt_ProductsAndServicesDomain_f2e28c15-81f3-4fbb-a08f-dffc4a190b6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_9f5c8a89-8b69-402b-8c29-bc4498ce1440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f2e28c15-81f3-4fbb-a08f-dffc4a190b6a" xlink:to="loc_us-gaap_ProductMember_9f5c8a89-8b69-402b-8c29-bc4498ce1440" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueRelatedPartyMember_23f1dbde-7db2-4764-bd35-f2666a917dd7" xlink:href="agio-20200930.xsd#agio_CollaborationRevenueRelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f2e28c15-81f3-4fbb-a08f-dffc4a190b6a" xlink:to="loc_agio_CollaborationRevenueRelatedPartyMember_23f1dbde-7db2-4764-bd35-f2666a917dd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueOtherMember_e826dced-1ff4-4f90-a0d3-d4aaa86b5a03" xlink:href="agio-20200930.xsd#agio_CollaborationRevenueOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f2e28c15-81f3-4fbb-a08f-dffc4a190b6a" xlink:to="loc_agio_CollaborationRevenueOtherMember_e826dced-1ff4-4f90-a0d3-d4aaa86b5a03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_c0e2fce1-995e-4eba-9442-08ac08950da3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f2e28c15-81f3-4fbb-a08f-dffc4a190b6a" xlink:to="loc_us-gaap_RoyaltyMember_c0e2fce1-995e-4eba-9442-08ac08950da3" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="agio-20200930.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended" id="if4e2a6944faa44389083ae872c3d67d8_CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="agio-20200930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i61a53c80f95544b1978100021380e14e_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_64510fd0-1ccc-4704-9441-d3acc6ee08c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_56cf7994-7880-4bac-99cd-c84cb724a485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64510fd0-1ccc-4704-9441-d3acc6ee08c9" xlink:to="loc_us-gaap_SharesOutstanding_56cf7994-7880-4bac-99cd-c84cb724a485" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_edd2e814-5e3f-419f-b9f4-8245a7d1b5e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64510fd0-1ccc-4704-9441-d3acc6ee08c9" xlink:to="loc_us-gaap_StockholdersEquity_edd2e814-5e3f-419f-b9f4-8245a7d1b5e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_09f6e562-0783-4f57-9e72-da78e8cf5d2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64510fd0-1ccc-4704-9441-d3acc6ee08c9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_09f6e562-0783-4f57-9e72-da78e8cf5d2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_18261082-cc81-462e-bb52-3875608bc367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64510fd0-1ccc-4704-9441-d3acc6ee08c9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_18261082-cc81-462e-bb52-3875608bc367" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_85083d02-e189-4e3d-a82d-119d52722885" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64510fd0-1ccc-4704-9441-d3acc6ee08c9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_85083d02-e189-4e3d-a82d-119d52722885" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c274c08b-4dc2-44c5-8c07-775e577ed0c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64510fd0-1ccc-4704-9441-d3acc6ee08c9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c274c08b-4dc2-44c5-8c07-775e577ed0c0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_48feeddc-9752-4f9d-85dd-967bd3069013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64510fd0-1ccc-4704-9441-d3acc6ee08c9" xlink:to="loc_us-gaap_NetIncomeLoss_48feeddc-9752-4f9d-85dd-967bd3069013" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_ab7da6db-c1cd-4f16-86c3-068b5c39d282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fd77c3b1-308d-484b-a37f-7ab05d1d7f03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_667fb748-b36a-45ed-a0ee-4d21687ef140" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_64510fd0-1ccc-4704-9441-d3acc6ee08c9" xlink:to="loc_us-gaap_StatementTable_667fb748-b36a-45ed-a0ee-4d21687ef140" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_60a2f785-5d03-499e-ba8b-98cf838f48f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_667fb748-b36a-45ed-a0ee-4d21687ef140" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_60a2f785-5d03-499e-ba8b-98cf838f48f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_60a2f785-5d03-499e-ba8b-98cf838f48f6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_60a2f785-5d03-499e-ba8b-98cf838f48f6" xlink:to="loc_us-gaap_EquityComponentDomain_60a2f785-5d03-499e-ba8b-98cf838f48f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a948f33a-f4da-47f6-80e6-2c1fda52124e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_60a2f785-5d03-499e-ba8b-98cf838f48f6" xlink:to="loc_us-gaap_EquityComponentDomain_a948f33a-f4da-47f6-80e6-2c1fda52124e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4b954aae-ba2b-414c-a155-75845288cae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a948f33a-f4da-47f6-80e6-2c1fda52124e" xlink:to="loc_us-gaap_CommonStockMember_4b954aae-ba2b-414c-a155-75845288cae3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_53540b2c-8f81-4f37-9aab-bf071dc7d623" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a948f33a-f4da-47f6-80e6-2c1fda52124e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_53540b2c-8f81-4f37-9aab-bf071dc7d623" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5a1c7ed8-fe5e-45eb-a85f-1058806e8ddf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a948f33a-f4da-47f6-80e6-2c1fda52124e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5a1c7ed8-fe5e-45eb-a85f-1058806e8ddf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_65a8645d-e5ba-409a-be6b-ae7ccbbf7341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a948f33a-f4da-47f6-80e6-2c1fda52124e" xlink:to="loc_us-gaap_RetainedEarningsMember_65a8645d-e5ba-409a-be6b-ae7ccbbf7341" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="agio-20200930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="i48fee1b4732e4c68af664cceba17928b_CondensedConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://agios.com/role/OverviewandBasisofPresentation" xlink:type="simple" xlink:href="agio-20200930.xsd#OverviewandBasisofPresentation"/>
  <link:definitionLink xlink:role="http://agios.com/role/OverviewandBasisofPresentation" xlink:type="extended" id="i9cfbfa821fcf4a969bf654f71cde231b_OverviewandBasisofPresentation"/>
  <link:roleRef roleURI="http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#OverviewandBasisofPresentationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails" xlink:type="extended" id="i773e9c25644443029cfa9f991198fda0_OverviewandBasisofPresentationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3e81cde4-4c69-4aaa-85fb-ea186bc99069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold_29721bf9-6f53-4e77-82bd-53fffc04ebfc" xlink:href="agio-20200930.xsd#agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3e81cde4-4c69-4aaa-85fb-ea186bc99069" xlink:to="loc_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold_29721bf9-6f53-4e77-82bd-53fffc04ebfc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold_d9df9d0b-0815-470d-9469-90f5aef12abd" xlink:href="agio-20200930.xsd#agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3e81cde4-4c69-4aaa-85fb-ea186bc99069" xlink:to="loc_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold_d9df9d0b-0815-470d-9469-90f5aef12abd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMilestoneMethodEligibleReceivable_b1626e8a-8a21-4375-8b47-f6f51fadcdb6" xlink:href="agio-20200930.xsd#agio_RevenueRecognitionMilestoneMethodEligibleReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3e81cde4-4c69-4aaa-85fb-ea186bc99069" xlink:to="loc_agio_RevenueRecognitionMilestoneMethodEligibleReceivable_b1626e8a-8a21-4375-8b47-f6f51fadcdb6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_85f2f0ed-d4d9-4c88-9901-c2de5841d2cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3e81cde4-4c69-4aaa-85fb-ea186bc99069" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_85f2f0ed-d4d9-4c88-9901-c2de5841d2cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_04ed35b8-b09b-40b6-bd90-08e6078410e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3e81cde4-4c69-4aaa-85fb-ea186bc99069" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_04ed35b8-b09b-40b6-bd90-08e6078410e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3dd4232b-b753-48bb-8732-c69a77e9bd8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_04ed35b8-b09b-40b6-bd90-08e6078410e6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3dd4232b-b753-48bb-8732-c69a77e9bd8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3dd4232b-b753-48bb-8732-c69a77e9bd8e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3dd4232b-b753-48bb-8732-c69a77e9bd8e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3dd4232b-b753-48bb-8732-c69a77e9bd8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cf0d23d4-2d0d-41c1-bd87-3584a0a8fd19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3dd4232b-b753-48bb-8732-c69a77e9bd8e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cf0d23d4-2d0d-41c1-bd87-3584a0a8fd19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_Agreement2010Member_45439e3a-78a9-48e4-b312-a7640cb04229" xlink:href="agio-20200930.xsd#agio_Agreement2010Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cf0d23d4-2d0d-41c1-bd87-3584a0a8fd19" xlink:to="loc_agio_Agreement2010Member_45439e3a-78a9-48e4-b312-a7640cb04229" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a7449536-4ffe-41ac-95c0-2476ff4d824d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_04ed35b8-b09b-40b6-bd90-08e6078410e6" xlink:to="loc_srt_CounterpartyNameAxis_a7449536-4ffe-41ac-95c0-2476ff4d824d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a7449536-4ffe-41ac-95c0-2476ff4d824d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a7449536-4ffe-41ac-95c0-2476ff4d824d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a7449536-4ffe-41ac-95c0-2476ff4d824d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e2e9b987-12b8-46f7-a134-bf1c95e4e0d8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a7449536-4ffe-41ac-95c0-2476ff4d824d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e2e9b987-12b8-46f7-a134-bf1c95e4e0d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CelgeneMember_4c7e34e3-d5e7-4ec8-b0bd-5a6b3bb23151" xlink:href="agio-20200930.xsd#agio_CelgeneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e2e9b987-12b8-46f7-a134-bf1c95e4e0d8" xlink:to="loc_agio_CelgeneMember_4c7e34e3-d5e7-4ec8-b0bd-5a6b3bb23151" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="agio-20200930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://agios.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="ibe178e275954436a9c7f6b18d8f915db_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="agio-20200930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i7435b3b42e9e4a2aa1c505e7222eb5ab_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="agio-20200930.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://agios.com/role/FairValueMeasurements" xlink:type="extended" id="icfb5a3354f124ef88f9ae598389fb29b_FairValueMeasurements"/>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="agio-20200930.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://agios.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i6b882033145f4c3c8c165a500b0179c1_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="ibab2d76ac79e4204924d46b97dcf9218_FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d3ba43bf-a5bd-4390-8c94-3ded3743c601" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_132987ae-db4a-45f8-944b-fa542d450126" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d3ba43bf-a5bd-4390-8c94-3ded3743c601" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_132987ae-db4a-45f8-944b-fa542d450126" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6f95ed35-df1c-4c19-8bfc-8f21dbe5ec24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d3ba43bf-a5bd-4390-8c94-3ded3743c601" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6f95ed35-df1c-4c19-8bfc-8f21dbe5ec24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_9908c850-ae82-466b-bae1-5c75c212aacd" xlink:href="agio-20200930.xsd#agio_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d3ba43bf-a5bd-4390-8c94-3ded3743c601" xlink:to="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_9908c850-ae82-466b-bae1-5c75c212aacd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_bd6b7419-b091-4692-8c9d-b038b67d18cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d3ba43bf-a5bd-4390-8c94-3ded3743c601" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_bd6b7419-b091-4692-8c9d-b038b67d18cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2046a978-6c21-4039-a169-ee7c5ebedf37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_bd6b7419-b091-4692-8c9d-b038b67d18cf" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2046a978-6c21-4039-a169-ee7c5ebedf37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2046a978-6c21-4039-a169-ee7c5ebedf37_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2046a978-6c21-4039-a169-ee7c5ebedf37" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2046a978-6c21-4039-a169-ee7c5ebedf37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_09b94de7-ed39-4717-b1ef-4c2f7409015c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2046a978-6c21-4039-a169-ee7c5ebedf37" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_09b94de7-ed39-4717-b1ef-4c2f7409015c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_89d0e014-aa06-454e-b13e-39374486f565" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_09b94de7-ed39-4717-b1ef-4c2f7409015c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_89d0e014-aa06-454e-b13e-39374486f565" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1ac7ddbb-833a-4428-b9e2-5dd510ce4118" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_bd6b7419-b091-4692-8c9d-b038b67d18cf" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1ac7ddbb-833a-4428-b9e2-5dd510ce4118" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1ac7ddbb-833a-4428-b9e2-5dd510ce4118_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1ac7ddbb-833a-4428-b9e2-5dd510ce4118" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1ac7ddbb-833a-4428-b9e2-5dd510ce4118_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b9baf6e2-802f-4035-87a5-ebcd1d50931c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1ac7ddbb-833a-4428-b9e2-5dd510ce4118" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b9baf6e2-802f-4035-87a5-ebcd1d50931c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3fdffa0e-00b9-4077-8a88-404648a976cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b9baf6e2-802f-4035-87a5-ebcd1d50931c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3fdffa0e-00b9-4077-8a88-404648a976cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a9d9fef6-2a20-4ae2-96c7-0c0f7d76f825" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b9baf6e2-802f-4035-87a5-ebcd1d50931c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a9d9fef6-2a20-4ae2-96c7-0c0f7d76f825" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f278cb5e-3358-453b-8041-f1b4e01b6e03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b9baf6e2-802f-4035-87a5-ebcd1d50931c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f278cb5e-3358-453b-8041-f1b4e01b6e03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_a66802e6-b983-433b-a138-8340146d236a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_bd6b7419-b091-4692-8c9d-b038b67d18cf" xlink:to="loc_us-gaap_InvestmentTypeAxis_a66802e6-b983-433b-a138-8340146d236a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_a66802e6-b983-433b-a138-8340146d236a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_a66802e6-b983-433b-a138-8340146d236a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_a66802e6-b983-433b-a138-8340146d236a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_82a38ec2-e152-4b38-8455-0c0d6bf80aa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_a66802e6-b983-433b-a138-8340146d236a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_82a38ec2-e152-4b38-8455-0c0d6bf80aa4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_849d52eb-d9cc-4ab2-a34f-5abf210d4c8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_82a38ec2-e152-4b38-8455-0c0d6bf80aa4" xlink:to="loc_us-gaap_CashEquivalentsMember_849d52eb-d9cc-4ab2-a34f-5abf210d4c8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_df57147c-8cfd-4ad5-bf48-807126c31604" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_82a38ec2-e152-4b38-8455-0c0d6bf80aa4" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_df57147c-8cfd-4ad5-bf48-807126c31604" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_e283cedc-2749-4c59-ba8a-8c7f44ed767e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_82a38ec2-e152-4b38-8455-0c0d6bf80aa4" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_e283cedc-2749-4c59-ba8a-8c7f44ed767e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6b82dd5f-93d0-42d4-b6ce-346d0aba6339" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_82a38ec2-e152-4b38-8455-0c0d6bf80aa4" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6b82dd5f-93d0-42d4-b6ce-346d0aba6339" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended" id="i5f99869515054c49bb22fd8c6cd7c34d_FairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42658d4d-e7be-49f4-85e5-3deb5aa96b51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability_a3451032-32dc-43eb-a82c-edebf408ed7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42658d4d-e7be-49f4-85e5-3deb5aa96b51" xlink:to="loc_us-gaap_FairValueNetAssetLiability_a3451032-32dc-43eb-a82c-edebf408ed7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4da9c541-51b9-4bef-94dc-41e054f55e59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42658d4d-e7be-49f4-85e5-3deb5aa96b51" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4da9c541-51b9-4bef-94dc-41e054f55e59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c6ff6b50-2080-4e99-a1ad-1a7e085f5ffe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4da9c541-51b9-4bef-94dc-41e054f55e59" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c6ff6b50-2080-4e99-a1ad-1a7e085f5ffe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c6ff6b50-2080-4e99-a1ad-1a7e085f5ffe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c6ff6b50-2080-4e99-a1ad-1a7e085f5ffe" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c6ff6b50-2080-4e99-a1ad-1a7e085f5ffe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c74978ef-11f7-4d5b-b209-193e05ddfe95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c6ff6b50-2080-4e99-a1ad-1a7e085f5ffe" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c74978ef-11f7-4d5b-b209-193e05ddfe95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_5d4f131a-1792-413f-9170-9a1f9d93004e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c74978ef-11f7-4d5b-b209-193e05ddfe95" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_5d4f131a-1792-413f-9170-9a1f9d93004e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_43d4e291-1861-4540-a064-9bba7a0a0427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4da9c541-51b9-4bef-94dc-41e054f55e59" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_43d4e291-1861-4540-a064-9bba7a0a0427" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_43d4e291-1861-4540-a064-9bba7a0a0427_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_43d4e291-1861-4540-a064-9bba7a0a0427" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_43d4e291-1861-4540-a064-9bba7a0a0427_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a69d7eff-ddce-4d6e-84d3-7a636b1bd640" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_43d4e291-1861-4540-a064-9bba7a0a0427" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a69d7eff-ddce-4d6e-84d3-7a636b1bd640" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_45fa3736-26c9-4a23-b68e-96cfcdae02a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a69d7eff-ddce-4d6e-84d3-7a636b1bd640" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_45fa3736-26c9-4a23-b68e-96cfcdae02a7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecurities" xlink:type="simple" xlink:href="agio-20200930.xsd#MarketableSecurities"/>
  <link:definitionLink xlink:role="http://agios.com/role/MarketableSecurities" xlink:type="extended" id="iffce295d93b145ab925d7cc49996ad04_MarketableSecurities"/>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="agio-20200930.xsd#MarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://agios.com/role/MarketableSecuritiesTables" xlink:type="extended" id="id62175f9eae044ebaff95ac20b76106b_MarketableSecuritiesTables"/>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#MarketableSecuritiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:type="extended" id="i17dd3347a3454d8db011f2beb3f5a405_MarketableSecuritiesAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#MarketableSecuritiesSummaryofMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails" xlink:type="extended" id="i9303f8b3da364af0b878a2ece39c274e_MarketableSecuritiesSummaryofMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b94da5ff-1f9f-4e62-9229-1be62a6384c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5392ce41-b9a0-4c4a-b537-0698c1c24174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b94da5ff-1f9f-4e62-9229-1be62a6384c3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5392ce41-b9a0-4c4a-b537-0698c1c24174" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_977559d0-beae-404d-80a2-7bf0df47c173" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b94da5ff-1f9f-4e62-9229-1be62a6384c3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_977559d0-beae-404d-80a2-7bf0df47c173" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8dbcd6b7-eb84-4674-b3ce-e415ddbdfe06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b94da5ff-1f9f-4e62-9229-1be62a6384c3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8dbcd6b7-eb84-4674-b3ce-e415ddbdfe06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1e04293b-3414-4149-a6e7-983afe2b6639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b94da5ff-1f9f-4e62-9229-1be62a6384c3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1e04293b-3414-4149-a6e7-983afe2b6639" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_911f3521-86bc-4337-9b6a-9d085df53587" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b94da5ff-1f9f-4e62-9229-1be62a6384c3" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_911f3521-86bc-4337-9b6a-9d085df53587" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_267dd0ed-7875-437e-8f10-61fab1deb021" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_911f3521-86bc-4337-9b6a-9d085df53587" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_267dd0ed-7875-437e-8f10-61fab1deb021" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_267dd0ed-7875-437e-8f10-61fab1deb021_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_267dd0ed-7875-437e-8f10-61fab1deb021" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_267dd0ed-7875-437e-8f10-61fab1deb021_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3e0908d2-1547-4bf5-8ba9-ba2a1248e6f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_267dd0ed-7875-437e-8f10-61fab1deb021" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3e0908d2-1547-4bf5-8ba9-ba2a1248e6f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentAssetMember_ccdfc19b-15e4-4bdd-83f3-9018b880907d" xlink:href="agio-20200930.xsd#agio_CurrentAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3e0908d2-1547-4bf5-8ba9-ba2a1248e6f8" xlink:to="loc_agio_CurrentAssetMember_ccdfc19b-15e4-4bdd-83f3-9018b880907d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_NonCurrentAssetsMember_50dbc9fb-2486-4e6c-970e-c2a2d0120dca" xlink:href="agio-20200930.xsd#agio_NonCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3e0908d2-1547-4bf5-8ba9-ba2a1248e6f8" xlink:to="loc_agio_NonCurrentAssetsMember_50dbc9fb-2486-4e6c-970e-c2a2d0120dca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_bd6125f1-6c97-4be5-a6f3-aa0dd1048116" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_911f3521-86bc-4337-9b6a-9d085df53587" xlink:to="loc_us-gaap_InvestmentTypeAxis_bd6125f1-6c97-4be5-a6f3-aa0dd1048116" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_bd6125f1-6c97-4be5-a6f3-aa0dd1048116_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_bd6125f1-6c97-4be5-a6f3-aa0dd1048116" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_bd6125f1-6c97-4be5-a6f3-aa0dd1048116_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_44421efa-85ab-4280-a94a-f21a4eb38bef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_bd6125f1-6c97-4be5-a6f3-aa0dd1048116" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_44421efa-85ab-4280-a94a-f21a4eb38bef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_14c353f0-b82c-4551-9422-c14a310c83a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_44421efa-85ab-4280-a94a-f21a4eb38bef" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_14c353f0-b82c-4551-9422-c14a310c83a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d03f431c-2f8e-4d5d-831c-a2892eb975d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_44421efa-85ab-4280-a94a-f21a4eb38bef" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d03f431c-2f8e-4d5d-831c-a2892eb975d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c8883d27-5bea-4c4e-980f-ab612eb2ccb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_44421efa-85ab-4280-a94a-f21a4eb38bef" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c8883d27-5bea-4c4e-980f-ab612eb2ccb3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/Inventory" xlink:type="simple" xlink:href="agio-20200930.xsd#Inventory"/>
  <link:definitionLink xlink:role="http://agios.com/role/Inventory" xlink:type="extended" id="i6547193fc1e446fb99657a107169fd47_Inventory"/>
  <link:roleRef roleURI="http://agios.com/role/InventoryTables" xlink:type="simple" xlink:href="agio-20200930.xsd#InventoryTables"/>
  <link:definitionLink xlink:role="http://agios.com/role/InventoryTables" xlink:type="extended" id="i1e8f2771f5a54bd482636a67698821f1_InventoryTables"/>
  <link:roleRef roleURI="http://agios.com/role/InventoryScheduleofInventoryDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#InventoryScheduleofInventoryDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/InventoryScheduleofInventoryDetails" xlink:type="extended" id="ia44bbe0c19a04c4c85bbedf10553b038_InventoryScheduleofInventoryDetails"/>
  <link:roleRef roleURI="http://agios.com/role/Leases" xlink:type="simple" xlink:href="agio-20200930.xsd#Leases"/>
  <link:definitionLink xlink:role="http://agios.com/role/Leases" xlink:type="extended" id="if5604d2434c64fb084de9ea4220872bb_Leases"/>
  <link:roleRef roleURI="http://agios.com/role/LeasesTables" xlink:type="simple" xlink:href="agio-20200930.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://agios.com/role/LeasesTables" xlink:type="extended" id="i3fdd428ee25345b4aa427ce29e0c8f96_LeasesTables"/>
  <link:roleRef roleURI="http://agios.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#LeasesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/LeasesAdditionalInformationDetails" xlink:type="extended" id="i586c63f3c0b64bc681b198beec41d322_LeasesAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails" xlink:type="extended" id="i8df74aaae87f409aa10d9c98dba292e5_LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"/>
  <link:roleRef roleURI="http://agios.com/role/AccruedExpenses" xlink:type="simple" xlink:href="agio-20200930.xsd#AccruedExpenses"/>
  <link:definitionLink xlink:role="http://agios.com/role/AccruedExpenses" xlink:type="extended" id="i31d0e533b0e941ddb7dc87e54eb8e58f_AccruedExpenses"/>
  <link:roleRef roleURI="http://agios.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="agio-20200930.xsd#AccruedExpensesTables"/>
  <link:definitionLink xlink:role="http://agios.com/role/AccruedExpensesTables" xlink:type="extended" id="icb1ebbbdb42f4a98a98dbe7a87ffd354_AccruedExpensesTables"/>
  <link:roleRef roleURI="http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#AccruedExpensesSummaryofAccruedExpensesDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails" xlink:type="extended" id="i20880a58ce334df1b1e9b36940d3f784_AccruedExpensesSummaryofAccruedExpensesDetails"/>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenue" xlink:type="simple" xlink:href="agio-20200930.xsd#ProductRevenue"/>
  <link:definitionLink xlink:role="http://agios.com/role/ProductRevenue" xlink:type="extended" id="i6070b2ebe9914d81ab932c6e3ab4e721_ProductRevenue"/>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueTables" xlink:type="simple" xlink:href="agio-20200930.xsd#ProductRevenueTables"/>
  <link:definitionLink xlink:role="http://agios.com/role/ProductRevenueTables" xlink:type="extended" id="i1927fd4ab81e4d5f835195a7966a8310_ProductRevenueTables"/>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ProductRevenueScheduleofProductRevenueDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails" xlink:type="extended" id="ibc23202327434a5fbf50bb3beb4a72e2_ProductRevenueScheduleofProductRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_fc9a43be-06f0-4f8d-8e34-af9f0da7a18a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2ff65b1d-8ea3-411d-a128-5a11877f02fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fc9a43be-06f0-4f8d-8e34-af9f0da7a18a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2ff65b1d-8ea3-411d-a128-5a11877f02fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_74311e48-a38e-447b-a36b-22229f018635" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fc9a43be-06f0-4f8d-8e34-af9f0da7a18a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_74311e48-a38e-447b-a36b-22229f018635" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cb1dfd1d-3eee-4117-8e65-41d7eec92839" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_74311e48-a38e-447b-a36b-22229f018635" xlink:to="loc_srt_ProductOrServiceAxis_cb1dfd1d-3eee-4117-8e65-41d7eec92839" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cb1dfd1d-3eee-4117-8e65-41d7eec92839_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_cb1dfd1d-3eee-4117-8e65-41d7eec92839" xlink:to="loc_srt_ProductsAndServicesDomain_cb1dfd1d-3eee-4117-8e65-41d7eec92839_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1ecef462-7130-41ef-8621-6c6ccafc483d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_cb1dfd1d-3eee-4117-8e65-41d7eec92839" xlink:to="loc_srt_ProductsAndServicesDomain_1ecef462-7130-41ef-8621-6c6ccafc483d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_3d157b92-afb5-4ed4-84c0-e1fb64a6901d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1ecef462-7130-41ef-8621-6c6ccafc483d" xlink:to="loc_us-gaap_ProductMember_3d157b92-afb5-4ed4-84c0-e1fb64a6901d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails" xlink:type="extended" id="ia3674aa424954da7aeef603a6c1e4226_ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"/>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ProductRevenueScheduleofRevenueRelatedReservesDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails" xlink:type="extended" id="i47bca16e760e422c90463e4eb0b1a6ba_ProductRevenueScheduleofRevenueRelatedReservesDetails"/>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails" xlink:type="extended" id="iefc72dcd129d423fa067454ee5c533be_ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreements"/>
  <link:definitionLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreements" xlink:type="extended" id="i7d3374ae7cc84b4bb36f8709043ae45b_CollaborationandLicenseAgreements"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsTables"/>
  <link:definitionLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsTables" xlink:type="extended" id="i86cd10bb94534c889e0209d526d0f050_CollaborationandLicenseAgreementsTables"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails" xlink:type="extended" id="ifa39ca6f7ea444aba42ade77c6c9ce9c_CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_178d71f9-68f0-4661-96b4-af172ca13922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold_ec1af21a-45fc-48e2-b8c7-552be11b993a" xlink:href="agio-20200930.xsd#agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_178d71f9-68f0-4661-96b4-af172ca13922" xlink:to="loc_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold_ec1af21a-45fc-48e2-b8c7-552be11b993a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold_532ec39c-599b-4598-9599-cf3a465aef9e" xlink:href="agio-20200930.xsd#agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_178d71f9-68f0-4661-96b4-af172ca13922" xlink:to="loc_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold_532ec39c-599b-4598-9599-cf3a465aef9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMilestoneMethodEligibleReceivable_4acb631d-6ef8-4bee-9e5e-62c04da8dc9e" xlink:href="agio-20200930.xsd#agio_RevenueRecognitionMilestoneMethodEligibleReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_178d71f9-68f0-4661-96b4-af172ca13922" xlink:to="loc_agio_RevenueRecognitionMilestoneMethodEligibleReceivable_4acb631d-6ef8-4bee-9e5e-62c04da8dc9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsTermOfAgreement_dad57c8c-eaa4-4a90-b8b2-cd263ef0e6f8" xlink:href="agio-20200930.xsd#agio_RevenueRecognitionMultipleDeliverableArrangementsTermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_178d71f9-68f0-4661-96b4-af172ca13922" xlink:to="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsTermOfAgreement_dad57c8c-eaa4-4a90-b8b2-cd263ef0e6f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfExtensions_6d93d1b1-b1c2-41ef-b73d-a06e06724f72" xlink:href="agio-20200930.xsd#agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfExtensions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_178d71f9-68f0-4661-96b4-af172ca13922" xlink:to="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfExtensions_6d93d1b1-b1c2-41ef-b73d-a06e06724f72" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfSpecialCaseExtensions_d8090746-7ed2-4cdc-b564-55fdffd64097" xlink:href="agio-20200930.xsd#agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfSpecialCaseExtensions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_178d71f9-68f0-4661-96b4-af172ca13922" xlink:to="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfSpecialCaseExtensions_d8090746-7ed2-4cdc-b564-55fdffd64097" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsSpecialCaseExtensionTerm_77e0b7ee-a733-42ba-a59c-f9e4c03bcbcc" xlink:href="agio-20200930.xsd#agio_RevenueRecognitionMultipleDeliverableArrangementsSpecialCaseExtensionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_178d71f9-68f0-4661-96b4-af172ca13922" xlink:to="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsSpecialCaseExtensionTerm_77e0b7ee-a733-42ba-a59c-f9e4c03bcbcc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_UpfrontPaymentAgreementExtensionFeeReceivable_9049db01-6c48-43b7-9cf8-62e478deb65c" xlink:href="agio-20200930.xsd#agio_UpfrontPaymentAgreementExtensionFeeReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_178d71f9-68f0-4661-96b4-af172ca13922" xlink:to="loc_agio_UpfrontPaymentAgreementExtensionFeeReceivable_9049db01-6c48-43b7-9cf8-62e478deb65c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_OptionExerciseFeeReceivable_2420c39a-0085-4dfb-a4ab-5411ed54861f" xlink:href="agio-20200930.xsd#agio_OptionExerciseFeeReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_178d71f9-68f0-4661-96b4-af172ca13922" xlink:to="loc_agio_OptionExerciseFeeReceivable_2420c39a-0085-4dfb-a4ab-5411ed54861f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMilestoneMethodEligibleReceivable_9c676f02-bdfb-4bfb-a17a-8861968c4a83" xlink:href="agio-20200930.xsd#agio_RevenueRecognitionMilestoneMethodEligibleReceivable"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e56a806a-098c-4910-807a-f921b98bd9f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_178d71f9-68f0-4661-96b4-af172ca13922" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e56a806a-098c-4910-807a-f921b98bd9f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c4d73f11-b0af-49ce-9b91-b17a3df0a9d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e56a806a-098c-4910-807a-f921b98bd9f5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c4d73f11-b0af-49ce-9b91-b17a3df0a9d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c4d73f11-b0af-49ce-9b91-b17a3df0a9d3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c4d73f11-b0af-49ce-9b91-b17a3df0a9d3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c4d73f11-b0af-49ce-9b91-b17a3df0a9d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e40ccf93-d01a-4454-b51f-d0b242471dc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c4d73f11-b0af-49ce-9b91-b17a3df0a9d3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e40ccf93-d01a-4454-b51f-d0b242471dc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_Agreement2010Member_3261c021-8eb0-4fa3-88b9-58c77603720d" xlink:href="agio-20200930.xsd#agio_Agreement2010Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e40ccf93-d01a-4454-b51f-d0b242471dc1" xlink:to="loc_agio_Agreement2010Member_3261c021-8eb0-4fa3-88b9-58c77603720d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MasterResearchAndCollaborationAgreementMember_d1c6119b-09f7-4696-a3ad-e649ab03054b" xlink:href="agio-20200930.xsd#agio_MasterResearchAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e40ccf93-d01a-4454-b51f-d0b242471dc1" xlink:to="loc_agio_MasterResearchAndCollaborationAgreementMember_d1c6119b-09f7-4696-a3ad-e649ab03054b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2cb8c26d-19b2-4435-afd4-5d0a5638d0c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e56a806a-098c-4910-807a-f921b98bd9f5" xlink:to="loc_srt_CounterpartyNameAxis_2cb8c26d-19b2-4435-afd4-5d0a5638d0c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2cb8c26d-19b2-4435-afd4-5d0a5638d0c0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2cb8c26d-19b2-4435-afd4-5d0a5638d0c0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2cb8c26d-19b2-4435-afd4-5d0a5638d0c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ef7580a9-afd5-4ce0-8c04-b1862b959e72" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2cb8c26d-19b2-4435-afd4-5d0a5638d0c0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ef7580a9-afd5-4ce0-8c04-b1862b959e72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CelgeneMember_b4a7b57a-09f7-41ce-b8a3-6ca25fe35dff" xlink:href="agio-20200930.xsd#agio_CelgeneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ef7580a9-afd5-4ce0-8c04-b1862b959e72" xlink:to="loc_agio_CelgeneMember_b4a7b57a-09f7-41ce-b8a3-6ca25fe35dff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RPIMember_5bbcb7e8-0021-4fba-8288-f56e51949259" xlink:href="agio-20200930.xsd#agio_RPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ef7580a9-afd5-4ce0-8c04-b1862b959e72" xlink:to="loc_agio_RPIMember_5bbcb7e8-0021-4fba-8288-f56e51949259" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_272ac560-1fca-4564-9489-13ad4cdf46c2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e56a806a-098c-4910-807a-f921b98bd9f5" xlink:to="loc_srt_RangeAxis_272ac560-1fca-4564-9489-13ad4cdf46c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_272ac560-1fca-4564-9489-13ad4cdf46c2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_272ac560-1fca-4564-9489-13ad4cdf46c2" xlink:to="loc_srt_RangeMember_272ac560-1fca-4564-9489-13ad4cdf46c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9481c737-abc7-4822-a8a1-dd765a248170" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_272ac560-1fca-4564-9489-13ad4cdf46c2" xlink:to="loc_srt_RangeMember_9481c737-abc7-4822-a8a1-dd765a248170" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_108ef063-dc18-4035-8e6b-c89ae5db1b61" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9481c737-abc7-4822-a8a1-dd765a248170" xlink:to="loc_srt_MaximumMember_108ef063-dc18-4035-8e6b-c89ae5db1b61" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsCollaborationRevenueDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails" xlink:type="extended" id="if7571d33e13745209f1f06039696718a_CollaborationandLicenseAgreementsCollaborationRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_366ab5e4-56c4-4d7c-bb80-ab0bd9c74de6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_75984c24-abf6-456d-9fc8-c18814ff004d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_366ab5e4-56c4-4d7c-bb80-ab0bd9c74de6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_75984c24-abf6-456d-9fc8-c18814ff004d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_e473431f-25a1-4a70-afa3-060ab80e9063" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_366ab5e4-56c4-4d7c-bb80-ab0bd9c74de6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_e473431f-25a1-4a70-afa3-060ab80e9063" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_adfb3b72-3e00-4782-913f-021445f414a4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e473431f-25a1-4a70-afa3-060ab80e9063" xlink:to="loc_srt_ProductOrServiceAxis_adfb3b72-3e00-4782-913f-021445f414a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_adfb3b72-3e00-4782-913f-021445f414a4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_adfb3b72-3e00-4782-913f-021445f414a4" xlink:to="loc_srt_ProductsAndServicesDomain_adfb3b72-3e00-4782-913f-021445f414a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_67b966f9-9366-492e-8fb0-f99ac846ed0a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_adfb3b72-3e00-4782-913f-021445f414a4" xlink:to="loc_srt_ProductsAndServicesDomain_67b966f9-9366-492e-8fb0-f99ac846ed0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ResearchServicesMember_f4292b8a-f31c-4eb5-9d49-bdcba259bcea" xlink:href="agio-20200930.xsd#agio_ResearchServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_67b966f9-9366-492e-8fb0-f99ac846ed0a" xlink:to="loc_agio_ResearchServicesMember_f4292b8a-f31c-4eb5-9d49-bdcba259bcea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CommercializationActivityMember_1966d08a-2d38-436e-adbe-dac226ffb35c" xlink:href="agio-20200930.xsd#agio_CommercializationActivityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_67b966f9-9366-492e-8fb0-f99ac846ed0a" xlink:to="loc_agio_CommercializationActivityMember_1966d08a-2d38-436e-adbe-dac226ffb35c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueRelatedPartyMember_93eedc9d-c620-4916-b222-806339ed6681" xlink:href="agio-20200930.xsd#agio_CollaborationRevenueRelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_67b966f9-9366-492e-8fb0-f99ac846ed0a" xlink:to="loc_agio_CollaborationRevenueRelatedPartyMember_93eedc9d-c620-4916-b222-806339ed6681" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails" xlink:type="extended" id="i2673c0aebc844d7fa011f0236fbadf1c_CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetAndLiabilityLineItems_4a4e6d75-c26c-48bb-ab1c-ef3f2fd8c5f2" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerAssetAndLiabilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ChangeInContractWithCustomerAssetRollForward_8488c847-258b-49b7-9b05-0a4c4b4059f4" xlink:href="agio-20200930.xsd#agio_ChangeInContractWithCustomerAssetRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_ContractWithCustomerAssetAndLiabilityLineItems_4a4e6d75-c26c-48bb-ab1c-ef3f2fd8c5f2" xlink:to="loc_agio_ChangeInContractWithCustomerAssetRollForward_8488c847-258b-49b7-9b05-0a4c4b4059f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_7c40e90a-aad8-4aee-8cf3-d41fd435470c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_8488c847-258b-49b7-9b05-0a4c4b4059f4" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_7c40e90a-aad8-4aee-8cf3-d41fd435470c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetRevenueRecognized_27921301-62e4-40f3-b0e2-ca218bb2b4de" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerAssetRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_8488c847-258b-49b7-9b05-0a4c4b4059f4" xlink:to="loc_agio_ContractWithCustomerAssetRevenueRecognized_27921301-62e4-40f3-b0e2-ca218bb2b4de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_b8ff2109-bab8-4682-8830-a020251a5e59" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_8488c847-258b-49b7-9b05-0a4c4b4059f4" xlink:to="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_b8ff2109-bab8-4682-8830-a020251a5e59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_4b25c4b2-1d2a-448d-b448-a29512cd4511" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ChangeInContractWithCustomerLiabilityRollForward_d8ee0739-e843-41d4-b772-c0bb9c422a30" xlink:href="agio-20200930.xsd#agio_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_ContractWithCustomerAssetAndLiabilityLineItems_4a4e6d75-c26c-48bb-ab1c-ef3f2fd8c5f2" xlink:to="loc_agio_ChangeInContractWithCustomerLiabilityRollForward_d8ee0739-e843-41d4-b772-c0bb9c422a30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_ac8ba642-bc6f-4e3f-a899-97166a2da4e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_ChangeInContractWithCustomerLiabilityRollForward_d8ee0739-e843-41d4-b772-c0bb9c422a30" xlink:to="loc_us-gaap_ContractWithCustomerLiability_ac8ba642-bc6f-4e3f-a899-97166a2da4e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7a79341b-4593-4809-9d60-8ed76cb88b92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_ChangeInContractWithCustomerLiabilityRollForward_d8ee0739-e843-41d4-b772-c0bb9c422a30" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7a79341b-4593-4809-9d60-8ed76cb88b92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_d6f14efe-8066-44a1-9dfe-fdfb9cbe0e73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_ChangeInContractWithCustomerLiabilityRollForward_d8ee0739-e843-41d4-b772-c0bb9c422a30" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_d6f14efe-8066-44a1-9dfe-fdfb9cbe0e73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_6e7f56c4-1de7-484a-bebb-4730bd95ff43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetAndLiabilityTable_c71b2317-4f3c-48d6-ba36-8045245e9528" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerAssetAndLiabilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_agio_ContractWithCustomerAssetAndLiabilityLineItems_4a4e6d75-c26c-48bb-ab1c-ef3f2fd8c5f2" xlink:to="loc_agio_ContractWithCustomerAssetAndLiabilityTable_c71b2317-4f3c-48d6-ba36-8045245e9528" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_0a4f2050-aca7-412a-b779-d250d5813634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agio_ContractWithCustomerAssetAndLiabilityTable_c71b2317-4f3c-48d6-ba36-8045245e9528" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_0a4f2050-aca7-412a-b779-d250d5813634" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0a4f2050-aca7-412a-b779-d250d5813634_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0a4f2050-aca7-412a-b779-d250d5813634" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0a4f2050-aca7-412a-b779-d250d5813634_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f87e8ed8-72b3-4df4-a632-2402b68f9460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0a4f2050-aca7-412a-b779-d250d5813634" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f87e8ed8-72b3-4df4-a632-2402b68f9460" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember_cc3e05cd-0de5-4189-88f2-fec333882e21" xlink:href="agio-20200930.xsd#agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f87e8ed8-72b3-4df4-a632-2402b68f9460" xlink:to="loc_agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember_cc3e05cd-0de5-4189-88f2-fec333882e21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_UnbilledReceivableDueFromRelatedPartiesCurrentMember_a5c0f2df-2a5c-4835-8c4c-a2fa2791943a" xlink:href="agio-20200930.xsd#agio_UnbilledReceivableDueFromRelatedPartiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f87e8ed8-72b3-4df4-a632-2402b68f9460" xlink:to="loc_agio_UnbilledReceivableDueFromRelatedPartiesCurrentMember_a5c0f2df-2a5c-4835-8c4c-a2fa2791943a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember_8c174aa2-d741-4434-a9ba-4a5488c0710d" xlink:href="agio-20200930.xsd#agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f87e8ed8-72b3-4df4-a632-2402b68f9460" xlink:to="loc_agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember_8c174aa2-d741-4434-a9ba-4a5488c0710d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DeferredRevenueCurrentMember_f6339be8-a54c-4796-a2d6-c3476255006c" xlink:href="agio-20200930.xsd#agio_DeferredRevenueCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f87e8ed8-72b3-4df4-a632-2402b68f9460" xlink:to="loc_agio_DeferredRevenueCurrentMember_f6339be8-a54c-4796-a2d6-c3476255006c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails" xlink:type="extended" id="ifc52a56770e9462d918037c54573da0e_CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails"/>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="extended" id="i5369a94abc014041964984a39461dd58_CollaborationandLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd933017-7049-4772-993a-20a6c9175ca8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_d45355f3-9f42-4639-aaae-c737d24c6e6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd933017-7049-4772-993a-20a6c9175ca8" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_d45355f3-9f42-4639-aaae-c737d24c6e6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold_1c44d243-599f-44cb-9cbf-12cfc8c0805a" xlink:href="agio-20200930.xsd#agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd933017-7049-4772-993a-20a6c9175ca8" xlink:to="loc_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold_1c44d243-599f-44cb-9cbf-12cfc8c0805a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized_0197d6d7-d342-4b77-bece-1691d67ba258" xlink:href="agio-20200930.xsd#agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd933017-7049-4772-993a-20a6c9175ca8" xlink:to="loc_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized_0197d6d7-d342-4b77-bece-1691d67ba258" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication_be5a0e82-6bd8-4809-b475-43be02a63d50" xlink:href="agio-20200930.xsd#agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd933017-7049-4772-993a-20a6c9175ca8" xlink:to="loc_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication_be5a0e82-6bd8-4809-b475-43be02a63d50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d0a411f-8904-4677-88ec-18657c18682e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd933017-7049-4772-993a-20a6c9175ca8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d0a411f-8904-4677-88ec-18657c18682e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_32333bf9-d177-43d2-8b0c-2286928088f8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d0a411f-8904-4677-88ec-18657c18682e" xlink:to="loc_srt_ProductOrServiceAxis_32333bf9-d177-43d2-8b0c-2286928088f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_32333bf9-d177-43d2-8b0c-2286928088f8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_32333bf9-d177-43d2-8b0c-2286928088f8" xlink:to="loc_srt_ProductsAndServicesDomain_32333bf9-d177-43d2-8b0c-2286928088f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3cee723a-45bc-4989-9cb1-d1490428484d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_32333bf9-d177-43d2-8b0c-2286928088f8" xlink:to="loc_srt_ProductsAndServicesDomain_3cee723a-45bc-4989-9cb1-d1490428484d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_bf77ec14-53e1-4402-8abc-32fc6e1bc38b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3cee723a-45bc-4989-9cb1-d1490428484d" xlink:to="loc_us-gaap_RoyaltyMember_bf77ec14-53e1-4402-8abc-32fc6e1bc38b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueRelatedPartyMember_712f0544-30e6-40b1-a7a9-bc2f74e2522e" xlink:href="agio-20200930.xsd#agio_CollaborationRevenueRelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3cee723a-45bc-4989-9cb1-d1490428484d" xlink:to="loc_agio_CollaborationRevenueRelatedPartyMember_712f0544-30e6-40b1-a7a9-bc2f74e2522e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_03cf7825-94eb-4dbe-a066-75dd55c85e17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d0a411f-8904-4677-88ec-18657c18682e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_03cf7825-94eb-4dbe-a066-75dd55c85e17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03cf7825-94eb-4dbe-a066-75dd55c85e17_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_03cf7825-94eb-4dbe-a066-75dd55c85e17" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03cf7825-94eb-4dbe-a066-75dd55c85e17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6155707-1917-4576-900b-e532de75b412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_03cf7825-94eb-4dbe-a066-75dd55c85e17" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6155707-1917-4576-900b-e532de75b412" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_Agreement2010Member_d651d716-fb74-4416-9dd4-daf4722f0783" xlink:href="agio-20200930.xsd#agio_Agreement2010Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6155707-1917-4576-900b-e532de75b412" xlink:to="loc_agio_Agreement2010Member_d651d716-fb74-4416-9dd4-daf4722f0783" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails" xlink:type="extended" id="ifd66cc8d741e4c6c887da3780a10c965_CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fe1baa9f-5f01-402d-a4d1-b65d66c90a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts_771050fb-fa08-4c0d-b2a0-5a880ed03f73" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fe1baa9f-5f01-402d-a4d1-b65d66c90a8d" xlink:to="loc_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts_771050fb-fa08-4c0d-b2a0-5a880ed03f73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable_5a94b2c5-26d8-40b4-b39b-dcfec8557812" xlink:href="agio-20200930.xsd#agio_ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fe1baa9f-5f01-402d-a4d1-b65d66c90a8d" xlink:to="loc_agio_ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable_5a94b2c5-26d8-40b4-b39b-dcfec8557812" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RoyaltyPercentageRemitted_3321d7b1-ddd0-4466-b8ff-b11b0a7a2f82" xlink:href="agio-20200930.xsd#agio_RoyaltyPercentageRemitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fe1baa9f-5f01-402d-a4d1-b65d66c90a8d" xlink:to="loc_agio_RoyaltyPercentageRemitted_3321d7b1-ddd0-4466-b8ff-b11b0a7a2f82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_9aa2ddd7-0366-4f1b-b9af-0163caf8e98b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fe1baa9f-5f01-402d-a4d1-b65d66c90a8d" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_9aa2ddd7-0366-4f1b-b9af-0163caf8e98b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_db31546e-99e6-4f15-8f4a-0f405b7ca2a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fe1baa9f-5f01-402d-a4d1-b65d66c90a8d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_db31546e-99e6-4f15-8f4a-0f405b7ca2a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized_b1dd56f3-8779-41e7-b3e3-2883a7c9df24" xlink:href="agio-20200930.xsd#agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fe1baa9f-5f01-402d-a4d1-b65d66c90a8d" xlink:to="loc_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized_b1dd56f3-8779-41e7-b3e3-2883a7c9df24" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable_f9df8979-3850-4df7-abca-a08f22e9e7a6" xlink:href="agio-20200930.xsd#agio_ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e59c3df8-538c-4120-be09-06e7f1fd4565" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fe1baa9f-5f01-402d-a4d1-b65d66c90a8d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e59c3df8-538c-4120-be09-06e7f1fd4565" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_083cc7b6-0d9b-4bdd-9bc2-556c839ed683" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e59c3df8-538c-4120-be09-06e7f1fd4565" xlink:to="loc_srt_CounterpartyNameAxis_083cc7b6-0d9b-4bdd-9bc2-556c839ed683" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_083cc7b6-0d9b-4bdd-9bc2-556c839ed683_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_083cc7b6-0d9b-4bdd-9bc2-556c839ed683" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_083cc7b6-0d9b-4bdd-9bc2-556c839ed683_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f849208-8b18-4309-ae81-056fcca79e34" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_083cc7b6-0d9b-4bdd-9bc2-556c839ed683" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f849208-8b18-4309-ae81-056fcca79e34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CStonePharmaceuticalsMember_21a93620-8356-4cdb-8a42-ac7f234c48d8" xlink:href="agio-20200930.xsd#agio_CStonePharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f849208-8b18-4309-ae81-056fcca79e34" xlink:to="loc_agio_CStonePharmaceuticalsMember_21a93620-8356-4cdb-8a42-ac7f234c48d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a7c43a45-bdd3-494f-8824-6bb74bc01b95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e59c3df8-538c-4120-be09-06e7f1fd4565" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a7c43a45-bdd3-494f-8824-6bb74bc01b95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a7c43a45-bdd3-494f-8824-6bb74bc01b95_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a7c43a45-bdd3-494f-8824-6bb74bc01b95" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a7c43a45-bdd3-494f-8824-6bb74bc01b95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2b6debf-044d-4e49-b4ac-a2718cfc9dea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a7c43a45-bdd3-494f-8824-6bb74bc01b95" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2b6debf-044d-4e49-b4ac-a2718cfc9dea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CStoneAgreementMember_bca269f5-577f-4eee-be82-d021df25e58b" xlink:href="agio-20200930.xsd#agio_CStoneAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2b6debf-044d-4e49-b4ac-a2718cfc9dea" xlink:to="loc_agio_CStoneAgreementMember_bca269f5-577f-4eee-be82-d021df25e58b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a78be859-8cde-4535-a4ca-d4e23c155c37" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e59c3df8-538c-4120-be09-06e7f1fd4565" xlink:to="loc_srt_ProductOrServiceAxis_a78be859-8cde-4535-a4ca-d4e23c155c37" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a78be859-8cde-4535-a4ca-d4e23c155c37_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a78be859-8cde-4535-a4ca-d4e23c155c37" xlink:to="loc_srt_ProductsAndServicesDomain_a78be859-8cde-4535-a4ca-d4e23c155c37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8150a2ad-47a5-47ec-a766-e7579ea147fe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a78be859-8cde-4535-a4ca-d4e23c155c37" xlink:to="loc_srt_ProductsAndServicesDomain_8150a2ad-47a5-47ec-a766-e7579ea147fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueRelatedPartyMember_1440da1f-237c-46df-bf70-93b03d0df861" xlink:href="agio-20200930.xsd#agio_CollaborationRevenueRelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8150a2ad-47a5-47ec-a766-e7579ea147fe" xlink:to="loc_agio_CollaborationRevenueRelatedPartyMember_1440da1f-237c-46df-bf70-93b03d0df861" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_0c5a07ad-c2bb-473a-a5c5-e815367bd10d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8150a2ad-47a5-47ec-a766-e7579ea147fe" xlink:to="loc_us-gaap_RoyaltyMember_0c5a07ad-c2bb-473a-a5c5-e815367bd10d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ffec818e-6b1b-45b8-b100-0cf63cffa607" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e59c3df8-538c-4120-be09-06e7f1fd4565" xlink:to="loc_srt_RangeAxis_ffec818e-6b1b-45b8-b100-0cf63cffa607" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ffec818e-6b1b-45b8-b100-0cf63cffa607_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ffec818e-6b1b-45b8-b100-0cf63cffa607" xlink:to="loc_srt_RangeMember_ffec818e-6b1b-45b8-b100-0cf63cffa607_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_24bacda0-09b2-4483-91d7-3b8a7ceb6fd2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ffec818e-6b1b-45b8-b100-0cf63cffa607" xlink:to="loc_srt_RangeMember_24bacda0-09b2-4483-91d7-3b8a7ceb6fd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_427a808d-e00b-4364-b1fe-c91de129ea4b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_24bacda0-09b2-4483-91d7-3b8a7ceb6fd2" xlink:to="loc_srt_MinimumMember_427a808d-e00b-4364-b1fe-c91de129ea4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a6be8ccd-3a84-406f-bf19-902066d1111e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_24bacda0-09b2-4483-91d7-3b8a7ceb6fd2" xlink:to="loc_srt_MaximumMember_a6be8ccd-3a84-406f-bf19-902066d1111e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails" xlink:type="extended" id="ie37a074e99e048e688456bb2f88979ec_CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_114ef618-18a8-4cf1-9964-4545b501eac2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1aa82d93-70b5-4e24-bce1-991b0e800b2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_114ef618-18a8-4cf1-9964-4545b501eac2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1aa82d93-70b5-4e24-bce1-991b0e800b2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4f3ea1f2-3e94-41c5-8bdd-31cb48ee8a5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_114ef618-18a8-4cf1-9964-4545b501eac2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4f3ea1f2-3e94-41c5-8bdd-31cb48ee8a5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fc6e3073-5cf1-4ad1-8245-ab5ad3b10bfd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4f3ea1f2-3e94-41c5-8bdd-31cb48ee8a5f" xlink:to="loc_srt_ProductOrServiceAxis_fc6e3073-5cf1-4ad1-8245-ab5ad3b10bfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fc6e3073-5cf1-4ad1-8245-ab5ad3b10bfd_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fc6e3073-5cf1-4ad1-8245-ab5ad3b10bfd" xlink:to="loc_srt_ProductsAndServicesDomain_fc6e3073-5cf1-4ad1-8245-ab5ad3b10bfd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ab1efce9-15bf-47cd-a7b4-db0ab623f42b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fc6e3073-5cf1-4ad1-8245-ab5ad3b10bfd" xlink:to="loc_srt_ProductsAndServicesDomain_ab1efce9-15bf-47cd-a7b4-db0ab623f42b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_c65485c3-8dab-46ac-a63f-5a1388047e80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ab1efce9-15bf-47cd-a7b4-db0ab623f42b" xlink:to="loc_us-gaap_LicenseAndServiceMember_c65485c3-8dab-46ac-a63f-5a1388047e80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceOtherMember_955796bd-9005-441a-b215-e14100e5d838" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ab1efce9-15bf-47cd-a7b4-db0ab623f42b" xlink:to="loc_us-gaap_ServiceOtherMember_955796bd-9005-441a-b215-e14100e5d838" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueOtherMember_58054969-57fa-4790-a44f-d88adadd2995" xlink:href="agio-20200930.xsd#agio_CollaborationRevenueOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ab1efce9-15bf-47cd-a7b4-db0ab623f42b" xlink:to="loc_agio_CollaborationRevenueOtherMember_58054969-57fa-4790-a44f-d88adadd2995" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_eb17614b-ea35-47a0-ae95-86d61d10a7f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4f3ea1f2-3e94-41c5-8bdd-31cb48ee8a5f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_eb17614b-ea35-47a0-ae95-86d61d10a7f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eb17614b-ea35-47a0-ae95-86d61d10a7f8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_eb17614b-ea35-47a0-ae95-86d61d10a7f8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_eb17614b-ea35-47a0-ae95-86d61d10a7f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f5c15c41-e35b-40a9-bc27-8100ad30212a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_eb17614b-ea35-47a0-ae95-86d61d10a7f8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f5c15c41-e35b-40a9-bc27-8100ad30212a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CStoneAgreementMember_00ab76ea-4e28-428c-a17f-1377e3cc25a7" xlink:href="agio-20200930.xsd#agio_CStoneAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f5c15c41-e35b-40a9-bc27-8100ad30212a" xlink:to="loc_agio_CStoneAgreementMember_00ab76ea-4e28-428c-a17f-1377e3cc25a7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails" xlink:type="extended" id="i9d668aa3f90543e589186522533bc3cc_CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8042d44-efe1-4375-b9d7-bcd1ceabd4e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ChangeInContractWithCustomerAssetRollForward_af2c4b49-3448-48b2-a21d-ff884c8b409b" xlink:href="agio-20200930.xsd#agio_ChangeInContractWithCustomerAssetRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8042d44-efe1-4375-b9d7-bcd1ceabd4e0" xlink:to="loc_agio_ChangeInContractWithCustomerAssetRollForward_af2c4b49-3448-48b2-a21d-ff884c8b409b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_f3cf5955-ea2a-4220-8378-007db07e8d05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_af2c4b49-3448-48b2-a21d-ff884c8b409b" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_f3cf5955-ea2a-4220-8378-007db07e8d05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetRevenueRecognized_d2e2181c-6c69-415d-9b24-3c6debe2b037" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerAssetRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_af2c4b49-3448-48b2-a21d-ff884c8b409b" xlink:to="loc_agio_ContractWithCustomerAssetRevenueRecognized_d2e2181c-6c69-415d-9b24-3c6debe2b037" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_02ba129c-622d-4a64-acbc-193d4a3e9305" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_af2c4b49-3448-48b2-a21d-ff884c8b409b" xlink:to="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_02ba129c-622d-4a64-acbc-193d4a3e9305" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_0878a565-dc25-4257-a8f4-e823f1f6a0c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee241c4c-282c-48bb-b3c5-c28cc783d27e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8042d44-efe1-4375-b9d7-bcd1ceabd4e0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee241c4c-282c-48bb-b3c5-c28cc783d27e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_23bd3307-52bc-41ca-bc60-7d9769b24e6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee241c4c-282c-48bb-b3c5-c28cc783d27e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_23bd3307-52bc-41ca-bc60-7d9769b24e6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_23bd3307-52bc-41ca-bc60-7d9769b24e6e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_23bd3307-52bc-41ca-bc60-7d9769b24e6e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_23bd3307-52bc-41ca-bc60-7d9769b24e6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7651be63-e814-4179-a8d7-a924490dd74d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_23bd3307-52bc-41ca-bc60-7d9769b24e6e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7651be63-e814-4179-a8d7-a924490dd74d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember_ca437dcd-37bf-400b-a7f2-bfed38c3022b" xlink:href="agio-20200930.xsd#agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7651be63-e814-4179-a8d7-a924490dd74d" xlink:to="loc_agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember_ca437dcd-37bf-400b-a7f2-bfed38c3022b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6fb200b0-369d-4878-873e-a7310e235983" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee241c4c-282c-48bb-b3c5-c28cc783d27e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6fb200b0-369d-4878-873e-a7310e235983" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6fb200b0-369d-4878-873e-a7310e235983_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6fb200b0-369d-4878-873e-a7310e235983" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6fb200b0-369d-4878-873e-a7310e235983_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20b78472-b962-44e0-8f01-394751cf1145" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6fb200b0-369d-4878-873e-a7310e235983" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20b78472-b962-44e0-8f01-394751cf1145" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CStoneAgreementMember_f5add6fd-7be7-49b5-963e-7f99e585a4a8" xlink:href="agio-20200930.xsd#agio_CStoneAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20b78472-b962-44e0-8f01-394751cf1145" xlink:to="loc_agio_CStoneAgreementMember_f5add6fd-7be7-49b5-963e-7f99e585a4a8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/SaleofFutureRevenue" xlink:type="simple" xlink:href="agio-20200930.xsd#SaleofFutureRevenue"/>
  <link:definitionLink xlink:role="http://agios.com/role/SaleofFutureRevenue" xlink:type="extended" id="i5e03e5accf774eaea297016ac17dc433_SaleofFutureRevenue"/>
  <link:roleRef roleURI="http://agios.com/role/SaleofFutureRevenueTables" xlink:type="simple" xlink:href="agio-20200930.xsd#SaleofFutureRevenueTables"/>
  <link:definitionLink xlink:role="http://agios.com/role/SaleofFutureRevenueTables" xlink:type="extended" id="i143c0dc9c0a74c6ba69a81ab79a7f0e1_SaleofFutureRevenueTables"/>
  <link:roleRef roleURI="http://agios.com/role/SaleofFutureRevenueAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#SaleofFutureRevenueAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/SaleofFutureRevenueAdditionalInformationDetails" xlink:type="extended" id="i95728fb081624fbfb100682ddffdc429_SaleofFutureRevenueAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d52da77e-8d8a-401d-bf57-f0b046971581" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold_49448299-5745-4fcf-b695-ca1710bc2a79" xlink:href="agio-20200930.xsd#agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d52da77e-8d8a-401d-bf57-f0b046971581" xlink:to="loc_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold_49448299-5745-4fcf-b695-ca1710bc2a79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold_867bc596-b04c-4673-ae49-258051f935ae" xlink:href="agio-20200930.xsd#agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d52da77e-8d8a-401d-bf57-f0b046971581" xlink:to="loc_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold_867bc596-b04c-4673-ae49-258051f935ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate_1560f283-60dc-4594-9448-f28aab092d34" xlink:href="agio-20200930.xsd#agio_PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d52da77e-8d8a-401d-bf57-f0b046971581" xlink:to="loc_agio_PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate_1560f283-60dc-4594-9448-f28aab092d34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue_4f04bb6d-b254-4c23-b073-96929a2c042a" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d52da77e-8d8a-401d-bf57-f0b046971581" xlink:to="loc_agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue_4f04bb6d-b254-4c23-b073-96929a2c042a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc7fb175-97e2-4407-acff-99030985dc83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d52da77e-8d8a-401d-bf57-f0b046971581" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc7fb175-97e2-4407-acff-99030985dc83" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_603a760f-01c5-415b-bc2b-7626b78b3cfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc7fb175-97e2-4407-acff-99030985dc83" xlink:to="loc_us-gaap_TypeOfArrangementAxis_603a760f-01c5-415b-bc2b-7626b78b3cfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_603a760f-01c5-415b-bc2b-7626b78b3cfb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_603a760f-01c5-415b-bc2b-7626b78b3cfb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_603a760f-01c5-415b-bc2b-7626b78b3cfb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bfac326e-11f2-4085-b2c0-a78c45fee257" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_603a760f-01c5-415b-bc2b-7626b78b3cfb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bfac326e-11f2-4085-b2c0-a78c45fee257" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_Agreement2010Member_4bc4641d-d083-44d6-b8cd-d2d77f9a98df" xlink:href="agio-20200930.xsd#agio_Agreement2010Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bfac326e-11f2-4085-b2c0-a78c45fee257" xlink:to="loc_agio_Agreement2010Member_4bc4641d-d083-44d6-b8cd-d2d77f9a98df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6982aa4f-3ad9-4bf3-ac26-8222b128e020" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc7fb175-97e2-4407-acff-99030985dc83" xlink:to="loc_srt_CounterpartyNameAxis_6982aa4f-3ad9-4bf3-ac26-8222b128e020" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6982aa4f-3ad9-4bf3-ac26-8222b128e020_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_6982aa4f-3ad9-4bf3-ac26-8222b128e020" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6982aa4f-3ad9-4bf3-ac26-8222b128e020_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d40e6437-54b0-4958-87cd-144b83eba311" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_6982aa4f-3ad9-4bf3-ac26-8222b128e020" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d40e6437-54b0-4958-87cd-144b83eba311" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CelgeneMember_285030d2-fc47-4486-8b75-ff763d1e0322" xlink:href="agio-20200930.xsd#agio_CelgeneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d40e6437-54b0-4958-87cd-144b83eba311" xlink:to="loc_agio_CelgeneMember_285030d2-fc47-4486-8b75-ff763d1e0322" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RPIMember_607c0ab5-7866-4ec0-8180-391b168563c2" xlink:href="agio-20200930.xsd#agio_RPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d40e6437-54b0-4958-87cd-144b83eba311" xlink:to="loc_agio_RPIMember_607c0ab5-7866-4ec0-8180-391b168563c2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/SaleofFutureRevenueScheduleofRoyaltyObligationDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#SaleofFutureRevenueScheduleofRoyaltyObligationDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/SaleofFutureRevenueScheduleofRoyaltyObligationDetails" xlink:type="extended" id="i62961033c42e4c818bb314730fef3f5d_SaleofFutureRevenueScheduleofRoyaltyObligationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c4fb2b36-0a30-4945-a103-eb34d5a370b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward_ee6a3c55-29fd-461c-97f3-1c3d1f033a87" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c4fb2b36-0a30-4945-a103-eb34d5a370b7" xlink:to="loc_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward_ee6a3c55-29fd-461c-97f3-1c3d1f033a87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueLiabilityNoncurrent_d92178f5-8707-407a-ab0f-04bf5a1a1a64" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward_ee6a3c55-29fd-461c-97f3-1c3d1f033a87" xlink:to="loc_agio_SaleOfFutureRevenueLiabilityNoncurrent_d92178f5-8707-407a-ab0f-04bf5a1a1a64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueIssuanceCosts_bce2259b-2b76-4b27-8528-885ff9d6df2b" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward_ee6a3c55-29fd-461c-97f3-1c3d1f033a87" xlink:to="loc_agio_SaleOfFutureRevenueIssuanceCosts_bce2259b-2b76-4b27-8528-885ff9d6df2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue_6e230432-4382-43f5-b209-729ad3a78bc3" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward_ee6a3c55-29fd-461c-97f3-1c3d1f033a87" xlink:to="loc_agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue_6e230432-4382-43f5-b209-729ad3a78bc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueInterestExpense_0944a7a2-66ba-40a3-bfb3-dec6d718a0bc" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward_ee6a3c55-29fd-461c-97f3-1c3d1f033a87" xlink:to="loc_agio_SaleOfFutureRevenueInterestExpense_0944a7a2-66ba-40a3-bfb3-dec6d718a0bc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueAmortizationOfIssuanceCosts_07ade6ed-9afd-4477-86e5-db0c82e4e7f4" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueAmortizationOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward_ee6a3c55-29fd-461c-97f3-1c3d1f033a87" xlink:to="loc_agio_SaleOfFutureRevenueAmortizationOfIssuanceCosts_07ade6ed-9afd-4477-86e5-db0c82e4e7f4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueLiabilityNoncurrent_6da32044-cdc4-48ed-8b89-31f4f69fadd6" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_078f7a5d-58f5-4801-b917-30aac1257dec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c4fb2b36-0a30-4945-a103-eb34d5a370b7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_078f7a5d-58f5-4801-b917-30aac1257dec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b107d509-a1c8-4bf1-b3db-e892477cb61c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_078f7a5d-58f5-4801-b917-30aac1257dec" xlink:to="loc_srt_CounterpartyNameAxis_b107d509-a1c8-4bf1-b3db-e892477cb61c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b107d509-a1c8-4bf1-b3db-e892477cb61c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b107d509-a1c8-4bf1-b3db-e892477cb61c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b107d509-a1c8-4bf1-b3db-e892477cb61c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f90a776-7f5a-4b89-9ede-71b82f7703d0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b107d509-a1c8-4bf1-b3db-e892477cb61c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f90a776-7f5a-4b89-9ede-71b82f7703d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RPIMember_beb3c351-e692-4759-9626-a8d868409b77" xlink:href="agio-20200930.xsd#agio_RPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f90a776-7f5a-4b89-9ede-71b82f7703d0" xlink:to="loc_agio_RPIMember_beb3c351-e692-4759-9626-a8d868409b77" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPayments" xlink:type="simple" xlink:href="agio-20200930.xsd#ShareBasedPayments"/>
  <link:definitionLink xlink:role="http://agios.com/role/ShareBasedPayments" xlink:type="extended" id="i53ee2256d1d8461082f2974a273aeef6_ShareBasedPayments"/>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="agio-20200930.xsd#ShareBasedPaymentsTables"/>
  <link:definitionLink xlink:role="http://agios.com/role/ShareBasedPaymentsTables" xlink:type="extended" id="i45b8ca6b606143c5969f7c08f8af14f0_ShareBasedPaymentsTables"/>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ShareBasedPaymentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="extended" id="ic6a5a19c4a524c6381f851c9feb71a17_ShareBasedPaymentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d289c9c-c795-4802-a436-8496cc6bfc1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e52e45b3-e4b3-4040-bf7d-eca7997c6a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d289c9c-c795-4802-a436-8496cc6bfc1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e52e45b3-e4b3-4040-bf7d-eca7997c6a4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5b5d1c12-53c2-4d09-a09e-0433df61763e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d289c9c-c795-4802-a436-8496cc6bfc1e" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5b5d1c12-53c2-4d09-a09e-0433df61763e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_88e28459-a825-4428-a88b-c8c0c0803a52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d289c9c-c795-4802-a436-8496cc6bfc1e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_88e28459-a825-4428-a88b-c8c0c0803a52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9b3e9294-12d4-4fcf-8017-1927cc589300" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d289c9c-c795-4802-a436-8496cc6bfc1e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9b3e9294-12d4-4fcf-8017-1927cc589300" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7ac41763-eaa9-4ac2-910c-524d2bbe7681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d289c9c-c795-4802-a436-8496cc6bfc1e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7ac41763-eaa9-4ac2-910c-524d2bbe7681" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_86417405-7f4f-4d13-8d9f-324bbf53925e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d289c9c-c795-4802-a436-8496cc6bfc1e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_86417405-7f4f-4d13-8d9f-324bbf53925e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_b2eb20ef-fd5b-4a97-b3cf-773ec93d8111" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d289c9c-c795-4802-a436-8496cc6bfc1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_b2eb20ef-fd5b-4a97-b3cf-773ec93d8111" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04e063f5-d834-449e-8214-22e13ce7ad39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d289c9c-c795-4802-a436-8496cc6bfc1e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04e063f5-d834-449e-8214-22e13ce7ad39" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b6046a72-7d78-4b62-a4c2-b4f094e60e72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04e063f5-d834-449e-8214-22e13ce7ad39" xlink:to="loc_us-gaap_PlanNameAxis_b6046a72-7d78-4b62-a4c2-b4f094e60e72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b6046a72-7d78-4b62-a4c2-b4f094e60e72_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_b6046a72-7d78-4b62-a4c2-b4f094e60e72" xlink:to="loc_us-gaap_PlanNameDomain_b6046a72-7d78-4b62-a4c2-b4f094e60e72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1b461d2c-5559-4a78-a282-4028010fbe53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_b6046a72-7d78-4b62-a4c2-b4f094e60e72" xlink:to="loc_us-gaap_PlanNameDomain_1b461d2c-5559-4a78-a282-4028010fbe53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember_82263230-0f08-4998-aafa-e0b46a2546e8" xlink:href="agio-20200930.xsd#agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1b461d2c-5559-4a78-a282-4028010fbe53" xlink:to="loc_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember_82263230-0f08-4998-aafa-e0b46a2546e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TwoThousandAndThirteenStockIncentivePlanMember_846ebebe-ecc2-491d-85c2-1d7d35354d8d" xlink:href="agio-20200930.xsd#agio_TwoThousandAndThirteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1b461d2c-5559-4a78-a282-4028010fbe53" xlink:to="loc_agio_TwoThousandAndThirteenStockIncentivePlanMember_846ebebe-ecc2-491d-85c2-1d7d35354d8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeeStockPurchasePlan2013Member_34c0b01e-afdc-4423-a83b-14f7a2d06b45" xlink:href="agio-20200930.xsd#agio_EmployeeStockPurchasePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1b461d2c-5559-4a78-a282-4028010fbe53" xlink:to="loc_agio_EmployeeStockPurchasePlan2013Member_34c0b01e-afdc-4423-a83b-14f7a2d06b45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_75f509d7-4b0e-4453-9253-a3dc5ac3a9e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04e063f5-d834-449e-8214-22e13ce7ad39" xlink:to="loc_us-gaap_AwardTypeAxis_75f509d7-4b0e-4453-9253-a3dc5ac3a9e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75f509d7-4b0e-4453-9253-a3dc5ac3a9e1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_75f509d7-4b0e-4453-9253-a3dc5ac3a9e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75f509d7-4b0e-4453-9253-a3dc5ac3a9e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_55f6a853-d2da-4667-a68a-723b0873a06b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_75f509d7-4b0e-4453-9253-a3dc5ac3a9e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_55f6a853-d2da-4667-a68a-723b0873a06b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b855b119-356b-4562-b20c-7bb92bc39124" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_55f6a853-d2da-4667-a68a-723b0873a06b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b855b119-356b-4562-b20c-7bb92bc39124" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember_c733d106-61f0-43ef-91e6-b2e8e3b1ba41" xlink:href="agio-20200930.xsd#agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_55f6a853-d2da-4667-a68a-723b0873a06b" xlink:to="loc_agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember_c733d106-61f0-43ef-91e6-b2e8e3b1ba41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MarketBasedStockUnitsMember_45edfe7d-37a3-4b6a-b94f-1ee6480e05ad" xlink:href="agio-20200930.xsd#agio_MarketBasedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_55f6a853-d2da-4667-a68a-723b0873a06b" xlink:to="loc_agio_MarketBasedStockUnitsMember_45edfe7d-37a3-4b6a-b94f-1ee6480e05ad" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ShareBasedPaymentsSummaryofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails" xlink:type="extended" id="i14514a6f2aa94e908d46dc08a956809c_ShareBasedPaymentsSummaryofStockOptionActivityDetails"/>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails" xlink:type="extended" id="id3bde11130d942de84b5f759bf4295b5_ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35d18417-4c62-43e8-8826-a07fd156a8f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e2849af9-c068-425a-83fc-90f3572853ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35d18417-4c62-43e8-8826-a07fd156a8f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e2849af9-c068-425a-83fc-90f3572853ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b3023019-a778-4c9c-b556-63446ba59f90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e2849af9-c068-425a-83fc-90f3572853ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b3023019-a778-4c9c-b556-63446ba59f90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_89947f41-0087-4efc-9551-d8e0693866db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e2849af9-c068-425a-83fc-90f3572853ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_89947f41-0087-4efc-9551-d8e0693866db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_db3b2d74-0811-4235-a2db-8928edb7848f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e2849af9-c068-425a-83fc-90f3572853ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_db3b2d74-0811-4235-a2db-8928edb7848f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bee1a749-0980-42fa-bd7e-0d8ba9c1b741" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e2849af9-c068-425a-83fc-90f3572853ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bee1a749-0980-42fa-bd7e-0d8ba9c1b741" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_86a6bca9-c142-456c-8614-cdf48721a307" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0afbcba4-e517-4d0a-b88d-5335e081793d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35d18417-4c62-43e8-8826-a07fd156a8f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0afbcba4-e517-4d0a-b88d-5335e081793d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_35867e4d-7fa6-499b-807f-357ec378da76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0afbcba4-e517-4d0a-b88d-5335e081793d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_35867e4d-7fa6-499b-807f-357ec378da76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_99d95adc-6000-4b94-9010-b0aa3fdafd62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0afbcba4-e517-4d0a-b88d-5335e081793d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_99d95adc-6000-4b94-9010-b0aa3fdafd62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_07849cdf-c1fb-4ff3-9be5-cc0c69cd34be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0afbcba4-e517-4d0a-b88d-5335e081793d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_07849cdf-c1fb-4ff3-9be5-cc0c69cd34be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7d160825-38e4-4947-8593-f59f1f6cef75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0afbcba4-e517-4d0a-b88d-5335e081793d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7d160825-38e4-4947-8593-f59f1f6cef75" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2ff14ea2-4f51-466c-b0ef-0c6c7cff8972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_032c505f-19d7-439d-944e-2fff9959ec6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35d18417-4c62-43e8-8826-a07fd156a8f4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_032c505f-19d7-439d-944e-2fff9959ec6d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e677fcf3-380e-412b-8022-8149f4b5eac1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_032c505f-19d7-439d-944e-2fff9959ec6d" xlink:to="loc_us-gaap_AwardTypeAxis_e677fcf3-380e-412b-8022-8149f4b5eac1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e677fcf3-380e-412b-8022-8149f4b5eac1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e677fcf3-380e-412b-8022-8149f4b5eac1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e677fcf3-380e-412b-8022-8149f4b5eac1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f980aff-ecdd-416c-be88-af27a51f9e50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e677fcf3-380e-412b-8022-8149f4b5eac1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f980aff-ecdd-416c-be88-af27a51f9e50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ae61dc0d-6c9f-484b-81d8-41d7163e7f93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f980aff-ecdd-416c-be88-af27a51f9e50" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ae61dc0d-6c9f-484b-81d8-41d7163e7f93" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails" xlink:type="extended" id="i19d13842264046dd8d921ccade5b1669_ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_026d808b-c97c-4c9e-a01f-e2156b2e4d31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_27eaf25d-7e5e-4f55-b1d6-90591481e4db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_026d808b-c97c-4c9e-a01f-e2156b2e4d31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_27eaf25d-7e5e-4f55-b1d6-90591481e4db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_041188cc-e297-4cab-950c-fcd5f3e06be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_27eaf25d-7e5e-4f55-b1d6-90591481e4db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_041188cc-e297-4cab-950c-fcd5f3e06be3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3562aa16-269f-4154-b02e-bc45024db649" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_27eaf25d-7e5e-4f55-b1d6-90591481e4db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3562aa16-269f-4154-b02e-bc45024db649" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_99f51166-d8ee-4498-901b-6bfe143cd146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_27eaf25d-7e5e-4f55-b1d6-90591481e4db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_99f51166-d8ee-4498-901b-6bfe143cd146" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5c6c6ac4-9b59-4e42-b184-ad3bee135038" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_27eaf25d-7e5e-4f55-b1d6-90591481e4db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5c6c6ac4-9b59-4e42-b184-ad3bee135038" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bb21b352-fdd5-405f-91b9-cb96295789d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_39511576-6566-4d4e-b423-91058403978e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_026d808b-c97c-4c9e-a01f-e2156b2e4d31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_39511576-6566-4d4e-b423-91058403978e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_73813d15-a402-42dd-8682-d05d44d03bd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_39511576-6566-4d4e-b423-91058403978e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_73813d15-a402-42dd-8682-d05d44d03bd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0eae6d22-8488-4cde-b3ba-333a9e63c619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_39511576-6566-4d4e-b423-91058403978e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0eae6d22-8488-4cde-b3ba-333a9e63c619" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f8eee697-068a-43c3-b636-2ed1e1432d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_39511576-6566-4d4e-b423-91058403978e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f8eee697-068a-43c3-b636-2ed1e1432d8c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_122662b6-ce9b-4f2d-9d3d-c625180df2eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_39511576-6566-4d4e-b423-91058403978e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_122662b6-ce9b-4f2d-9d3d-c625180df2eb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_36529199-f2f3-42ed-9ef8-df86c3b3fa95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0ae79af-fff1-4798-a87f-736fa3971088" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_026d808b-c97c-4c9e-a01f-e2156b2e4d31" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0ae79af-fff1-4798-a87f-736fa3971088" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5a4e7ac9-d6ed-4e47-9769-36aa89c8430f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0ae79af-fff1-4798-a87f-736fa3971088" xlink:to="loc_us-gaap_AwardTypeAxis_5a4e7ac9-d6ed-4e47-9769-36aa89c8430f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a4e7ac9-d6ed-4e47-9769-36aa89c8430f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5a4e7ac9-d6ed-4e47-9769-36aa89c8430f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a4e7ac9-d6ed-4e47-9769-36aa89c8430f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_466af65d-6828-48d6-999a-9777a850aee7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5a4e7ac9-d6ed-4e47-9769-36aa89c8430f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_466af65d-6828-48d6-999a-9777a850aee7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceBasedStockUnitMember_8f649bf2-c473-4107-af87-d5708385d5d2" xlink:href="agio-20200930.xsd#agio_PerformanceBasedStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_466af65d-6828-48d6-999a-9777a850aee7" xlink:to="loc_agio_PerformanceBasedStockUnitMember_8f649bf2-c473-4107-af87-d5708385d5d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MarketBasedStockUnitsMember_6cab809b-50ed-49fb-9577-95bd5fcffe57" xlink:href="agio-20200930.xsd#agio_MarketBasedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_466af65d-6828-48d6-999a-9777a850aee7" xlink:to="loc_agio_MarketBasedStockUnitsMember_6cab809b-50ed-49fb-9577-95bd5fcffe57" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails" xlink:type="extended" id="i533f170d837e473b963231d04da0d3e6_ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac807bc4-c422-4ae0-bddb-037616aa4421" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_60193473-4bd2-4aa5-9801-cbc6198f8832" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac807bc4-c422-4ae0-bddb-037616aa4421" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_60193473-4bd2-4aa5-9801-cbc6198f8832" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab945509-ddaa-4b12-9f16-15dcd6a3aedb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac807bc4-c422-4ae0-bddb-037616aa4421" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab945509-ddaa-4b12-9f16-15dcd6a3aedb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_01558a34-249b-491d-9d4f-ba83aa2f809f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab945509-ddaa-4b12-9f16-15dcd6a3aedb" xlink:to="loc_us-gaap_AwardTypeAxis_01558a34-249b-491d-9d4f-ba83aa2f809f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01558a34-249b-491d-9d4f-ba83aa2f809f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_01558a34-249b-491d-9d4f-ba83aa2f809f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01558a34-249b-491d-9d4f-ba83aa2f809f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_855cbb2a-c117-4a94-9af7-65ded254c859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_01558a34-249b-491d-9d4f-ba83aa2f809f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_855cbb2a-c117-4a94-9af7-65ded254c859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ec0bc5ae-d195-4f58-848a-ed66645a8821" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_855cbb2a-c117-4a94-9af7-65ded254c859" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ec0bc5ae-d195-4f58-848a-ed66645a8821" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f604f740-b289-4daa-b02b-07b6a71d42c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_855cbb2a-c117-4a94-9af7-65ded254c859" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f604f740-b289-4daa-b02b-07b6a71d42c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceBasedStockUnitMember_45fa82dc-63d1-46cc-8b98-d2a97ff3f8e4" xlink:href="agio-20200930.xsd#agio_PerformanceBasedStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_855cbb2a-c117-4a94-9af7-65ded254c859" xlink:to="loc_agio_PerformanceBasedStockUnitMember_45fa82dc-63d1-46cc-8b98-d2a97ff3f8e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeeStockPurchasePlan2013Member_9cda3c80-0fa0-4308-9240-32668b971c86" xlink:href="agio-20200930.xsd#agio_EmployeeStockPurchasePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_855cbb2a-c117-4a94-9af7-65ded254c859" xlink:to="loc_agio_EmployeeStockPurchasePlan2013Member_9cda3c80-0fa0-4308-9240-32668b971c86" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_OtherStockAwardsMember_6cd44765-d07c-4710-bdc0-5c2359b2b425" xlink:href="agio-20200930.xsd#agio_OtherStockAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_855cbb2a-c117-4a94-9af7-65ded254c859" xlink:to="loc_agio_OtherStockAwardsMember_6cd44765-d07c-4710-bdc0-5c2359b2b425" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails" xlink:type="extended" id="i28c5fe985c5640cc9af0178b0e1eb5a9_ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f9918780-aba6-4290-8f44-befc09515968" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2a4388c0-4864-401c-bd52-265dc4dd2c6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f9918780-aba6-4290-8f44-befc09515968" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2a4388c0-4864-401c-bd52-265dc4dd2c6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7bae417-28fb-44f9-b17b-0468560715a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f9918780-aba6-4290-8f44-befc09515968" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7bae417-28fb-44f9-b17b-0468560715a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a9aaeb83-6842-4abf-a3a0-22f240d78fb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7bae417-28fb-44f9-b17b-0468560715a1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a9aaeb83-6842-4abf-a3a0-22f240d78fb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a9aaeb83-6842-4abf-a3a0-22f240d78fb8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a9aaeb83-6842-4abf-a3a0-22f240d78fb8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a9aaeb83-6842-4abf-a3a0-22f240d78fb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d03a8fcb-17f8-4774-9ea6-e9778d9ba087" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a9aaeb83-6842-4abf-a3a0-22f240d78fb8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d03a8fcb-17f8-4774-9ea6-e9778d9ba087" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_29b5aba9-5244-4dce-a350-cceca4bbd655" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d03a8fcb-17f8-4774-9ea6-e9778d9ba087" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_29b5aba9-5244-4dce-a350-cceca4bbd655" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_35edfe32-9b1e-48b7-877f-03e92d736de6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d03a8fcb-17f8-4774-9ea6-e9778d9ba087" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_35edfe32-9b1e-48b7-877f-03e92d736de6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/LossperShare" xlink:type="simple" xlink:href="agio-20200930.xsd#LossperShare"/>
  <link:definitionLink xlink:role="http://agios.com/role/LossperShare" xlink:type="extended" id="i8dc3857e173849c983639beafdcc6116_LossperShare"/>
  <link:roleRef roleURI="http://agios.com/role/LossperShareTables" xlink:type="simple" xlink:href="agio-20200930.xsd#LossperShareTables"/>
  <link:definitionLink xlink:role="http://agios.com/role/LossperShareTables" xlink:type="extended" id="i7e295d5567124705af630693db3704ae_LossperShareTables"/>
  <link:roleRef roleURI="http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="extended" id="i72c93882e5bc464881a65e391a7bce4a_LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_453c1124-b0f8-43f1-be8e-a53b47db2b2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d1b2f3a3-4bb4-455b-8ed7-ca00d83c47be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_453c1124-b0f8-43f1-be8e-a53b47db2b2e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d1b2f3a3-4bb4-455b-8ed7-ca00d83c47be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8f9bc8bf-6558-4f8e-bae3-62c0e350bfdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_453c1124-b0f8-43f1-be8e-a53b47db2b2e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8f9bc8bf-6558-4f8e-bae3-62c0e350bfdd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_384f286f-fa9f-4334-9cf4-74d598395845" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8f9bc8bf-6558-4f8e-bae3-62c0e350bfdd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_384f286f-fa9f-4334-9cf4-74d598395845" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_384f286f-fa9f-4334-9cf4-74d598395845_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_384f286f-fa9f-4334-9cf4-74d598395845" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_384f286f-fa9f-4334-9cf4-74d598395845_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b4ba68f-788e-484e-a0c8-1af21cbfbb59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_384f286f-fa9f-4334-9cf4-74d598395845" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b4ba68f-788e-484e-a0c8-1af21cbfbb59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_12360eaa-8165-498e-9ed6-515207497ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b4ba68f-788e-484e-a0c8-1af21cbfbb59" xlink:to="loc_us-gaap_EmployeeStockOptionMember_12360eaa-8165-498e-9ed6-515207497ab5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_92fc29e6-4578-40d7-a44d-52384121b1ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b4ba68f-788e-484e-a0c8-1af21cbfbb59" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_92fc29e6-4578-40d7-a44d-52384121b1ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitMember_86c2baa5-d800-4839-8175-e8df272ed67b" xlink:href="agio-20200930.xsd#agio_PerformanceStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b4ba68f-788e-484e-a0c8-1af21cbfbb59" xlink:to="loc_agio_PerformanceStockUnitMember_86c2baa5-d800-4839-8175-e8df272ed67b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeePurchasePlanMember_b7056b1d-62eb-4ce2-89b8-e97704e1dad1" xlink:href="agio-20200930.xsd#agio_EmployeePurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b4ba68f-788e-484e-a0c8-1af21cbfbb59" xlink:to="loc_agio_EmployeePurchasePlanMember_b7056b1d-62eb-4ce2-89b8-e97704e1dad1" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>agio-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:deac00a5-3ebc-4b82-b8fc-c0af8bd8bb5e,g:0b2f6d2b-1088-4e3a-817f-9f8454765406-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_600f8a4b-167a-439c-af6d-8a42e53d3b06_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty_d43ce11c-a06d-46c7-8a90-7f98521e5288_terseLabel_en-US" xlink:label="lab_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue &#8211; related party</link:label>
    <link:label id="lab_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty_label_en-US" xlink:label="lab_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability, Related Party</link:label>
    <link:label id="lab_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty_documentation_en-US" xlink:label="lab_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty" xlink:href="agio-20200930.xsd#agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty" xlink:to="lab_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ff76fdcd-e526-4e54-b67d-35ca9697e72d_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a4d44513-2e46-41ed-b786-620db5f1d7dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock options, granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsTermOfAgreement_55645fe5-7b1a-4b3d-839e-6f55c53e21a8_terseLabel_en-US" xlink:label="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of agreements</link:label>
    <link:label id="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsTermOfAgreement_label_en-US" xlink:label="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition Multiple Deliverable Arrangements Term Of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsTermOfAgreement" xlink:href="agio-20200930.xsd#agio_RevenueRecognitionMultipleDeliverableArrangementsTermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsTermOfAgreement" xlink:to="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsTermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_be710b9b-fc0a-42fe-ab8c-072d7eac0762_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1d9478c7-0a52-498a-ba6a-1b7c99e562e6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value, Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember_e86fc505-a625-46f0-8891-95f7a4705c2b_terseLabel_en-US" xlink:label="lab_agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty receivable &#8211; related party</link:label>
    <link:label id="lab_agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember_label_en-US" xlink:label="lab_agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RoyaltyReceivableDuefromRelatedPartiesCurrentMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember" xlink:href="agio-20200930.xsd#agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember" xlink:to="lab_agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_b6d8294c-4dae-4f81-9f1b-538253649d22_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_ece8a892-8ab2-487e-a360-9c323bbd6157_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a4870418-e052-4995-a7ed-f03a1afc7c95_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_faff23bb-380e-45f1-9fd2-f8da6d8a2fa4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1daef933-6c16-40d2-84fe-0fd23a0eb763_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_11f075a0-97ff-46a7-a492-35736c05a4dd_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_37107409-147e-4f9a-b9e6-5650410e9138_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries_9fc6f24b-d075-4d1a-bf3e-0b4a59d0b01f_negatedTotalLabel_en-US" xlink:label="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total allowances and reserves, payments/returns relating to sales in the prior years</link:label>
    <link:label id="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries_label_en-US" xlink:label="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Prior Years Reserve Recoveries</link:label>
    <link:label id="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerPriorYearsReserveRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries" xlink:to="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_36e95687-7593-44af-acf4-dc85b90d92d9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_13d621ad-76b3-4dd4-a8f5-2bf6cf0d6b77_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Contract Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d9569e92-d7c2-44fd-b131-c43cd1417fc1_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fdeb3db7-2086-4c26-ba16-7b0e6d679b0d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value, Unvested shares beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_85545641-9aaa-40fc-8315-830f5c3d7425_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value, Unvested shares end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_Agreement2010Member_9a9bcf17-74ae-4612-adb3-3ff08e318f76_terseLabel_en-US" xlink:label="lab_agio_Agreement2010Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2010 Agreement</link:label>
    <link:label id="lab_agio_Agreement2010Member_label_en-US" xlink:label="lab_agio_Agreement2010Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement2010Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_Agreement2010Member" xlink:href="agio-20200930.xsd#agio_Agreement2010Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_Agreement2010Member" xlink:to="lab_agio_Agreement2010Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_55a20ac2-e881-4718-9cc6-c69bc126ff6f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember_01efb136-8cbd-41de-ba73-76b017a0e0f6_terseLabel_en-US" xlink:label="lab_agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration receivable &#8211; related party</link:label>
    <link:label id="lab_agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember_label_en-US" xlink:label="lab_agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CollaborationReceivableDuefromRelatedPartiesCurrentMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember" xlink:href="agio-20200930.xsd#agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember" xlink:to="lab_agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0f806305-d0a7-4317-b7b6-0dfa0dadc414_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_5c166fd5-746f-470b-bbd9-815e016bcda2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember_502ffb5c-d6bb-479b-a320-432529e8f797_terseLabel_en-US" xlink:label="lab_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Plan and 2013 Plan</link:label>
    <link:label id="lab_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember_label_en-US" xlink:label="lab_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" xlink:href="agio-20200930.xsd#agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" xlink:to="lab_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c1845cb0-c952-4b35-945b-03d66550c12d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries_67c42433-4aca-4b8a-be79-2af5c10f57c1_negatedTotalLabel_en-US" xlink:label="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total allowances and reserves, payments/returns relating to sales in the current year</link:label>
    <link:label id="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries_label_en-US" xlink:label="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Current Year Reserve Recoveries</link:label>
    <link:label id="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerCurrentYearReserveRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries" xlink:to="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_be5f6bfb-894b-443e-b08a-53a3a3eaac0f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3ce75f59-b0cc-475a-83ab-83adff8c5c1d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_3e142e8c-f306-4d20-886d-659f99ed7780_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_ee66e662-1e62-4d3b-a134-6bd62be3c9ba_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_SaleOfFutureRevenueIssuanceCosts_d3836ba2-b863-463e-99e3-37de992e41b3_negatedTerseLabel_en-US" xlink:label="lab_agio_SaleOfFutureRevenueIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_agio_SaleOfFutureRevenueIssuanceCosts_label_en-US" xlink:label="lab_agio_SaleOfFutureRevenueIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Future Revenue, Issuance Costs</link:label>
    <link:label id="lab_agio_SaleOfFutureRevenueIssuanceCosts_documentation_en-US" xlink:label="lab_agio_SaleOfFutureRevenueIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Future Revenue, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueIssuanceCosts" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_SaleOfFutureRevenueIssuanceCosts" xlink:to="lab_agio_SaleOfFutureRevenueIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_bc34a71a-120e-4050-8fd7-a3ca8a5a7281_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ec1d99dd-a20f-4c3b-8b41-0e63e1709a15_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_68b0a267-88af-449c-befb-31e46c76ca9d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_f70c48d0-830e-4f09-949e-e3285780156a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_OtherStockAwardsMember_3683419e-c11d-4027-884f-df9c5d58a0a6_terseLabel_en-US" xlink:label="lab_agio_OtherStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other stock awards</link:label>
    <link:label id="lab_agio_OtherStockAwardsMember_label_en-US" xlink:label="lab_agio_OtherStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Stock Awards [Member]</link:label>
    <link:label id="lab_agio_OtherStockAwardsMember_documentation_en-US" xlink:label="lab_agio_OtherStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Stock Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_OtherStockAwardsMember" xlink:href="agio-20200930.xsd#agio_OtherStockAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_OtherStockAwardsMember" xlink:to="lab_agio_OtherStockAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bb811eeb-6f98-4f8e-9e7a-c96c9922fbce_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d94d5e50-b50c-4ef1-ba77-37116d3c89ff_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock options, outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7cd73cfe-5042-4100-9d08-09147f1f71ff_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock options, outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3e34b2e7-db51-42b1-bdae-d0ac000ce6c7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_40a9e107-f511-45ae-a04b-a3a746ca3ede_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_0d6d378a-8f81-4cb1-9253-3c43c075a661_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opportunity to purchase of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CStoneAgreementMember_ca1d17cf-5499-43ac-8c03-e15191d514f6_terseLabel_en-US" xlink:label="lab_agio_CStoneAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CStone Agreement</link:label>
    <link:label id="lab_agio_CStoneAgreementMember_label_en-US" xlink:label="lab_agio_CStoneAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CStoneAgreementMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CStoneAgreementMember" xlink:href="agio-20200930.xsd#agio_CStoneAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CStoneAgreementMember" xlink:to="lab_agio_CStoneAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_5bc9a4e9-2a1a-485b-ad02-eb8642eb78f9_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_767fdaef-8ef2-4530-ae46-dfd4206bfce5_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_7bc5efc5-0833-4067-82f8-4195c4662d87_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued or outstanding at September 30, 2020 and December 31, 2019</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerTotalAllowancesAndReserves_df99c8ec-fe67-4ff6-9609-fa415cf25638_totalLabel_en-US" xlink:label="lab_agio_ContractWithCustomerTotalAllowancesAndReserves" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue-related reserves</link:label>
    <link:label id="lab_agio_ContractWithCustomerTotalAllowancesAndReserves_label_en-US" xlink:label="lab_agio_ContractWithCustomerTotalAllowancesAndReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Total Allowances And Reserves</link:label>
    <link:label id="lab_agio_ContractWithCustomerTotalAllowancesAndReserves_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerTotalAllowancesAndReserves" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerTotalAllowancesAndReserves" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerTotalAllowancesAndReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerTotalAllowancesAndReserves" xlink:to="lab_agio_ContractWithCustomerTotalAllowancesAndReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_DeferredRevenueCurrentMember_4f0e435a-88a1-4673-ae91-29cee02ac926_terseLabel_en-US" xlink:label="lab_agio_DeferredRevenueCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue &#8211; related party, current and net of current portions</link:label>
    <link:label id="lab_agio_DeferredRevenueCurrentMember_label_en-US" xlink:label="lab_agio_DeferredRevenueCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DeferredRevenueCurrentMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DeferredRevenueCurrentMember" xlink:href="agio-20200930.xsd#agio_DeferredRevenueCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_DeferredRevenueCurrentMember" xlink:to="lab_agio_DeferredRevenueCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_86892322-7fcc-4bd5-ba16-364487c92580_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c02a5972-6cad-41ae-a123-0a79e321395e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock options, exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_e0aa112d-c50c-4cae-8f9c-0724ae13be52_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_f2000ef9-9b3a-4994-8d26-ca2ad1509cb2_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on financing lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_b60e0c1e-d05a-47a5-a0f1-15f73a122684_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_47a7b6dd-39d4-40de-9abf-14f14ea0a42e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_fa9e0aec-3069-4c46-aa4a-c23da04ad602_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_c376c113-b491-414b-a74d-390f0d4d401f_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_22ad42da-38a0-4a9b-9999-6f54ea68320a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_22a0477d-f17d-4b76-ab10-073d1fecc90a_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_7064d00e-03ef-4293-bf1c-8a6a1452a6a9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfExtensions_2850f2a5-3382-4301-89d6-2e4c96f98def_terseLabel_en-US" xlink:label="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfExtensions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension period</link:label>
    <link:label id="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfExtensions_label_en-US" xlink:label="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfExtensions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition Multiple Deliverable Arrangements Number Of Extensions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfExtensions" xlink:href="agio-20200930.xsd#agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfExtensions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfExtensions" xlink:to="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfExtensions" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ProvisionForRightToRecoverProductInCurrentYear_516cc3de-e01c-4e63-9828-433ec25143b5_terseLabel_en-US" xlink:label="lab_agio_ProvisionForRightToRecoverProductInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns, current provisions relating to sales in the current year</link:label>
    <link:label id="lab_agio_ProvisionForRightToRecoverProductInCurrentYear_label_en-US" xlink:label="lab_agio_ProvisionForRightToRecoverProductInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Right To Recover Product In Current Year</link:label>
    <link:label id="lab_agio_ProvisionForRightToRecoverProductInCurrentYear_documentation_en-US" xlink:label="lab_agio_ProvisionForRightToRecoverProductInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProvisionForRightToRecoverProductInCurrentYear" xlink:href="agio-20200930.xsd#agio_ProvisionForRightToRecoverProductInCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ProvisionForRightToRecoverProductInCurrentYear" xlink:to="lab_agio_ProvisionForRightToRecoverProductInCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityLineItems_27dc7b85-345d-4933-aac1-9fe48bf31480_terseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset and Liability [Line Items]</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityLineItems_label_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset And Liability [Line Items]</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityLineItems_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset And Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetAndLiabilityLineItems" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerAssetAndLiabilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerAssetAndLiabilityLineItems" xlink:to="lab_agio_ContractWithCustomerAssetAndLiabilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_4c5bb8a4-edbc-444a-b726-090ffe58d153_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_715cafad-cbe3-4b51-a726-a85fb3db5ebc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Excluded from Calculation of Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ea886050-9d36-41d2-92f2-5387a8cf2308_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_c6f04da3-1062-427e-91ac-9114934124ba_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_7d3334e2-064e-418e-9a17-5ad675d60dd3_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_acd124e1-029b-4325-996a-3f45cf783d1d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_IncreaseDecreaseInOperatingLeaseLiability_3d2b539a-82c5-4279-bde1-24a7b1f1b083_terseLabel_en-US" xlink:label="lab_agio_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_agio_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_agio_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Liability</link:label>
    <link:label id="lab_agio_IncreaseDecreaseInOperatingLeaseLiability_documentation_en-US" xlink:label="lab_agio_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="agio-20200930.xsd#agio_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_agio_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_19eb4a5c-773d-45ef-a71e-e4ea75d636c6_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_f4dfd19d-238a-4eea-b1bc-22f72be1bfa1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share &#8211; basic and diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_GovernmentRebatesRollForward_eaebbd3c-c371-457f-81d3-2d04d4e9d06a_terseLabel_en-US" xlink:label="lab_agio_GovernmentRebatesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Rebates [Roll Forward]</link:label>
    <link:label id="lab_agio_GovernmentRebatesRollForward_label_en-US" xlink:label="lab_agio_GovernmentRebatesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Rebates [Roll Forward]</link:label>
    <link:label id="lab_agio_GovernmentRebatesRollForward_documentation_en-US" xlink:label="lab_agio_GovernmentRebatesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_GovernmentRebatesRollForward" xlink:href="agio-20200930.xsd#agio_GovernmentRebatesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_GovernmentRebatesRollForward" xlink:to="lab_agio_GovernmentRebatesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_1acfd663-223c-4801-aceb-6dae07669620_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RPIMember_63dad999-8a34-4068-b553-a1406daa6475_terseLabel_en-US" xlink:label="lab_agio_RPIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPI</link:label>
    <link:label id="lab_agio_RPIMember_label_en-US" xlink:label="lab_agio_RPIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPI [Member]</link:label>
    <link:label id="lab_agio_RPIMember_documentation_en-US" xlink:label="lab_agio_RPIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RPI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RPIMember" xlink:href="agio-20200930.xsd#agio_RPIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RPIMember" xlink:to="lab_agio_RPIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_62348419-88e8-4c74-8537-08ebfecd8002_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e3d77790-8cc3-4455-99e2-ade44faa4383_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_dc5d6d9a-d72a-4e0d-b58e-13fa956c0710_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d19962e1-d227-4177-bf0d-0ea06df723cd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_770dabcc-6118-41a2-a485-e1055ad780bf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued revenue-related reserves and other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_OperatingLeaseRightOfUseAssetAmortization_4203a3ab-425f-4a4a-a971-5cc15739aa51_terseLabel_en-US" xlink:label="lab_agio_OperatingLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating lease expense</link:label>
    <link:label id="lab_agio_OperatingLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_agio_OperatingLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Amortization</link:label>
    <link:label id="lab_agio_OperatingLeaseRightOfUseAssetAmortization_documentation_en-US" xlink:label="lab_agio_OperatingLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_OperatingLeaseRightOfUseAssetAmortization" xlink:href="agio-20200930.xsd#agio_OperatingLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_OperatingLeaseRightOfUseAssetAmortization" xlink:to="lab_agio_OperatingLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8e0092cc-3d72-4085-8b1f-9f8c5e708f88_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts_e48c5549-ed1c-4f16-9da6-1074403c7f1e_terseLabel_en-US" xlink:label="lab_agio_ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of future revenue, net of issuance costs</link:label>
    <link:label id="lab_agio_ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts_label_en-US" xlink:label="lab_agio_ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Future Revenues, Net Of Issuance Costs</link:label>
    <link:label id="lab_agio_ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_agio_ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Future Revenues, Net Of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts" xlink:href="agio-20200930.xsd#agio_ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts" xlink:to="lab_agio_ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_577335c9-bd0a-44d8-83dc-677ad0ad0331_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized_9027c834-6381-469d-bad6-d7c0346b4cb2_terseLabel_en-US" xlink:label="lab_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones achieved</link:label>
    <link:label id="lab_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized_label_en-US" xlink:label="lab_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contracts With Customers, Milestone Revenue Recognized</link:label>
    <link:label id="lab_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized_documentation_en-US" xlink:label="lab_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contracts With Customers, Milestone Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized" xlink:href="agio-20200930.xsd#agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized" xlink:to="lab_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_aadd46e9-f4cf-4e85-89bc-bf891e74ac6c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_28569bc5-3c28-4a5e-a8b8-7054acff26e1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_SaleOfFutureRevenuePolicyPolicyTextBlock_5926eec8-88e3-4318-8eaf-3e4c605b1ff8_terseLabel_en-US" xlink:label="lab_agio_SaleOfFutureRevenuePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to Sale of Future Revenue and Amortization of Issuance Costs</link:label>
    <link:label id="lab_agio_SaleOfFutureRevenuePolicyPolicyTextBlock_label_en-US" xlink:label="lab_agio_SaleOfFutureRevenuePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Future Revenue, Policy [Policy Text Block]</link:label>
    <link:label id="lab_agio_SaleOfFutureRevenuePolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_agio_SaleOfFutureRevenuePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Future Revenue, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenuePolicyPolicyTextBlock" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenuePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_SaleOfFutureRevenuePolicyPolicyTextBlock" xlink:to="lab_agio_SaleOfFutureRevenuePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_55f3115b-c6e9-4906-beff-e2ed5c71921e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_0190dbf9-03fc-4b02-81ab-737ba1fc72c8_negatedTerseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_label_en-US" xlink:label="lab_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ContractWithCustomerAssetProceedsFromCollectionOfReceivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables" xlink:to="lab_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CStonePharmaceuticalsMember_41f42a18-2326-4cd1-8146-6fdcc8b41bdc_terseLabel_en-US" xlink:label="lab_agio_CStonePharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CStone Pharmaceuticals</link:label>
    <link:label id="lab_agio_CStonePharmaceuticalsMember_label_en-US" xlink:label="lab_agio_CStonePharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CStonePharmaceuticalsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CStonePharmaceuticalsMember" xlink:href="agio-20200930.xsd#agio_CStonePharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CStonePharmaceuticalsMember" xlink:to="lab_agio_CStonePharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_be1772e4-eabb-43e5-8d90-455a675098dd_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerAllowanceAndReservesLiability_b804bf49-f90f-4ebf-9785-035b84dbf11f_terseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerAllowanceAndReservesLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of accrued expenses</link:label>
    <link:label id="lab_agio_ContractWithCustomerAllowanceAndReservesLiability_label_en-US" xlink:label="lab_agio_ContractWithCustomerAllowanceAndReservesLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Allowance And Reserves, Liability</link:label>
    <link:label id="lab_agio_ContractWithCustomerAllowanceAndReservesLiability_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerAllowanceAndReservesLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAllowanceAndReservesLiability" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerAllowanceAndReservesLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerAllowanceAndReservesLiability" xlink:to="lab_agio_ContractWithCustomerAllowanceAndReservesLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bca08d85-f02c-4f63-9e1a-12b3bed52477_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d8ef5f36-dfe0-4b8c-b7e0-a8e62a5b37f8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense for options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_EmployeeStockPurchasePlan2013Member_dd621b1a-7ae7-43b6-9e08-27b066bfbcc7_terseLabel_en-US" xlink:label="lab_agio_EmployeeStockPurchasePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_agio_EmployeeStockPurchasePlan2013Member_label_en-US" xlink:label="lab_agio_EmployeeStockPurchasePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EmployeeStockPurchasePlan2013Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeeStockPurchasePlan2013Member" xlink:href="agio-20200930.xsd#agio_EmployeeStockPurchasePlan2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_EmployeeStockPurchasePlan2013Member" xlink:to="lab_agio_EmployeeStockPurchasePlan2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9e0ff97c-c23a-4fd3-bd48-060a854871f5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue_a07a7520-1385-438b-a030-ce61a9ea9db7_terseLabel_en-US" xlink:label="lab_agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue</link:label>
    <link:label id="lab_agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue_2033d0dc-2f13-487d-9c1d-be452928d23f_negatedTerseLabel_en-US" xlink:label="lab_agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty related to the sale of future revenue</link:label>
    <link:label id="lab_agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue_label_en-US" xlink:label="lab_agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Future Revenues, Non-Cash Royalty Revenue</link:label>
    <link:label id="lab_agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue_documentation_en-US" xlink:label="lab_agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Future Revenues, Non-Cash Royalty Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue" xlink:to="lab_agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_IncreaseDecreaseInCollaborationReceivableOtherCurrent_62c9bfd6-dc0a-4842-8d70-83f8bcc6b7bd_negatedTerseLabel_en-US" xlink:label="lab_agio_IncreaseDecreaseInCollaborationReceivableOtherCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration receivable &#8211; other</link:label>
    <link:label id="lab_agio_IncreaseDecreaseInCollaborationReceivableOtherCurrent_label_en-US" xlink:label="lab_agio_IncreaseDecreaseInCollaborationReceivableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Collaboration Receivable, Other, Current</link:label>
    <link:label id="lab_agio_IncreaseDecreaseInCollaborationReceivableOtherCurrent_documentation_en-US" xlink:label="lab_agio_IncreaseDecreaseInCollaborationReceivableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseInCollaborationReceivableOtherCurrent" xlink:href="agio-20200930.xsd#agio_IncreaseDecreaseInCollaborationReceivableOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_IncreaseDecreaseInCollaborationReceivableOtherCurrent" xlink:to="lab_agio_IncreaseDecreaseInCollaborationReceivableOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_2a6ec154-debd-49ae-bbf6-ab1173fde298_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_445864e8-2d55-4f19-9b92-034887e508c3_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RoyaltyReceivableDuefromRelatedPartiesCurrent_5f537f36-48f7-4f6a-a7d0-36c0fe884dd8_terseLabel_en-US" xlink:label="lab_agio_RoyaltyReceivableDuefromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty receivable &#8211; related party</link:label>
    <link:label id="lab_agio_RoyaltyReceivableDuefromRelatedPartiesCurrent_label_en-US" xlink:label="lab_agio_RoyaltyReceivableDuefromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RoyaltyReceivableDuefromRelatedPartiesCurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RoyaltyReceivableDuefromRelatedPartiesCurrent" xlink:href="agio-20200930.xsd#agio_RoyaltyReceivableDuefromRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RoyaltyReceivableDuefromRelatedPartiesCurrent" xlink:to="lab_agio_RoyaltyReceivableDuefromRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_4c7e9846-f277-4b94-8f24-49f20d0b021a_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_8b340369-aec5-4693-8eab-b7bb2b3b7bb1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_743f677d-e3b3-453d-90eb-c0a73d45f71b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RevenueRecognitionMilestoneMethodEligibleReceivable_92cb6da0-0aff-428f-8626-3d8d2e524aa7_terseLabel_en-US" xlink:label="lab_agio_RevenueRecognitionMilestoneMethodEligibleReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone-based receivable payments, eligible to be received</link:label>
    <link:label id="lab_agio_RevenueRecognitionMilestoneMethodEligibleReceivable_label_en-US" xlink:label="lab_agio_RevenueRecognitionMilestoneMethodEligibleReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenueRecognitionMilestoneMethodEligibleReceivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMilestoneMethodEligibleReceivable" xlink:href="agio-20200930.xsd#agio_RevenueRecognitionMilestoneMethodEligibleReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RevenueRecognitionMilestoneMethodEligibleReceivable" xlink:to="lab_agio_RevenueRecognitionMilestoneMethodEligibleReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerAssetRevenueRecognized_ab67d002-8cbd-489b-9a16-cde244c2d9bb_terseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerAssetRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetRevenueRecognized_label_en-US" xlink:label="lab_agio_ContractWithCustomerAssetRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, Revenue Recognized</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetRevenueRecognized_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerAssetRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetRevenueRecognized" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerAssetRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerAssetRevenueRecognized" xlink:to="lab_agio_ContractWithCustomerAssetRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_a429d92a-383d-4f81-9c68-fa4024b353e4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_SaleOfFutureRevenueInterestExpense_b484093c-93ec-4455-a97b-d32f30ee00f2_terseLabel_en-US" xlink:label="lab_agio_SaleOfFutureRevenueInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense associated with the sale of future revenue</link:label>
    <link:label id="lab_agio_SaleOfFutureRevenueInterestExpense_label_en-US" xlink:label="lab_agio_SaleOfFutureRevenueInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Future Revenue, Interest Expense</link:label>
    <link:label id="lab_agio_SaleOfFutureRevenueInterestExpense_documentation_en-US" xlink:label="lab_agio_SaleOfFutureRevenueInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Future Revenue, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueInterestExpense" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_SaleOfFutureRevenueInterestExpense" xlink:to="lab_agio_SaleOfFutureRevenueInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_12d61409-7f5a-427d-9344-3fcb483f3333_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_785b4565-977d-461b-aef6-992e2810aa72_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_286ffc18-c21d-41f5-a909-883bc36cce6c_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_20dbcebb-03d6-48e7-bc55-8e39759ac7f8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_fc38b4c5-ea62-4b20-b79e-8a5545ed2c92_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold_2f20d159-b6ef-4955-8535-a69e548aa697_terseLabel_en-US" xlink:label="lab_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty rights sold</link:label>
    <link:label id="lab_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold_label_en-US" xlink:label="lab_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Portion Of Potential Milestone Payment Receivable For Specified Regulatory Milestone Sold</link:label>
    <link:label id="lab_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold_documentation_en-US" xlink:label="lab_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PortionOfPotentialMilestonPaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgramSold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold" xlink:href="agio-20200930.xsd#agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold" xlink:to="lab_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication_541d2faa-3629-43a3-ab37-75d06f59ba80_terseLabel_en-US" xlink:label="lab_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payment</link:label>
    <link:label id="lab_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication_label_en-US" xlink:label="lab_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" xlink:href="agio-20200930.xsd#agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" xlink:to="lab_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerPriorYearsReserveProvisions_faf6bdc9-757e-404e-ad8b-eb37d70b2799_totalLabel_en-US" xlink:label="lab_agio_ContractWithCustomerPriorYearsReserveProvisions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total allowances and reserves, adjustments relating to prior years</link:label>
    <link:label id="lab_agio_ContractWithCustomerPriorYearsReserveProvisions_label_en-US" xlink:label="lab_agio_ContractWithCustomerPriorYearsReserveProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Prior Years Reserve Provisions</link:label>
    <link:label id="lab_agio_ContractWithCustomerPriorYearsReserveProvisions_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerPriorYearsReserveProvisions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerPriorYearsReserveProvisions" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerPriorYearsReserveProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveProvisions" xlink:to="lab_agio_ContractWithCustomerPriorYearsReserveProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fa10916b-b295-4fb3-a0a4-d048cf87c7ac_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested shares beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7d22508b-bc64-4404-99e4-e7d84a277fa6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested shares end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_d2d0782c-c1d1-47fd-9638-25ddeb01dee5_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1be3b18e-0788-4d4e-9006-b276ca1d6e8a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CelgeneMember_d9363fa4-6d6f-46f3-8ea0-b116165f2ddf_terseLabel_en-US" xlink:label="lab_agio_CelgeneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Celgene</link:label>
    <link:label id="lab_agio_CelgeneMember_label_en-US" xlink:label="lab_agio_CelgeneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CelgeneMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CelgeneMember" xlink:href="agio-20200930.xsd#agio_CelgeneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CelgeneMember" xlink:to="lab_agio_CelgeneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_636d8cb5-8e4a-448f-a0dc-52d9ae5f9068_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_070779a2-0d9c-4454-bcc2-dcf2533820e1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_5f56dcd1-4e7f-45b6-a447-bf4c992bd7af_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_AccruedResearchAndDevelopmentCostsCurrent_9f8a9ea7-fa7e-4853-81d1-c58761a945ba_terseLabel_en-US" xlink:label="lab_agio_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development costs</link:label>
    <link:label id="lab_agio_AccruedResearchAndDevelopmentCostsCurrent_label_en-US" xlink:label="lab_agio_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AccruedResearchAndDevelopmentCostsCurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AccruedResearchAndDevelopmentCostsCurrent" xlink:href="agio-20200930.xsd#agio_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="lab_agio_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_f117e048-67d2-4097-b2a2-dc8bc8fe9018_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CollaborationReceivableDueFromRelatedPartiesCurrent_ca699ad8-abe5-4d2a-bb56-05424c069a6f_terseLabel_en-US" xlink:label="lab_agio_CollaborationReceivableDueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration receivable &#8211; related party</link:label>
    <link:label id="lab_agio_CollaborationReceivableDueFromRelatedPartiesCurrent_label_en-US" xlink:label="lab_agio_CollaborationReceivableDueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Receivable, Due From Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationReceivableDueFromRelatedPartiesCurrent" xlink:href="agio-20200930.xsd#agio_CollaborationReceivableDueFromRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CollaborationReceivableDueFromRelatedPartiesCurrent" xlink:to="lab_agio_CollaborationReceivableDueFromRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_44812e32-861d-468e-b0eb-a123e0fac103_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductReserve_9e71cdd3-be59-4056-8005-fbf27d7b684a_periodStartLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns, beginning balance</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductReserve_c3e940ab-e6a3-4e59-94e2-851fe2a4813f_periodEndLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns, ending balance</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductReserve_label_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Right To Recover Product, Reserve</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductReserve_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerRightToRecoverProductReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:to="lab_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_163bfe86-8d93-418d-8d51-3980224a519d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ResearchServicesMember_57cac794-2034-4837-ae16-d7da9a962f61_terseLabel_en-US" xlink:label="lab_agio_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">On-going research and development services</link:label>
    <link:label id="lab_agio_ResearchServicesMember_label_en-US" xlink:label="lab_agio_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ResearchServicesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ResearchServicesMember" xlink:href="agio-20200930.xsd#agio_ResearchServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ResearchServicesMember" xlink:to="lab_agio_ResearchServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_11d92038-7f6a-4906-ac3f-4e7dda518583_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period to recognize compensation expense (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bc300d48-8ce1-4502-bcec-dcba75018f8d_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_49cf30fd-c934-4ced-a5c5-cc081a9024a1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate fair value of debt securities in unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_3538378e-64bc-45ef-8acd-d9e7c9829b3e_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7a40d923-ae73-4b39-88f7-25fd33f79a0f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts included in the contract liability at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PerformanceStockUnitMember_e707b6f4-c70e-4d8b-b1fe-dcbbe8c75a7f_verboseLabel_en-US" xlink:label="lab_agio_PerformanceStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based stock units</link:label>
    <link:label id="lab_agio_PerformanceStockUnitMember_label_en-US" xlink:label="lab_agio_PerformanceStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PerformanceStockUnitMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitMember" xlink:href="agio-20200930.xsd#agio_PerformanceStockUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PerformanceStockUnitMember" xlink:to="lab_agio_PerformanceStockUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_c07fc733-5f31-4f8c-8ec0-c31ab44e8cf6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_9da8fd9c-3a3f-4df5-bd86-12e1af420b6f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_07705b7c-4ca9-4486-9c11-de8223843430_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_TwoThousandAndThirteenStockIncentivePlanMember_4fb8b42b-5609-4aba-a75c-cab51d9ddc1b_terseLabel_en-US" xlink:label="lab_agio_TwoThousandAndThirteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2013 Stock Incentive Plan</link:label>
    <link:label id="lab_agio_TwoThousandAndThirteenStockIncentivePlanMember_label_en-US" xlink:label="lab_agio_TwoThousandAndThirteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TwoThousandAndThirteenStockIncentivePlanMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TwoThousandAndThirteenStockIncentivePlanMember" xlink:href="agio-20200930.xsd#agio_TwoThousandAndThirteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_TwoThousandAndThirteenStockIncentivePlanMember" xlink:to="lab_agio_TwoThousandAndThirteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock_200c26c4-27c0-4f38-ab6b-e7f68e2b8fdc_terseLabel_en-US" xlink:label="lab_agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Royalty Revenue</link:label>
    <link:label id="lab_agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock_label_en-US" xlink:label="lab_agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From External Customers, Royalty Revenue [Table Text Block]</link:label>
    <link:label id="lab_agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock_documentation_en-US" xlink:label="lab_agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock" xlink:href="agio-20200930.xsd#agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock" xlink:to="lab_agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_ae0c3c41-a9b8-4df0-8b85-fc1dc89b6890_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_7afd0cca-ab79-4620-935a-38d1ca44f86d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_50335f1e-cf42-4037-8ea7-afe47a12bdf1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses_88b2e805-0f29-485b-bf16-10516c2ba9a9_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:to="lab_us-gaap_FinancingReceivableAllowanceForCreditLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_a3c3c9c4-3191-4808-b725-e520661b8743_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_UnbilledReceivableDueFromRelatedPartiesCurrentMember_4327507b-c9cd-4f55-affa-a04a47eb7a82_terseLabel_en-US" xlink:label="lab_agio_UnbilledReceivableDueFromRelatedPartiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled receivable - related party, net of current portions</link:label>
    <link:label id="lab_agio_UnbilledReceivableDueFromRelatedPartiesCurrentMember_label_en-US" xlink:label="lab_agio_UnbilledReceivableDueFromRelatedPartiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled Receivable, Due From Related Parties, Current [Member]</link:label>
    <link:label id="lab_agio_UnbilledReceivableDueFromRelatedPartiesCurrentMember_documentation_en-US" xlink:label="lab_agio_UnbilledReceivableDueFromRelatedPartiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled Receivable, Due From Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_UnbilledReceivableDueFromRelatedPartiesCurrentMember" xlink:href="agio-20200930.xsd#agio_UnbilledReceivableDueFromRelatedPartiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_UnbilledReceivableDueFromRelatedPartiesCurrentMember" xlink:to="lab_agio_UnbilledReceivableDueFromRelatedPartiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_f901bff3-0a51-4cc4-a9c0-45fe5dff7d25_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsSpecialCaseExtensionTerm_66338313-23e8-43a1-affa-1527f7037cf5_terseLabel_en-US" xlink:label="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsSpecialCaseExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special case extension term</link:label>
    <link:label id="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsSpecialCaseExtensionTerm_label_en-US" xlink:label="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsSpecialCaseExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition Multiple Deliverable Arrangements Special Case Extension Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsSpecialCaseExtensionTerm" xlink:href="agio-20200930.xsd#agio_RevenueRecognitionMultipleDeliverableArrangementsSpecialCaseExtensionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsSpecialCaseExtensionTerm" xlink:to="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsSpecialCaseExtensionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_381297d0-d044-4781-9697-64c3f05b17ac_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_156273b0-8083-464f-b948-e92e7ab43f7f_negatedLabel_en-US" xlink:label="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments, payments/returns relating to sales in the current year</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_label_en-US" xlink:label="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Contract Adjustment, Recoveries, Current Year</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" xlink:to="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_64fef954-3f51-4536-a05b-d1e75d1d7946_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_7bb3f3a8-8e10-4c3b-bcd2-71e1d4aec37a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of debt securities in unrealized loss position for less than one year</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f3efcb90-bdd6-4368-a103-9b93b248529c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_ec67d6d3-7efc-4a51-8ddc-1cad7c93dd20_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_f335f65b-4b4f-43dd-a37a-9df3ed451b25_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f62d8d1b-ad54-4e50-91f6-e42a93fbae3c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, outstanding, beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_28e660cd-05c5-4023-b097-02320e051f4e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, outstanding, ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_16a645b8-f21b-48fd-9f7d-5a0348312328_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenue &#8211; related party</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_32b9bc0b-c51f-4eae-aa60-45ca9d3218f2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward_8675615d-2271-48c4-94a1-543fce52497c_terseLabel_en-US" xlink:label="lab_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Future Revenue, Liability, Noncurrent [Roll Forward]</link:label>
    <link:label id="lab_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward_label_en-US" xlink:label="lab_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Future Revenue, Liability, Noncurrent [Roll Forward]</link:label>
    <link:label id="lab_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward_documentation_en-US" xlink:label="lab_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Future Revenue, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward" xlink:to="lab_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_32f0df7d-769d-46d6-88d9-1badefe75965_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e07a8fec-e9c6-46dc-997c-8dbead97feec_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_773b2965-b5f5-41e5-9f6f-d80fedadda51_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c99f13c3-6b0e-48d6-a800-85c6bf5e2d77_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current and non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_979d7b45-b587-47e9-abcf-22b7071dd247_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_c4924887-2661-4f3e-832d-db81029a2274_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts_64ceb0ce-eec9-4e10-bb33-7937e2c1c866_terseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial payment received</link:label>
    <link:label id="lab_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts_label_en-US" xlink:label="lab_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increase From Cash Receipts</link:label>
    <link:label id="lab_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts" xlink:to="lab_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_d1654d91-1f5c-4d70-9119-e3869e03c851_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_243e0504-7123-4d9e-9faa-08375b553b85_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock_b133b678-ab1f-4543-93ba-babf5687e33e_terseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Contract Assets and Liabilities, Product Revenue</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock_label_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset And Liability, Product Revenue [Table Text Block]</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" xlink:to="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_9b025328-2963-4697-8b66-8ee51d033fdd_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_47966fa3-661d-490b-84d1-4aae3baf2cbf_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_917b0fed-5452-4b54-9ab0-85305e07b630_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Performance-Based Units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Performance-based Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_fc5ee6aa-e31f-49c7-973b-a4eaca8aa8dd_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4c900db6-01d1-4aea-bf8f-7ad88ca3297e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b00e78e6-ccab-407c-80b9-c560190939a8_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_d54970cc-e5cd-41e3-8aa3-012da14bc3f7_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RoyaltyRevenueNonCash_9e3336aa-f62e-4f19-ada8-8fe657331776_negatedTerseLabel_en-US" xlink:label="lab_agio_RoyaltyRevenueNonCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue</link:label>
    <link:label id="lab_agio_RoyaltyRevenueNonCash_label_en-US" xlink:label="lab_agio_RoyaltyRevenueNonCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Revenue, Non-Cash</link:label>
    <link:label id="lab_agio_RoyaltyRevenueNonCash_documentation_en-US" xlink:label="lab_agio_RoyaltyRevenueNonCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Revenue, Non-Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RoyaltyRevenueNonCash" xlink:href="agio-20200930.xsd#agio_RoyaltyRevenueNonCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RoyaltyRevenueNonCash" xlink:to="lab_agio_RoyaltyRevenueNonCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_f2ab730e-c9fd-4ffc-a82e-7bffc31a4dcb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_6c2b36f4-ab13-4ce6-9eea-658b30c174a6_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_945b1cbc-c196-4ea6-9895-3ddd82ba7a24_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_a3944122-56bd-4855-8141-ec8ba0aad0d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_ab139685-eda1-45a5-ad3b-c95eac1a35c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_4cad4bbc-fded-4ce2-a0b9-a34b4f75d754_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_MarketBasedStockUnitsMember_f8e20667-addc-4ea2-a137-c945b5c2cd04_terseLabel_en-US" xlink:label="lab_agio_MarketBasedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-Based Stock Units</link:label>
    <link:label id="lab_agio_MarketBasedStockUnitsMember_label_en-US" xlink:label="lab_agio_MarketBasedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-Based Stock Units [Member]</link:label>
    <link:label id="lab_agio_MarketBasedStockUnitsMember_documentation_en-US" xlink:label="lab_agio_MarketBasedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-Based Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MarketBasedStockUnitsMember" xlink:href="agio-20200930.xsd#agio_MarketBasedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_MarketBasedStockUnitsMember" xlink:to="lab_agio_MarketBasedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerContractualAdjustmentReserve_cec6ce39-71b6-43d4-819c-b11504fe57d2_periodStartLabel_en-US" xlink:label="lab_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract adjustments, beginning balance</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractualAdjustmentReserve_29fa8e13-8880-4571-a2ac-b850e19b2110_periodEndLabel_en-US" xlink:label="lab_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract adjustments, ending balance</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractualAdjustmentReserve_label_en-US" xlink:label="lab_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Contractual Adjustment Reserve</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractualAdjustmentReserve_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerContractualAdjustmentReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:to="lab_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_SaleOfFutureRevenueRoyaltyObligationTableTextBlock_22114e3b-1eab-4aaf-9613-8891b2ca56ef_terseLabel_en-US" xlink:label="lab_agio_SaleOfFutureRevenueRoyaltyObligationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Royalty Obligation</link:label>
    <link:label id="lab_agio_SaleOfFutureRevenueRoyaltyObligationTableTextBlock_label_en-US" xlink:label="lab_agio_SaleOfFutureRevenueRoyaltyObligationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Future Revenue, Royalty Obligation [Table Text Block]</link:label>
    <link:label id="lab_agio_SaleOfFutureRevenueRoyaltyObligationTableTextBlock_documentation_en-US" xlink:label="lab_agio_SaleOfFutureRevenueRoyaltyObligationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Future Revenue, Royalty Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueRoyaltyObligationTableTextBlock" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueRoyaltyObligationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_SaleOfFutureRevenueRoyaltyObligationTableTextBlock" xlink:to="lab_agio_SaleOfFutureRevenueRoyaltyObligationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_SaleOfFutureRevenueAmortizationOfIssuanceCosts_f1d70c75-1f0b-417e-b878-eccfdbd301d7_terseLabel_en-US" xlink:label="lab_agio_SaleOfFutureRevenueAmortizationOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of issuance costs</link:label>
    <link:label id="lab_agio_SaleOfFutureRevenueAmortizationOfIssuanceCosts_label_en-US" xlink:label="lab_agio_SaleOfFutureRevenueAmortizationOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Future Revenue, Amortization Of Issuance Costs</link:label>
    <link:label id="lab_agio_SaleOfFutureRevenueAmortizationOfIssuanceCosts_documentation_en-US" xlink:label="lab_agio_SaleOfFutureRevenueAmortizationOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Future Revenue, Amortization Of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueAmortizationOfIssuanceCosts" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueAmortizationOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_SaleOfFutureRevenueAmortizationOfIssuanceCosts" xlink:to="lab_agio_SaleOfFutureRevenueAmortizationOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_6d604725-783c-46f6-9c13-c5a590c76dd3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_533185b3-9e31-4155-924b-fea9110be285_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net accretion of premium and discounts on investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractualAdjustmentsRollForward_8713e5ea-bea3-4187-baa8-cf0f8bd7612d_terseLabel_en-US" xlink:label="lab_agio_ContractualAdjustmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Adjustments [Roll Forward]</link:label>
    <link:label id="lab_agio_ContractualAdjustmentsRollForward_label_en-US" xlink:label="lab_agio_ContractualAdjustmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Adjustments [Roll Forward]</link:label>
    <link:label id="lab_agio_ContractualAdjustmentsRollForward_documentation_en-US" xlink:label="lab_agio_ContractualAdjustmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractualAdjustmentsRollForward" xlink:href="agio-20200930.xsd#agio_ContractualAdjustmentsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractualAdjustmentsRollForward" xlink:to="lab_agio_ContractualAdjustmentsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_fa3ddbe0-c7d3-402f-9c12-ea715787e550_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8d81ebae-d95e-4844-be0f-235f7aac8058_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7ed7ea36-55fe-4a08-96a7-84afe8af63e1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_086aa5ec-725c-48f5-98a2-ab93df7e7ec1_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_fb2c435b-9268-419f-86d0-ff6322cbad0e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_403f35e6-8566-44ca-97e0-5cac0c4872e0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_faba250b-0f0c-48f5-812b-fbc269ccdebc_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_980f14fa-8d9c-489d-93ac-7a5e80e8e2d2_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_8b2a0a9d-1635-47a5-925a-35783983a6b8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_504d0e0d-73f9-468c-8800-562095e24d3c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value, Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_0341191b-fada-4df4-924c-bd2325b5328e_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_89d846f6-8a7c-4922-a690-8746d07d3a3c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_4f25634b-fad5-4c00-9fe1-6dcd66165a4b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_0f10510b-7e77-484a-a3c3-e0763ed53ece_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9ce39e38-183a-4bad-bd91-1c511d06b9c3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Company's Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PriorYearProvisionForContractualAdjustments_9a805728-9a75-4255-94e3-bf7fb2eca4c9_terseLabel_en-US" xlink:label="lab_agio_PriorYearProvisionForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments, adjustments relating to prior year</link:label>
    <link:label id="lab_agio_PriorYearProvisionForContractualAdjustments_label_en-US" xlink:label="lab_agio_PriorYearProvisionForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Provision For Contractual Adjustments</link:label>
    <link:label id="lab_agio_PriorYearProvisionForContractualAdjustments_documentation_en-US" xlink:label="lab_agio_PriorYearProvisionForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PriorYearProvisionForContractualAdjustments" xlink:href="agio-20200930.xsd#agio_PriorYearProvisionForContractualAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PriorYearProvisionForContractualAdjustments" xlink:to="lab_agio_PriorYearProvisionForContractualAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_3bf0effc-1c7b-4145-8a12-fc9ed18267f1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CollaborationRevenueOtherMember_82261521-46c2-435f-ba89-8467c1d007ac_terseLabel_en-US" xlink:label="lab_agio_CollaborationRevenueOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue &#8211; other</link:label>
    <link:label id="lab_agio_CollaborationRevenueOtherMember_label_en-US" xlink:label="lab_agio_CollaborationRevenueOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue, Other [Member]</link:label>
    <link:label id="lab_agio_CollaborationRevenueOtherMember_documentation_en-US" xlink:label="lab_agio_CollaborationRevenueOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueOtherMember" xlink:href="agio-20200930.xsd#agio_CollaborationRevenueOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CollaborationRevenueOtherMember" xlink:to="lab_agio_CollaborationRevenueOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a7cfc340-637a-434a-bbb1-5a82b76e5c4e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CashEquivalentsAndAvailableForSaleSecurities_92372ace-f191-49bd-a873-bf12ba5bd7ac_totalLabel_en-US" xlink:label="lab_agio_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and marketable securities</link:label>
    <link:label id="lab_agio_CashEquivalentsAndAvailableForSaleSecurities_label_en-US" xlink:label="lab_agio_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CashEquivalentsAndAvailableForSaleSecurities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CashEquivalentsAndAvailableForSaleSecurities" xlink:href="agio-20200930.xsd#agio_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CashEquivalentsAndAvailableForSaleSecurities" xlink:to="lab_agio_CashEquivalentsAndAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_aa76161e-7feb-41fb-a356-2fbc5015cbe5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_4f3b0bee-d751-477f-93cc-d7e3cd4cbc8d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average incremental borrowing rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_87cd2260-f0e4-4c39-8a58-9356a30adb57_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Doubtful Accounts Receivable [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c10dc3d9-d5fe-44dd-942c-8bcb25a29b7b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_be808e45-aca7-4543-b5f3-b2d8469db228_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f6ef3af0-ebc7-4678-b4e1-fcad9e54fa4b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_InterestExpenseNonCashSaleOfFutureRevenue_25e406a1-b66d-42aa-b713-bb4778b00a9b_negatedTerseLabel_en-US" xlink:label="lab_agio_InterestExpenseNonCashSaleOfFutureRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense for the sale of future revenue</link:label>
    <link:label id="lab_agio_InterestExpenseNonCashSaleOfFutureRevenue_827b2f83-73b6-4e28-837c-8103a0cd6f9f_verboseLabel_en-US" xlink:label="lab_agio_InterestExpenseNonCashSaleOfFutureRevenue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense associated with the sale of future revenue</link:label>
    <link:label id="lab_agio_InterestExpenseNonCashSaleOfFutureRevenue_label_en-US" xlink:label="lab_agio_InterestExpenseNonCashSaleOfFutureRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Non-Cash, Sale Of Future Revenue</link:label>
    <link:label id="lab_agio_InterestExpenseNonCashSaleOfFutureRevenue_documentation_en-US" xlink:label="lab_agio_InterestExpenseNonCashSaleOfFutureRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Non-Cash, Sale Of Future Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_InterestExpenseNonCashSaleOfFutureRevenue" xlink:href="agio-20200930.xsd#agio_InterestExpenseNonCashSaleOfFutureRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_InterestExpenseNonCashSaleOfFutureRevenue" xlink:to="lab_agio_InterestExpenseNonCashSaleOfFutureRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4685b075-8fe9-4061-baa3-ad682156a2bc_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undiscounted minimum rental commitments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6efc245b-bce9-44cb-8a00-dd7306dfa98d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_857c982e-9f82-4cbb-9a8e-d3712be4c512_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_b6ed345b-d253-41e4-9497-c814b530b240_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease terms</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_44993b3e-30d1-4866-a1c8-315d9f7e1f19_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_e3505343-9567-4031-9f8f-dfecc6661db7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares used in computing net loss per share &#8211; basic and diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlockTableTextBlock_e8d0f135-67ad-44ef-b90d-094f919cf1a1_terseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Contract Assets and Liabilities, CStone Agreement</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlockTableTextBlock_label_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlock [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlockTableTextBlock" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlockTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlockTableTextBlock" xlink:to="lab_agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlockTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6e807b1e-0163-41cc-a96a-fa737593a6e1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_c3a9a21b-31dd-4162-8f9f-66e41f7bd54c_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_SaleOfFutureRevenueRoyaltyObligationAbstract_1e847ba5-ecca-4dcf-a17d-2f81b3393a8d_terseLabel_en-US" xlink:label="lab_agio_SaleOfFutureRevenueRoyaltyObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Future Revenue, Royalty Obligation [Abstract]</link:label>
    <link:label id="lab_agio_SaleOfFutureRevenueRoyaltyObligationAbstract_label_en-US" xlink:label="lab_agio_SaleOfFutureRevenueRoyaltyObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Future Revenue, Royalty Obligation [Abstract]</link:label>
    <link:label id="lab_agio_SaleOfFutureRevenueRoyaltyObligationAbstract_documentation_en-US" xlink:label="lab_agio_SaleOfFutureRevenueRoyaltyObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Future Revenue, Royalty Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueRoyaltyObligationAbstract" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueRoyaltyObligationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_SaleOfFutureRevenueRoyaltyObligationAbstract" xlink:to="lab_agio_SaleOfFutureRevenueRoyaltyObligationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9fc6487a-9f6b-4ea3-8d7f-b27c8000c134_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_cf7af9e4-2a9e-4c41-bb14-73141ac4806a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate_b7853fe1-fac1-4246-8f9a-24c29a6c83e9_terseLabel_en-US" xlink:label="lab_agio_PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated effective interest rate on royalty rights sold</link:label>
    <link:label id="lab_agio_PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate_label_en-US" xlink:label="lab_agio_PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payment Receivable For Specified Regulatory Milestone Event Program, Estimated Effective Interest Rate</link:label>
    <link:label id="lab_agio_PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate_documentation_en-US" xlink:label="lab_agio_PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payment Receivable For Specified Regulatory Milestone Event Program, Estimated Effective Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate" xlink:href="agio-20200930.xsd#agio_PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate" xlink:to="lab_agio_PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_a9f673b4-ebf5-48f6-a350-8c622ad6dc2c_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_bd31ef22-88f8-4e39-87bb-c43bbcf29093_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock options, forfeited/expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CommercializationActivityMember_0160e13f-f54e-4980-9eb3-1b15c7d0a899_terseLabel_en-US" xlink:label="lab_agio_CommercializationActivityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization activities</link:label>
    <link:label id="lab_agio_CommercializationActivityMember_label_en-US" xlink:label="lab_agio_CommercializationActivityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization Activity [Member]</link:label>
    <link:label id="lab_agio_CommercializationActivityMember_documentation_en-US" xlink:label="lab_agio_CommercializationActivityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CommercializationActivityMember" xlink:href="agio-20200930.xsd#agio_CommercializationActivityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CommercializationActivityMember" xlink:to="lab_agio_CommercializationActivityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_6f2068c2-99cb-4074-b149-b2cdf4847b8f_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ffe47289-62ad-4464-a2ab-c65655b88149_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CollaborationRevenueRelatedPartyMember_e60d74d7-8496-48df-883c-5d45d6d26438_terseLabel_en-US" xlink:label="lab_agio_CollaborationRevenueRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue &#8211; related party</link:label>
    <link:label id="lab_agio_CollaborationRevenueRelatedPartyMember_label_en-US" xlink:label="lab_agio_CollaborationRevenueRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue, Related Party [Member]</link:label>
    <link:label id="lab_agio_CollaborationRevenueRelatedPartyMember_documentation_en-US" xlink:label="lab_agio_CollaborationRevenueRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueRelatedPartyMember" xlink:href="agio-20200930.xsd#agio_CollaborationRevenueRelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CollaborationRevenueRelatedPartyMember" xlink:to="lab_agio_CollaborationRevenueRelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_4a2d70e5-e346-4cea-bcce-03d4d2b2e1d8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue &#8211; related party</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3e3ba8a0-865e-4f2b-8cbb-a9744fb871d2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c11050e0-b22c-4507-901d-52712067bca6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock options, vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4fd628ee-e6ce-449f-9294-5d351ed9f76f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bb4cd11c-590b-461c-b5cd-19d48941e1bf_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_54f49fe7-63b6-473b-901e-8e155586e3ae_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5d91ba29-367c-488d-82d1-d2ca234be13d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CurrentYearProvisionsForRebateReserve_71843272-f8af-4901-b9db-e0c0f3d9c6e4_terseLabel_en-US" xlink:label="lab_agio_CurrentYearProvisionsForRebateReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government rebates, current provisions relating to sales in the current year</link:label>
    <link:label id="lab_agio_CurrentYearProvisionsForRebateReserve_label_en-US" xlink:label="lab_agio_CurrentYearProvisionsForRebateReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Provisions For Rebate Reserve</link:label>
    <link:label id="lab_agio_CurrentYearProvisionsForRebateReserve_documentation_en-US" xlink:label="lab_agio_CurrentYearProvisionsForRebateReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentYearProvisionsForRebateReserve" xlink:href="agio-20200930.xsd#agio_CurrentYearProvisionsForRebateReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CurrentYearProvisionsForRebateReserve" xlink:to="lab_agio_CurrentYearProvisionsForRebateReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_MasterResearchAndCollaborationAgreementMember_85dd223c-1f7a-4f9f-9e05-083919e2a6aa_terseLabel_en-US" xlink:label="lab_agio_MasterResearchAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Agreement</link:label>
    <link:label id="lab_agio_MasterResearchAndCollaborationAgreementMember_label_en-US" xlink:label="lab_agio_MasterResearchAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MasterResearchAndCollaborationAgreementMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MasterResearchAndCollaborationAgreementMember" xlink:href="agio-20200930.xsd#agio_MasterResearchAndCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_MasterResearchAndCollaborationAgreementMember" xlink:to="lab_agio_MasterResearchAndCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8a1712c-a0e4-4f84-b1e9-a0794b4cde4c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PriorYearProvisionsForRebateReserve_541d8b00-cf90-4e84-9c86-d87561a42333_terseLabel_en-US" xlink:label="lab_agio_PriorYearProvisionsForRebateReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government rebates, adjustments relating to prior years</link:label>
    <link:label id="lab_agio_PriorYearProvisionsForRebateReserve_label_en-US" xlink:label="lab_agio_PriorYearProvisionsForRebateReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Provisions For Rebate Reserve</link:label>
    <link:label id="lab_agio_PriorYearProvisionsForRebateReserve_documentation_en-US" xlink:label="lab_agio_PriorYearProvisionsForRebateReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PriorYearProvisionsForRebateReserve" xlink:href="agio-20200930.xsd#agio_PriorYearProvisionsForRebateReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PriorYearProvisionsForRebateReserve" xlink:to="lab_agio_PriorYearProvisionsForRebateReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_4681ecc4-dd0c-49a8-9dde-8da2fe7bd378_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining unsatisfied performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_60fe2755-4013-44fc-afae-a417bf5b08c7_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDepreciationAndAmortization_0c365133-3e30-4238-af02-e1b1a581cb98_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_OtherDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDepreciationAndAmortization" xlink:to="lab_us-gaap_OtherDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_1e03a693-344a-4a26-ae1a-69578e020734_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_f0929014-df41-4255-8042-aa1ad5c14429_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_c250ae5e-30f2-4be3-9b67-da727bd95b11_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 125,000,000 shares authorized; 69,198,063 and 68,401,105 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_ad153b4e-bac2-4750-a4dd-45f502314fb8_negatedLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government rebates, payments/returns relating to sales in the current year</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_label_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Rebate Reserve, Recoveries In Current Year</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" xlink:to="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_1b9ae005-a015-41b3-924b-5abf7919806a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_f30d66a2-0f54-4453-8ae2-55ddeec69bdb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Revenue Allowance and Reserves</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_5574353a-86e1-4535-8579-da636c09cd7f_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent_edc953a2-87f5-45e4-a229-460306d5b478_negatedLabel_en-US" xlink:label="lab_agio_IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration receivable &#8211; related party</link:label>
    <link:label id="lab_agio_IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent_label_en-US" xlink:label="lab_agio_IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Collaboration Receivable Due From Related Parties, Current</link:label>
    <link:label id="lab_agio_IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent_documentation_en-US" xlink:label="lab_agio_IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent" xlink:href="agio-20200930.xsd#agio_IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent" xlink:to="lab_agio_IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_70a09d5e-f3b6-4ee7-8c7e-dd07ab9aeef2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_640d9872-5bc2-490c-a431-493030b8001d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_84e7ab4b-9402-4c34-aa59-384f59e4b0a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value, Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_102433a2-951f-4767-b92e-67819acf0c9e_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_36547af8-6058-4882-ac32-ccd03b190bfc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_93d8e8b3-1ca7-4418-9445-4bb36e28cb0a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ChangeInContractWithCustomerLiabilityRollForward_567a3eb4-8dd9-4e58-9aa3-e4e5a7cb32b9_terseLabel_en-US" xlink:label="lab_agio_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_agio_ChangeInContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_agio_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_agio_ChangeInContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_agio_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ChangeInContractWithCustomerLiabilityRollForward" xlink:href="agio-20200930.xsd#agio_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ChangeInContractWithCustomerLiabilityRollForward" xlink:to="lab_agio_ChangeInContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent_2b4e44a7-ed6f-45ec-9d9e-6cb559464f37_negatedTerseLabel_en-US" xlink:label="lab_agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty receivable &#8211; related party</link:label>
    <link:label id="lab_agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent_label_en-US" xlink:label="lab_agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent" xlink:href="agio-20200930.xsd#agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent" xlink:to="lab_agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock_12e6588c-a079-4e5c-b2f6-cc52788422ac_terseLabel_en-US" xlink:label="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaboration Revenue Under CStone Agreement</link:label>
    <link:label id="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock_label_en-US" xlink:label="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition Multiple Deliverable Arrangements Allocated By Performance Obligation Under CStone Agreement [Table Text Block]</link:label>
    <link:label id="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock_documentation_en-US" xlink:label="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition Multiple Deliverable Arrangements Allocated By Performance Obligation Under CStone Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock" xlink:href="agio-20200930.xsd#agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock" xlink:to="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_67c1047c-12b1-4bf3-a9d2-6121955a8d86_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_UpfrontPaymentAgreementExtensionFeeReceivable_c0dd4081-78e0-4487-97ca-9781305ecb89_terseLabel_en-US" xlink:label="lab_agio_UpfrontPaymentAgreementExtensionFeeReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment agreement extension fee receivable</link:label>
    <link:label id="lab_agio_UpfrontPaymentAgreementExtensionFeeReceivable_label_en-US" xlink:label="lab_agio_UpfrontPaymentAgreementExtensionFeeReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UpfrontPaymentAgreementExtensionFeeReceivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_UpfrontPaymentAgreementExtensionFeeReceivable" xlink:href="agio-20200930.xsd#agio_UpfrontPaymentAgreementExtensionFeeReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_UpfrontPaymentAgreementExtensionFeeReceivable" xlink:to="lab_agio_UpfrontPaymentAgreementExtensionFeeReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_d5dc2c9b-5b30-4203-b5dd-bdb9971663f6_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_be1eb3be-4aa0-4fe3-adbc-c1a29630d870_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_a255e27e-100f-4e50-9655-4e5fbc436141_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_92b78a8a-251d-4c93-916f-591e5a0982fc_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_12f4214d-b261-43d8-bbf9-32ef8d2dc978_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_87e86285-836c-4847-8e83-c518a1e5a875_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_feac82ec-4dd0-447c-a189-05fed022ac4a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_0bcca615-04c7-4bef-9ecb-e32bec3db144_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_4dbdb4cb-f649-43f3-9e2e-04cb36360cfa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ChangeInContractWithCustomerAssetRollForward_3800b436-c27d-4817-a9c1-67804176cc46_terseLabel_en-US" xlink:label="lab_agio_ChangeInContractWithCustomerAssetRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_agio_ChangeInContractWithCustomerAssetRollForward_label_en-US" xlink:label="lab_agio_ChangeInContractWithCustomerAssetRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Asset [Roll Forward]</link:label>
    <link:label id="lab_agio_ChangeInContractWithCustomerAssetRollForward_documentation_en-US" xlink:label="lab_agio_ChangeInContractWithCustomerAssetRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Asset [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ChangeInContractWithCustomerAssetRollForward" xlink:href="agio-20200930.xsd#agio_ChangeInContractWithCustomerAssetRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward" xlink:to="lab_agio_ChangeInContractWithCustomerAssetRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_15972b4e-b8df-4c06-a4a8-08cb6569cf1e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_2c264e31-1c18-4884-84e3-6445be941bd2_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d79370e6-2aa9-46e0-9974-4f5bb0519055_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total common stock equivalents excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock_27767f73-707c-4d8a-a9e6-3ebf5d7154f6_terseLabel_en-US" xlink:label="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Related Reserves</link:label>
    <link:label id="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock_label_en-US" xlink:label="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accounts Notes Loans And Financing Receivable1 [Table Text Block]</link:label>
    <link:label id="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock_documentation_en-US" xlink:label="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" xlink:href="agio-20200930.xsd#agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" xlink:to="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_843d24c5-7a3f-4a49-b2cf-4e301d357e1b_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0e7f648d-eb34-4d1a-9433-0d3d2f756f54_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_de56c36f-682b-47dc-80bb-99673b18dee0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_fda96326-e38d-43a6-bbcd-6fc93006457a_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_771141ac-39d7-45ef-bab5-23234c680ac3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_a5a54296-918c-46b0-bf96-1c95ca6b0745_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2d123821-64ce-484e-b195-2f16b29d9033_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_35340125-ab90-4775-ad81-7719380cb202_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_aa0cbb9e-7a14-4a4a-b92c-0ef1f2de8182_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_b0140172-d93a-4e0c-9c80-9d5e8de5a1cf_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_47771b7c-b52a-4b10-b6f2-dde95a92949f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e9e9dacf-7698-4b6e-93d2-68b3f05f909a_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_f3264d4b-ee71-437e-87b6-c823840adb5f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c9e44d15-57dd-4e04-9f25-9bcbfa9876ba_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_47d0672e-1a33-491e-8c90-da351a1a20ac_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining 2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_97db0ecb-991f-4de4-a561-e17ce6a836db_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bfd4f788-4296-4d3e-9880-f192b997af9a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_9eba7a40-afed-4f22-87a5-0db54c7a147e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_62661e46-b903-428b-b6e3-3fcd6f09ee24_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_2251e5ea-4f4c-49ee-b740-b89180e43bf7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a0569ca7-96d5-4935-a039-60bb3f5038f5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PerformanceBasedStockUnitMember_67185a34-6050-459c-bde6-a5f3b2871883_terseLabel_en-US" xlink:label="lab_agio_PerformanceBasedStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based stock units</link:label>
    <link:label id="lab_agio_PerformanceBasedStockUnitMember_label_en-US" xlink:label="lab_agio_PerformanceBasedStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Stock Unit [Member]</link:label>
    <link:label id="lab_agio_PerformanceBasedStockUnitMember_documentation_en-US" xlink:label="lab_agio_PerformanceBasedStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Stock Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceBasedStockUnitMember" xlink:href="agio-20200930.xsd#agio_PerformanceBasedStockUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PerformanceBasedStockUnitMember" xlink:to="lab_agio_PerformanceBasedStockUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_57465add-66bb-4618-b520-e54d87383879_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6c174a4b-b4f0-491c-aec8-69a621763dfb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_9508d6e7-2908-4856-bd4d-d2a0906be1d6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_ab2c747e-2c7a-4222-b3ed-846c92d34b0a_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_SaleOfFutureRevenueRoyaltyObligationTextBlock_d201f810-8ae8-4c14-86de-f0810c8e9a61_terseLabel_en-US" xlink:label="lab_agio_SaleOfFutureRevenueRoyaltyObligationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Future Revenue</link:label>
    <link:label id="lab_agio_SaleOfFutureRevenueRoyaltyObligationTextBlock_label_en-US" xlink:label="lab_agio_SaleOfFutureRevenueRoyaltyObligationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Future Revenue, Royalty Obligation [Text Block]</link:label>
    <link:label id="lab_agio_SaleOfFutureRevenueRoyaltyObligationTextBlock_documentation_en-US" xlink:label="lab_agio_SaleOfFutureRevenueRoyaltyObligationTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Future Revenue, Royalty Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueRoyaltyObligationTextBlock" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueRoyaltyObligationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_SaleOfFutureRevenueRoyaltyObligationTextBlock" xlink:to="lab_agio_SaleOfFutureRevenueRoyaltyObligationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_3cab5c0c-aefe-4386-a0b4-ded6ed099740_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion &#8211; related party</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember_700ac752-3709-4a80-81e8-6c11cb612384_verboseLabel_en-US" xlink:label="lab_agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration receivable - other</link:label>
    <link:label id="lab_agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember_label_en-US" xlink:label="lab_agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Receivable, Due From Related Parties, Current [Member]</link:label>
    <link:label id="lab_agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember_documentation_en-US" xlink:label="lab_agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember" xlink:href="agio-20200930.xsd#agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember" xlink:to="lab_agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_07f862da-e91c-48c6-88cf-b152d0e271d6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under 2013 ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_f3a97496-4c9f-4412-8c72-bbf285d0e7e9_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e28f7493-130b-4c61-83d7-e790023b413f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocated Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_367cb00c-5df6-451f-a4e0-606ac481f1b1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_0f18f036-211b-47d9-9cba-571526765a38_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock_e3ce9f5f-d469-401a-a89a-0051d36dd303_terseLabel_en-US" xlink:label="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaboration Revenue</link:label>
    <link:label id="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock_label_en-US" xlink:label="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition Multiple Deliverable Arrangements Allocated By Performance Obligation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock" xlink:href="agio-20200930.xsd#agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock" xlink:to="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_3fc7554c-476f-41cb-b0d6-c0b1db6e2ed7_negatedTerseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns, payments/returns relating to sales in the prior years</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_label_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Right To Recover Product, Prior Year Recoveries</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" xlink:to="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_af0124c4-56db-424f-afa3-d0b07af6409d_negatedTerseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government rebates, payments/returns relating to sales in the prior years</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_label_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Rebate Reserve, Recoveries In Prior Years</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" xlink:to="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CurrentAssetMember_abd37d72-800f-4c45-a0d3-b599f97ca953_terseLabel_en-US" xlink:label="lab_agio_CurrentAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_agio_CurrentAssetMember_label_en-US" xlink:label="lab_agio_CurrentAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CurrentAssetMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentAssetMember" xlink:href="agio-20200930.xsd#agio_CurrentAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CurrentAssetMember" xlink:to="lab_agio_CurrentAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_aa32e5db-4d00-4da3-a3c3-de69c8692f64_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasuries</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_OptionExerciseFeeReceivable_9bb50cfc-60d6-43cf-a9b9-d7361f145430_terseLabel_en-US" xlink:label="lab_agio_OptionExerciseFeeReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercise fee receivable</link:label>
    <link:label id="lab_agio_OptionExerciseFeeReceivable_label_en-US" xlink:label="lab_agio_OptionExerciseFeeReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OptionExerciseFeeReceivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_OptionExerciseFeeReceivable" xlink:href="agio-20200930.xsd#agio_OptionExerciseFeeReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_OptionExerciseFeeReceivable" xlink:to="lab_agio_OptionExerciseFeeReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_ede9135f-6510-43dd-96fe-ec082ddc9999_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_8cd9d566-ac32-43b0-a016-7c44635bdaeb_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing transactions</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_SaleOfFutureRevenueLiabilityNoncurrent_0186ca2e-3653-4b13-b26e-124fddbc71c4_terseLabel_en-US" xlink:label="lab_agio_SaleOfFutureRevenueLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to the sale of future revenue, net of debt issuance costs</link:label>
    <link:label id="lab_agio_SaleOfFutureRevenueLiabilityNoncurrent_b7a87ea9-dfe1-49f4-a543-561cfdf956e8_periodStartLabel_en-US" xlink:label="lab_agio_SaleOfFutureRevenueLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of future revenue</link:label>
    <link:label id="lab_agio_SaleOfFutureRevenueLiabilityNoncurrent_e7bf1dc2-17a3-49b3-a9f9-3f7ea1412173_periodEndLabel_en-US" xlink:label="lab_agio_SaleOfFutureRevenueLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to the sale of future revenue</link:label>
    <link:label id="lab_agio_SaleOfFutureRevenueLiabilityNoncurrent_label_en-US" xlink:label="lab_agio_SaleOfFutureRevenueLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Future Revenue, Liability, Noncurrent</link:label>
    <link:label id="lab_agio_SaleOfFutureRevenueLiabilityNoncurrent_documentation_en-US" xlink:label="lab_agio_SaleOfFutureRevenueLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Future Revenue, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueLiabilityNoncurrent" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_SaleOfFutureRevenueLiabilityNoncurrent" xlink:to="lab_agio_SaleOfFutureRevenueLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_045fbd2a-f45f-4849-9c28-44ec2801aaf0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under stock incentive plan and ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_391a5424-d719-4d67-9a50-c49dd7cc7f0f_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock options, exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_00fdc989-e0c6-496b-a427-0b0e42694fe1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligations satisfied in previous periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_121091fd-3e10-4673-a65c-1ff3d1269294_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock_4ce4fd82-1ac0-4589-af57-a81469e65efe_terseLabel_en-US" xlink:label="lab_agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Market-Based Units Activity</link:label>
    <link:label id="lab_agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Market-Based Units Activity [Table Text Block]</link:label>
    <link:label id="lab_agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock_documentation_en-US" xlink:label="lab_agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Market-Based Units Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock" xlink:href="agio-20200930.xsd#agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock" xlink:to="lab_agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_a7cf308e-3a89-4269-82b0-df00c7102157_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3c0cff8e-27eb-48e8-9007-6aadc5e0f641_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Undiscounted Minimum Rental Commitments Under Non-cancelable Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CollaborationReceivableOtherCurrent_615f608c-92e3-4e82-912c-78b2a6f213c1_terseLabel_en-US" xlink:label="lab_agio_CollaborationReceivableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration receivable &#8211; other</link:label>
    <link:label id="lab_agio_CollaborationReceivableOtherCurrent_label_en-US" xlink:label="lab_agio_CollaborationReceivableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CollaborationReceivableOtherCurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationReceivableOtherCurrent" xlink:href="agio-20200930.xsd#agio_CollaborationReceivableOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CollaborationReceivableOtherCurrent" xlink:to="lab_agio_CollaborationReceivableOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_e04f8457-f516-4317-8673-f6b1ae083139_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_bacac69b-c24c-4fb9-813a-b99b9b58401a_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_807379b9-6175-4957-ad1c-315967e3d380_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, forfeited/expired (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_f27b711c-20db-4630-8dcf-e18a41a3fe3b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of debt securities in significant unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_cae0b080-a522-4d30-ab2d-9df6f270ffba_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_3fe3707e-75f5-402b-bc89-a1e2c5bf0321_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_dc530a7a-502d-4a53-afb3-17eb15e8df47_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_81ef9f24-ac42-4229-bfea-9dc42aa05f51_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overview and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d6813a94-a5b4-4bb9-a8a2-faf4d568e028_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities arising from obtaining operating lease assets</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_87d80226-267a-4006-a50d-c1891237063e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_88daa2fb-46fb-4afc-9147-9d49657c8160_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f2451b53-156d-4d8b-9b51-8a8f76819733_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_2e97fc27-3f4a-4484-8c1a-4c81270350de_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RoyaltyPercentageRemitted_52f97af4-ea6d-4076-a69e-6d42244356ec_terseLabel_en-US" xlink:label="lab_agio_RoyaltyPercentageRemitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty percentage</link:label>
    <link:label id="lab_agio_RoyaltyPercentageRemitted_label_en-US" xlink:label="lab_agio_RoyaltyPercentageRemitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Percentage Remitted</link:label>
    <link:label id="lab_agio_RoyaltyPercentageRemitted_documentation_en-US" xlink:label="lab_agio_RoyaltyPercentageRemitted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RoyaltyPercentageRemitted" xlink:href="agio-20200930.xsd#agio_RoyaltyPercentageRemitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RoyaltyPercentageRemitted" xlink:to="lab_agio_RoyaltyPercentageRemitted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_25cd85c9-ee0f-4195-9378-3b77f64ca88d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b27f4829-1b97-4afc-b7d8-6dc57a3a2505_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_b2a76f2f-7358-4277-afee-8cd4dfdb4b18_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_d6e628eb-df92-420d-9bd0-1b1c237ba0f2_verboseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and other services</link:label>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_label_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServiceMember" xlink:to="lab_us-gaap_LicenseAndServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable_6b20f6a8-10a1-4347-9192-3eb2d711f6a8_terseLabel_en-US" xlink:label="lab_agio_ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future milestone payments</link:label>
    <link:label id="lab_agio_ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable_label_en-US" xlink:label="lab_agio_ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement Contract To Perform For Others Potential Milestone Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable" xlink:href="agio-20200930.xsd#agio_ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable" xlink:to="lab_agio_ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3bdc3162-4e43-4039-af0c-7a5b4b899a53_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_EmployeePurchasePlanMember_3b27bb4d-d2ba-4e09-ac1c-ec3e97d9679f_terseLabel_en-US" xlink:label="lab_agio_EmployeePurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan shares</link:label>
    <link:label id="lab_agio_EmployeePurchasePlanMember_label_en-US" xlink:label="lab_agio_EmployeePurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EmployeePurchasePlanMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeePurchasePlanMember" xlink:href="agio-20200930.xsd#agio_EmployeePurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_EmployeePurchasePlanMember" xlink:to="lab_agio_EmployeePurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_2f5990e5-ec7f-4bc3-a754-b0eb86fc0d00_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ba3fee61-c641-478e-8478-003b0c9c083e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_d5ebf88b-8ddc-427b-9c84-cb84405cb07c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities, beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_c9ef9509-dd2c-48db-8285-03c163f57331_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities, ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_826af022-8912-419e-bf28-c11661520deb_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityTable_9c79b306-4b26-4731-85db-2fe8c330710a_terseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset and Liability [Table]</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityTable_label_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset And Liability [Table]</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityTable_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset And Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetAndLiabilityTable" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerAssetAndLiabilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerAssetAndLiabilityTable" xlink:to="lab_agio_ContractWithCustomerAssetAndLiabilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1ba8771d-fb72-4f4f-923d-52c0608cc43e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under stock incentive plan and ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_0636e64b-46b4-45c2-b24b-82bb3fc5d1e2_negatedTerseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments, payments/returns relating to sales in the prior year</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_label_en-US" xlink:label="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Contract Adjustment, Recoveries, Prior Year</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" xlink:to="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerCurrentYearReserveProvisions_cfa517e4-b2a0-49ba-b8c4-d0689d090933_totalLabel_en-US" xlink:label="lab_agio_ContractWithCustomerCurrentYearReserveProvisions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total allowances and reserves, current provisions relating to sales in the current year</link:label>
    <link:label id="lab_agio_ContractWithCustomerCurrentYearReserveProvisions_label_en-US" xlink:label="lab_agio_ContractWithCustomerCurrentYearReserveProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Current Year Reserve Provisions</link:label>
    <link:label id="lab_agio_ContractWithCustomerCurrentYearReserveProvisions_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerCurrentYearReserveProvisions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerCurrentYearReserveProvisions" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerCurrentYearReserveProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveProvisions" xlink:to="lab_agio_ContractWithCustomerCurrentYearReserveProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_0d764543-60bb-49b0-be75-3ae8e98267e9_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9a7df19f-b0c7-4e41-842b-3713e0610ae3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerRebateReserve_c54a141e-1e09-4d64-95a0-64b84a8a832e_periodStartLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government rebates, beginning balance</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserve_0f319ab5-298b-4f19-a2a5-dfe8943a5d64_periodEndLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government rebates, ending balance</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserve_label_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Rebate Reserve</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserve_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserve" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerRebateReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerRebateReserve" xlink:to="lab_agio_ContractWithCustomerRebateReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_e7ed9eb9-c117-4376-9ead-7271c8f45a9a_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_4430338f-6f76-4435-849d-a2ffece76cb1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_14a896ea-fe9f-4370-85f8-a82b92772009_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_ab226e2d-dd30-4e27-867f-99ad1f9528a5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceOtherMember_2e30c97c-1d31-4092-ac37-8b7c5556744d_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other services</link:label>
    <link:label id="lab_us-gaap_ServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceOtherMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceOtherMember" xlink:to="lab_us-gaap_ServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d64751f5-3110-4ac3-8857-dab44aa3702c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0004fadf-2de7-4454-9b73-306b5a44334d_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_48e72399-67e3-4253-86d6-1bc256591fd5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10212607-8142-47ca-8ad5-fb1e1a77bdc6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ProvisionForRightToRecoverProductInPriorYears_39f80b94-570c-4960-a09f-57439864c3f2_terseLabel_en-US" xlink:label="lab_agio_ProvisionForRightToRecoverProductInPriorYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns, adjustments relating to prior years</link:label>
    <link:label id="lab_agio_ProvisionForRightToRecoverProductInPriorYears_label_en-US" xlink:label="lab_agio_ProvisionForRightToRecoverProductInPriorYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Right To Recover Product In Prior Years</link:label>
    <link:label id="lab_agio_ProvisionForRightToRecoverProductInPriorYears_documentation_en-US" xlink:label="lab_agio_ProvisionForRightToRecoverProductInPriorYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProvisionForRightToRecoverProductInPriorYears" xlink:href="agio-20200930.xsd#agio_ProvisionForRightToRecoverProductInPriorYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ProvisionForRightToRecoverProductInPriorYears" xlink:to="lab_agio_ProvisionForRightToRecoverProductInPriorYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_43c7e0a9-c488-47f8-8825-da342491966e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_07ac6c1e-fff7-4143-bc47-021f5b9e80b8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_557e19f1-9b66-45fb-90bb-ed2c2b99352f_negatedLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns, payments/returns relating to sales in the current year</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_label_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Right To Recover Product, Current Year Recoveries</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" xlink:to="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_ab4bed96-0c46-47d4-8a26-b0e1ee1c0ceb_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_9e133538-e391-47cb-8e42-a3bf47cd9e86_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_af5ea05f-df23-44ba-b3ec-d7cc205c4acd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, exercisable (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_b7edf559-b87c-445f-bdf5-798b1b4b70cc_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ProductReturnsRollForward_b8e0ee3f-7c03-47f7-9a7f-9526ace054b4_terseLabel_en-US" xlink:label="lab_agio_ProductReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Returns [Roll Forward]</link:label>
    <link:label id="lab_agio_ProductReturnsRollForward_label_en-US" xlink:label="lab_agio_ProductReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Returns [Roll Forward]</link:label>
    <link:label id="lab_agio_ProductReturnsRollForward_documentation_en-US" xlink:label="lab_agio_ProductReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProductReturnsRollForward" xlink:href="agio-20200930.xsd#agio_ProductReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ProductReturnsRollForward" xlink:to="lab_agio_ProductReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetAssetLiability_40bc99dc-b070-4d4f-974e-1f5f6eb424a0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_FairValueNetAssetLiability_label_en-US" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Asset (Liability)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetAssetLiability" xlink:to="lab_us-gaap_FairValueNetAssetLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_b7460845-bafe-401d-a0ad-f28c34b7658a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from stock option exercises and employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_bdbbc109-b52a-42e7-b50b-69a693fa452a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold_5c71235a-e5fe-43cd-83ae-3789a8630cc2_terseLabel_en-US" xlink:label="lab_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of future revenue</link:label>
    <link:label id="lab_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold_label_en-US" xlink:label="lab_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Potential Milestone Payment Receivable For Specified Regulatory Milestone Event Program Sold</link:label>
    <link:label id="lab_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold_documentation_en-US" xlink:label="lab_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Potential Milestone Payment Receivable For Specified Regulatory Milestone Event Program Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold" xlink:href="agio-20200930.xsd#agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold" xlink:to="lab_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_b156e27a-94f4-4ae2-8464-0a55b7d3ef37_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets, beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_e7de78b2-2f75-4d5e-a845-4f26eef9c393_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets, ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_8c28d28f-9222-4291-97c5-a7d01695cd55_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember_21cce111-3298-4ae5-9c36-55c118cdd7c5_terseLabel_en-US" xlink:label="lab_agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Unit, Not Probable of Meeting Vesting Criteria</link:label>
    <link:label id="lab_agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember_label_en-US" xlink:label="lab_agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Unit, Not Probable Of Meeting Vesting Criteria [Member]</link:label>
    <link:label id="lab_agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember_documentation_en-US" xlink:label="lab_agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Unit, Not Probable Of Meeting Vesting Criteria</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember" xlink:href="agio-20200930.xsd#agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember" xlink:to="lab_agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfSpecialCaseExtensions_4d27f280-d046-4211-935a-09b8adb33679_terseLabel_en-US" xlink:label="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfSpecialCaseExtensions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of allowable special case extensions</link:label>
    <link:label id="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfSpecialCaseExtensions_label_en-US" xlink:label="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfSpecialCaseExtensions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition Multiple Deliverable Arrangements Number Of Special Case Extensions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfSpecialCaseExtensions" xlink:href="agio-20200930.xsd#agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfSpecialCaseExtensions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfSpecialCaseExtensions" xlink:to="lab_agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfSpecialCaseExtensions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_f191e74b-c71b-4499-958b-b5d0f7ef1d51_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d9afb29c-7a47-4bbf-bb56-5cde9e3ef90e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_4ab1efe0-fc39-4efe-a8e2-134f35704cd9_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_f2876dbc-58d8-49af-a06f-21d28a0bdc2c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_74c56398-55a7-4725-b213-4174c5627494_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, vested and expected to vest (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CurrentYearProvisionForContractualAdjustments_5aeb6b87-4d53-46b7-9192-83f6f361254a_terseLabel_en-US" xlink:label="lab_agio_CurrentYearProvisionForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments, current provisions relating to sales in the current year</link:label>
    <link:label id="lab_agio_CurrentYearProvisionForContractualAdjustments_label_en-US" xlink:label="lab_agio_CurrentYearProvisionForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Provision For Contractual Adjustments</link:label>
    <link:label id="lab_agio_CurrentYearProvisionForContractualAdjustments_documentation_en-US" xlink:label="lab_agio_CurrentYearProvisionForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentYearProvisionForContractualAdjustments" xlink:href="agio-20200930.xsd#agio_CurrentYearProvisionForContractualAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CurrentYearProvisionForContractualAdjustments" xlink:to="lab_agio_CurrentYearProvisionForContractualAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_NonCurrentAssetsMember_e3f7d40e-2dfe-473a-9cb2-1b6167f6da1c_terseLabel_en-US" xlink:label="lab_agio_NonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current</link:label>
    <link:label id="lab_agio_NonCurrentAssetsMember_label_en-US" xlink:label="lab_agio_NonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NonCurrentAssetsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_NonCurrentAssetsMember" xlink:href="agio-20200930.xsd#agio_NonCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_NonCurrentAssetsMember" xlink:to="lab_agio_NonCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fa3723aa-0e57-4fa5-a0ca-6522789ae9e6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>agio-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:deac00a5-3ebc-4b82-b8fc-c0af8bd8bb5e,g:0b2f6d2b-1088-4e3a-817f-9f8454765406-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://agios.com/role/CoverPage" xlink:type="simple" xlink:href="agio-20200930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://agios.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_33b16160-2fb7-417c-9645-099f4133217c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_DocumentType_33b16160-2fb7-417c-9645-099f4133217c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_a8855372-eb17-4182-8178-0c920475c24a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_DocumentQuarterlyReport_a8855372-eb17-4182-8178-0c920475c24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_0a0fb20e-8dbf-44f5-be1b-8ac796f476bc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_DocumentPeriodEndDate_0a0fb20e-8dbf-44f5-be1b-8ac796f476bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_5d675f69-5a2a-4a00-b0ab-f7fb0e387cc8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_DocumentTransitionReport_5d675f69-5a2a-4a00-b0ab-f7fb0e387cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d5a49e2a-05a5-4fb9-b0b6-80c9ebce6a88" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_EntityFileNumber_d5a49e2a-05a5-4fb9-b0b6-80c9ebce6a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_085dfd57-8ddc-4e53-9030-dfe3f067f9b3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_EntityRegistrantName_085dfd57-8ddc-4e53-9030-dfe3f067f9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_db572ae8-4427-41cc-bf10-68b42acaee53" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_EntityIncorporationStateCountryCode_db572ae8-4427-41cc-bf10-68b42acaee53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6ad8c148-62d6-4ee8-9142-03d666efdc47" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_EntityTaxIdentificationNumber_6ad8c148-62d6-4ee8-9142-03d666efdc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_cc84e6bf-3f43-4215-b41d-5f79238593bd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_EntityAddressAddressLine1_cc84e6bf-3f43-4215-b41d-5f79238593bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_238aa194-268b-4a90-9977-7311191980cd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_EntityAddressCityOrTown_238aa194-268b-4a90-9977-7311191980cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5741ab2d-feed-430e-bdd4-0e6bbeaba3bb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_EntityAddressStateOrProvince_5741ab2d-feed-430e-bdd4-0e6bbeaba3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_6e12e8a3-b4eb-4112-9bab-970390de84eb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_EntityAddressPostalZipCode_6e12e8a3-b4eb-4112-9bab-970390de84eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_12f9fd9f-b041-4e29-a9a8-14ff7e08ac2e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_CityAreaCode_12f9fd9f-b041-4e29-a9a8-14ff7e08ac2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_6f22b7f0-6a0d-4928-a67f-390252709bcd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_LocalPhoneNumber_6f22b7f0-6a0d-4928-a67f-390252709bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6c4fef77-ff64-469d-a1ad-fa6622e0f2eb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_Security12bTitle_6c4fef77-ff64-469d-a1ad-fa6622e0f2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_20adb5d6-6bad-43a5-ad44-bc14c6251ee3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_TradingSymbol_20adb5d6-6bad-43a5-ad44-bc14c6251ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_643ec84c-67b0-423f-978d-153e2c99cb16" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_SecurityExchangeName_643ec84c-67b0-423f-978d-153e2c99cb16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_b669e239-d7be-444a-8850-a8e15c385226" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_EntityCurrentReportingStatus_b669e239-d7be-444a-8850-a8e15c385226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_e707b9fc-41e0-4ea1-afcb-425e3dd95b71" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_EntityInteractiveDataCurrent_e707b9fc-41e0-4ea1-afcb-425e3dd95b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_564bc48a-d6ad-4f8e-b3ee-5df99c70ba8f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_EntityFilerCategory_564bc48a-d6ad-4f8e-b3ee-5df99c70ba8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_bd74f388-4d47-4ff8-9031-10ec579787e4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_EntitySmallBusiness_bd74f388-4d47-4ff8-9031-10ec579787e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a94f7acc-d8c4-402e-aec5-8a6aa1f4d98e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_EntityEmergingGrowthCompany_a94f7acc-d8c4-402e-aec5-8a6aa1f4d98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_fce16301-bfac-4c28-aa07-c3c062241a58" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_EntityShellCompany_fce16301-bfac-4c28-aa07-c3c062241a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_458bbb51-2070-4f07-8451-cfe10a6b0bd0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_458bbb51-2070-4f07-8451-cfe10a6b0bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_bbb6a400-3e3f-4913-b92d-d0d6359e3d56" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_DocumentFiscalYearFocus_bbb6a400-3e3f-4913-b92d-d0d6359e3d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7b7f6e90-9390-4410-a04d-392e0327de6e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_DocumentFiscalPeriodFocus_7b7f6e90-9390-4410-a04d-392e0327de6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_575a0699-9f34-40b4-a4a8-4ee2f75169c1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_AmendmentFlag_575a0699-9f34-40b4-a4a8-4ee2f75169c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d5803abd-8013-4b7f-901b-db340eaee86f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_EntityCentralIndexKey_d5803abd-8013-4b7f-901b-db340eaee86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_5e53cd01-c2ee-488d-86df-ef8e7eb1926d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90dc6639-5173-408c-aa30-cb6ba496e048" xlink:to="loc_dei_CurrentFiscalYearEndDate_5e53cd01-c2ee-488d-86df-ef8e7eb1926d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="agio-20200930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://agios.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_49649635-556e-4442-bf83-2f03f72ac4a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_25f665ba-dc22-4aee-be5c-8d85f81b4e0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_49649635-556e-4442-bf83-2f03f72ac4a9" xlink:to="loc_us-gaap_AssetsAbstract_25f665ba-dc22-4aee-be5c-8d85f81b4e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3257cb91-70d7-46bb-915d-37a27de83e82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_25f665ba-dc22-4aee-be5c-8d85f81b4e0c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3257cb91-70d7-46bb-915d-37a27de83e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7e578e6c-070c-4801-a8b3-e2f686054e30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3257cb91-70d7-46bb-915d-37a27de83e82" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7e578e6c-070c-4801-a8b3-e2f686054e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d008d025-dd41-4d7d-94ab-3d724c74fa58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3257cb91-70d7-46bb-915d-37a27de83e82" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d008d025-dd41-4d7d-94ab-3d724c74fa58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_9e5ba67a-4c79-4e3e-bff3-5b30c1da398a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3257cb91-70d7-46bb-915d-37a27de83e82" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_9e5ba67a-4c79-4e3e-bff3-5b30c1da398a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationReceivableDueFromRelatedPartiesCurrent_b01a9041-1956-41a0-9c37-34290345d861" xlink:href="agio-20200930.xsd#agio_CollaborationReceivableDueFromRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3257cb91-70d7-46bb-915d-37a27de83e82" xlink:to="loc_agio_CollaborationReceivableDueFromRelatedPartiesCurrent_b01a9041-1956-41a0-9c37-34290345d861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationReceivableOtherCurrent_e2a4134c-968a-4e90-a0a9-a94dfae230ab" xlink:href="agio-20200930.xsd#agio_CollaborationReceivableOtherCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3257cb91-70d7-46bb-915d-37a27de83e82" xlink:to="loc_agio_CollaborationReceivableOtherCurrent_e2a4134c-968a-4e90-a0a9-a94dfae230ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RoyaltyReceivableDuefromRelatedPartiesCurrent_9da86875-79a6-4e0d-80fa-fcc9e2555d5e" xlink:href="agio-20200930.xsd#agio_RoyaltyReceivableDuefromRelatedPartiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3257cb91-70d7-46bb-915d-37a27de83e82" xlink:to="loc_agio_RoyaltyReceivableDuefromRelatedPartiesCurrent_9da86875-79a6-4e0d-80fa-fcc9e2555d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_242e8503-a46e-42c7-8005-ef833a7469bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3257cb91-70d7-46bb-915d-37a27de83e82" xlink:to="loc_us-gaap_InventoryNet_242e8503-a46e-42c7-8005-ef833a7469bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a4733570-8ac7-4037-b370-ea3a61f1d4b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3257cb91-70d7-46bb-915d-37a27de83e82" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a4733570-8ac7-4037-b370-ea3a61f1d4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a45f2a5a-0273-4fd3-8b23-22fa354f5f02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3257cb91-70d7-46bb-915d-37a27de83e82" xlink:to="loc_us-gaap_AssetsCurrent_a45f2a5a-0273-4fd3-8b23-22fa354f5f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_70dda207-32ab-4f40-b5ba-967bc5c69b1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_25f665ba-dc22-4aee-be5c-8d85f81b4e0c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_70dda207-32ab-4f40-b5ba-967bc5c69b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7ddcc220-fb94-41ca-8ca6-d5a619d37ea1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_25f665ba-dc22-4aee-be5c-8d85f81b4e0c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7ddcc220-fb94-41ca-8ca6-d5a619d37ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d85f4c0e-1674-497b-b503-f5db4684feed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_25f665ba-dc22-4aee-be5c-8d85f81b4e0c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d85f4c0e-1674-497b-b503-f5db4684feed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_bcc79a17-e9f6-4d38-9c23-40d7784d8d60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_25f665ba-dc22-4aee-be5c-8d85f81b4e0c" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_bcc79a17-e9f6-4d38-9c23-40d7784d8d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_271a664e-5b5d-4f92-947a-c74867e365b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_25f665ba-dc22-4aee-be5c-8d85f81b4e0c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_271a664e-5b5d-4f92-947a-c74867e365b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f04cc693-02eb-4d5b-af74-a1260066eefb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_25f665ba-dc22-4aee-be5c-8d85f81b4e0c" xlink:to="loc_us-gaap_Assets_f04cc693-02eb-4d5b-af74-a1260066eefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_212cda62-e565-4ae5-90fd-320f4e5d453e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_49649635-556e-4442-bf83-2f03f72ac4a9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_212cda62-e565-4ae5-90fd-320f4e5d453e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_bc0340b8-56ad-49b9-b58d-150969541330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_212cda62-e565-4ae5-90fd-320f4e5d453e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_bc0340b8-56ad-49b9-b58d-150969541330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ed225d69-fed6-4ce1-845a-30a33dd692d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bc0340b8-56ad-49b9-b58d-150969541330" xlink:to="loc_us-gaap_AccountsPayableCurrent_ed225d69-fed6-4ce1-845a-30a33dd692d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f73e7d60-3ba4-473f-a72a-420f7e010fd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bc0340b8-56ad-49b9-b58d-150969541330" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f73e7d60-3ba4-473f-a72a-420f7e010fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_dbb4a88d-56cf-4f47-9357-689d44a031fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bc0340b8-56ad-49b9-b58d-150969541330" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_dbb4a88d-56cf-4f47-9357-689d44a031fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_fa215588-e28e-42e6-b531-55ed57f558bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bc0340b8-56ad-49b9-b58d-150969541330" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_fa215588-e28e-42e6-b531-55ed57f558bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_0a6c65da-1e95-4003-bed4-2128777e082c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bc0340b8-56ad-49b9-b58d-150969541330" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_0a6c65da-1e95-4003-bed4-2128777e082c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_df363ad7-0f90-4bcd-8816-cdd3f45965ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bc0340b8-56ad-49b9-b58d-150969541330" xlink:to="loc_us-gaap_LiabilitiesCurrent_df363ad7-0f90-4bcd-8816-cdd3f45965ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5b553397-1552-4e5e-90ff-ba250adc080a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_212cda62-e565-4ae5-90fd-320f4e5d453e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_5b553397-1552-4e5e-90ff-ba250adc080a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_08cf776b-d8d9-44b9-bb90-3e1f591b7250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_212cda62-e565-4ae5-90fd-320f4e5d453e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_08cf776b-d8d9-44b9-bb90-3e1f591b7250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_e1e9bc64-7c01-41d1-a74e-44d28689c1f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_212cda62-e565-4ae5-90fd-320f4e5d453e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_e1e9bc64-7c01-41d1-a74e-44d28689c1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueLiabilityNoncurrent_27c589fd-90fd-42b1-af97-4da01a8bdef6" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_212cda62-e565-4ae5-90fd-320f4e5d453e" xlink:to="loc_agio_SaleOfFutureRevenueLiabilityNoncurrent_27c589fd-90fd-42b1-af97-4da01a8bdef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_38d7daea-7ed6-4f4d-b2ce-1981dfe8bce5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_212cda62-e565-4ae5-90fd-320f4e5d453e" xlink:to="loc_us-gaap_Liabilities_38d7daea-7ed6-4f4d-b2ce-1981dfe8bce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_71da308c-5c43-45ff-a255-b6484ad52fcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_212cda62-e565-4ae5-90fd-320f4e5d453e" xlink:to="loc_us-gaap_StockholdersEquityAbstract_71da308c-5c43-45ff-a255-b6484ad52fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_0a9fb04b-d848-4dfb-bc62-58f3093be013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_71da308c-5c43-45ff-a255-b6484ad52fcd" xlink:to="loc_us-gaap_PreferredStockValue_0a9fb04b-d848-4dfb-bc62-58f3093be013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7ff93fbf-cae5-4bcc-808c-9b4c2804d80f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_71da308c-5c43-45ff-a255-b6484ad52fcd" xlink:to="loc_us-gaap_CommonStockValue_7ff93fbf-cae5-4bcc-808c-9b4c2804d80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6da27904-80da-463f-a187-6633bae02aa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_71da308c-5c43-45ff-a255-b6484ad52fcd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6da27904-80da-463f-a187-6633bae02aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f3657673-cee6-4ec8-8bf8-2a517b82659f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_71da308c-5c43-45ff-a255-b6484ad52fcd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f3657673-cee6-4ec8-8bf8-2a517b82659f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b62b462c-41f1-4fe5-bf04-b2f787c3f10b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_71da308c-5c43-45ff-a255-b6484ad52fcd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b62b462c-41f1-4fe5-bf04-b2f787c3f10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1cdfe0dd-7b96-4a51-8b09-88d1171bfcbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_71da308c-5c43-45ff-a255-b6484ad52fcd" xlink:to="loc_us-gaap_StockholdersEquity_1cdfe0dd-7b96-4a51-8b09-88d1171bfcbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_28674b4a-9e0c-44b0-a7d3-9445c87e4fa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_212cda62-e565-4ae5-90fd-320f4e5d453e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_28674b4a-9e0c-44b0-a7d3-9445c87e4fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="agio-20200930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_306c03ff-456b-44d1-a870-495e45a4af58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_042dcf63-e28d-4221-82b3-72ed870e9202" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_306c03ff-456b-44d1-a870-495e45a4af58" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_042dcf63-e28d-4221-82b3-72ed870e9202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a9479f04-514f-4bf5-96de-b88b9f79f6da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_306c03ff-456b-44d1-a870-495e45a4af58" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a9479f04-514f-4bf5-96de-b88b9f79f6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_bea3bdb6-8429-4ae0-a296-4905b332b591" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_306c03ff-456b-44d1-a870-495e45a4af58" xlink:to="loc_us-gaap_PreferredStockSharesIssued_bea3bdb6-8429-4ae0-a296-4905b332b591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_17f1f97a-f269-49bf-b5ee-8930d193d249" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_306c03ff-456b-44d1-a870-495e45a4af58" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_17f1f97a-f269-49bf-b5ee-8930d193d249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ebb0547a-1712-4367-b096-cf9ceeaace9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_306c03ff-456b-44d1-a870-495e45a4af58" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ebb0547a-1712-4367-b096-cf9ceeaace9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b8750042-b1f1-4032-aaf7-9bc1eed82180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_306c03ff-456b-44d1-a870-495e45a4af58" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b8750042-b1f1-4032-aaf7-9bc1eed82180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b02bc62a-1a3c-4c9c-bb32-548ac41387bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_306c03ff-456b-44d1-a870-495e45a4af58" xlink:to="loc_us-gaap_CommonStockSharesIssued_b02bc62a-1a3c-4c9c-bb32-548ac41387bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_cdae291f-54a0-4b52-b40c-3df0451cea8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_306c03ff-456b-44d1-a870-495e45a4af58" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_cdae291f-54a0-4b52-b40c-3df0451cea8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="agio-20200930.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_57777e10-0c98-49e0-88c6-03afeda7b4a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d70317fd-f0cf-46f0-b90f-6962e979cf7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_57777e10-0c98-49e0-88c6-03afeda7b4a1" xlink:to="loc_us-gaap_StatementTable_d70317fd-f0cf-46f0-b90f-6962e979cf7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bd006f3c-fda2-4897-b2c9-a41261f63083" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d70317fd-f0cf-46f0-b90f-6962e979cf7f" xlink:to="loc_srt_ProductOrServiceAxis_bd006f3c-fda2-4897-b2c9-a41261f63083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f2e28c15-81f3-4fbb-a08f-dffc4a190b6a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_bd006f3c-fda2-4897-b2c9-a41261f63083" xlink:to="loc_srt_ProductsAndServicesDomain_f2e28c15-81f3-4fbb-a08f-dffc4a190b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_9f5c8a89-8b69-402b-8c29-bc4498ce1440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f2e28c15-81f3-4fbb-a08f-dffc4a190b6a" xlink:to="loc_us-gaap_ProductMember_9f5c8a89-8b69-402b-8c29-bc4498ce1440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueRelatedPartyMember_23f1dbde-7db2-4764-bd35-f2666a917dd7" xlink:href="agio-20200930.xsd#agio_CollaborationRevenueRelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f2e28c15-81f3-4fbb-a08f-dffc4a190b6a" xlink:to="loc_agio_CollaborationRevenueRelatedPartyMember_23f1dbde-7db2-4764-bd35-f2666a917dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueOtherMember_e826dced-1ff4-4f90-a0d3-d4aaa86b5a03" xlink:href="agio-20200930.xsd#agio_CollaborationRevenueOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f2e28c15-81f3-4fbb-a08f-dffc4a190b6a" xlink:to="loc_agio_CollaborationRevenueOtherMember_e826dced-1ff4-4f90-a0d3-d4aaa86b5a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_c0e2fce1-995e-4eba-9442-08ac08950da3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f2e28c15-81f3-4fbb-a08f-dffc4a190b6a" xlink:to="loc_us-gaap_RoyaltyMember_c0e2fce1-995e-4eba-9442-08ac08950da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_65d7b4da-906d-4636-8202-cda87795f700" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d70317fd-f0cf-46f0-b90f-6962e979cf7f" xlink:to="loc_us-gaap_StatementLineItems_65d7b4da-906d-4636-8202-cda87795f700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_5d76ee25-4c1e-4393-9a63-f3346d00207c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65d7b4da-906d-4636-8202-cda87795f700" xlink:to="loc_us-gaap_RevenuesAbstract_5d76ee25-4c1e-4393-9a63-f3346d00207c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a9670efe-86fb-4f54-8111-1642517f3ce3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_5d76ee25-4c1e-4393-9a63-f3346d00207c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a9670efe-86fb-4f54-8111-1642517f3ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_a765bba5-029b-407e-bf3c-d7da306c6ac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65d7b4da-906d-4636-8202-cda87795f700" xlink:to="loc_us-gaap_OperatingExpensesAbstract_a765bba5-029b-407e-bf3c-d7da306c6ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_85a74394-f5cd-4feb-bb03-ab32659039a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a765bba5-029b-407e-bf3c-d7da306c6ac5" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_85a74394-f5cd-4feb-bb03-ab32659039a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5a00141d-a52d-4690-a715-cd7def264b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a765bba5-029b-407e-bf3c-d7da306c6ac5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5a00141d-a52d-4690-a715-cd7def264b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d5a44fe6-c657-4184-96cc-9e087150886f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a765bba5-029b-407e-bf3c-d7da306c6ac5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d5a44fe6-c657-4184-96cc-9e087150886f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_090d0a80-54e0-4727-804c-b57dfdc4753b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a765bba5-029b-407e-bf3c-d7da306c6ac5" xlink:to="loc_us-gaap_CostsAndExpenses_090d0a80-54e0-4727-804c-b57dfdc4753b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d6734760-3093-479d-be43-f14f50d7a9e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65d7b4da-906d-4636-8202-cda87795f700" xlink:to="loc_us-gaap_OperatingIncomeLoss_d6734760-3093-479d-be43-f14f50d7a9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_35890c2a-77af-4300-9a86-7afffab342ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65d7b4da-906d-4636-8202-cda87795f700" xlink:to="loc_us-gaap_InvestmentIncomeInterest_35890c2a-77af-4300-9a86-7afffab342ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_InterestExpenseNonCashSaleOfFutureRevenue_b7b4865b-4fc3-416c-92e6-96b2b43c1ef4" xlink:href="agio-20200930.xsd#agio_InterestExpenseNonCashSaleOfFutureRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65d7b4da-906d-4636-8202-cda87795f700" xlink:to="loc_agio_InterestExpenseNonCashSaleOfFutureRevenue_b7b4865b-4fc3-416c-92e6-96b2b43c1ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_351b0b9e-1274-4743-978e-33eab3fe7e0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65d7b4da-906d-4636-8202-cda87795f700" xlink:to="loc_us-gaap_NetIncomeLoss_351b0b9e-1274-4743-978e-33eab3fe7e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_1f1308b0-0dc4-4511-9023-a64c9ec7f688" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65d7b4da-906d-4636-8202-cda87795f700" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_1f1308b0-0dc4-4511-9023-a64c9ec7f688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_94398260-20ad-446a-ac35-1ed0e838fefa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_65d7b4da-906d-4636-8202-cda87795f700" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_94398260-20ad-446a-ac35-1ed0e838fefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="agio-20200930.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_52b67fae-725e-4903-9fb3-e9bc66521853" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_866f9350-6503-4524-9ceb-b5e2a522a902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_52b67fae-725e-4903-9fb3-e9bc66521853" xlink:to="loc_us-gaap_NetIncomeLoss_866f9350-6503-4524-9ceb-b5e2a522a902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1116555e-8d0f-42a3-9205-49eca4d33f14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_52b67fae-725e-4903-9fb3-e9bc66521853" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1116555e-8d0f-42a3-9205-49eca4d33f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_187735c4-7d47-4385-aed7-faaaf3635d52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1116555e-8d0f-42a3-9205-49eca4d33f14" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_187735c4-7d47-4385-aed7-faaaf3635d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cc4a811d-2c2c-4e2a-9d5e-febb34507eac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_52b67fae-725e-4903-9fb3-e9bc66521853" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_cc4a811d-2c2c-4e2a-9d5e-febb34507eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="agio-20200930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_31cbb49a-18d2-49ef-8f76-3d8364be700e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_667fb748-b36a-45ed-a0ee-4d21687ef140" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_31cbb49a-18d2-49ef-8f76-3d8364be700e" xlink:to="loc_us-gaap_StatementTable_667fb748-b36a-45ed-a0ee-4d21687ef140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_60a2f785-5d03-499e-ba8b-98cf838f48f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_667fb748-b36a-45ed-a0ee-4d21687ef140" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_60a2f785-5d03-499e-ba8b-98cf838f48f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a948f33a-f4da-47f6-80e6-2c1fda52124e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_60a2f785-5d03-499e-ba8b-98cf838f48f6" xlink:to="loc_us-gaap_EquityComponentDomain_a948f33a-f4da-47f6-80e6-2c1fda52124e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4b954aae-ba2b-414c-a155-75845288cae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a948f33a-f4da-47f6-80e6-2c1fda52124e" xlink:to="loc_us-gaap_CommonStockMember_4b954aae-ba2b-414c-a155-75845288cae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_53540b2c-8f81-4f37-9aab-bf071dc7d623" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a948f33a-f4da-47f6-80e6-2c1fda52124e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_53540b2c-8f81-4f37-9aab-bf071dc7d623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5a1c7ed8-fe5e-45eb-a85f-1058806e8ddf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a948f33a-f4da-47f6-80e6-2c1fda52124e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5a1c7ed8-fe5e-45eb-a85f-1058806e8ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_65a8645d-e5ba-409a-be6b-ae7ccbbf7341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a948f33a-f4da-47f6-80e6-2c1fda52124e" xlink:to="loc_us-gaap_RetainedEarningsMember_65a8645d-e5ba-409a-be6b-ae7ccbbf7341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_64510fd0-1ccc-4704-9441-d3acc6ee08c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_667fb748-b36a-45ed-a0ee-4d21687ef140" xlink:to="loc_us-gaap_StatementLineItems_64510fd0-1ccc-4704-9441-d3acc6ee08c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_56cf7994-7880-4bac-99cd-c84cb724a485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64510fd0-1ccc-4704-9441-d3acc6ee08c9" xlink:to="loc_us-gaap_SharesOutstanding_56cf7994-7880-4bac-99cd-c84cb724a485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_edd2e814-5e3f-419f-b9f4-8245a7d1b5e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64510fd0-1ccc-4704-9441-d3acc6ee08c9" xlink:to="loc_us-gaap_StockholdersEquity_edd2e814-5e3f-419f-b9f4-8245a7d1b5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_09f6e562-0783-4f57-9e72-da78e8cf5d2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64510fd0-1ccc-4704-9441-d3acc6ee08c9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_09f6e562-0783-4f57-9e72-da78e8cf5d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_18261082-cc81-462e-bb52-3875608bc367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64510fd0-1ccc-4704-9441-d3acc6ee08c9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_18261082-cc81-462e-bb52-3875608bc367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_85083d02-e189-4e3d-a82d-119d52722885" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64510fd0-1ccc-4704-9441-d3acc6ee08c9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_85083d02-e189-4e3d-a82d-119d52722885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c274c08b-4dc2-44c5-8c07-775e577ed0c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64510fd0-1ccc-4704-9441-d3acc6ee08c9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c274c08b-4dc2-44c5-8c07-775e577ed0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_48feeddc-9752-4f9d-85dd-967bd3069013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64510fd0-1ccc-4704-9441-d3acc6ee08c9" xlink:to="loc_us-gaap_NetIncomeLoss_48feeddc-9752-4f9d-85dd-967bd3069013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_ab7da6db-c1cd-4f16-86c3-068b5c39d282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64510fd0-1ccc-4704-9441-d3acc6ee08c9" xlink:to="loc_us-gaap_SharesOutstanding_ab7da6db-c1cd-4f16-86c3-068b5c39d282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fd77c3b1-308d-484b-a37f-7ab05d1d7f03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64510fd0-1ccc-4704-9441-d3acc6ee08c9" xlink:to="loc_us-gaap_StockholdersEquity_fd77c3b1-308d-484b-a37f-7ab05d1d7f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="agio-20200930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://agios.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_fa494326-53a7-4ae7-b653-a4d91280c75d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ad09760f-6a62-4793-9cee-a49e651aee6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fa494326-53a7-4ae7-b653-a4d91280c75d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ad09760f-6a62-4793-9cee-a49e651aee6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a43a082b-cb91-4f47-b02f-1495df3d97fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ad09760f-6a62-4793-9cee-a49e651aee6b" xlink:to="loc_us-gaap_NetIncomeLoss_a43a082b-cb91-4f47-b02f-1495df3d97fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_74b0cc93-7856-4c6a-b0d8-8ac54027ab78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ad09760f-6a62-4793-9cee-a49e651aee6b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_74b0cc93-7856-4c6a-b0d8-8ac54027ab78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_89c6ef19-b58a-425b-8f67-25e51f4a9ca2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_74b0cc93-7856-4c6a-b0d8-8ac54027ab78" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_89c6ef19-b58a-425b-8f67-25e51f4a9ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f2354e22-8fc7-4e4d-bcbb-310dd165ce5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_74b0cc93-7856-4c6a-b0d8-8ac54027ab78" xlink:to="loc_us-gaap_ShareBasedCompensation_f2354e22-8fc7-4e4d-bcbb-310dd165ce5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2e493f93-3bf0-4b45-bb9d-63d69bd6435c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_74b0cc93-7856-4c6a-b0d8-8ac54027ab78" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2e493f93-3bf0-4b45-bb9d-63d69bd6435c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_bb98c07a-96c1-41de-a6cf-daa32c606db4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_74b0cc93-7856-4c6a-b0d8-8ac54027ab78" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_bb98c07a-96c1-41de-a6cf-daa32c606db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_OperatingLeaseRightOfUseAssetAmortization_be07067b-b729-4271-a6e0-d1bdda0ecdea" xlink:href="agio-20200930.xsd#agio_OperatingLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_74b0cc93-7856-4c6a-b0d8-8ac54027ab78" xlink:to="loc_agio_OperatingLeaseRightOfUseAssetAmortization_be07067b-b729-4271-a6e0-d1bdda0ecdea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_InterestExpenseNonCashSaleOfFutureRevenue_067652b4-d4dd-4996-956b-865c80763501" xlink:href="agio-20200930.xsd#agio_InterestExpenseNonCashSaleOfFutureRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_74b0cc93-7856-4c6a-b0d8-8ac54027ab78" xlink:to="loc_agio_InterestExpenseNonCashSaleOfFutureRevenue_067652b4-d4dd-4996-956b-865c80763501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RoyaltyRevenueNonCash_8b485f90-664e-4b9b-a8cf-4b3bea16bd07" xlink:href="agio-20200930.xsd#agio_RoyaltyRevenueNonCash"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_74b0cc93-7856-4c6a-b0d8-8ac54027ab78" xlink:to="loc_agio_RoyaltyRevenueNonCash_8b485f90-664e-4b9b-a8cf-4b3bea16bd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aae17a8f-f644-4ab8-a1f7-8c0eee71b9b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_74b0cc93-7856-4c6a-b0d8-8ac54027ab78" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aae17a8f-f644-4ab8-a1f7-8c0eee71b9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_39a2178f-50a1-499f-9ea6-8bb227a2cec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aae17a8f-f644-4ab8-a1f7-8c0eee71b9b3" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_39a2178f-50a1-499f-9ea6-8bb227a2cec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent_df212405-4a5f-4ee7-8594-ddcb1d559de0" xlink:href="agio-20200930.xsd#agio_IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aae17a8f-f644-4ab8-a1f7-8c0eee71b9b3" xlink:to="loc_agio_IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent_df212405-4a5f-4ee7-8594-ddcb1d559de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseInCollaborationReceivableOtherCurrent_26ff443d-32d2-4c48-98cb-7ce9c037439c" xlink:href="agio-20200930.xsd#agio_IncreaseDecreaseInCollaborationReceivableOtherCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aae17a8f-f644-4ab8-a1f7-8c0eee71b9b3" xlink:to="loc_agio_IncreaseDecreaseInCollaborationReceivableOtherCurrent_26ff443d-32d2-4c48-98cb-7ce9c037439c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent_c31fe50d-0b31-481e-8963-b465ebe0f9d4" xlink:href="agio-20200930.xsd#agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aae17a8f-f644-4ab8-a1f7-8c0eee71b9b3" xlink:to="loc_agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent_c31fe50d-0b31-481e-8963-b465ebe0f9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_582db469-e0f5-4196-8379-9ee2abd873d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aae17a8f-f644-4ab8-a1f7-8c0eee71b9b3" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_582db469-e0f5-4196-8379-9ee2abd873d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_402c185e-b203-4619-a7cc-bef4cef11ea3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aae17a8f-f644-4ab8-a1f7-8c0eee71b9b3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_402c185e-b203-4619-a7cc-bef4cef11ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8f721aa2-b0ff-4569-bf5d-a2c14e297ccf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aae17a8f-f644-4ab8-a1f7-8c0eee71b9b3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8f721aa2-b0ff-4569-bf5d-a2c14e297ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_170183dd-3eb6-4c73-9f58-6ae42c785594" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aae17a8f-f644-4ab8-a1f7-8c0eee71b9b3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_170183dd-3eb6-4c73-9f58-6ae42c785594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty_d92fe6cb-8279-4d3d-a757-da7d02610ac7" xlink:href="agio-20200930.xsd#agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aae17a8f-f644-4ab8-a1f7-8c0eee71b9b3" xlink:to="loc_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty_d92fe6cb-8279-4d3d-a757-da7d02610ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncreaseDecreaseInOperatingLeaseLiability_0b90ee0c-8bb9-4993-b5bc-244a8764230e" xlink:href="agio-20200930.xsd#agio_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aae17a8f-f644-4ab8-a1f7-8c0eee71b9b3" xlink:to="loc_agio_IncreaseDecreaseInOperatingLeaseLiability_0b90ee0c-8bb9-4993-b5bc-244a8764230e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f81a941b-34a6-4d76-8875-d5abe4c34e48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ad09760f-6a62-4793-9cee-a49e651aee6b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f81a941b-34a6-4d76-8875-d5abe4c34e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_60d5426a-7dcf-430e-9d24-9aeffe9b498c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fa494326-53a7-4ae7-b653-a4d91280c75d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_60d5426a-7dcf-430e-9d24-9aeffe9b498c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_a0ae774e-b05f-43e4-843a-ae22f23a8695" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_60d5426a-7dcf-430e-9d24-9aeffe9b498c" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_a0ae774e-b05f-43e4-843a-ae22f23a8695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_cf890cf2-bb91-408c-8220-64a9ae20138d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_60d5426a-7dcf-430e-9d24-9aeffe9b498c" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_cf890cf2-bb91-408c-8220-64a9ae20138d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4f9e5d90-ade8-44a1-838a-d8fa52dceeae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_60d5426a-7dcf-430e-9d24-9aeffe9b498c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4f9e5d90-ade8-44a1-838a-d8fa52dceeae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_72c9b203-ebd8-4e61-b5af-6b243d1d44cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_60d5426a-7dcf-430e-9d24-9aeffe9b498c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_72c9b203-ebd8-4e61-b5af-6b243d1d44cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7178b247-fa14-4553-8134-61214e636238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fa494326-53a7-4ae7-b653-a4d91280c75d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7178b247-fa14-4553-8134-61214e636238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_8bcbeccf-ef0a-4f39-9e12-29f7a096f16f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7178b247-fa14-4553-8134-61214e636238" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_8bcbeccf-ef0a-4f39-9e12-29f7a096f16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_10634085-2427-46d2-98c1-d8b04678f956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7178b247-fa14-4553-8134-61214e636238" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_10634085-2427-46d2-98c1-d8b04678f956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts_e302d424-fa77-44f6-957d-6aa5b8a69c52" xlink:href="agio-20200930.xsd#agio_ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7178b247-fa14-4553-8134-61214e636238" xlink:to="loc_agio_ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts_e302d424-fa77-44f6-957d-6aa5b8a69c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_30e91375-a55e-4c93-af68-92162081a9f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_7178b247-fa14-4553-8134-61214e636238" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_30e91375-a55e-4c93-af68-92162081a9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0fd0cbcf-ad61-4119-aabb-e3d91720e07e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fa494326-53a7-4ae7-b653-a4d91280c75d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0fd0cbcf-ad61-4119-aabb-e3d91720e07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_55b684d3-e511-4671-995e-b32cf6b21278" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fa494326-53a7-4ae7-b653-a4d91280c75d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_55b684d3-e511-4671-995e-b32cf6b21278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fa1f56ab-18e8-4a80-98b4-ffa0852b1fbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fa494326-53a7-4ae7-b653-a4d91280c75d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fa1f56ab-18e8-4a80-98b4-ffa0852b1fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_a3f23459-feb3-4c37-9c4c-52ecef8bba67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fa494326-53a7-4ae7-b653-a4d91280c75d" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_a3f23459-feb3-4c37-9c4c-52ecef8bba67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_9e1a8f82-cb27-4b7f-a885-aeff380467c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_a3f23459-feb3-4c37-9c4c-52ecef8bba67" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_9e1a8f82-cb27-4b7f-a885-aeff380467c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_19900657-1539-406d-9b5e-0d282571f50a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_a3f23459-feb3-4c37-9c4c-52ecef8bba67" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_19900657-1539-406d-9b5e-0d282571f50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/OverviewandBasisofPresentation" xlink:type="simple" xlink:href="agio-20200930.xsd#OverviewandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://agios.com/role/OverviewandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9f200abd-2f7f-4995-bf3c-f2a1e422f80f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_13f40a6c-3763-4be1-b589-89066b9dc533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9f200abd-2f7f-4995-bf3c-f2a1e422f80f" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_13f40a6c-3763-4be1-b589-89066b9dc533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#OverviewandBasisofPresentationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7254c847-9035-46fa-944a-17fa698f8e7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_04ed35b8-b09b-40b6-bd90-08e6078410e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7254c847-9035-46fa-944a-17fa698f8e7d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_04ed35b8-b09b-40b6-bd90-08e6078410e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3dd4232b-b753-48bb-8732-c69a77e9bd8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_04ed35b8-b09b-40b6-bd90-08e6078410e6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3dd4232b-b753-48bb-8732-c69a77e9bd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cf0d23d4-2d0d-41c1-bd87-3584a0a8fd19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3dd4232b-b753-48bb-8732-c69a77e9bd8e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cf0d23d4-2d0d-41c1-bd87-3584a0a8fd19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_Agreement2010Member_45439e3a-78a9-48e4-b312-a7640cb04229" xlink:href="agio-20200930.xsd#agio_Agreement2010Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cf0d23d4-2d0d-41c1-bd87-3584a0a8fd19" xlink:to="loc_agio_Agreement2010Member_45439e3a-78a9-48e4-b312-a7640cb04229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a7449536-4ffe-41ac-95c0-2476ff4d824d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_04ed35b8-b09b-40b6-bd90-08e6078410e6" xlink:to="loc_srt_CounterpartyNameAxis_a7449536-4ffe-41ac-95c0-2476ff4d824d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e2e9b987-12b8-46f7-a134-bf1c95e4e0d8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a7449536-4ffe-41ac-95c0-2476ff4d824d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e2e9b987-12b8-46f7-a134-bf1c95e4e0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CelgeneMember_4c7e34e3-d5e7-4ec8-b0bd-5a6b3bb23151" xlink:href="agio-20200930.xsd#agio_CelgeneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e2e9b987-12b8-46f7-a134-bf1c95e4e0d8" xlink:to="loc_agio_CelgeneMember_4c7e34e3-d5e7-4ec8-b0bd-5a6b3bb23151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3e81cde4-4c69-4aaa-85fb-ea186bc99069" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_04ed35b8-b09b-40b6-bd90-08e6078410e6" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3e81cde4-4c69-4aaa-85fb-ea186bc99069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold_29721bf9-6f53-4e77-82bd-53fffc04ebfc" xlink:href="agio-20200930.xsd#agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3e81cde4-4c69-4aaa-85fb-ea186bc99069" xlink:to="loc_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold_29721bf9-6f53-4e77-82bd-53fffc04ebfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold_d9df9d0b-0815-470d-9469-90f5aef12abd" xlink:href="agio-20200930.xsd#agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3e81cde4-4c69-4aaa-85fb-ea186bc99069" xlink:to="loc_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold_d9df9d0b-0815-470d-9469-90f5aef12abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMilestoneMethodEligibleReceivable_b1626e8a-8a21-4375-8b47-f6f51fadcdb6" xlink:href="agio-20200930.xsd#agio_RevenueRecognitionMilestoneMethodEligibleReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3e81cde4-4c69-4aaa-85fb-ea186bc99069" xlink:to="loc_agio_RevenueRecognitionMilestoneMethodEligibleReceivable_b1626e8a-8a21-4375-8b47-f6f51fadcdb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_85f2f0ed-d4d9-4c88-9901-c2de5841d2cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3e81cde4-4c69-4aaa-85fb-ea186bc99069" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_85f2f0ed-d4d9-4c88-9901-c2de5841d2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="agio-20200930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://agios.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bcb4f07f-8144-41b2-b0d1-213c03c6582e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8dda01ee-4b72-4374-bfba-d3d99e71fdb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bcb4f07f-8144-41b2-b0d1-213c03c6582e" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8dda01ee-4b72-4374-bfba-d3d99e71fdb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="agio-20200930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3b930a2a-2378-48a1-a181-8e7fec8b8198" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d0ff4aad-47ef-4c31-b3a7-6381c4af5936" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3b930a2a-2378-48a1-a181-8e7fec8b8198" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d0ff4aad-47ef-4c31-b3a7-6381c4af5936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_b2fd64eb-e682-4906-8a3f-206b9f80777b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3b930a2a-2378-48a1-a181-8e7fec8b8198" xlink:to="loc_us-gaap_UseOfEstimates_b2fd64eb-e682-4906-8a3f-206b9f80777b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_479e1c8f-553e-4b39-912d-64f02d56b3b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3b930a2a-2378-48a1-a181-8e7fec8b8198" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_479e1c8f-553e-4b39-912d-64f02d56b3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenuePolicyPolicyTextBlock_c3b57486-4671-454e-a29d-49a070df5222" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenuePolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3b930a2a-2378-48a1-a181-8e7fec8b8198" xlink:to="loc_agio_SaleOfFutureRevenuePolicyPolicyTextBlock_c3b57486-4671-454e-a29d-49a070df5222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_706b3a46-7c4f-4118-8e72-afdcd39f6daf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3b930a2a-2378-48a1-a181-8e7fec8b8198" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_706b3a46-7c4f-4118-8e72-afdcd39f6daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_efa97b84-fb54-4e6c-829b-ec43d521bb2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3b930a2a-2378-48a1-a181-8e7fec8b8198" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_efa97b84-fb54-4e6c-829b-ec43d521bb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_3cfe90ba-f194-4777-861b-aca6e71993b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3b930a2a-2378-48a1-a181-8e7fec8b8198" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_3cfe90ba-f194-4777-861b-aca6e71993b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_449f6fc7-8206-4d4e-882d-a57a1d81d832" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3b930a2a-2378-48a1-a181-8e7fec8b8198" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_449f6fc7-8206-4d4e-882d-a57a1d81d832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="agio-20200930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://agios.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f4db770f-3226-4175-8659-3970f5eb8942" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_265e35e1-f199-427d-8d3a-98183bd51ca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f4db770f-3226-4175-8659-3970f5eb8942" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_265e35e1-f199-427d-8d3a-98183bd51ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="agio-20200930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_398ecf13-f7ec-4ef6-baa9-8e1bfd9ac8e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_c27db8bd-630d-4932-84e3-694a705f071c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_398ecf13-f7ec-4ef6-baa9-8e1bfd9ac8e2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_c27db8bd-630d-4932-84e3-694a705f071c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8c2c1946-fedd-4cb6-a93b-be24d6920011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_bd6b7419-b091-4692-8c9d-b038b67d18cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8c2c1946-fedd-4cb6-a93b-be24d6920011" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_bd6b7419-b091-4692-8c9d-b038b67d18cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2046a978-6c21-4039-a169-ee7c5ebedf37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_bd6b7419-b091-4692-8c9d-b038b67d18cf" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2046a978-6c21-4039-a169-ee7c5ebedf37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_09b94de7-ed39-4717-b1ef-4c2f7409015c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2046a978-6c21-4039-a169-ee7c5ebedf37" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_09b94de7-ed39-4717-b1ef-4c2f7409015c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_89d0e014-aa06-454e-b13e-39374486f565" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_09b94de7-ed39-4717-b1ef-4c2f7409015c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_89d0e014-aa06-454e-b13e-39374486f565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1ac7ddbb-833a-4428-b9e2-5dd510ce4118" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_bd6b7419-b091-4692-8c9d-b038b67d18cf" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1ac7ddbb-833a-4428-b9e2-5dd510ce4118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b9baf6e2-802f-4035-87a5-ebcd1d50931c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1ac7ddbb-833a-4428-b9e2-5dd510ce4118" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b9baf6e2-802f-4035-87a5-ebcd1d50931c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3fdffa0e-00b9-4077-8a88-404648a976cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b9baf6e2-802f-4035-87a5-ebcd1d50931c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3fdffa0e-00b9-4077-8a88-404648a976cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a9d9fef6-2a20-4ae2-96c7-0c0f7d76f825" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b9baf6e2-802f-4035-87a5-ebcd1d50931c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a9d9fef6-2a20-4ae2-96c7-0c0f7d76f825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f278cb5e-3358-453b-8041-f1b4e01b6e03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b9baf6e2-802f-4035-87a5-ebcd1d50931c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f278cb5e-3358-453b-8041-f1b4e01b6e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_a66802e6-b983-433b-a138-8340146d236a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_bd6b7419-b091-4692-8c9d-b038b67d18cf" xlink:to="loc_us-gaap_InvestmentTypeAxis_a66802e6-b983-433b-a138-8340146d236a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_82a38ec2-e152-4b38-8455-0c0d6bf80aa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_a66802e6-b983-433b-a138-8340146d236a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_82a38ec2-e152-4b38-8455-0c0d6bf80aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_849d52eb-d9cc-4ab2-a34f-5abf210d4c8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_82a38ec2-e152-4b38-8455-0c0d6bf80aa4" xlink:to="loc_us-gaap_CashEquivalentsMember_849d52eb-d9cc-4ab2-a34f-5abf210d4c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_df57147c-8cfd-4ad5-bf48-807126c31604" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_82a38ec2-e152-4b38-8455-0c0d6bf80aa4" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_df57147c-8cfd-4ad5-bf48-807126c31604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_e283cedc-2749-4c59-ba8a-8c7f44ed767e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_82a38ec2-e152-4b38-8455-0c0d6bf80aa4" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_e283cedc-2749-4c59-ba8a-8c7f44ed767e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_6b82dd5f-93d0-42d4-b6ce-346d0aba6339" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_82a38ec2-e152-4b38-8455-0c0d6bf80aa4" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_6b82dd5f-93d0-42d4-b6ce-346d0aba6339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d3ba43bf-a5bd-4390-8c94-3ded3743c601" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_bd6b7419-b091-4692-8c9d-b038b67d18cf" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d3ba43bf-a5bd-4390-8c94-3ded3743c601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_132987ae-db4a-45f8-944b-fa542d450126" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d3ba43bf-a5bd-4390-8c94-3ded3743c601" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_132987ae-db4a-45f8-944b-fa542d450126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6f95ed35-df1c-4c19-8bfc-8f21dbe5ec24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d3ba43bf-a5bd-4390-8c94-3ded3743c601" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6f95ed35-df1c-4c19-8bfc-8f21dbe5ec24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_9908c850-ae82-466b-bae1-5c75c212aacd" xlink:href="agio-20200930.xsd#agio_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d3ba43bf-a5bd-4390-8c94-3ded3743c601" xlink:to="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_9908c850-ae82-466b-bae1-5c75c212aacd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3e703538-3883-43f0-a347-dbaefae72bca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4da9c541-51b9-4bef-94dc-41e054f55e59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3e703538-3883-43f0-a347-dbaefae72bca" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4da9c541-51b9-4bef-94dc-41e054f55e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c6ff6b50-2080-4e99-a1ad-1a7e085f5ffe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4da9c541-51b9-4bef-94dc-41e054f55e59" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c6ff6b50-2080-4e99-a1ad-1a7e085f5ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c74978ef-11f7-4d5b-b209-193e05ddfe95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c6ff6b50-2080-4e99-a1ad-1a7e085f5ffe" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c74978ef-11f7-4d5b-b209-193e05ddfe95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_5d4f131a-1792-413f-9170-9a1f9d93004e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c74978ef-11f7-4d5b-b209-193e05ddfe95" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_5d4f131a-1792-413f-9170-9a1f9d93004e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_43d4e291-1861-4540-a064-9bba7a0a0427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4da9c541-51b9-4bef-94dc-41e054f55e59" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_43d4e291-1861-4540-a064-9bba7a0a0427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a69d7eff-ddce-4d6e-84d3-7a636b1bd640" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_43d4e291-1861-4540-a064-9bba7a0a0427" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a69d7eff-ddce-4d6e-84d3-7a636b1bd640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_45fa3736-26c9-4a23-b68e-96cfcdae02a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a69d7eff-ddce-4d6e-84d3-7a636b1bd640" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_45fa3736-26c9-4a23-b68e-96cfcdae02a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42658d4d-e7be-49f4-85e5-3deb5aa96b51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4da9c541-51b9-4bef-94dc-41e054f55e59" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42658d4d-e7be-49f4-85e5-3deb5aa96b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability_a3451032-32dc-43eb-a82c-edebf408ed7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_42658d4d-e7be-49f4-85e5-3deb5aa96b51" xlink:to="loc_us-gaap_FairValueNetAssetLiability_a3451032-32dc-43eb-a82c-edebf408ed7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecurities" xlink:type="simple" xlink:href="agio-20200930.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://agios.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_52da11fc-4a7a-4cc8-8960-b2ff9c7d7619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_32f4efc6-fe1d-4f46-8bda-1cd658760732" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_52da11fc-4a7a-4cc8-8960-b2ff9c7d7619" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_32f4efc6-fe1d-4f46-8bda-1cd658760732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="agio-20200930.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_78c7f34b-c668-4815-8e23-861b5fc4dc6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_41989528-5316-488b-ac5c-98bef7210af0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_78c7f34b-c668-4815-8e23-861b5fc4dc6c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_41989528-5316-488b-ac5c-98bef7210af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#MarketableSecuritiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_730db1e8-a7b5-45a6-a082-588b4258bff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_e0101356-ae2f-4bae-8b67-10875b370731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_730db1e8-a7b5-45a6-a082-588b4258bff9" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_e0101356-ae2f-4bae-8b67-10875b370731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_b476339f-8167-4563-b2b3-2daf58bd27c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_730db1e8-a7b5-45a6-a082-588b4258bff9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_b476339f-8167-4563-b2b3-2daf58bd27c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses_724da21e-22c2-4121-ad27-12c0f6f492e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLosses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_730db1e8-a7b5-45a6-a082-588b4258bff9" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLosses_724da21e-22c2-4121-ad27-12c0f6f492e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_7ba6b48f-d8b9-4ec2-bf23-3e6bf16ed420" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_730db1e8-a7b5-45a6-a082-588b4258bff9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_7ba6b48f-d8b9-4ec2-bf23-3e6bf16ed420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_dfa2a1f0-e6fc-4d1f-abd3-4c50334b114b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_730db1e8-a7b5-45a6-a082-588b4258bff9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_dfa2a1f0-e6fc-4d1f-abd3-4c50334b114b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#MarketableSecuritiesSummaryofMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6fc2d258-516a-4769-b5b3-1b31fe6a28d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_911f3521-86bc-4337-9b6a-9d085df53587" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6fc2d258-516a-4769-b5b3-1b31fe6a28d3" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_911f3521-86bc-4337-9b6a-9d085df53587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_267dd0ed-7875-437e-8f10-61fab1deb021" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_911f3521-86bc-4337-9b6a-9d085df53587" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_267dd0ed-7875-437e-8f10-61fab1deb021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3e0908d2-1547-4bf5-8ba9-ba2a1248e6f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_267dd0ed-7875-437e-8f10-61fab1deb021" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3e0908d2-1547-4bf5-8ba9-ba2a1248e6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentAssetMember_ccdfc19b-15e4-4bdd-83f3-9018b880907d" xlink:href="agio-20200930.xsd#agio_CurrentAssetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3e0908d2-1547-4bf5-8ba9-ba2a1248e6f8" xlink:to="loc_agio_CurrentAssetMember_ccdfc19b-15e4-4bdd-83f3-9018b880907d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_NonCurrentAssetsMember_50dbc9fb-2486-4e6c-970e-c2a2d0120dca" xlink:href="agio-20200930.xsd#agio_NonCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3e0908d2-1547-4bf5-8ba9-ba2a1248e6f8" xlink:to="loc_agio_NonCurrentAssetsMember_50dbc9fb-2486-4e6c-970e-c2a2d0120dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_bd6125f1-6c97-4be5-a6f3-aa0dd1048116" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_911f3521-86bc-4337-9b6a-9d085df53587" xlink:to="loc_us-gaap_InvestmentTypeAxis_bd6125f1-6c97-4be5-a6f3-aa0dd1048116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_44421efa-85ab-4280-a94a-f21a4eb38bef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_bd6125f1-6c97-4be5-a6f3-aa0dd1048116" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_44421efa-85ab-4280-a94a-f21a4eb38bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_14c353f0-b82c-4551-9422-c14a310c83a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_44421efa-85ab-4280-a94a-f21a4eb38bef" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_14c353f0-b82c-4551-9422-c14a310c83a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d03f431c-2f8e-4d5d-831c-a2892eb975d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_44421efa-85ab-4280-a94a-f21a4eb38bef" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d03f431c-2f8e-4d5d-831c-a2892eb975d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c8883d27-5bea-4c4e-980f-ab612eb2ccb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_44421efa-85ab-4280-a94a-f21a4eb38bef" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c8883d27-5bea-4c4e-980f-ab612eb2ccb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b94da5ff-1f9f-4e62-9229-1be62a6384c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_911f3521-86bc-4337-9b6a-9d085df53587" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b94da5ff-1f9f-4e62-9229-1be62a6384c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5392ce41-b9a0-4c4a-b537-0698c1c24174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b94da5ff-1f9f-4e62-9229-1be62a6384c3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5392ce41-b9a0-4c4a-b537-0698c1c24174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_977559d0-beae-404d-80a2-7bf0df47c173" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b94da5ff-1f9f-4e62-9229-1be62a6384c3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_977559d0-beae-404d-80a2-7bf0df47c173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8dbcd6b7-eb84-4674-b3ce-e415ddbdfe06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b94da5ff-1f9f-4e62-9229-1be62a6384c3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8dbcd6b7-eb84-4674-b3ce-e415ddbdfe06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1e04293b-3414-4149-a6e7-983afe2b6639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b94da5ff-1f9f-4e62-9229-1be62a6384c3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1e04293b-3414-4149-a6e7-983afe2b6639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/Inventory" xlink:type="simple" xlink:href="agio-20200930.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://agios.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_33a28288-3880-4238-a4ed-0df65b68a07d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_599e0d86-bc30-431a-9068-e11e96c361bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_33a28288-3880-4238-a4ed-0df65b68a07d" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_599e0d86-bc30-431a-9068-e11e96c361bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/InventoryTables" xlink:type="simple" xlink:href="agio-20200930.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_a8f64831-ddf7-4c0b-a713-491929b51d4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2ed039e0-d094-42ae-8b9d-db2b8aafd05a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a8f64831-ddf7-4c0b-a713-491929b51d4e" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2ed039e0-d094-42ae-8b9d-db2b8aafd05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/InventoryScheduleofInventoryDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#InventoryScheduleofInventoryDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/InventoryScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_73e8c396-d438-4564-b40d-7429d7b0be4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_70c24667-267b-44b1-a8d6-456fd2ed5cba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_73e8c396-d438-4564-b40d-7429d7b0be4e" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_70c24667-267b-44b1-a8d6-456fd2ed5cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_c8221fa6-84cc-40c3-875d-67b1d3381fb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_73e8c396-d438-4564-b40d-7429d7b0be4e" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_c8221fa6-84cc-40c3-875d-67b1d3381fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7a039e9a-0cec-46e7-be65-770128b1e37c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_73e8c396-d438-4564-b40d-7429d7b0be4e" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7a039e9a-0cec-46e7-be65-770128b1e37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_75fa3e59-82c3-4517-97ac-cc15f9482146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_73e8c396-d438-4564-b40d-7429d7b0be4e" xlink:to="loc_us-gaap_InventoryNet_75fa3e59-82c3-4517-97ac-cc15f9482146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/Leases" xlink:type="simple" xlink:href="agio-20200930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://agios.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_58856da5-b666-4b89-8e2d-07f16d60b149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_cc32120c-4a68-4919-bea2-a8754e4a428e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_58856da5-b666-4b89-8e2d-07f16d60b149" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_cc32120c-4a68-4919-bea2-a8754e4a428e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesTables" xlink:type="simple" xlink:href="agio-20200930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f54e76e4-9ccd-4579-b31f-915d57d0e3a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f6c1a8fb-f56d-40dc-8680-8cab57d5d2ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f54e76e4-9ccd-4579-b31f-915d57d0e3a2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f6c1a8fb-f56d-40dc-8680-8cab57d5d2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1a8f1a02-86e2-4424-b55a-ec2b5516453c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_1098bb99-8007-4c7c-af12-5088fd2f0586" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1a8f1a02-86e2-4424-b55a-ec2b5516453c" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_1098bb99-8007-4c7c-af12-5088fd2f0586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_91a07453-29d8-46d7-8148-8f121de59430" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1a8f1a02-86e2-4424-b55a-ec2b5516453c" xlink:to="loc_us-gaap_OperatingLeaseCost_91a07453-29d8-46d7-8148-8f121de59430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_87b00542-6374-4874-840f-520be3fa2940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1a8f1a02-86e2-4424-b55a-ec2b5516453c" xlink:to="loc_us-gaap_OperatingLeasePayments_87b00542-6374-4874-840f-520be3fa2940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f03ba9b7-c264-4957-b546-2b1b661af31c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1a8f1a02-86e2-4424-b55a-ec2b5516453c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f03ba9b7-c264-4957-b546-2b1b661af31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3578519e-1871-4ac9-9d42-c0c5621060c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1a8f1a02-86e2-4424-b55a-ec2b5516453c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3578519e-1871-4ac9-9d42-c0c5621060c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ffa91d9e-67af-4710-bd55-3a76c5af12d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f2f27a95-b039-475f-bc0a-6670b3d1c2c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ffa91d9e-67af-4710-bd55-3a76c5af12d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f2f27a95-b039-475f-bc0a-6670b3d1c2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_86a77f2b-84c5-4671-98a5-c3c669827013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ffa91d9e-67af-4710-bd55-3a76c5af12d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_86a77f2b-84c5-4671-98a5-c3c669827013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ea85a113-3441-4282-b673-6479e0c572e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ffa91d9e-67af-4710-bd55-3a76c5af12d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ea85a113-3441-4282-b673-6479e0c572e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5cdfb60f-ec42-41b7-9787-3295f797939c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ffa91d9e-67af-4710-bd55-3a76c5af12d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5cdfb60f-ec42-41b7-9787-3295f797939c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_548de9c1-d313-4ee3-89ee-a1d4635e2fa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ffa91d9e-67af-4710-bd55-3a76c5af12d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_548de9c1-d313-4ee3-89ee-a1d4635e2fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e74d8c9b-1762-431a-8c10-338b54e564b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ffa91d9e-67af-4710-bd55-3a76c5af12d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e74d8c9b-1762-431a-8c10-338b54e564b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_590d4407-cc0b-4baf-8db9-8fec84080f7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ffa91d9e-67af-4710-bd55-3a76c5af12d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_590d4407-cc0b-4baf-8db9-8fec84080f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1e698e1b-629d-40bb-ad97-b960bddac690" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ffa91d9e-67af-4710-bd55-3a76c5af12d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1e698e1b-629d-40bb-ad97-b960bddac690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_63c92a93-f480-49c3-a301-92ebd6341fcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ffa91d9e-67af-4710-bd55-3a76c5af12d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_63c92a93-f480-49c3-a301-92ebd6341fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a22a6615-b097-429d-81d5-69328aa8bcf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ffa91d9e-67af-4710-bd55-3a76c5af12d2" xlink:to="loc_us-gaap_OperatingLeaseLiability_a22a6615-b097-429d-81d5-69328aa8bcf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1" xlink:type="simple" xlink:href="agio-20200930.xsd#LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1"/>
  <link:presentationLink xlink:role="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/AccruedExpenses" xlink:type="simple" xlink:href="agio-20200930.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://agios.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_dc75322c-a20e-4d95-af55-e617f1d1cbbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_8cbde216-867c-4ddb-af86-b074189a017b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_dc75322c-a20e-4d95-af55-e617f1d1cbbb" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_8cbde216-867c-4ddb-af86-b074189a017b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="agio-20200930.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_ec476383-75a4-4045-a906-2f757d5a7a90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_acc9cb66-ad9d-4408-9944-ff7c2acb33f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ec476383-75a4-4045-a906-2f757d5a7a90" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_acc9cb66-ad9d-4408-9944-ff7c2acb33f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#AccruedExpensesSummaryofAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_9d28a4b1-80c3-4662-93b8-5a2c93f85e56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2f4698ce-965b-4256-8381-51aae0bca149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_9d28a4b1-80c3-4662-93b8-5a2c93f85e56" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2f4698ce-965b-4256-8381-51aae0bca149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AccruedResearchAndDevelopmentCostsCurrent_e5ac61f2-fd7e-49d2-b2da-a4aa6d352c4e" xlink:href="agio-20200930.xsd#agio_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_9d28a4b1-80c3-4662-93b8-5a2c93f85e56" xlink:to="loc_agio_AccruedResearchAndDevelopmentCostsCurrent_e5ac61f2-fd7e-49d2-b2da-a4aa6d352c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_86002c7f-e044-4529-805d-c930ae3fc33f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_9d28a4b1-80c3-4662-93b8-5a2c93f85e56" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_86002c7f-e044-4529-805d-c930ae3fc33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_33d94a92-7fdc-4a36-993b-25e352a78dfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_9d28a4b1-80c3-4662-93b8-5a2c93f85e56" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_33d94a92-7fdc-4a36-993b-25e352a78dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f2dda436-153a-4f7a-84ea-3b46b11b96e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_9d28a4b1-80c3-4662-93b8-5a2c93f85e56" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f2dda436-153a-4f7a-84ea-3b46b11b96e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenue" xlink:type="simple" xlink:href="agio-20200930.xsd#ProductRevenue"/>
  <link:presentationLink xlink:role="http://agios.com/role/ProductRevenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8742d71b-fef4-4603-9341-965f657722ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_2b9924d8-648d-4bcd-8d14-4ed444141daa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8742d71b-fef4-4603-9341-965f657722ad" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_2b9924d8-648d-4bcd-8d14-4ed444141daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueTables" xlink:type="simple" xlink:href="agio-20200930.xsd#ProductRevenueTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/ProductRevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_10fb2779-d7f4-4ce7-865d-cfd8817e9253" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_73d2aa40-720e-4255-bbb9-5a1d0dcee88b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_10fb2779-d7f4-4ce7-865d-cfd8817e9253" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_73d2aa40-720e-4255-bbb9-5a1d0dcee88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_4aebcf67-de6f-4352-b6da-31afc914a157" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_10fb2779-d7f4-4ce7-865d-cfd8817e9253" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_4aebcf67-de6f-4352-b6da-31afc914a157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock_c25515ae-242b-4930-8dc2-ac1e99870b8d" xlink:href="agio-20200930.xsd#agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_10fb2779-d7f4-4ce7-865d-cfd8817e9253" xlink:to="loc_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock_c25515ae-242b-4930-8dc2-ac1e99870b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock_be291728-4d1a-4ca3-9381-b6d3a393057c" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_10fb2779-d7f4-4ce7-865d-cfd8817e9253" xlink:to="loc_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock_be291728-4d1a-4ca3-9381-b6d3a393057c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ProductRevenueScheduleofProductRevenueDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_083b821b-aa8c-414e-aaa2-89fae2fb6a0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_74311e48-a38e-447b-a36b-22229f018635" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_083b821b-aa8c-414e-aaa2-89fae2fb6a0e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_74311e48-a38e-447b-a36b-22229f018635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cb1dfd1d-3eee-4117-8e65-41d7eec92839" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_74311e48-a38e-447b-a36b-22229f018635" xlink:to="loc_srt_ProductOrServiceAxis_cb1dfd1d-3eee-4117-8e65-41d7eec92839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1ecef462-7130-41ef-8621-6c6ccafc483d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_cb1dfd1d-3eee-4117-8e65-41d7eec92839" xlink:to="loc_srt_ProductsAndServicesDomain_1ecef462-7130-41ef-8621-6c6ccafc483d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_3d157b92-afb5-4ed4-84c0-e1fb64a6901d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1ecef462-7130-41ef-8621-6c6ccafc483d" xlink:to="loc_us-gaap_ProductMember_3d157b92-afb5-4ed4-84c0-e1fb64a6901d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_fc9a43be-06f0-4f8d-8e34-af9f0da7a18a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_74311e48-a38e-447b-a36b-22229f018635" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_fc9a43be-06f0-4f8d-8e34-af9f0da7a18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2ff65b1d-8ea3-411d-a128-5a11877f02fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_fc9a43be-06f0-4f8d-8e34-af9f0da7a18a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2ff65b1d-8ea3-411d-a128-5a11877f02fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_59e9c9fc-d0b6-46c3-b652-dd48af232622" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractualAdjustmentsRollForward_373d35b4-0034-4520-b777-6eb1b2d8e84a" xlink:href="agio-20200930.xsd#agio_ContractualAdjustmentsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_59e9c9fc-d0b6-46c3-b652-dd48af232622" xlink:to="loc_agio_ContractualAdjustmentsRollForward_373d35b4-0034-4520-b777-6eb1b2d8e84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractualAdjustmentReserve_4c0b9323-336e-4f0c-96cc-94db55de0c54" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerContractualAdjustmentReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractualAdjustmentsRollForward_373d35b4-0034-4520-b777-6eb1b2d8e84a" xlink:to="loc_agio_ContractWithCustomerContractualAdjustmentReserve_4c0b9323-336e-4f0c-96cc-94db55de0c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentYearProvisionForContractualAdjustments_45540795-cd68-4733-adfa-c3813d0abb43" xlink:href="agio-20200930.xsd#agio_CurrentYearProvisionForContractualAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractualAdjustmentsRollForward_373d35b4-0034-4520-b777-6eb1b2d8e84a" xlink:to="loc_agio_CurrentYearProvisionForContractualAdjustments_45540795-cd68-4733-adfa-c3813d0abb43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PriorYearProvisionForContractualAdjustments_d0883c9a-6c95-4926-8599-0dc6d25c61cf" xlink:href="agio-20200930.xsd#agio_PriorYearProvisionForContractualAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractualAdjustmentsRollForward_373d35b4-0034-4520-b777-6eb1b2d8e84a" xlink:to="loc_agio_PriorYearProvisionForContractualAdjustments_d0883c9a-6c95-4926-8599-0dc6d25c61cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_a6ed57c4-0686-4fe3-9e23-cf89c46eead8" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractualAdjustmentsRollForward_373d35b4-0034-4520-b777-6eb1b2d8e84a" xlink:to="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_a6ed57c4-0686-4fe3-9e23-cf89c46eead8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_9be32439-c083-4c75-8d2e-c68d91d2e60f" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractualAdjustmentsRollForward_373d35b4-0034-4520-b777-6eb1b2d8e84a" xlink:to="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_9be32439-c083-4c75-8d2e-c68d91d2e60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractualAdjustmentReserve_090d8e20-cbfd-44e8-a1db-faf8dc6106e6" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerContractualAdjustmentReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractualAdjustmentsRollForward_373d35b4-0034-4520-b777-6eb1b2d8e84a" xlink:to="loc_agio_ContractWithCustomerContractualAdjustmentReserve_090d8e20-cbfd-44e8-a1db-faf8dc6106e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_GovernmentRebatesRollForward_47b59bc8-9a9f-45b7-bce1-dd423a33a812" xlink:href="agio-20200930.xsd#agio_GovernmentRebatesRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_59e9c9fc-d0b6-46c3-b652-dd48af232622" xlink:to="loc_agio_GovernmentRebatesRollForward_47b59bc8-9a9f-45b7-bce1-dd423a33a812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserve_83598066-51f4-41e2-9a5d-ff22030a7499" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerRebateReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_GovernmentRebatesRollForward_47b59bc8-9a9f-45b7-bce1-dd423a33a812" xlink:to="loc_agio_ContractWithCustomerRebateReserve_83598066-51f4-41e2-9a5d-ff22030a7499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentYearProvisionsForRebateReserve_1233f9a4-bd81-47e2-9e62-77733b9d608e" xlink:href="agio-20200930.xsd#agio_CurrentYearProvisionsForRebateReserve"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_GovernmentRebatesRollForward_47b59bc8-9a9f-45b7-bce1-dd423a33a812" xlink:to="loc_agio_CurrentYearProvisionsForRebateReserve_1233f9a4-bd81-47e2-9e62-77733b9d608e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PriorYearProvisionsForRebateReserve_2d3fb72d-8ea2-45a5-9f6f-800d25042a23" xlink:href="agio-20200930.xsd#agio_PriorYearProvisionsForRebateReserve"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_GovernmentRebatesRollForward_47b59bc8-9a9f-45b7-bce1-dd423a33a812" xlink:to="loc_agio_PriorYearProvisionsForRebateReserve_2d3fb72d-8ea2-45a5-9f6f-800d25042a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_00e7348b-f873-496c-9bc6-9d23584ac56b" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_GovernmentRebatesRollForward_47b59bc8-9a9f-45b7-bce1-dd423a33a812" xlink:to="loc_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_00e7348b-f873-496c-9bc6-9d23584ac56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_6a6caf90-09fa-4c45-8a86-e008512b49d8" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_GovernmentRebatesRollForward_47b59bc8-9a9f-45b7-bce1-dd423a33a812" xlink:to="loc_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_6a6caf90-09fa-4c45-8a86-e008512b49d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserve_27ee88c5-895a-444d-bad0-d195df5587dd" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerRebateReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_GovernmentRebatesRollForward_47b59bc8-9a9f-45b7-bce1-dd423a33a812" xlink:to="loc_agio_ContractWithCustomerRebateReserve_27ee88c5-895a-444d-bad0-d195df5587dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProductReturnsRollForward_9da6ecf5-f386-4473-b27f-8b80fe4e9225" xlink:href="agio-20200930.xsd#agio_ProductReturnsRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_59e9c9fc-d0b6-46c3-b652-dd48af232622" xlink:to="loc_agio_ProductReturnsRollForward_9da6ecf5-f386-4473-b27f-8b80fe4e9225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductReserve_ad181dcb-1d65-4b6b-92bb-e5d1b650337d" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerRightToRecoverProductReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ProductReturnsRollForward_9da6ecf5-f386-4473-b27f-8b80fe4e9225" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductReserve_ad181dcb-1d65-4b6b-92bb-e5d1b650337d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProvisionForRightToRecoverProductInCurrentYear_04125c08-8235-41f4-a488-9cba44f7f665" xlink:href="agio-20200930.xsd#agio_ProvisionForRightToRecoverProductInCurrentYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ProductReturnsRollForward_9da6ecf5-f386-4473-b27f-8b80fe4e9225" xlink:to="loc_agio_ProvisionForRightToRecoverProductInCurrentYear_04125c08-8235-41f4-a488-9cba44f7f665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProvisionForRightToRecoverProductInPriorYears_b0ec203b-834e-4912-aa4d-e7b9a9d59569" xlink:href="agio-20200930.xsd#agio_ProvisionForRightToRecoverProductInPriorYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ProductReturnsRollForward_9da6ecf5-f386-4473-b27f-8b80fe4e9225" xlink:to="loc_agio_ProvisionForRightToRecoverProductInPriorYears_b0ec203b-834e-4912-aa4d-e7b9a9d59569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_bd1afe64-77a8-4f38-a07e-8fdcfa36ea59" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ProductReturnsRollForward_9da6ecf5-f386-4473-b27f-8b80fe4e9225" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_bd1afe64-77a8-4f38-a07e-8fdcfa36ea59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_4d2c9d24-35bf-4144-a6d3-bcc3582b0231" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ProductReturnsRollForward_9da6ecf5-f386-4473-b27f-8b80fe4e9225" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_4d2c9d24-35bf-4144-a6d3-bcc3582b0231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductReserve_68e3168a-d0a2-49fc-b13e-39d12a25f4f5" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerRightToRecoverProductReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ProductReturnsRollForward_9da6ecf5-f386-4473-b27f-8b80fe4e9225" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductReserve_68e3168a-d0a2-49fc-b13e-39d12a25f4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_05c719da-5f39-4885-a0ad-ae9b12b99030" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_59e9c9fc-d0b6-46c3-b652-dd48af232622" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_05c719da-5f39-4885-a0ad-ae9b12b99030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_9ceab60f-4c66-483b-9d6f-49200efc6088" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerTotalAllowancesAndReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_05c719da-5f39-4885-a0ad-ae9b12b99030" xlink:to="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_9ceab60f-4c66-483b-9d6f-49200efc6088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerCurrentYearReserveProvisions_65a8bbe3-19fe-429e-918d-1aaf84152703" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerCurrentYearReserveProvisions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_05c719da-5f39-4885-a0ad-ae9b12b99030" xlink:to="loc_agio_ContractWithCustomerCurrentYearReserveProvisions_65a8bbe3-19fe-429e-918d-1aaf84152703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerPriorYearsReserveProvisions_f0c1acc6-4935-4099-bae8-200abe075edf" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerPriorYearsReserveProvisions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_05c719da-5f39-4885-a0ad-ae9b12b99030" xlink:to="loc_agio_ContractWithCustomerPriorYearsReserveProvisions_f0c1acc6-4935-4099-bae8-200abe075edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries_10694488-0d7b-450b-8e65-05f01cc17635" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerCurrentYearReserveRecoveries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_05c719da-5f39-4885-a0ad-ae9b12b99030" xlink:to="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries_10694488-0d7b-450b-8e65-05f01cc17635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries_d1451c97-947c-4676-9974-b96830f1d425" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerPriorYearsReserveRecoveries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_05c719da-5f39-4885-a0ad-ae9b12b99030" xlink:to="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries_d1451c97-947c-4676-9974-b96830f1d425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ProductRevenueScheduleofRevenueRelatedReservesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5f3685f7-a929-4f48-b585-179b45159a74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_8a965a86-a37a-42a0-9fba-30c153c76818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5f3685f7-a929-4f48-b585-179b45159a74" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_8a965a86-a37a-42a0-9fba-30c153c76818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAllowanceAndReservesLiability_7af445a4-68f7-4a2d-85fe-62fa9434c467" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerAllowanceAndReservesLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5f3685f7-a929-4f48-b585-179b45159a74" xlink:to="loc_agio_ContractWithCustomerAllowanceAndReservesLiability_7af445a4-68f7-4a2d-85fe-62fa9434c467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_1822e585-8930-4924-a4a0-4bd8a6f6dce6" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerTotalAllowancesAndReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5f3685f7-a929-4f48-b585-179b45159a74" xlink:to="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_1822e585-8930-4924-a4a0-4bd8a6f6dce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1910da1e-e01a-4785-8706-f475b985b41f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ChangeInContractWithCustomerAssetRollForward_ee3b3c94-a29e-4012-8fba-912bd1020906" xlink:href="agio-20200930.xsd#agio_ChangeInContractWithCustomerAssetRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1910da1e-e01a-4785-8706-f475b985b41f" xlink:to="loc_agio_ChangeInContractWithCustomerAssetRollForward_ee3b3c94-a29e-4012-8fba-912bd1020906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_7d8c5c4d-6797-4213-b95b-4a5709d885dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_ee3b3c94-a29e-4012-8fba-912bd1020906" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_7d8c5c4d-6797-4213-b95b-4a5709d885dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetRevenueRecognized_d7fb4861-36e0-4338-a6f3-0c04a5e2f046" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerAssetRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_ee3b3c94-a29e-4012-8fba-912bd1020906" xlink:to="loc_agio_ContractWithCustomerAssetRevenueRecognized_d7fb4861-36e0-4338-a6f3-0c04a5e2f046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_56fc32a0-c01f-4169-88b9-3519f7d5e5c9" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_ee3b3c94-a29e-4012-8fba-912bd1020906" xlink:to="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_56fc32a0-c01f-4169-88b9-3519f7d5e5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_7e4a1a4a-2084-4177-8fee-d8c6a26855e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_ee3b3c94-a29e-4012-8fba-912bd1020906" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_7e4a1a4a-2084-4177-8fee-d8c6a26855e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_9d93190b-606f-4812-9a8c-006da0ab8e74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4c94dfb9-d538-4967-be05-b29fbbb5c4f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_9d93190b-606f-4812-9a8c-006da0ab8e74" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4c94dfb9-d538-4967-be05-b29fbbb5c4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_5738c28f-a5e4-4473-928f-be6ac332f1a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock_fefd38a1-5a31-4657-8f46-f0bd8bef877c" xlink:href="agio-20200930.xsd#agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_5738c28f-a5e4-4473-928f-be6ac332f1a2" xlink:to="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock_fefd38a1-5a31-4657-8f46-f0bd8bef877c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_bc2d8062-b811-4083-801a-c99462a68054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_5738c28f-a5e4-4473-928f-be6ac332f1a2" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_bc2d8062-b811-4083-801a-c99462a68054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock_11fb1b4d-2838-4979-8649-299229b9e897" xlink:href="agio-20200930.xsd#agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_5738c28f-a5e4-4473-928f-be6ac332f1a2" xlink:to="loc_agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock_11fb1b4d-2838-4979-8649-299229b9e897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock_3e42bc9a-f1ba-491c-83a6-e01642df7cea" xlink:href="agio-20200930.xsd#agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_5738c28f-a5e4-4473-928f-be6ac332f1a2" xlink:to="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock_3e42bc9a-f1ba-491c-83a6-e01642df7cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlockTableTextBlock_48c53f1f-78ee-4fb5-bff9-f17dfb3e0dcf" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlockTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_5738c28f-a5e4-4473-928f-be6ac332f1a2" xlink:to="loc_agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlockTableTextBlock_48c53f1f-78ee-4fb5-bff9-f17dfb3e0dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_0f9ced94-f63c-465e-a545-7cac2951c7b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e56a806a-098c-4910-807a-f921b98bd9f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_0f9ced94-f63c-465e-a545-7cac2951c7b0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e56a806a-098c-4910-807a-f921b98bd9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c4d73f11-b0af-49ce-9b91-b17a3df0a9d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e56a806a-098c-4910-807a-f921b98bd9f5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c4d73f11-b0af-49ce-9b91-b17a3df0a9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e40ccf93-d01a-4454-b51f-d0b242471dc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c4d73f11-b0af-49ce-9b91-b17a3df0a9d3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e40ccf93-d01a-4454-b51f-d0b242471dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_Agreement2010Member_3261c021-8eb0-4fa3-88b9-58c77603720d" xlink:href="agio-20200930.xsd#agio_Agreement2010Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e40ccf93-d01a-4454-b51f-d0b242471dc1" xlink:to="loc_agio_Agreement2010Member_3261c021-8eb0-4fa3-88b9-58c77603720d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MasterResearchAndCollaborationAgreementMember_d1c6119b-09f7-4696-a3ad-e649ab03054b" xlink:href="agio-20200930.xsd#agio_MasterResearchAndCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e40ccf93-d01a-4454-b51f-d0b242471dc1" xlink:to="loc_agio_MasterResearchAndCollaborationAgreementMember_d1c6119b-09f7-4696-a3ad-e649ab03054b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2cb8c26d-19b2-4435-afd4-5d0a5638d0c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e56a806a-098c-4910-807a-f921b98bd9f5" xlink:to="loc_srt_CounterpartyNameAxis_2cb8c26d-19b2-4435-afd4-5d0a5638d0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ef7580a9-afd5-4ce0-8c04-b1862b959e72" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2cb8c26d-19b2-4435-afd4-5d0a5638d0c0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ef7580a9-afd5-4ce0-8c04-b1862b959e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CelgeneMember_b4a7b57a-09f7-41ce-b8a3-6ca25fe35dff" xlink:href="agio-20200930.xsd#agio_CelgeneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ef7580a9-afd5-4ce0-8c04-b1862b959e72" xlink:to="loc_agio_CelgeneMember_b4a7b57a-09f7-41ce-b8a3-6ca25fe35dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RPIMember_5bbcb7e8-0021-4fba-8288-f56e51949259" xlink:href="agio-20200930.xsd#agio_RPIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ef7580a9-afd5-4ce0-8c04-b1862b959e72" xlink:to="loc_agio_RPIMember_5bbcb7e8-0021-4fba-8288-f56e51949259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_272ac560-1fca-4564-9489-13ad4cdf46c2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e56a806a-098c-4910-807a-f921b98bd9f5" xlink:to="loc_srt_RangeAxis_272ac560-1fca-4564-9489-13ad4cdf46c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9481c737-abc7-4822-a8a1-dd765a248170" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_272ac560-1fca-4564-9489-13ad4cdf46c2" xlink:to="loc_srt_RangeMember_9481c737-abc7-4822-a8a1-dd765a248170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_108ef063-dc18-4035-8e6b-c89ae5db1b61" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9481c737-abc7-4822-a8a1-dd765a248170" xlink:to="loc_srt_MaximumMember_108ef063-dc18-4035-8e6b-c89ae5db1b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_178d71f9-68f0-4661-96b4-af172ca13922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e56a806a-098c-4910-807a-f921b98bd9f5" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_178d71f9-68f0-4661-96b4-af172ca13922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold_ec1af21a-45fc-48e2-b8c7-552be11b993a" xlink:href="agio-20200930.xsd#agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_178d71f9-68f0-4661-96b4-af172ca13922" xlink:to="loc_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold_ec1af21a-45fc-48e2-b8c7-552be11b993a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold_532ec39c-599b-4598-9599-cf3a465aef9e" xlink:href="agio-20200930.xsd#agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_178d71f9-68f0-4661-96b4-af172ca13922" xlink:to="loc_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold_532ec39c-599b-4598-9599-cf3a465aef9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMilestoneMethodEligibleReceivable_4acb631d-6ef8-4bee-9e5e-62c04da8dc9e" xlink:href="agio-20200930.xsd#agio_RevenueRecognitionMilestoneMethodEligibleReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_178d71f9-68f0-4661-96b4-af172ca13922" xlink:to="loc_agio_RevenueRecognitionMilestoneMethodEligibleReceivable_4acb631d-6ef8-4bee-9e5e-62c04da8dc9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsTermOfAgreement_dad57c8c-eaa4-4a90-b8b2-cd263ef0e6f8" xlink:href="agio-20200930.xsd#agio_RevenueRecognitionMultipleDeliverableArrangementsTermOfAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_178d71f9-68f0-4661-96b4-af172ca13922" xlink:to="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsTermOfAgreement_dad57c8c-eaa4-4a90-b8b2-cd263ef0e6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfExtensions_6d93d1b1-b1c2-41ef-b73d-a06e06724f72" xlink:href="agio-20200930.xsd#agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfExtensions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_178d71f9-68f0-4661-96b4-af172ca13922" xlink:to="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfExtensions_6d93d1b1-b1c2-41ef-b73d-a06e06724f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfSpecialCaseExtensions_d8090746-7ed2-4cdc-b564-55fdffd64097" xlink:href="agio-20200930.xsd#agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfSpecialCaseExtensions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_178d71f9-68f0-4661-96b4-af172ca13922" xlink:to="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfSpecialCaseExtensions_d8090746-7ed2-4cdc-b564-55fdffd64097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsSpecialCaseExtensionTerm_77e0b7ee-a733-42ba-a59c-f9e4c03bcbcc" xlink:href="agio-20200930.xsd#agio_RevenueRecognitionMultipleDeliverableArrangementsSpecialCaseExtensionTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_178d71f9-68f0-4661-96b4-af172ca13922" xlink:to="loc_agio_RevenueRecognitionMultipleDeliverableArrangementsSpecialCaseExtensionTerm_77e0b7ee-a733-42ba-a59c-f9e4c03bcbcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_UpfrontPaymentAgreementExtensionFeeReceivable_9049db01-6c48-43b7-9cf8-62e478deb65c" xlink:href="agio-20200930.xsd#agio_UpfrontPaymentAgreementExtensionFeeReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_178d71f9-68f0-4661-96b4-af172ca13922" xlink:to="loc_agio_UpfrontPaymentAgreementExtensionFeeReceivable_9049db01-6c48-43b7-9cf8-62e478deb65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_OptionExerciseFeeReceivable_2420c39a-0085-4dfb-a4ab-5411ed54861f" xlink:href="agio-20200930.xsd#agio_OptionExerciseFeeReceivable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_178d71f9-68f0-4661-96b4-af172ca13922" xlink:to="loc_agio_OptionExerciseFeeReceivable_2420c39a-0085-4dfb-a4ab-5411ed54861f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueRecognitionMilestoneMethodEligibleReceivable_9c676f02-bdfb-4bfb-a17a-8861968c4a83" xlink:href="agio-20200930.xsd#agio_RevenueRecognitionMilestoneMethodEligibleReceivable"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsCollaborationRevenueDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_841ecff9-f22b-4f6e-b4df-71712663221c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_e473431f-25a1-4a70-afa3-060ab80e9063" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_841ecff9-f22b-4f6e-b4df-71712663221c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_e473431f-25a1-4a70-afa3-060ab80e9063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_adfb3b72-3e00-4782-913f-021445f414a4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e473431f-25a1-4a70-afa3-060ab80e9063" xlink:to="loc_srt_ProductOrServiceAxis_adfb3b72-3e00-4782-913f-021445f414a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_67b966f9-9366-492e-8fb0-f99ac846ed0a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_adfb3b72-3e00-4782-913f-021445f414a4" xlink:to="loc_srt_ProductsAndServicesDomain_67b966f9-9366-492e-8fb0-f99ac846ed0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ResearchServicesMember_f4292b8a-f31c-4eb5-9d49-bdcba259bcea" xlink:href="agio-20200930.xsd#agio_ResearchServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_67b966f9-9366-492e-8fb0-f99ac846ed0a" xlink:to="loc_agio_ResearchServicesMember_f4292b8a-f31c-4eb5-9d49-bdcba259bcea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CommercializationActivityMember_1966d08a-2d38-436e-adbe-dac226ffb35c" xlink:href="agio-20200930.xsd#agio_CommercializationActivityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_67b966f9-9366-492e-8fb0-f99ac846ed0a" xlink:to="loc_agio_CommercializationActivityMember_1966d08a-2d38-436e-adbe-dac226ffb35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueRelatedPartyMember_93eedc9d-c620-4916-b222-806339ed6681" xlink:href="agio-20200930.xsd#agio_CollaborationRevenueRelatedPartyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_67b966f9-9366-492e-8fb0-f99ac846ed0a" xlink:to="loc_agio_CollaborationRevenueRelatedPartyMember_93eedc9d-c620-4916-b222-806339ed6681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_366ab5e4-56c4-4d7c-bb80-ab0bd9c74de6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e473431f-25a1-4a70-afa3-060ab80e9063" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_366ab5e4-56c4-4d7c-bb80-ab0bd9c74de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_75984c24-abf6-456d-9fc8-c18814ff004d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_366ab5e4-56c4-4d7c-bb80-ab0bd9c74de6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_75984c24-abf6-456d-9fc8-c18814ff004d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_9fdf81a0-6c4c-4535-9c19-5ad4d17b1ee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetAndLiabilityTable_c71b2317-4f3c-48d6-ba36-8045245e9528" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerAssetAndLiabilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_9fdf81a0-6c4c-4535-9c19-5ad4d17b1ee6" xlink:to="loc_agio_ContractWithCustomerAssetAndLiabilityTable_c71b2317-4f3c-48d6-ba36-8045245e9528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_0a4f2050-aca7-412a-b779-d250d5813634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractWithCustomerAssetAndLiabilityTable_c71b2317-4f3c-48d6-ba36-8045245e9528" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_0a4f2050-aca7-412a-b779-d250d5813634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f87e8ed8-72b3-4df4-a632-2402b68f9460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0a4f2050-aca7-412a-b779-d250d5813634" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f87e8ed8-72b3-4df4-a632-2402b68f9460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember_cc3e05cd-0de5-4189-88f2-fec333882e21" xlink:href="agio-20200930.xsd#agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f87e8ed8-72b3-4df4-a632-2402b68f9460" xlink:to="loc_agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember_cc3e05cd-0de5-4189-88f2-fec333882e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_UnbilledReceivableDueFromRelatedPartiesCurrentMember_a5c0f2df-2a5c-4835-8c4c-a2fa2791943a" xlink:href="agio-20200930.xsd#agio_UnbilledReceivableDueFromRelatedPartiesCurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f87e8ed8-72b3-4df4-a632-2402b68f9460" xlink:to="loc_agio_UnbilledReceivableDueFromRelatedPartiesCurrentMember_a5c0f2df-2a5c-4835-8c4c-a2fa2791943a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember_8c174aa2-d741-4434-a9ba-4a5488c0710d" xlink:href="agio-20200930.xsd#agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f87e8ed8-72b3-4df4-a632-2402b68f9460" xlink:to="loc_agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember_8c174aa2-d741-4434-a9ba-4a5488c0710d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DeferredRevenueCurrentMember_f6339be8-a54c-4796-a2d6-c3476255006c" xlink:href="agio-20200930.xsd#agio_DeferredRevenueCurrentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f87e8ed8-72b3-4df4-a632-2402b68f9460" xlink:to="loc_agio_DeferredRevenueCurrentMember_f6339be8-a54c-4796-a2d6-c3476255006c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetAndLiabilityLineItems_4a4e6d75-c26c-48bb-ab1c-ef3f2fd8c5f2" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerAssetAndLiabilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractWithCustomerAssetAndLiabilityTable_c71b2317-4f3c-48d6-ba36-8045245e9528" xlink:to="loc_agio_ContractWithCustomerAssetAndLiabilityLineItems_4a4e6d75-c26c-48bb-ab1c-ef3f2fd8c5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ChangeInContractWithCustomerAssetRollForward_8488c847-258b-49b7-9b05-0a4c4b4059f4" xlink:href="agio-20200930.xsd#agio_ChangeInContractWithCustomerAssetRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractWithCustomerAssetAndLiabilityLineItems_4a4e6d75-c26c-48bb-ab1c-ef3f2fd8c5f2" xlink:to="loc_agio_ChangeInContractWithCustomerAssetRollForward_8488c847-258b-49b7-9b05-0a4c4b4059f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_7c40e90a-aad8-4aee-8cf3-d41fd435470c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_8488c847-258b-49b7-9b05-0a4c4b4059f4" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_7c40e90a-aad8-4aee-8cf3-d41fd435470c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetRevenueRecognized_27921301-62e4-40f3-b0e2-ca218bb2b4de" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerAssetRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_8488c847-258b-49b7-9b05-0a4c4b4059f4" xlink:to="loc_agio_ContractWithCustomerAssetRevenueRecognized_27921301-62e4-40f3-b0e2-ca218bb2b4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_b8ff2109-bab8-4682-8830-a020251a5e59" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_8488c847-258b-49b7-9b05-0a4c4b4059f4" xlink:to="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_b8ff2109-bab8-4682-8830-a020251a5e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_4b25c4b2-1d2a-448d-b448-a29512cd4511" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_8488c847-258b-49b7-9b05-0a4c4b4059f4" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_4b25c4b2-1d2a-448d-b448-a29512cd4511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ChangeInContractWithCustomerLiabilityRollForward_d8ee0739-e843-41d4-b772-c0bb9c422a30" xlink:href="agio-20200930.xsd#agio_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractWithCustomerAssetAndLiabilityLineItems_4a4e6d75-c26c-48bb-ab1c-ef3f2fd8c5f2" xlink:to="loc_agio_ChangeInContractWithCustomerLiabilityRollForward_d8ee0739-e843-41d4-b772-c0bb9c422a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_ac8ba642-bc6f-4e3f-a899-97166a2da4e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerLiabilityRollForward_d8ee0739-e843-41d4-b772-c0bb9c422a30" xlink:to="loc_us-gaap_ContractWithCustomerLiability_ac8ba642-bc6f-4e3f-a899-97166a2da4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7a79341b-4593-4809-9d60-8ed76cb88b92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerLiabilityRollForward_d8ee0739-e843-41d4-b772-c0bb9c422a30" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7a79341b-4593-4809-9d60-8ed76cb88b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_d6f14efe-8066-44a1-9dfe-fdfb9cbe0e73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerLiabilityRollForward_d8ee0739-e843-41d4-b772-c0bb9c422a30" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_d6f14efe-8066-44a1-9dfe-fdfb9cbe0e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_6e7f56c4-1de7-484a-bebb-4730bd95ff43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerLiabilityRollForward_d8ee0739-e843-41d4-b772-c0bb9c422a30" xlink:to="loc_us-gaap_ContractWithCustomerLiability_6e7f56c4-1de7-484a-bebb-4730bd95ff43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_969e672d-7fcf-4834-a1ff-ab619211daa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_0df6f69d-9a04-4dcb-9df0-c377db25261b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_969e672d-7fcf-4834-a1ff-ab619211daa2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_0df6f69d-9a04-4dcb-9df0-c377db25261b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_d843cf66-2418-492a-ada3-585d90091596" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_969e672d-7fcf-4834-a1ff-ab619211daa2" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_d843cf66-2418-492a-ada3-585d90091596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_76e388ac-b23b-4e14-a929-7069bf2905c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d0a411f-8904-4677-88ec-18657c18682e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_76e388ac-b23b-4e14-a929-7069bf2905c9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d0a411f-8904-4677-88ec-18657c18682e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_32333bf9-d177-43d2-8b0c-2286928088f8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d0a411f-8904-4677-88ec-18657c18682e" xlink:to="loc_srt_ProductOrServiceAxis_32333bf9-d177-43d2-8b0c-2286928088f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3cee723a-45bc-4989-9cb1-d1490428484d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_32333bf9-d177-43d2-8b0c-2286928088f8" xlink:to="loc_srt_ProductsAndServicesDomain_3cee723a-45bc-4989-9cb1-d1490428484d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_bf77ec14-53e1-4402-8abc-32fc6e1bc38b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3cee723a-45bc-4989-9cb1-d1490428484d" xlink:to="loc_us-gaap_RoyaltyMember_bf77ec14-53e1-4402-8abc-32fc6e1bc38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueRelatedPartyMember_712f0544-30e6-40b1-a7a9-bc2f74e2522e" xlink:href="agio-20200930.xsd#agio_CollaborationRevenueRelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3cee723a-45bc-4989-9cb1-d1490428484d" xlink:to="loc_agio_CollaborationRevenueRelatedPartyMember_712f0544-30e6-40b1-a7a9-bc2f74e2522e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_03cf7825-94eb-4dbe-a066-75dd55c85e17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d0a411f-8904-4677-88ec-18657c18682e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_03cf7825-94eb-4dbe-a066-75dd55c85e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6155707-1917-4576-900b-e532de75b412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_03cf7825-94eb-4dbe-a066-75dd55c85e17" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6155707-1917-4576-900b-e532de75b412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_Agreement2010Member_d651d716-fb74-4416-9dd4-daf4722f0783" xlink:href="agio-20200930.xsd#agio_Agreement2010Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6155707-1917-4576-900b-e532de75b412" xlink:to="loc_agio_Agreement2010Member_d651d716-fb74-4416-9dd4-daf4722f0783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd933017-7049-4772-993a-20a6c9175ca8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5d0a411f-8904-4677-88ec-18657c18682e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd933017-7049-4772-993a-20a6c9175ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_d45355f3-9f42-4639-aaae-c737d24c6e6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd933017-7049-4772-993a-20a6c9175ca8" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_d45355f3-9f42-4639-aaae-c737d24c6e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold_1c44d243-599f-44cb-9cbf-12cfc8c0805a" xlink:href="agio-20200930.xsd#agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd933017-7049-4772-993a-20a6c9175ca8" xlink:to="loc_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold_1c44d243-599f-44cb-9cbf-12cfc8c0805a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized_0197d6d7-d342-4b77-bece-1691d67ba258" xlink:href="agio-20200930.xsd#agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd933017-7049-4772-993a-20a6c9175ca8" xlink:to="loc_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized_0197d6d7-d342-4b77-bece-1691d67ba258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication_be5a0e82-6bd8-4809-b475-43be02a63d50" xlink:href="agio-20200930.xsd#agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fd933017-7049-4772-993a-20a6c9175ca8" xlink:to="loc_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication_be5a0e82-6bd8-4809-b475-43be02a63d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_037fcf73-8d30-45e8-b4d4-0b859aab5db1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e59c3df8-538c-4120-be09-06e7f1fd4565" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_037fcf73-8d30-45e8-b4d4-0b859aab5db1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e59c3df8-538c-4120-be09-06e7f1fd4565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_083cc7b6-0d9b-4bdd-9bc2-556c839ed683" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e59c3df8-538c-4120-be09-06e7f1fd4565" xlink:to="loc_srt_CounterpartyNameAxis_083cc7b6-0d9b-4bdd-9bc2-556c839ed683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f849208-8b18-4309-ae81-056fcca79e34" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_083cc7b6-0d9b-4bdd-9bc2-556c839ed683" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f849208-8b18-4309-ae81-056fcca79e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CStonePharmaceuticalsMember_21a93620-8356-4cdb-8a42-ac7f234c48d8" xlink:href="agio-20200930.xsd#agio_CStonePharmaceuticalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f849208-8b18-4309-ae81-056fcca79e34" xlink:to="loc_agio_CStonePharmaceuticalsMember_21a93620-8356-4cdb-8a42-ac7f234c48d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a7c43a45-bdd3-494f-8824-6bb74bc01b95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e59c3df8-538c-4120-be09-06e7f1fd4565" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a7c43a45-bdd3-494f-8824-6bb74bc01b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2b6debf-044d-4e49-b4ac-a2718cfc9dea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a7c43a45-bdd3-494f-8824-6bb74bc01b95" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2b6debf-044d-4e49-b4ac-a2718cfc9dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CStoneAgreementMember_bca269f5-577f-4eee-be82-d021df25e58b" xlink:href="agio-20200930.xsd#agio_CStoneAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2b6debf-044d-4e49-b4ac-a2718cfc9dea" xlink:to="loc_agio_CStoneAgreementMember_bca269f5-577f-4eee-be82-d021df25e58b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a78be859-8cde-4535-a4ca-d4e23c155c37" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e59c3df8-538c-4120-be09-06e7f1fd4565" xlink:to="loc_srt_ProductOrServiceAxis_a78be859-8cde-4535-a4ca-d4e23c155c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8150a2ad-47a5-47ec-a766-e7579ea147fe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a78be859-8cde-4535-a4ca-d4e23c155c37" xlink:to="loc_srt_ProductsAndServicesDomain_8150a2ad-47a5-47ec-a766-e7579ea147fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueRelatedPartyMember_1440da1f-237c-46df-bf70-93b03d0df861" xlink:href="agio-20200930.xsd#agio_CollaborationRevenueRelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8150a2ad-47a5-47ec-a766-e7579ea147fe" xlink:to="loc_agio_CollaborationRevenueRelatedPartyMember_1440da1f-237c-46df-bf70-93b03d0df861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_0c5a07ad-c2bb-473a-a5c5-e815367bd10d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8150a2ad-47a5-47ec-a766-e7579ea147fe" xlink:to="loc_us-gaap_RoyaltyMember_0c5a07ad-c2bb-473a-a5c5-e815367bd10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ffec818e-6b1b-45b8-b100-0cf63cffa607" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e59c3df8-538c-4120-be09-06e7f1fd4565" xlink:to="loc_srt_RangeAxis_ffec818e-6b1b-45b8-b100-0cf63cffa607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_24bacda0-09b2-4483-91d7-3b8a7ceb6fd2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ffec818e-6b1b-45b8-b100-0cf63cffa607" xlink:to="loc_srt_RangeMember_24bacda0-09b2-4483-91d7-3b8a7ceb6fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_427a808d-e00b-4364-b1fe-c91de129ea4b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_24bacda0-09b2-4483-91d7-3b8a7ceb6fd2" xlink:to="loc_srt_MinimumMember_427a808d-e00b-4364-b1fe-c91de129ea4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a6be8ccd-3a84-406f-bf19-902066d1111e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_24bacda0-09b2-4483-91d7-3b8a7ceb6fd2" xlink:to="loc_srt_MaximumMember_a6be8ccd-3a84-406f-bf19-902066d1111e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fe1baa9f-5f01-402d-a4d1-b65d66c90a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e59c3df8-538c-4120-be09-06e7f1fd4565" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fe1baa9f-5f01-402d-a4d1-b65d66c90a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts_771050fb-fa08-4c0d-b2a0-5a880ed03f73" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fe1baa9f-5f01-402d-a4d1-b65d66c90a8d" xlink:to="loc_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts_771050fb-fa08-4c0d-b2a0-5a880ed03f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable_5a94b2c5-26d8-40b4-b39b-dcfec8557812" xlink:href="agio-20200930.xsd#agio_ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fe1baa9f-5f01-402d-a4d1-b65d66c90a8d" xlink:to="loc_agio_ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable_5a94b2c5-26d8-40b4-b39b-dcfec8557812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RoyaltyPercentageRemitted_3321d7b1-ddd0-4466-b8ff-b11b0a7a2f82" xlink:href="agio-20200930.xsd#agio_RoyaltyPercentageRemitted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fe1baa9f-5f01-402d-a4d1-b65d66c90a8d" xlink:to="loc_agio_RoyaltyPercentageRemitted_3321d7b1-ddd0-4466-b8ff-b11b0a7a2f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_9aa2ddd7-0366-4f1b-b9af-0163caf8e98b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fe1baa9f-5f01-402d-a4d1-b65d66c90a8d" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_9aa2ddd7-0366-4f1b-b9af-0163caf8e98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_db31546e-99e6-4f15-8f4a-0f405b7ca2a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fe1baa9f-5f01-402d-a4d1-b65d66c90a8d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_db31546e-99e6-4f15-8f4a-0f405b7ca2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized_b1dd56f3-8779-41e7-b3e3-2883a7c9df24" xlink:href="agio-20200930.xsd#agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_fe1baa9f-5f01-402d-a4d1-b65d66c90a8d" xlink:to="loc_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized_b1dd56f3-8779-41e7-b3e3-2883a7c9df24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable_f9df8979-3850-4df7-abca-a08f22e9e7a6" xlink:href="agio-20200930.xsd#agio_ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_bb6899a8-6a9f-442a-aaca-f14f6767150d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4f3ea1f2-3e94-41c5-8bdd-31cb48ee8a5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_bb6899a8-6a9f-442a-aaca-f14f6767150d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4f3ea1f2-3e94-41c5-8bdd-31cb48ee8a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fc6e3073-5cf1-4ad1-8245-ab5ad3b10bfd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4f3ea1f2-3e94-41c5-8bdd-31cb48ee8a5f" xlink:to="loc_srt_ProductOrServiceAxis_fc6e3073-5cf1-4ad1-8245-ab5ad3b10bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ab1efce9-15bf-47cd-a7b4-db0ab623f42b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fc6e3073-5cf1-4ad1-8245-ab5ad3b10bfd" xlink:to="loc_srt_ProductsAndServicesDomain_ab1efce9-15bf-47cd-a7b4-db0ab623f42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_c65485c3-8dab-46ac-a63f-5a1388047e80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ab1efce9-15bf-47cd-a7b4-db0ab623f42b" xlink:to="loc_us-gaap_LicenseAndServiceMember_c65485c3-8dab-46ac-a63f-5a1388047e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceOtherMember_955796bd-9005-441a-b215-e14100e5d838" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ab1efce9-15bf-47cd-a7b4-db0ab623f42b" xlink:to="loc_us-gaap_ServiceOtherMember_955796bd-9005-441a-b215-e14100e5d838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueOtherMember_58054969-57fa-4790-a44f-d88adadd2995" xlink:href="agio-20200930.xsd#agio_CollaborationRevenueOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ab1efce9-15bf-47cd-a7b4-db0ab623f42b" xlink:to="loc_agio_CollaborationRevenueOtherMember_58054969-57fa-4790-a44f-d88adadd2995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_eb17614b-ea35-47a0-ae95-86d61d10a7f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4f3ea1f2-3e94-41c5-8bdd-31cb48ee8a5f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_eb17614b-ea35-47a0-ae95-86d61d10a7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f5c15c41-e35b-40a9-bc27-8100ad30212a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_eb17614b-ea35-47a0-ae95-86d61d10a7f8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f5c15c41-e35b-40a9-bc27-8100ad30212a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CStoneAgreementMember_00ab76ea-4e28-428c-a17f-1377e3cc25a7" xlink:href="agio-20200930.xsd#agio_CStoneAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f5c15c41-e35b-40a9-bc27-8100ad30212a" xlink:to="loc_agio_CStoneAgreementMember_00ab76ea-4e28-428c-a17f-1377e3cc25a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_114ef618-18a8-4cf1-9964-4545b501eac2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4f3ea1f2-3e94-41c5-8bdd-31cb48ee8a5f" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_114ef618-18a8-4cf1-9964-4545b501eac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1aa82d93-70b5-4e24-bce1-991b0e800b2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_114ef618-18a8-4cf1-9964-4545b501eac2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1aa82d93-70b5-4e24-bce1-991b0e800b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_3d5b45e6-20b4-4495-8725-85be00207e43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee241c4c-282c-48bb-b3c5-c28cc783d27e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_3d5b45e6-20b4-4495-8725-85be00207e43" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee241c4c-282c-48bb-b3c5-c28cc783d27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_23bd3307-52bc-41ca-bc60-7d9769b24e6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee241c4c-282c-48bb-b3c5-c28cc783d27e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_23bd3307-52bc-41ca-bc60-7d9769b24e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7651be63-e814-4179-a8d7-a924490dd74d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_23bd3307-52bc-41ca-bc60-7d9769b24e6e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7651be63-e814-4179-a8d7-a924490dd74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember_ca437dcd-37bf-400b-a7f2-bfed38c3022b" xlink:href="agio-20200930.xsd#agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7651be63-e814-4179-a8d7-a924490dd74d" xlink:to="loc_agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember_ca437dcd-37bf-400b-a7f2-bfed38c3022b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6fb200b0-369d-4878-873e-a7310e235983" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee241c4c-282c-48bb-b3c5-c28cc783d27e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6fb200b0-369d-4878-873e-a7310e235983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20b78472-b962-44e0-8f01-394751cf1145" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6fb200b0-369d-4878-873e-a7310e235983" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20b78472-b962-44e0-8f01-394751cf1145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CStoneAgreementMember_f5add6fd-7be7-49b5-963e-7f99e585a4a8" xlink:href="agio-20200930.xsd#agio_CStoneAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_20b78472-b962-44e0-8f01-394751cf1145" xlink:to="loc_agio_CStoneAgreementMember_f5add6fd-7be7-49b5-963e-7f99e585a4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8042d44-efe1-4375-b9d7-bcd1ceabd4e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee241c4c-282c-48bb-b3c5-c28cc783d27e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8042d44-efe1-4375-b9d7-bcd1ceabd4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ChangeInContractWithCustomerAssetRollForward_af2c4b49-3448-48b2-a21d-ff884c8b409b" xlink:href="agio-20200930.xsd#agio_ChangeInContractWithCustomerAssetRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a8042d44-efe1-4375-b9d7-bcd1ceabd4e0" xlink:to="loc_agio_ChangeInContractWithCustomerAssetRollForward_af2c4b49-3448-48b2-a21d-ff884c8b409b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_f3cf5955-ea2a-4220-8378-007db07e8d05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_af2c4b49-3448-48b2-a21d-ff884c8b409b" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_f3cf5955-ea2a-4220-8378-007db07e8d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetRevenueRecognized_d2e2181c-6c69-415d-9b24-3c6debe2b037" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerAssetRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_af2c4b49-3448-48b2-a21d-ff884c8b409b" xlink:to="loc_agio_ContractWithCustomerAssetRevenueRecognized_d2e2181c-6c69-415d-9b24-3c6debe2b037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_02ba129c-622d-4a64-acbc-193d4a3e9305" xlink:href="agio-20200930.xsd#agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_af2c4b49-3448-48b2-a21d-ff884c8b409b" xlink:to="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_02ba129c-622d-4a64-acbc-193d4a3e9305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_0878a565-dc25-4257-a8f4-e823f1f6a0c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ChangeInContractWithCustomerAssetRollForward_af2c4b49-3448-48b2-a21d-ff884c8b409b" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_0878a565-dc25-4257-a8f4-e823f1f6a0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/SaleofFutureRevenue" xlink:type="simple" xlink:href="agio-20200930.xsd#SaleofFutureRevenue"/>
  <link:presentationLink xlink:role="http://agios.com/role/SaleofFutureRevenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueRoyaltyObligationAbstract_be6e9d00-b8d6-4ecc-a790-b229ae6962b1" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueRoyaltyObligationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueRoyaltyObligationTextBlock_f2e33726-4191-49a7-994b-57048de93c70" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueRoyaltyObligationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_SaleOfFutureRevenueRoyaltyObligationAbstract_be6e9d00-b8d6-4ecc-a790-b229ae6962b1" xlink:to="loc_agio_SaleOfFutureRevenueRoyaltyObligationTextBlock_f2e33726-4191-49a7-994b-57048de93c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/SaleofFutureRevenueTables" xlink:type="simple" xlink:href="agio-20200930.xsd#SaleofFutureRevenueTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/SaleofFutureRevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueRoyaltyObligationAbstract_1d9b384c-6455-4cbe-9b4d-8c109cb231b4" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueRoyaltyObligationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueRoyaltyObligationTableTextBlock_91846f02-2d40-4941-bcd5-76b7109815e5" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueRoyaltyObligationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_SaleOfFutureRevenueRoyaltyObligationAbstract_1d9b384c-6455-4cbe-9b4d-8c109cb231b4" xlink:to="loc_agio_SaleOfFutureRevenueRoyaltyObligationTableTextBlock_91846f02-2d40-4941-bcd5-76b7109815e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/SaleofFutureRevenueAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#SaleofFutureRevenueAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/SaleofFutureRevenueAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueRoyaltyObligationAbstract_b706f524-5c31-419f-8cfa-c882f0c0d3be" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueRoyaltyObligationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc7fb175-97e2-4407-acff-99030985dc83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_SaleOfFutureRevenueRoyaltyObligationAbstract_b706f524-5c31-419f-8cfa-c882f0c0d3be" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc7fb175-97e2-4407-acff-99030985dc83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_603a760f-01c5-415b-bc2b-7626b78b3cfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc7fb175-97e2-4407-acff-99030985dc83" xlink:to="loc_us-gaap_TypeOfArrangementAxis_603a760f-01c5-415b-bc2b-7626b78b3cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bfac326e-11f2-4085-b2c0-a78c45fee257" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_603a760f-01c5-415b-bc2b-7626b78b3cfb" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bfac326e-11f2-4085-b2c0-a78c45fee257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_Agreement2010Member_4bc4641d-d083-44d6-b8cd-d2d77f9a98df" xlink:href="agio-20200930.xsd#agio_Agreement2010Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bfac326e-11f2-4085-b2c0-a78c45fee257" xlink:to="loc_agio_Agreement2010Member_4bc4641d-d083-44d6-b8cd-d2d77f9a98df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6982aa4f-3ad9-4bf3-ac26-8222b128e020" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc7fb175-97e2-4407-acff-99030985dc83" xlink:to="loc_srt_CounterpartyNameAxis_6982aa4f-3ad9-4bf3-ac26-8222b128e020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d40e6437-54b0-4958-87cd-144b83eba311" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_6982aa4f-3ad9-4bf3-ac26-8222b128e020" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d40e6437-54b0-4958-87cd-144b83eba311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CelgeneMember_285030d2-fc47-4486-8b75-ff763d1e0322" xlink:href="agio-20200930.xsd#agio_CelgeneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d40e6437-54b0-4958-87cd-144b83eba311" xlink:to="loc_agio_CelgeneMember_285030d2-fc47-4486-8b75-ff763d1e0322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RPIMember_607c0ab5-7866-4ec0-8180-391b168563c2" xlink:href="agio-20200930.xsd#agio_RPIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d40e6437-54b0-4958-87cd-144b83eba311" xlink:to="loc_agio_RPIMember_607c0ab5-7866-4ec0-8180-391b168563c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d52da77e-8d8a-401d-bf57-f0b046971581" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_dc7fb175-97e2-4407-acff-99030985dc83" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d52da77e-8d8a-401d-bf57-f0b046971581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold_49448299-5745-4fcf-b695-ca1710bc2a79" xlink:href="agio-20200930.xsd#agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d52da77e-8d8a-401d-bf57-f0b046971581" xlink:to="loc_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold_49448299-5745-4fcf-b695-ca1710bc2a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold_867bc596-b04c-4673-ae49-258051f935ae" xlink:href="agio-20200930.xsd#agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d52da77e-8d8a-401d-bf57-f0b046971581" xlink:to="loc_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold_867bc596-b04c-4673-ae49-258051f935ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate_1560f283-60dc-4594-9448-f28aab092d34" xlink:href="agio-20200930.xsd#agio_PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d52da77e-8d8a-401d-bf57-f0b046971581" xlink:to="loc_agio_PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate_1560f283-60dc-4594-9448-f28aab092d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue_4f04bb6d-b254-4c23-b073-96929a2c042a" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d52da77e-8d8a-401d-bf57-f0b046971581" xlink:to="loc_agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue_4f04bb6d-b254-4c23-b073-96929a2c042a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/SaleofFutureRevenueScheduleofRoyaltyObligationDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#SaleofFutureRevenueScheduleofRoyaltyObligationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/SaleofFutureRevenueScheduleofRoyaltyObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueRoyaltyObligationAbstract_05dc771f-270d-43c1-8606-c93a9425d112" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueRoyaltyObligationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_078f7a5d-58f5-4801-b917-30aac1257dec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_SaleOfFutureRevenueRoyaltyObligationAbstract_05dc771f-270d-43c1-8606-c93a9425d112" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_078f7a5d-58f5-4801-b917-30aac1257dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b107d509-a1c8-4bf1-b3db-e892477cb61c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_078f7a5d-58f5-4801-b917-30aac1257dec" xlink:to="loc_srt_CounterpartyNameAxis_b107d509-a1c8-4bf1-b3db-e892477cb61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f90a776-7f5a-4b89-9ede-71b82f7703d0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b107d509-a1c8-4bf1-b3db-e892477cb61c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f90a776-7f5a-4b89-9ede-71b82f7703d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RPIMember_beb3c351-e692-4759-9626-a8d868409b77" xlink:href="agio-20200930.xsd#agio_RPIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f90a776-7f5a-4b89-9ede-71b82f7703d0" xlink:to="loc_agio_RPIMember_beb3c351-e692-4759-9626-a8d868409b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c4fb2b36-0a30-4945-a103-eb34d5a370b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_078f7a5d-58f5-4801-b917-30aac1257dec" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c4fb2b36-0a30-4945-a103-eb34d5a370b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward_ee6a3c55-29fd-461c-97f3-1c3d1f033a87" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c4fb2b36-0a30-4945-a103-eb34d5a370b7" xlink:to="loc_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward_ee6a3c55-29fd-461c-97f3-1c3d1f033a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueLiabilityNoncurrent_d92178f5-8707-407a-ab0f-04bf5a1a1a64" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward_ee6a3c55-29fd-461c-97f3-1c3d1f033a87" xlink:to="loc_agio_SaleOfFutureRevenueLiabilityNoncurrent_d92178f5-8707-407a-ab0f-04bf5a1a1a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueIssuanceCosts_bce2259b-2b76-4b27-8528-885ff9d6df2b" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward_ee6a3c55-29fd-461c-97f3-1c3d1f033a87" xlink:to="loc_agio_SaleOfFutureRevenueIssuanceCosts_bce2259b-2b76-4b27-8528-885ff9d6df2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue_6e230432-4382-43f5-b209-729ad3a78bc3" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward_ee6a3c55-29fd-461c-97f3-1c3d1f033a87" xlink:to="loc_agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue_6e230432-4382-43f5-b209-729ad3a78bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueInterestExpense_0944a7a2-66ba-40a3-bfb3-dec6d718a0bc" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueInterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward_ee6a3c55-29fd-461c-97f3-1c3d1f033a87" xlink:to="loc_agio_SaleOfFutureRevenueInterestExpense_0944a7a2-66ba-40a3-bfb3-dec6d718a0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueAmortizationOfIssuanceCosts_07ade6ed-9afd-4477-86e5-db0c82e4e7f4" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueAmortizationOfIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward_ee6a3c55-29fd-461c-97f3-1c3d1f033a87" xlink:to="loc_agio_SaleOfFutureRevenueAmortizationOfIssuanceCosts_07ade6ed-9afd-4477-86e5-db0c82e4e7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfFutureRevenueLiabilityNoncurrent_6da32044-cdc4-48ed-8b89-31f4f69fadd6" xlink:href="agio-20200930.xsd#agio_SaleOfFutureRevenueLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward_ee6a3c55-29fd-461c-97f3-1c3d1f033a87" xlink:to="loc_agio_SaleOfFutureRevenueLiabilityNoncurrent_6da32044-cdc4-48ed-8b89-31f4f69fadd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPayments" xlink:type="simple" xlink:href="agio-20200930.xsd#ShareBasedPayments"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_941905ff-af17-4b37-824c-6ae532360a49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_cc4e10a3-caef-485d-9e73-5bfd90df0fad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_941905ff-af17-4b37-824c-6ae532360a49" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_cc4e10a3-caef-485d-9e73-5bfd90df0fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="agio-20200930.xsd#ShareBasedPaymentsTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_987470c6-96ec-4d0c-9ba9-8a4f1133ba6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5db07696-b809-425e-8fd0-e1b73fb08a31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_987470c6-96ec-4d0c-9ba9-8a4f1133ba6d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5db07696-b809-425e-8fd0-e1b73fb08a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_d4e3db32-ed4f-474d-bb2d-de82d8c25aeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_987470c6-96ec-4d0c-9ba9-8a4f1133ba6d" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_d4e3db32-ed4f-474d-bb2d-de82d8c25aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_cdf918d7-968d-4b0d-a279-226f1a37f574" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_987470c6-96ec-4d0c-9ba9-8a4f1133ba6d" xlink:to="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_cdf918d7-968d-4b0d-a279-226f1a37f574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock_256d1a8f-c294-4c81-a5f7-79c427cb28f7" xlink:href="agio-20200930.xsd#agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_987470c6-96ec-4d0c-9ba9-8a4f1133ba6d" xlink:to="loc_agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock_256d1a8f-c294-4c81-a5f7-79c427cb28f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_b0ef7143-22ed-41cc-a157-796e47cc9881" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_987470c6-96ec-4d0c-9ba9-8a4f1133ba6d" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_b0ef7143-22ed-41cc-a157-796e47cc9881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a760285e-9a14-4ecc-b747-f180fd960346" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_987470c6-96ec-4d0c-9ba9-8a4f1133ba6d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a760285e-9a14-4ecc-b747-f180fd960346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ShareBasedPaymentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bf13e4b-e514-4bbf-a308-c11129bc6519" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04e063f5-d834-449e-8214-22e13ce7ad39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bf13e4b-e514-4bbf-a308-c11129bc6519" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04e063f5-d834-449e-8214-22e13ce7ad39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b6046a72-7d78-4b62-a4c2-b4f094e60e72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04e063f5-d834-449e-8214-22e13ce7ad39" xlink:to="loc_us-gaap_PlanNameAxis_b6046a72-7d78-4b62-a4c2-b4f094e60e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1b461d2c-5559-4a78-a282-4028010fbe53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_b6046a72-7d78-4b62-a4c2-b4f094e60e72" xlink:to="loc_us-gaap_PlanNameDomain_1b461d2c-5559-4a78-a282-4028010fbe53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember_82263230-0f08-4998-aafa-e0b46a2546e8" xlink:href="agio-20200930.xsd#agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1b461d2c-5559-4a78-a282-4028010fbe53" xlink:to="loc_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember_82263230-0f08-4998-aafa-e0b46a2546e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TwoThousandAndThirteenStockIncentivePlanMember_846ebebe-ecc2-491d-85c2-1d7d35354d8d" xlink:href="agio-20200930.xsd#agio_TwoThousandAndThirteenStockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1b461d2c-5559-4a78-a282-4028010fbe53" xlink:to="loc_agio_TwoThousandAndThirteenStockIncentivePlanMember_846ebebe-ecc2-491d-85c2-1d7d35354d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeeStockPurchasePlan2013Member_34c0b01e-afdc-4423-a83b-14f7a2d06b45" xlink:href="agio-20200930.xsd#agio_EmployeeStockPurchasePlan2013Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1b461d2c-5559-4a78-a282-4028010fbe53" xlink:to="loc_agio_EmployeeStockPurchasePlan2013Member_34c0b01e-afdc-4423-a83b-14f7a2d06b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_75f509d7-4b0e-4453-9253-a3dc5ac3a9e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04e063f5-d834-449e-8214-22e13ce7ad39" xlink:to="loc_us-gaap_AwardTypeAxis_75f509d7-4b0e-4453-9253-a3dc5ac3a9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_55f6a853-d2da-4667-a68a-723b0873a06b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_75f509d7-4b0e-4453-9253-a3dc5ac3a9e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_55f6a853-d2da-4667-a68a-723b0873a06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b855b119-356b-4562-b20c-7bb92bc39124" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_55f6a853-d2da-4667-a68a-723b0873a06b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b855b119-356b-4562-b20c-7bb92bc39124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember_c733d106-61f0-43ef-91e6-b2e8e3b1ba41" xlink:href="agio-20200930.xsd#agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_55f6a853-d2da-4667-a68a-723b0873a06b" xlink:to="loc_agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember_c733d106-61f0-43ef-91e6-b2e8e3b1ba41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MarketBasedStockUnitsMember_45edfe7d-37a3-4b6a-b94f-1ee6480e05ad" xlink:href="agio-20200930.xsd#agio_MarketBasedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_55f6a853-d2da-4667-a68a-723b0873a06b" xlink:to="loc_agio_MarketBasedStockUnitsMember_45edfe7d-37a3-4b6a-b94f-1ee6480e05ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d289c9c-c795-4802-a436-8496cc6bfc1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04e063f5-d834-449e-8214-22e13ce7ad39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d289c9c-c795-4802-a436-8496cc6bfc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e52e45b3-e4b3-4040-bf7d-eca7997c6a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d289c9c-c795-4802-a436-8496cc6bfc1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e52e45b3-e4b3-4040-bf7d-eca7997c6a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5b5d1c12-53c2-4d09-a09e-0433df61763e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d289c9c-c795-4802-a436-8496cc6bfc1e" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5b5d1c12-53c2-4d09-a09e-0433df61763e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_88e28459-a825-4428-a88b-c8c0c0803a52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d289c9c-c795-4802-a436-8496cc6bfc1e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_88e28459-a825-4428-a88b-c8c0c0803a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9b3e9294-12d4-4fcf-8017-1927cc589300" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d289c9c-c795-4802-a436-8496cc6bfc1e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9b3e9294-12d4-4fcf-8017-1927cc589300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7ac41763-eaa9-4ac2-910c-524d2bbe7681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d289c9c-c795-4802-a436-8496cc6bfc1e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7ac41763-eaa9-4ac2-910c-524d2bbe7681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_86417405-7f4f-4d13-8d9f-324bbf53925e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d289c9c-c795-4802-a436-8496cc6bfc1e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_86417405-7f4f-4d13-8d9f-324bbf53925e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_b2eb20ef-fd5b-4a97-b3cf-773ec93d8111" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d289c9c-c795-4802-a436-8496cc6bfc1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_b2eb20ef-fd5b-4a97-b3cf-773ec93d8111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ShareBasedPaymentsSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a4f27184-0c4d-400e-be6e-26d979789859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a0dd20b3-8fec-490e-b94a-ca31ccc7d7a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a4f27184-0c4d-400e-be6e-26d979789859" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a0dd20b3-8fec-490e-b94a-ca31ccc7d7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_870dc282-bb9e-4924-b356-9ad7b6710777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a0dd20b3-8fec-490e-b94a-ca31ccc7d7a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_870dc282-bb9e-4924-b356-9ad7b6710777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2db6e9f6-2692-4e3c-a01a-c8615bbb2178" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a0dd20b3-8fec-490e-b94a-ca31ccc7d7a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2db6e9f6-2692-4e3c-a01a-c8615bbb2178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_28962365-7617-4ce4-bb8e-d71e65dbb066" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a0dd20b3-8fec-490e-b94a-ca31ccc7d7a8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_28962365-7617-4ce4-bb8e-d71e65dbb066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ce959889-53da-4729-ba87-f11e731362d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a0dd20b3-8fec-490e-b94a-ca31ccc7d7a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ce959889-53da-4729-ba87-f11e731362d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_54bdea8e-8485-4293-8e1b-84d391ff7a9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a0dd20b3-8fec-490e-b94a-ca31ccc7d7a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_54bdea8e-8485-4293-8e1b-84d391ff7a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d7cb25cf-18d0-4d6a-b823-1882437cc8b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a4f27184-0c4d-400e-be6e-26d979789859" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d7cb25cf-18d0-4d6a-b823-1882437cc8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_ffb73f11-f7e8-4f4c-9c73-0f6a927f25fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a4f27184-0c4d-400e-be6e-26d979789859" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_ffb73f11-f7e8-4f4c-9c73-0f6a927f25fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ce02779-f3be-4f66-a472-43a87efceeed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a4f27184-0c4d-400e-be6e-26d979789859" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ce02779-f3be-4f66-a472-43a87efceeed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d68938f3-fc19-49dd-bec5-8ebb34d8fd70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ce02779-f3be-4f66-a472-43a87efceeed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d68938f3-fc19-49dd-bec5-8ebb34d8fd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1bc9de06-b31b-4d50-ad6b-254d1155df75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ce02779-f3be-4f66-a472-43a87efceeed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1bc9de06-b31b-4d50-ad6b-254d1155df75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6fa11eac-a81c-4b00-8ae5-68a1e1c049e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ce02779-f3be-4f66-a472-43a87efceeed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6fa11eac-a81c-4b00-8ae5-68a1e1c049e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8b8c015b-4568-44b6-bb4e-421646513e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ce02779-f3be-4f66-a472-43a87efceeed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8b8c015b-4568-44b6-bb4e-421646513e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c4724673-6c20-4bf2-9f51-be0757636c84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ce02779-f3be-4f66-a472-43a87efceeed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c4724673-6c20-4bf2-9f51-be0757636c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_97385776-04a0-4a99-ad2b-b51720cdaf71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a4f27184-0c4d-400e-be6e-26d979789859" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_97385776-04a0-4a99-ad2b-b51720cdaf71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0212e112-0afc-4290-b84c-f59c0f7e52e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a4f27184-0c4d-400e-be6e-26d979789859" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0212e112-0afc-4290-b84c-f59c0f7e52e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6479bb51-6da5-4f00-b85b-a78c1367e014" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_032c505f-19d7-439d-944e-2fff9959ec6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6479bb51-6da5-4f00-b85b-a78c1367e014" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_032c505f-19d7-439d-944e-2fff9959ec6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e677fcf3-380e-412b-8022-8149f4b5eac1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_032c505f-19d7-439d-944e-2fff9959ec6d" xlink:to="loc_us-gaap_AwardTypeAxis_e677fcf3-380e-412b-8022-8149f4b5eac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f980aff-ecdd-416c-be88-af27a51f9e50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e677fcf3-380e-412b-8022-8149f4b5eac1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f980aff-ecdd-416c-be88-af27a51f9e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ae61dc0d-6c9f-484b-81d8-41d7163e7f93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5f980aff-ecdd-416c-be88-af27a51f9e50" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ae61dc0d-6c9f-484b-81d8-41d7163e7f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35d18417-4c62-43e8-8826-a07fd156a8f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_032c505f-19d7-439d-944e-2fff9959ec6d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35d18417-4c62-43e8-8826-a07fd156a8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e2849af9-c068-425a-83fc-90f3572853ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35d18417-4c62-43e8-8826-a07fd156a8f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e2849af9-c068-425a-83fc-90f3572853ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b3023019-a778-4c9c-b556-63446ba59f90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e2849af9-c068-425a-83fc-90f3572853ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b3023019-a778-4c9c-b556-63446ba59f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_89947f41-0087-4efc-9551-d8e0693866db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e2849af9-c068-425a-83fc-90f3572853ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_89947f41-0087-4efc-9551-d8e0693866db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_db3b2d74-0811-4235-a2db-8928edb7848f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e2849af9-c068-425a-83fc-90f3572853ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_db3b2d74-0811-4235-a2db-8928edb7848f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bee1a749-0980-42fa-bd7e-0d8ba9c1b741" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e2849af9-c068-425a-83fc-90f3572853ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_bee1a749-0980-42fa-bd7e-0d8ba9c1b741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_86a6bca9-c142-456c-8614-cdf48721a307" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e2849af9-c068-425a-83fc-90f3572853ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_86a6bca9-c142-456c-8614-cdf48721a307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0afbcba4-e517-4d0a-b88d-5335e081793d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_35d18417-4c62-43e8-8826-a07fd156a8f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0afbcba4-e517-4d0a-b88d-5335e081793d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_35867e4d-7fa6-499b-807f-357ec378da76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0afbcba4-e517-4d0a-b88d-5335e081793d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_35867e4d-7fa6-499b-807f-357ec378da76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_99d95adc-6000-4b94-9010-b0aa3fdafd62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0afbcba4-e517-4d0a-b88d-5335e081793d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_99d95adc-6000-4b94-9010-b0aa3fdafd62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_07849cdf-c1fb-4ff3-9be5-cc0c69cd34be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0afbcba4-e517-4d0a-b88d-5335e081793d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_07849cdf-c1fb-4ff3-9be5-cc0c69cd34be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7d160825-38e4-4947-8593-f59f1f6cef75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0afbcba4-e517-4d0a-b88d-5335e081793d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7d160825-38e4-4947-8593-f59f1f6cef75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2ff14ea2-4f51-466c-b0ef-0c6c7cff8972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0afbcba4-e517-4d0a-b88d-5335e081793d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2ff14ea2-4f51-466c-b0ef-0c6c7cff8972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ef5e560-f8d3-4328-ad32-b1370fde0e12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0ae79af-fff1-4798-a87f-736fa3971088" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ef5e560-f8d3-4328-ad32-b1370fde0e12" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0ae79af-fff1-4798-a87f-736fa3971088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5a4e7ac9-d6ed-4e47-9769-36aa89c8430f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0ae79af-fff1-4798-a87f-736fa3971088" xlink:to="loc_us-gaap_AwardTypeAxis_5a4e7ac9-d6ed-4e47-9769-36aa89c8430f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_466af65d-6828-48d6-999a-9777a850aee7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5a4e7ac9-d6ed-4e47-9769-36aa89c8430f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_466af65d-6828-48d6-999a-9777a850aee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceBasedStockUnitMember_8f649bf2-c473-4107-af87-d5708385d5d2" xlink:href="agio-20200930.xsd#agio_PerformanceBasedStockUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_466af65d-6828-48d6-999a-9777a850aee7" xlink:to="loc_agio_PerformanceBasedStockUnitMember_8f649bf2-c473-4107-af87-d5708385d5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MarketBasedStockUnitsMember_6cab809b-50ed-49fb-9577-95bd5fcffe57" xlink:href="agio-20200930.xsd#agio_MarketBasedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_466af65d-6828-48d6-999a-9777a850aee7" xlink:to="loc_agio_MarketBasedStockUnitsMember_6cab809b-50ed-49fb-9577-95bd5fcffe57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_026d808b-c97c-4c9e-a01f-e2156b2e4d31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0ae79af-fff1-4798-a87f-736fa3971088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_026d808b-c97c-4c9e-a01f-e2156b2e4d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_27eaf25d-7e5e-4f55-b1d6-90591481e4db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_026d808b-c97c-4c9e-a01f-e2156b2e4d31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_27eaf25d-7e5e-4f55-b1d6-90591481e4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_041188cc-e297-4cab-950c-fcd5f3e06be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_27eaf25d-7e5e-4f55-b1d6-90591481e4db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_041188cc-e297-4cab-950c-fcd5f3e06be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3562aa16-269f-4154-b02e-bc45024db649" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_27eaf25d-7e5e-4f55-b1d6-90591481e4db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3562aa16-269f-4154-b02e-bc45024db649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_99f51166-d8ee-4498-901b-6bfe143cd146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_27eaf25d-7e5e-4f55-b1d6-90591481e4db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_99f51166-d8ee-4498-901b-6bfe143cd146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5c6c6ac4-9b59-4e42-b184-ad3bee135038" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_27eaf25d-7e5e-4f55-b1d6-90591481e4db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5c6c6ac4-9b59-4e42-b184-ad3bee135038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bb21b352-fdd5-405f-91b9-cb96295789d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_27eaf25d-7e5e-4f55-b1d6-90591481e4db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bb21b352-fdd5-405f-91b9-cb96295789d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_39511576-6566-4d4e-b423-91058403978e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_026d808b-c97c-4c9e-a01f-e2156b2e4d31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_39511576-6566-4d4e-b423-91058403978e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_73813d15-a402-42dd-8682-d05d44d03bd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_39511576-6566-4d4e-b423-91058403978e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_73813d15-a402-42dd-8682-d05d44d03bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0eae6d22-8488-4cde-b3ba-333a9e63c619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_39511576-6566-4d4e-b423-91058403978e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0eae6d22-8488-4cde-b3ba-333a9e63c619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f8eee697-068a-43c3-b636-2ed1e1432d8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_39511576-6566-4d4e-b423-91058403978e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f8eee697-068a-43c3-b636-2ed1e1432d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_122662b6-ce9b-4f2d-9d3d-c625180df2eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_39511576-6566-4d4e-b423-91058403978e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_122662b6-ce9b-4f2d-9d3d-c625180df2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_36529199-f2f3-42ed-9ef8-df86c3b3fa95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_39511576-6566-4d4e-b423-91058403978e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_36529199-f2f3-42ed-9ef8-df86c3b3fa95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_baa08ac8-92fd-4111-a6d5-5aa94348f5e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab945509-ddaa-4b12-9f16-15dcd6a3aedb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_baa08ac8-92fd-4111-a6d5-5aa94348f5e8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab945509-ddaa-4b12-9f16-15dcd6a3aedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_01558a34-249b-491d-9d4f-ba83aa2f809f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab945509-ddaa-4b12-9f16-15dcd6a3aedb" xlink:to="loc_us-gaap_AwardTypeAxis_01558a34-249b-491d-9d4f-ba83aa2f809f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_855cbb2a-c117-4a94-9af7-65ded254c859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_01558a34-249b-491d-9d4f-ba83aa2f809f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_855cbb2a-c117-4a94-9af7-65ded254c859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ec0bc5ae-d195-4f58-848a-ed66645a8821" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_855cbb2a-c117-4a94-9af7-65ded254c859" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ec0bc5ae-d195-4f58-848a-ed66645a8821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f604f740-b289-4daa-b02b-07b6a71d42c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_855cbb2a-c117-4a94-9af7-65ded254c859" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f604f740-b289-4daa-b02b-07b6a71d42c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceBasedStockUnitMember_45fa82dc-63d1-46cc-8b98-d2a97ff3f8e4" xlink:href="agio-20200930.xsd#agio_PerformanceBasedStockUnitMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_855cbb2a-c117-4a94-9af7-65ded254c859" xlink:to="loc_agio_PerformanceBasedStockUnitMember_45fa82dc-63d1-46cc-8b98-d2a97ff3f8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeeStockPurchasePlan2013Member_9cda3c80-0fa0-4308-9240-32668b971c86" xlink:href="agio-20200930.xsd#agio_EmployeeStockPurchasePlan2013Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_855cbb2a-c117-4a94-9af7-65ded254c859" xlink:to="loc_agio_EmployeeStockPurchasePlan2013Member_9cda3c80-0fa0-4308-9240-32668b971c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_OtherStockAwardsMember_6cd44765-d07c-4710-bdc0-5c2359b2b425" xlink:href="agio-20200930.xsd#agio_OtherStockAwardsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_855cbb2a-c117-4a94-9af7-65ded254c859" xlink:to="loc_agio_OtherStockAwardsMember_6cd44765-d07c-4710-bdc0-5c2359b2b425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac807bc4-c422-4ae0-bddb-037616aa4421" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ab945509-ddaa-4b12-9f16-15dcd6a3aedb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac807bc4-c422-4ae0-bddb-037616aa4421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_60193473-4bd2-4aa5-9801-cbc6198f8832" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ac807bc4-c422-4ae0-bddb-037616aa4421" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_60193473-4bd2-4aa5-9801-cbc6198f8832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0837f040-eee7-47b4-95c5-9a4655f4b9b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7bae417-28fb-44f9-b17b-0468560715a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0837f040-eee7-47b4-95c5-9a4655f4b9b4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7bae417-28fb-44f9-b17b-0468560715a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a9aaeb83-6842-4abf-a3a0-22f240d78fb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7bae417-28fb-44f9-b17b-0468560715a1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a9aaeb83-6842-4abf-a3a0-22f240d78fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d03a8fcb-17f8-4774-9ea6-e9778d9ba087" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a9aaeb83-6842-4abf-a3a0-22f240d78fb8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d03a8fcb-17f8-4774-9ea6-e9778d9ba087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_29b5aba9-5244-4dce-a350-cceca4bbd655" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d03a8fcb-17f8-4774-9ea6-e9778d9ba087" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_29b5aba9-5244-4dce-a350-cceca4bbd655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_35edfe32-9b1e-48b7-877f-03e92d736de6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d03a8fcb-17f8-4774-9ea6-e9778d9ba087" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_35edfe32-9b1e-48b7-877f-03e92d736de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f9918780-aba6-4290-8f44-befc09515968" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f7bae417-28fb-44f9-b17b-0468560715a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f9918780-aba6-4290-8f44-befc09515968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2a4388c0-4864-401c-bd52-265dc4dd2c6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f9918780-aba6-4290-8f44-befc09515968" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2a4388c0-4864-401c-bd52-265dc4dd2c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LossperShare" xlink:type="simple" xlink:href="agio-20200930.xsd#LossperShare"/>
  <link:presentationLink xlink:role="http://agios.com/role/LossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3f8624cb-7d86-4802-bf3b-0fa537cb9904" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_cf43fbd3-1f3d-4abe-8128-a5e03d5c214b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3f8624cb-7d86-4802-bf3b-0fa537cb9904" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_cf43fbd3-1f3d-4abe-8128-a5e03d5c214b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LossperShareTables" xlink:type="simple" xlink:href="agio-20200930.xsd#LossperShareTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/LossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_efa263bf-9ef1-430d-a183-15c43229bafd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_305481d3-c9f6-4a40-933a-174da84804ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_efa263bf-9ef1-430d-a183-15c43229bafd" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_305481d3-c9f6-4a40-933a-174da84804ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="agio-20200930.xsd#LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_840e01cd-307f-4c62-9c2a-907699ad34a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8f9bc8bf-6558-4f8e-bae3-62c0e350bfdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_840e01cd-307f-4c62-9c2a-907699ad34a3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8f9bc8bf-6558-4f8e-bae3-62c0e350bfdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_384f286f-fa9f-4334-9cf4-74d598395845" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8f9bc8bf-6558-4f8e-bae3-62c0e350bfdd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_384f286f-fa9f-4334-9cf4-74d598395845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b4ba68f-788e-484e-a0c8-1af21cbfbb59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_384f286f-fa9f-4334-9cf4-74d598395845" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b4ba68f-788e-484e-a0c8-1af21cbfbb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_12360eaa-8165-498e-9ed6-515207497ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b4ba68f-788e-484e-a0c8-1af21cbfbb59" xlink:to="loc_us-gaap_EmployeeStockOptionMember_12360eaa-8165-498e-9ed6-515207497ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_92fc29e6-4578-40d7-a44d-52384121b1ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b4ba68f-788e-484e-a0c8-1af21cbfbb59" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_92fc29e6-4578-40d7-a44d-52384121b1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitMember_86c2baa5-d800-4839-8175-e8df272ed67b" xlink:href="agio-20200930.xsd#agio_PerformanceStockUnitMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b4ba68f-788e-484e-a0c8-1af21cbfbb59" xlink:to="loc_agio_PerformanceStockUnitMember_86c2baa5-d800-4839-8175-e8df272ed67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeePurchasePlanMember_b7056b1d-62eb-4ce2-89b8-e97704e1dad1" xlink:href="agio-20200930.xsd#agio_EmployeePurchasePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4b4ba68f-788e-484e-a0c8-1af21cbfbb59" xlink:to="loc_agio_EmployeePurchasePlanMember_b7056b1d-62eb-4ce2-89b8-e97704e1dad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_453c1124-b0f8-43f1-be8e-a53b47db2b2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8f9bc8bf-6558-4f8e-bae3-62c0e350bfdd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_453c1124-b0f8-43f1-be8e-a53b47db2b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d1b2f3a3-4bb4-455b-8ed7-ca00d83c47be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_453c1124-b0f8-43f1-be8e-a53b47db2b2e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d1b2f3a3-4bb4-455b-8ed7-ca00d83c47be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>agio-20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:agio="http://agios.com/20200930"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="agio-20200930.xsd" xlink:type="simple"/>
    <context id="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifed18f9e51ed48aeb5b773bd6fa0af3f_I20201030">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2020-10-30</instant>
        </period>
    </context>
    <context id="i6e634a7c4e2544d38a5d4db27a521e32_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia1370538e8004f039f21787ab6a847b3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i902ffdd5069945e4a1e2d8259b7aa937_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if9bd25f418764e27874e4887f9629cba_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iac48a829910e4ec2be6c0709f8ab5d04_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i15c6da9822264b9abd38a7580c17d5b2_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if6645fba9caf44b8b8bcb42c98bf2278_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia038c518019748b78ce08495d4f16d87_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6be33be9efa74778b57706d8c1dc08f4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id5a1fdf43a234d5c9fb4b6957bdd5c72_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1ad876aa13d343ee93185f8c0c654899_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if80b6528409e4dfebe89f52e9c71dd73_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib30ef62521f14a1a8085c15b3b924dcb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib271d15ecd62424c99f55144e625afde_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9d4b033413e949bdb33308f291e151d7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib72090a087094a15a97bb50cce1d461f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia5e859f8f93d478cbc47d931bf3d4f16_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8bd62d81b9224846bad804af424c7c55_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic73499b256364473912a51549d885406_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib3d4f0ce49ea478683a5e066d98b9657_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i83a0c267e8c14a0b8cb5af9dc8889826_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie94a42df3bd64de59963733402e60f0b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i14d2deb841a8484bbb9f4d6e7db83773_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia39f990b1b954fd4b7055ed175a61da7_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i84f838015f2c4600ab21342b2ab257bb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie226d1a9de1e4a689a12ba5ade263cbf_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2e3117ca1e3d475081f74ed85067fdd9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i74af35b6091d4e40bc61c88695b202c8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i633904fd4bf04f1db95a04a559e03ad2_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id355d6bb2f5148079147b0cb69a30e3a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i78340b4431bb4f3cb0c67e9c396fe87c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7bda0d5bb34046e6976dbdd780aa978b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7e478fecc462477aa454e3d9436e4752_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia6ddd43f0d1749b3b53381bd19850103_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id32fe94f97e84076b84beaff756aa3fa_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8dac01400f8a441eaf95cdb7f2c88e1e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibc5c534cd84f4787a526c269ef4c6151_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie481c63be9664fed98e565204a85caf1_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if50f19fc8ffb45ec878303df8a922a99_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2f336477ca834d10a759110a6b168a44_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2c742c6a37f940b1b7230f3dad49ebc6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="idaea355a6eee4c84b610bb5a3998cb0a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if74da64f69904adba74c4a3593889ebc_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="icafe5156f770497288825e054150807e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5e51e0bf32b84c06bc802cf158d85892_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic794988e2ef64d2d903b700cc61ab8ac_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib5e2bd57c0864b8ca52c0dbc9e5247eb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie77331352e8e487ab5aaa801714a9478_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9f5eb666df1f4354b1d4dcf993b7fd72_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="icfb43edba9e24d7aa4bc0b84a542b1a4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic221521f25684d8291dde2458b8fd56d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iddbd8fd3a9234d15a8eda0993f4f1137_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iccd377f04511411f8b9b576f6daddde7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia7a7de9468d1492cb68a6b85d84c50e3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i958a5eaaa1994c0e8785e2290bffb78c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8ee3f08f37a94847b4581c44661b6945_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if10cfda3b1ae42dd94275ef357f4b6ab_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i23e8641cdf9d4a0ba36b18e83e1f74f5_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i09874c19ef114cc9a325361e8c04db94_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i0aee4cc470d44c5e99067c41afb5f002_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i44c7bfd7973b423691bd63d2af7d57aa_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ic76020b398604ca1bf1af8adacc2ffce_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i5c08cf4ec15f402aadb383d3cf0aac8d_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ia32695c6f95b4eecbd80e2ba29818b2d_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i8bf3fa70c71d4e65bfa404b0233a7d5e_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="iac1252d10b6040f4876c7756be3e4a76_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i99487a9075154d1481319c8e1e5c20c8_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i2989a9b9047443f9a4e2a2c0bb1625f4_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8f6dcdda42cf4c478aff8535b767c4c4_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib8b377237524434a885c88b184553ef7_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i7159c55a54a64257836b127ebdbe79ca_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="icc3e62b98968494bba8bee317e04525f_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i14619843617f40c7a9cf1f66f71c1c27_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ib4f71ec0a74244a898c7f64d6f7c861d_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i9327aef1d4d84255b2eb04bc36f39536_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i33d12dc0073b41d0b953c2cd4414bb09_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i1053b3953d9d41a4b58d1f9f40168930_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i96e9cac9a5b245e1ab992da2a4f3b707_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1c451a043eeb4e1c90f9351c338a270c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie090a495a771498fa103545475845412_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i711e80bbc9f74ab3b7066dfb0f019bfb_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i382fc23536884c45afe5acfaef266947_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i53f5dfe3b6464427a8673fa0c75cf825_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i1c8d5ed345084b43bbf0c55a4d2ee227_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i9c9f7f3cb6d047899b09ad580b69156b_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ife55cfc6e645489a9aa97a13da6dfe00_I20200611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CelgeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:Agreement2010Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-11</instant>
        </period>
    </context>
    <context id="ied54aa2a3f7e42998c98d6f9afe5e255_D20200611-20200611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <startDate>2020-06-11</startDate>
            <endDate>2020-06-11</endDate>
        </period>
    </context>
    <context id="idf22f68ca84c40088ac574f70d88d77d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:Agreement2010Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i543ea632249a45b4b913803db254e6d2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i71a231d7d6a8434383ad19d455d7141a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie11b847113844524904871ec37728936_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i039327938bac4cc0a80cd5dc934f1d1d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if7218efcd2284c88a1600bcc960ede96_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib2e5aaad6c904909a156e5d4b4f185fe_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if555a5ee5cf0408a86be0d8a8d59801f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i821a817349064dcc8e6938597d3db79e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iaed01c1b899c4709b5accd32d8312191_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i08437c72c35449abacdc997fcf6867a2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6b4d1304c21246dc941d6150f7c3972e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ideab8d3cd8824f7ebaadb03c9812b1b1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i744b349803e74e989804d827439ae1f4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3f2d69b28ccb4f61b622f3b366b4804b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iedf6f8c98e70432c9500860ae91e2b2d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic6132c63023e4bc0bb7db5e06ab568fd_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie484602594fc4892b37a19ce7a0605b8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4a819345c25a47a78c1b9247bebd1445_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i12994fbfaa05455592901db5a2d7fb86_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7596257a08c149ec9fafbb992990cc54_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2bf8521cd905445da506519413d478f2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7ee1c71ed01b4620aa8b7c580a5c2c35_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iff55f01694f94e28b5c7fd66fab94514_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib489bc944aa14ea39dfa0ea27a8ccdda_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i68f2b8cd5ee04a16971376df19807a05_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic8ead45948574c9f9ee622f88491ada5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8047261250f94d8eb8d6c0f98068c56e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7bbfc1e3bc29413aba5926d90622f3d0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iafa6f804a3734443b6af52bbcd7cda22_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iadc513dfb0aa455792b1559bd9ff0b07_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i204de70f9ce54574b913c7c1a1f5bec6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8ac3885e5cc24c1a9b936fd11ed191f3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2b8e02d6bad0479cb0dd2303c690ac0b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i015ac4920a1c4c3a9611d7a7be258105_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1c2c48c0358445ac84d1add069e26cb6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i23d92d9ecc2b4415b962d6feb4c7a44a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib2575fe6eebf402cbdb0a3e5509d729d_D20200611-20200611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:RPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-11</startDate>
            <endDate>2020-06-11</endDate>
        </period>
    </context>
    <context id="i5e16d3756d704760a00e78beb3a53457_D20160501-20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CelgeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:MasterResearchAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-01</startDate>
            <endDate>2016-05-31</endDate>
        </period>
    </context>
    <context id="ic19c9efe1bc441b28792cb1fb430006c_I20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CelgeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:MasterResearchAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-31</instant>
        </period>
    </context>
    <context id="i4bbc2d1419c542459a401e63c7eca48e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i03d3c6ff3eaa4f96a6b43c3884afbdd5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i635a87f89b85400aa10e6ca171a7869f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8a9429c5ed7c4eafa27ec8b3c0962e9c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i231960ca9c014f48bb976e41d6c6d505_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CommercializationActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i332309b5d2244ef5b9ecb08809dcbd9f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CommercializationActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i85fcfba1e36545e493bcf708b4e9df68_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CommercializationActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3b78993cbec4481bbc686cda5de776b1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CommercializationActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i21cd91eb1d2842528666b7c51b692515_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CollaborationReceivableDuefromRelatedPartiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i822eacbd7a3140f7a5ad55739d7525b2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CollaborationReceivableDuefromRelatedPartiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i60e99bcf39eb4a1198ea4cb7a6f6bc0c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CollaborationReceivableDuefromRelatedPartiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i11fc8fb499ea4d2cb1eb548dd4ca43db_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:UnbilledReceivableDueFromRelatedPartiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3f99babce6584b2ba9dc951305e2fc7b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:UnbilledReceivableDueFromRelatedPartiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id771f4009bfa4c4bbdedf06974f817e1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:UnbilledReceivableDueFromRelatedPartiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id866c85fcea34845a31e92f2f2b956a9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:RoyaltyReceivableDuefromRelatedPartiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5ed0f7fca6824f939606850129df11d9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:RoyaltyReceivableDuefromRelatedPartiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3b35d322903843578f6a68da48ebf6bb_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:RoyaltyReceivableDuefromRelatedPartiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib908b1f10858485dad4c2ae0e63c92ea_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:DeferredRevenueCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i99f701a2e0cb4e8b8665c215666a581f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:DeferredRevenueCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i29d069dedee94effb0e3fe4e2557d773_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:DeferredRevenueCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i18ae39e61005422296a6185b1b3642ac_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="if60bb09a8e0d4226ba3167b23f5cb3a4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0f0956f37ec44b6bb6d0f4fa5248bef0_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i54571e1728c5451ab4e07db6c9467aee_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i08ba0b22d8f3450e8b229803691aa936_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if7c63d1760f04d71aa4c373f08d1f88e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iddeab0bd8cc74b7db5aebf3e35be317a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i107aa1a97aea4de79780fd1a3849f4c9_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7731b8f59ba649e78547d1a6207a646b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib6c5708e816d4a5a9da9fda8e44e426a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i84dcb1f3e8204171af357b73d909bde3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i47b3d55b232f4b37b1ce3de5d1256c7a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0fa5e00c5e3b4d8a94adfcd4dc578cea_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9bf86b21d1ec42508367f7984e0d709b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i313f3bed2b4d41b1b3befbd3ba0eb04d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i461b9941feeb4551aaa603496fbf1cbf_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i63a35d727f94435cb7df160054110884_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CollaborationReceivableDueFromRelatedPartiesCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i01071852f46a4d4dadbc5092fae50573_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CollaborationReceivableDueFromRelatedPartiesCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0fc858c76d804b0094142147dcd5fabf_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CollaborationReceivableDueFromRelatedPartiesCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie9648064ef4d46a89718d0c2f677340c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibc55bcf17208425a91152e001413e76a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaf00db5bcb514269bb6f8b107e6bda6d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i87a76a2d90d94c09897329e40592f335_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icb29efd46e8a49fcac140e1509cd977e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib1af4d73a6f24932b9251f45c0dc1886_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:CStonePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:CStoneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic35eee998d714c1eb9833f09bbeecf44_I20200611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2020-06-11</instant>
        </period>
    </context>
    <context id="i921c8ef362934a03b834f05fd487675a_I20200611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:RPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-11</instant>
        </period>
    </context>
    <context id="i7a10fdb988c14ed4b148d6aab1625976_D20200612-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:RPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-12</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6317ec5824324379aa89da98e74f17b5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:RPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibf7298c7e23d4bc79ec2339352a2c49b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:RPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i21d7d92ef32c4570af111a2c6296175e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">agio:RPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9d699758856a480db8a54b5c63108b48_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5f9615d7d1de4efaa136793d0d91cefc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i42fd0d585d7e44eb875c04c73f32f4f3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3d04844a7e1741f4b543721609a357af_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ieaba62f70942436b9630689bd74a2d35_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i91da41946dd44926b3eb2a6c70cedcec_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic195c0c995c94bb99b62faec4ada3a82_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceBasedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i16638a665f8b48bda553a1b68fe9582c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceBasedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie97254b0a3bd414a957ad2f9c5b213a2_D20180101-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceBasedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="idd2bc890754e428c838e48a9739bb6ca_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceBasedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i174a0833a8f7445eab78db94209d6095_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i511c756fbbb74474b18ddbc87da9898f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:MarketBasedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3b990092bc0c49da82be729ba6370e53_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:MarketBasedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2c31701e76ca45a499b9de7eb21dcc8c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:MarketBasedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i88427bac77074d34bf85fa93670c9058_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3878b4c8c3294913aa799ef8147b4a81_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6d8671ea0b684937a1904b1b3c85413c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="icf949780f933480e95db1152a36fe193_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i03bf9b8187f0451d9f3b63e3cf6178da_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i09fde5e4560a422a85918a18e444182d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4bd07546e3954875b0cf85d146e836c1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id8a5352cdcf54a3dbc6e981a9f2d988e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ice9aeab243b54c76ba9666c481969a67_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i357045d6181740eeae955e96b15cf9ae_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie651fcd18fce4247ae0c8601b611a96b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceBasedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic805411b96ea4c5f9301de6e30503f1f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceBasedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i798423a51884438da4abc925685536ec_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceBasedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id5e015813aa04cc5b172ca860a6d9adb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i49a46c45215d41c8aa7526c20b7d66b5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idbd22adb7da84d4385fef484796aface_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6718bfa0a37a457e90f8816b0655456b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i454184cf989649608cb48e499349776d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:OtherStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i03016330feec4c92b5f1d60dc4e263e1_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:OtherStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic370bb45afd5438bade9612c8288612a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:OtherStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1f25d07cfaa34641ae0ed3f419c27b42_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:OtherStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i27fa78f0171d419fbd8f33e0452c4ae6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3b35ca8234b946a59c38dcb3c34529b6_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i03be922ff7cb4cf492b6d47edf9144c9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia14da64b4d914e7ca355088908976d71_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i94a210d561984f12a0afc697ddbaea44_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4effbc54b019404fbb07e9b964ce6494_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icf1c03f73f434b93ac3f9ad188cac55e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i64b9b9df1ff7448d85c07ee71a10ce67_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i158dfd79c688479084d989c430f722ec_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idefd32a8ce2246baa8ff2d8323b75046_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7607646d4b3b4f108a7e2b95056780a1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i98274e1aae044562a57287ce093c0a26_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i02527e9e8cad486f90f2ce345b3c2608_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib7f3d9262b9a4930b2cf048450740cd9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1179a5820c534eac932533d105b3c232_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i824f503805804c518c65ccdbfb63cb4c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i086f8600af974684a490cec7619bf25c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7d2dbb49a82349ac86136605ab26307a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie4d9eaf7cb8641d0852c0cdf98b22872_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i85f451c88a3e4c928e436beab4f05862_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7a52ff240e81427b90c795cee938d4b5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4879e95ef7744941b0e26ca90bfc6605_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9d57d7b84fb04a96892f11a0576100dd_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic96c925a7d99431399902b60bcb6babb_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="security">
        <measure>agio:security</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="extension">
        <measure>agio:extension</measure>
    </unit>
    <dei:DocumentFiscalYearFocus
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80L2ZyYWc6NGVmMTVjMmI1ZmEyNDc0NTgwZDExNjUwYjk2MmY4YzIvdGFibGU6MjQ1NjFkNWM1ZGEwNDdhYmIyMzU2ZTY1ODc2ZmE0ZmIvdGFibGVyYW5nZToyNDU2MWQ1YzVkYTA0N2FiYjIzNTZlNjU4NzZmYTRmYl8zLTEtMS0xLTA_0521348b-5543-4901-adf2-c77897bc9df3">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80L2ZyYWc6NGVmMTVjMmI1ZmEyNDc0NTgwZDExNjUwYjk2MmY4YzIvdGFibGU6MjQ1NjFkNWM1ZGEwNDdhYmIyMzU2ZTY1ODc2ZmE0ZmIvdGFibGVyYW5nZToyNDU2MWQ1YzVkYTA0N2FiYjIzNTZlNjU4NzZmYTRmYl80LTEtMS0xLTA_66d79948-331b-4e46-a12f-b92ab73e730e">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80L2ZyYWc6NGVmMTVjMmI1ZmEyNDc0NTgwZDExNjUwYjk2MmY4YzIvdGFibGU6MjQ1NjFkNWM1ZGEwNDdhYmIyMzU2ZTY1ODc2ZmE0ZmIvdGFibGVyYW5nZToyNDU2MWQ1YzVkYTA0N2FiYjIzNTZlNjU4NzZmYTRmYl81LTEtMS0xLTA_1052cdf1-bdf1-4e26-9ec0-cd1fe80f2fdc">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80L2ZyYWc6NGVmMTVjMmI1ZmEyNDc0NTgwZDExNjUwYjk2MmY4YzIvdGV4dHJlZ2lvbjo0ZWYxNWMyYjVmYTI0NzQ1ODBkMTE2NTBiOTYyZjhjMl85MQ_65603b69-f1b5-4c8c-98de-2f2f40632098">0001439222</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80L2ZyYWc6NGVmMTVjMmI1ZmEyNDc0NTgwZDExNjUwYjk2MmY4YzIvdGV4dHJlZ2lvbjo0ZWYxNWMyYjVmYTI0NzQ1ODBkMTE2NTBiOTYyZjhjMl84OQ_bef15f09-1694-43fa-8bdb-b66565a95bf3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGV4dHJlZ2lvbjphMDkzZGE0N2M2OWQ0NTExYjQyYmYyMThkOTgwNDFmMF84Mg_8128f591-7222-4c20-ad83-5f63a47dfa87">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6MzQ2ZjJlOWFkMzEzNDVlYzhjMDc1NDg2MzlkZjk5YTEvdGFibGVyYW5nZTozNDZmMmU5YWQzMTM0NWVjOGMwNzU0ODYzOWRmOTlhMV8wLTAtMS0xLTA_7d8a4437-331b-410e-b7ad-e6fab3a6e093">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGV4dHJlZ2lvbjphMDkzZGE0N2M2OWQ0NTExYjQyYmYyMThkOTgwNDFmMF8xMzE_6793fc5c-a22d-4b51-927a-80af24332274">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6MTkyYjUzOWEyNDAxNDIzN2E5OTRkNTU4ZDY5NjNkNDUvdGFibGVyYW5nZToxOTJiNTM5YTI0MDE0MjM3YTk5NGQ1NThkNjk2M2Q0NV8wLTAtMS0xLTA_9d748bc3-0705-4313-8ccc-c8198e88d548">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGV4dHJlZ2lvbjphMDkzZGE0N2M2OWQ0NTExYjQyYmYyMThkOTgwNDFmMF8xNjM_5da110b2-c904-42bd-a3c7-a119d5fb01bc">001-36014</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGV4dHJlZ2lvbjphMDkzZGE0N2M2OWQ0NTExYjQyYmYyMThkOTgwNDFmMF8xNjg_1299a76b-0d33-4e5c-93e1-bd206781898b">AGIOS PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6OTY1OGNmNTU3ZGI3NDlkNGJkNTFhM2ZiYTA5ZDczZDEvdGFibGVyYW5nZTo5NjU4Y2Y1NTdkYjc0OWQ0YmQ1MWEzZmJhMDlkNzNkMV8wLTAtMS0xLTA_e7f1e855-475c-4160-b3be-b66166291d50">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6OTY1OGNmNTU3ZGI3NDlkNGJkNTFhM2ZiYTA5ZDczZDEvdGFibGVyYW5nZTo5NjU4Y2Y1NTdkYjc0OWQ0YmQ1MWEzZmJhMDlkNzNkMV8wLTMtMS0xLTA_5e86b0cb-4cda-467f-88e9-01585c15a133">26-0662915</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6OTY1OGNmNTU3ZGI3NDlkNGJkNTFhM2ZiYTA5ZDczZDEvdGFibGVyYW5nZTo5NjU4Y2Y1NTdkYjc0OWQ0YmQ1MWEzZmJhMDlkNzNkMV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjphZGVkNjQzMTE1MGU0MTc5YWNmZmQ4YmY4NmNmZjdkNl80_73552abc-9537-4464-9fd6-f84fc61bae23">88 Sidney Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6OTY1OGNmNTU3ZGI3NDlkNGJkNTFhM2ZiYTA5ZDczZDEvdGFibGVyYW5nZTo5NjU4Y2Y1NTdkYjc0OWQ0YmQ1MWEzZmJhMDlkNzNkMV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjphZGVkNjQzMTE1MGU0MTc5YWNmZmQ4YmY4NmNmZjdkNl84_b90e793b-9a45-4d30-a622-67ad7b452e79">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6OTY1OGNmNTU3ZGI3NDlkNGJkNTFhM2ZiYTA5ZDczZDEvdGFibGVyYW5nZTo5NjU4Y2Y1NTdkYjc0OWQ0YmQ1MWEzZmJhMDlkNzNkMV8zLTAtMS0xLTAvdGV4dHJlZ2lvbjphZGVkNjQzMTE1MGU0MTc5YWNmZmQ4YmY4NmNmZjdkNl8xMg_2cb5b2d5-96cf-44ba-9154-6b904e43a2a6">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6OTY1OGNmNTU3ZGI3NDlkNGJkNTFhM2ZiYTA5ZDczZDEvdGFibGVyYW5nZTo5NjU4Y2Y1NTdkYjc0OWQ0YmQ1MWEzZmJhMDlkNzNkMV8zLTMtMS0xLTA_b5d200a0-3fb7-42e5-b90d-cf387f5ed73e">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGV4dHJlZ2lvbjphMDkzZGE0N2M2OWQ0NTExYjQyYmYyMThkOTgwNDFmMF8yMzI_a863effc-6cc8-4883-9e08-9d45af30c4e9">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGV4dHJlZ2lvbjphMDkzZGE0N2M2OWQ0NTExYjQyYmYyMThkOTgwNDFmMF8yMzY_7b911cc6-d9fe-4c4a-9f65-2d51dc1d4e75">649-8600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6NGZjMWE0NjJlM2U1NDRkOTlmZjMzZWFiMGUyZTM2YTYvdGFibGVyYW5nZTo0ZmMxYTQ2MmUzZTU0NGQ5OWZmMzNlYWIwZTJlMzZhNl8xLTAtMS0xLTA_e00a7c1e-8890-4597-a0be-a413b4318d1b">Common Stock, Par Value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6NGZjMWE0NjJlM2U1NDRkOTlmZjMzZWFiMGUyZTM2YTYvdGFibGVyYW5nZTo0ZmMxYTQ2MmUzZTU0NGQ5OWZmMzNlYWIwZTJlMzZhNl8xLTEtMS0xLTA_c5d2e63d-d035-4bfa-b8f0-38004919bd2e">AGIO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6NGZjMWE0NjJlM2U1NDRkOTlmZjMzZWFiMGUyZTM2YTYvdGFibGVyYW5nZTo0ZmMxYTQ2MmUzZTU0NGQ5OWZmMzNlYWIwZTJlMzZhNl8xLTItMS0xLTA_355d5835-815d-4455-ae74-a035319346ee">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGV4dHJlZ2lvbjphMDkzZGE0N2M2OWQ0NTExYjQyYmYyMThkOTgwNDFmMF83ODk_b996f177-9fe1-4bfd-ba2d-f2a0b4f54447">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGV4dHJlZ2lvbjphMDkzZGE0N2M2OWQ0NTExYjQyYmYyMThkOTgwNDFmMF8xMTE2_c45279f9-9155-4817-8781-27ed9b70e53e">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6YmQ1NWM4ZGQ1ZWQzNDQwMzlhMDliNzhjN2E0ZjVhOGIvdGFibGVyYW5nZTpiZDU1YzhkZDVlZDM0NDAzOWEwOWI3OGM3YTRmNWE4Yl8wLTAtMS0xLTA_312643a0-3664-43ac-bf33-9df8257088cf">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6YmQ1NWM4ZGQ1ZWQzNDQwMzlhMDliNzhjN2E0ZjVhOGIvdGFibGVyYW5nZTpiZDU1YzhkZDVlZDM0NDAzOWEwOWI3OGM3YTRmNWE4Yl8xLTMtMS0xLTA_080f0a7f-eead-4f05-a02f-5f27dab038cd">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGFibGU6YmQ1NWM4ZGQ1ZWQzNDQwMzlhMDliNzhjN2E0ZjVhOGIvdGFibGVyYW5nZTpiZDU1YzhkZDVlZDM0NDAzOWEwOWI3OGM3YTRmNWE4Yl8yLTMtMS0xLTA_878b35f0-ffbe-402c-8d89-24e0ac249889">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGV4dHJlZ2lvbjphMDkzZGE0N2M2OWQ0NTExYjQyYmYyMThkOTgwNDFmMF8xODU4_11ab709e-e8c6-4a50-b4b8-2c33296454b2">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ifed18f9e51ed48aeb5b773bd6fa0af3f_I20201030"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xL2ZyYWc6YTA5M2RhNDdjNjlkNDUxMWI0MmJmMjE4ZDk4MDQxZjAvdGV4dHJlZ2lvbjphMDkzZGE0N2M2OWQ0NTExYjQyYmYyMThkOTgwNDFmMF8xOTYw_eed584f7-e8f1-43ab-b600-aeb5332e82b6"
      unitRef="shares">69259817</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMy0xLTEtMS0w_acef6189-e151-4a51-8716-4228dcf0fe5e"
      unitRef="usd">104855000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMy0zLTEtMS0w_33737f48-812b-44c0-9271-40513e6414ed"
      unitRef="usd">80931000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfNC0xLTEtMS0w_502804bf-ef8b-494a-bb6d-177727a30b95"
      unitRef="usd">500684000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfNC0zLTEtMS0w_79215eaf-4c1b-4551-ac48-66d9dccc05f6"
      unitRef="usd">483946000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfNS0xLTEtMS0w_c7907154-4e5e-44d6-baca-148aeb58474c"
      unitRef="usd">18989000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfNS0zLTEtMS0w_bde645e8-834c-46cf-8c3a-a8364f6de770"
      unitRef="usd">8952000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <agio:CollaborationReceivableDueFromRelatedPartiesCurrent
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfNi0xLTEtMS0w_eb2a501d-9837-4a11-ae84-72d71a67e3bf"
      unitRef="usd">2334000</agio:CollaborationReceivableDueFromRelatedPartiesCurrent>
    <agio:CollaborationReceivableDueFromRelatedPartiesCurrent
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfNi0zLTEtMS0w_25100598-ef62-43d2-ab87-4f3ad0476173"
      unitRef="usd">1539000</agio:CollaborationReceivableDueFromRelatedPartiesCurrent>
    <agio:CollaborationReceivableOtherCurrent
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfNy0xLTEtMS0w_6b76f16b-ba02-4511-bd2b-16cfd7c064fd"
      unitRef="usd">1992000</agio:CollaborationReceivableOtherCurrent>
    <agio:CollaborationReceivableOtherCurrent
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfNy0zLTEtMS0w_31050125-67d0-4833-8f90-326c28216546"
      unitRef="usd">1928000</agio:CollaborationReceivableOtherCurrent>
    <agio:RoyaltyReceivableDuefromRelatedPartiesCurrent
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfOC0xLTEtMS0w_05a6804f-8bc3-4682-b192-77bacc6232f8"
      unitRef="usd">0</agio:RoyaltyReceivableDuefromRelatedPartiesCurrent>
    <agio:RoyaltyReceivableDuefromRelatedPartiesCurrent
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfOC0zLTEtMS0w_ff5363b6-f7a2-40e1-b5b5-16d389330e6d"
      unitRef="usd">2900000</agio:RoyaltyReceivableDuefromRelatedPartiesCurrent>
    <us-gaap:InventoryNet
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfOS0xLTEtMS0w_90f80dcb-8702-4c8b-96ee-20527700aa2e"
      unitRef="usd">11371000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfOS0zLTEtMS0w_c6618734-63f2-4552-8fdf-60c8c41593fe"
      unitRef="usd">7331000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTAtMS0xLTEtMA_82e7c1b0-3e86-4099-815f-ffd2ae5d6fff"
      unitRef="usd">28861000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTAtMy0xLTEtMA_baba7f37-10e1-4fe2-b3fc-ef991e76a008"
      unitRef="usd">24177000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTEtMS0xLTEtMA_06cb70e2-db9c-4ccb-9d81-8a2621c17214"
      unitRef="usd">669086000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTEtMy0xLTEtMA_844f82ae-2509-42f6-860c-5204dd17bcc9"
      unitRef="usd">611704000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTItMS0xLTEtMA_4d2c4d64-2cfc-44fe-913c-b94d67df15cb"
      unitRef="usd">116889000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTItMy0xLTEtMA_3416c1a6-7068-4381-83a2-a55d4e2528ad"
      unitRef="usd">152929000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTMtMS0xLTEtMA_eb0260c2-8da6-4cb2-ad56-7b9ed2c469e3"
      unitRef="usd">86952000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTMtMy0xLTEtMA_b7a97f27-3b0f-46f7-9451-706a18533c8a"
      unitRef="usd">93643000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTQtMS0xLTEtMA_3c66a5b8-45fa-44bc-916f-021f7e30c623"
      unitRef="usd">33495000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTQtMy0xLTEtMA_50a54c4a-bde3-411e-9155-07df776296d0"
      unitRef="usd">31472000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTUtMS0xLTEtMA_115abaf5-cbc8-483c-bfcf-dea0f33012cb"
      unitRef="usd">677000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTUtMy0xLTEtMA_653fdac8-a83b-4b3f-a8a9-2e4726955b14"
      unitRef="usd">993000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTYtMS0xLTEtMA_b2060fc8-3a96-4d06-bdbf-2bdf21b18bf9"
      unitRef="usd">1350000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTYtMy0xLTEtMA_b7f00b07-2e85-4b54-bdb7-51173d263614"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTctMS0xLTEtMA_ac9d036a-2102-4720-8c46-7b9c96f22873"
      unitRef="usd">908449000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMTctMy0xLTEtMA_93ef8396-552a-49b7-b79c-6fb10b6124d6"
      unitRef="usd">890741000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjAtMS0xLTEtMA_6a1c5d78-0c99-4ac9-800f-1abd34a80730"
      unitRef="usd">12853000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjAtMy0xLTEtMA_aab145f6-9cb8-4c3b-a6b1-7fded3a0c52c"
      unitRef="usd">21896000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjEtMS0xLTEtMA_69cb1942-c1ba-4dec-9560-6be33520e786"
      unitRef="usd">49724000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjEtMy0xLTEtMA_ee8ab8a4-e458-403c-8f84-02ef48454abd"
      unitRef="usd">53142000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjItMS0xLTEtMA_014cb380-cc7f-466f-8011-1e58d01da207"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjItMy0xLTEtMA_4c85c8e4-431d-4b8d-9bdf-e375b045ec99"
      unitRef="usd">10933000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjMtMS0xLTEtMA_f05eb028-2f81-4202-8837-33d8a4615f20"
      unitRef="usd">6881000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjMtMy0xLTEtMA_08ad91c8-2638-404f-9764-04a046faa314"
      unitRef="usd">6642000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjQtMS0xLTEtMA_7648b369-a85d-4539-9da8-b40de75a34ae"
      unitRef="usd">313000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjQtMy0xLTEtMA_ae124fc8-550c-434d-818b-27b3a3e00d09"
      unitRef="usd">273000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjYtMS0xLTEtMA_1fc721e7-d5e9-4fd8-ad9d-f4fa67efb497"
      unitRef="usd">69771000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjYtMy0xLTEtMA_2470fc9c-d177-40bb-bddb-d94878a1f72e"
      unitRef="usd">92886000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjctMS0xLTEtMA_8480dd82-e97a-4660-addc-f63ab10d146f"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjctMy0xLTEtMA_8d14fa78-06af-41ca-91d8-3c9e60e3d3ee"
      unitRef="usd">50580000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjgtMS0xLTEtMA_70f4f0af-9198-475b-8e8f-59cc1e98acba"
      unitRef="usd">99693000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjgtMy0xLTEtMA_70abef6f-e401-48b8-a16f-3a3231602bf2"
      unitRef="usd">106074000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjktMS0xLTEtMA_4150fda2-ed03-430f-b617-f5e0281247c7"
      unitRef="usd">412000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMjktMy0xLTEtMA_0960d6e8-862a-4c62-b333-cbfd2af60f39"
      unitRef="usd">673000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <agio:SaleOfFutureRevenueLiabilityNoncurrent
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzAtMS0xLTEtMA_da928817-0a5e-4adc-8e50-2ff01a4fe2fe"
      unitRef="usd">258121000</agio:SaleOfFutureRevenueLiabilityNoncurrent>
    <agio:SaleOfFutureRevenueLiabilityNoncurrent
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzAtMy0xLTEtMA_de19f45e-462c-472a-882f-5e7c872c6def"
      unitRef="usd">0</agio:SaleOfFutureRevenueLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzEtMS0xLTEtMA_ae4dd551-a218-4471-99d8-3947fc160dc3"
      unitRef="usd">427997000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzEtMy0xLTEtMA_3393bf5b-eb0f-4a5d-b72f-7e3b6ad07729"
      unitRef="usd">250213000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjE5ZjUxZTYzMTBjZTRkZGViYjFiNjZiZWQ2ZDY1MGY5XzIx_5593368c-223e-4712-9978-40bf440d3d22"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjE5ZjUxZTYzMTBjZTRkZGViYjFiNjZiZWQ2ZDY1MGY5XzIx_994e6cfa-ec8c-4abe-bebc-7427cc82b46e"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjE5ZjUxZTYzMTBjZTRkZGViYjFiNjZiZWQ2ZDY1MGY5XzM1_35128c0c-1647-444f-949d-0b49690a7427"
      unitRef="shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjE5ZjUxZTYzMTBjZTRkZGViYjFiNjZiZWQ2ZDY1MGY5XzM1_aaf081fd-ebda-4e6b-9771-23464f0bbdec"
      unitRef="shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjE5ZjUxZTYzMTBjZTRkZGViYjFiNjZiZWQ2ZDY1MGY5XzU3_0156d3f3-27f8-4e5a-98ce-e80d2b9bcfb0"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjE5ZjUxZTYzMTBjZTRkZGViYjFiNjZiZWQ2ZDY1MGY5XzU3_a9ea175c-0fd5-4694-9521-50ab0fd7c193"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjE5ZjUxZTYzMTBjZTRkZGViYjFiNjZiZWQ2ZDY1MGY5XzU3_ae2f2a14-beb1-4789-8b44-6fbf00858c26"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOjE5ZjUxZTYzMTBjZTRkZGViYjFiNjZiZWQ2ZDY1MGY5XzU3_b9adec17-da34-41e6-add2-0623a20c8b6c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzMtMS0xLTEtMA_5bde958b-f726-4b4e-9a81-aa75b80b9c73"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzMtMy0xLTEtMA_a4beed46-defe-40a2-8612-5db1898bf2be"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjhkMGIxM2I3YjdiYTRiNzdhOWZkMTJmYzMyYTRlOGY2XzE4_22904584-9016-4c06-bdb6-d96300d08e66"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjhkMGIxM2I3YjdiYTRiNzdhOWZkMTJmYzMyYTRlOGY2XzE4_36912072-4c28-408c-80bb-d9c764995116"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjhkMGIxM2I3YjdiYTRiNzdhOWZkMTJmYzMyYTRlOGY2XzMy_2025ed91-e39f-4e44-9a01-eea78fddc392"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjhkMGIxM2I3YjdiYTRiNzdhOWZkMTJmYzMyYTRlOGY2XzMy_d7309e58-0d64-498c-b32a-f0edf4c278d4"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjhkMGIxM2I3YjdiYTRiNzdhOWZkMTJmYzMyYTRlOGY2XzU0_1d232e69-20cd-4da8-a4f7-514aba94d78b"
      unitRef="shares">69198063</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjhkMGIxM2I3YjdiYTRiNzdhOWZkMTJmYzMyYTRlOGY2XzU0_71e9995b-222d-465a-9911-4e973935df97"
      unitRef="shares">69198063</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjhkMGIxM2I3YjdiYTRiNzdhOWZkMTJmYzMyYTRlOGY2XzYx_2ce13757-da7e-4d2d-a3b0-50904e5e49b5"
      unitRef="shares">68401105</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjhkMGIxM2I3YjdiYTRiNzdhOWZkMTJmYzMyYTRlOGY2XzYx_d2f2588c-d116-4d6e-be81-2ec41e837e2c"
      unitRef="shares">68401105</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzQtMS0xLTEtMA_332b3ad0-78d3-4d78-96de-341d5da09ba4"
      unitRef="usd">69000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzQtMy0xLTEtMA_11c479db-174f-4738-ae43-585ddc429578"
      unitRef="usd">68000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzUtMS0xLTEtMA_ece7a9b1-3b62-4836-82c4-5411ebd261c4"
      unitRef="usd">2225538000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzUtMy0xLTEtMA_a0c2f24f-31d7-45e6-91ae-603c740d6425"
      unitRef="usd">2156363000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzYtMS0xLTEtMA_ec368694-ded0-471b-a203-7bb01eb5d967"
      unitRef="usd">663000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzYtMy0xLTEtMA_f468567d-3b98-4221-8189-1d63525b0a6f"
      unitRef="usd">202000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzctMS0xLTEtMA_6a875194-ca48-4093-a3f7-016cbf0d7c63"
      unitRef="usd">-1745818000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzctMy0xLTEtMA_f11406fd-3416-4ee4-94bd-be9b0faeb454"
      unitRef="usd">-1516105000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzgtMS0xLTEtMA_1b59e105-c253-44f5-b531-63fcc2654684"
      unitRef="usd">480452000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzgtMy0xLTEtMA_84070512-47ef-4940-b8a5-893e6162e76d"
      unitRef="usd">640528000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzktMS0xLTEtMA_548095a1-3c32-45ad-80b6-99c2f3c2cf0d"
      unitRef="usd">908449000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xNi9mcmFnOjZjYWQyOGJkMzUyMzQ4ZDNiNzI4YjhlMTA1YTg1ZmQ2L3RhYmxlOmU4MjQ3YjI4ODhiOTQzYzY4ZWY5ODQzZWFhYWIzMjY1L3RhYmxlcmFuZ2U6ZTgyNDdiMjg4OGI5NDNjNjhlZjk4NDNlYWFhYjMyNjVfMzktMy0xLTEtMA_58123956-56af-4d7f-a4b6-a957c967f8e3"
      unitRef="usd">890741000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i902ffdd5069945e4a1e2d8259b7aa937_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMy0xLTEtMS0w_ee75e748-f734-4627-b83a-624196f28132"
      unitRef="usd">31716000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9bd25f418764e27874e4887f9629cba_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMy0zLTEtMS0w_14f0e384-07e2-4865-a7b3-c9c8d7b102a4"
      unitRef="usd">17422000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac48a829910e4ec2be6c0709f8ab5d04_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMy01LTEtMS0w_00904f98-d794-47ac-ae6d-0f542ee12268"
      unitRef="usd">81971000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15c6da9822264b9abd38a7580c17d5b2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMy03LTEtMS0w_54910873-1abf-40b4-a474-7e0a93f29cef"
      unitRef="usd">40287000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6645fba9caf44b8b8bcb42c98bf2278_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNC0xLTEtMS0w_db608ef0-67aa-4956-a556-c24f590ec93a"
      unitRef="usd">1206000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia038c518019748b78ce08495d4f16d87_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNC0zLTEtMS0w_57e63c24-d532-4ac7-898c-0bd564f41c2a"
      unitRef="usd">5516000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6be33be9efa74778b57706d8c1dc08f4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNC01LTEtMS0w_99483f8b-7b0a-4c47-a24d-2e4502e20fa2"
      unitRef="usd">67038000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5a1fdf43a234d5c9fb4b6957bdd5c72_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNC03LTEtMS0w_8b6029ba-5286-432b-a5c2-261113679bfb"
      unitRef="usd">32414000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ad876aa13d343ee93185f8c0c654899_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNS0xLTEtMS0w_fa6bc8d7-fd0a-4540-9e2e-5fd24b9e367b"
      unitRef="usd">1101000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if80b6528409e4dfebe89f52e9c71dd73_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNS0zLTEtMS0w_a7335076-db98-4786-ba71-11422610642e"
      unitRef="usd">420000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib30ef62521f14a1a8085c15b3b924dcb_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNS01LTEtMS0w_68641d46-1c02-4d8b-ba42-68a9ecaa1a51"
      unitRef="usd">2786000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib271d15ecd62424c99f55144e625afde_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNS03LTEtMS0w_bfe05a0c-e0f2-46d0-9486-051cad7328ba"
      unitRef="usd">2202000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d4b033413e949bdb33308f291e151d7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNi0xLTEtMS0w_fb1fb438-0e56-41bf-a105-b6e21db07cbe"
      unitRef="usd">683000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib72090a087094a15a97bb50cce1d461f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNi0zLTEtMS0w_20251276-e588-4100-86e3-535656016d19"
      unitRef="usd">2666000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5e859f8f93d478cbc47d931bf3d4f16_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNi01LTEtMS0w_4b5dacb2-ebbb-4330-b16d-1680e9263b33"
      unitRef="usd">7356000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8bd62d81b9224846bad804af424c7c55_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNi03LTEtMS0w_66ca3e60-865e-48f1-8d2f-bc560b4c8531"
      unitRef="usd">7569000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNy0xLTEtMS0w_af5ab40c-7893-4d8e-aa2b-2b697dd64fc5"
      unitRef="usd">34706000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNy0zLTEtMS0w_51b8ac2f-d5f8-4b0a-b6c3-ccb6cc3ac8fc"
      unitRef="usd">26024000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNy01LTEtMS0w_a665c1f6-7541-4e48-9ec5-323cd953f86f"
      unitRef="usd">159151000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfNy03LTEtMS0w_5c5357b9-fcca-45e7-a790-9b16693f1dfd"
      unitRef="usd">82472000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfOS0xLTEtMS0w_9540a9a7-e9bf-4a1b-ad8a-1360a0b363a5"
      unitRef="usd">638000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfOS0zLTEtMS0w_83119fb5-bab2-4334-bf55-fe958e7e7eb7"
      unitRef="usd">393000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfOS01LTEtMS0w_f1dad492-25ec-4535-9b02-7887e1f11299"
      unitRef="usd">1846000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfOS03LTEtMS0w_e07c77d6-da8e-41b1-bb66-68e58645870b"
      unitRef="usd">1030000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTAtMS0xLTEtMA_20a8bff9-fbd4-4200-b686-e1f86f320254"
      unitRef="usd">89555000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTAtMy0xLTEtMA_85fb8a7d-1ed9-4d77-92af-52b225b8b133"
      unitRef="usd">101672000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTAtNS0xLTEtMA_553d6eac-dba2-4ab4-be17-77f45e360e8b"
      unitRef="usd">271728000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTAtNy0xLTEtMA_f64da5c8-6337-4cd1-bfb7-fab0155f13d0"
      unitRef="usd">304646000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTEtMS0xLTEtMA_3137ab6b-439d-40ab-bd1e-526aea7f2190"
      unitRef="usd">34840000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTEtMy0xLTEtMA_377af897-d547-4a93-a67b-85a9c69cfaf1"
      unitRef="usd">33019000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTEtNS0xLTEtMA_7640cb6f-c04c-466f-9adc-98226477f5c2"
      unitRef="usd">109292000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTEtNy0xLTEtMA_67da7177-e011-4aa6-8e95-15181f4317e7"
      unitRef="usd">97200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTItMS0xLTEtMA_41a76af9-060a-4b58-98ae-e02650c0a5f9"
      unitRef="usd">125033000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTItMy0xLTEtMA_3c8bb676-e6a5-4481-ad4b-b124be17f1e8"
      unitRef="usd">135084000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTItNS0xLTEtMA_2c6caf04-d204-4368-97eb-aa8c996d941f"
      unitRef="usd">382866000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTItNy0xLTEtMA_86334f77-7c40-4e52-8e57-c380302edd89"
      unitRef="usd">402876000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTMtMS0xLTEtMA_0c0bf784-930e-4986-94d9-dac299ca8184"
      unitRef="usd">-90327000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTMtMy0xLTEtMA_d3536e69-86f2-4d90-a4e8-ca176c6f61ae"
      unitRef="usd">-109060000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTMtNS0xLTEtMA_f4e6253d-8d70-40f2-8ff4-1e218c0aa27c"
      unitRef="usd">-223715000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTMtNy0xLTEtMA_61d825ee-e938-443c-96c2-a2f009d41933"
      unitRef="usd">-320404000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTQtMS0xLTEtMA_389d09a1-18b2-44af-8642-a6162278e2a8"
      unitRef="usd">1115000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTQtMy0xLTEtMA_da8ab768-7cba-4c17-a553-b62203e08ad5"
      unitRef="usd">2887000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTQtNS0xLTEtMA_d51e9f35-265e-4efa-95c3-ff51ef3e8383"
      unitRef="usd">5820000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTQtNy0xLTEtMA_bc45a1ef-bb33-42d9-a54d-8088f79dc217"
      unitRef="usd">11282000</us-gaap:InvestmentIncomeInterest>
    <agio:InterestExpenseNonCashSaleOfFutureRevenue
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTUtMS0xLTEtMA_d82fec9a-fc28-4974-b7e6-eb9b5176b5ee"
      unitRef="usd">9767000</agio:InterestExpenseNonCashSaleOfFutureRevenue>
    <agio:InterestExpenseNonCashSaleOfFutureRevenue
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTUtMy0xLTEtMA_8d90002d-4bd7-4aac-92bd-357524afa6f0"
      unitRef="usd">0</agio:InterestExpenseNonCashSaleOfFutureRevenue>
    <agio:InterestExpenseNonCashSaleOfFutureRevenue
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTUtNS0xLTEtMA_a6e31a27-787e-44f8-a0f4-5d0e3e3e84eb"
      unitRef="usd">11818000</agio:InterestExpenseNonCashSaleOfFutureRevenue>
    <agio:InterestExpenseNonCashSaleOfFutureRevenue
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTUtNy0xLTEtMA_43a0567f-80a9-4b71-8793-aa75d73ae9c3"
      unitRef="usd">0</agio:InterestExpenseNonCashSaleOfFutureRevenue>
    <us-gaap:NetIncomeLoss
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTYtMS0xLTEtMA_79770292-3c3c-4578-8289-6840fec6f199"
      unitRef="usd">-98979000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTYtMy0xLTEtMA_547c9ffc-3019-4925-ad61-6ba3d6067f66"
      unitRef="usd">-106173000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTYtNS0xLTEtMA_3417b3e6-90d6-4306-aa96-68fd34d7d8c0"
      unitRef="usd">-229713000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTYtNy0xLTEtMA_8162c3e0-e812-4302-b890-728eea32cc26"
      unitRef="usd">-309122000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTctMS0xLTEtMA_359cb9bc-c61e-485e-a6e3-cef12bafe764"
      unitRef="usdPerShare">-1.43</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTctMy0xLTEtMA_c2b07eb9-7cc1-4e88-ac90-ceabc89e6ada"
      unitRef="usdPerShare">-1.81</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTctNS0xLTEtMA_fed957cd-748f-46a0-a8c1-c6081fc268e6"
      unitRef="usdPerShare">-3.33</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTctNy0xLTEtMA_95cbd11c-f3ae-46aa-9683-aca69f25e481"
      unitRef="usdPerShare">-5.27</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTgtMS0xLTEtMA_18425d8d-4cf9-4fff-85b4-e83c8411e5e4"
      unitRef="shares">69144061</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTgtMy0xLTEtMA_3717325c-eafe-4a36-85a8-c4fab21b7d65"
      unitRef="shares">58803534</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTgtNS0xLTEtMA_38014f0f-9b53-41f0-bf17-311db4bc9e08"
      unitRef="shares">68905853</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8xOS9mcmFnOjNlMTYxOTY1NjYwYzQwZjlhNWVhZjA2N2FiN2EyOWI4L3RhYmxlOjAwNTZiYzVmZjJjOTRmN2E4NjIyMGNkZmRmOGRjNjYwL3RhYmxlcmFuZ2U6MDA1NmJjNWZmMmM5NGY3YTg2MjIwY2RmZGY4ZGM2NjBfMTgtNy0xLTEtMA_2a7e1da3-a3ce-4f74-b740-bd9d0923e2cb"
      unitRef="shares">58661607</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yMi9mcmFnOjhmMGIzMDk5NTRhNTQ2NmE4NWNhMTAwNTIyMzUzMjM0L3RhYmxlOjlkZDk1MDk2MjNhYTQyNzI4ZWRjMDViMGM3NDRmMmNlL3RhYmxlcmFuZ2U6OWRkOTUwOTYyM2FhNDI3MjhlZGMwNWIwYzc0NGYyY2VfMi0xLTEtMS0w_79770292-3c3c-4578-8289-6840fec6f199"
      unitRef="usd">-98979000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yMi9mcmFnOjhmMGIzMDk5NTRhNTQ2NmE4NWNhMTAwNTIyMzUzMjM0L3RhYmxlOjlkZDk1MDk2MjNhYTQyNzI4ZWRjMDViMGM3NDRmMmNlL3RhYmxlcmFuZ2U6OWRkOTUwOTYyM2FhNDI3MjhlZGMwNWIwYzc0NGYyY2VfMi0zLTEtMS0w_547c9ffc-3019-4925-ad61-6ba3d6067f66"
      unitRef="usd">-106173000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yMi9mcmFnOjhmMGIzMDk5NTRhNTQ2NmE4NWNhMTAwNTIyMzUzMjM0L3RhYmxlOjlkZDk1MDk2MjNhYTQyNzI4ZWRjMDViMGM3NDRmMmNlL3RhYmxlcmFuZ2U6OWRkOTUwOTYyM2FhNDI3MjhlZGMwNWIwYzc0NGYyY2VfMi01LTEtMS0w_aeb05931-d16a-41fa-abe6-ad0c6da1f727"
      unitRef="usd">-229713000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yMi9mcmFnOjhmMGIzMDk5NTRhNTQ2NmE4NWNhMTAwNTIyMzUzMjM0L3RhYmxlOjlkZDk1MDk2MjNhYTQyNzI4ZWRjMDViMGM3NDRmMmNlL3RhYmxlcmFuZ2U6OWRkOTUwOTYyM2FhNDI3MjhlZGMwNWIwYzc0NGYyY2VfMi03LTEtMS0w_4d39a752-acbe-4d8e-8e61-391d058f6bdd"
      unitRef="usd">-309122000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yMi9mcmFnOjhmMGIzMDk5NTRhNTQ2NmE4NWNhMTAwNTIyMzUzMjM0L3RhYmxlOjlkZDk1MDk2MjNhYTQyNzI4ZWRjMDViMGM3NDRmMmNlL3RhYmxlcmFuZ2U6OWRkOTUwOTYyM2FhNDI3MjhlZGMwNWIwYzc0NGYyY2VfNC0xLTEtMS0w_b9462cc3-d924-4f08-ad5b-f2df9e2cb681"
      unitRef="usd">-973000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yMi9mcmFnOjhmMGIzMDk5NTRhNTQ2NmE4NWNhMTAwNTIyMzUzMjM0L3RhYmxlOjlkZDk1MDk2MjNhYTQyNzI4ZWRjMDViMGM3NDRmMmNlL3RhYmxlcmFuZ2U6OWRkOTUwOTYyM2FhNDI3MjhlZGMwNWIwYzc0NGYyY2VfNC0zLTEtMS0w_840d9023-1ea9-4e32-a10c-07fcb3e8b9d2"
      unitRef="usd">-26000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yMi9mcmFnOjhmMGIzMDk5NTRhNTQ2NmE4NWNhMTAwNTIyMzUzMjM0L3RhYmxlOjlkZDk1MDk2MjNhYTQyNzI4ZWRjMDViMGM3NDRmMmNlL3RhYmxlcmFuZ2U6OWRkOTUwOTYyM2FhNDI3MjhlZGMwNWIwYzc0NGYyY2VfNC01LTEtMS0w_9d078113-3ad8-4974-85e8-cdce68619970"
      unitRef="usd">461000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yMi9mcmFnOjhmMGIzMDk5NTRhNTQ2NmE4NWNhMTAwNTIyMzUzMjM0L3RhYmxlOjlkZDk1MDk2MjNhYTQyNzI4ZWRjMDViMGM3NDRmMmNlL3RhYmxlcmFuZ2U6OWRkOTUwOTYyM2FhNDI3MjhlZGMwNWIwYzc0NGYyY2VfNC03LTEtMS0w_efc19c07-d4ef-4988-8ebc-90270c890bb4"
      unitRef="usd">2635000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yMi9mcmFnOjhmMGIzMDk5NTRhNTQ2NmE4NWNhMTAwNTIyMzUzMjM0L3RhYmxlOjlkZDk1MDk2MjNhYTQyNzI4ZWRjMDViMGM3NDRmMmNlL3RhYmxlcmFuZ2U6OWRkOTUwOTYyM2FhNDI3MjhlZGMwNWIwYzc0NGYyY2VfNS0xLTEtMS0w_dccadc2c-12e3-46a1-b17a-e30d7f94b02d"
      unitRef="usd">-99952000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yMi9mcmFnOjhmMGIzMDk5NTRhNTQ2NmE4NWNhMTAwNTIyMzUzMjM0L3RhYmxlOjlkZDk1MDk2MjNhYTQyNzI4ZWRjMDViMGM3NDRmMmNlL3RhYmxlcmFuZ2U6OWRkOTUwOTYyM2FhNDI3MjhlZGMwNWIwYzc0NGYyY2VfNS0zLTEtMS0w_90f33741-3c71-4c74-af6c-1970be613742"
      unitRef="usd">-106199000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yMi9mcmFnOjhmMGIzMDk5NTRhNTQ2NmE4NWNhMTAwNTIyMzUzMjM0L3RhYmxlOjlkZDk1MDk2MjNhYTQyNzI4ZWRjMDViMGM3NDRmMmNlL3RhYmxlcmFuZ2U6OWRkOTUwOTYyM2FhNDI3MjhlZGMwNWIwYzc0NGYyY2VfNS01LTEtMS0w_54a915dd-a2ce-4bc4-9820-299b3c28e3b9"
      unitRef="usd">-229252000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yMi9mcmFnOjhmMGIzMDk5NTRhNTQ2NmE4NWNhMTAwNTIyMzUzMjM0L3RhYmxlOjlkZDk1MDk2MjNhYTQyNzI4ZWRjMDViMGM3NDRmMmNlL3RhYmxlcmFuZ2U6OWRkOTUwOTYyM2FhNDI3MjhlZGMwNWIwYzc0NGYyY2VfNS03LTEtMS0w_f7bd315a-c4b0-4792-b0d2-c615d69260ea"
      unitRef="usd">-306487000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="ib3d4f0ce49ea478683a5e066d98b9657_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMi0xLTEtMS0w_e3f31e59-82e6-4aba-ae22-1c4e8a23fbf5"
      unitRef="shares">68401105</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib3d4f0ce49ea478683a5e066d98b9657_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMi0zLTEtMS0w_a66e645f-476a-426b-a295-0c8006884870"
      unitRef="usd">68000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i83a0c267e8c14a0b8cb5af9dc8889826_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMi01LTEtMS0w_765b0323-0fc9-4954-a3f7-3076000b267c"
      unitRef="usd">2156363000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie94a42df3bd64de59963733402e60f0b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMi03LTEtMS0w_9d39fb91-bf3c-4cd0-805a-e65360372a84"
      unitRef="usd">202000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i14d2deb841a8484bbb9f4d6e7db83773_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMi05LTEtMS0w_6e9b30a0-27f9-415b-afcf-8db0af56fc8b"
      unitRef="usd">-1516105000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMi0xMS0xLTEtMA_7dd86ec2-4bf1-484f-8159-12e6dc818b2f"
      unitRef="usd">640528000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia39f990b1b954fd4b7055ed175a61da7_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfNC0xLTEtMS0w_0f8eee1a-848c-419e-9c3a-f0dc87bd6204"
      unitRef="shares">388820</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia39f990b1b954fd4b7055ed175a61da7_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfNC0zLTEtMS0w_a16bde61-0b21-4fe1-9f10-da8f34491f2a"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i84f838015f2c4600ab21342b2ab257bb_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfNC01LTEtMS0w_63fd3b1d-728b-4248-9b1f-48f81aa1b9dc"
      unitRef="usd">5464000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie226d1a9de1e4a689a12ba5ade263cbf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfNC0xMS0xLTEtMA_ea21c8ef-d1f1-4f59-9029-efd1edcb7679"
      unitRef="usd">5465000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i84f838015f2c4600ab21342b2ab257bb_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfNS01LTEtMS0w_0c910561-0c56-41f9-b93a-66049959c91c"
      unitRef="usd">19690000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie226d1a9de1e4a689a12ba5ade263cbf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfNS0xMS0xLTEtMA_4565fa93-f909-4839-b91d-8dddfb608b87"
      unitRef="usd">19690000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2e3117ca1e3d475081f74ed85067fdd9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfNi03LTEtMS0w_a41c185d-f533-4ec8-81d1-04567ffd3d1a"
      unitRef="usd">-128000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie226d1a9de1e4a689a12ba5ade263cbf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfNi0xMS0xLTEtMA_29c6c5ec-8129-42e8-a70c-ba7233121d39"
      unitRef="usd">-128000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i74af35b6091d4e40bc61c88695b202c8_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfNy05LTEtMS0w_bca6fb9f-2a59-47be-bd51-d18d74d84c1f"
      unitRef="usd">-40256000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie226d1a9de1e4a689a12ba5ade263cbf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfNy0xMS0xLTEtMA_7f5beccb-3b33-4219-98f2-d12b34ee40e4"
      unitRef="usd">-40256000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i633904fd4bf04f1db95a04a559e03ad2_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfOS0xLTEtMS0w_ce4c4db0-63c3-4359-97b7-952ab3c9a77c"
      unitRef="shares">68789925</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i633904fd4bf04f1db95a04a559e03ad2_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfOS0zLTEtMS0w_d238d604-4702-415a-891d-acd0624cbdae"
      unitRef="usd">69000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id355d6bb2f5148079147b0cb69a30e3a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfOS01LTEtMS0w_5f499657-0e4c-45cb-8518-b47fb60b2b21"
      unitRef="usd">2181517000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i78340b4431bb4f3cb0c67e9c396fe87c_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfOS03LTEtMS0w_81d0b63b-ff88-44c0-87c8-6647deeb0d84"
      unitRef="usd">74000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7bda0d5bb34046e6976dbdd780aa978b_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfOS05LTEtMS0w_8e58b8fb-d818-4382-a934-518df6663b7e"
      unitRef="usd">-1556361000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7e478fecc462477aa454e3d9436e4752_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfOS0xMS0xLTEtMA_379e4bdc-bb7b-455e-8c39-53ac89c19e74"
      unitRef="usd">625299000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia6ddd43f0d1749b3b53381bd19850103_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTEtMS0xLTEtMA_9be7db46-5713-498f-8884-8b49b2ec70fe"
      unitRef="shares">268771</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id32fe94f97e84076b84beaff756aa3fa_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTEtNS0xLTEtMA_8949ec87-c083-48fb-a9b7-43fbe167920b"
      unitRef="usd">1652000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8dac01400f8a441eaf95cdb7f2c88e1e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTEtMTEtMS0xLTA_18e31f6f-51b8-43dd-a4e6-1b250990bc32"
      unitRef="usd">1652000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id32fe94f97e84076b84beaff756aa3fa_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTItNS0xLTEtMA_48f6ec36-22b7-466d-82b6-08c870507c8c"
      unitRef="usd">20430000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8dac01400f8a441eaf95cdb7f2c88e1e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTItMTEtMS0xLTA_e90e6e12-8a21-4a7b-905a-0025da70a7a1"
      unitRef="usd">20430000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibc5c534cd84f4787a526c269ef4c6151_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTMtNy0xLTEtMA_ae57c622-957b-45ed-afea-c41c2ae23554"
      unitRef="usd">1562000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8dac01400f8a441eaf95cdb7f2c88e1e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTMtMTEtMS0xLTA_d4a6f6e5-e200-40b3-a011-824efcff571f"
      unitRef="usd">1562000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ie481c63be9664fed98e565204a85caf1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTQtOS0xLTEtMA_ebf159cc-c291-4970-b2e5-fdad38e89d5c"
      unitRef="usd">-90478000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8dac01400f8a441eaf95cdb7f2c88e1e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTQtMTEtMS0xLTA_6f8c417d-3137-4880-8f6c-6aea780f966c"
      unitRef="usd">-90478000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="if50f19fc8ffb45ec878303df8a922a99_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTYtMS0xLTEtMA_b43ada67-7a2b-4531-b5f1-a3e554f48df5"
      unitRef="shares">69058696</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if50f19fc8ffb45ec878303df8a922a99_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTYtMy0xLTEtMA_774a0077-4317-40c6-8c5c-c30a6fbebc8a"
      unitRef="usd">69000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2f336477ca834d10a759110a6b168a44_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTYtNS0xLTEtMA_5258df9f-3ac5-483a-bb2e-d32e5c298e12"
      unitRef="usd">2203599000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2c742c6a37f940b1b7230f3dad49ebc6_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTYtNy0xLTEtMA_b517ce34-230d-4521-add9-c3dd235a7f3c"
      unitRef="usd">1636000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idaea355a6eee4c84b610bb5a3998cb0a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTYtOS0xLTEtMA_20c4689b-db94-4666-b495-37fd1e1a1b17"
      unitRef="usd">-1646839000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if74da64f69904adba74c4a3593889ebc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTYtMTEtMS0xLTA_d972580d-db60-442c-939b-28b6fd35b891"
      unitRef="usd">558465000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="icafe5156f770497288825e054150807e_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTctMS0xLTEtNDQ_4a26d513-8085-446b-b8d4-9801fd9c50eb"
      unitRef="shares">139367</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5e51e0bf32b84c06bc802cf158d85892_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTctNS0xLTEtNDQ_ebfcf74e-6b47-41e9-872d-3c885f7b2459"
      unitRef="usd">3532000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTctMTEtMS0xLTQ0_e7a17bd3-ccfa-4a3f-8e24-5ab8bee7a74c"
      unitRef="usd">3532000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5e51e0bf32b84c06bc802cf158d85892_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTgtNS0xLTEtNDQ_274f5d8b-56ec-40d8-86d4-6773127b58a3"
      unitRef="usd">18407000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTgtMTEtMS0xLTQ0_073348de-fdea-40ab-bfc8-7a5c594a5424"
      unitRef="usd">18407000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic794988e2ef64d2d903b700cc61ab8ac_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTktNy0xLTEtNDQ_0ce3e6b5-8e63-4c3e-939c-709eb4585734"
      unitRef="usd">-973000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMTktMTEtMS0xLTQ0_32758415-1fca-414d-b1f4-715a828b010c"
      unitRef="usd">-973000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ib5e2bd57c0864b8ca52c0dbc9e5247eb_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMjAtOS0xLTEtNDQ_33df12ba-18e5-4bff-80d9-6f37c213c880"
      unitRef="usd">-98979000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMjAtMTEtMS0xLTQ0_ef60c08f-a484-4d47-a4b3-ec298aab78f3"
      unitRef="usd">-98979000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ie77331352e8e487ab5aaa801714a9478_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMjEtMS0xLTEtMTAx_d878ef75-60c5-4671-9f64-fd1f1130d252"
      unitRef="shares">69198063</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie77331352e8e487ab5aaa801714a9478_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMjEtMy0xLTEtMTAx_ce324f92-0a87-4b46-834b-a98b7abfc5d2"
      unitRef="usd">69000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9f5eb666df1f4354b1d4dcf993b7fd72_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMjEtNS0xLTEtMTAx_82a80add-1569-4b83-b267-3fecbd963a8c"
      unitRef="usd">2225538000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icfb43edba9e24d7aa4bc0b84a542b1a4_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMjEtNy0xLTEtMTAx_db333cec-6c62-45bc-9e26-a15c51215b11"
      unitRef="usd">663000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic221521f25684d8291dde2458b8fd56d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMjEtOS0xLTEtMTAx_2e2f465b-a38e-420a-a585-052ce650613c"
      unitRef="usd">-1745818000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOjMxYTE2YWU4ZDAwMDQ3ZmE4ZDhiMDYwN2MzZDBlYjUzL3RhYmxlcmFuZ2U6MzFhMTZhZThkMDAwNDdmYThkOGIwNjA3YzNkMGViNTNfMjEtMTEtMS0xLTEwMQ_b0ad303e-cb19-4a67-9caf-c2b3732dec00"
      unitRef="usd">480452000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="iddbd8fd3a9234d15a8eda0993f4f1137_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMi0xLTEtMS0w_56871918-6682-4e6c-83b7-e98ca625194f"
      unitRef="shares">58218653</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iddbd8fd3a9234d15a8eda0993f4f1137_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMi0zLTEtMS0w_d6f80a33-24b5-440d-b235-378085b9e0bf"
      unitRef="usd">58000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iccd377f04511411f8b9b576f6daddde7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMi01LTEtMS0w_f669d26d-c23e-4b3a-a790-1b187bdee0f5"
      unitRef="usd">1794283000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia7a7de9468d1492cb68a6b85d84c50e3_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMi03LTEtMS0w_6541a5f2-8b7f-444d-acc4-f4614c25e3b8"
      unitRef="usd">-2171000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i958a5eaaa1994c0e8785e2290bffb78c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMi05LTEtMS0w_b71e4ed7-df43-441c-8cfd-8fbb4fdf3d4b"
      unitRef="usd">-1104633000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8ee3f08f37a94847b4581c44661b6945_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMi0xMS0xLTEtMA_ee6b07e4-ac20-4084-965f-2c6c477ab495"
      unitRef="usd">687537000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if10cfda3b1ae42dd94275ef357f4b6ab_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMy0xLTEtMS0w_cd742a75-3710-4c7f-b302-b950da888039"
      unitRef="shares">441168</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if10cfda3b1ae42dd94275ef357f4b6ab_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMy0zLTEtMS0w_ec9f9dc8-ece6-4642-9fd9-4968cc122f5c"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i23e8641cdf9d4a0ba36b18e83e1f74f5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMy01LTEtMS0w_f2fcb045-66a9-4048-ae9f-a1b4fa86f9e7"
      unitRef="usd">6002000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i09874c19ef114cc9a325361e8c04db94_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMy0xMS0xLTEtMA_7d670df8-686a-483b-a8dd-aef2aea7c789"
      unitRef="usd">6003000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i23e8641cdf9d4a0ba36b18e83e1f74f5_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfNC01LTEtMS0w_2a919db0-baed-4c04-b9c8-d7d9ad7a0638"
      unitRef="usd">18108000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i09874c19ef114cc9a325361e8c04db94_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfNC0xMS0xLTEtMA_1e2bb72d-a48c-48cf-8531-9231762cc4eb"
      unitRef="usd">18108000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0aee4cc470d44c5e99067c41afb5f002_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfNS03LTEtMS0w_d2e5abea-097c-4baf-b658-4c90af81aa42"
      unitRef="usd">1687000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i09874c19ef114cc9a325361e8c04db94_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfNS0xMS0xLTEtMA_2d2d056c-2a64-42aa-aa89-bd608931008b"
      unitRef="usd">1687000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i44c7bfd7973b423691bd63d2af7d57aa_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfNy05LTEtMS0w_560522cf-4a1a-42f5-b495-e3d2bd2f04a5"
      unitRef="usd">-93078000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i09874c19ef114cc9a325361e8c04db94_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfNy0xMS0xLTEtMA_c11ed887-c506-42f3-8c77-e30cff888b11"
      unitRef="usd">-93078000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ic76020b398604ca1bf1af8adacc2ffce_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfOC0xLTEtMS0w_1dcb5557-0e38-4834-90bf-a25dc5da8516"
      unitRef="shares">58659821</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic76020b398604ca1bf1af8adacc2ffce_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfOC0zLTEtMS0w_6ce3ba46-eb36-481c-80aa-aabd552d987c"
      unitRef="usd">59000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5c08cf4ec15f402aadb383d3cf0aac8d_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfOC01LTEtMS0w_7eb91963-ac97-4f0d-99eb-79d4345acbaa"
      unitRef="usd">1818393000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia32695c6f95b4eecbd80e2ba29818b2d_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfOC03LTEtMS0w_eaac4daf-184c-4177-869c-97fc02f7f280"
      unitRef="usd">-484000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8bf3fa70c71d4e65bfa404b0233a7d5e_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfOC05LTEtMS0w_ed40b5a5-1412-4bc3-aa4d-9740e24401d5"
      unitRef="usd">-1197711000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iac1252d10b6040f4876c7756be3e4a76_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfOC0xMS0xLTEtMA_483171be-9a65-40ea-b415-95e2e050b5f6"
      unitRef="usd">620257000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i99487a9075154d1481319c8e1e5c20c8_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTAtMS0xLTEtMA_6576ea78-ce9a-4d18-9253-e069c43b9809"
      unitRef="shares">89365</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2989a9b9047443f9a4e2a2c0bb1625f4_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTAtNS0xLTEtMA_bfdebf7e-3d79-4f92-9789-756d46ac662f"
      unitRef="usd">2770000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8f6dcdda42cf4c478aff8535b767c4c4_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTAtMTEtMS0xLTA_82a36378-e991-4f02-a7fa-ab7fe7ab6647"
      unitRef="usd">2770000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2989a9b9047443f9a4e2a2c0bb1625f4_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTEtNS0xLTEtMA_11fb47b0-eee2-4807-aea0-0abd65532044"
      unitRef="usd">18547000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8f6dcdda42cf4c478aff8535b767c4c4_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTEtMTEtMS0xLTA_b791b832-2e3f-4567-a7a1-62b48d102033"
      unitRef="usd">18547000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib8b377237524434a885c88b184553ef7_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTItNy0xLTEtMA_13d0b462-c487-4cc2-a788-9f58aad786c7"
      unitRef="usd">974000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8f6dcdda42cf4c478aff8535b767c4c4_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTItMTEtMS0xLTA_b2046752-c977-42f1-b58d-7a1905bf083c"
      unitRef="usd">974000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i7159c55a54a64257836b127ebdbe79ca_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTMtOS0xLTEtMA_336a0c08-8cbd-44b6-a6c4-3c17aefe4d15"
      unitRef="usd">-109871000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8f6dcdda42cf4c478aff8535b767c4c4_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTMtMTEtMS0xLTA_80ca9f1b-8b82-4ce3-bfbf-ae9972669b06"
      unitRef="usd">-109871000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="icc3e62b98968494bba8bee317e04525f_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTUtMS0xLTEtMA_cebb243d-2aeb-4134-b94e-adb588f6a64e"
      unitRef="shares">58749186</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="icc3e62b98968494bba8bee317e04525f_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTUtMy0xLTEtMA_1f0d97d6-41af-499c-818a-72d9bab9c63e"
      unitRef="usd">59000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i14619843617f40c7a9cf1f66f71c1c27_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTUtNS0xLTEtMA_c08966ee-3390-4603-a6db-820fdfc6e445"
      unitRef="usd">1839710000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib4f71ec0a74244a898c7f64d6f7c861d_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTUtNy0xLTEtMA_abe0cdac-b712-4ce6-ab4a-fed4204d1755"
      unitRef="usd">490000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9327aef1d4d84255b2eb04bc36f39536_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTUtOS0xLTEtMA_e8bb908d-387e-49f2-8240-c8a9993bf8a3"
      unitRef="usd">-1307582000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i33d12dc0073b41d0b953c2cd4414bb09_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTUtMTEtMS0xLTA_81dba3a3-55c0-4c1d-afd0-86c876aa8dfd"
      unitRef="usd">532677000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i1053b3953d9d41a4b58d1f9f40168930_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTYtMS0xLTEtNTk_92b610fc-6570-4ffd-9aae-3fd2fd150821"
      unitRef="shares">128505</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i96e9cac9a5b245e1ab992da2a4f3b707_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTYtNS0xLTEtNTk_c03af969-3533-4b63-9f79-02ec403b97a3"
      unitRef="usd">3225000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTYtMTEtMS0xLTU5_73f3e322-1373-4383-9008-8284b440a105"
      unitRef="usd">3225000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i96e9cac9a5b245e1ab992da2a4f3b707_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTctNS0xLTEtNTk_19625df2-aca2-49b9-bc10-a5968e4896d7"
      unitRef="usd">18588000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTctMTEtMS0xLTU5_d2745d10-6885-4a19-9af4-e65fa8f50eaa"
      unitRef="usd">18588000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1c451a043eeb4e1c90f9351c338a270c_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTgtNy0xLTEtNTk_ecf55ae8-e1bd-4f90-8583-817f3d67b515"
      unitRef="usd">-26000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTgtMTEtMS0xLTU5_b82bb911-28d0-49e4-9249-594ff89dab42"
      unitRef="usd">-26000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ie090a495a771498fa103545475845412_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTktOS0xLTEtNTk_f207851c-f42d-441e-8989-04c03d44f1f8"
      unitRef="usd">-106173000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMTktMTEtMS0xLTU5_37c678f0-97d3-4490-b069-e54a592888e1"
      unitRef="usd">-106173000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i711e80bbc9f74ab3b7066dfb0f019bfb_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMjAtMS0xLTEtNzE_fcaa487b-1302-4a01-9caa-a2e051018f59"
      unitRef="shares">58877691</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i711e80bbc9f74ab3b7066dfb0f019bfb_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMjAtMy0xLTEtNzE_7c55d546-a45b-4ad2-9396-6e51bf471fcf"
      unitRef="usd">59000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i382fc23536884c45afe5acfaef266947_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMjAtNS0xLTEtNzE_476b3508-5384-400f-aecf-fb1ed7be5c11"
      unitRef="usd">1861523000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i53f5dfe3b6464427a8673fa0c75cf825_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMjAtNy0xLTEtNzE_3c97d777-07f5-44eb-89af-ead3b5d462cb"
      unitRef="usd">464000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1c8d5ed345084b43bbf0c55a4d2ee227_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMjAtOS0xLTEtNzE_685759a3-174d-4bc2-8fa6-30c6aac62ddd"
      unitRef="usd">-1413755000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9c9f7f3cb6d047899b09ad580b69156b_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yNS9mcmFnOmI4MWJmNzlkYWZkNjQ3Mjg4OWFhODMxMGI3ZGQwZGFjL3RhYmxlOmU0YmQ4OTZhYzgwZDRmZjI5NTFhMTBlNGExMmUxMzY4L3RhYmxlcmFuZ2U6ZTRiZDg5NmFjODBkNGZmMjk1MWExMGU0YTEyZTEzNjhfMjAtMTEtMS0xLTcx_96068c68-26b1-4adb-86a9-565b8368431e"
      unitRef="usd">448291000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMy0xLTEtMS0w_f21e3901-c477-44f1-8968-93334b060c7f"
      unitRef="usd">-229713000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMy0zLTEtMS0w_384dfb64-12d9-4eb6-ab36-758643397b15"
      unitRef="usd">-309122000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNS0xLTEtMS0w_5f73f522-9cff-47f9-a235-45237f356b40"
      unitRef="usd">7307000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNS0zLTEtMS0w_2d87bc34-5af1-4209-bf3d-45e8fc437d6a"
      unitRef="usd">6124000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNi0xLTEtMS0w_26b3f1d5-4a75-49af-8d34-d29b1197cf06"
      unitRef="usd">58527000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNi0zLTEtMS0w_a5aad2f3-8e9b-499b-9449-2c98e445ea83"
      unitRef="usd">55243000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNy0xLTEtMS0w_d47b1cc6-2ea5-4cec-952e-220a295d4f88"
      unitRef="usd">-1521000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNy0zLTEtMS0w_0b663d05-dd48-4a96-a9f3-b8f71b2c2596"
      unitRef="usd">2772000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfOC0xLTEtMS0w_90d10d8a-6073-4a82-b704-3ff649e81d55"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfOC0zLTEtMS0w_b7c2614c-998e-4250-a4c5-be8744c3b499"
      unitRef="usd">-466000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <agio:OperatingLeaseRightOfUseAssetAmortization
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfOS0xLTEtMS0w_a862d1e2-42f7-44b3-a526-418a74b15e2f"
      unitRef="usd">6691000</agio:OperatingLeaseRightOfUseAssetAmortization>
    <agio:OperatingLeaseRightOfUseAssetAmortization
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfOS0zLTEtMS0w_b5fe704c-cc0b-49c1-b690-c2d899f277d7"
      unitRef="usd">6341000</agio:OperatingLeaseRightOfUseAssetAmortization>
    <agio:InterestExpenseNonCashSaleOfFutureRevenue
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTAtMS0xLTEtMA_2659fa23-c065-4728-8d59-e7ef20667ba1"
      unitRef="usd">11818000</agio:InterestExpenseNonCashSaleOfFutureRevenue>
    <agio:InterestExpenseNonCashSaleOfFutureRevenue
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTAtMy0xLTEtMA_5a41e659-f011-4934-bc6c-65d30f0dafbc"
      unitRef="usd">0</agio:InterestExpenseNonCashSaleOfFutureRevenue>
    <agio:RoyaltyRevenueNonCash
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTEtMS0xLTEtMA_837e1ef3-ffac-4e71-9ac5-6929b9a73523"
      unitRef="usd">4341000</agio:RoyaltyRevenueNonCash>
    <agio:RoyaltyRevenueNonCash
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTEtMy0xLTEtMA_9838ae27-274c-43f7-b4dc-bfc9685d9e67"
      unitRef="usd">0</agio:RoyaltyRevenueNonCash>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTMtMS0xLTEtMA_38204963-1517-4c90-a302-153ab901f35a"
      unitRef="usd">10037000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTMtMy0xLTEtMA_01784a60-c700-4907-946f-d318b086cb7d"
      unitRef="usd">2030000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <agio:IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTQtMS0xLTEtMA_67e13102-fe28-4d87-925f-6e4fc66c753e"
      unitRef="usd">795000</agio:IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent>
    <agio:IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTQtMy0xLTEtMA_3cd71bad-6f88-4241-8d00-bbe1c8085901"
      unitRef="usd">-624000</agio:IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent>
    <agio:IncreaseDecreaseInCollaborationReceivableOtherCurrent
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTUtMS0xLTEtMA_3f66a606-0201-4e7d-ad11-a596fa0a8172"
      unitRef="usd">64000</agio:IncreaseDecreaseInCollaborationReceivableOtherCurrent>
    <agio:IncreaseDecreaseInCollaborationReceivableOtherCurrent
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTUtMy0xLTEtMA_60dfefc3-fa65-4a34-a08b-a3113befe8e5"
      unitRef="usd">199000</agio:IncreaseDecreaseInCollaborationReceivableOtherCurrent>
    <agio:IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTYtMS0xLTEtMA_359b8b6f-a3e4-43d4-a2a8-b5a1432e2a5c"
      unitRef="usd">-2900000</agio:IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent>
    <agio:IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTYtMy0xLTEtMA_0d01ca14-d9a9-4957-9ad6-2e4674738137"
      unitRef="usd">366000</agio:IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTctMS0xLTEtMA_e9766720-2db5-4df1-ad96-f94e5654107e"
      unitRef="usd">4040000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTctMy0xLTEtMA_4df9b6b5-ec0a-44f5-9d2c-5718c57590ef"
      unitRef="usd">4980000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTktMS0xLTEtMA_12688003-071c-4ec5-a0ca-ec19180c87e9"
      unitRef="usd">6033000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMTktMy0xLTEtMA_e3500ae5-a987-4daf-89bc-6d56e46d8249"
      unitRef="usd">3552000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjAtMS0xLTEtMA_9f0c2e1b-1667-45eb-8f60-128f52e05853"
      unitRef="usd">-7640000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjAtMy0xLTEtMA_a02e6824-9966-4ec0-9985-f1fff0a87a8a"
      unitRef="usd">2649000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjEtMS0xLTEtMA_6e3c64d0-9394-44a1-8423-8580fe777587"
      unitRef="usd">162000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjEtMy0xLTEtMA_8e9ab893-f6ef-45b7-a6c0-2339e26a6f7b"
      unitRef="usd">4602000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <agio:IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjItMS0xLTEtMA_53f44d8f-7de2-4a56-9878-acff2a55d167"
      unitRef="usd">-61513000</agio:IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty>
    <agio:IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjItMy0xLTEtMA_3d54e6ec-8590-4f73-978e-7760bed71d24"
      unitRef="usd">-25849000</agio:IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty>
    <agio:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjMtMS0xLTEtMA_a029582e-e411-4553-b554-ea00cb1ab822"
      unitRef="usd">-6112000</agio:IncreaseDecreaseInOperatingLeaseLiability>
    <agio:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjMtMy0xLTEtMA_3062fd6b-7d99-4d7a-9dec-69019c689dfd"
      unitRef="usd">-4190000</agio:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjUtMS0xLTEtMA_78d9628e-d897-4380-873f-e4b875d0cc45"
      unitRef="usd">-241362000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjUtMy0xLTEtMA_ca76f2e4-a7c3-4626-b63b-3d85f542eaa0"
      unitRef="usd">-277011000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjctMS0xLTEtMA_c9ceb9f2-cd24-49cd-8389-d7534b6a4554"
      unitRef="usd">430624000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjctMy0xLTEtMA_00bf22a9-5295-4550-a886-54d4acf48933"
      unitRef="usd">194822000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjgtMS0xLTEtMA_3ad491e4-79fa-41ba-a522-1eaa99a8753d"
      unitRef="usd">448866000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjgtMy0xLTEtMA_1a93eef5-ce6d-4992-bad1-f334172b0aae"
      unitRef="usd">476382000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjktMS0xLTEtMA_43025246-3e80-48b7-827f-d5b64957ee87"
      unitRef="usd">13892000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMjktMy0xLTEtMA_d1dc3014-5222-40a6-abeb-4315537033a5"
      unitRef="usd">5347000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMzAtMS0xLTEtMA_fe2b0fce-9626-4bcd-868b-f255f40acb49"
      unitRef="usd">4350000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMzAtMy0xLTEtMA_7beb904e-0bea-42dc-a6f6-7e039bdae678"
      unitRef="usd">276213000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMzItMS0xLTEtMA_901f60a5-bfc2-4d4f-8980-12b2656f41be"
      unitRef="usd">250000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMzItMy0xLTEtMA_edb60e42-3db7-45cd-94d4-363f75a0a017"
      unitRef="usd">0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMzUtMS0xLTEtMA_cbc7271f-dae4-4f26-bf5f-ab23f6e17f93"
      unitRef="usd">10649000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMzUtMy0xLTEtMA_a325bb20-f083-4648-8689-1916e453c051"
      unitRef="usd">12005000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <agio:ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMzYtMS0xLTEtMA_9e33df90-b359-46e4-9393-40960df55e36"
      unitRef="usd">250537000</agio:ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts>
    <agio:ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMzYtMy0xLTEtMA_5778acfd-6338-46c6-a32c-10a9ee95ebfa"
      unitRef="usd">0</agio:ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMzgtMS0xLTEtMA_9b6adbca-dd7b-4fa4-820a-9bd1d3f9711a"
      unitRef="usd">260936000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMzgtMy0xLTEtMA_00c8ef4f-6d4a-46ba-bd0b-d6a619e5aaf4"
      unitRef="usd">12005000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMzktMS0xLTEtMA_add52332-bbac-4483-ab7a-a5a4e73695b7"
      unitRef="usd">23924000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfMzktMy0xLTEtMA_552c0df4-0249-414c-ad7a-aea1519524eb"
      unitRef="usd">11207000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNDAtMS0xLTEtMA_9c150023-49aa-4d0e-8497-04006426422e"
      unitRef="usd">80931000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8ee3f08f37a94847b4581c44661b6945_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNDAtMy0xLTEtMA_48c4a1f4-a7d4-44be-a1ec-6959dcac4e3d"
      unitRef="usd">70502000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNDEtMS0xLTEtMA_18942250-65ce-46d6-b3a4-16e94414b47f"
      unitRef="usd">104855000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9c9f7f3cb6d047899b09ad580b69156b_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNDEtMy0xLTEtMA_adf09229-0a4f-455c-a3f2-40bc2b9bcf7b"
      unitRef="usd">81709000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNDMtMS0xLTEtMA_25d8d7fe-9293-4b97-81f4-77cf6e481662"
      unitRef="usd">185000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNDMtMy0xLTEtMA_bc19ad3e-a38e-4122-8ea6-c63db382854c"
      unitRef="usd">2089000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNDYtMS0xLTEtMA_e66ad4e7-4f26-4389-9251-7fd3dfb017bf"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8yOC9mcmFnOmM2ZmUzYTA0NmYxNDQ4NjU5NTJhZmNiNzkzMzhmNzdjL3RhYmxlOjI4NTVmZTgzY2QzMjRjN2FhODJhOWQ2MzdiZWFjYmQ2L3RhYmxlcmFuZ2U6Mjg1NWZlODNjZDMyNGM3YWE4MmE5ZDYzN2JlYWNiZDZfNDYtMy0xLTEtMA_094add9a-2b1a-4ade-9276-d59ab3092f45"
      unitRef="usd">42322000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8zNC9mcmFnOjg5NDU1Y2U3NzY0ODRmYzlhMThkNjEzMDMzMGNjMGVmL3RleHRyZWdpb246ODk0NTVjZTc3NjQ4NGZjOWExOGQ2MTMwMzMwY2MwZWZfNDY5Nw_40959fe0-66ba-4748-b063-8ea86b220bdd">Overview and Basis of Presentation&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;References to Agios&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Throughout this Quarterly Report on Form&#160;10-Q,&#160;&#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our,&#x201d; and similar expressions, except where the context requires otherwise, refer to Agios Pharmaceuticals, Inc. and its consolidated subsidiaries, and &#x201c;our Board of Directors&#x201d; refers to the board of directors of Agios Pharmaceuticals, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a biopharmaceutical company committed to transforming patients&#x2019; lives through scientific leadership in the field of cellular metabolism and adjacent areas of biology, with the goal of creating differentiated, small molecule medicines for patients in the areas of hematologic malignancies, solid tumors and rare genetic diseases, or RGDs. To address these focus areas, we take a systems biology approach to deeply understand disease states, drive the discovery and validation of novel therapeutic targets, and define patient selection strategies, thereby increasing the probability that our experimental medicines will have the desired therapeutic effect. We are located in Cambridge, Massachusetts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated balance sheet as of September&#160;30, 2020, the condensed consolidated statements of operations, comprehensive loss and stockholders' equity for the three and nine months ended September 30, 2020 and 2019, and the condensed consolidated statements of cash flows for the nine months ended September 30, 2020 and 2019 are unaudited. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of our management, reflect all adjustments, which include only normal recurring adjustments, necessary to fairly state our financial position as of September&#160;30, 2020, our results of operations and stockholders' equity for the three and nine months ended September 30, 2020 and 2019, and cash flows for the nine months ended September 30, 2020 and 2019. The financial data and the other financial information disclosed in these notes to the condensed consolidated financial statements related to the three and nine-month periods are also unaudited. The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2020 or for any other future annual or interim period. The condensed consolidated balance sheet data as of December&#160;31, 2019 was derived from our audited financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles, or U.S. GAAP. The condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019 that was filed with the Securities and Exchange Commission, or the SEC, on February&#160;19, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include our accounts and the accounts of our wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared in conformity with U.S. GAAP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain the pandemic or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 11, 2020, we sold our tiered, sales-based royalty rights on worldwide net sales of IDHIFA&#xae; (enasidenib), as well as our rights to receive up to $55.0&#160;million in outstanding regulatory milestone payments from Bristol Myers Squibb, or BMS, to Royalty Pharma, or RPI, for $255.0&#160;million. Under the 2010 Agreement, we remain eligible to receive a $25.0&#160;million potential &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;milestone payment for the enasidenib program upon achievement of a specified ex-U.S. commercial milestone event, as well as reimbursement for costs incurred for our co-commercialization efforts and development activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, we had cash, cash equivalents and marketable securities of $722.4 million. Although we have incurred recurring losses and expect to continue to incur losses for the foreseeable future, we expect our cash, cash equivalents and marketable securities will be sufficient to fund current operations for at least the next twelve months from the issuance date of these financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8zNC9mcmFnOjg5NDU1Y2U3NzY0ODRmYzlhMThkNjEzMDMzMGNjMGVmL3RleHRyZWdpb246ODk0NTVjZTc3NjQ4NGZjOWExOGQ2MTMwMzMwY2MwZWZfNDY5OA_51236d8b-e2ad-4607-9f54-d799602c81af">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated balance sheet as of September&#160;30, 2020, the condensed consolidated statements of operations, comprehensive loss and stockholders' equity for the three and nine months ended September 30, 2020 and 2019, and the condensed consolidated statements of cash flows for the nine months ended September 30, 2020 and 2019 are unaudited. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of our management, reflect all adjustments, which include only normal recurring adjustments, necessary to fairly state our financial position as of September&#160;30, 2020, our results of operations and stockholders' equity for the three and nine months ended September 30, 2020 and 2019, and cash flows for the nine months ended September 30, 2020 and 2019. The financial data and the other financial information disclosed in these notes to the condensed consolidated financial statements related to the three and nine-month periods are also unaudited. The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2020 or for any other future annual or interim period. The condensed consolidated balance sheet data as of December&#160;31, 2019 was derived from our audited financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles, or U.S. GAAP. The condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019 that was filed with the Securities and Exchange Commission, or the SEC, on February&#160;19, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include our accounts and the accounts of our wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared in conformity with U.S. GAAP.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8zNC9mcmFnOjg5NDU1Y2U3NzY0ODRmYzlhMThkNjEzMDMzMGNjMGVmL3RleHRyZWdpb246ODk0NTVjZTc3NjQ4NGZjOWExOGQ2MTMwMzMwY2MwZWZfNDY5NQ_75bceb17-708e-4558-92e3-2ba6f0ea80bd">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain the pandemic or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <agio:RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold
      contextRef="ife55cfc6e645489a9aa97a13da6dfe00_I20200611"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8zNC9mcmFnOjg5NDU1Y2U3NzY0ODRmYzlhMThkNjEzMDMzMGNjMGVmL3RleHRyZWdpb246ODk0NTVjZTc3NjQ4NGZjOWExOGQ2MTMwMzMwY2MwZWZfMzgyNA_58ca2c90-30c3-4b25-a64f-a07725cac0ef"
      unitRef="usd">55000000.0</agio:RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold>
    <agio:ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold
      contextRef="ied54aa2a3f7e42998c98d6f9afe5e255_D20200611-20200611"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8zNC9mcmFnOjg5NDU1Y2U3NzY0ODRmYzlhMThkNjEzMDMzMGNjMGVmL3RleHRyZWdpb246ODk0NTVjZTc3NjQ4NGZjOWExOGQ2MTMwMzMwY2MwZWZfMzkzOA_8287a6bc-d453-40d1-a316-2096f60b9a79"
      unitRef="usd">255000000.0</agio:ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold>
    <agio:RevenueRecognitionMilestoneMethodEligibleReceivable
      contextRef="idf22f68ca84c40088ac574f70d88d77d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8zNC9mcmFnOjg5NDU1Y2U3NzY0ODRmYzlhMThkNjEzMDMzMGNjMGVmL3RleHRyZWdpb246ODk0NTVjZTc3NjQ4NGZjOWExOGQ2MTMwMzMwY2MwZWZfNDAwMA_25b26e4b-7bc3-4c17-93cd-5200be855d81"
      unitRef="usd">25000000.0</agio:RevenueRecognitionMilestoneMethodEligibleReceivable>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8zNC9mcmFnOjg5NDU1Y2U3NzY0ODRmYzlhMThkNjEzMDMzMGNjMGVmL3RleHRyZWdpb246ODk0NTVjZTc3NjQ4NGZjOWExOGQ2MTMwMzMwY2MwZWZfNDMwNA_00506c18-3a90-4a5f-8819-d0aaf6703097"
      unitRef="usd">722400000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8zNy9mcmFnOjZjZjBmNjk5NTU1ZTQxMjZiMzc3ZTBkZTE1OGVlMmQzL3RleHRyZWdpb246NmNmMGY2OTk1NTVlNDEyNmIzNzdlMGRlMTU4ZWUyZDNfMzMzNg_1a9afa69-a1fe-4b23-80be-cfc3bab37346">Summary of Significant Accounting Policies&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant accounting policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board, or FASB issued Accounting Standards Update, or ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which introduces new guidance for the accounting for credit losses on instruments within its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. Credit losses relating to available-for-sale debt securities will also be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. The guidance is effective for fiscal years beginning after December 31, 2019, including interim periods within those years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the quarter ended March 31, 2020, we adopted ASU 2016-13, which eliminated the concept of other-than-temporary impairments and required credit losses on debt securities to be recorded through an allowance for credit losses instead of as a reduction in the amortized cost basis of the securities. Application of the amendments is through a cumulative-effect adjustment to retained earnings as of the effective date. Based upon our analysis, the adoption of this final rule did not have a material impact on the financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liability related to sale of future revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We treat the sale of future revenue to RPI as a debt financing, as we have significant continuing involvement in the generation of the cash flows. As result, we recorded the proceeds from this transaction as a liability related to the sale of future revenue to be amortized to interest expense using the effective interest rate method over the life of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The liability related to sale of future revenue and the related interest expense are based on our current estimates of future royalties expected to be paid over the life of the arrangement. We will periodically assess the expected royalty payments using a combination of internal projections and forecasts from external sources. To the extent our future estimates of royalty payments are greater or less than previous estimates or the estimated timing of such payments is materially different than its previous estimates, we will prospectively recognize related non-cash interest expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For further discussion of the sale of future revenue, refer to Note 10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sale of Future Revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amortization of issuance costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We treated the liability related to sale of future revenue as a debt financing. As such, the long-term liability is initially recorded at its proceeds, net of deferred costs. Issuance costs, fees directly related to the sale of future revenue, are offset against initial carrying value of the long-term liability and are amortized on a straight-line basis over the remaining patent life of the product to an operating expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no other material changes to the significant accounting policies previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8zNy9mcmFnOjZjZjBmNjk5NTU1ZTQxMjZiMzc3ZTBkZTE1OGVlMmQzL3RleHRyZWdpb246NmNmMGY2OTk1NTVlNDEyNmIzNzdlMGRlMTU4ZWUyZDNfMjc0ODc3OTA3Mjc4MQ_9cd717a5-6b66-46b6-bbbc-7675c8608c6a">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board, or FASB issued Accounting Standards Update, or ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which introduces new guidance for the accounting for credit losses on instruments within its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. Credit losses relating to available-for-sale debt securities will also be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. The guidance is effective for fiscal years beginning after December 31, 2019, including interim periods within those years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the quarter ended March 31, 2020, we adopted ASU 2016-13, which eliminated the concept of other-than-temporary impairments and required credit losses on debt securities to be recorded through an allowance for credit losses instead of as a reduction in the amortized cost basis of the securities. Application of the amendments is through a cumulative-effect adjustment to retained earnings as of the effective date. Based upon our analysis, the adoption of this final rule did not have a material impact on the financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <agio:SaleOfFutureRevenuePolicyPolicyTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl8zNy9mcmFnOjZjZjBmNjk5NTU1ZTQxMjZiMzc3ZTBkZTE1OGVlMmQzL3RleHRyZWdpb246NmNmMGY2OTk1NTVlNDEyNmIzNzdlMGRlMTU4ZWUyZDNfMjc0ODc3OTA3Mjc4MA_166f0bd7-14b5-4bab-a4a0-a95c92a07d26">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liability related to sale of future revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We treat the sale of future revenue to RPI as a debt financing, as we have significant continuing involvement in the generation of the cash flows. As result, we recorded the proceeds from this transaction as a liability related to the sale of future revenue to be amortized to interest expense using the effective interest rate method over the life of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The liability related to sale of future revenue and the related interest expense are based on our current estimates of future royalties expected to be paid over the life of the arrangement. We will periodically assess the expected royalty payments using a combination of internal projections and forecasts from external sources. To the extent our future estimates of royalty payments are greater or less than previous estimates or the estimated timing of such payments is materially different than its previous estimates, we will prospectively recognize related non-cash interest expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For further discussion of the sale of future revenue, refer to Note 10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sale of Future Revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amortization of issuance costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We treated the liability related to sale of future revenue as a debt financing. As such, the long-term liability is initially recorded at its proceeds, net of deferred costs. Issuance costs, fees directly related to the sale of future revenue, are offset against initial carrying value of the long-term liability and are amortized on a straight-line basis over the remaining patent life of the product to an operating expense.&lt;/span&gt;&lt;/div&gt;</agio:SaleOfFutureRevenuePolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RleHRyZWdpb246YjExODg3NjJlN2IxNDVhNzhmZDU2YjkzMmNlNDczMTdfMTkzMA_04648071-13b9-4830-a331-bccc729bf527">Fair Value Measurements&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record cash equivalents and marketable securities at fair value. Accounting Standards Codification, or ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our cash equivalents and marketable securities measured at fair value on a recurring basis as of September&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents and marketable securities have been initially valued at the transaction price and subsequently, at the end of each reporting period, valued utilizing third-party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches, and observable market inputs to determine value. After completing our validation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no changes to the valuation methods during the nine months ended September 30, 2020. We evaluate transfers between levels at the end of each reporting period. We have no financial assets or liabilities that were classified as Level 3 at any point during the nine months ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RleHRyZWdpb246YjExODg3NjJlN2IxNDVhNzhmZDU2YjkzMmNlNDczMTdfMTkzMQ_311af4b9-dc8a-46fe-8b38-2a66170cb0c7">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record cash equivalents and marketable securities at fair value. Accounting Standards Codification, or ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RleHRyZWdpb246YjExODg3NjJlN2IxNDVhNzhmZDU2YjkzMmNlNDczMTdfMTkzMw_1d642415-ff4e-46fb-8656-a9b14f553dbb">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our cash equivalents and marketable securities measured at fair value on a recurring basis as of September&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i543ea632249a45b4b913803db254e6d2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfMS0xLTEtMS0w_183ae7ef-7b24-4f0d-87cc-083ed7001f4c"
      unitRef="usd">54494000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i71a231d7d6a8434383ad19d455d7141a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfMS0zLTEtMS0w_544c9442-4221-49b4-9000-1318908884de"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie11b847113844524904871ec37728936_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfMS01LTEtMS0w_23bb58bc-19ad-4131-a27a-cd975fd5c3b9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i039327938bac4cc0a80cd5dc934f1d1d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfMS03LTEtMS0w_0f02b69f-3cb7-451a-898b-987215e4789b"
      unitRef="usd">54494000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if7218efcd2284c88a1600bcc960ede96_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfMi0xLTEtMS0w_01faf268-8293-4f61-bef8-cbf3b31bf951"
      unitRef="usd">54494000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib2e5aaad6c904909a156e5d4b4f185fe_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfMi0zLTEtMS0w_6b431e1c-e2dd-4edc-90c2-89534e6f0663"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if555a5ee5cf0408a86be0d8a8d59801f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfMi01LTEtMS0w_31c6f475-ad34-4cce-8c61-1cebabed2cdb"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i821a817349064dcc8e6938597d3db79e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfMi03LTEtMS0w_76f6deb6-24e9-4a7e-9102-fa72d718e039"
      unitRef="usd">54494000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaed01c1b899c4709b5accd32d8312191_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfNi0xLTEtMS0w_d348441b-e22c-4597-941a-bc7d54d8de0d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i08437c72c35449abacdc997fcf6867a2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfNi0zLTEtMS0w_744e4f41-0def-4ac2-a6ad-6b23ed484e00"
      unitRef="usd">145087000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6b4d1304c21246dc941d6150f7c3972e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfNi01LTEtMS0w_de206ab4-ae0d-4578-8a19-2b5991e30b5d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ideab8d3cd8824f7ebaadb03c9812b1b1_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfNi03LTEtMS0w_a9cad327-acc3-4735-9bab-ab079f90a674"
      unitRef="usd">145087000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i744b349803e74e989804d827439ae1f4_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfNy0xLTEtMS0w_ce73a5d7-4dba-48d0-a9eb-d9cedeaacc40"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3f2d69b28ccb4f61b622f3b366b4804b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfNy0zLTEtMS0w_f1dee12c-6347-40a7-9093-115fbf21d228"
      unitRef="usd">155725000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iedf6f8c98e70432c9500860ae91e2b2d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfNy01LTEtMS0w_c6020f54-7c09-4c36-bbe1-ed8f8d7418ff"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic6132c63023e4bc0bb7db5e06ab568fd_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfNy03LTEtMS0w_3a329d8a-f44e-4de5-b326-c782f76cb6b6"
      unitRef="usd">155725000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie484602594fc4892b37a19ce7a0605b8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfOC0xLTEtMS0w_bdd776f3-3906-461d-bd31-d228582b1111"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4a819345c25a47a78c1b9247bebd1445_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfOC0zLTEtMS0w_8d002365-1da7-4777-b685-aa28991bbb81"
      unitRef="usd">316761000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i12994fbfaa05455592901db5a2d7fb86_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfOC01LTEtMS0w_f8a5abbd-e666-4c87-b03b-06a400c08923"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7596257a08c149ec9fafbb992990cc54_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfOC03LTEtMS0w_1b9fd941-f4e5-4235-99af-fc600a325c7e"
      unitRef="usd">316761000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if7218efcd2284c88a1600bcc960ede96_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfOS0xLTEtMS0w_28495d79-e4a5-4a5e-b6bf-4fd90a71fbbc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib2e5aaad6c904909a156e5d4b4f185fe_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfOS0zLTEtMS0w_b8cef74e-ceed-4697-bff0-c1ba45189ddf"
      unitRef="usd">617573000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if555a5ee5cf0408a86be0d8a8d59801f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfOS01LTEtMS0w_1e315ba7-0193-4d77-8b28-47fbdd9a1fbc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i821a817349064dcc8e6938597d3db79e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfOS03LTEtMS0w_2a87ef7b-0300-4cf1-934d-53f5bc155aa1"
      unitRef="usd">617573000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <agio:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="if7218efcd2284c88a1600bcc960ede96_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfMTAtMS0xLTEtMA_3f4f6692-7365-4c41-a385-6ddbfdb474ab"
      unitRef="usd">54494000</agio:CashEquivalentsAndAvailableForSaleSecurities>
    <agio:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="ib2e5aaad6c904909a156e5d4b4f185fe_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfMTAtMy0xLTEtMA_9a550e86-1afd-400d-a200-0c78042e9607"
      unitRef="usd">617573000</agio:CashEquivalentsAndAvailableForSaleSecurities>
    <agio:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="if555a5ee5cf0408a86be0d8a8d59801f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfMTAtNS0xLTEtMA_affe695f-1cc4-4e9e-86dc-c71a732cff56"
      unitRef="usd">0</agio:CashEquivalentsAndAvailableForSaleSecurities>
    <agio:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="i821a817349064dcc8e6938597d3db79e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RhYmxlOmUyZjBjMjlhNjE2NDQzOGZhM2UyNGYwMjVhODJhM2Q1L3RhYmxlcmFuZ2U6ZTJmMGMyOWE2MTY0NDM4ZmEzZTI0ZjAyNWE4MmEzZDVfMTAtNy0xLTEtMA_614917bb-72f8-4b20-b90f-a9c87ba033d8"
      unitRef="usd">672067000</agio:CashEquivalentsAndAvailableForSaleSecurities>
    <us-gaap:FairValueNetAssetLiability
      contextRef="if555a5ee5cf0408a86be0d8a8d59801f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80MC9mcmFnOmIxMTg4NzYyZTdiMTQ1YTc4ZmQ1NmI5MzJjZTQ3MzE3L3RleHRyZWdpb246YjExODg3NjJlN2IxNDVhNzhmZDU2YjkzMmNlNDczMTdfMTgzNw_0552fc51-4ce9-4884-93db-c8ad83931fb9"
      unitRef="usd">0</us-gaap:FairValueNetAssetLiability>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfMjE3OQ_eb6635c2-d627-4054-806c-221f5c962bf4">Marketable Securities&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketable securities are classified as available-for-sale pursuant to ASC 320, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments &#x2013; Debt and Equity Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and are recorded at fair value. Unrealized gains are included as a component of accumulated other comprehensive income in the condensed consolidated balance sheets and statements of stockholders&#x2019; equity and a component of total comprehensive loss in the condensed consolidated statements of comprehensive loss, until realized. Unrealized losses are evaluated for impairment under ASC 326, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to determine if the impairment is credit-related or noncredit-related. Credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings, and noncredit-related impairment is recognized in other comprehensive income, net of taxes. Realized gains and losses are included in investment income on a specific-identification basis. There were no material realized gains or losses on marketable securities for the three and nine months ended September 30, 2020 or 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities at September&#160;30, 2020 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities at December&#160;31, 2019 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020 and December&#160;31, 2019, we held both current and non-current investments. Investments classified as current have maturities of less than one year. Investments classified as non-current are those that: (i)&#160;have a maturity of greater than one year, and (ii)&#160;we do not intend to liquidate within the next twelve months, although these funds are available for use and, therefore, are classified as available-for-sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020 and December&#160;31, 2019, we held 74 and 113 debt securities, respectively, that were in an unrealized loss position for less than one year. We did not record an allowance for credit losses as of September&#160;30, 2020 and December&#160;31, 2019 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at September&#160;30, 2020 and December&#160;31, 2019 was $247.7 million and $345.7 million, respectively. There were no individual securities that were in a significant unrealized loss position as of September&#160;30, 2020 and December&#160;31, 2019. Given our intent and ability to hold such securities until recovery, and the lack of significant change in the credit risk of these investments, we do not consider these marketable securities to be impaired as of September&#160;30, 2020 and December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfMjE3NA_6b43b5e5-df8b-4554-a3d0-d87483d26e50">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketable securities are classified as available-for-sale pursuant to ASC 320, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments &#x2013; Debt and Equity Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and are recorded at fair value. Unrealized gains are included as a component of accumulated other comprehensive income in the condensed consolidated balance sheets and statements of stockholders&#x2019; equity and a component of total comprehensive loss in the condensed consolidated statements of comprehensive loss, until realized. Unrealized losses are evaluated for impairment under ASC 326, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses&lt;/span&gt;, to determine if the impairment is credit-related or noncredit-related. Credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings, and noncredit-related impairment is recognized in other comprehensive income, net of taxes. Realized gains and losses are included in investment income on a specific-identification basis.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfOTI0_257d3681-625f-4449-8c0e-8f750a652c4d"
      unitRef="usd">0</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfOTI0_3e8832bf-f506-41ce-ab0c-3f45f39baf50"
      unitRef="usd">0</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfOTI0_b557d037-b8de-4f84-bfca-7720dc57d63a"
      unitRef="usd">0</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfOTI0_c3964a53-67c4-43b8-9ac9-50264b44214a"
      unitRef="usd">0</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfMjE3Ng_cb2131af-d033-4844-88bd-49533c8a3381">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities at September&#160;30, 2020 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities at December&#160;31, 2019 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2bf8521cd905445da506519413d478f2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMy0xLTEtMS0w_d5220954-6faf-4cea-a4b4-f2bd843e9220"
      unitRef="usd">139583000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2bf8521cd905445da506519413d478f2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMy0zLTEtMS0w_bdb0623c-e5f8-47b5-acd3-2d8e33a75cc4"
      unitRef="usd">380000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2bf8521cd905445da506519413d478f2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMy01LTEtMS0w_e27cde85-bdbf-4d54-9fef-4f61e92fb591"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2bf8521cd905445da506519413d478f2_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMy03LTEtMS0w_1c7b2f43-c4bf-49f0-b5cd-5276a345a6ea"
      unitRef="usd">139959000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7ee1c71ed01b4620aa8b7c580a5c2c35_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfNC0xLTEtMS0w_3d83897f-bb03-4f94-8dbd-9ea9d4cca52b"
      unitRef="usd">94336000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7ee1c71ed01b4620aa8b7c580a5c2c35_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfNC0zLTEtMS0w_bd3339ca-ace4-4cd2-8f53-7edddbe0902e"
      unitRef="usd">77000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7ee1c71ed01b4620aa8b7c580a5c2c35_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfNC01LTEtMS0w_e4e7282d-8366-4dc3-84c2-604f3cab6a07"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7ee1c71ed01b4620aa8b7c580a5c2c35_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfNC03LTEtMS0w_9160e84a-896b-46f2-8381-d622d5baa257"
      unitRef="usd">94402000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iff55f01694f94e28b5c7fd66fab94514_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfNS0xLTEtMS0w_866cc900-cbbe-4784-8ef7-6669fb057e9a"
      unitRef="usd">265999000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iff55f01694f94e28b5c7fd66fab94514_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfNS0zLTEtMS0w_b0f0d2a5-40a2-4d78-81b5-56c25ecdee5f"
      unitRef="usd">367000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iff55f01694f94e28b5c7fd66fab94514_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfNS01LTEtMS0w_9d2dfa31-1313-4f9a-a22a-1eedff27726a"
      unitRef="usd">43000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iff55f01694f94e28b5c7fd66fab94514_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfNS03LTEtMS0w_e82db871-722e-4379-adc8-c89141ec8d19"
      unitRef="usd">266323000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib489bc944aa14ea39dfa0ea27a8ccdda_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfNi0xLTEtMS0w_842c80cb-2bec-4a3c-b0f3-b0ceba76ea75"
      unitRef="usd">499918000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib489bc944aa14ea39dfa0ea27a8ccdda_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfNi0zLTEtMS0w_941cbcea-63f9-4502-a9db-15126a05aab6"
      unitRef="usd">824000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib489bc944aa14ea39dfa0ea27a8ccdda_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfNi01LTEtMS0w_5a756fe9-cd11-462e-8bcd-59d14bf4c3b0"
      unitRef="usd">58000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib489bc944aa14ea39dfa0ea27a8ccdda_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfNi03LTEtMS0w_5ec5f7ef-5649-43f9-8f3c-866a75be6ee9"
      unitRef="usd">500684000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i68f2b8cd5ee04a16971376df19807a05_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTEtMS0xLTEtMA_84a21553-7ab8-4f73-b134-215e3ecad65a"
      unitRef="usd">5132000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i68f2b8cd5ee04a16971376df19807a05_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTEtMy0xLTEtMA_36b90968-b262-4349-a8ad-df3df76b5fae"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i68f2b8cd5ee04a16971376df19807a05_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTEtNS0xLTEtMA_baca65ae-697f-4f5b-8a63-51071081cf1c"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i68f2b8cd5ee04a16971376df19807a05_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTEtNy0xLTEtMA_6963837b-201c-4f20-8de9-ba2cfffe43e0"
      unitRef="usd">5128000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic8ead45948574c9f9ee622f88491ada5_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTItMS0xLTEtMA_12c51fbc-01cf-48a0-b427-dc70c8ac17f9"
      unitRef="usd">61320000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic8ead45948574c9f9ee622f88491ada5_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTItMy0xLTEtMA_9c7da279-9d3e-420b-95d4-a0b89f3b97a8"
      unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic8ead45948574c9f9ee622f88491ada5_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTItNS0xLTEtMA_5800f711-4b4c-456e-b4b0-4c9e5d691a56"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic8ead45948574c9f9ee622f88491ada5_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTItNy0xLTEtMA_7f008347-d6fa-473a-8195-f965d5de3f40"
      unitRef="usd">61323000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8047261250f94d8eb8d6c0f98068c56e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTMtMS0xLTEtMA_c5c0ddcd-c7af-44ff-85a8-fc791e6bd421"
      unitRef="usd">50540000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8047261250f94d8eb8d6c0f98068c56e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTMtMy0xLTEtMA_fb4d893e-d8b1-47a3-acba-7df1b57ac823"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8047261250f94d8eb8d6c0f98068c56e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTMtNS0xLTEtMA_04d5026e-082e-4118-955c-7897e7c6bf63"
      unitRef="usd">103000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8047261250f94d8eb8d6c0f98068c56e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTMtNy0xLTEtMA_423b2cf3-ba0b-4b5a-af47-38d0c48955d1"
      unitRef="usd">50438000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7bbfc1e3bc29413aba5926d90622f3d0_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTQtMS0xLTEtMA_496b9b74-66fb-43cc-903a-e6cc6d805878"
      unitRef="usd">116992000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7bbfc1e3bc29413aba5926d90622f3d0_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTQtMy0xLTEtMA_3dc9699c-bb15-4493-b4ab-f3395b6aed47"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7bbfc1e3bc29413aba5926d90622f3d0_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTQtNS0xLTEtMA_36958802-2f45-4353-bf12-5a98d3e361f2"
      unitRef="usd">113000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7bbfc1e3bc29413aba5926d90622f3d0_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTQtNy0xLTEtMA_f59c35b2-f96b-4528-b045-0764ae98400c"
      unitRef="usd">116889000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTUtMS0xLTEtMA_fb70ac88-5ed3-413a-a62b-44a3a6910be0"
      unitRef="usd">616910000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTUtMy0xLTEtMA_7e2c92eb-1585-4548-8910-249a3e2d09ac"
      unitRef="usd">834000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTUtNS0xLTEtMA_46670ad7-f0c7-4dfb-be9a-c94d7bc58c6f"
      unitRef="usd">171000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOjhlNzcyZjhhODIyZTRhYmU4MDBjNDE5OGM5NTlmYzBmL3RhYmxlcmFuZ2U6OGU3NzJmOGE4MjJlNGFiZTgwMGM0MTk4Yzk1OWZjMGZfMTUtNy0xLTEtMA_80cbe29f-01df-4581-9397-c82025af2e3f"
      unitRef="usd">617573000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iafa6f804a3734443b6af52bbcd7cda22_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMi0xLTEtMS0w_b911027a-a039-4e61-9bc1-622a135c19a6"
      unitRef="usd">178721000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iafa6f804a3734443b6af52bbcd7cda22_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMi0zLTEtMS0w_7538bd29-f4a6-421b-9a79-095e7aec00b6"
      unitRef="usd">58000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iafa6f804a3734443b6af52bbcd7cda22_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMi01LTEtMS0w_e9099212-6507-4482-a797-031e091ec9d1"
      unitRef="usd">38000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iafa6f804a3734443b6af52bbcd7cda22_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMi03LTEtMS0w_3ab69457-feef-4687-bce6-01b8d85f6ecf"
      unitRef="usd">178741000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iadc513dfb0aa455792b1559bd9ff0b07_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMy0xLTEtMS0w_61fc061f-460f-4635-9148-9f60ea7d2ba8"
      unitRef="usd">80228000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iadc513dfb0aa455792b1559bd9ff0b07_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMy0zLTEtMS0w_4d4f22f3-5889-42c2-987f-a3b658f0ccc1"
      unitRef="usd">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iadc513dfb0aa455792b1559bd9ff0b07_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMy01LTEtMS0w_dcff74b2-0283-4d20-beba-35a87da1c8f6"
      unitRef="usd">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iadc513dfb0aa455792b1559bd9ff0b07_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMy03LTEtMS0w_bc4ab5c6-7134-460a-8af3-9f32743a6d14"
      unitRef="usd">80229000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i204de70f9ce54574b913c7c1a1f5bec6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfNC0xLTEtMS0w_80576af6-2274-402b-b10c-fc9fb9a77bea"
      unitRef="usd">224928000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i204de70f9ce54574b913c7c1a1f5bec6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfNC0zLTEtMS0w_00cb2552-c41c-4297-b041-ee718cf328c1"
      unitRef="usd">139000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i204de70f9ce54574b913c7c1a1f5bec6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfNC01LTEtMS0w_5dd55f32-ece4-49f4-a4e5-b7e34fb08e98"
      unitRef="usd">91000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i204de70f9ce54574b913c7c1a1f5bec6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfNC03LTEtMS0w_ea754307-e6a8-4268-b445-ddd1a4b30c89"
      unitRef="usd">224976000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8ac3885e5cc24c1a9b936fd11ed191f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfNS0xLTEtMS0w_a080799b-eea7-437a-922b-6e01b8bbe32f"
      unitRef="usd">483877000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8ac3885e5cc24c1a9b936fd11ed191f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfNS0zLTEtMS0w_3981f6ef-154f-4f8a-8f4d-0d5ec46db791"
      unitRef="usd">214000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8ac3885e5cc24c1a9b936fd11ed191f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfNS01LTEtMS0w_b4befbdd-fa54-4474-9109-5ee9a445457f"
      unitRef="usd">145000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8ac3885e5cc24c1a9b936fd11ed191f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfNS03LTEtMS0w_7c1d631a-f7de-4d91-811d-9ce1fda32b56"
      unitRef="usd">483946000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2b8e02d6bad0479cb0dd2303c690ac0b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfOS0xLTEtMS0w_fdc4f57f-c9cb-4148-9592-f432186d0707"
      unitRef="usd">35296000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2b8e02d6bad0479cb0dd2303c690ac0b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfOS0zLTEtMS0w_47901377-ab19-48a3-abd1-11740bb5ce91"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2b8e02d6bad0479cb0dd2303c690ac0b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfOS01LTEtMS0w_6ad43d3e-2623-4f3c-982e-e63cde0fd814"
      unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2b8e02d6bad0479cb0dd2303c690ac0b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfOS03LTEtMS0w_824a3435-75ba-47d0-814d-e232f87ae558"
      unitRef="usd">35286000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i015ac4920a1c4c3a9611d7a7be258105_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTAtMS0xLTEtMA_178f02d3-b592-4340-914e-d5b976b1a5cc"
      unitRef="usd">17587000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i015ac4920a1c4c3a9611d7a7be258105_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTAtMy0xLTEtMA_aec19473-e6ac-43ba-9db5-a77a7c5c3d37"
      unitRef="usd">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i015ac4920a1c4c3a9611d7a7be258105_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTAtNS0xLTEtMA_47e30803-69a0-4e48-ba30-dd0f6848c85e"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i015ac4920a1c4c3a9611d7a7be258105_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTAtNy0xLTEtMA_1fdd8169-e644-487a-b95c-0f97fd1e1beb"
      unitRef="usd">17591000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1c2c48c0358445ac84d1add069e26cb6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTEtMS0xLTEtMA_eface8b0-acc6-49ea-9d8b-365c77fa94fe"
      unitRef="usd">99913000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1c2c48c0358445ac84d1add069e26cb6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTEtMy0xLTEtMA_d3e278d6-20b4-4a03-9ca9-012dfac244dd"
      unitRef="usd">239000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1c2c48c0358445ac84d1add069e26cb6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTEtNS0xLTEtMA_f322867b-c109-4eb7-a5ad-b7f3a9358ddc"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1c2c48c0358445ac84d1add069e26cb6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTEtNy0xLTEtMA_54175bb7-178b-4690-96d3-12dc83242ab2"
      unitRef="usd">100052000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i23d92d9ecc2b4415b962d6feb4c7a44a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTItMS0xLTEtMA_540e21f3-95bb-45d5-866b-e19f576595d0"
      unitRef="usd">152796000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i23d92d9ecc2b4415b962d6feb4c7a44a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTItMy0xLTEtMA_fa7df1ef-eb06-4f2c-ad21-ca1ae0da486c"
      unitRef="usd">256000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i23d92d9ecc2b4415b962d6feb4c7a44a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTItNS0xLTEtMA_277b9440-765b-4701-a7bb-59aa6a3fdbdf"
      unitRef="usd">123000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i23d92d9ecc2b4415b962d6feb4c7a44a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTItNy0xLTEtMA_077a9626-6b5f-4b29-8c43-ed130d6d32b5"
      unitRef="usd">152929000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTMtMS0xLTEtMA_96021050-86ba-4da0-9800-4ee8e1100290"
      unitRef="usd">636673000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTMtMy0xLTEtMA_9a7d7223-0378-4deb-ba97-b50db3b00fb0"
      unitRef="usd">470000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTMtNS0xLTEtMA_587a5cba-c777-48d8-8d0b-71738d69397b"
      unitRef="usd">268000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RhYmxlOmRlNWYxMDczYTkzYTRhNGU5ZDVmMWNkNmFhNTUzNGQzL3RhYmxlcmFuZ2U6ZGU1ZjEwNzNhOTNhNGE0ZTlkNWYxY2Q2YWE1NTM0ZDNfMTMtNy0xLTEtMA_fb9c0fe8-a7c2-4ce0-a67f-ea25a204afd1"
      unitRef="usd">636875000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfMTUzMA_e7a052cb-6525-43d4-abc9-d91ad4c7ad81"
      unitRef="security">74</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfMTUzNw_a0dd9427-6cfc-421a-86b1-5d18f49c1253"
      unitRef="security">113</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfMTY0Mw_3b2d765f-223e-45ae-8907-08d82317925f"
      unitRef="usd">0</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <us-gaap:FinancingReceivableAllowanceForCreditLosses
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfMTY0Mw_c149330c-7afd-45ea-9447-7b762377d58d"
      unitRef="usd">0</us-gaap:FinancingReceivableAllowanceForCreditLosses>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfMTgyMg_dbdb2bc1-c76f-4bd9-b1a9-03b2cd9532a6"
      unitRef="usd">247700000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfMTgyOQ_3ef5dc6d-66af-462d-9809-50715681cc7e"
      unitRef="usd">345700000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfMTg1OA_0216e6b3-9349-4f15-a867-6efb03e88505"
      unitRef="security">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80My9mcmFnOjUwOWViYWFjNjQ2NTQ5ZDE4MzgyZmE5ZjY5NjE4YWEwL3RleHRyZWdpb246NTA5ZWJhYWM2NDY1NDlkMTgzODJmYTlmNjk2MThhYTBfMTg1OA_87ab21aa-d9b2-4e85-b9c8-2c1eeaed5246"
      unitRef="security">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80Ni9mcmFnOmE0OTYzZjE3ZjlhNDQxZjA4ZThhMjBmNTk5ZWYyYmIxL3RleHRyZWdpb246YTQ5NjNmMTdmOWE0NDFmMDhlOGEyMGY1OTllZjJiYjFfMTA3_5fc38e43-9918-4641-96ff-2fbc96585de3">Inventory&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory, which consists of commercial supply of TIBSOVO&#xae;, consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80Ni9mcmFnOmE0OTYzZjE3ZjlhNDQxZjA4ZThhMjBmNTk5ZWYyYmIxL3RleHRyZWdpb246YTQ5NjNmMTdmOWE0NDFmMDhlOGEyMGY1OTllZjJiYjFfMTA4_a383f5b8-8126-478e-897c-73c7d1fcdf74">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory, which consists of commercial supply of TIBSOVO&#xae;, consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80Ni9mcmFnOmE0OTYzZjE3ZjlhNDQxZjA4ZThhMjBmNTk5ZWYyYmIxL3RhYmxlOjgwMmViNjc0Nzc3NTQ5NDFhNWJiODdmNGMzNDI4N2FmL3RhYmxlcmFuZ2U6ODAyZWI2NzQ3Nzc1NDk0MWE1YmI4N2Y0YzM0Mjg3YWZfMS0xLTEtMS0w_e778d392-5a2d-4703-ac00-55959cd346ea"
      unitRef="usd">1406000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80Ni9mcmFnOmE0OTYzZjE3ZjlhNDQxZjA4ZThhMjBmNTk5ZWYyYmIxL3RhYmxlOjgwMmViNjc0Nzc3NTQ5NDFhNWJiODdmNGMzNDI4N2FmL3RhYmxlcmFuZ2U6ODAyZWI2NzQ3Nzc1NDk0MWE1YmI4N2Y0YzM0Mjg3YWZfMS0zLTEtMS0w_625d2909-c889-4d36-879d-74424966c2c2"
      unitRef="usd">180000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80Ni9mcmFnOmE0OTYzZjE3ZjlhNDQxZjA4ZThhMjBmNTk5ZWYyYmIxL3RhYmxlOjgwMmViNjc0Nzc3NTQ5NDFhNWJiODdmNGMzNDI4N2FmL3RhYmxlcmFuZ2U6ODAyZWI2NzQ3Nzc1NDk0MWE1YmI4N2Y0YzM0Mjg3YWZfMi0xLTEtMS0w_556dda90-7b21-4a40-900b-0a6caadf65da"
      unitRef="usd">9166000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80Ni9mcmFnOmE0OTYzZjE3ZjlhNDQxZjA4ZThhMjBmNTk5ZWYyYmIxL3RhYmxlOjgwMmViNjc0Nzc3NTQ5NDFhNWJiODdmNGMzNDI4N2FmL3RhYmxlcmFuZ2U6ODAyZWI2NzQ3Nzc1NDk0MWE1YmI4N2Y0YzM0Mjg3YWZfMi0zLTEtMS0w_03e8d3fb-fcab-465c-9df7-a979b8c2b7ee"
      unitRef="usd">6808000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80Ni9mcmFnOmE0OTYzZjE3ZjlhNDQxZjA4ZThhMjBmNTk5ZWYyYmIxL3RhYmxlOjgwMmViNjc0Nzc3NTQ5NDFhNWJiODdmNGMzNDI4N2FmL3RhYmxlcmFuZ2U6ODAyZWI2NzQ3Nzc1NDk0MWE1YmI4N2Y0YzM0Mjg3YWZfMy0xLTEtMS0w_0b2c1dda-0b01-4f83-a364-b08b4502f943"
      unitRef="usd">799000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80Ni9mcmFnOmE0OTYzZjE3ZjlhNDQxZjA4ZThhMjBmNTk5ZWYyYmIxL3RhYmxlOjgwMmViNjc0Nzc3NTQ5NDFhNWJiODdmNGMzNDI4N2FmL3RhYmxlcmFuZ2U6ODAyZWI2NzQ3Nzc1NDk0MWE1YmI4N2Y0YzM0Mjg3YWZfMy0zLTEtMS0w_0480a7df-2624-4e4d-b1a2-0a99dd6e908d"
      unitRef="usd">343000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80Ni9mcmFnOmE0OTYzZjE3ZjlhNDQxZjA4ZThhMjBmNTk5ZWYyYmIxL3RhYmxlOjgwMmViNjc0Nzc3NTQ5NDFhNWJiODdmNGMzNDI4N2FmL3RhYmxlcmFuZ2U6ODAyZWI2NzQ3Nzc1NDk0MWE1YmI4N2Y0YzM0Mjg3YWZfNC0xLTEtMS0w_712d26f1-6dd7-4426-b809-df0aacdbf822"
      unitRef="usd">11371000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80Ni9mcmFnOmE0OTYzZjE3ZjlhNDQxZjA4ZThhMjBmNTk5ZWYyYmIxL3RhYmxlOjgwMmViNjc0Nzc3NTQ5NDFhNWJiODdmNGMzNDI4N2FmL3RhYmxlcmFuZ2U6ODAyZWI2NzQ3Nzc1NDk0MWE1YmI4N2Y0YzM0Mjg3YWZfNC0zLTEtMS0w_7b67bd16-1080-4857-8585-23e533a54b3e"
      unitRef="usd">7331000</us-gaap:InventoryNet>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfMTM5NA_5a3838c8-069c-4758-b768-0d2d54f8ccc7">Leases&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our building leases are comprised of office and laboratory space under non-cancelable operating leases. These lease agreements have remaining lease terms of seven years and contain various clauses for renewal at our option. The renewal options were not included in the calculation of the operating lease assets and the operating lease liabilities as the renewal options are not reasonably certain of being exercised. The lease agreements do not contain residual value guarantees. Operating lease costs for the three and nine months ended September 30, 2020 were $3.8 million and $11.4&#160;million, respectively, and cash paid for amounts included in the measurement of operating lease liabilities for the three and nine months ended September 30, 2020 were $3.5 million and $10.9&#160;million, respectively. Operating lease costs for the three and nine months ended September 30, 2019 were $3.8&#160;million and $10.6&#160;million, respectively, and cash paid for amounts included in the measurement of operating lease liabilities for the three and nine months ended September 30, 2019 were $2.2&#160;million and $8.5&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have not entered into any material short-term leases or financing leases as of September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, undiscounted minimum rental commitments under non-cancelable leases, for each of the next five years and total thereafter were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.583%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Undiscounted minimum rental commitments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,621)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;In arriving at the operating lease liabilities as of September&#160;30, 2020 and December&#160;31, 2019, we applied the weighted-average incremental borrowing rate of 5.7% for both periods over a weighted-average remaining lease term of 7.4 years and 8.2 years, respectively.</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfMTcy_ba70f1b5-67da-4b55-83f0-f59dfa44df0c">P7Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseCost
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfNTIy_576672f1-8f55-4388-83fd-9d7a72336e8c"
      unitRef="usd">3800000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfNTI5_163e1b43-4418-4c38-97d8-434cd519a74a"
      unitRef="usd">11400000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfNjQ4_aaab4d64-6fcf-40ea-96a1-d46e858fb4ff"
      unitRef="usd">3500000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfNjU1_ae8595de-a632-46e3-a100-d1e262a2519f"
      unitRef="usd">10900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseCost
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfMTA5OTUxMTYyOTE5NQ_b0be073f-3ea2-40ec-93a9-fe32a4a68e53"
      unitRef="usd">3800000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfMTA5OTUxMTYyOTIwMg_dcb8121f-965a-4c4e-bb04-5032e775187e"
      unitRef="usd">10600000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfMTA5OTUxMTYyOTIyOQ_4a45d367-86d4-4d48-91be-c33eedc1f762"
      unitRef="usd">2200000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfMTA5OTUxMTYyOTIzNw_a5d44e70-6b06-42d7-8519-4ec27e675f0a"
      unitRef="usd">8500000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfMTM5Ng_3fab3faf-d7ae-44f5-b4ab-ff3a686c84c3">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, undiscounted minimum rental commitments under non-cancelable leases, for each of the next five years and total thereafter were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.583%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Undiscounted minimum rental commitments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,621)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RhYmxlOjI0ZDVhYzYzMmI4NTQzYzlhNTExNjM5YTBjNzgxMGJhL3RhYmxlcmFuZ2U6MjRkNWFjNjMyYjg1NDNjOWE1MTE2MzlhMGM3ODEwYmFfMS0xLTEtMS0w_86114459-db9d-47ec-88bc-b3130f250582"
      unitRef="usd">2364000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RhYmxlOjI0ZDVhYzYzMmI4NTQzYzlhNTExNjM5YTBjNzgxMGJhL3RhYmxlcmFuZ2U6MjRkNWFjNjMyYjg1NDNjOWE1MTE2MzlhMGM3ODEwYmFfMi0xLTEtMS0w_5cb011ae-c94e-40d1-936d-dcbe7472d11a"
      unitRef="usd">14380000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RhYmxlOjI0ZDVhYzYzMmI4NTQzYzlhNTExNjM5YTBjNzgxMGJhL3RhYmxlcmFuZ2U6MjRkNWFjNjMyYjg1NDNjOWE1MTE2MzlhMGM3ODEwYmFfMy0xLTEtMS0w_4bae0d89-04a7-4d36-8815-b721dcc75b30"
      unitRef="usd">16773000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RhYmxlOjI0ZDVhYzYzMmI4NTQzYzlhNTExNjM5YTBjNzgxMGJhL3RhYmxlcmFuZ2U6MjRkNWFjNjMyYjg1NDNjOWE1MTE2MzlhMGM3ODEwYmFfNC0xLTEtMS0w_5c716656-000f-4265-8d48-3a1954797f65"
      unitRef="usd">18126000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RhYmxlOjI0ZDVhYzYzMmI4NTQzYzlhNTExNjM5YTBjNzgxMGJhL3RhYmxlcmFuZ2U6MjRkNWFjNjMyYjg1NDNjOWE1MTE2MzlhMGM3ODEwYmFfNS0xLTEtMS0w_283ed00a-fb32-4cca-ba69-971f95d701bb"
      unitRef="usd">18660000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RhYmxlOjI0ZDVhYzYzMmI4NTQzYzlhNTExNjM5YTBjNzgxMGJhL3RhYmxlcmFuZ2U6MjRkNWFjNjMyYjg1NDNjOWE1MTE2MzlhMGM3ODEwYmFfNi0xLTEtMS0w_031db82e-6f98-43a9-9567-badac4b22a44"
      unitRef="usd">19507000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RhYmxlOjI0ZDVhYzYzMmI4NTQzYzlhNTExNjM5YTBjNzgxMGJhL3RhYmxlcmFuZ2U6MjRkNWFjNjMyYjg1NDNjOWE1MTE2MzlhMGM3ODEwYmFfNy0xLTEtMS0w_3cd99c30-2372-4757-9d0d-5eecc2446b3f"
      unitRef="usd">44385000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RhYmxlOjI0ZDVhYzYzMmI4NTQzYzlhNTExNjM5YTBjNzgxMGJhL3RhYmxlcmFuZ2U6MjRkNWFjNjMyYjg1NDNjOWE1MTE2MzlhMGM3ODEwYmFfOC0xLTEtMS0w_67fda882-5f77-470f-b00f-e8acf55e3b69"
      unitRef="usd">134195000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RhYmxlOjI0ZDVhYzYzMmI4NTQzYzlhNTExNjM5YTBjNzgxMGJhL3RhYmxlcmFuZ2U6MjRkNWFjNjMyYjg1NDNjOWE1MTE2MzlhMGM3ODEwYmFfOS0xLTEtMS0w_01e896d8-b5e1-45fe-82e7-8b00b283411e"
      unitRef="usd">27621000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RhYmxlOjI0ZDVhYzYzMmI4NTQzYzlhNTExNjM5YTBjNzgxMGJhL3RhYmxlcmFuZ2U6MjRkNWFjNjMyYjg1NDNjOWE1MTE2MzlhMGM3ODEwYmFfMTAtMS0xLTEtMA_074c0072-50ab-4ed5-827f-94d093bda10f"
      unitRef="usd">106574000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfMTMwMQ_81d50b24-d28d-4645-8699-e305da5b9e05"
      unitRef="number">0.057</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfMTMwMQ_b0a1ae7c-0e6b-4401-901f-65357a2a4c69"
      unitRef="number">0.057</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfMTM2OQ_117e71b4-1bd2-4be7-84ac-83d15d0fcf0d">P7Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl80OS9mcmFnOjgyMzU2OGJjNjA5MjRhMjU5YTAwZmQ4YmRkZjg0YjcwL3RleHRyZWdpb246ODIzNTY4YmM2MDkyNGEyNTlhMDBmZDhiZGRmODRiNzBfMTM3Ng_4195e7a1-f3db-4cf0-b592-534f242d0a44">P8Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81Mi9mcmFnOjYwODkxZTQ4ZmEwMjQwZjE5Njk3OThiYTRhYTY2ODE5L3RleHRyZWdpb246NjA4OTFlNDhmYTAyNDBmMTk2OTc5OGJhNGFhNjY4MTlfNzI_e09148e1-b819-4ef0-9b31-c74eae3b7c94">Accrued Expenses&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued revenue-related reserves and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81Mi9mcmFnOjYwODkxZTQ4ZmEwMjQwZjE5Njk3OThiYTRhYTY2ODE5L3RleHRyZWdpb246NjA4OTFlNDhmYTAyNDBmMTk2OTc5OGJhNGFhNjY4MTlfNzE_55c6e1bd-3c5a-4fb5-b4e2-a62af07538d0">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, &lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued revenue-related reserves and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81Mi9mcmFnOjYwODkxZTQ4ZmEwMjQwZjE5Njk3OThiYTRhYTY2ODE5L3RhYmxlOmMyYzg3Y2YxMjU0ZjQwODRiZTJjZjdmMjkxNDViMzMwL3RhYmxlcmFuZ2U6YzJjODdjZjEyNTRmNDA4NGJlMmNmN2YyOTE0NWIzMzBfMS0xLTEtMS0w_1bc50cf9-0a70-44f0-adc1-6a867a09cbd2"
      unitRef="usd">19044000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81Mi9mcmFnOjYwODkxZTQ4ZmEwMjQwZjE5Njk3OThiYTRhYTY2ODE5L3RhYmxlOmMyYzg3Y2YxMjU0ZjQwODRiZTJjZjdmMjkxNDViMzMwL3RhYmxlcmFuZ2U6YzJjODdjZjEyNTRmNDA4NGJlMmNmN2YyOTE0NWIzMzBfMS0zLTEtMS0w_3fcbc25f-8d90-4155-83da-02913094fc87"
      unitRef="usd">18982000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <agio:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81Mi9mcmFnOjYwODkxZTQ4ZmEwMjQwZjE5Njk3OThiYTRhYTY2ODE5L3RhYmxlOmMyYzg3Y2YxMjU0ZjQwODRiZTJjZjdmMjkxNDViMzMwL3RhYmxlcmFuZ2U6YzJjODdjZjEyNTRmNDA4NGJlMmNmN2YyOTE0NWIzMzBfMi0xLTEtMS0w_dd3856f3-fdba-4f17-af79-0e5d62055cef"
      unitRef="usd">16188000</agio:AccruedResearchAndDevelopmentCostsCurrent>
    <agio:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81Mi9mcmFnOjYwODkxZTQ4ZmEwMjQwZjE5Njk3OThiYTRhYTY2ODE5L3RhYmxlOmMyYzg3Y2YxMjU0ZjQwODRiZTJjZjdmMjkxNDViMzMwL3RhYmxlcmFuZ2U6YzJjODdjZjEyNTRmNDA4NGJlMmNmN2YyOTE0NWIzMzBfMi0zLTEtMS0w_b00181ac-f4b0-4231-a0f5-a837013f12f2"
      unitRef="usd">21777000</agio:AccruedResearchAndDevelopmentCostsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81Mi9mcmFnOjYwODkxZTQ4ZmEwMjQwZjE5Njk3OThiYTRhYTY2ODE5L3RhYmxlOmMyYzg3Y2YxMjU0ZjQwODRiZTJjZjdmMjkxNDViMzMwL3RhYmxlcmFuZ2U6YzJjODdjZjEyNTRmNDA4NGJlMmNmN2YyOTE0NWIzMzBfMy0xLTEtMS0w_5d81fce3-cbb7-403d-9484-9c58ea6af02d"
      unitRef="usd">3474000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81Mi9mcmFnOjYwODkxZTQ4ZmEwMjQwZjE5Njk3OThiYTRhYTY2ODE5L3RhYmxlOmMyYzg3Y2YxMjU0ZjQwODRiZTJjZjdmMjkxNDViMzMwL3RhYmxlcmFuZ2U6YzJjODdjZjEyNTRmNDA4NGJlMmNmN2YyOTE0NWIzMzBfMy0zLTEtMS0w_5a413d24-8627-4973-98fa-f51f000592bf"
      unitRef="usd">8335000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81Mi9mcmFnOjYwODkxZTQ4ZmEwMjQwZjE5Njk3OThiYTRhYTY2ODE5L3RhYmxlOmMyYzg3Y2YxMjU0ZjQwODRiZTJjZjdmMjkxNDViMzMwL3RhYmxlcmFuZ2U6YzJjODdjZjEyNTRmNDA4NGJlMmNmN2YyOTE0NWIzMzBfNC0xLTEtMS0w_b9701d52-e6fe-4a8b-ae51-11ec72b9b25b"
      unitRef="usd">11018000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81Mi9mcmFnOjYwODkxZTQ4ZmEwMjQwZjE5Njk3OThiYTRhYTY2ODE5L3RhYmxlOmMyYzg3Y2YxMjU0ZjQwODRiZTJjZjdmMjkxNDViMzMwL3RhYmxlcmFuZ2U6YzJjODdjZjEyNTRmNDA4NGJlMmNmN2YyOTE0NWIzMzBfNC0zLTEtMS0w_da175105-0473-410d-82a7-c0dedea3d2a8"
      unitRef="usd">4048000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81Mi9mcmFnOjYwODkxZTQ4ZmEwMjQwZjE5Njk3OThiYTRhYTY2ODE5L3RhYmxlOmMyYzg3Y2YxMjU0ZjQwODRiZTJjZjdmMjkxNDViMzMwL3RhYmxlcmFuZ2U6YzJjODdjZjEyNTRmNDA4NGJlMmNmN2YyOTE0NWIzMzBfNS0xLTEtMS0w_017e514b-fbc1-4a61-a0da-94e9b7b0e71f"
      unitRef="usd">49724000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81Mi9mcmFnOjYwODkxZTQ4ZmEwMjQwZjE5Njk3OThiYTRhYTY2ODE5L3RhYmxlOmMyYzg3Y2YxMjU0ZjQwODRiZTJjZjdmMjkxNDViMzMwL3RhYmxlcmFuZ2U6YzJjODdjZjEyNTRmNDA4NGJlMmNmN2YyOTE0NWIzMzBfNS0zLTEtMS0w_c8552609-d816-410f-a83d-7b8fc8996ec6"
      unitRef="usd">53142000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RleHRyZWdpb246ZDMzYjRkYmEwYmUzNDY3Yzk0ZGE1NjU4MGRhMzRjYmNfNzcy_ac6db41e-8b48-47a0-b716-f4d72c0f8baa">Product Revenue&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell TIBSOVO&#xae;, our wholly owned product, to a limited number of specialty distributors and specialty pharmacy providers, or collectively, the Customers. The Customers subsequently resell TIBSOVO&#xae; to pharmacies or dispense directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of TIBSOVO&#xae;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance obligation related to the sale of TIBSOVO&#xae; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reserves for Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contractual Adjustments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally provide Customers with discounts, including prompt pay discounts, and allowances that are explicitly stated in the contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from certain Customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks for fees and discounts represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are estimated using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated channel mix and are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Rebates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government rebates include Medicare, TriCare, and Medicaid rebates, which we estimate using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the amount of product sales that may be returned by Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate product return liabilities using the expected value method, based on available industry data, including our visibility into the inventory remaining in the distribution channel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the nine months ended September 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Government Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in the prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(677)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue-related reserves above, included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Component of accrued expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in our contract assets during the nine months ended September 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92,467)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)  Additions to contract assets relate to amounts billed to Customers for product sales and deductions to contract assets primarily relate to collection of receivables during the reporting period.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RleHRyZWdpb246ZDMzYjRkYmEwYmUzNDY3Yzk0ZGE1NjU4MGRhMzRjYmNfMjQ_08f12fa4-d653-4885-a051-3f6bd78dd194">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sell TIBSOVO&#xae;, our wholly owned product, to a limited number of specialty distributors and specialty pharmacy providers, or collectively, the Customers. The Customers subsequently resell TIBSOVO&#xae; to pharmacies or dispense directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of TIBSOVO&#xae;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance obligation related to the sale of TIBSOVO&#xae; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reserves for Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contractual Adjustments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally provide Customers with discounts, including prompt pay discounts, and allowances that are explicitly stated in the contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from certain Customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks for fees and discounts represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are estimated using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated channel mix and are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Rebates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government rebates include Medicare, TriCare, and Medicaid rebates, which we estimate using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the amount of product sales that may be returned by Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate product return liabilities using the expected value method, based on available industry data, including our visibility into the inventory remaining in the distribution channel.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RleHRyZWdpb246ZDMzYjRkYmEwYmUzNDY3Yzk0ZGE1NjU4MGRhMzRjYmNfNzYz_75b30aaf-3c53-4361-aa1a-0dc08f15a89f">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i902ffdd5069945e4a1e2d8259b7aa937_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmJlZWNhZTBiMTlmNzRlNzA5YzQ0NGFmMjI1MWY3ZGNjL3RhYmxlcmFuZ2U6YmVlY2FlMGIxOWY3NGU3MDljNDQ0YWYyMjUxZjdkY2NfMi0xLTEtMS0w_ee75e748-f734-4627-b83a-624196f28132"
      unitRef="usd">31716000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9bd25f418764e27874e4887f9629cba_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmJlZWNhZTBiMTlmNzRlNzA5YzQ0NGFmMjI1MWY3ZGNjL3RhYmxlcmFuZ2U6YmVlY2FlMGIxOWY3NGU3MDljNDQ0YWYyMjUxZjdkY2NfMi0zLTEtMS0w_14f0e384-07e2-4865-a7b3-c9c8d7b102a4"
      unitRef="usd">17422000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac48a829910e4ec2be6c0709f8ab5d04_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmJlZWNhZTBiMTlmNzRlNzA5YzQ0NGFmMjI1MWY3ZGNjL3RhYmxlcmFuZ2U6YmVlY2FlMGIxOWY3NGU3MDljNDQ0YWYyMjUxZjdkY2NfMi01LTEtMS0w_1e2d87c1-f509-41fb-8b6f-b9d35f67093c"
      unitRef="usd">81971000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15c6da9822264b9abd38a7580c17d5b2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmJlZWNhZTBiMTlmNzRlNzA5YzQ0NGFmMjI1MWY3ZGNjL3RhYmxlcmFuZ2U6YmVlY2FlMGIxOWY3NGU3MDljNDQ0YWYyMjUxZjdkY2NfMi03LTEtMS0w_a2e8e31f-217a-49ae-94d6-f72935291d35"
      unitRef="usd">40287000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RleHRyZWdpb246ZDMzYjRkYmEwYmUzNDY3Yzk0ZGE1NjU4MGRhMzRjYmNfNzY0_4e59fdb3-2899-46a6-adfa-70b0679b2a9d">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the nine months ended September 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Government Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,260)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in the prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(677)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <agio:ContractWithCustomerContractualAdjustmentReserve
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfMS0xLTEtMS0w_dc5dc261-5516-4844-b04b-4231802a9b70"
      unitRef="usd">874000</agio:ContractWithCustomerContractualAdjustmentReserve>
    <agio:ContractWithCustomerRebateReserve
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfMS0zLTEtMS0w_fcd61b56-59e8-45e9-986a-32b6394ffdf6"
      unitRef="usd">1124000</agio:ContractWithCustomerRebateReserve>
    <agio:ContractWithCustomerRightToRecoverProductReserve
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfMS01LTEtMS0w_6259d6b5-e269-4813-982c-055d66c9068e"
      unitRef="usd">1798000</agio:ContractWithCustomerRightToRecoverProductReserve>
    <agio:ContractWithCustomerTotalAllowancesAndReserves
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfMS03LTEtMS0w_ff45e6a0-5adc-44d5-b5ed-23556f27353e"
      unitRef="usd">3796000</agio:ContractWithCustomerTotalAllowancesAndReserves>
    <agio:CurrentYearProvisionForContractualAdjustments
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfMi0xLTEtMS0w_522eddaa-4ed6-4ecf-b2a4-0a12c44eacab"
      unitRef="usd">10261000</agio:CurrentYearProvisionForContractualAdjustments>
    <agio:CurrentYearProvisionsForRebateReserve
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfMi0zLTEtMS0w_e5b9ed9f-3554-4630-aa5f-acc8110c9ee1"
      unitRef="usd">9299000</agio:CurrentYearProvisionsForRebateReserve>
    <agio:ProvisionForRightToRecoverProductInCurrentYear
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfMi01LTEtMS0w_ef5b15eb-8d98-404a-aca3-42f78aae54a9"
      unitRef="usd">1296000</agio:ProvisionForRightToRecoverProductInCurrentYear>
    <agio:ContractWithCustomerCurrentYearReserveProvisions
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfMi03LTEtMS0w_4bf4b870-b705-4264-b941-fdfee0a3c6b9"
      unitRef="usd">20856000</agio:ContractWithCustomerCurrentYearReserveProvisions>
    <agio:PriorYearProvisionForContractualAdjustments
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfMy0xLTEtMS0w_7fe1617d-8768-4659-a5d5-6d48db0c9060"
      unitRef="usd">-3000</agio:PriorYearProvisionForContractualAdjustments>
    <agio:PriorYearProvisionsForRebateReserve
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfMy0zLTEtMS0w_f4d954d0-24a6-44c8-bb6a-be9585b3dd45"
      unitRef="usd">122000</agio:PriorYearProvisionsForRebateReserve>
    <agio:ProvisionForRightToRecoverProductInPriorYears
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfMy01LTEtMS0w_2fe219b1-8484-4517-9dba-c4d77342869d"
      unitRef="usd">-476000</agio:ProvisionForRightToRecoverProductInPriorYears>
    <agio:ContractWithCustomerPriorYearsReserveProvisions
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfMy03LTEtMS0w_07e63720-addb-4ed8-a14c-5bdaf5a74032"
      unitRef="usd">-357000</agio:ContractWithCustomerPriorYearsReserveProvisions>
    <agio:ContractWithCustomerContractAdjustmentRecoveriesCurrentYear
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfNC0xLTEtMS0w_fe45262c-2f44-4213-a194-87d96ea5eb6d"
      unitRef="usd">8966000</agio:ContractWithCustomerContractAdjustmentRecoveriesCurrentYear>
    <agio:ContractWithCustomerRebateReserveRecoveriesInCurrentYear
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfNC0zLTEtMS0w_e9032865-2812-493c-84a8-b1f7e546dd90"
      unitRef="usd">2260000</agio:ContractWithCustomerRebateReserveRecoveriesInCurrentYear>
    <agio:ContractWithCustomerRightToRecoverProductCurrentYearRecoveries
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfNC01LTEtMS0w_0fdeb7e5-f8f9-4c9a-971f-40485d0e5adf"
      unitRef="usd">0</agio:ContractWithCustomerRightToRecoverProductCurrentYearRecoveries>
    <agio:ContractWithCustomerCurrentYearReserveRecoveries
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfNC03LTEtMS0w_a679110c-dbd9-4a73-b733-3762678c536e"
      unitRef="usd">11226000</agio:ContractWithCustomerCurrentYearReserveRecoveries>
    <agio:ContractWithCustomerContractAdjustmentRecoveriesPriorYear
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfNS0xLTEtMS0w_60ef4c40-2f8c-4c2c-b611-4bff47c7ab78"
      unitRef="usd">653000</agio:ContractWithCustomerContractAdjustmentRecoveriesPriorYear>
    <agio:ContractWithCustomerRebateReserveRecoveriesInPriorYears
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfNS0zLTEtMS0w_0db31c74-4807-4397-a9ad-243913b46d50"
      unitRef="usd">677000</agio:ContractWithCustomerRebateReserveRecoveriesInPriorYears>
    <agio:ContractWithCustomerRightToRecoverProductPriorYearRecoveries
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfNS01LTEtMS0w_f66842f2-4bbf-43a8-a6e8-4ff2e71019aa"
      unitRef="usd">0</agio:ContractWithCustomerRightToRecoverProductPriorYearRecoveries>
    <agio:ContractWithCustomerPriorYearsReserveRecoveries
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfNS03LTEtMS0w_9716a988-d2a0-430a-81bc-2b94d8fce31a"
      unitRef="usd">1330000</agio:ContractWithCustomerPriorYearsReserveRecoveries>
    <agio:ContractWithCustomerContractualAdjustmentReserve
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfNi0xLTEtMS0w_1c1d55a2-4d33-49bc-96f0-19703f0ad5c3"
      unitRef="usd">1513000</agio:ContractWithCustomerContractualAdjustmentReserve>
    <agio:ContractWithCustomerRebateReserve
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfNi0zLTEtMS0w_c437dcf7-6800-4afa-8dab-fbb04c511ba0"
      unitRef="usd">7608000</agio:ContractWithCustomerRebateReserve>
    <agio:ContractWithCustomerRightToRecoverProductReserve
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfNi01LTEtMS0w_b3760b61-62a3-438f-9a68-f6a8ff0a561a"
      unitRef="usd">2618000</agio:ContractWithCustomerRightToRecoverProductReserve>
    <agio:ContractWithCustomerTotalAllowancesAndReserves
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOmNhZDdhZWI3OTcxZjQ5MTY4ZDRlNGNhYjc4MDZkYmU0L3RhYmxlcmFuZ2U6Y2FkN2FlYjc5NzFmNDkxNjhkNGU0Y2FiNzgwNmRiZTRfNi03LTEtMS0w_598151ce-8a0f-4301-83e0-ade6dcacd597"
      unitRef="usd">11739000</agio:ContractWithCustomerTotalAllowancesAndReserves>
    <agio:ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RleHRyZWdpb246ZDMzYjRkYmEwYmUzNDY3Yzk0ZGE1NjU4MGRhMzRjYmNfNzcw_b08a1ab5-9a7f-4596-941e-dc0b72caa89f">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue-related reserves above, included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Component of accrued expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</agio:ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOjNkNGQ2ODg4MzQwMjRlMGVhNTRiMGJmMTE4NzNmOGYzL3RhYmxlcmFuZ2U6M2Q0ZDY4ODgzNDAyNGUwZWE1NGIwYmYxMTg3M2Y4ZjNfMS0xLTEtMS0w_ccfa7bdb-29c2-4891-a630-0a2d2e3159dc"
      unitRef="usd">732000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOjNkNGQ2ODg4MzQwMjRlMGVhNTRiMGJmMTE4NzNmOGYzL3RhYmxlcmFuZ2U6M2Q0ZDY4ODgzNDAyNGUwZWE1NGIwYmYxMTg3M2Y4ZjNfMS0zLTEtMS0w_2a1c73a8-c682-4471-a30f-25c92c3961b6"
      unitRef="usd">540000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <agio:ContractWithCustomerAllowanceAndReservesLiability
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOjNkNGQ2ODg4MzQwMjRlMGVhNTRiMGJmMTE4NzNmOGYzL3RhYmxlcmFuZ2U6M2Q0ZDY4ODgzNDAyNGUwZWE1NGIwYmYxMTg3M2Y4ZjNfMi0xLTEtMS0w_a9f5c00c-4c4e-4087-bf69-5aaa372b87db"
      unitRef="usd">11007000</agio:ContractWithCustomerAllowanceAndReservesLiability>
    <agio:ContractWithCustomerAllowanceAndReservesLiability
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOjNkNGQ2ODg4MzQwMjRlMGVhNTRiMGJmMTE4NzNmOGYzL3RhYmxlcmFuZ2U6M2Q0ZDY4ODgzNDAyNGUwZWE1NGIwYmYxMTg3M2Y4ZjNfMi0zLTEtMS0w_231819f4-c222-4f92-9470-2a15541ecb76"
      unitRef="usd">3256000</agio:ContractWithCustomerAllowanceAndReservesLiability>
    <agio:ContractWithCustomerTotalAllowancesAndReserves
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOjNkNGQ2ODg4MzQwMjRlMGVhNTRiMGJmMTE4NzNmOGYzL3RhYmxlcmFuZ2U6M2Q0ZDY4ODgzNDAyNGUwZWE1NGIwYmYxMTg3M2Y4ZjNfMy0xLTEtMS0w_d3a0ccc4-b6ed-4110-b025-9288c94d1dd7"
      unitRef="usd">11739000</agio:ContractWithCustomerTotalAllowancesAndReserves>
    <agio:ContractWithCustomerTotalAllowancesAndReserves
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOjNkNGQ2ODg4MzQwMjRlMGVhNTRiMGJmMTE4NzNmOGYzL3RhYmxlcmFuZ2U6M2Q0ZDY4ODgzNDAyNGUwZWE1NGIwYmYxMTg3M2Y4ZjNfMy0zLTEtMS0w_dd704dba-c113-4768-9a6d-a77637fb0db1"
      unitRef="usd">3796000</agio:ContractWithCustomerTotalAllowancesAndReserves>
    <agio:ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RleHRyZWdpb246ZDMzYjRkYmEwYmUzNDY3Yzk0ZGE1NjU4MGRhMzRjYmNfNzYy_10875acd-7e0a-4bf4-b1fa-a73cb7a27e58">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in our contract assets during the nine months ended September 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92,467)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)  Additions to contract assets relate to amounts billed to Customers for product sales and deductions to contract assets primarily relate to collection of receivables during the reporting period.</agio:ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOjJkMDYyNWYzNDdkOTRlZWQ5ZjBmNjIyODBhMGQ3YzdkL3RhYmxlcmFuZ2U6MmQwNjI1ZjM0N2Q5NGVlZDlmMGY2MjI4MGEwZDdjN2RfMi0xLTEtMS0w_2c82a61d-4cb2-4e26-95d7-f907929e8a3a"
      unitRef="usd">8952000</us-gaap:ContractWithCustomerAssetNet>
    <agio:ContractWithCustomerAssetRevenueRecognized
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOjJkMDYyNWYzNDdkOTRlZWQ5ZjBmNjIyODBhMGQ3YzdkL3RhYmxlcmFuZ2U6MmQwNjI1ZjM0N2Q5NGVlZDlmMGY2MjI4MGEwZDdjN2RfMi0zLTEtMS0w_f4f0a6f6-5803-4b53-9d96-5afc597a692d"
      unitRef="usd">102504000</agio:ContractWithCustomerAssetRevenueRecognized>
    <agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOjJkMDYyNWYzNDdkOTRlZWQ5ZjBmNjIyODBhMGQ3YzdkL3RhYmxlcmFuZ2U6MmQwNjI1ZjM0N2Q5NGVlZDlmMGY2MjI4MGEwZDdjN2RfMi01LTEtMS0w_2752d308-0af7-4e31-a344-e0e3be98626f"
      unitRef="usd">92467000</agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81NS9mcmFnOmQzM2I0ZGJhMGJlMzQ2N2M5NGRhNTY1ODBkYTM0Y2JjL3RhYmxlOjJkMDYyNWYzNDdkOTRlZWQ5ZjBmNjIyODBhMGQ3YzdkL3RhYmxlcmFuZ2U6MmQwNjI1ZjM0N2Q5NGVlZDlmMGY2MjI4MGEwZDdjN2RfMi03LTEtMS0w_755c6338-bb8c-4cb9-8ecd-125c5b61cde0"
      unitRef="usd">18989000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTEyMjA_3eee5f2b-1897-4d50-8b10-09fda6b1942b">Collaboration and License Agreements &lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounting analysis and revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our collaboration and license agreements typically involve us granting licenses of our intellectual property and performing research and development services in exchange of upfront fees, milestone payments and royalty payments. Since December 31, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2019, there have been no material changes to the key terms of our collaboration or license agreements. For further information on the terms and conditions of our existing collaboration and license agreements, please see the notes to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized, we performed the following steps: (i) identified the promised goods or services in the contract; (ii) determined whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measured the transaction price, including the constraint on variable consideration; (iv) allocated the transaction price to the performance obligations; and (v) recognized revenue when (or as) we satisfied each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalty revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties and sales-based milestones and in which the license is deemed to be the predominant item to which the royalties relate, we recognize royalty revenue upon the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Milestone revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At each reporting period we evaluate whether milestones are considered probable of being reached and, to the extent that a significant reversal would not occur in future periods, estimate the amount to be included in the transaction price using the most likely amount method.&#160;Milestone payments that are not within our control, such as regulatory approvals, are considered constrained and are excluded from the transaction price until those approvals are received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Celgene Corporation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have entered into the following collaboration agreements, or collectively, the Collaboration Agreements, with Celgene, a wholly owned subsidiary of BMS, which is a related party through ownership of our common stock: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In April 2010, we entered into a discovery and development collaboration and license agreement focused on cancer metabolism, or the 2010 Agreement, which was amended in October 2011 and July 2014. The discovery phase of the 2010 Agreement expired in April 2016. On August 15, 2016, we terminated the 2010 Agreement as to the program directed to the isocitrate dehydrogenase 1, or IDH1, target, for which ivosidenib was the lead development candidate. Accordingly, the sole program remaining under the 2010 Agreement is IDHIFA&#xae; (enasidenib), a co-commercialized licensed program for which Celgene leads and funds global development and commercialization activities. On June 11, 2020, we sold our tiered, sales-based royalty rights on worldwide net sales of IDHIFA&#xae; (enasidenib), as well as our rights to receive up to $55.0&#160;million in outstanding regulatory milestone payments from BMS, to RPI for $255.0&#160;million. Under the 2010 Agreement, we remain eligible to receive a $25.0&#160;million potential milestone payment for the enasidenib program upon achievement of a specified ex-U.S. commercial milestone event, as well as reimbursement for costs incurred for our co-commercialization efforts and development activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In April&#160;2015, we entered into a joint worldwide development and profit share collaboration and license agreement with Celgene, and our wholly owned subsidiary, Agios International Sarl, entered into a collaboration and license agreement with Celgene International II Sarl, or collectively, the AG-881 Agreements, to establish a worldwide collaboration focused on the development and commercialization of vorasidenib products. Under the AG-881 Agreements, we and Celgene split all worldwide development costs for vorasidenib, subject to specified exceptions. The AG-881 Agreements were terminated effective September 4, 2018, upon which we received sole global rights to vorasidenib. In connection with the termination of the AG-881 Agreements, Celgene will be eligible to receive royalties from us at a low single-digit percentage rate on worldwide net sales of products containing vorasidenib.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;In May&#160;2016, we entered into a master research and collaboration agreement with Celgene, or the 2016 Agreement, focused on metabolic immuno-oncology, or MIO, a developing field which aims to modulate the activity of relevant immune cells by targeting critical metabolic nodes, thereby enhancing the immune mediated anti-tumor response. The initial four-year research term of the 2016 Agreement ended May 2020. On March 25, 2020 Celgene declined the option to extend the research agreement for up to two, or in specified cases, up to four additional one-year terms which would have required the payment of a $40.0&#160;million extension fee. Further, on April 10, 2020 Celgene notified us that they will be declining to elect any program as a continuation program under the 2016 agreement. Celgene had designated AG-270, our inhibitor of methionine adenosyltransferase 2a, or MAT2A, as a development candidate under the 2016 Agreement. On March 25, 2020, Celgene notified us of their decision to decline their option to enter into a Development &amp;amp; Commercialization Agreement with respect to the MAT2A program under the 2016 Agreement which &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;would have required the payment of a $30.0&#160;million fee. As a result of the decisions, the research services were fully satisfied as of May 17, 2020, no additional performance obligations remain under the 2016 Agreement and we are no longer eligible for any milestone payments for the 2016 Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September 30, 2020 and 2019, we recognized the following collaboration revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Services performed that were considered performance obligations as of the modification dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;On-going research and development services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Services performed that were not considered performance obligations as of the modification dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercialization activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenue - related party&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in our contract assets and liabilities during the nine months ended September 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration receivable &#x2013; related party &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unbilled receivable - related party &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(346)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty receivable &#x2013; related party &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue &#x2013; related party, current and net of current portions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63,934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(1)  Additions to collaboration receivables - related party relate to amounts billed to Celgene for reimbursable costs incurred by us during the reporting period. Deductions to receivables relate to collection of receivables during the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(2)  Unbilled receivables - related party amounts relate to future reimbursable costs to Celgene.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)  Additions to royalty receivables - related party relate to amounts billed to Celgene during the reporting period. Deductions to receivables relate to collection of receivables during the reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)  Additions to deferred revenue - related party relate to consideration from Celgene during the reporting period. Deductions relate to deferred revenue recognized as revenue during the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in collaboration revenue from on-going research and development services during the three and nine months ended September&#160;30, 2020 is primarily due to our updated estimate of the future costs that would be incurred from on-going research and development services to complete one of our performance obligations under the 2016 Agreement that is recognized over time using an input method, due to Celgene&#x2019;s decision to decline extending the research term in the first quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September 30, 2020 and 2019, we recognized the following as revenue due to changes in the contract liability balances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.333%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts included in the contract liability at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance obligations satisfied in previous periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, the aggregate amount of the transaction price allocated to performance obligations that are partially unsatisfied was $4.5 million. This amount is expected to be recognized as performance obligations are satisfied through September 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalty revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the underlying performance obligation, or delivery of the enasidenib license, had been satisfied as of June 2014, royalty revenue is recognized as the related sales occur. During the three and nine months ended September 30, 2020 and 2019, we recognized the following as royalty revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenue &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 11, 2020, we sold our tiered, sales-based royalty rights on worldwide net sales of IDHIFA&#xae; (enasidenib), as well as our rights to receive up to $55.0&#160;million in outstanding regulatory milestone payments from BMS, to RPI for $255.0&#160;million. For further discussion of the sale of future revenue, refer to Note 10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sale of Future Revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Milestone revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No milestones were achieved during the three and nine months ended September 30, 2020 or 2019. The next potential milestone expected to be achieved under the remaining terms of our Collaboration Agreements is the achievement of a specified ex-U.S. commercial milestone event, which would result in a milestone payment of $25.0 million under the 2010 Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CStone Pharmaceuticals &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, we and CStone Pharmaceuticals, or CStone, entered into an exclusive license agreement, or the CStone Agreement, to grant CStone specified intellectual property licenses to enable CStone to develop and commercialize certain products containing ivosidenib in mainland China, Hong Kong, Macau and Taiwan, or the CStone Territory. We retain development and commercialization rights for the rest of the world. On March 2, 2020, we amended the CStone Agreement to include Singapore as part of the CStone Territory. Pursuant to the CStone Agreement, CStone will initially be responsible for the development and commercialization of ivosidenib in acute myeloid leukemia, or AML, cholangiocarcinoma, and, at our discretion, brain cancer indications. CStone is responsible for all costs it incurs in developing, obtaining regulatory approval of, and commercializing ivosidenib in the CStone Territory, as well as certain costs incurred by us. Pursuant to the CStone Agreement, we received an initial upfront payment in the amount of $12.0 million and are entitled to receive up to an additional $407.0 million in milestone payments upon the achievement of certain development, regulatory and sales milestone events. We will also be entitled to receive tiered royalties, ranging from 15% to 19% percent, on annual net sales, if any, of ivosidenib in the CStone Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September 30, 2020 and 2019, we recognized the following collaboration revenue -other:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Services performed that were considered performance obligations as of the inception date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License and other services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Services performed that were not considered performance obligations as of the inception date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenue - other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents changes in our contract assets during the nine months ended September 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration receivable - other&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)    Additions to contract assets relate to amounts receivable from CStone. Deductions to contract assets relate to collection of receivables during the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, the aggregate amount of the transaction price allocated to performance obligations that are partially unsatisfied was $0.5 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalty revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The license was determined to be the predominant item to which sales-based royalties and sales-based milestones relate. As the license was delivered in June 2018, we will recognize royalty revenue when the related sales occur. To date, no royalties have been received under the CStone Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Milestone revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No milestones were earned during the three and nine months ended September 30, 2020 and 2019. The next potential milestone expected to be achieved under the CStone Agreement is the dosing of the first patient in a local study in a solid tumor indication in mainland China. Achievement of this event will result in a milestone payment of $5.0 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <agio:RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold
      contextRef="ife55cfc6e645489a9aa97a13da6dfe00_I20200611"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMzM4MQ_ff89900f-bfc8-49e4-b3c4-a7c4dd117e27"
      unitRef="usd">55000000.0</agio:RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold>
    <agio:ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold
      contextRef="ib2575fe6eebf402cbdb0a3e5509d729d_D20200611-20200611"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMzQ1MA_2266f1d8-2597-41af-b0ed-e4262f399fbf"
      unitRef="usd">255000000.0</agio:ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold>
    <agio:RevenueRecognitionMilestoneMethodEligibleReceivable
      contextRef="idf22f68ca84c40088ac574f70d88d77d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMzUxMg_25b26e4b-7bc3-4c17-93cd-5200be855d81"
      unitRef="usd">25000000.0</agio:RevenueRecognitionMilestoneMethodEligibleReceivable>
    <agio:RevenueRecognitionMultipleDeliverableArrangementsTermOfAgreement
      contextRef="i5e16d3756d704760a00e78beb3a53457_D20160501-20160531"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTEyMTQ_db325fa4-46ad-4635-8a40-2937a43513a2">P4Y</agio:RevenueRecognitionMultipleDeliverableArrangementsTermOfAgreement>
    <agio:RevenueRecognitionMultipleDeliverableArrangementsNumberOfExtensions
      contextRef="i5e16d3756d704760a00e78beb3a53457_D20160501-20160531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfNTEzMQ_c903b800-0b60-43ef-b224-1103c5506871"
      unitRef="extension">2</agio:RevenueRecognitionMultipleDeliverableArrangementsNumberOfExtensions>
    <agio:RevenueRecognitionMultipleDeliverableArrangementsNumberOfSpecialCaseExtensions
      contextRef="i5e16d3756d704760a00e78beb3a53457_D20160501-20160531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfNTE2NA_7ed16c67-87fb-49dc-bc61-a2774a177ceb"
      unitRef="extension">4</agio:RevenueRecognitionMultipleDeliverableArrangementsNumberOfSpecialCaseExtensions>
    <agio:RevenueRecognitionMultipleDeliverableArrangementsSpecialCaseExtensionTerm
      contextRef="i5e16d3756d704760a00e78beb3a53457_D20160501-20160531"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTEyMjM_42a5f61c-0aef-42ca-8936-a21cbc6726e1">P1Y</agio:RevenueRecognitionMultipleDeliverableArrangementsSpecialCaseExtensionTerm>
    <agio:UpfrontPaymentAgreementExtensionFeeReceivable
      contextRef="i5e16d3756d704760a00e78beb3a53457_D20160501-20160531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfNTIzNQ_e4c0f41f-16dd-411c-b855-5926621c6ce7"
      unitRef="usd">40000000.0</agio:UpfrontPaymentAgreementExtensionFeeReceivable>
    <agio:OptionExerciseFeeReceivable
      contextRef="ic19c9efe1bc441b28792cb1fb430006c_I20160531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfNTc4OA_929b3e08-4a51-42d4-8eca-4741c5571b73"
      unitRef="usd">30000000.0</agio:OptionExerciseFeeReceivable>
    <agio:RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfNTQ5NzU1ODE1MDExNg_5a448beb-c813-4a06-a5c0-1806d96c4a2b">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September 30, 2020 and 2019, we recognized the following collaboration revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Services performed that were considered performance obligations as of the modification dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;On-going research and development services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Services performed that were not considered performance obligations as of the modification dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercialization activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenue - related party&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</agio:RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4bbc2d1419c542459a401e63c7eca48e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjYwYjBkYjFmZmU4ZTQ3NDRhMDIwNTQ4ODBlZjU4ZmQ3L3RhYmxlcmFuZ2U6NjBiMGRiMWZmZThlNDc0NGEwMjA1NDg4MGVmNThmZDdfNC0xLTEtMS0w_b1f5b22b-61fd-4ce0-8281-bd5f608adc67"
      unitRef="usd">199000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03d3c6ff3eaa4f96a6b43c3884afbdd5_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjYwYjBkYjFmZmU4ZTQ3NDRhMDIwNTQ4ODBlZjU4ZmQ3L3RhYmxlcmFuZ2U6NjBiMGRiMWZmZThlNDc0NGEwMjA1NDg4MGVmNThmZDdfNC0zLTEtMS0w_c808cfea-fc22-4331-848f-26446731789a"
      unitRef="usd">4695000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i635a87f89b85400aa10e6ca171a7869f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjYwYjBkYjFmZmU4ZTQ3NDRhMDIwNTQ4ODBlZjU4ZmQ3L3RhYmxlcmFuZ2U6NjBiMGRiMWZmZThlNDc0NGEwMjA1NDg4MGVmNThmZDdfNC01LTEtMS0w_bfee0931-a9f2-4f96-805f-8c1db021c773"
      unitRef="usd">64133000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a9429c5ed7c4eafa27ec8b3c0962e9c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjYwYjBkYjFmZmU4ZTQ3NDRhMDIwNTQ4ODBlZjU4ZmQ3L3RhYmxlcmFuZ2U6NjBiMGRiMWZmZThlNDc0NGEwMjA1NDg4MGVmNThmZDdfNC03LTEtMS0w_f05eef96-2172-4c54-9223-5f9332b570d1"
      unitRef="usd">29915000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i231960ca9c014f48bb976e41d6c6d505_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjYwYjBkYjFmZmU4ZTQ3NDRhMDIwNTQ4ODBlZjU4ZmQ3L3RhYmxlcmFuZ2U6NjBiMGRiMWZmZThlNDc0NGEwMjA1NDg4MGVmNThmZDdfOC0xLTEtMS0w_c5128e62-5cbb-43bc-94fe-a680e2e50444"
      unitRef="usd">1007000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i332309b5d2244ef5b9ecb08809dcbd9f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjYwYjBkYjFmZmU4ZTQ3NDRhMDIwNTQ4ODBlZjU4ZmQ3L3RhYmxlcmFuZ2U6NjBiMGRiMWZmZThlNDc0NGEwMjA1NDg4MGVmNThmZDdfOC0zLTEtMS0w_88c341bb-f09b-40b8-8035-00e00db691b9"
      unitRef="usd">821000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85fcfba1e36545e493bcf708b4e9df68_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjYwYjBkYjFmZmU4ZTQ3NDRhMDIwNTQ4ODBlZjU4ZmQ3L3RhYmxlcmFuZ2U6NjBiMGRiMWZmZThlNDc0NGEwMjA1NDg4MGVmNThmZDdfOC01LTEtMS0w_a88cfbf4-add9-4d67-8c22-a9459bafd59b"
      unitRef="usd">2905000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b78993cbec4481bbc686cda5de776b1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjYwYjBkYjFmZmU4ZTQ3NDRhMDIwNTQ4ODBlZjU4ZmQ3L3RhYmxlcmFuZ2U6NjBiMGRiMWZmZThlNDc0NGEwMjA1NDg4MGVmNThmZDdfOC03LTEtMS0w_f479db40-6285-4444-8ffa-6707fcb8d3a3"
      unitRef="usd">2499000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6645fba9caf44b8b8bcb42c98bf2278_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjYwYjBkYjFmZmU4ZTQ3NDRhMDIwNTQ4ODBlZjU4ZmQ3L3RhYmxlcmFuZ2U6NjBiMGRiMWZmZThlNDc0NGEwMjA1NDg4MGVmNThmZDdfOS0xLTEtMS0w_16dcb823-d09c-4ee0-9b5c-318e1b6e6d80"
      unitRef="usd">1206000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia038c518019748b78ce08495d4f16d87_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjYwYjBkYjFmZmU4ZTQ3NDRhMDIwNTQ4ODBlZjU4ZmQ3L3RhYmxlcmFuZ2U6NjBiMGRiMWZmZThlNDc0NGEwMjA1NDg4MGVmNThmZDdfOS0zLTEtMS0w_c1207584-61fc-4f30-b862-99ee9a37266b"
      unitRef="usd">5516000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6be33be9efa74778b57706d8c1dc08f4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjYwYjBkYjFmZmU4ZTQ3NDRhMDIwNTQ4ODBlZjU4ZmQ3L3RhYmxlcmFuZ2U6NjBiMGRiMWZmZThlNDc0NGEwMjA1NDg4MGVmNThmZDdfOS01LTEtMS0w_c456af71-3e88-4c08-a7b1-a1362d250c2f"
      unitRef="usd">67038000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5a1fdf43a234d5c9fb4b6957bdd5c72_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjYwYjBkYjFmZmU4ZTQ3NDRhMDIwNTQ4ODBlZjU4ZmQ3L3RhYmxlcmFuZ2U6NjBiMGRiMWZmZThlNDc0NGEwMjA1NDg4MGVmNThmZDdfOS03LTEtMS0w_de937e21-308c-4e8f-b5f9-5d2dee30eff5"
      unitRef="usd">32414000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfNTQ5NzU1ODE1MDExNw_ec0afbfe-6aff-4962-92f3-f16319417288">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in our contract assets and liabilities during the nine months ended September 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration receivable &#x2013; related party &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unbilled receivable - related party &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(346)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty receivable &#x2013; related party &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue &#x2013; related party, current and net of current portions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63,934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(1)  Additions to collaboration receivables - related party relate to amounts billed to Celgene for reimbursable costs incurred by us during the reporting period. Deductions to receivables relate to collection of receivables during the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;(2)  Unbilled receivables - related party amounts relate to future reimbursable costs to Celgene.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)  Additions to royalty receivables - related party relate to amounts billed to Celgene during the reporting period. Deductions to receivables relate to collection of receivables during the reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)  Additions to deferred revenue - related party relate to consideration from Celgene during the reporting period. Deductions relate to deferred revenue recognized as revenue during the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September 30, 2020 and 2019, we recognized the following as revenue due to changes in the contract liability balances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.333%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts included in the contract liability at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance obligations satisfied in previous periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i21cd91eb1d2842528666b7c51b692515_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfMi0xLTEtMS0w_b68bd2b2-f843-4481-8f3d-92d602234c4b"
      unitRef="usd">1539000</us-gaap:ContractWithCustomerAssetNet>
    <agio:ContractWithCustomerAssetRevenueRecognized
      contextRef="i822eacbd7a3140f7a5ad55739d7525b2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfMi0zLTEtMS0w_38aaba32-2320-40c0-8ad9-8e0c2cd15caa"
      unitRef="usd">4228000</agio:ContractWithCustomerAssetRevenueRecognized>
    <agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables
      contextRef="i822eacbd7a3140f7a5ad55739d7525b2_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfMi01LTEtMS0w_829fae80-6c8c-4af8-82f2-7836d56d4ab2"
      unitRef="usd">4693000</agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i60e99bcf39eb4a1198ea4cb7a6f6bc0c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfMi03LTEtMS0w_79bdc941-2faa-490d-98d8-1c99dbccca9e"
      unitRef="usd">1074000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i11fc8fb499ea4d2cb1eb548dd4ca43db_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfMy0xLTEtMS0w_e80684a0-fd1a-4d9f-be43-3b770cbf8749"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <agio:ContractWithCustomerAssetRevenueRecognized
      contextRef="i3f99babce6584b2ba9dc951305e2fc7b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfMy0zLTEtMS0w_64a5d84f-ed02-4a5c-b57c-eaef7416283d"
      unitRef="usd">1606000</agio:ContractWithCustomerAssetRevenueRecognized>
    <agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables
      contextRef="i3f99babce6584b2ba9dc951305e2fc7b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfMy01LTEtMS0w_8af1b3bb-c37e-4688-8805-b36b8822661c"
      unitRef="usd">346000</agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="id771f4009bfa4c4bbdedf06974f817e1_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfMy03LTEtMS0w_29aa65fe-c902-4b0a-a6c1-1afb456a09fa"
      unitRef="usd">1260000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="id866c85fcea34845a31e92f2f2b956a9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfNC0xLTEtMS0w_93141477-2af3-463f-baba-a28ae4952fa7"
      unitRef="usd">2900000</us-gaap:ContractWithCustomerAssetNet>
    <agio:ContractWithCustomerAssetRevenueRecognized
      contextRef="i5ed0f7fca6824f939606850129df11d9_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfNC0zLTEtMS0w_e2f6a3aa-a8ca-400a-8b4b-39df9e809f61"
      unitRef="usd">5015000</agio:ContractWithCustomerAssetRevenueRecognized>
    <agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables
      contextRef="i5ed0f7fca6824f939606850129df11d9_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfNC01LTEtMS0w_2a9761a6-f568-482d-92c5-92db8a79dc7f"
      unitRef="usd">7915000</agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i3b35d322903843578f6a68da48ebf6bb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfNC03LTEtMS0w_87f87218-85e7-4b80-bc4a-dfbdad1e2ecc"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ib908b1f10858485dad4c2ae0e63c92ea_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfNi0xLTEtMS0w_7c0a5273-7798-4ac0-9a3f-7904593d3832"
      unitRef="usd">61513000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i99f701a2e0cb4e8b8665c215666a581f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfNi0zLTEtMS0w_07828c32-9f11-41f1-9199-44803c73763d"
      unitRef="usd">2421000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="i99f701a2e0cb4e8b8665c215666a581f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfNi01LTEtMS0w_0b0786ea-d82a-46b6-84f2-02ffe38bf51e"
      unitRef="usd">63934000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i29d069dedee94effb0e3fe4e2557d773_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmVkYzhiNGZiYTYwNjRmMTI4NDNlNzlhZTQzMjMyMmJiL3RhYmxlcmFuZ2U6ZWRjOGI0ZmJhNjA2NGYxMjg0M2U3OWFlNDMyMzIyYmJfNi03LTEtMS0w_d146bcb2-0138-4a68-87b6-ed0751ae61fd"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmNjMWIwZmI0ZDNlNzQ0YTA4YWY5NjIwYjA5YWJmZDlkL3RhYmxlcmFuZ2U6Y2MxYjBmYjRkM2U3NDRhMDhhZjk2MjBiMDlhYmZkOWRfMi0xLTEtMS0w_b9f271b4-3c82-4ffb-937f-21ad4c41e48e"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmNjMWIwZmI0ZDNlNzQ0YTA4YWY5NjIwYjA5YWJmZDlkL3RhYmxlcmFuZ2U6Y2MxYjBmYjRkM2U3NDRhMDhhZjk2MjBiMDlhYmZkOWRfMi0zLTEtMS0w_59f6fe5a-0275-4f76-b6a1-6b16c80e4f13"
      unitRef="usd">4404000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmNjMWIwZmI0ZDNlNzQ0YTA4YWY5NjIwYjA5YWJmZDlkL3RhYmxlcmFuZ2U6Y2MxYjBmYjRkM2U3NDRhMDhhZjk2MjBiMDlhYmZkOWRfMi01LTEtMS0w_4d5fd732-dff4-421e-8bcf-a74433b759d3"
      unitRef="usd">61513000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmNjMWIwZmI0ZDNlNzQ0YTA4YWY5NjIwYjA5YWJmZDlkL3RhYmxlcmFuZ2U6Y2MxYjBmYjRkM2U3NDRhMDhhZjk2MjBiMDlhYmZkOWRfMi03LTEtMS0w_9a616567-adbc-4102-991a-a47936d1fe15"
      unitRef="usd">28823000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmNjMWIwZmI0ZDNlNzQ0YTA4YWY5NjIwYjA5YWJmZDlkL3RhYmxlcmFuZ2U6Y2MxYjBmYjRkM2U3NDRhMDhhZjk2MjBiMDlhYmZkOWRfMy0xLTEtMS0w_965331ea-76c0-4635-91f4-b60f7ce10d68"
      unitRef="usd">0</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmNjMWIwZmI0ZDNlNzQ0YTA4YWY5NjIwYjA5YWJmZDlkL3RhYmxlcmFuZ2U6Y2MxYjBmYjRkM2U3NDRhMDhhZjk2MjBiMDlhYmZkOWRfMy0zLTEtMS0w_778a0fe1-8996-434c-a339-9f579988285e"
      unitRef="usd">0</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmNjMWIwZmI0ZDNlNzQ0YTA4YWY5NjIwYjA5YWJmZDlkL3RhYmxlcmFuZ2U6Y2MxYjBmYjRkM2U3NDRhMDhhZjk2MjBiMDlhYmZkOWRfMy01LTEtMS0w_008b106f-d93c-4a68-a1df-cae1381294b6"
      unitRef="usd">0</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOmNjMWIwZmI0ZDNlNzQ0YTA4YWY5NjIwYjA5YWJmZDlkL3RhYmxlcmFuZ2U6Y2MxYjBmYjRkM2U3NDRhMDhhZjk2MjBiMDlhYmZkOWRfMy03LTEtMS0w_e4e593a8-e8f8-415f-aca3-071a1ac6a75e"
      unitRef="usd">0</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfNzcxMw_7ee0162e-2b96-4199-8ef9-bfb6980ffdaa"
      unitRef="usd">4500000</us-gaap:RevenueRemainingPerformanceObligation>
    <agio:RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTEyMjE_9ea2e0c0-892d-4034-9e07-72ef023454bd">During the three and nine months ended September 30, 2020 and 2019, we recognized the following as royalty revenue:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.332%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenue &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</agio:RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d4b033413e949bdb33308f291e151d7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjIwMTc2ZjIxNjk5NjQyYzU5NjdjMDhmMmY3M2M3YTlkL3RhYmxlcmFuZ2U6MjAxNzZmMjE2OTk2NDJjNTk2N2MwOGYyZjczYzdhOWRfMi0xLTEtMS0w_c0696796-b1c3-426c-9b5c-a407b2aec183"
      unitRef="usd">683000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib72090a087094a15a97bb50cce1d461f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjIwMTc2ZjIxNjk5NjQyYzU5NjdjMDhmMmY3M2M3YTlkL3RhYmxlcmFuZ2U6MjAxNzZmMjE2OTk2NDJjNTk2N2MwOGYyZjczYzdhOWRfMi0zLTEtMS0w_36f5e9eb-0298-4180-ad79-b57ed7bbde91"
      unitRef="usd">2666000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5e859f8f93d478cbc47d931bf3d4f16_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjIwMTc2ZjIxNjk5NjQyYzU5NjdjMDhmMmY3M2M3YTlkL3RhYmxlcmFuZ2U6MjAxNzZmMjE2OTk2NDJjNTk2N2MwOGYyZjczYzdhOWRfMi01LTEtMS0w_30ea6617-a7ae-4443-bcac-ca355502895b"
      unitRef="usd">7356000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8bd62d81b9224846bad804af424c7c55_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjIwMTc2ZjIxNjk5NjQyYzU5NjdjMDhmMmY3M2M3YTlkL3RhYmxlcmFuZ2U6MjAxNzZmMjE2OTk2NDJjNTk2N2MwOGYyZjczYzdhOWRfMi03LTEtMS0w_684ea507-5f25-43cb-99aa-e8ff135d38ea"
      unitRef="usd">7569000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <agio:RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold
      contextRef="ife55cfc6e645489a9aa97a13da6dfe00_I20200611"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfODIzOQ_ff89900f-bfc8-49e4-b3c4-a7c4dd117e27"
      unitRef="usd">55000000.0</agio:RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold>
    <agio:ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold
      contextRef="ib2575fe6eebf402cbdb0a3e5509d729d_D20200611-20200611"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfODMwOA_2266f1d8-2597-41af-b0ed-e4262f399fbf"
      unitRef="usd">255000000.0</agio:ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold>
    <agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfODQyNg_22674662-13dc-4b2f-bc11-7d1dfe24d5e4"
      unitRef="usd">0</agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized>
    <agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfODQyNg_8fdd646f-2b36-47bb-8538-97e1ecb86777"
      unitRef="usd">0</agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized>
    <agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfODQyNg_9aa1330d-a1e0-4df1-9b8c-ddb72048c47e"
      unitRef="usd">0</agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized>
    <agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfODQyNg_e23f7908-e845-46b3-911d-914c9506082e"
      unitRef="usd">0</agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized>
    <agio:PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication
      contextRef="idf22f68ca84c40088ac574f70d88d77d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfODcwMQ_ffd8cccf-cd89-4f43-9a9c-ebead87cea01"
      unitRef="usd">25000000.0</agio:PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication>
    <agio:ContractWithCustomerLiabilityIncreaseFromCashReceipts
      contextRef="i18ae39e61005422296a6185b1b3642ac_D20180601-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfOTc5MQ_7b0fb940-297a-49c0-8b2f-ee50f52d4ca6"
      unitRef="usd">12000000.0</agio:ContractWithCustomerLiabilityIncreaseFromCashReceipts>
    <agio:ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable
      contextRef="if60bb09a8e0d4226ba3167b23f5cb3a4_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfOTg0Mg_11e2f3a4-ef18-4b97-841f-f05a7511148d"
      unitRef="usd">407000000.0</agio:ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable>
    <agio:RoyaltyPercentageRemitted
      contextRef="i0f0956f37ec44b6bb6d0f4fa5248bef0_D20180601-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTAwMTg_a4ee81ef-1a26-4f3d-a0b3-02292b9077bf"
      unitRef="number">0.15</agio:RoyaltyPercentageRemitted>
    <agio:RoyaltyPercentageRemitted
      contextRef="i54571e1728c5451ab4e07db6c9467aee_D20180601-20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTAwMjQ_730200bc-ec41-4e1e-b612-91933c91148d"
      unitRef="number">0.19</agio:RoyaltyPercentageRemitted>
    <agio:RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTEyMTc_0c51639e-e9b1-4d70-8d14-87acd1f2bbfa">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September 30, 2020 and 2019, we recognized the following collaboration revenue -other:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Services performed that were considered performance obligations as of the inception date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License and other services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Services performed that were not considered performance obligations as of the inception date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenue - other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</agio:RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08ba0b22d8f3450e8b229803691aa936_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjM2YzVkODlhM2ViZDQ2YjJiMDc3ZGJjMGM2MDg2MTllL3RhYmxlcmFuZ2U6MzZjNWQ4OWEzZWJkNDZiMmIwNzdkYmMwYzYwODYxOWVfMy0xLTEtMS0w_7f0d67d0-62f7-405e-882b-41e8dfa26a83"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7c63d1760f04d71aa4c373f08d1f88e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjM2YzVkODlhM2ViZDQ2YjJiMDc3ZGJjMGM2MDg2MTllL3RhYmxlcmFuZ2U6MzZjNWQ4OWEzZWJkNDZiMmIwNzdkYmMwYzYwODYxOWVfMy0zLTEtMS0w_44649c67-0576-4494-ad36-77fa7434cf33"
      unitRef="usd">-103000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iddeab0bd8cc74b7db5aebf3e35be317a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjM2YzVkODlhM2ViZDQ2YjJiMDc3ZGJjMGM2MDg2MTllL3RhYmxlcmFuZ2U6MzZjNWQ4OWEzZWJkNDZiMmIwNzdkYmMwYzYwODYxOWVfMy01LTEtMS0w_3c31b4ca-0188-43bc-a32b-d492f1413d9a"
      unitRef="usd">192000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i107aa1a97aea4de79780fd1a3849f4c9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjM2YzVkODlhM2ViZDQ2YjJiMDc3ZGJjMGM2MDg2MTllL3RhYmxlcmFuZ2U6MzZjNWQ4OWEzZWJkNDZiMmIwNzdkYmMwYzYwODYxOWVfMy03LTEtMS0w_3933efcf-7958-40bf-adfc-a90e252be1b1"
      unitRef="usd">-103000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7731b8f59ba649e78547d1a6207a646b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjM2YzVkODlhM2ViZDQ2YjJiMDc3ZGJjMGM2MDg2MTllL3RhYmxlcmFuZ2U6MzZjNWQ4OWEzZWJkNDZiMmIwNzdkYmMwYzYwODYxOWVfNS0xLTEtMS0w_635d1c2f-2b82-4989-922c-09d56a60a19d"
      unitRef="usd">1101000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6c5708e816d4a5a9da9fda8e44e426a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjM2YzVkODlhM2ViZDQ2YjJiMDc3ZGJjMGM2MDg2MTllL3RhYmxlcmFuZ2U6MzZjNWQ4OWEzZWJkNDZiMmIwNzdkYmMwYzYwODYxOWVfNS0zLTEtMS0w_6924f813-b520-477e-babf-2b191536e40c"
      unitRef="usd">523000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84dcb1f3e8204171af357b73d909bde3_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjM2YzVkODlhM2ViZDQ2YjJiMDc3ZGJjMGM2MDg2MTllL3RhYmxlcmFuZ2U6MzZjNWQ4OWEzZWJkNDZiMmIwNzdkYmMwYzYwODYxOWVfNS01LTEtMS0w_fe5b87d8-d081-464c-b676-f8a7579df659"
      unitRef="usd">2594000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47b3d55b232f4b37b1ce3de5d1256c7a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjM2YzVkODlhM2ViZDQ2YjJiMDc3ZGJjMGM2MDg2MTllL3RhYmxlcmFuZ2U6MzZjNWQ4OWEzZWJkNDZiMmIwNzdkYmMwYzYwODYxOWVfNS03LTEtMS0w_e306ad43-ff83-4b9b-bc1a-223164445a80"
      unitRef="usd">2305000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0fa5e00c5e3b4d8a94adfcd4dc578cea_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjM2YzVkODlhM2ViZDQ2YjJiMDc3ZGJjMGM2MDg2MTllL3RhYmxlcmFuZ2U6MzZjNWQ4OWEzZWJkNDZiMmIwNzdkYmMwYzYwODYxOWVfNy0xLTEtMS0w_e88bf6d7-d2eb-4a96-9e71-bbb6c08f8f5f"
      unitRef="usd">1101000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9bf86b21d1ec42508367f7984e0d709b_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjM2YzVkODlhM2ViZDQ2YjJiMDc3ZGJjMGM2MDg2MTllL3RhYmxlcmFuZ2U6MzZjNWQ4OWEzZWJkNDZiMmIwNzdkYmMwYzYwODYxOWVfNy0zLTEtMS0w_4d74a1f1-dc87-4a71-8298-eae673e4b4f7"
      unitRef="usd">420000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i313f3bed2b4d41b1b3befbd3ba0eb04d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjM2YzVkODlhM2ViZDQ2YjJiMDc3ZGJjMGM2MDg2MTllL3RhYmxlcmFuZ2U6MzZjNWQ4OWEzZWJkNDZiMmIwNzdkYmMwYzYwODYxOWVfNy01LTEtMS0w_614d596d-1380-46ec-ae07-415c6545145b"
      unitRef="usd">2786000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i461b9941feeb4551aaa603496fbf1cbf_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjM2YzVkODlhM2ViZDQ2YjJiMDc3ZGJjMGM2MDg2MTllL3RhYmxlcmFuZ2U6MzZjNWQ4OWEzZWJkNDZiMmIwNzdkYmMwYzYwODYxOWVfNy03LTEtMS0w_8d31b777-45cd-44ce-a99f-4a9d2fc7f6ad"
      unitRef="usd">2202000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <agio:ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlockTableTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTEyMjc_a1ecb4bb-b7a8-4451-b20d-d82676652825">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents changes in our contract assets during the nine months ended September 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration receivable - other&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)    Additions to contract assets relate to amounts receivable from CStone. Deductions to contract assets relate to collection of receivables during the reporting period.&lt;/span&gt;&lt;/div&gt;</agio:ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlockTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i63a35d727f94435cb7df160054110884_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjQxMDljZTNiODY3YjQ5MmI4MTM1YzNkMGE1NDExYmM0L3RhYmxlcmFuZ2U6NDEwOWNlM2I4NjdiNDkyYjgxMzVjM2QwYTU0MTFiYzRfMi0xLTEtMS0w_484125a5-e64f-41db-9e06-bbaa45136155"
      unitRef="usd">1928000</us-gaap:ContractWithCustomerAssetNet>
    <agio:ContractWithCustomerAssetRevenueRecognized
      contextRef="i01071852f46a4d4dadbc5092fae50573_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjQxMDljZTNiODY3YjQ5MmI4MTM1YzNkMGE1NDExYmM0L3RhYmxlcmFuZ2U6NDEwOWNlM2I4NjdiNDkyYjgxMzVjM2QwYTU0MTFiYzRfMi0zLTEtMS0w_a602ef23-86f6-4ad4-b965-d3cd698ab95c"
      unitRef="usd">2786000</agio:ContractWithCustomerAssetRevenueRecognized>
    <agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables
      contextRef="i01071852f46a4d4dadbc5092fae50573_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjQxMDljZTNiODY3YjQ5MmI4MTM1YzNkMGE1NDExYmM0L3RhYmxlcmFuZ2U6NDEwOWNlM2I4NjdiNDkyYjgxMzVjM2QwYTU0MTFiYzRfMi01LTEtMS0w_024a83ee-5007-429c-8ab9-c32f706e6ca1"
      unitRef="usd">2722000</agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i0fc858c76d804b0094142147dcd5fabf_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RhYmxlOjQxMDljZTNiODY3YjQ5MmI4MTM1YzNkMGE1NDExYmM0L3RhYmxlcmFuZ2U6NDEwOWNlM2I4NjdiNDkyYjgxMzVjM2QwYTU0MTFiYzRfMi03LTEtMS0w_1dba9938-7dad-4cb0-945d-2cbf77c3f5ce"
      unitRef="usd">1992000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ie9648064ef4d46a89718d0c2f677340c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTA1ODc_6a1e6ea2-3b24-4b09-a4ac-b390d268e459"
      unitRef="usd">500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc55bcf17208425a91152e001413e76a_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTA4NDM_fa4ba82a-6dee-4cd7-bb3c-0b83607b4196"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized
      contextRef="iaf00db5bcb514269bb6f8b107e6bda6d_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTA5MjE_106aa9c1-ae31-44ee-b4fc-2127597003a9"
      unitRef="usd">0</agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized>
    <agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized
      contextRef="i87a76a2d90d94c09897329e40592f335_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTA5MjE_c2b69d24-5470-4dd9-a5d9-458e8c0388ab"
      unitRef="usd">0</agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized>
    <agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized
      contextRef="icb29efd46e8a49fcac140e1509cd977e_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTA5MjE_f1ca938e-caee-4a17-b325-fb867197bc8a"
      unitRef="usd">0</agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized>
    <agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized
      contextRef="ib1af4d73a6f24932b9251f45c0dc1886_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTA5MjE_f3590eb8-443a-4dfb-8930-ec527e62f60c"
      unitRef="usd">0</agio:RevenueFromContractsWithCustomersMilestoneRevenueRecognized>
    <agio:ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable
      contextRef="ie9648064ef4d46a89718d0c2f677340c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl81OC9mcmFnOjRmNzBlNjUwZTQwOTRiNjdhYjFmOGExMWI5ZWE2OTkwL3RleHRyZWdpb246NGY3MGU2NTBlNDA5NGI2N2FiMWY4YTExYjllYTY5OTBfMTEyMTI_8e99cfbd-448e-4465-8c91-f8a2f06d58a6"
      unitRef="usd">5000000.0</agio:ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable>
    <agio:SaleOfFutureRevenueRoyaltyObligationTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RleHRyZWdpb246NDE1ZTUzNmU1Zjg2NDZjNmI2M2M0MDFjMDNlMjk3NDRfMzU2Mg_500de401-465d-4975-b6f2-7bda904a5fe1">Sale of Future Revenue&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 11, 2020, we sold our tiered, sales-based royalty rights on worldwide net sales of IDHIFA&#xae; (enasidenib), as well as our rights to receive up to $55.0&#160;million in outstanding regulatory milestone payments from BMS, to RPI for $255.0&#160;million. The gross proceeds of $255.0&#160;million approximate the fair value of the liability related to the sale of future revenue based on a discounted cash flow model. The fair value for the liability related to the sale of future revenue at the time of the transaction was based on our current estimates of future royalties expected to be paid to RPI over the remaining patent life of the product, which are considered level 3 inputs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Purchase Agreement, although we sold all of our rights to receive royalties on worldwide net sales of IDHIFA&#xae; and future regulatory milestone payments, we continue to co-promote IDHIFA&#xae; and are therefore involved in the generation of these royalties. Due to our continuing involvement, we will continue to account for any royalties earned as revenue. We recorded the net proceeds from this transaction as a liability related to sale of future revenue, or Royalty Obligation, that will be amortized using the effective interest method over the remaining patent life. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As royalties are remitted to RPI from BMS, the balance of the Royalty Obligation will be effectively repaid over the life of the BMS license agreement. In order to determine the amortization of the Royalty Obligation, we are required to estimate the total amount of future royalty payments to RPI over the life of the BMS license agreement. The $255.0&#160;million recorded will be accreted to the total of these royalty payments as interest expense over the life of the Royalty Obligation. At execution, our estimate of this total interest expense resulted in an effective annual interest rate of approximately 16.4%. This estimate contains significant assumptions that impact both the amount recorded at execution and the interest expense that will be recognized over the royalty period. We will periodically assess the estimated royalty payments to RPI from BMS and to the extent the amount or timing of such payments is materially different than the original estimates, an adjustment will be recorded prospectively to increase or decrease interest expense. There are a number of factors that could materially affect the amount and timing of royalty payments to RPI from BMS, and correspondingly, the amount of interest expense recorded by us, most of which are not within our control. Such factors include, but are not limited to, delays or discontinuation of development of enasidenib, regulatory approval, changing standards of care, the introduction of competing products, manufacturing or other delays, generic competition, intellectual property matters, adverse events that result in governmental health authority imposed restrictions on the use of the drug products, significant changes in foreign exchange rates as the royalties remitted to RPI are made in U.S. dollars (USD) while the underlying sales of enasidenib will be made in currencies other than USD, and other events or circumstances that are not currently foreseen. Changes to any of these factors could result in increases or decreases to both royalty revenues and interest expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the activity of the Royalty Obligation since the transaction inception through September 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from the sale of future revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non-cash royalty related to the sale of future revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense associated with the sale of future revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Liability related to the sale of future revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;During the three and nine months ended September 30, 2020, $2.7&#160;million and $4.3 million of non-cash royalty revenue from net sales of IDHIFA&#xae; were recognized, respectively</agio:SaleOfFutureRevenueRoyaltyObligationTextBlock>
    <agio:RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold
      contextRef="ife55cfc6e645489a9aa97a13da6dfe00_I20200611"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RleHRyZWdpb246NDE1ZTUzNmU1Zjg2NDZjNmI2M2M0MDFjMDNlMjk3NDRfMTg0_b31f9eab-a1d4-4027-8fc3-74edfeb1068b"
      unitRef="usd">55000000.0</agio:RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold>
    <agio:ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold
      contextRef="ib2575fe6eebf402cbdb0a3e5509d729d_D20200611-20200611"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RleHRyZWdpb246NDE1ZTUzNmU1Zjg2NDZjNmI2M2M0MDFjMDNlMjk3NDRfMjUz_86d039c4-a88b-4a39-8ba3-3f9bbd7fb1aa"
      unitRef="usd">255000000.0</agio:ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold>
    <agio:ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold
      contextRef="ib2575fe6eebf402cbdb0a3e5509d729d_D20200611-20200611"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RleHRyZWdpb246NDE1ZTUzNmU1Zjg2NDZjNmI2M2M0MDFjMDNlMjk3NDRfMjc5_c5ce1d45-6711-4a88-9569-0822c61bc045"
      unitRef="usd">255000000.0</agio:ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold>
    <agio:ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold
      contextRef="ib2575fe6eebf402cbdb0a3e5509d729d_D20200611-20200611"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RleHRyZWdpb246NDE1ZTUzNmU1Zjg2NDZjNmI2M2M0MDFjMDNlMjk3NDRfMTYwNw_e9a44b42-3372-45eb-b101-531c04a7102f"
      unitRef="usd">255000000.0</agio:ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold>
    <agio:PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate
      contextRef="ic35eee998d714c1eb9833f09bbeecf44_I20200611"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RleHRyZWdpb246NDE1ZTUzNmU1Zjg2NDZjNmI2M2M0MDFjMDNlMjk3NDRfMTg1Nw_8b3af950-4a82-4fd1-9553-f0d83930d1e7"
      unitRef="number">0.164</agio:PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate>
    <agio:SaleOfFutureRevenueRoyaltyObligationTableTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RleHRyZWdpb246NDE1ZTUzNmU1Zjg2NDZjNmI2M2M0MDFjMDNlMjk3NDRfMzU2Mw_d2629c43-5133-493c-af8a-c599dfa6b6b6">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the activity of the Royalty Obligation since the transaction inception through September 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from the sale of future revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Non-cash royalty related to the sale of future revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense associated with the sale of future revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Liability related to the sale of future revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</agio:SaleOfFutureRevenueRoyaltyObligationTableTextBlock>
    <agio:SaleOfFutureRevenueLiabilityNoncurrent
      contextRef="i921c8ef362934a03b834f05fd487675a_I20200611"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RhYmxlOjliYWZiMTBjYjI3YzQxODhiOTdmNGIzMWY4NmJkMjQxL3RhYmxlcmFuZ2U6OWJhZmIxMGNiMjdjNDE4OGI5N2Y0YjMxZjg2YmQyNDFfMS0xLTEtMS0w_dd0c0061-0c71-4520-a1f5-ddb7c5caa2ba"
      unitRef="usd">255000000</agio:SaleOfFutureRevenueLiabilityNoncurrent>
    <agio:SaleOfFutureRevenueIssuanceCosts
      contextRef="i7a10fdb988c14ed4b148d6aab1625976_D20200612-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RhYmxlOjliYWZiMTBjYjI3YzQxODhiOTdmNGIzMWY4NmJkMjQxL3RhYmxlcmFuZ2U6OWJhZmIxMGNiMjdjNDE4OGI5N2Y0YjMxZjg2YmQyNDFfMi0xLTEtMS0w_88d4dd26-008b-4ddc-9663-2fd7529241d9"
      unitRef="usd">4463000</agio:SaleOfFutureRevenueIssuanceCosts>
    <agio:SaleOfFutureRevenuesNonCashRoyaltyRevenue
      contextRef="i7a10fdb988c14ed4b148d6aab1625976_D20200612-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RhYmxlOjliYWZiMTBjYjI3YzQxODhiOTdmNGIzMWY4NmJkMjQxL3RhYmxlcmFuZ2U6OWJhZmIxMGNiMjdjNDE4OGI5N2Y0YjMxZjg2YmQyNDFfMy0xLTEtMS0w_c1545d20-b244-4c85-b76e-e99837c78eae"
      unitRef="usd">4341000</agio:SaleOfFutureRevenuesNonCashRoyaltyRevenue>
    <agio:SaleOfFutureRevenueInterestExpense
      contextRef="i7a10fdb988c14ed4b148d6aab1625976_D20200612-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RhYmxlOjliYWZiMTBjYjI3YzQxODhiOTdmNGIzMWY4NmJkMjQxL3RhYmxlcmFuZ2U6OWJhZmIxMGNiMjdjNDE4OGI5N2Y0YjMxZjg2YmQyNDFfNC0xLTEtMS0w_a253b4c6-4d22-4ab1-910c-7d134a010ebc"
      unitRef="usd">11818000</agio:SaleOfFutureRevenueInterestExpense>
    <agio:SaleOfFutureRevenueAmortizationOfIssuanceCosts
      contextRef="i7a10fdb988c14ed4b148d6aab1625976_D20200612-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RhYmxlOjliYWZiMTBjYjI3YzQxODhiOTdmNGIzMWY4NmJkMjQxL3RhYmxlcmFuZ2U6OWJhZmIxMGNiMjdjNDE4OGI5N2Y0YjMxZjg2YmQyNDFfNS0xLTEtMS0w_0fd7412d-ec34-443b-95c7-80fc7ab70290"
      unitRef="usd">107000</agio:SaleOfFutureRevenueAmortizationOfIssuanceCosts>
    <agio:SaleOfFutureRevenueLiabilityNoncurrent
      contextRef="i6317ec5824324379aa89da98e74f17b5_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RhYmxlOjliYWZiMTBjYjI3YzQxODhiOTdmNGIzMWY4NmJkMjQxL3RhYmxlcmFuZ2U6OWJhZmIxMGNiMjdjNDE4OGI5N2Y0YjMxZjg2YmQyNDFfNi0xLTEtMS0w_112174e5-f9e9-403f-85d0-ee0811cfd143"
      unitRef="usd">258121000</agio:SaleOfFutureRevenueLiabilityNoncurrent>
    <agio:SaleOfFutureRevenuesNonCashRoyaltyRevenue
      contextRef="ibf7298c7e23d4bc79ec2339352a2c49b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RleHRyZWdpb246NDE1ZTUzNmU1Zjg2NDZjNmI2M2M0MDFjMDNlMjk3NDRfMTA5OTUxMTYzMTUwNQ_a6b40393-27ec-43a9-a7bb-ff88e40267eb"
      unitRef="usd">2700000</agio:SaleOfFutureRevenuesNonCashRoyaltyRevenue>
    <agio:SaleOfFutureRevenuesNonCashRoyaltyRevenue
      contextRef="i21d7d92ef32c4570af111a2c6296175e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82MS9mcmFnOjQxNWU1MzZlNWY4NjQ2YzZiNjNjNDAxYzAzZTI5NzQ0L3RleHRyZWdpb246NDE1ZTUzNmU1Zjg2NDZjNmI2M2M0MDFjMDNlMjk3NDRfMTA5OTUxMTYzMTUxMw_24dd667a-bc6a-4925-b331-c03db766fe73"
      unitRef="usd">4300000</agio:SaleOfFutureRevenuesNonCashRoyaltyRevenue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMjczMQ_ecb77a30-46cb-4239-9126-99d4a38e866d">Share-Based Payments&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2013 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2013, our Board of Directors adopted and, in July 2013 our stockholders approved, the 2013 Stock Incentive Plan, or the 2013 Plan. The 2013 Plan became effective upon the closing of our initial public offering and provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock units, or RSUs, performance-based stock units, or PSUs, and other stock-based awards to employees, non-employees and non-employee directors. Following the adoption of the 2013 Plan, we granted no further stock options or other awards under the 2007 Stock Incentive Plan, or the 2007 Plan. Any options or awards outstanding under the 2007 Plan at the time of adoption of the 2013 Plan remain outstanding and effective. As of September&#160;30, 2020, the total number of shares reserved under the 2007 Plan and the 2013 Plan was 10,680,089, and we had 2,919,442 shares available for future issuance under the 2013 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents stock option activity for the nine months ended September 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Stock&#160;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,201,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(339,284)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(448,901)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,370,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,067,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,370,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2020, there was approximately $77.4 million of total unrecognized compensation expense related to unvested stock option awards, which we expect to recognize over a weighted-average period of approximately 2.4 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents RSU activity for the nine months ended September 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Stock&#160;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date&#160;Fair&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(258,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(132,805)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,205,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, there was approximately $41.7 million of total unrecognized compensation expense related to RSUs, which we expect to recognize over a weighted-average period of approximately 1.9 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance-based stock units &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents PSU activity for the nine months ended September 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Stock&#160;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date&#160;Fair&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense associated with these PSUs is recognized if the underlying performance condition is considered probable of achievement using our management&#x2019;s best estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, there was no unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered probable of achievement, and $5.9 million of total unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered not probable of achievement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Market-based stock units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents market-based stock unit, or MSU, activity for the nine months ended September 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.690%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of MSUs are estimated using a Monte Carlo simulation model. Assumptions and estimates utilized in the model include the risk-free interest rate, dividend yield, expected stock volatility and the estimated period to achievement of the market condition. As of September&#160;30, 2020, there was no remaining unrecognized compensation expense related to MSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2013 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 Employee Stock Purchase Plan, or the 2013 ESPP. We issued and sold 120,293 and 77,981 shares of common stock during the nine months ended September 30, 2020 and 2019, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 836,363 shares of our common stock. As of September&#160;30, 2020, we had 471,353 shares of common stock available for future issuance under the 2013 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses related to stock options and stock-based awards were allocated as follows in the condensed consolidated statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i9d699758856a480db8a54b5c63108b48_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMTQ3_43cb3cee-0442-4484-82bf-f3e81495bfee"
      unitRef="shares">10680089</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i5f9615d7d1de4efaa136793d0d91cefc_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMTYy_166daba9-b7cb-445d-8061-29af58b806ee"
      unitRef="shares">2919442</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMjczMg_44953a4a-7bcf-4ec6-8fe3-d417d2bd8c0f">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents stock option activity for the nine months ended September 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Stock&#160;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,201,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(339,284)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(448,901)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,370,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,067,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,370,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfMS0xLTEtMS0w_3dd3672b-e7f0-4f0a-8bda-7d3895942930"
      unitRef="shares">6201485</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia1370538e8004f039f21787ab6a847b3_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfMS0zLTEtMS0w_dfa89889-8241-45c4-8fe6-dc2e5ae52627"
      unitRef="usdPerShare">58.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfMi0xLTEtMS0w_98469100-8369-4670-a2b2-0de684df12fe"
      unitRef="shares">956945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfMi0zLTEtMS0w_c3e442a3-570f-4e17-93ef-fca71d01ff78"
      unitRef="usdPerShare">49.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfMy0xLTEtMS0w_6964b5d3-8e8e-4dcc-a199-b69b5c2915ab"
      unitRef="shares">339284</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfMy0zLTEtMS0w_8b5b51d5-8867-4f68-8525-5c8bddb46249"
      unitRef="usdPerShare">19.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfNC0xLTEtMS0w_4ec4ea43-954e-4d9d-b908-67a9945c4949"
      unitRef="shares">448901</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfNC0zLTEtMS0w_951612d5-4c4a-4df8-bfc3-05711a503953"
      unitRef="usdPerShare">65.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfNS0xLTEtMS0w_facff0f0-ffdc-4784-b94d-e7a29d38c405"
      unitRef="shares">6370245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfNS0zLTEtMS0w_46cee2ed-b382-4ac3-a289-080205053fab"
      unitRef="usdPerShare">58.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfNi0xLTEtMS0w_ee40f17c-f04d-428b-96b8-15d48d61966d"
      unitRef="shares">4067553</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfNi0zLTEtMS0w_8e9518d5-325b-469b-bcb7-2b1ed7965ab3"
      unitRef="usdPerShare">61.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfNy0xLTEtMS0w_e1b01b48-4f6f-4048-925c-b0c4b7663266"
      unitRef="shares">6370245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i6e634a7c4e2544d38a5d4db27a521e32_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmQ0N2MxZDhmY2M5YTQ2MzA4YjE2OTY3YTU1NzI0NDM5L3RhYmxlcmFuZ2U6ZDQ3YzFkOGZjYzlhNDYzMDhiMTY5NjdhNTU3MjQ0MzlfNy0zLTEtMS0w_a19f70f3-03b8-479f-8c8d-f259dd61c2f0"
      unitRef="usdPerShare">58.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i5f9615d7d1de4efaa136793d0d91cefc_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMzMz_5c4fa73e-9c6c-4f2e-ad4a-6c70f206bf23"
      unitRef="usd">77400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i42fd0d585d7e44eb875c04c73f32f4f3_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfNDk3_0a099c19-cd48-41a3-8018-e6f2aa4d5e4e">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMjcyNg_f1772855-e989-443e-b06e-63f59d06b033">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents RSU activity for the nine months ended September 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Stock&#160;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date&#160;Fair&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(258,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(132,805)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,205,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i3d04844a7e1741f4b543721609a357af_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjJhOTJkYmQ1NWU1ODQxMmQ5ZjU2YmJmMzVkYzI5NmM4L3RhYmxlcmFuZ2U6MmE5MmRiZDU1ZTU4NDEyZDlmNTZiYmYzNWRjMjk2YzhfMS0xLTEtMS0w_b4843774-6a3c-416f-897d-e071eb3d8289"
      unitRef="shares">766953</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i3d04844a7e1741f4b543721609a357af_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjJhOTJkYmQ1NWU1ODQxMmQ5ZjU2YmJmMzVkYzI5NmM4L3RhYmxlcmFuZ2U6MmE5MmRiZDU1ZTU4NDEyZDlmNTZiYmYzNWRjMjk2YzhfMS0zLTEtMS0w_80f60b6c-b03b-409e-9e29-94c044f654a4"
      unitRef="usdPerShare">63.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ieaba62f70942436b9630689bd74a2d35_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjJhOTJkYmQ1NWU1ODQxMmQ5ZjU2YmJmMzVkYzI5NmM4L3RhYmxlcmFuZ2U6MmE5MmRiZDU1ZTU4NDEyZDlmNTZiYmYzNWRjMjk2YzhfMi0xLTEtMS0w_c766712b-38fa-490a-ba36-cf47c40c9f07"
      unitRef="shares">829791</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ieaba62f70942436b9630689bd74a2d35_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjJhOTJkYmQ1NWU1ODQxMmQ5ZjU2YmJmMzVkYzI5NmM4L3RhYmxlcmFuZ2U6MmE5MmRiZDU1ZTU4NDEyZDlmNTZiYmYzNWRjMjk2YzhfMi0zLTEtMS0w_d2f507ab-a589-4af4-82c0-617f155be158"
      unitRef="usdPerShare">50.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ieaba62f70942436b9630689bd74a2d35_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjJhOTJkYmQ1NWU1ODQxMmQ5ZjU2YmJmMzVkYzI5NmM4L3RhYmxlcmFuZ2U6MmE5MmRiZDU1ZTU4NDEyZDlmNTZiYmYzNWRjMjk2YzhfMy0xLTEtMS0w_75f5e114-540c-4d32-b4ec-b480711a1a5b"
      unitRef="shares">258461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ieaba62f70942436b9630689bd74a2d35_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjJhOTJkYmQ1NWU1ODQxMmQ5ZjU2YmJmMzVkYzI5NmM4L3RhYmxlcmFuZ2U6MmE5MmRiZDU1ZTU4NDEyZDlmNTZiYmYzNWRjMjk2YzhfMy0zLTEtMS0w_01afba6b-2f12-4535-8ac5-1cad2e71bf15"
      unitRef="usdPerShare">69.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ieaba62f70942436b9630689bd74a2d35_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjJhOTJkYmQ1NWU1ODQxMmQ5ZjU2YmJmMzVkYzI5NmM4L3RhYmxlcmFuZ2U6MmE5MmRiZDU1ZTU4NDEyZDlmNTZiYmYzNWRjMjk2YzhfNC0xLTEtMS0w_b8dd9de3-2d5f-4098-b528-dc79a1c865c1"
      unitRef="shares">132805</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ieaba62f70942436b9630689bd74a2d35_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjJhOTJkYmQ1NWU1ODQxMmQ5ZjU2YmJmMzVkYzI5NmM4L3RhYmxlcmFuZ2U6MmE5MmRiZDU1ZTU4NDEyZDlmNTZiYmYzNWRjMjk2YzhfNC0zLTEtMS0w_053835a8-cbcd-4146-a18c-873faf6e87bb"
      unitRef="usdPerShare">58.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i91da41946dd44926b3eb2a6c70cedcec_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjJhOTJkYmQ1NWU1ODQxMmQ5ZjU2YmJmMzVkYzI5NmM4L3RhYmxlcmFuZ2U6MmE5MmRiZDU1ZTU4NDEyZDlmNTZiYmYzNWRjMjk2YzhfNS0xLTEtMS0w_32dc4e67-9d6a-4305-94f4-f75de981009d"
      unitRef="shares">1205478</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i91da41946dd44926b3eb2a6c70cedcec_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjJhOTJkYmQ1NWU1ODQxMmQ5ZjU2YmJmMzVkYzI5NmM4L3RhYmxlcmFuZ2U6MmE5MmRiZDU1ZTU4NDEyZDlmNTZiYmYzNWRjMjk2YzhfNS0zLTEtMS0w_03f7882d-c1bb-47fd-a408-638f4a3cf23e"
      unitRef="usdPerShare">53.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i91da41946dd44926b3eb2a6c70cedcec_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfNjE0_59ebc908-6019-4144-80bc-5fc297960496"
      unitRef="usd">41700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ieaba62f70942436b9630689bd74a2d35_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfNzU0_469bd65c-244b-475d-88ac-92a2748830b4">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMjczNA_4abcc49f-6876-417f-aaad-3442aa3bfb8a">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents PSU activity for the nine months ended September 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.636%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Stock&#160;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date&#160;Fair&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,920)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic195c0c995c94bb99b62faec4ada3a82_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjk1MGM4YjkyYTEzYzQ1OGNhYzY1ZWZiMDE4ODYyZmZkL3RhYmxlcmFuZ2U6OTUwYzhiOTJhMTNjNDU4Y2FjNjVlZmIwMTg4NjJmZmRfMS0xLTEtMS0w_24151d09-00ab-4f4c-a591-121fb555a599"
      unitRef="shares">218143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ic195c0c995c94bb99b62faec4ada3a82_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjk1MGM4YjkyYTEzYzQ1OGNhYzY1ZWZiMDE4ODYyZmZkL3RhYmxlcmFuZ2U6OTUwYzhiOTJhMTNjNDU4Y2FjNjVlZmIwMTg4NjJmZmRfMS0zLTEtMS0w_013a9989-1eb3-49d4-8623-190897327d7b"
      unitRef="usdPerShare">55.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i16638a665f8b48bda553a1b68fe9582c_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjk1MGM4YjkyYTEzYzQ1OGNhYzY1ZWZiMDE4ODYyZmZkL3RhYmxlcmFuZ2U6OTUwYzhiOTJhMTNjNDU4Y2FjNjVlZmIwMTg4NjJmZmRfMi0xLTEtMS0w_4a0cc95c-f4be-4322-bd84-dc558ac8ef39"
      unitRef="shares">20622</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i16638a665f8b48bda553a1b68fe9582c_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjk1MGM4YjkyYTEzYzQ1OGNhYzY1ZWZiMDE4ODYyZmZkL3RhYmxlcmFuZ2U6OTUwYzhiOTJhMTNjNDU4Y2FjNjVlZmIwMTg4NjJmZmRfMi0zLTEtMS0w_3c0cca62-1393-4067-8782-57fa3a4d229f"
      unitRef="usdPerShare">48.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i16638a665f8b48bda553a1b68fe9582c_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjk1MGM4YjkyYTEzYzQ1OGNhYzY1ZWZiMDE4ODYyZmZkL3RhYmxlcmFuZ2U6OTUwYzhiOTJhMTNjNDU4Y2FjNjVlZmIwMTg4NjJmZmRfMy0xLTEtMS0w_920fb205-be7c-4ddd-a8b5-30aec2b5a4d2"
      unitRef="shares">78920</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i16638a665f8b48bda553a1b68fe9582c_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjk1MGM4YjkyYTEzYzQ1OGNhYzY1ZWZiMDE4ODYyZmZkL3RhYmxlcmFuZ2U6OTUwYzhiOTJhMTNjNDU4Y2FjNjVlZmIwMTg4NjJmZmRfMy0zLTEtMS0w_f8a2f005-64d7-4663-80de-c856d8fa6400"
      unitRef="usdPerShare">54.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ie97254b0a3bd414a957ad2f9c5b213a2_D20180101-20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjk1MGM4YjkyYTEzYzQ1OGNhYzY1ZWZiMDE4ODYyZmZkL3RhYmxlcmFuZ2U6OTUwYzhiOTJhMTNjNDU4Y2FjNjVlZmIwMTg4NjJmZmRfNC0xLTEtMS0w_a738d545-b8d7-48e8-b267-eeaff527a583"
      unitRef="shares">17616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ie97254b0a3bd414a957ad2f9c5b213a2_D20180101-20180930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjk1MGM4YjkyYTEzYzQ1OGNhYzY1ZWZiMDE4ODYyZmZkL3RhYmxlcmFuZ2U6OTUwYzhiOTJhMTNjNDU4Y2FjNjVlZmIwMTg4NjJmZmRfNC0zLTEtMS0w_550b8b4b-3d22-48fc-bb24-63a549cb2472"
      unitRef="usdPerShare">61.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="idd2bc890754e428c838e48a9739bb6ca_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjk1MGM4YjkyYTEzYzQ1OGNhYzY1ZWZiMDE4ODYyZmZkL3RhYmxlcmFuZ2U6OTUwYzhiOTJhMTNjNDU4Y2FjNjVlZmIwMTg4NjJmZmRfNS0xLTEtMS0w_3a31e5d9-c26c-478d-b4d4-8170c977879e"
      unitRef="shares">142229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="idd2bc890754e428c838e48a9739bb6ca_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjk1MGM4YjkyYTEzYzQ1OGNhYzY1ZWZiMDE4ODYyZmZkL3RhYmxlcmFuZ2U6OTUwYzhiOTJhMTNjNDU4Y2FjNjVlZmIwMTg4NjJmZmRfNS0zLTEtMS0w_91ad98d6-9f73-4853-9c8a-894c4f63d8b4"
      unitRef="usdPerShare">54.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i174a0833a8f7445eab78db94209d6095_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMTA1Ng_a7d9ce2d-9482-4d4b-a9c0-6b7525eb9ce7"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i174a0833a8f7445eab78db94209d6095_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMTE5OA_20f8849f-2982-44fc-a15c-a4e57e0c6a8c"
      unitRef="usd">5900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <agio:ScheduleOfMarketBasedUnitsActivityTableTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMjcyNw_061b58ba-6357-4599-a760-37ceaf5c1d81">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents market-based stock unit, or MSU, activity for the nine months ended September 30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.687%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.690%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</agio:ScheduleOfMarketBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i511c756fbbb74474b18ddbc87da9898f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjBmZDRlZWVjYTIzZDQ2MDBiNjVlMmM4ZWVlN2E0YjFjL3RhYmxlcmFuZ2U6MGZkNGVlZWNhMjNkNDYwMGI2NWUyYzhlZWU3YTRiMWNfMS0xLTEtMS0w_aa39ee40-4192-4d39-8368-d7bf79dc3398"
      unitRef="shares">42695</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i511c756fbbb74474b18ddbc87da9898f_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjBmZDRlZWVjYTIzZDQ2MDBiNjVlMmM4ZWVlN2E0YjFjL3RhYmxlcmFuZ2U6MGZkNGVlZWNhMjNkNDYwMGI2NWUyYzhlZWU3YTRiMWNfMS0zLTEtMS0w_bb65762c-7706-4a64-945a-50de69654d64"
      unitRef="usdPerShare">41.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i3b990092bc0c49da82be729ba6370e53_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjBmZDRlZWVjYTIzZDQ2MDBiNjVlMmM4ZWVlN2E0YjFjL3RhYmxlcmFuZ2U6MGZkNGVlZWNhMjNkNDYwMGI2NWUyYzhlZWU3YTRiMWNfMi0xLTEtMS0w_400e6f52-1b0a-42d4-afb5-504ba3111265"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3b990092bc0c49da82be729ba6370e53_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjBmZDRlZWVjYTIzZDQ2MDBiNjVlMmM4ZWVlN2E0YjFjL3RhYmxlcmFuZ2U6MGZkNGVlZWNhMjNkNDYwMGI2NWUyYzhlZWU3YTRiMWNfMi0zLTEtMS0w_ea691fe2-14e9-44c6-89fe-671d46fe895d"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i2c31701e76ca45a499b9de7eb21dcc8c_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjBmZDRlZWVjYTIzZDQ2MDBiNjVlMmM4ZWVlN2E0YjFjL3RhYmxlcmFuZ2U6MGZkNGVlZWNhMjNkNDYwMGI2NWUyYzhlZWU3YTRiMWNfNS0xLTEtMS0w_9b78ab59-e94c-44e3-b652-935606d4b9b5"
      unitRef="shares">42695</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i2c31701e76ca45a499b9de7eb21dcc8c_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjBmZDRlZWVjYTIzZDQ2MDBiNjVlMmM4ZWVlN2E0YjFjL3RhYmxlcmFuZ2U6MGZkNGVlZWNhMjNkNDYwMGI2NWUyYzhlZWU3YTRiMWNfNS0zLTEtMS0w_077429e7-f7e6-4fa7-b07c-e4b848fa5563"
      unitRef="usdPerShare">41.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i2c31701e76ca45a499b9de7eb21dcc8c_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMjc0ODc3OTA3MjI5Mg_cb5b37f6-6572-4275-bc8d-00444d58a2a3"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i88427bac77074d34bf85fa93670c9058_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMjEwMQ_3ac6325a-756c-4cb6-976e-0b4629e9f29b"
      unitRef="shares">120293</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i3878b4c8c3294913aa799ef8147b4a81_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMjEwOA_1ad5563e-b933-4af8-8f38-f81d624d0ea2"
      unitRef="shares">77981</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="i88427bac77074d34bf85fa93670c9058_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMjI5Mw_058f8c25-0a8b-4070-8d04-a4868e2c3465"
      unitRef="shares">836363</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i6d8671ea0b684937a1904b1b3c85413c_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMjM0MQ_410d1664-64e5-41a2-a29d-3b69ceba3514"
      unitRef="shares">471353</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMjcyOQ_b040c8bd-4503-4b38-b4bc-c1edf12bb971">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icf949780f933480e95db1152a36fe193_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfMi0xLTEtMS0w_d6af0348-c032-4f9a-9f9f-bff82b15eb40"
      unitRef="usd">11289000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i03bf9b8187f0451d9f3b63e3cf6178da_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfMi0zLTEtMS0w_2f85bf56-abb6-4f92-915c-5f5e8e73a87a"
      unitRef="usd">11552000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i09fde5e4560a422a85918a18e444182d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfMi01LTEtMS0w_159f5891-f531-496f-8b4c-49a69eb98d44"
      unitRef="usd">34395000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4bd07546e3954875b0cf85d146e836c1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfMi03LTEtMS0w_a1f264c5-3648-4317-b8cc-af3ac834bf24"
      unitRef="usd">37065000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id8a5352cdcf54a3dbc6e981a9f2d988e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfMy0xLTEtMS0w_1e744758-4452-4d9e-a59c-99aeb0cd2c46"
      unitRef="usd">6538000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ice9aeab243b54c76ba9666c481969a67_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfMy0zLTEtMS0w_09267b09-746d-4b06-ab69-0314128a83d5"
      unitRef="usd">4917000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ieaba62f70942436b9630689bd74a2d35_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfMy01LTEtMS0w_380a3bd0-1cee-4621-a0b3-cfcafa0fd58d"
      unitRef="usd">20450000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i357045d6181740eeae955e96b15cf9ae_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfMy03LTEtMS0w_1d1a31f1-3359-4e84-9c17-fc86f9942477"
      unitRef="usd">14708000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie651fcd18fce4247ae0c8601b611a96b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNC0xLTEtMS0w_eb2def5b-ed6a-4a3c-bcf6-c6f60d822d8a"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic805411b96ea4c5f9301de6e30503f1f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNC0zLTEtMS0w_bde55223-37ab-4d11-adce-aa7ae0c94ba7"
      unitRef="usd">1495000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i16638a665f8b48bda553a1b68fe9582c_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNC01LTEtMS0w_0613e83b-e531-4eca-b440-999986e60aef"
      unitRef="usd">1866000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i798423a51884438da4abc925685536ec_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNC03LTEtMS0w_31744bc9-e64e-4db2-af44-dc7bbe6b5300"
      unitRef="usd">1681000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id5e015813aa04cc5b172ca860a6d9adb_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNS0xLTEtMS0w_12d5134c-2991-4c9a-9009-e1c9df671441"
      unitRef="usd">339000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i49a46c45215d41c8aa7526c20b7d66b5_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNS0zLTEtMS0w_0aec7700-b83e-4568-bf0a-1632be9840c8"
      unitRef="usd">350000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idbd22adb7da84d4385fef484796aface_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNS01LTEtMS0w_2c31d2af-5169-43cc-a767-64a52b4e9538"
      unitRef="usd">1035000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6718bfa0a37a457e90f8816b0655456b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNS03LTEtMS0w_f9a6a35b-867f-41ee-a345-f7ff2210b8b6"
      unitRef="usd">1070000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i454184cf989649608cb48e499349776d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNi0xLTEtMS0w_2df29681-6ec6-445d-ae2e-8fa5d430f648"
      unitRef="usd">241000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i03016330feec4c92b5f1d60dc4e263e1_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNi0zLTEtMS0w_160b7382-702b-41e1-8d80-71c1aa3e3a4b"
      unitRef="usd">274000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic370bb45afd5438bade9612c8288612a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNi01LTEtMS0w_32845598-9518-49e3-a1bc-82b75a56129b"
      unitRef="usd">781000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1f25d07cfaa34641ae0ed3f419c27b42_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNi03LTEtMS0w_429814fd-3b8a-4385-a750-c4d0903839ba"
      unitRef="usd">719000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNy0xLTEtMS0w_b3f742f0-cedc-4506-9f53-483fe2aa91a6"
      unitRef="usd">18407000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNy0zLTEtMS0w_823a73c2-be33-4b02-9597-4355ae4ce6aa"
      unitRef="usd">18588000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNy01LTEtMS0w_b5b46e83-762b-4a37-a9e4-16f809be4967"
      unitRef="usd">58527000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOmVmZjQ4ZGE4Zjk5NDRiMzc4ZDM4ZWQyZjJkN2Q1MjdkL3RhYmxlcmFuZ2U6ZWZmNDhkYThmOTk0NGIzNzhkMzhlZDJmMmQ3ZDUyN2RfNy03LTEtMS0w_5062a4ed-41f1-4812-9bc0-087cc6e71dc0"
      unitRef="usd">55243000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RleHRyZWdpb246YzZiM2I3Zjk1ZDJkNDY2OTg4MmFlNDBhOGI2ZDdlZmVfMjcyMw_1b00c83e-fbfe-4a6c-87ad-8a342cceb6b7">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses related to stock options and stock-based awards were allocated as follows in the condensed consolidated statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i27fa78f0171d419fbd8f33e0452c4ae6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjkwNWFmYzk3MDIzMTQwZDA4MWZiYzgzNjU2MGJiM2FhL3RhYmxlcmFuZ2U6OTA1YWZjOTcwMjMxNDBkMDgxZmJjODM2NTYwYmIzYWFfMi0xLTEtMS0w_e3df64e5-5400-4ab1-85d4-51520626e902"
      unitRef="usd">8742000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3b35ca8234b946a59c38dcb3c34529b6_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjkwNWFmYzk3MDIzMTQwZDA4MWZiYzgzNjU2MGJiM2FhL3RhYmxlcmFuZ2U6OTA1YWZjOTcwMjMxNDBkMDgxZmJjODM2NTYwYmIzYWFfMi0zLTEtMS0w_fabc37e0-fd59-4664-9a0b-2a5fe84a0132"
      unitRef="usd">9860000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i03be922ff7cb4cf492b6d47edf9144c9_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjkwNWFmYzk3MDIzMTQwZDA4MWZiYzgzNjU2MGJiM2FhL3RhYmxlcmFuZ2U6OTA1YWZjOTcwMjMxNDBkMDgxZmJjODM2NTYwYmIzYWFfMi01LTEtMS0w_e97adefc-0222-4a20-b3ee-b5765fb77a09"
      unitRef="usd">28464000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia14da64b4d914e7ca355088908976d71_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjkwNWFmYzk3MDIzMTQwZDA4MWZiYzgzNjU2MGJiM2FhL3RhYmxlcmFuZ2U6OTA1YWZjOTcwMjMxNDBkMDgxZmJjODM2NTYwYmIzYWFfMi03LTEtMS0w_402fc0fe-3b3c-45af-a048-62cf13555a2a"
      unitRef="usd">29969000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i94a210d561984f12a0afc697ddbaea44_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjkwNWFmYzk3MDIzMTQwZDA4MWZiYzgzNjU2MGJiM2FhL3RhYmxlcmFuZ2U6OTA1YWZjOTcwMjMxNDBkMDgxZmJjODM2NTYwYmIzYWFfMy0xLTEtMS0w_1733824c-e06e-4c73-a60d-09ba636e3898"
      unitRef="usd">9665000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4effbc54b019404fbb07e9b964ce6494_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjkwNWFmYzk3MDIzMTQwZDA4MWZiYzgzNjU2MGJiM2FhL3RhYmxlcmFuZ2U6OTA1YWZjOTcwMjMxNDBkMDgxZmJjODM2NTYwYmIzYWFfMy0zLTEtMS0w_b42ca46d-d344-4198-95d5-f4d2f8dfee84"
      unitRef="usd">8728000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icf1c03f73f434b93ac3f9ad188cac55e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjkwNWFmYzk3MDIzMTQwZDA4MWZiYzgzNjU2MGJiM2FhL3RhYmxlcmFuZ2U6OTA1YWZjOTcwMjMxNDBkMDgxZmJjODM2NTYwYmIzYWFfMy01LTEtMS0w_6b8d66ee-d209-47e2-af91-35c9a8b64a75"
      unitRef="usd">30063000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i64b9b9df1ff7448d85c07ee71a10ce67_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjkwNWFmYzk3MDIzMTQwZDA4MWZiYzgzNjU2MGJiM2FhL3RhYmxlcmFuZ2U6OTA1YWZjOTcwMjMxNDBkMDgxZmJjODM2NTYwYmIzYWFfMy03LTEtMS0w_60c93f81-daea-4040-adc7-45ed808c446d"
      unitRef="usd">25274000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjkwNWFmYzk3MDIzMTQwZDA4MWZiYzgzNjU2MGJiM2FhL3RhYmxlcmFuZ2U6OTA1YWZjOTcwMjMxNDBkMDgxZmJjODM2NTYwYmIzYWFfNC0xLTEtMS0w_d3b671f5-c4cd-49bf-b367-3d97f8519118"
      unitRef="usd">18407000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjkwNWFmYzk3MDIzMTQwZDA4MWZiYzgzNjU2MGJiM2FhL3RhYmxlcmFuZ2U6OTA1YWZjOTcwMjMxNDBkMDgxZmJjODM2NTYwYmIzYWFfNC0zLTEtMS0w_f5b0885a-13cd-4a8d-bc85-519b4eff77d8"
      unitRef="usd">18588000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjkwNWFmYzk3MDIzMTQwZDA4MWZiYzgzNjU2MGJiM2FhL3RhYmxlcmFuZ2U6OTA1YWZjOTcwMjMxNDBkMDgxZmJjODM2NTYwYmIzYWFfNC01LTEtMS0w_9403b6f6-10be-40fc-a042-01aa27241794"
      unitRef="usd">58527000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82NC9mcmFnOmM2YjNiN2Y5NWQyZDQ2Njk4ODJhZTQwYThiNmQ3ZWZlL3RhYmxlOjkwNWFmYzk3MDIzMTQwZDA4MWZiYzgzNjU2MGJiM2FhL3RhYmxlcmFuZ2U6OTA1YWZjOTcwMjMxNDBkMDgxZmJjODM2NTYwYmIzYWFfNC03LTEtMS0w_eff42502-176d-4b74-935c-45490318a23d"
      unitRef="usd">55243000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RleHRyZWdpb246MDM1Yzc0NjYxZTU3NGM2NDg0ODg4MWY4MzZkN2NmODhfNDc0_5499c37b-5cdd-4001-89c8-454b72bb5439">Loss per ShareBasic net loss per share is calculated by dividing net loss by the weighted-average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury stock method. For purposes of the dilutive net loss per share calculation, stock options, RSUs, PSUs and MSUs for which the performance and market vesting conditions, respectively, have been deemed probable, and 2013 ESPP shares are considered to &lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;be common stock equivalents, while PSUs and MSUs with performance and market vesting conditions, respectively, that were not deemed probable as of September&#160;30, 2020 are not considered to be common stock equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since we had a net loss for all periods presented, the effect of all potentially dilutive securities is anti-dilutive. Accordingly, basic and diluted net loss per share was the same for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.734%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three and Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,370,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,185,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,205,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,588,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,932,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RleHRyZWdpb246MDM1Yzc0NjYxZTU3NGM2NDg0ODg4MWY4MzZkN2NmODhfMjc0ODc3OTA2OTkxNQ_24dbb68f-f5b8-4e0e-a44f-cd800965d7f2">Basic net loss per share is calculated by dividing net loss by the weighted-average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury stock method. For purposes of the dilutive net loss per share calculation, stock options, RSUs, PSUs and MSUs for which the performance and market vesting conditions, respectively, have been deemed probable, and 2013 ESPP shares are considered to be common stock equivalents, while PSUs and MSUs with performance and market vesting conditions, respectively, that were not deemed probable as of September&#160;30, 2020 are not considered to be common stock equivalents.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RleHRyZWdpb246MDM1Yzc0NjYxZTU3NGM2NDg0ODg4MWY4MzZkN2NmODhfNDcx_d51e7db8-b718-47c4-ad20-a8056934e58c">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.734%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three and Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,370,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,185,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,205,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,588,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,932,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i158dfd79c688479084d989c430f722ec_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfMi0xLTEtMS0w_45704fad-954f-4f84-bd10-6b183f182a83"
      unitRef="shares">6370245</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idefd32a8ce2246baa8ff2d8323b75046_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfMi0xLTEtMS0w_a4192fa3-a150-487c-9c95-6e4fc3680144"
      unitRef="shares">6370245</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7607646d4b3b4f108a7e2b95056780a1_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfMi0zLTEtMS0w_10ddaf80-60fb-49ca-9c71-b34762c59fed"
      unitRef="shares">6185935</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i98274e1aae044562a57287ce093c0a26_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfMi0zLTEtMS0w_55462da0-2a0c-476f-85e0-bf5e4c53625f"
      unitRef="shares">6185935</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i02527e9e8cad486f90f2ce345b3c2608_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfMy0xLTEtMS0w_06303ae3-08dd-4231-a166-737554f55cbe"
      unitRef="shares">1205478</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib7f3d9262b9a4930b2cf048450740cd9_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfMy0xLTEtMS0w_759c67ff-d9c1-4368-90e0-d94bf2adabe3"
      unitRef="shares">1205478</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1179a5820c534eac932533d105b3c232_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfMy0zLTEtMS0w_34d47764-b80d-41fa-9f08-bbff508b44a1"
      unitRef="shares">733100</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i824f503805804c518c65ccdbfb63cb4c_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfMy0zLTEtMS0w_d34b5208-ab28-4c74-aec7-a3e0424f7018"
      unitRef="shares">733100</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i086f8600af974684a490cec7619bf25c_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfNC0xLTEtMS0w_063e5ad8-c612-4d44-8317-b323773a64ca"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7d2dbb49a82349ac86136605ab26307a_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfNC0xLTEtMS0w_120cd947-49d4-4dfc-91c2-a0a027b4b854"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie4d9eaf7cb8641d0852c0cdf98b22872_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfNC0zLTEtMS0w_297bdd37-cee7-4164-aa82-b1f5767ab08b"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i85f451c88a3e4c928e436beab4f05862_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfNC0zLTEtMS0w_dbabda04-4121-4106-84b6-e1a51ed41475"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7a52ff240e81427b90c795cee938d4b5_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfNS0xLTEtMS0w_bc6b0602-945d-4724-ab53-9d7cd886d90f"
      unitRef="shares">13201</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4879e95ef7744941b0e26ca90bfc6605_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfNS0xLTEtMS0w_e3292d77-99ff-45f4-99b0-d42b1208c41a"
      unitRef="shares">13201</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9d57d7b84fb04a96892f11a0576100dd_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfNS0zLTEtMS0w_472202f9-b1d5-4b23-9f49-ce6c9be83a68"
      unitRef="shares">13754</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic96c925a7d99431399902b60bcb6babb_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfNS0zLTEtMS0w_d488a53d-0dea-4ffd-80c8-7bc245c512d4"
      unitRef="shares">13754</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfNi0xLTEtMS0w_49f8bb56-a4b8-43ac-a707-83d380698f8e"
      unitRef="shares">7588924</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfNi0xLTEtMS0w_94799962-a2c3-4454-827d-d8f0dd58f0ff"
      unitRef="shares">7588924</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic73499b256364473912a51549d885406_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfNi0zLTEtMS0w_7af52342-c0e7-45a5-90b5-b7272054d8c9"
      unitRef="shares">6932789</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idf353d3aa11040e29fb5fe626ad734d6_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQxNzQwMDQxMDFjNDQ4M2JiZDEzNGJlN2NlNThmZjMyL3NlYzo0MTc0MDA0MTAxYzQ0ODNiYmQxMzRiZTdjZTU4ZmYzMl82Ny9mcmFnOjAzNWM3NDY2MWU1NzRjNjQ4NDg4ODFmODM2ZDdjZjg4L3RhYmxlOmQ1NGE1NTU3ZDcwZTQ4MGM4MWEwOWYxNjhjNmY2MTUzL3RhYmxlcmFuZ2U6ZDU0YTU1NTdkNzBlNDgwYzgxYTA5ZjE2OGM2ZjYxNTNfNi0zLTEtMS0w_e4d4b535-18b7-45af-8848-b3779aab93a5"
      unitRef="shares">6932789</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518048231000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Oct. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AGIOS PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-0662915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">88 Sidney Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">649-8600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AGIO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,259,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001439222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518049556680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 104,855<span></span>
</td>
<td class="nump">$ 80,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">500,684<span></span>
</td>
<td class="nump">483,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">18,989<span></span>
</td>
<td class="nump">8,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_CollaborationReceivableDueFromRelatedPartiesCurrent', window );">Collaboration receivable &#8211; related party</a></td>
<td class="nump">2,334<span></span>
</td>
<td class="nump">1,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_CollaborationReceivableOtherCurrent', window );">Collaboration receivable &#8211; other</a></td>
<td class="nump">1,992<span></span>
</td>
<td class="nump">1,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RoyaltyReceivableDuefromRelatedPartiesCurrent', window );">Royalty receivable &#8211; related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">11,371<span></span>
</td>
<td class="nump">7,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">28,861<span></span>
</td>
<td class="nump">24,177<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">669,086<span></span>
</td>
<td class="nump">611,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">116,889<span></span>
</td>
<td class="nump">152,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">86,952<span></span>
</td>
<td class="nump">93,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">33,495<span></span>
</td>
<td class="nump">31,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Financing lease assets</a></td>
<td class="nump">677<span></span>
</td>
<td class="nump">993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,350<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">908,449<span></span>
</td>
<td class="nump">890,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">12,853<span></span>
</td>
<td class="nump">21,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">49,724<span></span>
</td>
<td class="nump">53,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue &#8211; related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">6,881<span></span>
</td>
<td class="nump">6,642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Financing lease liabilities</a></td>
<td class="nump">313<span></span>
</td>
<td class="nump">273<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">69,771<span></span>
</td>
<td class="nump">92,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion &#8211; related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">99,693<span></span>
</td>
<td class="nump">106,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Financing lease liabilities, net of current portion</a></td>
<td class="nump">412<span></span>
</td>
<td class="nump">673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_SaleOfFutureRevenueLiabilityNoncurrent', window );">Liability related to the sale of future revenue, net of debt issuance costs</a></td>
<td class="nump">258,121<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">427,997<span></span>
</td>
<td class="nump">250,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued or outstanding at September 30, 2020 and December 31, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 125,000,000 shares authorized; 69,198,063 and 68,401,105 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,225,538<span></span>
</td>
<td class="nump">2,156,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">663<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,745,818)<span></span>
</td>
<td class="num">(1,516,105)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">480,452<span></span>
</td>
<td class="nump">640,528<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 908,449<span></span>
</td>
<td class="nump">$ 890,741<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_CollaborationReceivableDueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_CollaborationReceivableDueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_CollaborationReceivableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_CollaborationReceivableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RoyaltyReceivableDuefromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RoyaltyReceivableDuefromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_SaleOfFutureRevenueLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Future Revenue, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_SaleOfFutureRevenueLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518134155512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">69,198,063<span></span>
</td>
<td class="nump">68,401,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">69,198,063<span></span>
</td>
<td class="nump">68,401,105<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518049558264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 34,706<span></span>
</td>
<td class="nump">$ 26,024<span></span>
</td>
<td class="nump">$ 159,151<span></span>
</td>
<td class="nump">$ 82,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">638<span></span>
</td>
<td class="nump">393<span></span>
</td>
<td class="nump">1,846<span></span>
</td>
<td class="nump">1,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">89,555<span></span>
</td>
<td class="nump">101,672<span></span>
</td>
<td class="nump">271,728<span></span>
</td>
<td class="nump">304,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">34,840<span></span>
</td>
<td class="nump">33,019<span></span>
</td>
<td class="nump">109,292<span></span>
</td>
<td class="nump">97,200<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expenses</a></td>
<td class="nump">125,033<span></span>
</td>
<td class="nump">135,084<span></span>
</td>
<td class="nump">382,866<span></span>
</td>
<td class="nump">402,876<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(90,327)<span></span>
</td>
<td class="num">(109,060)<span></span>
</td>
<td class="num">(223,715)<span></span>
</td>
<td class="num">(320,404)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income, net</a></td>
<td class="nump">1,115<span></span>
</td>
<td class="nump">2,887<span></span>
</td>
<td class="nump">5,820<span></span>
</td>
<td class="nump">11,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_InterestExpenseNonCashSaleOfFutureRevenue', window );">Non-cash interest expense for the sale of future revenue</a></td>
<td class="num">(9,767)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11,818)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (98,979)<span></span>
</td>
<td class="num">$ (106,173)<span></span>
</td>
<td class="num">$ (229,713)<span></span>
</td>
<td class="num">$ (309,122)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share &#8211; basic and diluted (in usd per share)</a></td>
<td class="num">$ (1.43)<span></span>
</td>
<td class="num">$ (1.81)<span></span>
</td>
<td class="num">$ (3.33)<span></span>
</td>
<td class="num">$ (5.27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of common shares used in computing net loss per share &#8211; basic and diluted (in usd per share)</a></td>
<td class="nump">69,144,061<span></span>
</td>
<td class="nump">58,803,534<span></span>
</td>
<td class="nump">68,905,853<span></span>
</td>
<td class="nump">58,661,607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 31,716<span></span>
</td>
<td class="nump">$ 17,422<span></span>
</td>
<td class="nump">$ 81,971<span></span>
</td>
<td class="nump">$ 40,287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=agio_CollaborationRevenueRelatedPartyMember', window );">Collaboration revenue &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,206<span></span>
</td>
<td class="nump">5,516<span></span>
</td>
<td class="nump">67,038<span></span>
</td>
<td class="nump">32,414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=agio_CollaborationRevenueOtherMember', window );">Collaboration revenue &#8211; other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,101<span></span>
</td>
<td class="nump">420<span></span>
</td>
<td class="nump">2,786<span></span>
</td>
<td class="nump">2,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 683<span></span>
</td>
<td class="nump">$ 2,666<span></span>
</td>
<td class="nump">$ 7,356<span></span>
</td>
<td class="nump">$ 7,569<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_InterestExpenseNonCashSaleOfFutureRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Expense, Non-Cash, Sale Of Future Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_InterestExpenseNonCashSaleOfFutureRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=agio_CollaborationRevenueRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=agio_CollaborationRevenueRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=agio_CollaborationRevenueOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=agio_CollaborationRevenueOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518047678488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (98,979)<span></span>
</td>
<td class="num">$ (106,173)<span></span>
</td>
<td class="num">$ (229,713)<span></span>
</td>
<td class="num">$ (309,122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on available-for-sale securities</a></td>
<td class="num">(973)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="nump">461<span></span>
</td>
<td class="nump">2,635<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (99,952)<span></span>
</td>
<td class="num">$ (106,199)<span></span>
</td>
<td class="num">$ (229,252)<span></span>
</td>
<td class="num">$ (306,487)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518138484264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,218,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 687,537<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">$ 1,794,283<span></span>
</td>
<td class="num">$ (2,171)<span></span>
</td>
<td class="num">$ (1,104,633)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP</a></td>
<td class="nump">6,003<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">6,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">18,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">1,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(93,078)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93,078)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,659,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="nump">620,257<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">1,818,393<span></span>
</td>
<td class="num">(484)<span></span>
</td>
<td class="num">(1,197,711)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,218,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">687,537<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">1,794,283<span></span>
</td>
<td class="num">(2,171)<span></span>
</td>
<td class="num">(1,104,633)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(309,122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,877,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">448,291<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">1,861,523<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="num">(1,413,755)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,659,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="nump">620,257<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">1,818,393<span></span>
</td>
<td class="num">(484)<span></span>
</td>
<td class="num">(1,197,711)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP</a></td>
<td class="nump">2,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">18,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(109,871)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(109,871)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,749,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">532,677<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">1,839,710<span></span>
</td>
<td class="nump">490<span></span>
</td>
<td class="num">(1,307,582)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP</a></td>
<td class="nump">3,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">18,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(106,173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(106,173)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,877,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">448,291<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">1,861,523<span></span>
</td>
<td class="nump">464<span></span>
</td>
<td class="num">(1,413,755)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,401,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">640,528<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
<td class="nump">2,156,363<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="num">(1,516,105)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP</a></td>
<td class="nump">5,465<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">5,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">19,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(40,256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,256)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,789,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">625,299<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">2,181,517<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="num">(1,556,361)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,401,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 640,528<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
<td class="nump">2,156,363<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="num">(1,516,105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP (in shares)</a></td>
<td class="nump">339,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (229,713)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,198,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">480,452<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">2,225,538<span></span>
</td>
<td class="nump">663<span></span>
</td>
<td class="num">(1,745,818)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,789,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">625,299<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">2,181,517<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="num">(1,556,361)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP</a></td>
<td class="nump">1,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">20,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">1,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(90,478)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90,478)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,058,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">558,465<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">2,203,599<span></span>
</td>
<td class="nump">1,636<span></span>
</td>
<td class="num">(1,646,839)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP</a></td>
<td class="nump">3,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">18,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(98,979)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(98,979)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,198,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">$ 480,452<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 2,225,538<span></span>
</td>
<td class="nump">$ 663<span></span>
</td>
<td class="num">$ (1,745,818)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518049575048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (229,713)<span></span>
</td>
<td class="num">$ (309,122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">7,307<span></span>
</td>
<td class="nump">6,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">58,527<span></span>
</td>
<td class="nump">55,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net accretion of premium and discounts on investments</a></td>
<td class="nump">1,521<span></span>
</td>
<td class="num">(2,772)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on disposal of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_OperatingLeaseRightOfUseAssetAmortization', window );">Non-cash operating lease expense</a></td>
<td class="nump">6,691<span></span>
</td>
<td class="nump">6,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_InterestExpenseNonCashSaleOfFutureRevenue', window );">Non-cash interest expense associated with the sale of future revenue</a></td>
<td class="nump">11,818<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RoyaltyRevenueNonCash', window );">Non-cash royalty revenue</a></td>
<td class="num">(4,341)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Accounts receivable, net</a></td>
<td class="num">(10,037)<span></span>
</td>
<td class="num">(2,030)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent', window );">Collaboration receivable &#8211; related party</a></td>
<td class="num">(795)<span></span>
</td>
<td class="nump">624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_IncreaseDecreaseInCollaborationReceivableOtherCurrent', window );">Collaboration receivable &#8211; other</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(199)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent', window );">Royalty receivable &#8211; related party</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="num">(366)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(4,040)<span></span>
</td>
<td class="num">(4,980)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current and non-current assets</a></td>
<td class="num">(6,033)<span></span>
</td>
<td class="num">(3,552)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(7,640)<span></span>
</td>
<td class="nump">2,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">4,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty', window );">Deferred revenue &#8211; related party</a></td>
<td class="num">(61,513)<span></span>
</td>
<td class="num">(25,849)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(6,112)<span></span>
</td>
<td class="num">(4,190)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(241,362)<span></span>
</td>
<td class="num">(277,011)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(430,624)<span></span>
</td>
<td class="num">(194,822)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities and sales of marketable securities</a></td>
<td class="nump">448,866<span></span>
</td>
<td class="nump">476,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(13,892)<span></span>
</td>
<td class="num">(5,347)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">4,350<span></span>
</td>
<td class="nump">276,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on financing lease obligations</a></td>
<td class="num">(250)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Net proceeds from stock option exercises and employee stock purchase plan</a></td>
<td class="nump">10,649<span></span>
</td>
<td class="nump">12,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts', window );">Proceeds from the sale of future revenue, net of issuance costs</a></td>
<td class="nump">250,537<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">260,936<span></span>
</td>
<td class="nump">12,005<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">23,924<span></span>
</td>
<td class="nump">11,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of the period</a></td>
<td class="nump">80,931<span></span>
</td>
<td class="nump">70,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of the period</a></td>
<td class="nump">104,855<span></span>
</td>
<td class="nump">81,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Additions to property and equipment in accounts payable and accrued expenses</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">2,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liabilities arising from obtaining operating lease assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 42,322<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_IncreaseDecreaseInCollaborationReceivableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_IncreaseDecreaseInCollaborationReceivableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_InterestExpenseNonCashSaleOfFutureRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Expense, Non-Cash, Sale Of Future Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_InterestExpenseNonCashSaleOfFutureRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_OperatingLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use Asset, Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_OperatingLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Future Revenues, Net Of Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RoyaltyRevenueNonCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Revenue, Non-Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RoyaltyRevenueNonCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518045042904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Overview and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Overview and Basis of Presentation</a></td>
<td class="text">Overview and Basis of Presentation<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">References to Agios</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout this Quarterly Report on Form&#160;10-Q,&#160;&#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; and similar expressions, except where the context requires otherwise, refer to Agios Pharmaceuticals, Inc. and its consolidated subsidiaries, and &#8220;our Board of Directors&#8221; refers to the board of directors of Agios Pharmaceuticals, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company committed to transforming patients&#8217; lives through scientific leadership in the field of cellular metabolism and adjacent areas of biology, with the goal of creating differentiated, small molecule medicines for patients in the areas of hematologic malignancies, solid tumors and rare genetic diseases, or RGDs. To address these focus areas, we take a systems biology approach to deeply understand disease states, drive the discovery and validation of novel therapeutic targets, and define patient selection strategies, thereby increasing the probability that our experimental medicines will have the desired therapeutic effect. We are located in Cambridge, Massachusetts.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of September&#160;30, 2020, the condensed consolidated statements of operations, comprehensive loss and stockholders' equity for the three and nine months ended September 30, 2020 and 2019, and the condensed consolidated statements of cash flows for the nine months ended September 30, 2020 and 2019 are unaudited. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of our management, reflect all adjustments, which include only normal recurring adjustments, necessary to fairly state our financial position as of September&#160;30, 2020, our results of operations and stockholders' equity for the three and nine months ended September 30, 2020 and 2019, and cash flows for the nine months ended September 30, 2020 and 2019. The financial data and the other financial information disclosed in these notes to the condensed consolidated financial statements related to the three and nine-month periods are also unaudited. The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2020 or for any other future annual or interim period. The condensed consolidated balance sheet data as of December&#160;31, 2019 was derived from our audited financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles, or U.S. GAAP. The condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019 that was filed with the Securities and Exchange Commission, or the SEC, on February&#160;19, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include our accounts and the accounts of our wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared in conformity with U.S. GAAP.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain the pandemic or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 11, 2020, we sold our tiered, sales-based royalty rights on worldwide net sales of IDHIFA&#174; (enasidenib), as well as our rights to receive up to $55.0&#160;million in outstanding regulatory milestone payments from Bristol Myers Squibb, or BMS, to Royalty Pharma, or RPI, for $255.0&#160;million. Under the 2010 Agreement, we remain eligible to receive a $25.0&#160;million potential </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">milestone payment for the enasidenib program upon achievement of a specified ex-U.S. commercial milestone event, as well as reimbursement for costs incurred for our co-commercialization efforts and development activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, we had cash, cash equivalents and marketable securities of $722.4 million. Although we have incurred recurring losses and expect to continue to incur losses for the foreseeable future, we expect our cash, cash equivalents and marketable securities will be sufficient to fund current operations for at least the next twelve months from the issuance date of these financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518045101112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant accounting policies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board, or FASB issued Accounting Standards Update, or ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which introduces new guidance for the accounting for credit losses on instruments within its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. Credit losses relating to available-for-sale debt securities will also be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. The guidance is effective for fiscal years beginning after December 31, 2019, including interim periods within those years. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the quarter ended March 31, 2020, we adopted ASU 2016-13, which eliminated the concept of other-than-temporary impairments and required credit losses on debt securities to be recorded through an allowance for credit losses instead of as a reduction in the amortized cost basis of the securities. Application of the amendments is through a cumulative-effect adjustment to retained earnings as of the effective date. Based upon our analysis, the adoption of this final rule did not have a material impact on the financial statements. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability related to sale of future revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We treat the sale of future revenue to RPI as a debt financing, as we have significant continuing involvement in the generation of the cash flows. As result, we recorded the proceeds from this transaction as a liability related to the sale of future revenue to be amortized to interest expense using the effective interest rate method over the life of the arrangement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liability related to sale of future revenue and the related interest expense are based on our current estimates of future royalties expected to be paid over the life of the arrangement. We will periodically assess the expected royalty payments using a combination of internal projections and forecasts from external sources. To the extent our future estimates of royalty payments are greater or less than previous estimates or the estimated timing of such payments is materially different than its previous estimates, we will prospectively recognize related non-cash interest expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further discussion of the sale of future revenue, refer to Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale of Future Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization of issuance costs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We treated the liability related to sale of future revenue as a debt financing. As such, the long-term liability is initially recorded at its proceeds, net of deferred costs. Issuance costs, fees directly related to the sale of future revenue, are offset against initial carrying value of the long-term liability and are amortized on a straight-line basis over the remaining patent life of the product to an operating expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes to the significant accounting policies previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518045042904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record cash equivalents and marketable securities at fair value. Accounting Standards Codification, or ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash equivalents and marketable securities measured at fair value on a recurring basis as of September&#160;30, 2020:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,494&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,494&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,494&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,494&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617,573&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617,573&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,494&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617,573&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672,067&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents and marketable securities have been initially valued at the transaction price and subsequently, at the end of each reporting period, valued utilizing third-party pricing services or other market observable data. The pricing services utilize industry standard valuation models, including both income and market-based approaches, and observable market inputs to determine value. After completing our validation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of September&#160;30, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to the valuation methods during the nine months ended September 30, 2020. We evaluate transfers between levels at the end of each reporting period. We have no financial assets or liabilities that were classified as Level 3 at any point during the nine months ended September 30, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518045116264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable securities are classified as available-for-sale pursuant to ASC 320, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments &#8211; Debt and Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and are recorded at fair value. Unrealized gains are included as a component of accumulated other comprehensive income in the condensed consolidated balance sheets and statements of stockholders&#8217; equity and a component of total comprehensive loss in the condensed consolidated statements of comprehensive loss, until realized. Unrealized losses are evaluated for impairment under ASC 326, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to determine if the impairment is credit-related or noncredit-related. Credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings, and noncredit-related impairment is recognized in other comprehensive income, net of taxes. Realized gains and losses are included in investment income on a specific-identification basis. There were no material realized gains or losses on marketable securities for the three and nine months ended September 30, 2020 or 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities at September&#160;30, 2020 consisted of the following:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,992&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,910&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617,573&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities at December&#160;31, 2019 consisted of the following:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,877&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636,673&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(268)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636,875&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020 and December&#160;31, 2019, we held both current and non-current investments. Investments classified as current have maturities of less than one year. Investments classified as non-current are those that: (i)&#160;have a maturity of greater than one year, and (ii)&#160;we do not intend to liquidate within the next twelve months, although these funds are available for use and, therefore, are classified as available-for-sale.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020 and December&#160;31, 2019, we held 74 and 113 debt securities, respectively, that were in an unrealized loss position for less than one year. We did not record an allowance for credit losses as of September&#160;30, 2020 and December&#160;31, 2019 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at September&#160;30, 2020 and December&#160;31, 2019 was $247.7 million and $345.7 million, respectively. There were no individual securities that were in a significant unrealized loss position as of September&#160;30, 2020 and December&#160;31, 2019. Given our intent and ability to hold such securities until recovery, and the lack of significant change in the credit risk of these investments, we do not consider these marketable securities to be impaired as of September&#160;30, 2020 and December&#160;31, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518052823448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, which consists of commercial supply of TIBSOVO&#174;, consists of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.597%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,166&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,808&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,331&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518045071752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our building leases are comprised of office and laboratory space under non-cancelable operating leases. These lease agreements have remaining lease terms of seven years and contain various clauses for renewal at our option. The renewal options were not included in the calculation of the operating lease assets and the operating lease liabilities as the renewal options are not reasonably certain of being exercised. The lease agreements do not contain residual value guarantees. Operating lease costs for the three and nine months ended September 30, 2020 were $3.8 million and $11.4&#160;million, respectively, and cash paid for amounts included in the measurement of operating lease liabilities for the three and nine months ended September 30, 2020 were $3.5 million and $10.9&#160;million, respectively. Operating lease costs for the three and nine months ended September 30, 2019 were $3.8&#160;million and $10.6&#160;million, respectively, and cash paid for amounts included in the measurement of operating lease liabilities for the three and nine months ended September 30, 2019 were $2.2&#160;million and $8.5&#160;million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not entered into any material short-term leases or financing leases as of September&#160;30, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, undiscounted minimum rental commitments under non-cancelable leases, for each of the next five years and total thereafter were as follows:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.217%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.583%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undiscounted minimum rental commitments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,195&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,621)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,574&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>In arriving at the operating lease liabilities as of September&#160;30, 2020 and December&#160;31, 2019, we applied the weighted-average incremental borrowing rate of 5.7% for both periods over a weighted-average remaining lease term of 7.4 years and 8.2 years, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518045036536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,188&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,777&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued revenue-related reserves and other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,018&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,048&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,724&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,142&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518045146952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Product Revenue</a></td>
<td class="text">Product Revenue<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell TIBSOVO&#174;, our wholly owned product, to a limited number of specialty distributors and specialty pharmacy providers, or collectively, the Customers. The Customers subsequently resell TIBSOVO&#174; to pharmacies or dispense directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of TIBSOVO&#174;.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation related to the sale of TIBSOVO&#174; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer. </span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,716&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,422&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,971&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,287&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reserves for Variable Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Adjustments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally provide Customers with discounts, including prompt pay discounts, and allowances that are explicitly stated in the contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from certain Customers.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are estimated using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated channel mix and are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government rebates include Medicare, TriCare, and Medicaid rebates, which we estimate using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Returns</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the amount of product sales that may be returned by Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate product return liabilities using the expected value method, based on available industry data, including our visibility into the inventory remaining in the distribution channel.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government Rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provisions relating to sales in the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/returns relating to sales in the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,966)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/returns relating to sales in the prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(677)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,330)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,608&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,618&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,739&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue-related reserves above, included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Component of accrued expenses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,739&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,796&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in our contract assets during the nine months ended September 30, 2020:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,952&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,504&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,467)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,989&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)  Additions to contract assets relate to amounts billed to Customers for product sales and deductions to contract assets primarily relate to collection of receivables during the reporting period.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518043767384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>Revenue Recognition and Deferred Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text">Collaboration and License Agreements <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting analysis and revenue recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration and license agreements typically involve us granting licenses of our intellectual property and performing research and development services in exchange of upfront fees, milestone payments and royalty payments. Since December 31, </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019, there have been no material changes to the key terms of our collaboration or license agreements. For further information on the terms and conditions of our existing collaboration and license agreements, please see the notes to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized, we performed the following steps: (i) identified the promised goods or services in the contract; (ii) determined whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measured the transaction price, including the constraint on variable consideration; (iv) allocated the transaction price to the performance obligations; and (v) recognized revenue when (or as) we satisfied each performance obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties and sales-based milestones and in which the license is deemed to be the predominant item to which the royalties relate, we recognize royalty revenue upon the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestone revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting period we evaluate whether milestones are considered probable of being reached and, to the extent that a significant reversal would not occur in future periods, estimate the amount to be included in the transaction price using the most likely amount method.&#160;Milestone payments that are not within our control, such as regulatory approvals, are considered constrained and are excluded from the transaction price until those approvals are received.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Celgene Corporation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into the following collaboration agreements, or collectively, the Collaboration Agreements, with Celgene, a wholly owned subsidiary of BMS, which is a related party through ownership of our common stock: </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2010, we entered into a discovery and development collaboration and license agreement focused on cancer metabolism, or the 2010 Agreement, which was amended in October 2011 and July 2014. The discovery phase of the 2010 Agreement expired in April 2016. On August 15, 2016, we terminated the 2010 Agreement as to the program directed to the isocitrate dehydrogenase 1, or IDH1, target, for which ivosidenib was the lead development candidate. Accordingly, the sole program remaining under the 2010 Agreement is IDHIFA&#174; (enasidenib), a co-commercialized licensed program for which Celgene leads and funds global development and commercialization activities. On June 11, 2020, we sold our tiered, sales-based royalty rights on worldwide net sales of IDHIFA&#174; (enasidenib), as well as our rights to receive up to $55.0&#160;million in outstanding regulatory milestone payments from BMS, to RPI for $255.0&#160;million. Under the 2010 Agreement, we remain eligible to receive a $25.0&#160;million potential milestone payment for the enasidenib program upon achievement of a specified ex-U.S. commercial milestone event, as well as reimbursement for costs incurred for our co-commercialization efforts and development activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April&#160;2015, we entered into a joint worldwide development and profit share collaboration and license agreement with Celgene, and our wholly owned subsidiary, Agios International Sarl, entered into a collaboration and license agreement with Celgene International II Sarl, or collectively, the AG-881 Agreements, to establish a worldwide collaboration focused on the development and commercialization of vorasidenib products. Under the AG-881 Agreements, we and Celgene split all worldwide development costs for vorasidenib, subject to specified exceptions. The AG-881 Agreements were terminated effective September 4, 2018, upon which we received sole global rights to vorasidenib. In connection with the termination of the AG-881 Agreements, Celgene will be eligible to receive royalties from us at a low single-digit percentage rate on worldwide net sales of products containing vorasidenib.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">In May&#160;2016, we entered into a master research and collaboration agreement with Celgene, or the 2016 Agreement, focused on metabolic immuno-oncology, or MIO, a developing field which aims to modulate the activity of relevant immune cells by targeting critical metabolic nodes, thereby enhancing the immune mediated anti-tumor response. The initial four-year research term of the 2016 Agreement ended May 2020. On March 25, 2020 Celgene declined the option to extend the research agreement for up to two, or in specified cases, up to four additional one-year terms which would have required the payment of a $40.0&#160;million extension fee. Further, on April 10, 2020 Celgene notified us that they will be declining to elect any program as a continuation program under the 2016 agreement. Celgene had designated AG-270, our inhibitor of methionine adenosyltransferase 2a, or MAT2A, as a development candidate under the 2016 Agreement. On March 25, 2020, Celgene notified us of their decision to decline their option to enter into a Development &amp; Commercialization Agreement with respect to the MAT2A program under the 2016 Agreement which </span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">would have required the payment of a $30.0&#160;million fee. As a result of the decisions, the research services were fully satisfied as of May 17, 2020, no additional performance obligations remain under the 2016 Agreement and we are no longer eligible for any milestone payments for the 2016 Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2020 and 2019, we recognized the following collaboration revenue:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Services performed that were considered performance obligations as of the modification dates</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On-going research and development services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Services performed that were not considered performance obligations as of the modification dates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercialization activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue - related party</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,516&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,038&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,414&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in our contract assets and liabilities during the nine months ended September 30, 2020:</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration receivable &#8211; related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,693)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unbilled receivable - related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(346)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty receivable &#8211; related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,915)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue &#8211; related party, current and net of current portions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,421&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,934)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1)  Additions to collaboration receivables - related party relate to amounts billed to Celgene for reimbursable costs incurred by us during the reporting period. Deductions to receivables relate to collection of receivables during the reporting period.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(2)  Unbilled receivables - related party amounts relate to future reimbursable costs to Celgene.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)  Additions to royalty receivables - related party relate to amounts billed to Celgene during the reporting period. Deductions to receivables relate to collection of receivables during the reporting period. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)  Additions to deferred revenue - related party relate to consideration from Celgene during the reporting period. Deductions relate to deferred revenue recognized as revenue during the reporting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in collaboration revenue from on-going research and development services during the three and nine months ended September&#160;30, 2020 is primarily due to our updated estimate of the future costs that would be incurred from on-going research and development services to complete one of our performance obligations under the 2016 Agreement that is recognized over time using an input method, due to Celgene&#8217;s decision to decline extending the research term in the first quarter of 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2020 and 2019, we recognized the following as revenue due to changes in the contract liability balances:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.333%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts included in the contract liability at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance obligations satisfied in previous periods</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the aggregate amount of the transaction price allocated to performance obligations that are partially unsatisfied was $4.5 million. This amount is expected to be recognized as performance obligations are satisfied through September 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the underlying performance obligation, or delivery of the enasidenib license, had been satisfied as of June 2014, royalty revenue is recognized as the related sales occur. During the three and nine months ended September 30, 2020 and 2019, we recognized the following as royalty revenue:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.332%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue &#8211; related party</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,666&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,569&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 11, 2020, we sold our tiered, sales-based royalty rights on worldwide net sales of IDHIFA&#174; (enasidenib), as well as our rights to receive up to $55.0&#160;million in outstanding regulatory milestone payments from BMS, to RPI for $255.0&#160;million. For further discussion of the sale of future revenue, refer to Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale of Future Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestone revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No milestones were achieved during the three and nine months ended September 30, 2020 or 2019. The next potential milestone expected to be achieved under the remaining terms of our Collaboration Agreements is the achievement of a specified ex-U.S. commercial milestone event, which would result in a milestone payment of $25.0 million under the 2010 Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CStone Pharmaceuticals </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, we and CStone Pharmaceuticals, or CStone, entered into an exclusive license agreement, or the CStone Agreement, to grant CStone specified intellectual property licenses to enable CStone to develop and commercialize certain products containing ivosidenib in mainland China, Hong Kong, Macau and Taiwan, or the CStone Territory. We retain development and commercialization rights for the rest of the world. On March 2, 2020, we amended the CStone Agreement to include Singapore as part of the CStone Territory. Pursuant to the CStone Agreement, CStone will initially be responsible for the development and commercialization of ivosidenib in acute myeloid leukemia, or AML, cholangiocarcinoma, and, at our discretion, brain cancer indications. CStone is responsible for all costs it incurs in developing, obtaining regulatory approval of, and commercializing ivosidenib in the CStone Territory, as well as certain costs incurred by us. Pursuant to the CStone Agreement, we received an initial upfront payment in the amount of $12.0 million and are entitled to receive up to an additional $407.0 million in milestone payments upon the achievement of certain development, regulatory and sales milestone events. We will also be entitled to receive tiered royalties, ranging from 15% to 19% percent, on annual net sales, if any, of ivosidenib in the CStone Territory.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2020 and 2019, we recognized the following collaboration revenue -other:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Services performed that were considered performance obligations as of the inception date</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and other services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Services performed that were not considered performance obligations as of the inception date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue - other</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,786&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,202&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents changes in our contract assets during the nine months ended September 30, 2020:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets (1)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration receivable - other</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,928&#160;</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,786&#160;</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,722)</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992&#160;</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    Additions to contract assets relate to amounts receivable from CStone. Deductions to contract assets relate to collection of receivables during the reporting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the aggregate amount of the transaction price allocated to performance obligations that are partially unsatisfied was $0.5 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The license was determined to be the predominant item to which sales-based royalties and sales-based milestones relate. As the license was delivered in June 2018, we will recognize royalty revenue when the related sales occur. To date, no royalties have been received under the CStone Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestone revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No milestones were earned during the three and nine months ended September 30, 2020 and 2019. The next potential milestone expected to be achieved under the CStone Agreement is the dosing of the first patient in a local study in a solid tumor indication in mainland China. Achievement of this event will result in a milestone payment of $5.0 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518044941960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Future Revenue<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_SaleOfFutureRevenueRoyaltyObligationAbstract', window );"><strong>Sale of Future Revenue, Royalty Obligation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_SaleOfFutureRevenueRoyaltyObligationTextBlock', window );">Sale of Future Revenue</a></td>
<td class="text">Sale of Future Revenue<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 11, 2020, we sold our tiered, sales-based royalty rights on worldwide net sales of IDHIFA&#174; (enasidenib), as well as our rights to receive up to $55.0&#160;million in outstanding regulatory milestone payments from BMS, to RPI for $255.0&#160;million. The gross proceeds of $255.0&#160;million approximate the fair value of the liability related to the sale of future revenue based on a discounted cash flow model. The fair value for the liability related to the sale of future revenue at the time of the transaction was based on our current estimates of future royalties expected to be paid to RPI over the remaining patent life of the product, which are considered level 3 inputs. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Purchase Agreement, although we sold all of our rights to receive royalties on worldwide net sales of IDHIFA&#174; and future regulatory milestone payments, we continue to co-promote IDHIFA&#174; and are therefore involved in the generation of these royalties. Due to our continuing involvement, we will continue to account for any royalties earned as revenue. We recorded the net proceeds from this transaction as a liability related to sale of future revenue, or Royalty Obligation, that will be amortized using the effective interest method over the remaining patent life. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As royalties are remitted to RPI from BMS, the balance of the Royalty Obligation will be effectively repaid over the life of the BMS license agreement. In order to determine the amortization of the Royalty Obligation, we are required to estimate the total amount of future royalty payments to RPI over the life of the BMS license agreement. The $255.0&#160;million recorded will be accreted to the total of these royalty payments as interest expense over the life of the Royalty Obligation. At execution, our estimate of this total interest expense resulted in an effective annual interest rate of approximately 16.4%. This estimate contains significant assumptions that impact both the amount recorded at execution and the interest expense that will be recognized over the royalty period. We will periodically assess the estimated royalty payments to RPI from BMS and to the extent the amount or timing of such payments is materially different than the original estimates, an adjustment will be recorded prospectively to increase or decrease interest expense. There are a number of factors that could materially affect the amount and timing of royalty payments to RPI from BMS, and correspondingly, the amount of interest expense recorded by us, most of which are not within our control. Such factors include, but are not limited to, delays or discontinuation of development of enasidenib, regulatory approval, changing standards of care, the introduction of competing products, manufacturing or other delays, generic competition, intellectual property matters, adverse events that result in governmental health authority imposed restrictions on the use of the drug products, significant changes in foreign exchange rates as the royalties remitted to RPI are made in U.S. dollars (USD) while the underlying sales of enasidenib will be made in currencies other than USD, and other events or circumstances that are not currently foreseen. Changes to any of these factors could result in increases or decreases to both royalty revenues and interest expense. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity of the Royalty Obligation since the transaction inception through September 30, 2020:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the sale of future revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,463)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-cash royalty related to the sale of future revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,341)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense associated with the sale of future revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liability related to the sale of future revenue</span></div></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,121&#160;</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>During the three and nine months ended September 30, 2020, $2.7&#160;million and $4.3 million of non-cash royalty revenue from net sales of IDHIFA&#174; were recognized, respectively<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_SaleOfFutureRevenueRoyaltyObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Future Revenue, Royalty Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_SaleOfFutureRevenueRoyaltyObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_SaleOfFutureRevenueRoyaltyObligationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Future Revenue, Royalty Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_SaleOfFutureRevenueRoyaltyObligationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518045194024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payments</a></td>
<td class="text">Share-Based Payments<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2013 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2013, our Board of Directors adopted and, in July 2013 our stockholders approved, the 2013 Stock Incentive Plan, or the 2013 Plan. The 2013 Plan became effective upon the closing of our initial public offering and provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock units, or RSUs, performance-based stock units, or PSUs, and other stock-based awards to employees, non-employees and non-employee directors. Following the adoption of the 2013 Plan, we granted no further stock options or other awards under the 2007 Stock Incentive Plan, or the 2007 Plan. Any options or awards outstanding under the 2007 Plan at the time of adoption of the 2013 Plan remain outstanding and effective. As of September&#160;30, 2020, the total number of shares reserved under the 2007 Plan and the 2013 Plan was 10,680,089, and we had 2,919,442 shares available for future issuance under the 2013 Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock options</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents stock option activity for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,201,485&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956,945&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339,284)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(448,901)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,370,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,067,553&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.23&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,370,245&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.85&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, there was approximately $77.4 million of total unrecognized compensation expense related to unvested stock option awards, which we expect to recognize over a weighted-average period of approximately 2.4 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted stock units</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents RSU activity for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant&#160;Date&#160;Fair&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766,953&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,791&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(258,461)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132,805)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205,478&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.77&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, there was approximately $41.7 million of total unrecognized compensation expense related to RSUs, which we expect to recognize over a weighted-average period of approximately 1.9 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-based stock units </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents PSU activity for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.668%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant&#160;Date&#160;Fair&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,920)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,616)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,229&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.28&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense associated with these PSUs is recognized if the underlying performance condition is considered probable of achievement using our management&#8217;s best estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, there was no unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered probable of achievement, and $5.9 million of total unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered not probable of achievement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Market-based stock units</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents market-based stock unit, or MSU, activity for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.690%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,695&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,695&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.50&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of MSUs are estimated using a Monte Carlo simulation model. Assumptions and estimates utilized in the model include the risk-free interest rate, dividend yield, expected stock volatility and the estimated period to achievement of the market condition. As of September&#160;30, 2020, there was no remaining unrecognized compensation expense related to MSUs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2013 Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 Employee Stock Purchase Plan, or the 2013 ESPP. We issued and sold 120,293 and 77,981 shares of common stock during the nine months ended September 30, 2020 and 2019, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 836,363 shares of our common stock. As of September&#160;30, 2020, we had 471,353 shares of common stock available for future issuance under the 2013 ESPP.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation expense</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,065&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,407&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,588&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,527&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,243&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses related to stock options and stock-based awards were allocated as follows in the condensed consolidated statements of operations:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,860&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,665&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,063&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,274&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,407&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,588&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,527&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,243&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518045127320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss per Share</a></td>
<td class="text">Loss per ShareBasic net loss per share is calculated by dividing net loss by the weighted-average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury stock method. For purposes of the dilutive net loss per share calculation, stock options, RSUs, PSUs and MSUs for which the performance and market vesting conditions, respectively, have been deemed probable, and 2013 ESPP shares are considered to <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be common stock equivalents, while PSUs and MSUs with performance and market vesting conditions, respectively, that were not deemed probable as of September&#160;30, 2020 are not considered to be common stock equivalents.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we had a net loss for all periods presented, the effect of all potentially dilutive securities is anti-dilutive. Accordingly, basic and diluted net loss per share was the same for all periods presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:71.734%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.115%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.117%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three and Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,370,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,185,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,588,924&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,932,789&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518049046744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of September&#160;30, 2020, the condensed consolidated statements of operations, comprehensive loss and stockholders' equity for the three and nine months ended September 30, 2020 and 2019, and the condensed consolidated statements of cash flows for the nine months ended September 30, 2020 and 2019 are unaudited. The unaudited condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of our management, reflect all adjustments, which include only normal recurring adjustments, necessary to fairly state our financial position as of September&#160;30, 2020, our results of operations and stockholders' equity for the three and nine months ended September 30, 2020 and 2019, and cash flows for the nine months ended September 30, 2020 and 2019. The financial data and the other financial information disclosed in these notes to the condensed consolidated financial statements related to the three and nine-month periods are also unaudited. The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2020 or for any other future annual or interim period. The condensed consolidated balance sheet data as of December&#160;31, 2019 was derived from our audited financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles, or U.S. GAAP. The condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2019 that was filed with the Securities and Exchange Commission, or the SEC, on February&#160;19, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include our accounts and the accounts of our wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared in conformity with U.S. GAAP.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain the pandemic or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board, or FASB issued Accounting Standards Update, or ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which introduces new guidance for the accounting for credit losses on instruments within its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. Credit losses relating to available-for-sale debt securities will also be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. The guidance is effective for fiscal years beginning after December 31, 2019, including interim periods within those years. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the quarter ended March 31, 2020, we adopted ASU 2016-13, which eliminated the concept of other-than-temporary impairments and required credit losses on debt securities to be recorded through an allowance for credit losses instead of as a reduction in the amortized cost basis of the securities. Application of the amendments is through a cumulative-effect adjustment to retained earnings as of the effective date. Based upon our analysis, the adoption of this final rule did not have a material impact on the financial statements. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_SaleOfFutureRevenuePolicyPolicyTextBlock', window );">Liability Related to Sale of Future Revenue and Amortization of Issuance Costs</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability related to sale of future revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We treat the sale of future revenue to RPI as a debt financing, as we have significant continuing involvement in the generation of the cash flows. As result, we recorded the proceeds from this transaction as a liability related to the sale of future revenue to be amortized to interest expense using the effective interest rate method over the life of the arrangement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liability related to sale of future revenue and the related interest expense are based on our current estimates of future royalties expected to be paid over the life of the arrangement. We will periodically assess the expected royalty payments using a combination of internal projections and forecasts from external sources. To the extent our future estimates of royalty payments are greater or less than previous estimates or the estimated timing of such payments is materially different than its previous estimates, we will prospectively recognize related non-cash interest expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further discussion of the sale of future revenue, refer to Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale of Future Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization of issuance costs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We treated the liability related to sale of future revenue as a debt financing. As such, the long-term liability is initially recorded at its proceeds, net of deferred costs. Issuance costs, fees directly related to the sale of future revenue, are offset against initial carrying value of the long-term liability and are amortized on a straight-line basis over the remaining patent life of the product to an operating expense.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record cash equivalents and marketable securities at fair value. Accounting Standards Codification, or ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, directly or indirectly, for substantially the full term of the asset or liability.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable securities are classified as available-for-sale pursuant to ASC 320, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments &#8211; Debt and Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and are recorded at fair value. Unrealized gains are included as a component of accumulated other comprehensive income in the condensed consolidated balance sheets and statements of stockholders&#8217; equity and a component of total comprehensive loss in the condensed consolidated statements of comprehensive loss, until realized. Unrealized losses are evaluated for impairment under ASC 326, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span>, to determine if the impairment is credit-related or noncredit-related. Credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings, and noncredit-related impairment is recognized in other comprehensive income, net of taxes. Realized gains and losses are included in investment income on a specific-identification basis.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Product Revenue</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell TIBSOVO&#174;, our wholly owned product, to a limited number of specialty distributors and specialty pharmacy providers, or collectively, the Customers. The Customers subsequently resell TIBSOVO&#174; to pharmacies or dispense directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of TIBSOVO&#174;.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation related to the sale of TIBSOVO&#174; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer. </span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reserves for Variable Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Adjustments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally provide Customers with discounts, including prompt pay discounts, and allowances that are explicitly stated in the contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from certain Customers.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks for fees and discounts represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are estimated using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated channel mix and are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government rebates include Medicare, TriCare, and Medicaid rebates, which we estimate using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Returns</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the amount of product sales that may be returned by Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate product return liabilities using the expected value method, based on available industry data, including our visibility into the inventory remaining in the distribution channel.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per Share</a></td>
<td class="text">Basic net loss per share is calculated by dividing net loss by the weighted-average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury stock method. For purposes of the dilutive net loss per share calculation, stock options, RSUs, PSUs and MSUs for which the performance and market vesting conditions, respectively, have been deemed probable, and 2013 ESPP shares are considered to be common stock equivalents, while PSUs and MSUs with performance and market vesting conditions, respectively, that were not deemed probable as of September&#160;30, 2020 are not considered to be common stock equivalents.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_SaleOfFutureRevenuePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Future Revenue, Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_SaleOfFutureRevenuePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518045098360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash equivalents and marketable securities measured at fair value on a recurring basis as of September&#160;30, 2020:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,494&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,494&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,494&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,494&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617,573&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617,573&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,494&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617,573&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672,067&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518045116264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities at September&#160;30, 2020 consisted of the following:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,992&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,910&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617,573&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities at December&#160;31, 2019 consisted of the following:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,877&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,929&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636,673&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(268)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636,875&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518139583080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, which consists of commercial supply of TIBSOVO&#174;, consists of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.597%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,166&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,808&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,331&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518045193464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Undiscounted Minimum Rental Commitments Under Non-cancelable Leases</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, undiscounted minimum rental commitments under non-cancelable leases, for each of the next five years and total thereafter were as follows:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.217%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.583%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undiscounted minimum rental commitments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,195&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,621)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,574&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518141544744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, <br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,188&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,777&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued revenue-related reserves and other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,018&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,048&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,724&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,142&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518049083912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Product Revenue</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,716&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,422&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,971&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,287&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Product Revenue Allowance and Reserves</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government Rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provisions relating to sales in the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/returns relating to sales in the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,966)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/returns relating to sales in the prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(677)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,330)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,608&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,618&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,739&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock', window );">Schedule of Revenue Related Reserves</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue-related reserves above, included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Component of accrued expenses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,739&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,796&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock', window );">Schedule of Changes in Contract Assets and Liabilities, Product Revenue</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in our contract assets during the nine months ended September 30, 2020:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,952&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,504&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,467)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,989&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)  Additions to contract assets relate to amounts billed to Customers for product sales and deductions to contract assets primarily relate to collection of receivables during the reporting period.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518044933768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>Revenue Recognition and Deferred Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock', window );">Schedule of Collaboration Revenue</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2020 and 2019, we recognized the following collaboration revenue:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Services performed that were considered performance obligations as of the modification dates</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On-going research and development services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Services performed that were not considered performance obligations as of the modification dates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercialization activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue - related party</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,516&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,038&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,414&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Changes in Contract Assets and Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in our contract assets and liabilities during the nine months ended September 30, 2020:</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration receivable &#8211; related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,693)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unbilled receivable - related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(346)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty receivable &#8211; related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,915)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue &#8211; related party, current and net of current portions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,421&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,934)</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(1)  Additions to collaboration receivables - related party relate to amounts billed to Celgene for reimbursable costs incurred by us during the reporting period. Deductions to receivables relate to collection of receivables during the reporting period.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(2)  Unbilled receivables - related party amounts relate to future reimbursable costs to Celgene.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)  Additions to royalty receivables - related party relate to amounts billed to Celgene during the reporting period. Deductions to receivables relate to collection of receivables during the reporting period. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)  Additions to deferred revenue - related party relate to consideration from Celgene during the reporting period. Deductions relate to deferred revenue recognized as revenue during the reporting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2020 and 2019, we recognized the following as revenue due to changes in the contract liability balances:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.333%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts included in the contract liability at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance obligations satisfied in previous periods</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock', window );">Schedule of Royalty Revenue</a></td>
<td class="text">During the three and nine months ended September 30, 2020 and 2019, we recognized the following as royalty revenue:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.332%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue &#8211; related party</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,666&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,569&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock', window );">Schedule of Collaboration Revenue Under CStone Agreement</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2020 and 2019, we recognized the following collaboration revenue -other:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Services performed that were considered performance obligations as of the inception date</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and other services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Services performed that were not considered performance obligations as of the inception date</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenue - other</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,101&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,786&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,202&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlockTableTextBlock', window );">Schedule of Changes in Contract Assets and Liabilities, CStone Agreement</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents changes in our contract assets during the nine months ended September 30, 2020:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets (1)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration receivable - other</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,928&#160;</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,786&#160;</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,722)</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1.5pt solid #000;padding:0 1pt"/><td style="border-bottom:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992&#160;</span></td><td style="border-bottom:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)    Additions to contract assets relate to amounts receivable from CStone. Deductions to contract assets relate to collection of receivables during the reporting period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition Multiple Deliverable Arrangements Allocated By Performance Obligation Under CStone Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518045116264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Future Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_SaleOfFutureRevenueRoyaltyObligationAbstract', window );"><strong>Sale of Future Revenue, Royalty Obligation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_SaleOfFutureRevenueRoyaltyObligationTableTextBlock', window );">Schedule of Royalty Obligation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity of the Royalty Obligation since the transaction inception through September 30, 2020:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the sale of future revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,463)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-cash royalty related to the sale of future revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,341)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense associated with the sale of future revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liability related to the sale of future revenue</span></div></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,121&#160;</span></td><td style="border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_SaleOfFutureRevenueRoyaltyObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Future Revenue, Royalty Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_SaleOfFutureRevenueRoyaltyObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_SaleOfFutureRevenueRoyaltyObligationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Future Revenue, Royalty Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_SaleOfFutureRevenueRoyaltyObligationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518049095672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Company's Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents stock option activity for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,201,485&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956,945&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339,284)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(448,901)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,370,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2020</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,067,553&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.23&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,370,245&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.85&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Unvested Stock Unit Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents RSU activity for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant&#160;Date&#160;Fair&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766,953&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829,791&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(258,461)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132,805)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205,478&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.77&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Schedule of Performance-Based Units</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents PSU activity for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.668%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Grant&#160;Date&#160;Fair&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218,143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,920)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,616)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,229&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.28&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock', window );">Schedule of Market-Based Units Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents market-based stock unit, or MSU, activity for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:68.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.690%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,695&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,695&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.50&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,065&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,407&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,588&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,527&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,243&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocated Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses related to stock options and stock-based awards were allocated as follows in the condensed consolidated statements of operations:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,860&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,665&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,063&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,274&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,407&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,588&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,527&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,243&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Market-Based Units Activity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518046745960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Common Stock Excluded from Calculation of Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span></div><div style="margin-bottom:9pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:71.734%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.115%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.117%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three and Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,370,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,185,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,588,924&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,932,789&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518047141688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Overview and Basis of Presentation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 11, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold', window );">Proceeds from the sale of future revenue</a></td>
<td class="nump">$ 255,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 722,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=agio_Agreement2010Member', window );">2010 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RevenueRecognitionMilestoneMethodEligibleReceivable', window );">Milestone-based receivable payments, eligible to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=agio_Agreement2010Member', window );">2010 Agreement | Celgene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold', window );">Royalty rights sold</a></td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Potential Milestone Payment Receivable For Specified Regulatory Milestone Event Program Sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PortionOfPotentialMilestonPaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgramSold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RevenueRecognitionMilestoneMethodEligibleReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RevenueRecognitionMilestoneMethodEligibleReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=agio_Agreement2010Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=agio_Agreement2010Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=agio_CelgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=agio_CelgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518051874440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 617,573<span></span>
</td>
<td class="nump">$ 636,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">54,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">617,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_CashEquivalentsAndAvailableForSaleSecurities', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">672,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">54,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">145,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">155,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">316,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">54,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_CashEquivalentsAndAvailableForSaleSecurities', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">54,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">54,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">617,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_CashEquivalentsAndAvailableForSaleSecurities', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">617,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">145,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">155,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">316,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_CashEquivalentsAndAvailableForSaleSecurities', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;3 | Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;3 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;3 | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_CashEquivalentsAndAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_CashEquivalentsAndAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518047994632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value of assets (liabilities)</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518052056760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>security</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">Realized gain (loss) on marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of debt securities in unrealized loss position for less than one year | security</a></td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLosses', window );">Allowance for credit loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Aggregate fair value of debt securities in unrealized loss position</a></td>
<td class="nump">$ 247,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 247,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of debt securities in significant unrealized loss position | security</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=SL6953423-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518048964344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Summary of Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 616,910<span></span>
</td>
<td class="nump">$ 636,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">834<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(171)<span></span>
</td>
<td class="num">(268)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">617,573<span></span>
</td>
<td class="nump">636,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_CurrentAssetMember', window );">Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">499,918<span></span>
</td>
<td class="nump">483,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">824<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(58)<span></span>
</td>
<td class="num">(145)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">500,684<span></span>
</td>
<td class="nump">483,946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_CurrentAssetMember', window );">Current | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">139,583<span></span>
</td>
<td class="nump">178,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">380<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">139,959<span></span>
</td>
<td class="nump">178,741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_CurrentAssetMember', window );">Current | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">94,336<span></span>
</td>
<td class="nump">80,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">94,402<span></span>
</td>
<td class="nump">80,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_CurrentAssetMember', window );">Current | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">265,999<span></span>
</td>
<td class="nump">224,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">266,323<span></span>
</td>
<td class="nump">224,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_NonCurrentAssetsMember', window );">Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">116,992<span></span>
</td>
<td class="nump">152,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(113)<span></span>
</td>
<td class="num">(123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">116,889<span></span>
</td>
<td class="nump">152,929<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_NonCurrentAssetsMember', window );">Non-current | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">5,132<span></span>
</td>
<td class="nump">35,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">5,128<span></span>
</td>
<td class="nump">35,286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_NonCurrentAssetsMember', window );">Non-current | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">61,320<span></span>
</td>
<td class="nump">17,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">61,323<span></span>
</td>
<td class="nump">17,591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_NonCurrentAssetsMember', window );">Non-current | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">50,540<span></span>
</td>
<td class="nump">99,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(103)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 50,438<span></span>
</td>
<td class="nump">$ 100,052<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=agio_CurrentAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=agio_CurrentAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=agio_NonCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=agio_NonCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518044996568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 1,406<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">9,166<span></span>
</td>
<td class="nump">6,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">799<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 11,371<span></span>
</td>
<td class="nump">$ 7,331<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518049454824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease terms</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 11.4<span></span>
</td>
<td class="nump">$ 10.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in measurement of lease liabilities</a></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average incremental borrowing rate</a></td>
<td class="nump">5.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518140525656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Undiscounted Minimum Rental Commitments Under Non-cancelable Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remaining 2020</a></td>
<td class="nump">$ 2,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">14,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">16,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">18,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">18,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">19,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">44,385<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Undiscounted minimum rental commitments</a></td>
<td class="nump">134,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Interest</a></td>
<td class="num">(27,621)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 106,574<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518047510024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 19,044<span></span>
</td>
<td class="nump">$ 18,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_AccruedResearchAndDevelopmentCostsCurrent', window );">Accrued research and development costs</a></td>
<td class="nump">16,188<span></span>
</td>
<td class="nump">21,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">3,474<span></span>
</td>
<td class="nump">8,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued revenue-related reserves and other</a></td>
<td class="nump">11,018<span></span>
</td>
<td class="nump">4,048<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 49,724<span></span>
</td>
<td class="nump">$ 53,142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518047481928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue - Schedule of Product Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 34,706<span></span>
</td>
<td class="nump">$ 26,024<span></span>
</td>
<td class="nump">$ 159,151<span></span>
</td>
<td class="nump">$ 82,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 31,716<span></span>
</td>
<td class="nump">$ 17,422<span></span>
</td>
<td class="nump">$ 81,971<span></span>
</td>
<td class="nump">$ 40,287<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518051971432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue - Schedule of Product Revenue Allowance and Reserves (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractualAdjustmentsRollForward', window );"><strong>Contractual Adjustments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerContractualAdjustmentReserve', window );">Contract adjustments, beginning balance</a></td>
<td class="nump">$ 874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_CurrentYearProvisionForContractualAdjustments', window );">Contractual adjustments, current provisions relating to sales in the current year</a></td>
<td class="nump">10,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_PriorYearProvisionForContractualAdjustments', window );">Contractual adjustments, adjustments relating to prior year</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear', window );">Contractual adjustments, payments/returns relating to sales in the current year</a></td>
<td class="num">(8,966)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear', window );">Contractual adjustments, payments/returns relating to sales in the prior year</a></td>
<td class="num">(653)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerContractualAdjustmentReserve', window );">Contract adjustments, ending balance</a></td>
<td class="nump">1,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_GovernmentRebatesRollForward', window );"><strong>Government Rebates [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerRebateReserve', window );">Government rebates, beginning balance</a></td>
<td class="nump">1,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_CurrentYearProvisionsForRebateReserve', window );">Government rebates, current provisions relating to sales in the current year</a></td>
<td class="nump">9,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_PriorYearProvisionsForRebateReserve', window );">Government rebates, adjustments relating to prior years</a></td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear', window );">Government rebates, payments/returns relating to sales in the current year</a></td>
<td class="num">(2,260)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears', window );">Government rebates, payments/returns relating to sales in the prior years</a></td>
<td class="num">(677)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerRebateReserve', window );">Government rebates, ending balance</a></td>
<td class="nump">7,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ProductReturnsRollForward', window );"><strong>Product Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerRightToRecoverProductReserve', window );">Returns, beginning balance</a></td>
<td class="nump">1,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ProvisionForRightToRecoverProductInCurrentYear', window );">Returns, current provisions relating to sales in the current year</a></td>
<td class="nump">1,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ProvisionForRightToRecoverProductInPriorYears', window );">Returns, adjustments relating to prior years</a></td>
<td class="num">(476)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries', window );">Returns, payments/returns relating to sales in the current year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries', window );">Returns, payments/returns relating to sales in the prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerRightToRecoverProductReserve', window );">Returns, ending balance</a></td>
<td class="nump">2,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Allowance for Doubtful Accounts Receivable [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerTotalAllowancesAndReserves', window );">Total revenue-related reserves</a></td>
<td class="nump">11,739<span></span>
</td>
<td class="nump">$ 3,796<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerCurrentYearReserveProvisions', window );">Total allowances and reserves, current provisions relating to sales in the current year</a></td>
<td class="nump">20,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerPriorYearsReserveProvisions', window );">Total allowances and reserves, adjustments relating to prior years</a></td>
<td class="num">(357)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerCurrentYearReserveRecoveries', window );">Total allowances and reserves, payments/returns relating to sales in the current year</a></td>
<td class="num">(11,226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerPriorYearsReserveRecoveries', window );">Total allowances and reserves, payments/returns relating to sales in the prior years</a></td>
<td class="num">$ (1,330)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerContractualAdjustmentReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerContractualAdjustmentReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerCurrentYearReserveProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerCurrentYearReserveProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerCurrentYearReserveRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerCurrentYearReserveRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerPriorYearsReserveProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerPriorYearsReserveProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerPriorYearsReserveRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerPriorYearsReserveRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerRebateReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerRebateReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerRightToRecoverProductReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerRightToRecoverProductReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerTotalAllowancesAndReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerTotalAllowancesAndReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractualAdjustmentsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractualAdjustmentsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_CurrentYearProvisionForContractualAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_CurrentYearProvisionForContractualAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_CurrentYearProvisionsForRebateReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_CurrentYearProvisionsForRebateReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_GovernmentRebatesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_GovernmentRebatesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_PriorYearProvisionForContractualAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_PriorYearProvisionForContractualAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_PriorYearProvisionsForRebateReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_PriorYearProvisionsForRebateReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ProductReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ProductReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ProvisionForRightToRecoverProductInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ProvisionForRightToRecoverProductInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ProvisionForRightToRecoverProductInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ProvisionForRightToRecoverProductInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518134288024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Product Revenue - Schedule of Revenue-Related Reserves (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Reduction of accounts receivable</a></td>
<td class="nump">$ 732<span></span>
</td>
<td class="nump">$ 540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAllowanceAndReservesLiability', window );">Component of accrued expenses</a></td>
<td class="nump">11,007<span></span>
</td>
<td class="nump">3,256<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerTotalAllowancesAndReserves', window );">Total revenue-related reserves</a></td>
<td class="nump">$ 11,739<span></span>
</td>
<td class="nump">$ 3,796<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerAllowanceAndReservesLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerAllowanceAndReservesLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerTotalAllowancesAndReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerTotalAllowancesAndReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518049424952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue - Schedule of Changes in Contract Assets and Liabilities, Product Revenue (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ChangeInContractWithCustomerAssetRollForward', window );"><strong>Contract assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, beginning balance</a></td>
<td class="nump">$ 8,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetRevenueRecognized', window );">Additions</a></td>
<td class="nump">102,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables', window );">Deductions</a></td>
<td class="num">(92,467)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, ending balance</a></td>
<td class="nump">$ 18,989<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ChangeInContractWithCustomerAssetRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Asset [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ChangeInContractWithCustomerAssetRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerAssetRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerAssetRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518051984920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Celgene Purchase Agreements (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 11, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2016 </div>
<div>USD ($) </div>
<div>extension</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold', window );">Proceeds from the sale of future revenue</a></td>
<td class="nump">$ 255,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=agio_RPIMember', window );">RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold', window );">Proceeds from the sale of future revenue</a></td>
<td class="nump">255,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=agio_Agreement2010Member', window );">2010 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RevenueRecognitionMilestoneMethodEligibleReceivable', window );">Milestone-based receivable payments, eligible to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=agio_Agreement2010Member', window );">2010 Agreement | Celgene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold', window );">Royalty rights sold</a></td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=agio_MasterResearchAndCollaborationAgreementMember', window );">2016 Agreement | Celgene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RevenueRecognitionMultipleDeliverableArrangementsTermOfAgreement', window );">Term of agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfExtensions', window );">Extension period | extension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfSpecialCaseExtensions', window );">Number of allowable special case extensions | extension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RevenueRecognitionMultipleDeliverableArrangementsSpecialCaseExtensionTerm', window );">Special case extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_UpfrontPaymentAgreementExtensionFeeReceivable', window );">Upfront payment agreement extension fee receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_OptionExerciseFeeReceivable', window );">Option exercise fee receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_OptionExerciseFeeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_OptionExerciseFeeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Potential Milestone Payment Receivable For Specified Regulatory Milestone Event Program Sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PortionOfPotentialMilestonPaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgramSold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RevenueRecognitionMilestoneMethodEligibleReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RevenueRecognitionMilestoneMethodEligibleReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfExtensions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfExtensions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfSpecialCaseExtensions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfSpecialCaseExtensions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RevenueRecognitionMultipleDeliverableArrangementsSpecialCaseExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RevenueRecognitionMultipleDeliverableArrangementsSpecialCaseExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RevenueRecognitionMultipleDeliverableArrangementsTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RevenueRecognitionMultipleDeliverableArrangementsTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_UpfrontPaymentAgreementExtensionFeeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_UpfrontPaymentAgreementExtensionFeeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=agio_RPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=agio_RPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=agio_Agreement2010Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=agio_Agreement2010Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=agio_CelgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=agio_CelgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=agio_MasterResearchAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=agio_MasterResearchAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518052753592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Collaboration Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 34,706<span></span>
</td>
<td class="nump">$ 26,024<span></span>
</td>
<td class="nump">$ 159,151<span></span>
</td>
<td class="nump">$ 82,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=agio_ResearchServicesMember', window );">On-going research and development services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">4,695<span></span>
</td>
<td class="nump">64,133<span></span>
</td>
<td class="nump">29,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=agio_CommercializationActivityMember', window );">Commercialization activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="nump">821<span></span>
</td>
<td class="nump">2,905<span></span>
</td>
<td class="nump">2,499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=agio_CollaborationRevenueRelatedPartyMember', window );">Collaboration revenue &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 1,206<span></span>
</td>
<td class="nump">$ 5,516<span></span>
</td>
<td class="nump">$ 67,038<span></span>
</td>
<td class="nump">$ 32,414<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=agio_ResearchServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=agio_ResearchServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=agio_CommercializationActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=agio_CommercializationActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=agio_CollaborationRevenueRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=agio_CollaborationRevenueRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518048002536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Schedule of Changes in Contract Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ChangeInContractWithCustomerAssetRollForward', window );"><strong>Contract assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetRevenueRecognized', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables', window );">Deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(92,467)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, ending balance</a></td>
<td class="nump">$ 18,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ChangeInContractWithCustomerLiabilityRollForward', window );"><strong>Contract liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 4,404<span></span>
</td>
<td class="nump">61,513<span></span>
</td>
<td class="nump">$ 28,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember', window );">Collaboration receivable &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ChangeInContractWithCustomerAssetRollForward', window );"><strong>Contract assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetRevenueRecognized', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables', window );">Deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,693)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, ending balance</a></td>
<td class="nump">1,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_UnbilledReceivableDueFromRelatedPartiesCurrentMember', window );">Unbilled receivable - related party, net of current portions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ChangeInContractWithCustomerAssetRollForward', window );"><strong>Contract assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetRevenueRecognized', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables', window );">Deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(346)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, ending balance</a></td>
<td class="nump">1,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember', window );">Royalty receivable &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ChangeInContractWithCustomerAssetRollForward', window );"><strong>Contract assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetRevenueRecognized', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables', window );">Deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,915)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_DeferredRevenueCurrentMember', window );">Deferred revenue &#8211; related party, current and net of current portions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ChangeInContractWithCustomerLiabilityRollForward', window );"><strong>Contract liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63,934)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities, ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ChangeInContractWithCustomerAssetRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Asset [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ChangeInContractWithCustomerAssetRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ChangeInContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ChangeInContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerAssetRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerAssetRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=agio_UnbilledReceivableDueFromRelatedPartiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=agio_UnbilledReceivableDueFromRelatedPartiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=agio_DeferredRevenueCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=agio_DeferredRevenueCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518043774008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Schedule of Revenues as a Result of Changes in Contract Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>Revenue Recognition and Deferred Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Amounts included in the contract liability at the beginning of the period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,404<span></span>
</td>
<td class="nump">$ 61,513<span></span>
</td>
<td class="nump">$ 28,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Performance obligations satisfied in previous periods</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518052010632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 11, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining unsatisfied performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold', window );">Proceeds from the sale of future revenue</a></td>
<td class="nump">$ 255,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized', window );">Milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=agio_Agreement2010Member', window );">2010 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication', window );">Potential milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Potential Milestone Payment Receivable For Specified Regulatory Milestone Event Program Sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contracts With Customers, Milestone Revenue Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=agio_Agreement2010Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=agio_Agreement2010Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518052697880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - CStone Pharmaceuticals Purchase Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining unsatisfied performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,706,000<span></span>
</td>
<td class="nump">$ 26,024,000<span></span>
</td>
<td class="nump">159,151,000<span></span>
</td>
<td class="nump">$ 82,472,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized', window );">Milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=agio_CollaborationRevenueRelatedPartyMember', window );">Collaboration revenue &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,206,000<span></span>
</td>
<td class="nump">5,516,000<span></span>
</td>
<td class="nump">67,038,000<span></span>
</td>
<td class="nump">32,414,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">683,000<span></span>
</td>
<td class="nump">2,666,000<span></span>
</td>
<td class="nump">7,356,000<span></span>
</td>
<td class="nump">7,569,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=agio_CStonePharmaceuticalsMember', window );">CStone Pharmaceuticals | CStone Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts', window );">Initial payment received</a></td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable', window );">Potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining unsatisfied performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized', window );">Milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=agio_CStonePharmaceuticalsMember', window );">CStone Pharmaceuticals | CStone Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RoyaltyPercentageRemitted', window );">Royalty percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=agio_CStonePharmaceuticalsMember', window );">CStone Pharmaceuticals | CStone Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable', window );">Potential future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 407,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RoyaltyPercentageRemitted', window );">Royalty percentage</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=agio_CStonePharmaceuticalsMember', window );">CStone Pharmaceuticals | CStone Agreement | Royalty revenue &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contracts With Customers, Milestone Revenue Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RoyaltyPercentageRemitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RoyaltyPercentageRemitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=agio_CollaborationRevenueRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=agio_CollaborationRevenueRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=agio_CStonePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=agio_CStonePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=agio_CStoneAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=agio_CStoneAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518051832904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Schedule of Collaboration Revenue from CStone Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 34,706<span></span>
</td>
<td class="nump">$ 26,024<span></span>
</td>
<td class="nump">$ 159,151<span></span>
</td>
<td class="nump">$ 82,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and other services | CStone Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(103)<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceOtherMember', window );">Other services | CStone Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">1,101<span></span>
</td>
<td class="nump">523<span></span>
</td>
<td class="nump">2,594<span></span>
</td>
<td class="nump">2,305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=agio_CollaborationRevenueOtherMember', window );">Collaboration revenue &#8211; other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">1,101<span></span>
</td>
<td class="nump">420<span></span>
</td>
<td class="nump">2,786<span></span>
</td>
<td class="nump">2,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=agio_CollaborationRevenueOtherMember', window );">Collaboration revenue &#8211; other | CStone Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 1,101<span></span>
</td>
<td class="nump">$ 420<span></span>
</td>
<td class="nump">$ 2,786<span></span>
</td>
<td class="nump">$ 2,202<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=agio_CStoneAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=agio_CStoneAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=agio_CollaborationRevenueOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=agio_CollaborationRevenueOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518048704104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Changes in Contract Assets and Liabilities Under CStone Agreement (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ChangeInContractWithCustomerAssetRollForward', window );"><strong>Contract assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, beginning balance</a></td>
<td class="nump">$ 8,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetRevenueRecognized', window );">Additions</a></td>
<td class="nump">102,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables', window );">Deductions</a></td>
<td class="num">(92,467)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, ending balance</a></td>
<td class="nump">18,989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember', window );">Collaboration receivable - other | CStone Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ChangeInContractWithCustomerAssetRollForward', window );"><strong>Contract assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, beginning balance</a></td>
<td class="nump">1,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetRevenueRecognized', window );">Additions</a></td>
<td class="nump">2,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables', window );">Deductions</a></td>
<td class="num">(2,722)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, ending balance</a></td>
<td class="nump">$ 1,992<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ChangeInContractWithCustomerAssetRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Asset [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ChangeInContractWithCustomerAssetRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerAssetRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerAssetRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=agio_CStoneAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=agio_CStoneAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518048230120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Future Revenue - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 11, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold', window );">Proceeds from the sale of future revenue</a></td>
<td class="nump">$ 255,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate', window );">Estimated effective interest rate on royalty rights sold</a></td>
<td class="nump">16.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=agio_RPIMember', window );">RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold', window );">Proceeds from the sale of future revenue</a></td>
<td class="nump">$ 255,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue', window );">Non-cash royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="nump">$ 4,341,000<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=agio_Agreement2010Member', window );">2010 Agreement | Celgene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold', window );">Royalty rights sold</a></td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payment Receivable For Specified Regulatory Milestone Event Program, Estimated Effective Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Potential Milestone Payment Receivable For Specified Regulatory Milestone Event Program Sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PortionOfPotentialMilestonPaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgramSold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Future Revenues, Non-Cash Royalty Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=agio_RPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=agio_RPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=agio_Agreement2010Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=agio_Agreement2010Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=agio_CelgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=agio_CelgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518052006872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Future Revenue - Schedule of Royalty Obligation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward', window );"><strong>Sale of Future Revenue, Liability, Noncurrent [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_SaleOfFutureRevenueLiabilityNoncurrent', window );">Proceeds from the sale of future revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_SaleOfFutureRevenueLiabilityNoncurrent', window );">Liability related to the sale of future revenue</a></td>
<td class="nump">$ 258,121<span></span>
</td>
<td class="nump">$ 258,121<span></span>
</td>
<td class="nump">258,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=agio_RPIMember', window );">RPI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward', window );"><strong>Sale of Future Revenue, Liability, Noncurrent [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_SaleOfFutureRevenueLiabilityNoncurrent', window );">Proceeds from the sale of future revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_SaleOfFutureRevenueIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,463)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue', window );">Non-cash royalty related to the sale of future revenue</a></td>
<td class="num">(2,700)<span></span>
</td>
<td class="num">(4,341)<span></span>
</td>
<td class="num">(4,300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_SaleOfFutureRevenueInterestExpense', window );">Non-cash interest expense associated with the sale of future revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_SaleOfFutureRevenueAmortizationOfIssuanceCosts', window );">Amortization of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_agio_SaleOfFutureRevenueLiabilityNoncurrent', window );">Liability related to the sale of future revenue</a></td>
<td class="nump">$ 258,121<span></span>
</td>
<td class="nump">$ 258,121<span></span>
</td>
<td class="nump">$ 258,121<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_SaleOfFutureRevenueAmortizationOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Future Revenue, Amortization Of Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_SaleOfFutureRevenueAmortizationOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_SaleOfFutureRevenueInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Future Revenue, Interest Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_SaleOfFutureRevenueInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_SaleOfFutureRevenueIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Future Revenue, Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_SaleOfFutureRevenueIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_SaleOfFutureRevenueLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Future Revenue, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_SaleOfFutureRevenueLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Future Revenue, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Future Revenues, Non-Cash Royalty Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=agio_RPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=agio_RPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518134325992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense for options</a></td>
<td class="nump">$ 41,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period to recognize compensation expense (in years)</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agio_MarketBasedStockUnitsMember', window );">Market-Based Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense for options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember', window );">2007 Plan and 2013 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="nump">10,680,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agio_TwoThousandAndThirteenStockIncentivePlanMember', window );">2013 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance (in shares)</a></td>
<td class="nump">2,919,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense for options</a></td>
<td class="nump">$ 77,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period to recognize compensation expense (in years)</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agio_TwoThousandAndThirteenStockIncentivePlanMember', window );">2013 Stock Incentive Plan | Performance Stock Unit, Not Probable of Meeting Vesting Criteria</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense for options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation expense</a></td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agio_EmployeeStockPurchasePlan2013Member', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance (in shares)</a></td>
<td class="nump">471,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under 2013 ESPP (in shares)</a></td>
<td class="nump">120,293<span></span>
</td>
<td class="nump">77,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Opportunity to purchase of common stock (in shares)</a></td>
<td class="nump">836,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_MarketBasedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_MarketBasedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agio_TwoThousandAndThirteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agio_TwoThousandAndThirteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agio_EmployeeStockPurchasePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agio_EmployeeStockPurchasePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518134659144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Summary of Stock Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock options, outstanding, beginning balance (in shares)</a></td>
<td class="nump">6,201,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options, granted (in shares)</a></td>
<td class="nump">956,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of stock options, exercised (in shares)</a></td>
<td class="num">(339,284)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of stock options, forfeited/expired (in shares)</a></td>
<td class="num">(448,901)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock options, outstanding, ending balance (in shares)</a></td>
<td class="nump">6,370,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of stock options, exercisable (in shares)</a></td>
<td class="nump">4,067,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of stock options, vested and expected to vest (in shares)</a></td>
<td class="nump">6,370,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, outstanding, beginning balance (in usd per share)</a></td>
<td class="nump">$ 58.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, granted (in usd per share)</a></td>
<td class="nump">49.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercised (in usd per share)</a></td>
<td class="nump">19.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, forfeited/expired (in usd per share)</a></td>
<td class="nump">65.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, outstanding, ending balance (in usd per share)</a></td>
<td class="nump">58.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercisable (in usd per share)</a></td>
<td class="nump">61.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, vested and expected to vest (in usd per share)</a></td>
<td class="nump">$ 58.85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518141349944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Summary of Unvested RSUs Activity (Details) - Restricted stock units<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares beginning of period (in shares) | shares</a></td>
<td class="nump">766,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">829,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(258,461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(132,805)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares end of period (in shares) | shares</a></td>
<td class="nump">1,205,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Unvested shares beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 63.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Granted (in usd per share) | $ / shares</a></td>
<td class="nump">50.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Vested (in usd per share) | $ / shares</a></td>
<td class="nump">69.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">58.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Unvested shares end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 53.77<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518051897512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Schedule of Performance-Based and Market- Based Units (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agio_PerformanceBasedStockUnitMember', window );">Performance-based stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares beginning of period (in shares)</a></td>
<td class="nump">218,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">20,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(78,920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,616)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares end of period (in shares)</a></td>
<td class="nump">142,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Unvested shares beginning of period (in usd per share)</a></td>
<td class="nump">$ 55.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Granted (in usd per share)</a></td>
<td class="nump">48.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Vested (in usd per share)</a></td>
<td class="nump">54.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Forfeited (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Unvested shares end of period (in usd per share)</a></td>
<td class="nump">$ 54.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agio_MarketBasedStockUnitsMember', window );">Market-Based Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares beginning of period (in shares)</a></td>
<td class="nump">42,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares end of period (in shares)</a></td>
<td class="nump">42,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Unvested shares beginning of period (in usd per share)</a></td>
<td class="nump">$ 41.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Granted (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Unvested shares end of period (in usd per share)</a></td>
<td class="nump">$ 41.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_PerformanceBasedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_PerformanceBasedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_MarketBasedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_MarketBasedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518052077304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 18,407<span></span>
</td>
<td class="nump">$ 18,588<span></span>
</td>
<td class="nump">$ 58,527<span></span>
</td>
<td class="nump">$ 55,243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">11,289<span></span>
</td>
<td class="nump">11,552<span></span>
</td>
<td class="nump">34,395<span></span>
</td>
<td class="nump">37,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">6,538<span></span>
</td>
<td class="nump">4,917<span></span>
</td>
<td class="nump">20,450<span></span>
</td>
<td class="nump">14,708<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agio_PerformanceBasedStockUnitMember', window );">Performance-based stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
<td class="nump">1,866<span></span>
</td>
<td class="nump">1,681<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agio_EmployeeStockPurchasePlan2013Member', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="nump">1,035<span></span>
</td>
<td class="nump">1,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agio_OtherStockAwardsMember', window );">Other stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 274<span></span>
</td>
<td class="nump">$ 781<span></span>
</td>
<td class="nump">$ 719<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_PerformanceBasedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_PerformanceBasedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_EmployeeStockPurchasePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_EmployeeStockPurchasePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_OtherStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_OtherStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518051982856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Expenses Related to Equity-Based Awards (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 18,407<span></span>
</td>
<td class="nump">$ 18,588<span></span>
</td>
<td class="nump">$ 58,527<span></span>
</td>
<td class="nump">$ 55,243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">8,742<span></span>
</td>
<td class="nump">9,860<span></span>
</td>
<td class="nump">28,464<span></span>
</td>
<td class="nump">29,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 9,665<span></span>
</td>
<td class="nump">$ 8,728<span></span>
</td>
<td class="nump">$ 30,063<span></span>
</td>
<td class="nump">$ 25,274<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140518134450280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share - Common Stock Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">7,588,924<span></span>
</td>
<td class="nump">6,932,789<span></span>
</td>
<td class="nump">7,588,924<span></span>
</td>
<td class="nump">6,932,789<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">6,370,245<span></span>
</td>
<td class="nump">6,185,935<span></span>
</td>
<td class="nump">6,370,245<span></span>
</td>
<td class="nump">6,185,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">1,205,478<span></span>
</td>
<td class="nump">733,100<span></span>
</td>
<td class="nump">1,205,478<span></span>
</td>
<td class="nump">733,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agio_PerformanceStockUnitMember', window );">Performance-based stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agio_EmployeePurchasePlanMember', window );">Employee stock purchase plan shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total common stock equivalents excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">13,201<span></span>
</td>
<td class="nump">13,754<span></span>
</td>
<td class="nump">13,201<span></span>
</td>
<td class="nump">13,754<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agio_PerformanceStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agio_PerformanceStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agio_EmployeePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agio_EmployeePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>72
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M&-3N6]3N1,MV^)QS+;66V^%P(SB(-P;P^UI*_7ABOA"-7P3/_@502P,$%
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M69*RJ@&H_V\YE\>79H#A3G[Q'U!+ P04    " !'8F51K'0<+0T#   6"0
M&    'AL+W=O<FMS:&5E=',O<VAE970U+GAM;*566V^;,!3^*Q;J0RNM!0R!
M4B61FLNT2NM6->OV,.W!"4ZP:G!F.TFW7[]C0UA"":JV%_#E^\[EX]B'_D[(
M9Y51JM%+S@LU<#*MUS>NJQ89S8FZ$FM:P,Y2R)QHF,J5J]:2DM22<NYBSXO<
MG+#"&?;MVH,<]L5&<U;0!XG4)L^)_#6B7.P&CN_L%Q[9*M-FP1WVUV1%9U0_
MK1\DS-S:2LIR6B@F"B3I<N#<^C?3V. MX"NC.W4P1B:3N1#/9G*7#AS/!$0Y
M76AC@<!K2\>4<V,(POA9V71JEX9X.-Y;?V]SAUSF1-&QX-]8JK.!<^V@E"[)
MANM'L?M JWQZQMY"<&6?:%=A/0<M-DJ+O")#!#DKRC=YJ70X(("==@*N"+A)
M"$\0@HH0O-5#6!'"MWKH502;NEOF;H6;$$V&?2EV2!HT6#,#J[YE@UZL,'4R
MTQ)V&?#T<"R*%+XZ31&,E. L)1HF,PTO* >MD%C"5@Y%F)GJV%+T42B%+M'3
M;(+.SR[0&6(%^I*)C2)%JOJNAJB,;7=113 J(\ G(@C0O2ATIM 4(DE;^)-N
M?M+!=T&-6A*\EV2$.PW.Z/H*!=X[A#WLM<0S?C/=3]K2^3_OTW_V?B1&4-='
M8.T%I^SM"^%U'=P5"Y%3]/UVKK2$ _^CPUU8NPNMN_"$NT]P,W*HK[8R*IF1
M99KK;SN\3*Z3&++<'GZ=%ICO17X<'.,F+3B,D]AOX*8MN,!+?(QKW%&FO3K3
M7J>PGW5&)5H<*7IN4K^ \V2$[5 SJGU$G6H^%= Z./L-![HRO8+.@<S]O"6,
MDSFGE]!J+A7A%"FZV$BF&6T5OW34.Q*_*>FX!82CANRO,6'D-R1_C<%1T&O7
M.ZZUB#NU.*[=4S46M]18DO1P(]$6F*FQI%&+DQ8<U!ANVINVX (O"J_C1L[N
MP46?4[FR'59!%6T*79[I>K5NXK>V=S761_[-V&]9GT#3+WOT7_/E'\,]D2M6
M*,3I$EQY5S%\'EEVX7*BQ=JVF;G0T+3L,(,?%RH- /:70NC]Q#BH?X6&?P!0
M2P,$%     @ 1V)E4>J;$QJ?"   6S0  !@   !X;"]W;W)K<VAE971S+W-H
M965T-BYX;6S%FVUOVD@0Q[^*A4ZZ5CJ*]]'K*HE4'J+KZ1ZBIKU[[8(3K!J;
MVB9IO_VMC</BW=DU4+A[DT R.Q[OP_\W,X:KY[SX4B[CN/*^K=*LO!XLJVK]
M=C0JY\MX%95O\G6<R?\\Y,4JJN3;XG%4KHLX6C2#5ND(^SX?K:(D&]Q<-7^[
M*VZN\DV5)EE\5WCE9K6*BN_C.,V?KP=H\/*'#\GCLJK_,+JY6D>/\7U<?5K?
M%?+=:.=ED:SBK$SRS"OBA^O!._3VEN-Z0&/Q=Q(_EWNOO?I6/N?YE_K-^\7U
MP*\CBM-X7M4N(OGK*9[$:5I[DG%\;9T.=M>L!^Z_?O%^V]R\O)G/41E/\O2?
M9%$MKP=BX"WBAVB35A_RYU_C]H98[6^>IV7STWMN;?V!-]^45;YJ!\L(5DFV
M_1U]:R=B;P BE@&X'8 /'4#: 40;@ /+ -H.H-H RBT#6#N Z5>PW31O!_!F
M[K>3U<ST-*JBFZLB?_:*VEIZJU\TR]6,EA.<9/7.NJ\*^=]$CJMN)GFVD/LD
M7GCR59FGR2*JY)O[2OZ2&Z@JO?Q!OLOG7Y9YNHB+\F=O]G635-^]H??I?NJ]
M^NFU]Y.79-['9;XIHVQ17HTJ&5?M?31O8QAO8\"6&#[F590"PR;N89-\M9)[
MLPD.&#UUCWZW6"3UWHY2[RY*%L/WF3>)U@D<R:S'UWR^66W29N;^JI9Q(2=S
M)0_ZLCZ!3['WZO>\+%][[[-YOHH!][>'NY_&#\D\J;I.1G+1=RN/=RN/&Z_4
MXG4</R99EF2/\F2F43:78<IE+)=1$<M8HTI>:O[&(^@7#_M(0,NS]<\:_[6"
M/=TP@9'@C%R-GH#(R"XR<F1D!T0SWOKD>]%P$3 2[&+9!FV:,=$UF9HF* @I
M%J1K-S/MAA@%J&MU"U@AY%-.++-$=[-$G;/4;O^RWOY>4I8;N3LV\C 7+W^2
M$Y?5LNVMY21Z\FAZL_N[N_U5AA:5&HM**4)<P,&R7;#L$L%"Z\R, +GO:TLS
M8>82:HL,NL'P7?+=77+G7392-*Q!M_#D49?T+Z.&G_&W^C5T],?<B ,)Y.M;
MLL^J$VZP"S=PAKN5JGE'JI)&H[Q7::U84+R!&8D\9]K)Z#'J1"MVT0IGM'_*
M-*N."@I*&-<;AL0/M%F\[37K!!;N @N=@<VRA4-%_XB*G6Z%T($+ 17E+)1*
M"H>%?(5V_YC #@AFW'KL' OL8Z:K:&O7D=%0V[. +[EI!0EU'04,AU10;?$@
M*X3"($"VB=K+@="%4=A>X' 6(H5I="RG#Z$A,N$,XK"U<_(0\ 4#$3"$B B9
M.9&(5.: W*F#2R3:H9W+$C]$V*+Z2)$8N5'L5H#[>"W7RK<K #*9RX0( A[:
M=K;"+G)SUY2 OFC&R"0CI0*'2-\Y)F--"3!]R3.!&#9V#G!1;BB :31$%)&
M,<L\*7 C-[E[%:!7QI&)Z!X=5YA&;DZ#"M OY2:$82D/#EA' .BPE)N&D)0#
M5FXI5TD"<F<)%\J*D9DZB)!PV[Y3J0-RYPYGS(N1F4C@(/#UE>RQZI:2*M7
M[E3CE,P70_D!H]K^G/::=4-6T,=NZ)^4_6*3\V&@;>]9CU$WWKURW9T'N-"&
M(:+ZH3#0>X!A-SQ%7NPFKYN!OVTR-P.Q"6<F AI*7%@B4W3&1]'Y@&C&&" R
MP3S0M;.U<VHGX*M6S@#Y^K8!2N_0UQ?0-!HB6</(;-,R3RI7P!>IT?ND$P,Y
M !;,MV@G5LS&;F:?43NQ"6^",=-7LL>J>Q\*[]B-]Y.T$P*R3!KUB/O,NB$K
MRF(W94_33J#\QEP_!&ZC;KP*L]B-6:=VFD24DLA10/2CUV_8;7<J>I*C"O5C
MZP=B$M)=/Q %2>*&Y GU S'I!]8/K9U3.P%?</T 7=2H'P C=_U %)S)&9OI
M\")"!3OU95UL"VZOG?Z#_71X'4TB<^HS+/1UA!KO^CJ:OC!BG'!C'0'#O:YL
MNXY (8\8XO:I4KD"^5^:ZL2D-A%"8$O>312SR7_65R<FIQGE3%_M_LXZ[,B2
M_Q*%>W+^YCH!^N8AUY.J::]9-V1%=G*!!CN!BF/]U,WZK+H1*["3TYOL!$ S
M]3'C^O'LM>L&IRA.SM1HK\\5< A-?G,1B#"TI7!4 9S^0*<=C&9,H4X[PZ&&
MP DU.^U<QR3@"R,A)5%_+@,8ZM7K+6 CU;46:TLV054V0<_89P<I24V$NRE)
M%<+I#_;904I2LW\.4A*RTRE)S10 IB1D:% 2,')3DJJ$@KH3BLM0<DQ-KA,2
M8F%!!]U[4NZFNDO5J%G"#S&6Y;GM\;QB,SVJ]V[/ZF&YHL 3ZA"%PN>VR!1*
MJ1NESJS>(E<F(JGP*</Z/N<'R)7I"\LZFA$=<H AUP_#+6 T1 %E EEH2!6_
MZ;&-]V.90X$FO)LY"M74C>J^IP*6=33A#&-''+".IB\+=DQ#$SM UN#&CLH;
MZ$6:[+V?E %:Z7)Q;:U4IK()YLXFSOEA&:!YSO5#.^VSZMZ'PCUSX_Z4C)V9
M@,<^)7K&WFO6#5DE <R=!)R4L3/@^3CCVB3/^JRZ$2L6L].?>#.@4 Y]:GPN
MIM^N&YP"+_N1!^-[;7A8/9E9-LNJC D>6FH)MO=YM&,?C/=%,V9 7<N$62(S
MLT0VI!/PA;%/F*[#,\ 024W4%Q!Z,LXI%R2T3)3*%=A%NNQ]XLF DIN$A%L>
MZS'%;.9F]CG%TX0W8<00SQZK[GTHO#,WWD\23Y.A2%9'^A/57K-NR(JSS,W9
MT\03Z*J'>N]]UF?5_;BF(BUWD]8EGARH@T,1!MH)O>VWZP:G\,F/ZKT?6S]P
MH%1VU@]<49*[*7E"_<#-^A>L'P [0SP!&[A^@)P9]0-@9*D?1GM?LZB_=B.3
M;9F"EUX:/\BA_IM SG6Q_2;+]DV5KYMO7GS.JRI?-2^7<22UJ#:0_W_(\^KE
M3?UECMWWB6[^!5!+ P04    " !'8F51?M7FX5X'  #\'0  &    'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;)U9;7/C*!+^*Y1O:^NN:CT6H#?/)JG*9&[V
MYL/>IB;[\AE+.&9'$EK R>1^_0&2A2,0\=V71,)-Z^FFNQ\:KIZY^"H/E"KP
MK6TZ>;TZ*-6_WVQD=: MD>]X3SO]RYZ+EBC]*AXWLA>4U'92VVQ0DN2;EK!N
M=7-EQ^[%S14_JH9U]%X >6Q;(EX^T(8_7Z_@ZC3PA3T>E!G8W%SUY)$^4/5;
M?R_TVV;24K.6=I+Q#@BZOU[=PO=W:6(F6(G?&7V69\_ F++C_*MY^5Q?KQ*#
MB#:T4D8%T?^>Z!UM&J-)X_AK5+J:OFDFGC^?M'^RQFMC=D32.][\P6IUN%Z5
M*U#3/3DVZ@M__A<=#<J,OHHWTOX%SX-L4:Q =92*M^-DC:!EW?"??!L=<39!
MZPE/0.,$-)^0+DS XP1L#1V06;,^$D5NK@1_!L)(:VWFP?K&SM;6L,XLXX,2
M^E>FYZF;.][5>E%H#?23Y VKB=(O#TK_TZNE).![<$?D 7S2*R[!&OSV\!'\
M_;M_@.\ Z\"O!WZ4I*OEU49I-$;GIAJ__&'X,EKX\A;\S#MUD."?&D']>OY&
M6S&9@DZF?$!1A0^T?P=P\@- "4H">.XNG@ZW$3AX\BRV^O""OE]Z*HABW>,0
MJDPQ*B-JTTEM:M6F"VK_K5.[X3+H\&%F;F>:_'VZ62.T+2"^VCR=.R(@AY,M
M1&B2>P4MFZ!E48MOZS]UP Y1H[A.\HIW%6LHZ$;,9M0\5R:>CB;H= CQ@)_>
M1QR53VCRJ*,^4EW7*D:&:M'5@+1<*/8?.Q#RWJ N._-*@9-BYCI?*(<H#?NM
MF) 64:0/BE=?UZ88U:#BK:[0<D!-OYEG&@);>#BR,D-SM &I#*4X#+><X)9O
M1B"I*D$M1ET>M)];=FRMDVLF*WZT=:/3J_M$QX (V5!ZZ&"&X,P$7VB-BF(A
M4K>3"=NH"3\1$WB=0=MS29K!"A.)ZL6:0?\ZLMX #^'>>I"2&6A?(LWS,&28
MN$J=Q/W.N[7-')<Q#=5!$PN34>6K>,VW<Q^'I' *%P"?40N\###K%!4Z$DY(
M 9&2F]34 ?_,U &H P5Z&:A9A_U1'075U>.)=L>P4= /'%C"<FZ5+Y8LF(2<
M2>@RDP1_(8T.EAA,Y(=N>N[6$:8OM@3340^,<\_=@72/5,[*JY14YZ4)[X:1
M'6O>++70D1*,L])M-6:]+KF4/9%=0W\PI3[HE]3W"TP2/"]>(3F4X"7G.):"
M612KWO$U9,?%4&,=8/#]WTH$X8]ZJ+&AV1-=#H(69#ZR8IO-\?M2^1)50,=J
M,$YK;Z+G.IE$$+7/7>L\G8,.",'M=@&U8S@8I[@O4[K\'][V60QMDWG)#4BM
M\6+1=5P'XV3W65-8I[@((PN04YJD'K20V+9<"F1'8C#.8O>"]H35IZHZI+9=
M?MTY"*%QVY'.U*S3NZT!05M\SEKG"9YO'4-B6&\JPK8@1VXH3FY3 >G)BPF/
M$$3DT]2ZR#UW!\10GBZ$,')LAN)LIA&*(W7>#B(,,%..YOA\H31/ECSHJ G%
MJ>DCW5.]R/6)DBY/,!0@JAQF7ML0DD-9N>A:1U<(1Z'_,MO0G-%3$"\.X86>
MGP-B*=PNI!UR7(?>[L#>[&""N$.$ED+L1TA(L"@2N+ E0X[[4+Q%^VQWY!<W
MI<C1$HK3TOU15 =BBI#>PK5$?*7*5GE)=>E9]DB ;5*<G-/DZ)$@+:7E4LN*
M'#.A.#/="UY16DNP%[S5R-4(UY9.LR?]'RWR:2A-R_*,B$:# G)%CLLE>QQA
MH3AAO5J(RWL:%. HB,NM%YH!N0RGQ0)LQV4HSF534FG(3ZS6B;5[&?O'"Q(K
MT&_AS.,%7PH5.8(+[3!VW(63:%)]8AWIJHN3"CO*P7'*N2<OXQE<!_;31X8:
MR7<->[2;P*!+L$\RNE;/71*06BB/V/$0?J-%TBO9OTHJ:<XW=)4<SS2HJ-AI
MMT+;ON$OE(XR_1B\H&](\(P&^Q0$DW-R'^T*B*$DR19L.SO2BQ/5ZV*QW+7:
MWL<,,RF/>MDHJ+@,[[NPSU)ZG3*O&PK(+2V58S)\(9.=)]W^S6@>@?LDA?)D
MB^>5+B 76PM'93C>QEGPML\U'&S-,!%E'TRI>](KLW#PA/W.#.&M1SH!,;W+
M2!9J'79<B=]HX9:P J+ CCZRKC/NU^%C(DP7<,;KH!D^*99Z >8'# &Q(LF6
M-IS8,2>.,V?4#&I:D3<-\$D0)FF9S3OI@%P)BV1AWXD=5^(R6K@?CGW?V&L.
MTMB3RX9+D\4:>.?.KB8.TB:YY%""=))4@0+\&HQC0!QGP-NZ9E:;.24/$[<)
M=#)KE(:C[0MZ$^S3'RP]3P<X,BD7')TZADSCW5UD@P^(8-+\8DLJWRG"ANB?
M35GN7,=OY\'*.%YX^"(IPM[F<7-VC]92\6BO%R6P#A_NH:;1Z0KSUE[<S<8_
MP/=WPT6D4S/<B_Y,A,YOJ8W::Y7)NT*[6@Q7C<.+XKV]K=MQI7AK'P^4U%08
M ?W[GG-U>C$?F"Y\;_X+4$L#!!0    ( $=B95$BJ!R'B0H  .(:   8
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MH/0(T#-X;;0O'?RD<\P?ZT_(J-ZRM+/L.OTJX"W68YA/$TBGZ?0K>//>TWG
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MXU(*Z,P7<#[7VFT7+&#W6>CF/U!+ P04    " !'8F51G">KWH8"  !'!0
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M%R'58$W@I.9+>?263B79^>4O2"FY>=^3+Y;T\X/=;6N7O6$W@T]&^]+!C[K
MXGO[/F'H@&1'(+?918>/6/=@D,20)5ERP=^@2VP0_ TN)@:_WZR<MW3W?USP
M.>Q\#H//X3\FZZ(=%]:UJT6.BX@JQZ'=8G0$^+FA9]5(54B] =7*A$7(355;
MZ;  LZ:_M<P1A"Y B96QPAN[A^ 2&KH "]KH#[G0.=*Y0J"B):5GESWXM:3
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MX<5TXH'JUT%O&-DZ">ZD(4&[8T4;%)4-H/M22G,R;(%Q)Z]^ E!+ P04
M" !'8F51X:0I<8P(  !&%@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6S%6%%SV[@1_BL8W<V-/<-8(B5+5L[VC.WTVCSDSI.DR4.G#Q"Y$M&0! .
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M"X &SNP(N(!T3<8K=)5BQJI0&^F";!9^T]:(E<5S T+A>##=KE5P':L"QS
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M ?_O8HUWK@&" $<65A\0\C6R;V*[KK 7/FR5&E5[ZYEI-M #G!-D2VQDW99
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MPZ&04/SQL?CA3S?3Z?()Q:<5N)12+!ZS&7>HE>2N8P,M.QQE7E^1;(!3B-0
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M+H#O"R'T\((;C+^N7/X/4$L#!!0    ( $=B95$H*8!#5 0  &T*   9
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M1BN+&&( &@'N?XE*CA8):?C'P,MQ[2R<S'8MOOI@.N=[PCRB4>KRXO3?=X(
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MU=)2Y-:;FD968P.I.HC8J>E7Q)+*QE5&<%F]'!E\YZ;49F%3V+8;^O"]M,
M=FZU*>"[H=U]6M+-J#EU*VWH(^^D$YB&>BGA)_4K_5>7ZJ]_>7IU>?FS^M@*
M>X527P='_SIO*RGRY5I#:CJP.6P-&W#?)W8-"5K+IJ'(O\KR_W-#*(D(P-9&
M^P-MQ]UY)[N*)8UR3XC8H8R:2'^,K!)+&-['V6*3 XVTB>@V3(FV1MSI4YN.
M-W5*DZ1VN>QU6O2CPJ@[+A)=TPGJ/L>.G<?RTQ@F'4HX6]E.<[W.YRT#QR5;
M)9&67=WHB=Q:]%R!XN.>[&!G= 8V23.P^<K3T3W"(GU<CCM+ZI@CH/,L@\ZS
MHUCQ;@2#\1!F'^0<%_.>CZSWX@I67S58%)"#-F_8UT3H!D^9@^&5,.418<K;
M]M[$D^OLX=>4T/B(2%J_Q<'1)(-^F;=*3/O8(I<VG TXL?##^8B+$R:=X+C6
M2!<9E9C4G(0<S $V+T=@J%N:1+H?<E*9#L?+:PWE43DO\\G/96-[2Z?>]=Q$
MWKFD<5R+K9L4.\,GL0!,!MHP5BSZR5KI$$(.?<>V X9#_^B[QP_LKQT)W\N+
M\;+3Q='(NXV).7*JO?>8CDOX3/$*M/GM[:N[]Y_>__4OET]^^'FR>^@7*<"$
M.8"B!@VSQX%[1>1(D$S+9)C2D;?3H7>Q?SQ^U2VT7^IJ3=+N+?F<D;/"/(FB
M"CN[20UHR3'Y+6,EX@,&94ZUJSKI%Z>Q0K*AC]0R&8/I$:1Q:4R\I?)<#B7H
MBZP]EWS@\F9L5XYZ,+\VQ)B)-[NRC(F/+A __:*BL,F+96N UI-A&)GC-QQ.
M<Z)B+4DX71+EX*.*MC['5T#;>[QOUJ>MF3OD":Z!S%28?H75SO&F^B(3$%67
MXSM6!$;JC' WIG(H<!9:3B(W#">6!K7CDPO:M Y,92[D_ ![W;0\8#[@\2!0
MQXTX8>,VC(5'C; R[8:3,5'/B$1UO7?-%NM,74$'0/),U;3JG(T%OUW2P=NZ
MB]4BMUMJTR"6Y)Y/.1%UH>+)$EG\DT9)18!]0\2E3DV##^GXC$O#1'WYD&H'
M8/D"CDG?,E>0L_JB;Q _W;BN%#;KR/ND2;6A"2DIP\83,2E!(XE,9N:C)U:7
M3:CE7&3C\M,87F/D>(/B(U;$\;0S'[:--,=QO5F/S5Z39XDA1F!1;(U]H3])
M<3_.E6A0<=I4=MO+.*,)HB.H0U^L\7I<(]6+XRV4M+5&Z&!5\^8HV]IX%LR'
M-"R_WSQ\'.V!HH?N4_;I]EBM=JRRFXLW^\3C(6T:*RV/C5Y,BKR]NV@#MU(K
MRU!"DU"D:3?OT>6K7AL(1V$E))FC)YZ1%/![4Z +'QX8LPTSWL2[FUO]C!$_
M4L^-#X:VP[2B:R[1A531&^E:L+/I@Z]X2.C3?DSM$T>'J]+QB?0+0OY*,)+Q
MJPB(A1MS0L;%LMYE70>R0AXDDNBZ1:*LJ2%3F5Q[K1:"#=P9R@\FJ:GI1@;A
MLRI:<KPE59D4^\>7S6@=S XP1-,7+<74,Y."43J)DU@12G-:<>[B.[A@)I9P
M"$4!L;LBZC'S-#+RTQ5?#2_NOHT3TP%NB[)D:;_E75#BE2UNBN:8U_U&X.\-
M^$D10K;=WDU;>^5,_6V$NP\"=^5'$0'S':AWAKJ-'BC]F[<W_(*4EX]MD6L%
MC5?CBO__+,UX2G;>&PH9>?8:_/_6UM0G'"VXBA<VLX4X1V:>F(A7!CY,57DK
MYS"U'^;  _@)L(4RI8LI$+LP]3,=R1^A#_@Q5HI"PTEJ4D?=HH15KTGGN==+
M(@"2\CZ;307'VS.;"3]?WN!S0AHK)T\W&S<D8L.)CPRRV'\"YD/KV'\'8N6)
MQD&DWT9?XX'12;&9ZE+*RU@<V!-EC#)-4A:^MPC;5.1'I+(H5?':KXLF8ESB
M1JZ)V'"L<+\L?N9Q>?P8BLH^6%#= 9#W%S['!= /#RHF;TT2%19:NA7@DE4L
M?:?$"8"YM*C\<#QZ3+OS5,>(90&!]C2?0]*8>O#)!>+O"1,1ZKKLDCU*A924
MJ2@N.Y=GZK5M!BZX'J"O\+XT:X:0(TJ.J0RS$(F(9\Q2+>]5:>_XM,+:4/.*
MSZ/'"*1>?AC\.LJ2"!3T0/(%((Y7B;(>>Y:;ULJ\1T3)X2K@^</=1_R]Q5_!
M;WHQDNA^J[X9V\&*>BVD9[Z?)G?+NK$J'8^?:RH)ZPC334P55Q>7C]0O=[>W
MR;RL:G1P/@<[9$Q.+-AZFYHS8?W3"L?+BK%/N:7T]D\;4,$]OOAYYT+\@Q>P
M=T^?%[_BXJMO]%LUJO* M/*#KOQI_CW<M?P*;'Q<?DSW#J2+*L3&S##TXNS)
MCR?*R^_3Y$WO.OY-V-3UP&5^"=H$U>D!?#]SKD]O:(+\*\&7_P-02P,$%
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MZ-W]NA.L6OL[;:XLWI#^N,)/$JF= ;Y?*&4/@DMP_,B9?@-02P,$%     @
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ML@HG$?6B1?.$T71F/0_5SZ%<T%W;(L;0[3/*#:/I&:L]QBXPJK>,(C#&0!,
MD%6-O\0U" J?'2RII^ %F;' 5 U.>TDZI0&Q=*2U)@N8I6!!_6\OX/A*T;GN
M++G;$RJ4GQQ<K0(I'$$>%\/2+S+(RK@X2[V=0S:,1Z/"VP5D9W&6#[U=>GLX
M##X#R,[C03J"^]?;2Z\P>/N)#J1_!%E1QMGY *[(E>KJX#@?Q<,\.X'O+1KF
M/&BH!PC.%EQPQS'$I<-X,"KAO7\KV>M.B6859I"%P-,WZFYW-^9F?7>_NO<S
M\IJ9%5>6$)84FIZ.!A&8?N[T"Z?;T.L+[6AR!+.A48W&.]#Y4FNW7?@+=L-_
M^A=02P,$%     @ 1V)E42R\#@*I @  HP4  !D   !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL?51-;]LP#/TKA-%#"WCU9QHG2 (D;8?U4"!HN^TP[*#8
M=&Q4MCQ)3MI_/TIVO*QH<HE%B7Q\)/,XVPOYJ@I$#6\5K]7<*;1NIIZGT@(K
MIJY%@S6]Y$)63),IMYYJ)++,!E7<"WW_QJM863N+F;U;R\5,M)J7-:XEJ+:J
MF'Q?(1?[N1,XAXNG<EMH<^$M9@W;XC/J[\U:DN4-*%E98:U*48/$?.XL@^DJ
M-O[6X4>)>W5T!E/)1HA78SQD<\<WA)!CJ@T"H\\.;Y%S T0T_O28SI#2!!Z?
M#^A?;>U4RX8IO!7\9YGI8NXD#F28LY;K)['_AGT](X.7"J[L+^P[WRAR(&V5
M%E4?3 RJLNZ^[*WOPU% XI\("/N T/+N$EF6=TRSQ4R*/4CC36CF8$NUT42N
MK,U0GK6DUY+B]&*9IK+%#.[?:,P*%5R^L U'=37S-,$;)R_MH58=5'@":@*/
MHM:%@OLZP^S_>(]H#=S" [=5>!;P&9MKB'P70C_TS^!%0ZV1Q8M.X*W9NZT-
M6)V!+9QQ!;^6&Z4E_3M^GTD1#REBFR(^19E$D[4<0>3PL;6?=?0LFA'D5#4L
MQ;E#BE,H=^@,$\/#Q%)!$E':I-0%0BXX*:VLMU.X?*CI2K2*"E970/W46&U0
MVJ;>8=H;@3MP345E4)E5S 4$$]>/8W-(W$D2#FZ&#)-I83N9X8ZTW9!2-<4K
MK2"X<8,D@3!PQ^/Q$-1(D:,R:F8<<B3FD1N/8TC<*!H=0>^P;O&+1,YTGXKJ
M[H8FJ$ )0>#Z00(Q<4O@16B"8Q^;<@'QQ!V'AOLH<H,XA,^FZQT)IT*YM>O!
M=+2M=:>AX7;80,M.>/_<N_7UR.2VK!5PS"G4OQZ/')#=2N@,+1HKPXW0)&I[
M+&B+HC0.])X+H0^&23#LY<5?4$L#!!0    ( $=B95&F8WTCE 0  !(,   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;)U76W/J-A#^*SMNIP,S;FP+
ML"$%9@CIY<ST=#))VCYT^B!L@=5C2ZXD0])?WY5L?" );GI>T'6_W?WV8C$_
M2/5)YXP9>"H+H1=>;DQU'00ZS5E)]96LF,"3K50E-;A4NT!7BM',"95%0,(P
M#DK*A;><N[T[M9S+VA1<L#L%NBY+JIYO6"$/"R_RCAOW?)<;NQ$LYQ7=L0=F
M?JWN%*Z"#B7C)1.:2P&*;1?>*KJ^2>Q]=^$WS@[Z9 [6DXV4G^SB0[;P0FL0
M*UAJ+ +%8<_6K"@L$)KQ=XOI=2JMX.G\B/Z#\QU]V5#-UK+XG6<F7WA3#S*V
MI75A[N7A)];Z,[%XJ2RT^X5#<S<A'J2U-K)LA=&"DHMFI$\M#R<"T_"" &D%
MB+.[4>2LO*6&+N=*'D#9VXAF)\Y5)XW&<6&#\F 4GG*4,\L[);,Z-7#/]DS4
M# :/=%,P/9P'!M'MG2!MD6X:)'(!:08?I3"YAN]%QK)S^0"MZDPC1]-N2"_@
M ZNN8!3Z0$(2]N"-.E='#F]T >_HXE;)$M9HJ\*40+I-#FM'-%/PQVJCW?Z?
M/0K'G<*Q4SB^Y !64%87#.067O#\%KV]8+8XKW5%4[;PL/HT4WOF+1]SQ=@9
M[X"L&59NT!=+W2^(TG<^^"# Y++65&1ZZ)C&GVAV,CM:KAK+?1#8*KZ&4>0G
M48R3*/''A.!D&OFS),+)./3)-($>!B<=@Y,O91!6!384*E(&:#ON.DKT6\3V
MZKA$+.:)M!JXV(&Q-='V+?X/T]@'"JM9.]6NL7#S#%P HVENC34H7YT3!_3,
MX%85I-2PG50<P;#%.D%A@U8V06-O!,W&YOIEZ(X)7=,"5ME?F-#8.HV&'^6>
M*6'GR-$&E6D<3:V$AD=I\/)-XPM0 [<L;;5$?A-\C&HRMD'V(]*,R6QJHX]C
MC&6CE 5&3_?<MFF-;A74.,XD:(J=Q+)BG4K;N\^,*H@P0^((9CZ9S1"3(!8)
M_>DD/C/]%*M2'-FQPAH&HR%$F'*#<1(/<35)AG!'GYU0H%KGWF?(8.K/8@M"
MT*!P"-]\-241^0X&$5I%XO^#>V9A/$$;!W&2G$+ZHQ&J..'[=5@=Q9-HA&/B
MQZ&EFOAQ9$>T*!G-^JHJ[JHJ?G=5':OIWKK%^NNH%_5"';D4:RO@6]4J:8^Q
M?#:8G3XRF!:US7.D4M8*4HE9+S1NX$S+@F=.K*TZ<%\[[0-5)T6)=:C;DM6O
MBN.<Z+,TOV>V2.T# =F@:2KK)O52QO>N[#$2(]O>)N,0BZRLI+#9TUQ6->IE
M3Y4U5ML(A6&"M4$PD?_#\RZ>QUKJB6O2Q35Y=US7.16[)CF[3]U*:^3-=9^?
M.=WP@AML._Y[ODV]BM_?0MVIY3?];%X;\,9$VIB8U<H)?6DS/(OP*LNX<<WI
M]AAK_0)D_4+_(!K"ZG4N'+]]V#0F-B6BD/B3T/;%P8SXXQBK'3?Q=/IVG08G
M[S1\;>S<:Q3)L'J:)UNWVSUX5\T[[_/UYK7\D:H=1S\*MD71\"K!CYQJ7J#-
MPLC*O?HVTN#3QDUS?+0S92_@^59*<UQ8!=W?@.6_4$L#!!0    ( $=B95&:
MRN/W\@4  -,5   9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;-586V_;
M-A3^*X17# Z@QKI9MM+$@)-L6(%U#9)T>QCV0$NT3502/9**F_[ZG4/J9L?6
MLG9MMP>;I$B>\YTK#WF^%?*]6C.FR8<\*]3%8*WUYFPT4LF:Y52=B@TK8&8I
M9$XU#.5JI#:2T=1LRK.1[[K1**>\&,S.S;<;.3L7I<YXP6XD466>4_EXR3*Q
MO1AX@_K#+5^M-7X8S<XW=,7NF'ZWN9$P&C544IZS0G%1$,F6%X.Y=W8YQ?5F
MP:^<;56G3U"2A1#O<? ZO1BX"(AE+-%(@4+SP*Y8EB$A@/%G17/0L,2-W7Y-
M_4<C.\BRH(I=B>PWGNKUQ6 Z("E;TC+3MV+[$ZOD&2.]1&3*_).M73L)!B0I
ME19YM1D0Y+RP+?U0Z:&S8>H>V>!7&WR#VS(R**^IIK-S*;9$XFJ@AATCJMD-
MX'B!1KG3$F8Y[-,SD":C"R&IU5&1DI]Y CIG9+Z2C('ZM2+#>[K(F#HY'VE@
MB1M'247^TI+WCY"/R1M1Z+4B/Q0I2W?WCP!J@]>O\5[ZO03OV.:4!*Y#?-=W
M>^@%C?R!H1<<H7?+'EA1,G++$K$J>*.%:[9D4K*4U M^GR^4EN!$?_1P#1NN
MH>$:'I,"8BLM,T;$DNQ:H&)W2-.])#%XS]2&)NQB -&IF'Q@@]EU*7FQ(GK-
MX ?F-*(5L)/DUBP,S4) J9KE"R8;S9J%ONO%#MDR"#ZCG(^P%$DM ;'8(N%D
M![NTV,_(O>'5M?P>BU\00L_\\'4!G$2I (8ZL8@03:=W!Q*"IRJR81)SD\%&
M-<"5#'!!UD@9VJ^:ID4"VEYD?&6P*D(5*A_%R47*ESRQ,J14 \VWQ<N50 %1
MDU0F:Z./%.3+Q 9C@JB:_0OBQ3'\ATX4CZ&-0L<+ NCXL1-[XWZ<A="?C?5*
MY#F3":<9_TC;3 >N#).>X[H3,O4]XCNQ.X;_$-#>"TVSP\8C+Z&7 6% 0Z5^
M1/D<WXV@'3MC#]MHXKC!%#H!4/-"TA,/XR8>QL^/AS4M5@"=%R!:84*.S)5B
MD(=L>J(+GAGI#@5)+Y_#07*_X](:4QTQLYCZDA:-*"4:RR*B+:*L1432-N">
M$V9G^YY^S9)JA>>0>9IRZP#7H)W$=G>)7.WAN=JS:<+X@Q'H^^_ ";Q7>\8=
M>B?&P./ NK#OHUV'Z,N!G7$G(7E7@'P9;.K0VW>3H7]B>?BO8%<$#C,,PN@$
MG2=RR:UXI!FL^GM P!8]U05O<R%ZAA,,HI9T(V]7Z4VNKGWX(&T'CE-8!;%K
MDB#4.^!L]:>-D%:]P_"$1* 0+\!8@;@91H$3!V$+ 7766D:+)W%4BZB>*,F.
M< _-18GN52D6OD!ALF(%>J*$=3Q?E%(9125":?0_ S4EBT=2[OB99 8\C"!]
M<)&>=KT%"'<!M0 0=%48@1JZ:WI)HYD/N,-346L!6X[+4I>2'9*ME?[4.,".
M=N43U_DTO7XSC85[ J7[WGI<FOIHL)ZUE"+_Q^*TQ)[P[9SJ5#5?^PE_X7IB
M!X=509M_<6FR'_^/4)-G>&"JKU-VS"L'@WC,2J1P'!@<\CBS8"M>%"A==89;
M94)VK3,*9M[0#?%HM9D'BH>I,_4#<G.D(%#0JB6W[.&L>N  NB*L&KK'VIX#
M.VH.[.C9!W:=W'M*UUYBWZ9T15=K4LM7K%MO=YD>.0?!%:;&#YPHPIIKX@1C
MVXZCN,^ D\: D\^[@4":A\Q#KNZT*#J7P4/6[>7T'[J8D)<"5LG_V_T$4@TP
MKPO^YGZ.BC#R=.\B;4H9>JXMX6*_&?V[=Y$]7&]WL7B.YWID[&,=-8Y#^ _@
M_M%_\[#BO*CV0EH$96(,3*:1:4&[?;X_;7Q_^@5N&\ZS8J&?\^=<-;[UU0+K
MWJ/7BZ[M8G.)J*TVA([OV\M$#+YXH'S>Y?.TF.OPL360L<-^U7:<SJ=5;H<<
M;=1Y:(-+]\H\)X+E$*=]<VN^-B^6<_M0URZWSYUOJ(2Z0)&,+6&K>SJ!FZNT
M3XAVH,7&/-LMA-8B-]TUHQ"<N #FET+H>H ,FG?<V5]02P,$%     @ 1V)E
M4:[V*MW0 @  608  !D   !X;"]W;W)K<VAE971S+W-H965T,C@N>&ULE57?
M3]LP$/Y73M$>0.K(C[;0H;82L*%-&AL"MCU,>W"32V/AV)GO0F%__6PG9$6#
M:GMI?+Z[[_O.]EWG&V-OJ4)DN*^5ID54,3?'<4QYA;6@ ].@=I[2V%JP,^TZ
MIL:B*$)2K>(L20[C6D@=+>=A[](NYZ9E)35>6J"VKH5].$5E-HLHC1XWKN2Z
M8K\1+^>-6.,U\I?FTCHK'E *6:,F:318+!?127I\.O'Q(>"KQ UMK<%7LC+F
MUAL?BD64>$&H,&>/(-SG#L]0*0_D9/SL,:.!TB=NKQ_1ST/MKI:5(#PSZILL
MN%I$LP@*+$6K^,ILWF-?S]3CY491^(5-%SN=1)"WQ*;NDYV"6NKN*^[[<]A*
MF"4O)&1]0A9T=T1!Y5O!8CFW9@/61SLTOPBEAFPG3FI_*==LG5>Z/%Y>"X5@
M2CAON;4(5WB'ND78NQ$KA;0_C]F1^- X[P%/.\#L!< W<&$T5P3O=('%T_S8
MB1L49H\*3[.=@-?8', X&4&69,D.O/%0\3C@C?^KXA%<F0>A^ $^KY1<B_!D
MOI^LB*U[.#]V\$X&WDG@G;S$Z_JI:#ONO[F>.^B=>+Y;CZD1.2XBUXZ$]@ZC
MY4V%4!KE6DWJ-;"_1*#*; C8>4(+2,?K)'C[F9))ZAR#TQ6N272]XS>;L.+*
MFG9=@;L5QGJ%=KB:8]B3WF]:$KJ@_6="X-*:'+$@**VI POUMU%VMV'[]_<*
MLNETE"0)?"!JA=>4&V*"O<EH<CC>AT]&O\X%56#[&BPJP5@ FUVX+GT\2;?2
MI69TI\> ]V[.D3LC(I/+ +617.T"2]/1+)W!26TLRU_=^;DH^51QFAS!1RE6
M4LE_ENG+GXW2+(7G'EZ\U>XUVG48:N3H6LU=YP^[P]P\Z<;%G_!NZ%X(NY::
M0&'I4I.#HVD$MAMDG<&F"<-C9=B-HK"LW.Q'ZP.<OS2&'PU/,/R;+'\#4$L#
M!!0    ( $=B95%4T(EHPP4  $$1   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;,U8WV_;-A#^5P[>L"6 *DL4]2M+ CAINO6A31 G[<.P!UJB;2&2
MJ)%T'/_W.U**;'>N8 0KL!>+HLB[C_R^.QY]OA;R22TYU_!2E;6Z&"VU;L[&
M8Y4M><64*QI>XY>YD!73^"H78]5(SG([J2K'Q/.B<<6*>G1Y;OONY.6Y6.FR
MJ/F=!+6J*B8W5[P4ZXN1/WKMN"\62VTZQI?G#5OP*=>/S9W$MW%O)2\J7JM"
MU"#Y_&(T\<^N4C/>#OA2\+7::8-9R4R()_/R,;\8>080+WFFC06&CV=^S<O2
M&$(8?W<V1[U+,W&W_6K]@UT[KF7&%+\6Y=<BU\N+43*"G,_9JM3W8OT'[]83
M&GN9*)7]A74WUAM!ME):5-UD1% 5=?MD+]T^'#.!=!.(Q=TZLBC?,\TNSZ58
M@S2CT9IIV*7:V0BNJ TI4RWQ:X'S].5TR21_=X7KRN&.;7"[M8*3!S8KN3H]
M'VMT80:.L\[<56N.?,=<"I]$K9<*;NJ<Y_OSQPBMQT=>\5V108-3WK@0> X0
MCW@#]H)^O8&U%PRN=[:[7IA(R>H%M^T_)S.E)6KEKP%GM'=&K3/Z/6<80OFJ
MY"#F<"VJAM6;7Q5,M<B>X+:QJIP8519Z<VBK!XV;:#U3#<OXQ0C#47'YS$>7
M#TL.<U%BJ!7U K2A$>Q70ZNRCD6S#0=TC,,E:)Q6HWVH6O:X80]P[S6O9ESV
M!)S!YY7MP 5]M8+G^;O),Y<8OW#SPF56* YWLL@XW*ZTTJS.#1"FX3W/.EN^
ML>6G$#GX<&@2PL\0)F[DP^_( UJ$-(R<E(9 4S>AO=T<3H(@=4A"3\%/W= '
MC,LY+W#&^.:E*:0906GBI)Y_"E'HILFW(/Z](D01Q)Y#:(<"T73^[-X=GD,=
M+XJ=, QP3N2[)( O7!G@Z GX2X,9!U^T@&?L/MKO@.#"7G#AH. >Z^<62*NQ
MQ[K0@PH;M/8&A=U/'W^ L*PL -,;AP^LD/"%E2L._5J5"6EU6&-QA$IJ>0I<
M2GN%)21UXM2'T'.#GKT3$B8.C8QX4M<G6WG!B1\0)_'"4T-5X!_R?8!B'P4>
M.C1.#,6!&\=#%$<]Q='1.>6.2WLLU]EK"C>,JT-,#QI] ]-W_S>FB9\X/C5,
MAZ$;;9DFGA,1 C1Q:=H3'6.2(!ZR2=UDG^?8B?SHU$1U&AQ+,R4.(:GQ3%V2
M#)$<]R3'1Y/\B<DGKG?Y'0SI0<-O(+IJW;<G9GN"K!"$ \CYI^FC\P-4<!3?
MN.E1:I(G]=W0Z^G^Y:>$^.2W_GD<A=\8&V PZ1E,CF;0)N..0%,&8$G+[!F,
MIQ:V.<PV,%DSF</#IN'PL<[*E=FVKX5>%K7=TVN!&UFW!FHERB)G;9K'1UNS
MH9_;!O?/&#Z8 0;Q'A9&"[RE/ML%SK? F06N#?#B%?AZ"SSK@6>[P-4><-$#
MAP(I4IT:U1D\+"7G>S4E?#;RVNLY^6A\B97"XU>=MHRV.:%O37=*'X4\^YB;
MD[1MA"'!1D"=P$H@B/%T#^$>98-UC-Y3O<)C.PP2+ !2/S:IA88F_IW82_:2
M\;?1HGH]8L&#7GPGB2+\C1(?;JJF%!M<93N\6<ELB=.A*5D-6/! 8'PX7F"F
M>;$'M[BOLAMM=U\!H3Z0F$*,]F)<[H/0K&R'#-&'R\<#SXO;1IC8@PH;)+9I
M%*N38"@6TCX6TJ-C88+$9JPO40:BXI"&!_T<UG!G3>$-LF1=6:;VU&"*MMVM
MZO9TS276?SW<K2KA;=+^[\2,TN0,56*1Y_P9;]:-O;QL>4V<F!I5IR@T#Y_$
M%#;4-%(GC3 >\!J,R=Z!!:\18&E-L1POF(6Y_IB;<F\M=2*,![2(9QMF3"\*
M@* V4&X_6&;CG6MMQ>7"7MX5^EC5NKWA]KW]_P.3]EJ\'=[^N8"'Z*) KDL^
MQZF>&V/E*]L+>_NB16,OR3.A\<IMFTO.<B[- /P^%T*_OA@'_;\FE_\ 4$L#
M!!0    ( $=B95'C&583&P,  (,&   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;'U5VV[;, S]%<(#A@UP:\=.FJ1+ O0V;, Z%$VW/0Q[4&PZ%JJ+
M*\E-^_>CY,1KL*8OUHWG\)"BZ-E&FWM;(SIXDD+9>50[UYPFB2UJE,P>ZP85
MG53:2.9H:=:);0RR,H"D2+(T/4DDXRI:S,+>C5G,=.L$5WACP+92,O-\CD)O
MYM$@VFW<\G7M_$:RF#5LC4MT/YH;0ZND9RFY1&6Y5F"PFD=G@]/SH;</!C\Y
M;NR+.?A(5EK?^\77<AZE7A *+)QG8#0\X@4*X8E(QL.6,^I=>N#+^8[]<XB=
M8EDQBQ=:_.*EJ^?1)((2*]8*=ZLW7W ;S\CS%5K8\(5-9WLRC:!HK=-R"R8%
MDJMN9$_;/+P 3-(#@&P+R(+NSE%0><D<6\R,WH#QUL3F)R'4@"9Q7/E+63I#
MIYQP;O%-6PL-&EC6S"!\N&,K@?;C+'%$[DV28DMTWA%E!XBF<*V5JRU<J1++
M?7Q"HGIEV4[9>?8FX1*;8\C3&+(T2]_@R_M(\\"7'^"[8D9QM;9PTT?[^VQE
MG:'"^/,&_[#G'P;^X0'^"RTEE=G2Z>(>KIX*T5(>H#):P@4312M8*$-=P247
MK:.S_Q6]EO8WO?HW>VH;5N \HD=IT3QBM+BK$2HMZ,$1/12=,!N$X4/+'YE
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MC\>C"$S7\KJ%TTUH,ROMJ&F%:4U_"33>@,XKK=UNX1WT_YW%7U!+ P04
M" !'8F51?^2#W^H"  !2"   &0   'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6S-5EUOVC 4_2M7T1Y:J24??+45( '5M$[KALJZ/4Q[,,F%6'5L:CM0I/WX
M79LT0QM$VEMY2/QU#N>>>VUGL%7ZR>2(%EX*(<TPR*U=WX2A27,LF&FI-4J:
M62I=,$M=O0K-6B/+/*@081)%O;!@7 :C@1^;Z=% E59PB3,-IBP*IG<3%&H[
M#.+@=>"!KW+K!L+18,U6.$?[N)YIZH4U2\8+E(8K"1J7PV <WTSCR '\BF\<
MM^:@#2Z4A5)/KG.7#8/(*4*!J744C%X;G*(0CHET/%>D0?V?#GC8?F5_[X.G
M8!;,X%2)[SRS^3"X"B##)2N%?5#;#U@%U'5\J1+&/V%;K8T"2$MC55&!24'!
MY?[-7BHC#@!Q[P0@J0#)WX#N"4"[ K1]H'ME/JQ;9MEHH-46M%M-;*[AO?%H
MBH9+E\:YU33+"6='7S:H-\YM)C.8,,,-J"7,-!J4EGFG+V&<9=PUF8 [N2\=
M-W%VBY9Q8<YIR>/\%L[>G0]"2Z(<=9A6 B9[ <D) 1]+V8(XOH D2J(C\&DS
M?([K%K2C8_"0K*C]2&H_$L_7/L%'Y2#80FGFJ@O&6C.Y0BI;:[Q#GY6\3$\M
M@:_4-,S7IX$?GX@:[BP6YF>#L'8MK.V%=4X(FVF5(F8&EEH58',$PP2Z9"U+
M6VJD/;5!6>*Q#.R9>Y[9[>O-*.EV(_\;A)LCHCJUJ$ZCJ"DS^06D] 1\+OF&
M%)%3%]XJDRMM+RWJ KC<H+'>Q6,9[OPCKY\DG09YW5I>MU%>$L41C%<:?7H:
MDM"K"7MOJSKZM;!^8Z3W7)##2N*E.],R*H84*1T+JI UVQ7[K*#@*^Z&K((%
M5FLP.Y:2_I&*:2J8JUKGU7]D!'X!'> KE-A@P75-??VV<A-'?\[8J#'J![5C
MPNY NSO%@%'BF.F3BN70]1/;-#PX\-UM>\_TBI-R@4N"1JT^[0N]O\#V':O6
M_@Y8*$LWBF_F=.FC=@MH?JF4?>VX:Z7^C!C]!E!+ P04    " !'8F51#L3*
MF(0%  !/*0  &0   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6S-FEUOVS84
MAO\*X15#"V2Q^"FG<PPLR=(5:( @3KJ+81>,S<1"9,FE:+L#]N-'R8J.,ED:
M[?%"-XGU<0X/STL]>BUKO$WU2[90RJ#ORSC)S@<+8U8?A\-LME!+F9VF*Y78
M(T^I7DIC-_7S,%MI)>=%T#(>DB 0PZ6,DL%D7.R[U9-QNC9QE*A;C;+U<BGU
M7Q<J3K?G SQXW7$7/2],OF,X&:_DLYHJ\["ZU79K6&691TN59%&:(*V>S@>_
MX(^781%0G/$U4MNL]AGE4WE,TY=\X_/\?!#D%:E8S4R>0MI_&W6IXCC/9.OX
M5B8=5&/F@?7/K]FOB\G;R3S*3%VF\>_1W"S.!Z,!FJLGN8[-7;K]3943XGF^
M61IGQ5^T+<\-!FBVSDRZ+(-M!<LHV?V7W\M&U (P:PD@90!Q#:!E "TFNJNL
MF-:5-'(RUND6Z?QLFRW_4/2FB+:SB9)<QJG1]FADX\SD6D8:?97Q6J$;);.U
M5E8CDZ&?T*7,%NC7;^MH(^-BETSFZ$;J%V7D8ZS05,W6.C*1REXCYT@:5$N8
MJX3N\M-TE#RC"YE%&7I_9>.C./M@AWB87J'W[SZ@=RA*T/TB76=VC&P\-'9B
M>7G#63F)B]TD2,LDIFIUBFAP@DA @CWAE]WA5VIFPW$>CL_>A@]M.ZN>DJJG
MI,A'_[.G)W;2L4QFMEO%-?E)I^N5[<4)NHX2NS^2,9H::8JFVXZO\J6=H3^^
MV(SHL]V=_=E1#ZWJH44]K*6>^]38<98@759)MZ_7NV2B2)938#,1..0A'0\W
M]9[N.8V*4<BKT][4RJI:66>M]=[5%^0)+*2.CO!J%-X+A415CW!0:)9?<0JN
MN'WB[/+P6M<Y8V=L?]/#:OC0YP()&S7\:X&\*6)4%3$ZH@<%=9PK&S4K"TD@
MPOV5G565G?W?-8G^WO&R5;TW ^, Z!ST8J'BVOT">UJJ92+'M8J!KIAXD./A
M='J*[G5QO+%:WHX,',6T'VH +7$W+@^\<LML=4DPX\&HY0+!P%/,/6CR*=TH
MG10M::OS[?C 3RSZH0P@%7ME*FY"%7,>DI;;*0:JXFZL.L(KU:M4VZY8"_SH
MJ@[P$Y_U0AT"7"6!3W7*;'5U*!:AP/O5(4!3TDU3-W6^J(V*$>Z:><V;]L.<
M$J J<;&G+G>4,I'C'84 18E7BI(F18.6$@"@I!N@/MQ/.81K>P"NI-N='K1(
M#W-"!'A*PGZL6R K.<:P[A6FZ4N[A &N$A_&%(1Q]T042$K[X5 I,)6Z.%3W
MK[M-F]IR-5. +/5A44&80XT1K7WU[X=EI0!;ZA6VU!FV%&!+?;C5&M".<$<4
M\$K[X5TIL)9Z]:ZTZ5W;) *X4A^V=2<1Z9HTP)3VPZ0R0"MS,:DN-QC6]*<M
M"C# */.*4=;$:-=3(08L9=TL]>&,RB&<BP.\LF[O>M R/<P:L=HC4]:/E0N
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MVRISH(W!'G]R]\_M:S@GGM/=YF,2QN1X;H.<G31W:6^HVC.A@6-N,>'@XT4
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M1+;:G1/DD0?]RH/^_^]DS5+!5BRFPISOZN;V[7]HO%,3+B+F38A"M'_PY<Y
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M0Y["+_+C]SB'F6?F,Z+O_K:@Q+$]8(5N[#]5^QV&+4?E,,1(UV:+D[,;.0"
M%=ZQ'^^_\?)L^>S#%58TQJ<N2@RJ$J/+$B9#(0R31 >:+8ZB*'&-ML(M'E^:
MP"9-S<*)&8.H2YWB+7Z!Z@2VE2>@L5YM4<A1V,&*U'A,A0*;AV,YO7&LH](6
M1U'BVK"PHCGVTWQ@II]ZS,(*QOC$U0NL0(O'UB^P"5 *L6$N,PK+T7>L7J)
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MN8EF6C6&XJ5]\"NN]/BPRUP/>! &H,_7G*N=869(]Y>1? )02P,$%     @
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MP=T$653WT'2&D8V;U;4TV&%N6>';#,HZX'DII=D;=OR'US[[!U!+ P04
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MFKG,8Z8&;^ :H-[O&),/"^V@'>57_P)02P,$%     @ 1V)E45GA]1&<!
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M<0L1CA<,J4>3$)I1> (C8!\AQV_WQ*%9[7PU1J&9HT],L2%1:FX(_;(M\0O
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MN]+B1;)U?K?WS*1D2?ZX(GA.N#90WQ=,S;SR17=0W5@/_P-02P,$%     @
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MFYZ6413OA**C^-I>A)^XTM=JVXSUVPJ$ >CO2\[5OF,<5*^U\;]02P,$%
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MZ79LAXF^DZ$P!OI[S+EZF)B>7-WR1C\!4$L#!!0    ( $=B95'E$'VE4 ,
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M@#545DUI-=!B:QO!I=#85MK7#!MY*LT"G%\+H0\#8Z#Y:S#Y%U!+ P04
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MS'5_#L($Z.<;SM7^QA1H._[Y3U!+ P04    " !'8F51QNA5>$,"  !^"P
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MX'Z7;?>]Q-:S BECG< )=H$X+(G6H,2]<9K.3?!%"K7V8E,:A;DBFV RP_V
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !'8F514,S538T$  #:)P
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MF)1N8F;=',/<U6H8DY).S"R=US("T.!\>;7-GKMQC$FY)V9VSZZF.-QE(PM
MW)X*MC FY9Z8V3T'3!S*_TRN?;->A#$I]\3,[GE7"AU^EC7O-<:D[!,SV^=M
M0=0.ZQ2O6E,62I@M1&*V+)10%DJ8+41'\QYC4A9*F"U$8TXP)F6AA+VC0A7#
MN ^0D"T5]IX*A8D[ 0EEH>24ZV:/*<:D+)2<= 8TPIB4A1)F"]&8YQB3LE#"
M;"$:\P)C4A9*F"U$8U[BMB1EH9390A3F8]/_.6!2%DJ9+71D=KXO[# F9:&4
MV4)',;<RPIB4A5)F"W4N(KP6R1B3LE#*;*$CF/N:$V.2K7UF"Y&8[0<0* NE
MW-V;(YB[,@EC4A9*3]#&.6"VHTE9*#W%.MQ95\,SI2R4_K\K<6=B8LL2$OTL
MV.Q)?,'/G5 6&C46ZN^?)<O50AN5_PM?X6$\DT4V=:)^V?;!D[3N:RVJHIC
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M[4_J7:;/0R[7GJ\U7O\GJ9[.Y^;KY2_+KYUXOV@O."?X=^?Q+U!+ P04
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M4')O<',O8V]R92YX;6Q02P$"% ,4    " !'8F51F5R<(Q &  "<)P  $P
M            @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M $=B95')U@-=.@4  &D5   8              " @0T(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " !'8F512&=LWZH&   ='   &
M            @(%]#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ 1V)E426J*5K: @  OPD  !@              ("!710  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( $=B95':6%W,RP4  )\7
M   8              " @6T7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    " !'8F51K'0<+0T#   6"0  &               @(%N'0
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ 1V)E4>J;$QJ?
M"   6S0  !@              ("!L2   'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( $=B95%^U>;A7@<  /P=   8              "
M@88I  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !'8F51
M(J@<AXD*  #B&@  &               @($:,0  >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ 1V)E45YDG-CI!@  ;Q$  !@
M     ("!V3L  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M $=B95$G3''8C@4  "P.   9              " @?A"  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ 1V)E4=BYT;/M!@  (A(  !D
M             ("!O4@  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    " !'8F51G">KWH8"  !'!0  &0              @('A3P  >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( $=B95'-PBZ^(P0
M ( *   9              " @9Y2  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ 1V)E43&<G4*< @  GP4  !D              ("!
M^%8  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !'8F51
MX:0I<8P(  !&%@  &0              @('+60  >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( $=B95'";7,XFA$  &XZ   9
M      " @8YB  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ 1V)E466]YX2A!P  8!,  !D              ("!7W0  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !'8F51\\?X7K((  !I&0
M&0              @($W?   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( $=B95$H*8!#5 0  &T*   9              " @2"%  !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ 1V)E4<Y"SF&)
M$@  ,3@  !D              ("!JXD  'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    " !'8F51Y6<RB?X"   E!P  &0
M@(%KG   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( $=B
M95'$VMQ^Q@,  / (   9              " @:"?  !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ 1V)E4>C-P#R6 @  4@4  !D
M         ("!G:,  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M    " !'8F511RX2%-4"   (!@  &0              @(%JI@  >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( $=B95$LO X"J0(  *,%
M   9              " @7:I  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
M4$L! A0#%     @ 1V)E4:9C?2.4!   $@P  !D              ("!5JP
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !'8F51FLKC
M]_(%  #3%0  &0              @($AL0  >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;%!+ 0(4 Q0    ( $=B95&N]BK=T (  %D&   9
M  " @4JW  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
M1V)E4530B6C#!0  01$  !D              ("!4;H  'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"% ,4    " !'8F51XQE6$QL#  "#!@  &0
M            @(%+P   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4
M Q0    ( $=B95%_Y(/?Z@(  %((   9              " @9W#  !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ 1V)E40[$RIB$!0
M3RD  !D              ("!OL8  'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6Q02P$"% ,4    " !'8F510L5<\"H"  "9!   &0              @(%Y
MS   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( $=B95'=
M.,(Q4P,  !@+   9              " @=K.  !X;"]W;W)K<VAE971S+W-H
M965T,S0N>&UL4$L! A0#%     @ 1V)E4<FL?G#F!0  +2$  !D
M     ("!9-(  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $=B95'57 QDN (  $<(   9              "
M@9GD  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ 1V)E
M47?+)?23!   RQ0  !D              ("!B.<  'AL+W=O<FMS:&5E=',O
M<VAE970T,2YX;6Q02P$"% ,4    " !'8F51+Y @UW\"  #Y!0  &0
M        @(%2[   >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0
M   ( $=B95'0S+K"<P(   T&   9              " @0CO  !X;"]W;W)K
M<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ 1V)E4<I>/X*F P  * X
M !D              ("!LO$  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q0
M2P$"% ,4    " !'8F51H_NM[&8#  #6"P  &0              @(&/]0
M>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( $=B95%9X?41
MG 0   \5   9              " @2SY  !X;"]W;W)K<VAE971S+W-H965T
M-#8N>&UL4$L! A0#%     @ 1V)E42*.YC+X @  *P@  !D
M ("!__T  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " !'
M8F517]8-O>T"   S"0  &0              @($N 0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( $=B95$)&-@&K@0  +T6   9
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M970U,RYX;6Q02P$"% ,4    " !'8F51]NORL&H$  #"$0  &0
M    @(&X%@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    (
M $=B95&378!8TP,  & .   9              " @5D; 0!X;"]W;W)K<VAE
M971S+W-H965T-34N>&UL4$L! A0#%     @ 1V)E48PW66BC P  )@P  !D
M             ("!8Q\! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"
M% ,4    " !'8F51=^-$GTL$  "7$@  &0              @($](P$ >&PO
M=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( $=B95$3'LO<"P0
M /@0   9              " @;\G 0!X;"]W;W)K<VAE971S+W-H965T-3@N
M>&UL4$L! A0#%     @ 1V)E4<K6\O1# P  ] H  !D              ("!
M 2P! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " !'8F51
MT<A]IJ4#  #]#P  &0              @(%[+P$ >&PO=V]R:W-H965T<R]S
M:&5E=#8P+GAM;%!+ 0(4 Q0    ( $=B95'&Z%5X0P(  'X+   -
M      "  5<S 0!X;"]S='EL97,N>&UL4$L! A0#%     @ 1V)E49>*NQS
M    $P(   L              ( !Q34! %]R96QS+RYR96QS4$L! A0#%
M  @ 1V)E45#,U4V-!   VB<   \              ( !KC8! 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( $=B95&8&UJ>^P$  ,LC   :
M  "  6@[ 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M $=B95%TTL9BW@$  %HC   3              "  9L] 0!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@    !$ $0 DQ(  *H_ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>241</ContextCount>
  <ElementCount>337</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Overview and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/OverviewandBasisofPresentation</Role>
      <ShortName>Overview and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2109104 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2113105 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2116106 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2120107 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2123108 - Disclosure - Product Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ProductRevenue</Role>
      <ShortName>Product Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2129109 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CollaborationandLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2139110 - Disclosure - Sale of Future Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/SaleofFutureRevenue</Role>
      <ShortName>Sale of Future Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2143111 - Disclosure - Share-Based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPayments</Role>
      <ShortName>Share-Based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2151112 - Disclosure - Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/LossperShare</Role>
      <ShortName>Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://agios.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/FairValueMeasurements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/MarketableSecurities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/Inventory</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2317304 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/Leases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2321305 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/AccruedExpenses</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2324306 - Disclosure - Product Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ProductRevenueTables</Role>
      <ShortName>Product Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/ProductRevenue</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2330307 - Disclosure - Collaboration and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CollaborationandLicenseAgreementsTables</Role>
      <ShortName>Collaboration and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/CollaborationandLicenseAgreements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2340308 - Disclosure - Sale of Future Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/SaleofFutureRevenueTables</Role>
      <ShortName>Sale of Future Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/SaleofFutureRevenue</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2344309 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/ShareBasedPayments</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2352310 - Disclosure - Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/LossperShareTables</Role>
      <ShortName>Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/LossperShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Overview and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails</Role>
      <ShortName>Overview and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Fair Value Measurements - Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Marketable Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Marketable Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Summary of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2415406 - Disclosure - Inventory - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/InventoryScheduleofInventoryDetails</Role>
      <ShortName>Inventory - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2418407 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2419408 - Disclosure - Leases - Schedule of Undiscounted Minimum Rental Commitments Under Non-cancelable Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails</Role>
      <ShortName>Leases - Schedule of Undiscounted Minimum Rental Commitments Under Non-cancelable Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2422409 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Summary of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2425410 - Disclosure - Product Revenue - Schedule of Product Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails</Role>
      <ShortName>Product Revenue - Schedule of Product Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2426411 - Disclosure - Product Revenue - Schedule of Product Revenue Allowance and Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails</Role>
      <ShortName>Product Revenue - Schedule of Product Revenue Allowance and Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2427412 - Disclosure - Product Revenue - Schedule of Revenue-Related Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails</Role>
      <ShortName>Product Revenue - Schedule of Revenue-Related Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2428413 - Disclosure - Product Revenue - Schedule of Changes in Contract Assets and Liabilities, Product Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails</Role>
      <ShortName>Product Revenue - Schedule of Changes in Contract Assets and Liabilities, Product Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2431414 - Disclosure - Collaboration and License Agreements - Celgene Purchase Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails</Role>
      <ShortName>Collaboration and License Agreements - Celgene Purchase Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2432415 - Disclosure - Collaboration and License Agreements - Collaboration Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails</Role>
      <ShortName>Collaboration and License Agreements - Collaboration Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2433416 - Disclosure - Collaboration and License Agreements - Schedule of Changes in Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails</Role>
      <ShortName>Collaboration and License Agreements - Schedule of Changes in Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Collaboration and License Agreements - Schedule of Revenues as a Result of Changes in Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails</Role>
      <ShortName>Collaboration and License Agreements - Schedule of Revenues as a Result of Changes in Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaboration and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Collaboration and License Agreements - CStone Pharmaceuticals Purchase Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails</Role>
      <ShortName>Collaboration and License Agreements - CStone Pharmaceuticals Purchase Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Collaboration and License Agreements - Schedule of Collaboration Revenue from CStone Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails</Role>
      <ShortName>Collaboration and License Agreements - Schedule of Collaboration Revenue from CStone Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Collaboration and License Agreements - Changes in Contract Assets and Liabilities Under CStone Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails</Role>
      <ShortName>Collaboration and License Agreements - Changes in Contract Assets and Liabilities Under CStone Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2441422 - Disclosure - Sale of Future Revenue - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/SaleofFutureRevenueAdditionalInformationDetails</Role>
      <ShortName>Sale of Future Revenue - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - Sale of Future Revenue - Schedule of Royalty Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/SaleofFutureRevenueScheduleofRoyaltyObligationDetails</Role>
      <ShortName>Sale of Future Revenue - Schedule of Royalty Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2445424 - Disclosure - Share-Based Payments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails</Role>
      <ShortName>Share-Based Payments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2446425 - Disclosure - Share-Based Payments - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails</Role>
      <ShortName>Share-Based Payments - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2447426 - Disclosure - Share-Based Payments - Summary of Unvested RSUs Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails</Role>
      <ShortName>Share-Based Payments - Summary of Unvested RSUs Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2448427 - Disclosure - Share-Based Payments - Schedule of Performance-Based and Market- Based Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails</Role>
      <ShortName>Share-Based Payments - Schedule of Performance-Based and Market- Based Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2449428 - Disclosure - Share-Based Payments - Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails</Role>
      <ShortName>Share-Based Payments - Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2450429 - Disclosure - Share-Based Payments - Expenses Related to Equity-Based Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails</Role>
      <ShortName>Share-Based Payments - Expenses Related to Equity-Based Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="agio-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2453430 - Disclosure - Loss per Share - Common Stock Excluded from Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails</Role>
      <ShortName>Loss per Share - Common Stock Excluded from Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="agio-20200930.htm">agio-20200930.htm</File>
    <File>agio-20200930.xsd</File>
    <File>agio-20200930_cal.xml</File>
    <File>agio-20200930_def.xml</File>
    <File>agio-20200930_lab.xml</File>
    <File>agio-20200930_pre.xml</File>
    <File>exhibit31-1x09x30x20.htm</File>
    <File>exhibit31-2x09x30x20.htm</File>
    <File>exhibit32-1x09x30x20.htm</File>
    <File>exhibit32-2x09x30x20.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>77
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "agio-20200930.htm": {
   "axisCustom": 0,
   "axisStandard": 13,
   "contextCount": 241,
   "dts": {
    "calculationLink": {
     "local": [
      "agio-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "agio-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "agio-20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "agio-20200930_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "agio-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "agio-20200930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 406,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 67,
   "keyStandard": 270,
   "memberCustom": 26,
   "memberStandard": 22,
   "nsprefix": "agio",
   "nsuri": "http://agios.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://agios.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - Fair Value Measurements",
     "role": "http://agios.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109104 - Disclosure - Marketable Securities",
     "role": "http://agios.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113105 - Disclosure - Inventory",
     "role": "http://agios.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116106 - Disclosure - Leases",
     "role": "http://agios.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120107 - Disclosure - Accrued Expenses",
     "role": "http://agios.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123108 - Disclosure - Product Revenue",
     "role": "http://agios.com/role/ProductRevenue",
     "shortName": "Product Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129109 - Disclosure - Collaboration and License Agreements",
     "role": "http://agios.com/role/CollaborationandLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "agio:SaleOfFutureRevenueRoyaltyObligationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139110 - Disclosure - Sale of Future Revenue",
     "role": "http://agios.com/role/SaleofFutureRevenue",
     "shortName": "Sale of Future Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "agio:SaleOfFutureRevenueRoyaltyObligationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143111 - Disclosure - Share-Based Payments",
     "role": "http://agios.com/role/ShareBasedPayments",
     "shortName": "Share-Based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2151112 - Disclosure - Loss per Share",
     "role": "http://agios.com/role/LossperShare",
     "shortName": "Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i6e634a7c4e2544d38a5d4db27a521e32_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://agios.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i6e634a7c4e2544d38a5d4db27a521e32_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://agios.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Marketable Securities (Tables)",
     "role": "http://agios.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - Inventory (Tables)",
     "role": "http://agios.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317304 - Disclosure - Leases (Tables)",
     "role": "http://agios.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321305 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://agios.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324306 - Disclosure - Product Revenue (Tables)",
     "role": "http://agios.com/role/ProductRevenueTables",
     "shortName": "Product Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "agio:RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330307 - Disclosure - Collaboration and License Agreements (Tables)",
     "role": "http://agios.com/role/CollaborationandLicenseAgreementsTables",
     "shortName": "Collaboration and License Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "agio:RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "agio:SaleOfFutureRevenueRoyaltyObligationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340308 - Disclosure - Sale of Future Revenue (Tables)",
     "role": "http://agios.com/role/SaleofFutureRevenueTables",
     "shortName": "Sale of Future Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "agio:SaleOfFutureRevenueRoyaltyObligationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344309 - Disclosure - Share-Based Payments (Tables)",
     "role": "http://agios.com/role/ShareBasedPaymentsTables",
     "shortName": "Share-Based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i6e634a7c4e2544d38a5d4db27a521e32_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i6e634a7c4e2544d38a5d4db27a521e32_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2352310 - Disclosure - Loss per Share (Tables)",
     "role": "http://agios.com/role/LossperShareTables",
     "shortName": "Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ied54aa2a3f7e42998c98d6f9afe5e255_D20200611-20200611",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "agio:ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Overview and Basis of Presentation - Additional Information (Details)",
     "role": "http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails",
     "shortName": "Overview and Basis of Presentation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i6e634a7c4e2544d38a5d4db27a521e32_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i6e634a7c4e2544d38a5d4db27a521e32_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Fair Value Measurements - Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i821a817349064dcc8e6938597d3db79e_I20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "if555a5ee5cf0408a86be0d8a8d59801f_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueNetAssetLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "role": "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "if555a5ee5cf0408a86be0d8a8d59801f_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueNetAssetLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:MarketableSecuritiesRealizedGainLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - Marketable Securities - Additional Information (Details)",
     "role": "http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails",
     "shortName": "Marketable Securities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:MarketableSecuritiesRealizedGainLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i6e634a7c4e2544d38a5d4db27a521e32_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details)",
     "role": "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails",
     "shortName": "Marketable Securities - Summary of Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i6e634a7c4e2544d38a5d4db27a521e32_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i6e634a7c4e2544d38a5d4db27a521e32_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415406 - Disclosure - Inventory - Schedule of Inventory (Details)",
     "role": "http://agios.com/role/InventoryScheduleofInventoryDetails",
     "shortName": "Inventory - Schedule of Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i6e634a7c4e2544d38a5d4db27a521e32_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i6e634a7c4e2544d38a5d4db27a521e32_I20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418407 - Disclosure - Leases - Additional Information (Details)",
     "role": "http://agios.com/role/LeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i6e634a7c4e2544d38a5d4db27a521e32_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419408 - Disclosure - Leases - Schedule of Undiscounted Minimum Rental Commitments Under Non-cancelable Leases (Details)",
     "role": "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails",
     "shortName": "Leases - Schedule of Undiscounted Minimum Rental Commitments Under Non-cancelable Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i6e634a7c4e2544d38a5d4db27a521e32_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i6e634a7c4e2544d38a5d4db27a521e32_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422409 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details)",
     "role": "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails",
     "shortName": "Accrued Expenses - Summary of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i6e634a7c4e2544d38a5d4db27a521e32_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://agios.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425410 - Disclosure - Product Revenue - Schedule of Product Revenue (Details)",
     "role": "http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails",
     "shortName": "Product Revenue - Schedule of Product Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ia1370538e8004f039f21787ab6a847b3_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "agio:ContractWithCustomerContractualAdjustmentReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426411 - Disclosure - Product Revenue - Schedule of Product Revenue Allowance and Reserves (Details)",
     "role": "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails",
     "shortName": "Product Revenue - Schedule of Product Revenue Allowance and Reserves (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ia1370538e8004f039f21787ab6a847b3_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "agio:ContractWithCustomerContractualAdjustmentReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "agio:ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i6e634a7c4e2544d38a5d4db27a521e32_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427412 - Disclosure - Product Revenue - Schedule of Revenue-Related Reserves (Details)",
     "role": "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails",
     "shortName": "Product Revenue - Schedule of Revenue-Related Reserves (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "agio:ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i6e634a7c4e2544d38a5d4db27a521e32_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "agio:ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ia1370538e8004f039f21787ab6a847b3_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428413 - Disclosure - Product Revenue - Schedule of Changes in Contract Assets and Liabilities, Product Revenue (Details)",
     "role": "http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails",
     "shortName": "Product Revenue - Schedule of Changes in Contract Assets and Liabilities, Product Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ied54aa2a3f7e42998c98d6f9afe5e255_D20200611-20200611",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "agio:ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431414 - Disclosure - Collaboration and License Agreements - Celgene Purchase Agreements (Details)",
     "role": "http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails",
     "shortName": "Collaboration and License Agreements - Celgene Purchase Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i5e16d3756d704760a00e78beb3a53457_D20160501-20160531",
      "decimals": null,
      "lang": "en-US",
      "name": "agio:RevenueRecognitionMultipleDeliverableArrangementsTermOfAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432415 - Disclosure - Collaboration and License Agreements - Collaboration Revenue (Details)",
     "role": "http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails",
     "shortName": "Collaboration and License Agreements - Collaboration Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "agio:RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i4bbc2d1419c542459a401e63c7eca48e_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "agio:ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ia1370538e8004f039f21787ab6a847b3_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433416 - Disclosure - Collaboration and License Agreements - Schedule of Changes in Contract Assets and Liabilities (Details)",
     "role": "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails",
     "shortName": "Collaboration and License Agreements - Schedule of Changes in Contract Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i21cd91eb1d2842528666b7c51b692515_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Collaboration and License Agreements - Schedule of Revenues as a Result of Changes in Contract Liabilities (Details)",
     "role": "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails",
     "shortName": "Collaboration and License Agreements - Schedule of Revenues as a Result of Changes in Contract Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i6e634a7c4e2544d38a5d4db27a521e32_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - Collaboration and License Agreements - Additional Information (Details)",
     "role": "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
     "shortName": "Collaboration and License Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i6e634a7c4e2544d38a5d4db27a521e32_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Collaboration and License Agreements - CStone Pharmaceuticals Purchase Agreement (Details)",
     "role": "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
     "shortName": "Collaboration and License Agreements - CStone Pharmaceuticals Purchase Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i18ae39e61005422296a6185b1b3642ac_D20180601-20180630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "agio:ContractWithCustomerLiabilityIncreaseFromCashReceipts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "role": "http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Collaboration and License Agreements - Schedule of Collaboration Revenue from CStone Agreement (Details)",
     "role": "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails",
     "shortName": "Collaboration and License Agreements - Schedule of Collaboration Revenue from CStone Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "agio:RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i08ba0b22d8f3450e8b229803691aa936_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "agio:ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ia1370538e8004f039f21787ab6a847b3_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Collaboration and License Agreements - Changes in Contract Assets and Liabilities Under CStone Agreement (Details)",
     "role": "http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails",
     "shortName": "Collaboration and License Agreements - Changes in Contract Assets and Liabilities Under CStone Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "agio:ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlockTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i63a35d727f94435cb7df160054110884_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ied54aa2a3f7e42998c98d6f9afe5e255_D20200611-20200611",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "agio:ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441422 - Disclosure - Sale of Future Revenue - Additional Information (Details)",
     "role": "http://agios.com/role/SaleofFutureRevenueAdditionalInformationDetails",
     "shortName": "Sale of Future Revenue - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ic35eee998d714c1eb9833f09bbeecf44_I20200611",
      "decimals": "3",
      "lang": "en-US",
      "name": "agio:PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ia1370538e8004f039f21787ab6a847b3_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "agio:SaleOfFutureRevenueLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - Sale of Future Revenue - Schedule of Royalty Obligation (Details)",
     "role": "http://agios.com/role/SaleofFutureRevenueScheduleofRoyaltyObligationDetails",
     "shortName": "Sale of Future Revenue - Schedule of Royalty Obligation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "agio:SaleOfFutureRevenueRoyaltyObligationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i921c8ef362934a03b834f05fd487675a_I20200611",
      "decimals": "-3",
      "lang": "en-US",
      "name": "agio:SaleOfFutureRevenueLiabilityNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i91da41946dd44926b3eb2a6c70cedcec_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445424 - Disclosure - Share-Based Payments - Additional Information (Details)",
     "role": "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
     "shortName": "Share-Based Payments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i91da41946dd44926b3eb2a6c70cedcec_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ia1370538e8004f039f21787ab6a847b3_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446425 - Disclosure - Share-Based Payments - Summary of Stock Option Activity (Details)",
     "role": "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails",
     "shortName": "Share-Based Payments - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ia1370538e8004f039f21787ab6a847b3_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i3d04844a7e1741f4b543721609a357af_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447426 - Disclosure - Share-Based Payments - Summary of Unvested RSUs Activity (Details)",
     "role": "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails",
     "shortName": "Share-Based Payments - Summary of Unvested RSUs Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i3d04844a7e1741f4b543721609a357af_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ic195c0c995c94bb99b62faec4ada3a82_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448427 - Disclosure - Share-Based Payments - Schedule of Performance-Based and Market- Based Units (Details)",
     "role": "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
     "shortName": "Share-Based Payments - Schedule of Performance-Based and Market- Based Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ic195c0c995c94bb99b62faec4ada3a82_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449428 - Disclosure - Share-Based Payments - Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations (Details)",
     "role": "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails",
     "shortName": "Share-Based Payments - Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "icf949780f933480e95db1152a36fe193_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450429 - Disclosure - Share-Based Payments - Expenses Related to Equity-Based Awards (Details)",
     "role": "http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails",
     "shortName": "Share-Based Payments - Expenses Related to Equity-Based Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "i27fa78f0171d419fbd8f33e0452c4ae6_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iddbd8fd3a9234d15a8eda0993f4f1137_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "if10cfda3b1ae42dd94275ef357f4b6ab_D20190101-20190331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453430 - Disclosure - Loss per Share - Common Stock Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "role": "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails",
     "shortName": "Loss per Share - Common Stock Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "ide09d8eb4c5940b78cf0122a2e50e028_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Overview and Basis of Presentation",
     "role": "http://agios.com/role/OverviewandBasisofPresentation",
     "shortName": "Overview and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://agios.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "agio-20200930.htm",
      "contextRef": "iee4a5ab8902d4bbf8428bce6286c9915_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 51,
   "tag": {
    "agio_AccruedResearchAndDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "AccruedResearchAndDevelopmentCostsCurrent",
        "terseLabel": "Accrued research and development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_Agreement2010Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Agreement2010Member",
        "terseLabel": "2010 Agreement"
       }
      }
     },
     "localname": "Agreement2010Member",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails",
      "http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails",
      "http://agios.com/role/SaleofFutureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_CStoneAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CStoneAgreementMember",
        "terseLabel": "CStone Agreement"
       }
      }
     },
     "localname": "CStoneAgreementMember",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_CStonePharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CStonePharmaceuticalsMember",
        "terseLabel": "CStone Pharmaceuticals"
       }
      }
     },
     "localname": "CStonePharmaceuticalsMember",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_CashEquivalentsAndAvailableForSaleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "CashEquivalentsAndAvailableForSaleSecurities",
        "totalLabel": "Total cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecurities",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_CelgeneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CelgeneMember",
        "terseLabel": "Celgene"
       }
      }
     },
     "localname": "CelgeneMember",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails",
      "http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails",
      "http://agios.com/role/SaleofFutureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_ChangeInContractWithCustomerAssetRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change In Contract With Customer, Asset [Roll Forward]",
        "label": "Change In Contract With Customer, Asset [Roll Forward]",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerAssetRollForward",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails",
      "http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "agio_ChangeInContractWithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change In Contract With Customer, Liability [Roll Forward]",
        "label": "Change In Contract With Customer, Liability [Roll Forward]",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityRollForward",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "agio_CollaborationReceivableDueFromRelatedPartiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Collaboration Receivable, Due From Related Parties, Current",
        "terseLabel": "Collaboration receivable \u2013 related party"
       }
      }
     },
     "localname": "CollaborationReceivableDueFromRelatedPartiesCurrent",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_CollaborationReceivableDueFromRelatedPartiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Collaboration Receivable, Due From Related Parties, Current [Member]",
        "verboseLabel": "Collaboration receivable - other"
       }
      }
     },
     "localname": "CollaborationReceivableDueFromRelatedPartiesCurrentMember",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_CollaborationReceivableDuefromRelatedPartiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CollaborationReceivableDuefromRelatedPartiesCurrentMember",
        "terseLabel": "Collaboration receivable \u2013 related party"
       }
      }
     },
     "localname": "CollaborationReceivableDuefromRelatedPartiesCurrentMember",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_CollaborationReceivableOtherCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "CollaborationReceivableOtherCurrent",
        "terseLabel": "Collaboration receivable \u2013 other"
       }
      }
     },
     "localname": "CollaborationReceivableOtherCurrent",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_CollaborationRevenueOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Collaboration Revenue, Other [Member]",
        "terseLabel": "Collaboration revenue \u2013 other"
       }
      }
     },
     "localname": "CollaborationRevenueOtherMember",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails",
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_CollaborationRevenueRelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Collaboration Revenue, Related Party [Member]",
        "terseLabel": "Collaboration revenue \u2013 related party"
       }
      }
     },
     "localname": "CollaborationRevenueRelatedPartyMember",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails",
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_CommercializationActivityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commercialization Activity",
        "label": "Commercialization Activity [Member]",
        "terseLabel": "Commercialization activities"
       }
      }
     },
     "localname": "CommercializationActivityMember",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_ContractWithCustomerAllowanceAndReservesLiability": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails": {
       "order": 2.0,
       "parentTag": "agio_ContractWithCustomerTotalAllowancesAndReserves",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Allowance And Reserves, Liability",
        "terseLabel": "Component of accrued expenses"
       }
      }
     },
     "localname": "ContractWithCustomerAllowanceAndReservesLiability",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlockTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlock [Table Text Block]",
        "terseLabel": "Schedule of Changes in Contract Assets and Liabilities, CStone Agreement"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityCStoneAgreementTableTextBlockTableTextBlock",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "agio_ContractWithCustomerAssetAndLiabilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract With Customer, Asset And Liability",
        "label": "Contract With Customer, Asset And Liability [Line Items]",
        "terseLabel": "Contract with Customer, Asset and Liability [Line Items]"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityLineItems",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Asset And Liability, Product Revenue [Table Text Block]",
        "terseLabel": "Schedule of Changes in Contract Assets and Liabilities, Product Revenue"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ProductRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "agio_ContractWithCustomerAssetAndLiabilityTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract With Customer, Asset And Liability",
        "label": "Contract With Customer, Asset And Liability [Table]",
        "terseLabel": "Contract with Customer, Asset and Liability [Table]"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTable",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "ContractWithCustomerAssetProceedsFromCollectionOfReceivables",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetProceedsFromCollectionOfReceivables",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails",
      "http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerAssetRevenueRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Asset, Revenue Recognized",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetRevenueRecognized",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails",
      "http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 3.0,
       "parentTag": "agio_ContractWithCustomerCurrentYearReserveRecoveries",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Contract Adjustment, Recoveries, Current Year",
        "negatedLabel": "Contractual adjustments, payments/returns relating to sales in the current year"
       }
      }
     },
     "localname": "ContractWithCustomerContractAdjustmentRecoveriesCurrentYear",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 2.0,
       "parentTag": "agio_ContractWithCustomerPriorYearsReserveRecoveries",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Contract Adjustment, Recoveries, Prior Year",
        "negatedTerseLabel": "Contractual adjustments, payments/returns relating to sales in the prior year"
       }
      }
     },
     "localname": "ContractWithCustomerContractAdjustmentRecoveriesPriorYear",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerContractualAdjustmentReserve": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 1.0,
       "parentTag": "agio_ContractWithCustomerTotalAllowancesAndReserves",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Contractual Adjustment Reserve",
        "periodEndLabel": "Contract adjustments, ending balance",
        "periodStartLabel": "Contract adjustments, beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerContractualAdjustmentReserve",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerCurrentYearReserveProvisions": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Current Year Reserve Provisions",
        "totalLabel": "Total allowances and reserves, current provisions relating to sales in the current year"
       }
      }
     },
     "localname": "ContractWithCustomerCurrentYearReserveProvisions",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerCurrentYearReserveRecoveries": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Current Year Reserve Recoveries",
        "negatedTotalLabel": "Total allowances and reserves, payments/returns relating to sales in the current year"
       }
      }
     },
     "localname": "ContractWithCustomerCurrentYearReserveRecoveries",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerLiabilityIncreaseFromCashReceipts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Liability, Increase From Cash Receipts",
        "terseLabel": "Initial payment received"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreaseFromCashReceipts",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerPriorYearsReserveProvisions": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Prior Years Reserve Provisions",
        "totalLabel": "Total allowances and reserves, adjustments relating to prior years"
       }
      }
     },
     "localname": "ContractWithCustomerPriorYearsReserveProvisions",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerPriorYearsReserveRecoveries": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Prior Years Reserve Recoveries",
        "negatedTotalLabel": "Total allowances and reserves, payments/returns relating to sales in the prior years"
       }
      }
     },
     "localname": "ContractWithCustomerPriorYearsReserveRecoveries",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerRebateReserve": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 2.0,
       "parentTag": "agio_ContractWithCustomerTotalAllowancesAndReserves",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Rebate Reserve",
        "periodEndLabel": "Government rebates, ending balance",
        "periodStartLabel": "Government rebates, beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerRebateReserve",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 2.0,
       "parentTag": "agio_ContractWithCustomerCurrentYearReserveRecoveries",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer Rebate Reserve, Recoveries In Current Year",
        "negatedLabel": "Government rebates, payments/returns relating to sales in the current year"
       }
      }
     },
     "localname": "ContractWithCustomerRebateReserveRecoveriesInCurrentYear",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 3.0,
       "parentTag": "agio_ContractWithCustomerPriorYearsReserveRecoveries",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer Rebate Reserve, Recoveries In Prior Years",
        "negatedTerseLabel": "Government rebates, payments/returns relating to sales in the prior years"
       }
      }
     },
     "localname": "ContractWithCustomerRebateReserveRecoveriesInPriorYears",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 1.0,
       "parentTag": "agio_ContractWithCustomerCurrentYearReserveRecoveries",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer Right To Recover Product, Current Year Recoveries",
        "negatedLabel": "Returns, payments/returns relating to sales in the current year"
       }
      }
     },
     "localname": "ContractWithCustomerRightToRecoverProductCurrentYearRecoveries",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 1.0,
       "parentTag": "agio_ContractWithCustomerPriorYearsReserveRecoveries",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer Right To Recover Product, Prior Year Recoveries",
        "negatedTerseLabel": "Returns, payments/returns relating to sales in the prior years"
       }
      }
     },
     "localname": "ContractWithCustomerRightToRecoverProductPriorYearRecoveries",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerRightToRecoverProductReserve": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 3.0,
       "parentTag": "agio_ContractWithCustomerTotalAllowancesAndReserves",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Right To Recover Product, Reserve",
        "periodEndLabel": "Returns, ending balance",
        "periodStartLabel": "Returns, beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerRightToRecoverProductReserve",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractWithCustomerTotalAllowancesAndReserves": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contract With Customer, Total Allowances And Reserves",
        "totalLabel": "Total revenue-related reserves"
       }
      }
     },
     "localname": "ContractWithCustomerTotalAllowancesAndReserves",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails",
      "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ContractualAdjustmentsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Contractual Adjustments [Roll Forward]",
        "terseLabel": "Contractual Adjustments [Roll Forward]"
       }
      }
     },
     "localname": "ContractualAdjustmentsRollForward",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "agio_CurrentAssetMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CurrentAssetMember",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentAssetMember",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_CurrentYearProvisionForContractualAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 1.0,
       "parentTag": "agio_ContractWithCustomerCurrentYearReserveProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Current Year Provision For Contractual Adjustments",
        "terseLabel": "Contractual adjustments, current provisions relating to sales in the current year"
       }
      }
     },
     "localname": "CurrentYearProvisionForContractualAdjustments",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_CurrentYearProvisionsForRebateReserve": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 2.0,
       "parentTag": "agio_ContractWithCustomerCurrentYearReserveProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Current Year Provisions For Rebate Reserve",
        "terseLabel": "Government rebates, current provisions relating to sales in the current year"
       }
      }
     },
     "localname": "CurrentYearProvisionsForRebateReserve",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_DeferredRevenueCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "DeferredRevenueCurrentMember",
        "terseLabel": "Deferred revenue \u2013 related party, current and net of current portions"
       }
      }
     },
     "localname": "DeferredRevenueCurrentMember",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_EmployeePurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "EmployeePurchasePlanMember",
        "terseLabel": "Employee stock purchase plan shares"
       }
      }
     },
     "localname": "EmployeePurchasePlanMember",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_EmployeeStockPurchasePlan2013Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "EmployeeStockPurchasePlan2013Member",
        "terseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlan2013Member",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_GovernmentRebatesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Government Rebates [Roll Forward]",
        "terseLabel": "Government Rebates [Roll Forward]"
       }
      }
     },
     "localname": "GovernmentRebatesRollForward",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "agio_IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Increase (Decrease) In Collaboration Receivable Due From Related Parties, Current",
        "negatedLabel": "Collaboration receivable \u2013 related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInCollaborationReceivableDueFromRelatedPartiesCurrent",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_IncreaseDecreaseInCollaborationReceivableOtherCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Increase (Decrease) In Collaboration Receivable, Other, Current",
        "negatedTerseLabel": "Collaboration receivable \u2013 other"
       }
      }
     },
     "localname": "IncreaseDecreaseInCollaborationReceivableOtherCurrent",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Increase (Decrease) in Contract with Customer, Liability, Related Party",
        "terseLabel": "Deferred revenue \u2013 related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Liability",
        "label": "Increase (Decrease) In Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent",
        "negatedTerseLabel": "Royalty receivable \u2013 related party"
       }
      }
     },
     "localname": "IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_InterestExpenseNonCashSaleOfFutureRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest Expense, Non-Cash, Sale Of Future Revenue",
        "label": "Interest Expense, Non-Cash, Sale Of Future Revenue",
        "negatedTerseLabel": "Non-cash interest expense for the sale of future revenue",
        "verboseLabel": "Non-cash interest expense associated with the sale of future revenue"
       }
      }
     },
     "localname": "InterestExpenseNonCashSaleOfFutureRevenue",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_MarketBasedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Market-Based Stock Units",
        "label": "Market-Based Stock Units [Member]",
        "terseLabel": "Market-Based Stock Units"
       }
      }
     },
     "localname": "MarketBasedStockUnitsMember",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_MasterResearchAndCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "MasterResearchAndCollaborationAgreementMember",
        "terseLabel": "2016 Agreement"
       }
      }
     },
     "localname": "MasterResearchAndCollaborationAgreementMember",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_NonCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NonCurrentAssetsMember",
        "terseLabel": "Non-current"
       }
      }
     },
     "localname": "NonCurrentAssetsMember",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_OperatingLeaseRightOfUseAssetAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease, Right-Of-Use Asset, Amortization",
        "label": "Operating Lease, Right-Of-Use Asset, Amortization",
        "terseLabel": "Non-cash operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortization",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_OptionExerciseFeeReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "OptionExerciseFeeReceivable",
        "terseLabel": "Option exercise fee receivable"
       }
      }
     },
     "localname": "OptionExerciseFeeReceivable",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_OtherStockAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Stock Awards",
        "label": "Other Stock Awards [Member]",
        "terseLabel": "Other stock awards"
       }
      }
     },
     "localname": "OtherStockAwardsMember",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_PerformanceBasedStockUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance-Based Stock Unit",
        "label": "Performance-Based Stock Unit [Member]",
        "terseLabel": "Performance-based stock units"
       }
      }
     },
     "localname": "PerformanceBasedStockUnitMember",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_PerformanceStockUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "PerformanceStockUnitMember",
        "verboseLabel": "Performance-based stock units"
       }
      }
     },
     "localname": "PerformanceStockUnitMember",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Stock Unit, Not Probable Of Meeting Vesting Criteria",
        "label": "Performance Stock Unit, Not Probable Of Meeting Vesting Criteria [Member]",
        "terseLabel": "Performance Stock Unit, Not Probable of Meeting Vesting Criteria"
       }
      }
     },
     "localname": "PerformanceStockUnitNotProbableOfMeetingVestingCriteriaMember",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication",
        "terseLabel": "Potential milestone payment"
       }
      }
     },
     "localname": "PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential Milestone Payment Receivable For Specified Regulatory Milestone Event Program, Estimated Effective Interest Rate",
        "label": "Potential Milestone Payment Receivable For Specified Regulatory Milestone Event Program, Estimated Effective Interest Rate",
        "terseLabel": "Estimated effective interest rate on royalty rights sold"
       }
      }
     },
     "localname": "PotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramEstimatedEffectiveInterestRate",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/SaleofFutureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "agio_PriorYearProvisionForContractualAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 3.0,
       "parentTag": "agio_ContractWithCustomerPriorYearsReserveProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Prior Year Provision For Contractual Adjustments",
        "terseLabel": "Contractual adjustments, adjustments relating to prior year"
       }
      }
     },
     "localname": "PriorYearProvisionForContractualAdjustments",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_PriorYearProvisionsForRebateReserve": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 2.0,
       "parentTag": "agio_ContractWithCustomerPriorYearsReserveProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Prior Year Provisions For Rebate Reserve",
        "terseLabel": "Government rebates, adjustments relating to prior years"
       }
      }
     },
     "localname": "PriorYearProvisionsForRebateReserve",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds From Sale Of Future Revenues, Net Of Issuance Costs",
        "label": "Proceeds From Sale Of Future Revenues, Net Of Issuance Costs",
        "terseLabel": "Proceeds from the sale of future revenue, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromSaleOfFutureRevenuesNetOfIssuanceCosts",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds From Sale Of Potential Milestone Payment Receivable For Specified Regulatory Milestone Event Program Sold",
        "label": "Proceeds From Sale Of Potential Milestone Payment Receivable For Specified Regulatory Milestone Event Program Sold",
        "terseLabel": "Proceeds from the sale of future revenue"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventProgramSold",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails",
      "http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails",
      "http://agios.com/role/SaleofFutureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ProductReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Product Returns [Roll Forward]",
        "terseLabel": "Product Returns [Roll Forward]"
       }
      }
     },
     "localname": "ProductReturnsRollForward",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "agio_ProvisionForRightToRecoverProductInCurrentYear": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 3.0,
       "parentTag": "agio_ContractWithCustomerCurrentYearReserveProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Provision For Right To Recover Product In Current Year",
        "terseLabel": "Returns, current provisions relating to sales in the current year"
       }
      }
     },
     "localname": "ProvisionForRightToRecoverProductInCurrentYear",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ProvisionForRightToRecoverProductInPriorYears": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "order": 1.0,
       "parentTag": "agio_ContractWithCustomerPriorYearsReserveProvisions",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Provision For Right To Recover Product In Prior Years",
        "terseLabel": "Returns, adjustments relating to prior years"
       }
      }
     },
     "localname": "ProvisionForRightToRecoverProductInPriorYears",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_RPIMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "RPI",
        "label": "RPI [Member]",
        "terseLabel": "RPI"
       }
      }
     },
     "localname": "RPIMember",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails",
      "http://agios.com/role/SaleofFutureRevenueAdditionalInformationDetails",
      "http://agios.com/role/SaleofFutureRevenueScheduleofRoyaltyObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Research And Development Arrangement Contract To Perform For Others Potential Milestone Payable",
        "terseLabel": "Potential future milestone payments"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayable",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ResearchServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ResearchServicesMember",
        "terseLabel": "On-going research and development services"
       }
      }
     },
     "localname": "ResearchServicesMember",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_RevenueFromContractsWithCustomersMilestoneRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue From Contracts With Customers, Milestone Revenue Recognized",
        "label": "Revenue From Contracts With Customers, Milestone Revenue Recognized",
        "terseLabel": "Milestones achieved"
       }
      }
     },
     "localname": "RevenueFromContractsWithCustomersMilestoneRevenueRecognized",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Revenue From External Customers, Royalty Revenue [Table Text Block]",
        "terseLabel": "Schedule of Royalty Revenue"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersRoyaltyRevenueTableTextBlock",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "agio_RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "PortionOfPotentialMilestonPaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgramSold",
        "label": "Revenue, Portion Of Potential Milestone Payment Receivable For Specified Regulatory Milestone Sold",
        "terseLabel": "Royalty rights sold"
       }
      }
     },
     "localname": "RevenuePortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneSold",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails",
      "http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails",
      "http://agios.com/role/SaleofFutureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_RevenueRecognitionMilestoneMethodEligibleReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "RevenueRecognitionMilestoneMethodEligibleReceivable",
        "terseLabel": "Milestone-based receivable payments, eligible to be received"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodEligibleReceivable",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails",
      "http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue Recognition Multiple Deliverable Arrangements Allocated By Performance Obligation [Table Text Block]",
        "terseLabel": "Schedule of Collaboration Revenue"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationTableTextBlock",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "agio_RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue Recognition Multiple Deliverable Arrangements Allocated By Performance Obligation Under CStone Agreement",
        "label": "Revenue Recognition Multiple Deliverable Arrangements Allocated By Performance Obligation Under CStone Agreement [Table Text Block]",
        "terseLabel": "Schedule of Collaboration Revenue Under CStone Agreement"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsAllocatedByPerformanceObligationUnderCStoneAgreementTableTextBlock",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfExtensions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue Recognition Multiple Deliverable Arrangements Number Of Extensions",
        "terseLabel": "Extension period"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsNumberOfExtensions",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "agio_RevenueRecognitionMultipleDeliverableArrangementsNumberOfSpecialCaseExtensions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue Recognition Multiple Deliverable Arrangements Number Of Special Case Extensions",
        "terseLabel": "Number of allowable special case extensions"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsNumberOfSpecialCaseExtensions",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "agio_RevenueRecognitionMultipleDeliverableArrangementsSpecialCaseExtensionTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue Recognition Multiple Deliverable Arrangements Special Case Extension Term",
        "terseLabel": "Special case extension term"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsSpecialCaseExtensionTerm",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "agio_RevenueRecognitionMultipleDeliverableArrangementsTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue Recognition Multiple Deliverable Arrangements Term Of Agreement",
        "terseLabel": "Term of agreements"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsTermOfAgreement",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "agio_RoyaltyPercentageRemitted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Royalty Percentage Remitted",
        "terseLabel": "Royalty percentage"
       }
      }
     },
     "localname": "RoyaltyPercentageRemitted",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "agio_RoyaltyReceivableDuefromRelatedPartiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "RoyaltyReceivableDuefromRelatedPartiesCurrent",
        "terseLabel": "Royalty receivable \u2013 related party"
       }
      }
     },
     "localname": "RoyaltyReceivableDuefromRelatedPartiesCurrent",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_RoyaltyReceivableDuefromRelatedPartiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "RoyaltyReceivableDuefromRelatedPartiesCurrentMember",
        "terseLabel": "Royalty receivable \u2013 related party"
       }
      }
     },
     "localname": "RoyaltyReceivableDuefromRelatedPartiesCurrentMember",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_RoyaltyRevenueNonCash": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty Revenue, Non-Cash",
        "label": "Royalty Revenue, Non-Cash",
        "negatedTerseLabel": "Non-cash royalty revenue"
       }
      }
     },
     "localname": "RoyaltyRevenueNonCash",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_SaleOfFutureRevenueAmortizationOfIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale Of Future Revenue, Amortization Of Issuance Costs",
        "label": "Sale Of Future Revenue, Amortization Of Issuance Costs",
        "terseLabel": "Amortization of issuance costs"
       }
      }
     },
     "localname": "SaleOfFutureRevenueAmortizationOfIssuanceCosts",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/SaleofFutureRevenueScheduleofRoyaltyObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_SaleOfFutureRevenueInterestExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale Of Future Revenue, Interest Expense",
        "label": "Sale Of Future Revenue, Interest Expense",
        "terseLabel": "Non-cash interest expense associated with the sale of future revenue"
       }
      }
     },
     "localname": "SaleOfFutureRevenueInterestExpense",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/SaleofFutureRevenueScheduleofRoyaltyObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_SaleOfFutureRevenueIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale Of Future Revenue, Issuance Costs",
        "label": "Sale Of Future Revenue, Issuance Costs",
        "negatedTerseLabel": "Issuance costs"
       }
      }
     },
     "localname": "SaleOfFutureRevenueIssuanceCosts",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/SaleofFutureRevenueScheduleofRoyaltyObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_SaleOfFutureRevenueLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale Of Future Revenue, Liability, Noncurrent",
        "label": "Sale Of Future Revenue, Liability, Noncurrent",
        "periodEndLabel": "Liability related to the sale of future revenue",
        "periodStartLabel": "Proceeds from the sale of future revenue",
        "terseLabel": "Liability related to the sale of future revenue, net of debt issuance costs"
       }
      }
     },
     "localname": "SaleOfFutureRevenueLiabilityNoncurrent",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets",
      "http://agios.com/role/SaleofFutureRevenueScheduleofRoyaltyObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_SaleOfFutureRevenueLiabilityNoncurrentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale Of Future Revenue, Liability, Noncurrent",
        "label": "Sale Of Future Revenue, Liability, Noncurrent [Roll Forward]",
        "terseLabel": "Sale of Future Revenue, Liability, Noncurrent [Roll Forward]"
       }
      }
     },
     "localname": "SaleOfFutureRevenueLiabilityNoncurrentRollForward",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/SaleofFutureRevenueScheduleofRoyaltyObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "agio_SaleOfFutureRevenuePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale Of Future Revenue, Policy",
        "label": "Sale Of Future Revenue, Policy [Policy Text Block]",
        "terseLabel": "Liability Related to Sale of Future Revenue and Amortization of Issuance Costs"
       }
      }
     },
     "localname": "SaleOfFutureRevenuePolicyPolicyTextBlock",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "agio_SaleOfFutureRevenueRoyaltyObligationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of Future Revenue, Royalty Obligation",
        "label": "Sale of Future Revenue, Royalty Obligation [Abstract]",
        "terseLabel": "Sale of Future Revenue, Royalty Obligation [Abstract]"
       }
      }
     },
     "localname": "SaleOfFutureRevenueRoyaltyObligationAbstract",
     "nsuri": "http://agios.com/20200930",
     "xbrltype": "stringItemType"
    },
    "agio_SaleOfFutureRevenueRoyaltyObligationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale Of Future Revenue, Royalty Obligation",
        "label": "Sale Of Future Revenue, Royalty Obligation [Table Text Block]",
        "terseLabel": "Schedule of Royalty Obligation"
       }
      }
     },
     "localname": "SaleOfFutureRevenueRoyaltyObligationTableTextBlock",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/SaleofFutureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "agio_SaleOfFutureRevenueRoyaltyObligationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale Of Future Revenue, Royalty Obligation",
        "label": "Sale Of Future Revenue, Royalty Obligation [Text Block]",
        "terseLabel": "Sale of Future Revenue"
       }
      }
     },
     "localname": "SaleOfFutureRevenueRoyaltyObligationTextBlock",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/SaleofFutureRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "agio_SaleOfFutureRevenuesNonCashRoyaltyRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale Of Future Revenues, Non-Cash Royalty Revenue",
        "label": "Sale Of Future Revenues, Non-Cash Royalty Revenue",
        "negatedTerseLabel": "Non-cash royalty related to the sale of future revenue",
        "terseLabel": "Non-cash royalty revenue"
       }
      }
     },
     "localname": "SaleOfFutureRevenuesNonCashRoyaltyRevenue",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/SaleofFutureRevenueAdditionalInformationDetails",
      "http://agios.com/role/SaleofFutureRevenueScheduleofRoyaltyObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Schedule Of Accounts Notes Loans And Financing Receivable1 [Table Text Block]",
        "terseLabel": "Schedule of Revenue Related Reserves"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ProductRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "agio_ScheduleOfMarketBasedUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule Of Market-Based Units Activity",
        "label": "Schedule Of Market-Based Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Market-Based Units Activity"
       }
      }
     },
     "localname": "ScheduleOfMarketBasedUnitsActivityTableTextBlock",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "agio_TwoThousandAndThirteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "TwoThousandAndThirteenStockIncentivePlanMember",
        "terseLabel": "2013 Stock Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandAndThirteenStockIncentivePlanMember",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember",
        "terseLabel": "2007 Plan and 2013 Plan"
       }
      }
     },
     "localname": "TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_UnbilledReceivableDueFromRelatedPartiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unbilled Receivable, Due From Related Parties, Current",
        "label": "Unbilled Receivable, Due From Related Parties, Current [Member]",
        "terseLabel": "Unbilled receivable - related party, net of current portions"
       }
      }
     },
     "localname": "UnbilledReceivableDueFromRelatedPartiesCurrentMember",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "agio_UpfrontPaymentAgreementExtensionFeeReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "UpfrontPaymentAgreementExtensionFeeReceivable",
        "terseLabel": "Upfront payment agreement extension fee receivable"
       }
      }
     },
     "localname": "UpfrontPaymentAgreementExtensionFeeReceivable",
     "nsuri": "http://agios.com/20200930",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r41",
      "r79"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails",
      "http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails",
      "http://agios.com/role/SaleofFutureRevenueAdditionalInformationDetails",
      "http://agios.com/role/SaleofFutureRevenueScheduleofRoyaltyObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r203",
      "r204",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r317",
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r203",
      "r204",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r317",
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r121",
      "r182",
      "r186",
      "r295",
      "r316",
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Products and Services [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails",
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations",
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r121",
      "r182",
      "r186",
      "r295",
      "r316",
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Products and Services [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails",
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations",
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r194",
      "r203",
      "r204",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r317",
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r194",
      "r203",
      "r204",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r317",
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails",
      "http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails",
      "http://agios.com/role/SaleofFutureRevenueAdditionalInformationDetails",
      "http://agios.com/role/SaleofFutureRevenueScheduleofRoyaltyObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net accretion of premium and discounts on investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails",
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r34"
     ],
     "calculation": {
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r43",
      "r46",
      "r47",
      "r81",
      "r82",
      "r83",
      "r247",
      "r320",
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r230",
      "r231",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r205",
      "r207",
      "r235",
      "r236"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r207",
      "r226",
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r20",
      "r125",
      "r145"
     ],
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails": {
       "order": 1.0,
       "parentTag": "agio_ContractWithCustomerTotalAllowancesAndReserves",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Reduction of accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Allowance for Doubtful Accounts Receivable [Roll Forward]"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total common stock equivalents excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails",
      "http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails",
      "http://agios.com/role/SaleofFutureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r78",
      "r110",
      "r113",
      "r119",
      "r143",
      "r245",
      "r248",
      "r263",
      "r297",
      "r309"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r40",
      "r78",
      "r143",
      "r245",
      "r248",
      "r263"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r130",
      "r148"
     ],
     "calculation": {
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r127",
      "r131",
      "r148",
      "r299"
     ],
     "calculation": {
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "agio_CashEquivalentsAndAvailableForSaleSecurities",
       "weight": 1.0
      },
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "verboseLabel": "Total marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r129",
      "r148"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r129",
      "r148"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r208",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails",
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r251",
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails",
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r72",
      "r73",
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Additions to property and equipment in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r29",
      "r71"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "agio_CashEquivalentsAndAvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Total cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents, and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r66",
      "r71",
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of the period",
        "periodStartLabel": "Cash and cash equivalents at beginning of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r66",
      "r264"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r241",
      "r242",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails",
      "http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails",
      "http://agios.com/role/SaleofFutureRevenueAdditionalInformationDetails",
      "http://agios.com/role/SaleofFutureRevenueScheduleofRoyaltyObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares available for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r81",
      "r82"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 125,000,000 shares authorized; 69,198,063 and 68,401,105 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r50",
      "r52",
      "r53",
      "r57",
      "r303",
      "r315"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Changes in Contract Assets and Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r159",
      "r161",
      "r183"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "periodEndLabel": "Contract assets, ending balance",
        "periodStartLabel": "Contract assets, beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails",
      "http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsandLiabilitiesProductRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r159",
      "r161",
      "r183"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r159",
      "r160",
      "r183"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Contract liabilities, ending balance",
        "periodStartLabel": "Contract liabilities, beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r159",
      "r160",
      "r183"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue \u2013 related party"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r159",
      "r160",
      "r183"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion \u2013 related party"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Amounts included in the contract liability at the beginning of the period",
        "verboseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofChangesinContractAssetsandLiabilitiesDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r169"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Performance obligations satisfied in previous periods"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofRevenuesasaResultofChangesinContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r195",
      "r202",
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r60",
      "r295"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total cost and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions",
        "terseLabel": "Number of debt securities in unrealized loss position for less than one year"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r136",
      "r149",
      "r151"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Aggregate fair value of debt securities in unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r137",
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of debt securities in significant unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails",
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r182",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails",
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Product Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ProductRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Payments"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share \u2013 basic and diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r95",
      "r96"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/LossperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period to recognize compensation expense (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense for options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r85",
      "r90",
      "r92",
      "r99",
      "r144",
      "r157",
      "r158",
      "r230",
      "r231",
      "r232",
      "r239",
      "r240",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r253",
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r253",
      "r261",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r254",
      "r285",
      "r286",
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value, Hierarchy [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r253",
      "r254",
      "r256",
      "r257",
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r195",
      "r196",
      "r201",
      "r202",
      "r254",
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r195",
      "r196",
      "r201",
      "r202",
      "r254",
      "r286"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r254",
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r285",
      "r286",
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r258",
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of asset after deduction of liability.",
        "label": "Fair Value, Net Asset (Liability)",
        "terseLabel": "Fair value of assets (liabilities)"
       }
      }
     },
     "localname": "FairValueNetAssetLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r273"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Financing lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r273"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Financing lease liabilities, net of current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r274",
      "r278"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payments on financing lease obligations"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Financing lease assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLosses": {
     "auth_ref": [
      "r124",
      "r145",
      "r146",
      "r147",
      "r300"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement.",
        "label": "Financing Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit loss"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Gain on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "Selling, general and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current and non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r21",
      "r152"
     ],
     "calculation": {
      "http://agios.com/role/InventoryScheduleofInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/InventoryScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r39"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://agios.com/role/InventoryScheduleofInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets",
      "http://agios.com/role/InventoryScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r23",
      "r152"
     ],
     "calculation": {
      "http://agios.com/role/InventoryScheduleofInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/InventoryScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r22",
      "r152"
     ],
     "calculation": {
      "http://agios.com/role/InventoryScheduleofInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/InventoryScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r63",
      "r109"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r142",
      "r296",
      "r308",
      "r341"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Undiscounted Minimum Rental Commitments Under Non-cancelable Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Undiscounted minimum rental commitments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remaining 2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease terms"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33",
      "r78",
      "r114",
      "r143",
      "r246",
      "r248",
      "r249",
      "r263"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r78",
      "r143",
      "r263",
      "r298",
      "r311"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35",
      "r78",
      "r143",
      "r246",
      "r248",
      "r249",
      "r263"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and Service [Member]",
        "verboseLabel": "License and other services"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Realized Gain (Loss)",
        "terseLabel": "Realized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r66",
      "r67",
      "r70"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r48",
      "r51",
      "r55",
      "r70",
      "r78",
      "r84",
      "r86",
      "r87",
      "r88",
      "r89",
      "r91",
      "r92",
      "r93",
      "r110",
      "r112",
      "r115",
      "r118",
      "r120",
      "r143",
      "r263",
      "r301",
      "r313"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations",
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing transactions"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Cost and expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r110",
      "r112",
      "r115",
      "r118",
      "r120"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r277",
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r273"
     ],
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r273"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r273"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r275",
      "r278"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r281",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average incremental borrowing rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r280",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Overview and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/OverviewandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r34"
     ],
     "calculation": {
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued revenue-related reserves and other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/AccruedExpensesSummaryofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r49",
      "r52",
      "r54",
      "r56",
      "r157",
      "r265",
      "r270",
      "r271",
      "r302",
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive (loss) income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r42",
      "r44"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized (loss) gain on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherDepreciationAndAmortization": {
     "auth_ref": [
      "r61",
      "r69",
      "r154"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.",
        "label": "Other Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "OtherDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r208",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued or outstanding at September 30, 2020 and December 31, 2019"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r27",
      "r28"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r65",
      "r229"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Net proceeds from stock option exercises and employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturities and sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product revenue, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations",
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r155",
      "r312"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r238",
      "r342"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails",
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r158",
      "r233",
      "r310",
      "r323",
      "r324"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r85",
      "r90",
      "r92",
      "r144",
      "r230",
      "r231",
      "r232",
      "r239",
      "r240",
      "r320",
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r107",
      "r108",
      "r111",
      "r116",
      "r117",
      "r121",
      "r122",
      "r123",
      "r181",
      "r182",
      "r295"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCollaborationRevenueDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails",
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations",
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r77",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Product Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r171",
      "r172",
      "r185",
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Product Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ProductRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue Recognition and Deferred Revenue [Abstract]"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining unsatisfied performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r279",
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease liabilities arising from obtaining operating lease assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty revenue \u2013 related party"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Product Revenue Allowance and Reserves"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ProductRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/LossperShareCommonStockExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Common Stock Excluded from Calculation of Diluted Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/LossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Marketable Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r134",
      "r135",
      "r138",
      "r139",
      "r140",
      "r141",
      "r305",
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails",
      "http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails",
      "http://agios.com/role/SaleofFutureRevenueAdditionalInformationDetails",
      "http://agios.com/role/SaleofFutureRevenueScheduleofRoyaltyObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense by Award Type Included Within the Condensed Consolidated Statements of Operations"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r207",
      "r225",
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Allocated Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r24",
      "r25",
      "r26"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.",
        "label": "Schedule of Nonvested Performance-based Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Performance-Based Units"
       }
      }
     },
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Unvested Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r208",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r210",
      "r221",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Company's Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ServiceOtherMember": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, financial service, and other financial service, classified as other.",
        "label": "Service, Other [Member]",
        "terseLabel": "Other services"
       }
      }
     },
     "localname": "ServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value, Forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value, Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested shares end of period (in shares)",
        "periodStartLabel": "Unvested shares beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-average grant date fair value, Unvested shares end of period (in usd per share)",
        "periodStartLabel": "Weighted-average grant date fair value, Unvested shares beginning of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value, Vested (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsExpensesRelatedtoEquityBasedAwardsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee",
        "terseLabel": "Opportunity to purchase of common stock (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common stock reserved for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of stock options, exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, exercisable (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of stock options, forfeited/expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of stock options, granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r212",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of stock options, outstanding, ending balance (in shares)",
        "periodStartLabel": "Number of stock options, outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-average exercise price, outstanding, ending balance (in usd per share)",
        "periodStartLabel": "Weighted-average exercise price, outstanding, beginning balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of stock options, vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, vested and expected to vest (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r206",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofPerformanceBasedandMarketBasedUnitsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedWithintheCondensedConsolidatedStatementsofOperationsDetails",
      "http://agios.com/role/ShareBasedPaymentsSummaryofUnvestedRSUsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, forfeited/expired (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r37",
      "r81",
      "r82",
      "r83",
      "r85",
      "r90",
      "r92",
      "r99",
      "r144",
      "r157",
      "r158",
      "r230",
      "r231",
      "r232",
      "r239",
      "r240",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r320",
      "r321",
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations",
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r99",
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations",
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r13",
      "r14",
      "r157",
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued under 2013 ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r14",
      "r157",
      "r158",
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of stock options, exercised (in shares)",
        "terseLabel": "Common stock issued under stock incentive plan and ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://agios.com/role/ShareBasedPaymentsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r37",
      "r157",
      "r158"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Common stock issued under stock incentive plan and ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r17",
      "r18",
      "r78",
      "r126",
      "r143",
      "r263"
     ],
     "calculation": {
      "http://agios.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets",
      "http://agios.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCStonePharmaceuticalsPurchaseAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsCelgenePurchaseAgreementsDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsChangesinContractAssetsandLiabilitiesUnderCStoneAgreementDetails",
      "http://agios.com/role/CollaborationandLicenseAgreementsScheduleofCollaborationRevenuefromCStoneAgreementDetails",
      "http://agios.com/role/OverviewandBasisofPresentationAdditionalInformationDetails",
      "http://agios.com/role/SaleofFutureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "Government securities"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r195",
      "r202",
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasuries"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://agios.com/role/MarketableSecuritiesSummaryofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average number of common shares used in computing net loss per share \u2013 basic and diluted (in usd per share)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://agios.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL108322424-203045"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(7)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r343": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r344": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r345": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r346": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r347": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r348": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>78
<FILENAME>0001439222-20-000069-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001439222-20-000069-xbrl.zip
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M[EPB.;T+@<7(V.)8UK1CX$DMA<W>*/<FEH& TL9@W&N#R%MI&RKD%)W2K$8
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MN>OLEIY@HPWFO#9$B;Q,67O-=01MC>*Y1,/;RCFQV:'E)!MI(A\DFJ.[2@I
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M_*P0<J]9;:Y6P$Q^^IF1%6Z^_=/[GI;K%4WY)(J?QR.?<[TW#.:/;YK2'_-
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M?CVJ(9Z^PB^NVWWPV;CLRK^>B#MW(!MC1U_9NOEIV\OFA;UP(8+0:"J:BE
M"%'8J  ]"1<\K\R2,69:-0CVWXT7G9ZS'0QM.QC<-G+CC:]G[G\VC]WNYB*?
MIPRFT$'D]O!XLQMRA5%LN-.&WX_^4^,PMQ3YLA_+$JT<M_<O"_-_H^,4Z[X=
ME"NZ0L-V.GA$SO;D;,"_C]LY%S#L-5P<'X G'J<#1C^E/%=UC=;'C3,#5Q(*
MY]J<LP7YZRR%1L!O,0[(AQ[UHX]E5$!9HUR2/FC\AN=#FVD,CI'E#O9[>9W
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MU?(-(JS4Z%H*[3PO0&I6.&I8H12JM)>,LZ275DNS8'_,41A4IS8JQC1J>WY
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M ($L)N*4422?^D8E48KH86W=V*Z4LD5E=K6,MGV><U7F^U'FK]^5V<CD#.I
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M<0S_O/*IVV ^7?[<O[SLXW'HC:Z[^U.9G0)PWF^_34A172'$QD#]P5S.CWF
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M)%)E/0AG#;5KZ\9VA9)+,5^GCA.KX\3NKT:][NVZMUN\MZ<AZ+3&HG7Y5-<
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M0II)ZZ5$":B 2VV$<HSKZ(*+VGJ\@2U<AQ(LTC#>&NV,"RF$4$@]-<1X%PB
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MB!0&2-X 92*H3R0Y%H-V47K&FK$<BG4EO^B;5Y2M*%M1=K$H*T62(47A%"@
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MP^%^YX^#H\_#*Y^O#8A]^1/^\K*/QZ&7G^J?/Y/.*8ZJ_$T3\A*-V=^<@&/
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MH=7KI)F;S3M>Y,S<KDY>OT ^6H7[DU];I;A"#*T3.QR?/;,3LGMF(TL.](O
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M,+.-(4OX]!+*%.5F']0;SBD -<CJX+1_SBFQW=KM=BO1FUJCBW>C%C;#V.V
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MLZAX-!K^!K8B59P9&TGB#;W8/$ Z6[#Z?53,BJ 0#\XBKD,N_Q8="L9'V'$
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MR_\>[W^'/KU\3S]^^?I]KP=]?.F_[QT&V"./ON^??L9"T.0%0=SG BM:<V2
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MBA\<BAL_WP: \)RU&ZN"HI0AS)0&$(X..9MK?PD<'',8)P<@#"9^ \ - #<
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M'\G!8;?[Z<M_.A^__)XS1[+/(GG >0X;B"$:F <GR,@$5GARWDBA18BLVAU
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M.:J8@L)M3 @R&IRC[!F_<YVR#6C^^5+*5[9G\3-UR<JZ4L2&J6'K&WL ]37
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M;@H<[8]C"R9U6/0[+%N5U6"T#A@M%"CQ#A,"EI(W',PE' @R3 84P"167-$
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MJ+&?YWP\L-TGDK6V)K=^*$WAI_%NUVEY"V1CNUG(SQ-=J0$5O-(%Z>9BY0@
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MVB7;Y+X+M]? 5P-?#7RW ;X\U</^AU@<.U:%-6H<O!4.SA*F)!4F2"=0I-*
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M)6IKMPC!SRR2C:U,]?_^Q>ZNVL:5.'\M;E_">69Q-(Y9(QWF(5%#HE**<.Y
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MUL?*[BW<3P515FPP4_XN&9YSQF9_,#VQ^0HD6AC2C46+:6_N\DR-C6H9@=*
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M)F!I0@PQ&AY3<CBR%'FD0JB@%+M_'VMMLMP2%.8J<1,  N\ !0C+)HO42"M
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M!>>!:2L"#XXJ*RB)C#YK,4I]G.8AX&W^.$VR/B6<,$HI>,25YN"9\("BLM3
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MX'L\ODR=\A3,*7:_W9^C3:F&4A.E7"1*.=T^^88E<4([BR03"G%A#+)*8L3
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MH=4JO:HJ#>IL)4T*&PYJ+9V1#$MM7%#<TL"N/IY<J_02J?0LO<(TM@QB1$3
MX4=<4H(L=@SYY&VR. 6A0SZ<T.3WYSRH=7IY=9H)A;D(DNC<-3%&&XT0T4A'
MA$]@P>L\P;+K]"Q/0 *QC"2"&!,&Y<:4R'BB4/):)I-!6ZG<^+VI\#*YWG<]
M\/1BL@'O+S6"NV]2X(H96#UHBE*0Y /1R<<LNS9B$&1,G"0$@@FW8%+@.@+9
M&I4>')6V_YC+!T1'0TS"H1BD1=PRCYQ/$GF9) Z:TJ#M@[&[7@T-3[%?<R]7
MXU7HL]=8<$(@;(B6>Y% 7TF(,C(L,$LDU1F!95?JN;86(0I!*4-,68=X(! ^
M!#!OUA:8-MS9[&HT^8-MSM8JO80J3:1DVDHIDG9<NV"%8!8,M$X01FCJZXS
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M/ZM.&WX\G5G!8?3@11RW8:SMO.+';33YVWICTX/B9BN<E]$5IZ:P%UWO,)S
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M92<Y.SQ5=O%XU,WP5^*=/'G9G8(IR\@$=\C?@[M__',+X'.W#R\2,MQ.[0B
M5_6H9NY%46# -H:G0U#NX>0=,Z_]H&]S3Z1^;O9Q!,!94*-T=)H\J(($N$\8
M9"M9-68:^CY(9P7_/VP)C\86M@=_Z.1O#>Q16>-&Y4.,_=\04X[WQK.2G<7*
M/6Z,/9#VV.,;1-!U\'SS*TP[9Y5&).U.=N:*59AXN(-V1BQ8I=G49T^DHM<O
M X[#@A_SPZH8]J_ DF74KG+'W\#K[[3]+:#CW]?(5N74S(G7RWC[VV#+.';(
MLM+^T<\=:'IM-TLW9-TM<06(Z+NM?Y-&=Y2]#%1EK7]D?RR[3:!,[V97ES8K
MH&:5I_/#@B]86GV-I19\_G&G%I#4@[9K@R<PB4/S[3.8E6>!X!Z# 6W"6A0C
MVP:\:1S .\!M*^V8RN;IU4.>HDA!I?%8*R4 .'5PR?2ESJ4**M7)#DVYT/H1
M6.7N*<P4B$ GCKY#Q&,+DFRV_J=9_26<YHX0PZPCP]-> $]J##:MK4^5$ON#
M/D0<^^V^A]"MW8,U+!Y';H;1..D/.N$$)O 7866C[(D4UVUNK?)WBL:"C(\3
M3I4?>XL ]<H;PF]_?#H&'SMC;Q=NU,D7_W'0[L$K_SM[G/^OGP/5E@7'LMG8
MM>T3B*/*$S[!Q%GPP&)YL0(F:30.W\?QYLV#\OV<!I@DJTJ\V<ZM=?K[ ]N=
MV9?*SYET(;GQKN-XMEWUR1N_X,Q)'7^PN3^(Q8\K+GWC[=8FS.VP0OP?,)K=
M=[]_VOE[!_Q&Q?_5^,=LUO[K:@&T(4<*Y\7PXS\_9K&I#"D$(L/R'CG5?DX8
MS^?]KI?J7CPI[8[L?J^?5S_?NI+:7]U[6-H,^DG3PUY^531]33!<QXV3@W[E
M?AQG%P$^4*+XT#"!V3L8E"\4R8/9[@]<.U336]0+HIB2?FGDT /&7$*_848,
M""Q&E>WR8,O[8_T% .E-W?+LC>MB@2%,&[LW=MR.*ZLFQ( '_<%T9:LV,U5B
M)^O;YN8D2_%F-.@?17B[UM3";>[G;$CYXIO69IG@\XMZZW6\$@_'BUM>9P=B
MG.IM*"YO8WN]?@XS*X7(-PD#>U*Y2?F3//)IRBS%&/*^ZZSS#HSW_QLV_AA[
M?%7WJ?&+P3W>#_IY8BOWZ=\C,!"-SS#W__CCWZWW_S6-EF=XW/!@%(HO"5Z(
MK9Z2/8/L-^2N98-NB8G!D SZG9SJ?%^*#PE,3,:BT"[IVUF*Z1BD<#@Z*O&7
M;4PGQ('_E=K'*$?9\'*=TEUMVO<'EJ=?!;MAO(0SQ0-USZVT8*7 ]P4T&XSV
MBT<"5GG:\_,FFW49<IO3^_Z>]QDG_O#NV(S\X@'M#$U=UQ[_M=*Q,^O;^2!$
M+UX]@.NULW=!)7.\?T'*GE(!*P"_Z]S<6FDRK!\5"<^IU#0H>8#3;",?!+1>
MB%_Z2\_LC]C)04NS$K@.*.MX'[>:H5'V4H;SCEOLV9L<-WH)J*Z+H]8;;V:W
M>QA/CB[BR551AL^]<4LNY.Y^';W1KRO.VU2)\HB&\ 89$V%<1_T<AH+7 8K;
M'I[W!R9J,EZJL7]0 3D\^=W;S8F',%N;:SR$^ES)1.[G>B_5;6M7_XC("T#B
M&[WWWGF<69\"0@:)VX1T%P*Q5"'7%#\JHWQ2A>H19J0];J8(QCUF%!_T3VVG
MVK  ]ZY=VL=V^B<H]$?YFP&N*!L5W79 Q[G_]A$\-R=]]N':G)]J]*MMAMR^
M<6@[571T#L*F\67\F<=<;'?>!YV&CAGZ\EN.CLKV:>Z&>- >A(DA*,G$,?G?
MY1>/"=YYEN;[W"NG!SZ5W-EZ8Z?7^&L$TTG(^$!##@F*\P,CJ%ZW60U[_(!J
M/DXGH\LV<[H*U[[BN4,,_S][[]K<MI5L#?\55)Z<4TD5I(C4/7[.5"FVD_A,
M'.?8GIDZ[Y>W0!(4,08!#D!*X?SZIU=W[PLNI$A9ED@9'V9BD2"PL7?OWGU9
MO;KZ;F:>Y=V^/3T]/**Y3%,UV/PV[D5\C;:8L&;H"K)%<@[8+24KP.;U3P4.
MF#1XN\1Q]>%?BV0P8$_DI[<?0CS@O0[_#P[V2JCRCS><'0^^[?M/?PZ&SKL%
M#MCXP(MP6)]$SG3(%HQ59P](LNF&U)8>JV%P]<M!__Q(M@K]^^SX[#E,3C,^
MY[WT2CNO8>:1,H"U0N)_36*#B-/?O=ML8-\-BHBF9X8H.HR>$ G_ _<D9_@=
MKC9E]GG61;I6>)=J>))S62PY,(%$R629D@+,:<YA.4()D,5)_RN6*>DH"5%\
MO/H# )(TEJC%[2093H+$-I!F9Q VY9^,A:#%Z9T:U6V:7=O(JXZP?2W=4K9:
MZF^O/O:O6,^^93A)_S34<(4YR<A&2#F;2>K)G !DOY>B)%GCSW!3[O![T#SI
M#IHZ'W-I-BW4+0_"&Y=_$PW[A5ZHKG_4._,"=5]0ZE966C^6.+XQ^;B"O/]_
M"1 /RV8C2E/L;$G5#!G8P9V6.?_$L "8\P@.^5-*OQ<UV2[4JQ-LSH=*EU,2
MZ&ED$$$,K4(..D.L:*H2C+6=58)&]*'YZ:$9A,AMTW_4C..0;OIO.D3)EIDL
M1P4Y93F, WHC_O,:#I9LJE>_OGOU:^C"X(,E^<IR\%XM2%HAS:]L"NYC/)QD
M_)J,=>/Q2T1?K]T7?;9EC@NIS[T$[R)-W;0'C)S1:P4(/8Y)9/(P -)O!DAC
M:/*HP6Q9+!CC^"F!R!R\Y]7^XZ_OPQ4QANKU>G7(J5B%U$'#<?P,FR9/EXA<
M1!ER0Z26__BK?RFDO)&0YNH8S<F2+YM9< Z]5$D[MH@;-PZ#?T8+!$L%!9PF
M8]K7W,5=(:) $Y?YD'/L&AZ9%'EF;R"YS!C71P7C!VSTO#3;F38CK1-N8",H
MQD"OS8K9G(HL9;!)FN<C1@[0)+PUZ[#R>*J" "0GHB<5IVPB3R?<)N1)S)>S
M./@N Q ]_9Y_8$)-M)8ZGM(<J1.&P6!2!5%5P"XO;-;=G=&DG^28QKNET):*
M 8-F+5BATL_[X?'!2"_,K]/E$-A)>SU=("]?1C2IP#U#]U3=QZI4,+050@?=
M^>?!37*3RV56?CF1QD'@M,Q]N\1>L4F$C$2,;(_2K7\R_(0, 'P>Q2NP?']X
M^4I2DO#WMDQ)N@$Q:.M/@Z=]X 2@"\3AQTCAW)$G$*]ZJ^FJ+)(#(&^:E+CO
MTJQ<:SHI+T_.:"#DPY)&%H0P/PXB;[>)4V06:=HXVFM::C^.N+ML)-02&I >
MY[B Q,1+"U*TQ9X4? \#0>.80])S@(%N.#M%T[S@-"1-61P5Z9+.6 1,''['
MW&4=.@FXFI7X)!$JAB'M8%'0EB;%RTJ20HXEML&"R%CISP$Q\SX&6I;DY'?:
M7<%E:.W#QUZ%%6FCQBK\IJMPU5B%IYB^T)SB4O2CE1;;E$GY93QWER:Q,L3Q
M70[I;/>0[,&G>&FP[%(30>Y[E%W[]2 VL0/D"T-#[H^>/5N#GGUBK.Q+U/I
M4UT-AZC'AR+\ TZ7 ;V]-A4ZSV#_(MPX-"\<N1>>V1>V,';[D5B1"J06OY2,
MDP#G/;"S"(#]<S&Z=A5MMJ3)&LQ%/(N<Q;FES#MK#)EO 'M-Y0.7/&$L&[Z2
M9 [EH"N %5_@LV%.+R(Q*/IYL8A'FY06,?N9"^GC8X7?&%,I30SBM&+&Q1R
MQSRH,:@C.0Q>"VI=*TDDD<OH$?**<.ZF"A,1Y=O?->7[83&=PIU"&:<G&RW;
MZHN/?.TX'U<%*R396\HLK^R=X01ZUXXD_C,I>;+6RK2K,7G(VH][J_?+?2J.
M<#6E7NGH9U=,[(PE^F8ZBZ1(U=8GYB(C/VE=XW..%L,Q+F=<D X]=/7^P\'+
M_.\'?:N5)1*B]>\<T[#3A$ )UXEQ5AOAH7R*(%5^FY&BSCA-'%RG^0#Z )P]
ME:2IOZ=O<APTK/MM.8D1.H%PEHR.U(0#LKJXZ!^(-@2_QE%*YM>[XCK*3#@
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M$R\61TYG<_&Z;$<0=7(T'JJ[3[*XSA-RV*1NU9Y*^0KA'!?_.YA+S17U04%
M.0J@IYG860E([I;W$9<W'\"F,28J3$OS-QI3&I.2.8A+<.G-3:+?M5BW6S3^
MDPRF4AH/&]1""VJ@6]['6]XT(KO5;-T&+DV[^'#XB>S=L61I8.L;3!R750@6
M-44D%8UC6AN;L(%>,K*C6]_'6U]_PPH<*YX) *IF&-=66X%X_NE[9\QJY\(W
M5XK/-ZG-?#$?:AVLNH[B^G(W[ %DOBV17XL2>$YG2[" &WO7(AHZ"-Q+X[!0
MF>KWMT2!ZVA]!3!4'_4<4 1WAA!-/+X:CI=)M"!)<Y*XB),-SOD^.BX10D]+
M]*B1%5?XL%% R!*Z2V"Y\_0?T]C4JH4#4R7I:,O<2M/Q1;*"S[0]G>*C5O":
MF7MT=L=C+J39X78;2]%D'2=4*>CT%]E6 =MMGWNT0@)X>_G^'1= 17-3&K Z
M+,TU4SDGQ5QE025\X_<8E=3>()Y$Z=BICZ'F$J&U%BD::'3&[&,'$,P:D/UI
MZLR4ZWN( B<N7O'"N>+4^/[IRO5'F<G25KAUINQCKZZKV,<*8ID2CY=2$@#N
M.*B<T8I(%3D0D@7O[& +HK"^+"?/N:$F(_%!9^D].:&M75B(OCS5E6:P:=(T
MS602__)_!\4/?WD&=MM'3L\9_Z!D=DSZN50#WU6NX!&M6993K7IPY0M, Z\F
M,A>L)KH;P16@54JJY[V8+NMTM+M%L2I EKM)=X,2DX&IXN6Z&%0Q\ZMN7D;<
MJ.1_RHK5.VW@78(SK,"FN7:WWVGS*RX,L*UKOK__QMTU[;_EU.SH>7!EV@\A
M30SF2T';AH98Q_"1@+[D@,R!.*UE=Q@N'=]$Z<)+%+:9?+SIO'[(>>%WY6WK
M'.VZ,%>+S!/9X=QP&9PZ&_9ZUV[2]<ZWMH>T;1[)C9MM+^AJ"W9.A(LF93Y0
M!0WX?9T^(ZBP:S*^UQ+]0S]@""I^5A&NN@"K6R-E^[9. )0["5LF6PDM'2A7
M_Y^M=/":GW\?,+M,4SJM_#+#RF9"&-];!K\^!/]QA^#?@;$\/8*_4ZX/H%Q_
M>?/;Z]#R7 ./>XT21%[M PO>$0U\W*)IH2V95,[I5!SNGZ$U*X=[XU"G6VRG
M49-2U:AF9[7NTK)I:;V%8<'R*<)J[-<M-&&U8@T%'%9;0O:/^KW.A'A2*?_U
M7>_TZ >2L@^_]"]#0;K1F0!_=Q:4,QBB7 JYV290V5<J0H.A;^1VK>'1NDFJ
MAH>47Z/Z,2I&:^UD7\SQ8&<1K=Y$=0NYMCV4JP28W,9&H<EZ@(W2B?]N6-!5
MC]"Y@&$P(CU\$*/+@>NEQ30599N!+=W_E*X0!"$EL[&)LQBV>(J"L$Y):DUA
M:\D]";)K-,"\5DU9DUX3_EK5G;?]I/"%&[@Y+=7'RU:[]<)[U9Z+,ZY,0KAS
MC.P)4#EO7WV@\V;:'13=3MF?G>*W6VS?'7ZR\#I-:!;!X)"G47:=Y,.H&"89
M?\8'SX3\Z"(OZ5-N7OTY7FHGO8\@O2_3J*#51OO6]29,+318T&KG4WKX".*]
M(-OZ )?37TQ;-D!#^VR.18[KP/U:#% 8L6] QY8N#TR;WUI +\^0;QX*X"H7
MWCMP*H(KM2&*=ROYE<+(UPA&!J;-:)8GCFY5?GM+OZ7'2YGD0U@Z-4W/(#((
MQ^^OKAR4"3PZ<%X:_#DMKV_["17E//B7=![#.SRSP^*9!=]E?QTTSX^[MT^[
M9K?23\,RE6:U[KIUQ=XI['V0%[J9)LJQH RFD%Q)-9[BE?]QE6Q^B[;<HUC7
MVF?:=D5<C*Y,"F629H#.H$ U/(M,,$_*$GTHOZ28[(S&^+N;P >7^4Y%?F$5
M69/^=3K2CW5TNO(9Z4HL$-/W!J[+_7/7GIW@/(#@O/G]U9M?WMWI$]VM=D#!
M+&+SG?RG_[T1H)9P:[ RWKI[4=:=.;3>&F*#'X,__AI<(2B"(KGNQ'["_?/J
M_9N_OZ;E<%E"W3+]4-S2 _0%$DFNG.,>=BA&6R1PKS8WF>6RP!9CBMH0E9-9
M.5X@HL9+!20@LYA4#GZ2$"'/IJVR(9)G=9?03A4_AO'W\N.;OU]]?'WP,?2"
MFL749=Y($O+Y2O&0JMF"0TLB(8WH4D,H[@X3?8$(OS*KD^QP:H[AMY:Q60^"
MKR.PL\]B"B'M_=BKQ$>;$=%-A7>-G#*Z890'0I$D++DJZ[XN+'=9G@=+X67*
M1BK%1\](BI_'27[E#NX'.*:;8?T#_]QVI_9\$J7<""?9S,_N#NFG]9=:T2S8
MV[\;7J@W&<WD?#$7/H1?F6M>*)_>_&KYKA5#SO1@%>&Q$2![$%8EJ4R&G]*8
M^R)!9S$;WFQ1E N4'W '@&'NO/[5M8NF:++F?N79=6[)Y=:Y8OS*;W[]FOTQ
M89?[,?C(;4TP3V^O/O:OVOM+O/UX]0=M>]G/0\3DBL^@N^RV\D,&6^U6XZCK
M#)2%$L5:SD H$!7%4LDPL(H!KZ*-7(B-.M/NQ?;(#[&;H@8@@BX1L9&^NT[)
MR\TR6C(=%EU9Y<!4FF$\Y!9PSVGI:Q&]:QM(?Q[]&67<_8F[_$W-.$U(D#3)
M' W_UMQBE ]CNDW,LU0199QLY11-BEDEI0L:2P?'MW#\DPZ.OP-CV0\X_A/)
MJ!Q&MI!9ZI.A)C;2#%DT.)A%9!*+>L!=KN/I$"W3X S5U06]WY!;?0P#P'@!
M[J+SR4$Z#H.?<NZLZQ[#FHYMIIT+#3_J(FYOG9P=G_G6R:M?W[WZM=TZ684B
M[2R4W;!0ZF:$]3QEE;'-RL7@GYR*J^9]T^5T-N&-]69U3.U(>P:/8N4T&B:E
M]MPB]W1NRF,;]-?R]- 0)9O>8U7D[MR&GD/7LN<V@4.2WV9>D$2Y]3DZ\AEN
M[F[OR<L3VI._8XA>UZ0__OK^"^9SNCWW&5Z!2#G8PTF4I7'<,K@AZY.VA&D;
MUW#2/[Q\M4$92?-NW7FV6E[>L5U2"6C,:![H.)M:#I#]>/'/?DW+4=/.D4)R
MD\(&SGV^.NF]:CJR&FP^-X#-9Z!-$18L2XWG*.]PG==C6<?@^B\+<3JYA^A'
M)UVZ<Y+"THY[W^6QO9G)AYAW<6CZ;0A3T(B\-(51W,3/J:_)-J_;SL%H./8\
M%B0CM,R!5.'C6T&\%[)\VGZ]W+CDSWBXP.-#TU'=ZSY?:5WB=P-.XVM]A\F"
MY@8;CF1Y"&:G1<;EA8B7\"#]-LR61Y*WGY(\+:OOP8DJ?K_;A'NKN&9"*\.Q
MCH1*!C:.S9:6[@ ^<S+YM[.<>YV1S3Z74P-;-%9:JFC(+49-%%>9Y7A6X^(F
MH7?<DPUY9SM1>LEA,A,P6B1MHLMMQ)0M4=M3)O%;S6'.M8;5ZWVY:OUL7P#;
M(D55;"NM*)/FYEC/I-*CVOQJ)8VH:;EKAJQOD":?T%C%2*5KQB/B6#,7)HGI
M%.8URG8[RHH2DVW-@?#RR0E)0*/;I3%\5-3DBVB:X[X54K4624M&__7-W7&8
MB_XWZRGR>OU'L%Q7MK%"'WA,X;N9FO#/0<6_U'9PW"WM@)O6TYIRMV+N)#6(
M8ZBP(?*5I!!C[0N4L6W"=J]:N2AS*NF_BN_;ITS/J@Z&TQF=7:5M<'N?YF]H
MZ;8?4K+E['QD7,==C>=;7T!YQ4V<OQC%Q0'G5V=E_*/YQPMT"4^CY8])Q@_G
M'[T@VW2.++S>D^;)1<0/CR0J/B_H?R-S?_WZD+_Z83YJ?G=R>7AVO/KKH\/>
M/;\[OCBYUR_7#;9W='AZ>?H%!GMZSREXDL'NU<Q^H<&>'1UO=-L?>#_(GJ#-
MA8WZ7]\<?^/24!P/^?$HZ+'N-?>[SZ67C4O[LS]Q\8M&:JZ^DT4'/K1VN[CK
M:#\2FE*H];>BS5\WM;G5;E_?U/R.<V[#F=E0T%K>&[&XIWGKADW$;_W=F^P_
M_T_O[.@%PG)TGU'Y_4/(@+M4#STV:6=SK<3":[W8*^F E;/!Q-S]ME_3E'GV
MX)>5I3V<F\\3IX>2J#V<N)I0W:&*F\S6PV$<C\<O[K7)VK0WW>'Q_=DC\=/9
M(RE_W$22[C\/F\A7=_?N[D]T]ZT5@%+;U[9YP/_M[_)^-SW3"]GW(=I*WVOK
MUV:@OEC;S-Q1\*1&[H8S]VU]FK9Z1?_5"MQUI][MN!>>]\[$B/^<US1[8(O7
M[83N:Q6ZWGEXTN]W0M<)W2.^VT4OO#SO=4+7"=TCOMO)4=B_.'\ZH;NO?[M_
MYNW+2MVA&KD!8)2]W@N;Y>?FYY_C\-[IHO2WF]S6+;I[<MP+^T?;6HEK1.E+
MZ<ZO>Y%.P].M3?END1YYD<[.PZ/CBVZ5=GN5COOA2>_DZ5;IZPE+K3^W&2_W
M):)4&\GOIB;U[LEO+^P=[;^O\\P7Z:1_U"W1;B]1/SR_V/_HZ+-?I/[1$T83
MOQX?^WV^C%(NZ.B\ZP?U"2Z..X=@MY>H'YZ==;[UCB_2>7A\VBW2SB_2Z=GE
M_GG6BBO1$I0>RN%]<,G&@#!9I(M=/N:E8J6H5:S<PQ[][#G;-OGU((OT3+-F
M#S,WNZU;CD_"\ZWS%%]B@W]A1Z_;6-W&>ESS]RP\ZF\;#^\V5K>QNHUU1Z#^
M]#+LG=XS5-_MK&YG=3MK%=ZO'YZ<WS,L_*0;BSW4'[B,_R\;$@7(VPV*'_ZR
MYQ0*[=0;%0J%X #M>HI1\#]5DL;@AAE@&M_T+ND73\>C)]WG*C0ZOGN-,7Y[
M<:@007IZ:FC&'(_&7?090^;?<!PV&_R*)@7]BQT#E7)4TNSX0YU5:T9XL+V3
MP^- !QIRR#^)4N:P&I?Q'+T\(E!DVGL,6Q/\!]6D =_9N['P ZX;"H8_*A+Z
M X]TK#YEE-+2@31PRN.M-$J6VVX_.GZ8S! F6%G)$T=X,HL+\+R 7RO(!REZ
M .);YECF"VC*SX(KTU; L"F5\3#/1G6ZT?MRPESNUR[V2^97RC8V]=T7[L$>
M/S\[/ _J^WLC=ISZ]K[[1QON[A4;_*3GC91YK*H_VWQ#'Y\<GJW>T9O=9ZNI
M:GUKL(4M9B.^)_IS3D&)IOM6Z<R$"HQITF[S13H*!CQ4\#6-I%E1GAU(ZX^5
M)'6&/DYHGZ1M ?TLMH1EK2JB7*TC>#@)&,J&^76&%E(!*"<#>H,X (7?M:S,
M;#'O>@K8G=@_[7H*[,!8GK:GP&.?A&LE<AK/)_G(TH"_C%.P+S)VXOQ%6:$3
MIW]SDS0:.NDXPX9H50X)ZG1=\[^CS<PFIR'U[NC(17?8V(C:PCS9"7MD'3&;
M<A325+_>CH[VLHV0KV-LVT%>L8ZQ;<\&VS&V=8QM'6/;,V-L:PF/[K: ="Q;
M'75;)U2[,W$==9NKF2NEV8$ADN\XW+J[?[UW_YJ*9<NY-HOQXA0=N\Q7RBYS
MMC61P.[5)G82MT\2=WRY;:5:)W&=Q'T>D\'%R?Y78'<RMU\R=W3\A-0,7U%!
M^0HP15=#OCW<]3(\/3WMBE]W>Y5Z1[WP;&M4<K=,C[Q,_?->>-[O6-IV?)F.
MCT["LZVMPQTH)M^_DWJ#!L<=3=M]ZI4O3CH2L%U?I>/PJ+<M946W2H]N6EV&
M_<O][RKPS)?I\CSL'^VA<_U0)8&[>\3?B8>]?R;O$:I^'W*9GEL$[D'G9K?5
M2Z]_&AX=WY-.;R_JZ;N=U>VL)]E9Q[2S+N[)B=[MK&YG=3MKE7]YT0\O[LLN
MVNVL;F=U.VME^RW:6>?[N+/N20+S!2:8[[@MRT/3B]Q+VA:?*40H'7+[8@9[
M+:0H1X>]!KO#X[*W5%E75M(45(?=]X9].TGH^@05R>6P2 8Q:!#2_%89"BJY
M^E?>'<T*'P85>&HPH2&ZDN)I/L+,Q2G(6N3-Z?O;F"Z[P40S7\*(F1+&2"I,
MZ(_K/!_A'C?TF+Q8*D$#_4Q?8H0IP&3G($F(DQNLR\^OKH)H-BOR&RQ7O7;Y
M&3.KM.ZYYT:RLO&.[!\='CTYW\H]MN1Q__#RP;9D.SU3E<ZEO#NS9T;8U!GZ
MHA-:I9@I3LH\R^)4"%5"/"==,(]!.<^'GPX&K HPP70[X7W16X>6]@7S1N<G
MOJ3!T,& GV,!H1IN\^(3_7L8/V-EL^.T"7<*W7Z\]5I-\XX$X\[M&F(S3:-_
MDDR0 %P7T30,2&^05,UQQY%AZA!."-ZW/S:I,SK.B)UD-N@X(_9LL!UG1,<9
MT7%&?"G.B.#1Z2+VK3K]\\KZ'Z2F?]^FK&.)Z%@B.I:(+Q;\?IU%93**LV00
M?/?FU:]]\D<FR2 AYW83'?Z I?\/,]?/.PVSWWF6_NFVB+YMM]DCIB<[R>XD
MVR\%/>MDNY/MYRC;%^?WK!?M)+N3[)V6[./P>.N>6H\BVP]4,+C3(O?F)O?]
MCM[G^AU?=[U,[SCL79QW54T[ODJ7X45__VEJGODJG1R%1_VND'/'5^GL*#P^
MNF='S!VBW]G=P.#?\\)%!J]^.;BXZ'T??/<'#82.ZP>*$GZEC!2GX='I$_)1
M=(NTD8()CY^2-*1;I WMWJ/>MG9OMTJ/O4HGX<G1/6L"]\B??KJS^FTRCV;)
M332G _JO[X-H.,<?G2M]/X:0\.QX6V'MS/_'7B50KW6N](ZOTG$O/.EUS%6[
MODK]\/+H"??2([G23SK'Y$#WSX^"[]Y>?>Q?==[SYR7;CSL*VUU?I'[8[]\S
MM]8MTJ-%NL.+LR=TR[I%V@A_$1Z==[[S%SV9SX[/@N]>_?JN$M<.1DDYI%\G
MV2(>=7[T]LKE?/^;P#SS)8(/_80IM&Z1-K.D3DZZ1=KQ13J_!P!X_SSH)SVD
M+T_HD/X= _PESH('"'-_W69EG[SH+G&VXXO4"R^W#I]VB_3HNK]WV<6C=GR1
M3L+>UBTT.B]Z\_E]-P>U4X4-9Y9&\W%>3 WOS1=I1?S,[<K+\.BT:U:Q\XMT
M?-+AA7=\D?K'X=E9YT?O^BI=AB>]/41U;U</MMM-W(0G=)04\7!^-[_=XY)$
M;&.E?D:!YNYMC!/RU^^;J]OS0MRO=LU/R6DYW=:PZ-9\K]>\1W;*R=;]Z;I%
MW^]%/[T,ST[N&8WM2M$_=_I?^DS3L',,R?1GV3A?MR%_?!)>]CH4_:ZOTAFY
M6]O&KKM5>O1:!_!+=6' 75^FH\OPJ/^$.N^YX^C/:9)_CH9)FLP3NB-.ZC<?
M&X=U\)_1=/8BR)&0Z' !]W! POYY!PS8]56B$^'RHENEW5ZEX_.P]Y38[6Z5
M-EJET_#ROAR'3^EB/WS.X4F70=(.2?9%$P\;3]WGV*[/*C9U GC3/3-RNQ&/
M[-;\'FM^VKMG]4:WYONYYKV3B[!_?,\J\&[1]W713\++RWMBEW8L\?# _9CW
MP%:ZRT1Z &A&UX1]A]BVGW43]HO+\/2^M Y/VH.]VU@[(T/=QFI-2_3"L_//
M0Y1T.ZO;6=W.:H"5SU% ?\\H?+>SNIW5[:Q5(?FCD_#LONS+3[JSV&W]@?NN
M_V7+WO:754G]XKWM^8X_)N1))L/U:])W/N=[W^=\Y?F<KTWZ_2#X.$F*4? _
MBZB8QT60CP,T*@UNRL.V;WJ7] NSQ(\L:_)>DYB<YV$11V4<)%DPW\BW+C'Z
M;WO]PUY 8TJ!'!SG13"GF\VY,_8TY_[/<;/_LTS',)_.HH*^F^>;_HJFZC8J
M@UF1D-301 2C18R?1\&W9X=G=AS^RR2NR\XP+^>\!/':*]H?87Y!PRT2FAZF
M7A 8AGGMEVE4O'GUZ])<P?-F?C6D><>>T6>,BN0FSH+!DJ;0FT$:#OTS+N=Y
M!GS'<)+0Q(]PV:_O_O[N=QI,0?MSB^DR8Z.'SQ/!=]*RX9-?W_5.CWZX>OO;
MAU_ZES+D0RN&C7VK G-"JN3%C.8+=_J1@2?T'B],=WGN/._]2K?YD?M)-"!U
MLYBO_DFC;>[C*V#>%/VSZESX_S\IS&AFT75\,* E_G00C6FP/T;I;;0LO_FA
MJO1(O_D36'_WE6\X'G^Q-Q1%2_*9%RP6/](Q$A>XBL84[<Q8 I+R\7]]\W^2
MD]XY_?2$?+GAR<G%\6 PZAV?#.+S87QZ,1X?]___<U)D.'0@WR_I@20\Y?_]
M(?I+VS)N>B"=/9<#Z7?Z;?#V#H6,\^GN"_?ZN#KN'UXVCJL,[[SM:77WC]8<
M5OVCP^.-3JL05Y\>7K1>G&_ .!#RQW23DQ7GHY+_[>C9>.K-TQ9GXT:+L^71
M6)^:36:_/EWVQ>C*+(O].= Y6P8TC!NZ/%^4$-T4*C$OEC)CX&,DXWOIS[!=
MWR,[4XO9N*"7#V;1DK< WM2_%_D(>4$3C<U#;U62XJ6;_*MJE#;?V!>5=D&8
MRR^2$J.@OR=1.J=?TETS%-1ZNY(>HK?308R3HIQ7QT"[3N^;)M.$$:Y9D:<I
M;F#ENN^]MQ4/\[LK$HGKF/Y>S+#?^1$S6FJ,8$223>)RF\PG.H39!"_:"]+E
M=#8A/:6RFF1W3=1*JVD_O)WS5C7[!LM&TQF\R4CWQ3S?KVMIM?7O>]DX3.GE
MV#%T]B%[HO22:30KXQ_-/UZ0I-,66?Z89#PP_E%+?;BSI Z/Q)K2?*G>7[\^
MY*]JWK-\=W)Y>':\^NNCP]X]OSN^.+G7+]<-MG=T>'IY^@4&>WK/*7B2P>[5
MS'ZAP9X='6]TVSLP!'?"0;:X]+)Q:4OP45RZQXFT7=2LR8::$R !N]%J\;YN
MV@H;0 B>Z]3XOL!=,[.AH#UI/+K^UNV1U^_>9!)UG4_(!J-3K]R$7'.+G;0R
M_'H'!F?W! 0FVB80FTU>^"N;N-YE)U2=4'U9H?KB5$Z[R^!DG9>$G9<PR.+Y
MX_(T/<PD/^\,[GZG:'MA;VOF@.=!4]/)]G.7[7YX<;&3;#R=;'>R_=F]YR_Z
M]R3"[F2[D^V=ENU>+^Q?["1WWF?6>*_"LNV-1_)[GAT,HW(BZ3"X)IJ8MGG(
M,A+PPG@Q7Q1Q4,0W<;:X7PG3=G/W ,6 FRS/GE0$?G<9GI^=-V)^#RNGCU@%
MVJW^-JO_G__GHM_KO_BL>M!.!O9;!KZC4_2B=]&I@*]S^7==!7P&P'['\8QM
MD!/832]A-]DO7]?LI@]J-_TL=M-[L9ON <)_2E C@ZV&DRB[%MQ=2_PZ2'S$
M532?%\E@(7 :![URR#USAR*: R4VYRMBFE$%N;4"KL+@=I(,)V1\CA9#X/D8
M'U>Y4QP5F<#NC@Y/C_X#S^[Q/\9%#N1;0LLRHTG(1X)-JP\L7]#3%O-R3E\"
M@$7O\RE65% \7!2":AM$:90-X^U*"@YKLYC=T^9F<)L':6O\/"K+?)@PZ2+P
M8^MN50#5C.$JAFS#%[D?I.RKVM\/C&GN=O_N[OY-$-K[L/DW>X\]W_OM<-+?
M\K(4(7E'\L%P:Y&0WTFV\67CK3NLZ$XB&CNLZ)X-ML.*=EC1#BO:846?&IW6
MP?HZK&@G5+LR<1U6U,R%\TQRZYET6-$.E_&P2>6C\+B_15:Y QQU@KT7@LT]
MG\Z..LGN)/N927:_?QR>]TX[R>XD^YE)]G'_*#PY.MDQR?[J$:+Q/$C]1$@'
M^'DLX_PBO#R_[/!>7^GR]X[.PM[Y<;?^7^GZ]_N79.AUZ_^UKO\QN;"]?G\7
MU__YDBG?B0<)&(?;>[$UCO,I@5QNS%784]H28^:WS6I&WVXLSI/.X1.P2%M>
MQ@F-@ZXSE**"X@(>+"Z'13( 3^,@O^$E->2K>DW&H+@TO[4_M\2CZWZOPI]=
M6[;6O<=_?>Y^?UA<9Z<-GH<V>#22WEW7!<GHO[ZYFPW[XO2;U0J$ SA]-@&_
M[)*N@((F_UHD(W#=8J9>1K-$::SS13&,FT#0EM&??<G!;XEL_2##AOV1FC?;
M#Q6^=N-]2(# !EX;_YA!284*Z29C^'KBMI) H,PF#(/;.)A$)-CC!6\YAGP[
M/6=^3GMU&A=#,.P"/<WS]_'-3Q_>_?T=W?#\Y$5H>(Q#1^P;TDZ:T];@P8"(
MF#9F,ATLBC)F6F&,K\B744K"I>S'9<!M"D0I8"P,'!XHU7P079.]P->%H&T>
M+89S&0__.8SC$6XPC!-P38O.QI24Y8(1ZC3H61&/XP):AX8X_!3JG(%4.@UF
MBP%)$5U&EV!G8X##/!LNZ =@:"9M0V,#'_0P-L3(F)D\D[LQ83B-<CQ.4F#.
MF=T^3D%J+*N!AXWIC?+; _I-[7'E8=?0P39T..\:.NS 6+ZNA@YK)?)=%ER1
M DB#BNKD/<(E([KUYP=DRAQ(H8RJ2JNT2-F(><3F3^-+KD]Y279(%OQG-)V]
MH'^3@90M@]]^>\D_Y>](TY$")7TVA[:1$B :R#1:BB)A/5/&*2GJ"5E7K*E%
MD7IZBC2^Z#=Z/@W@6G25:CUZ2]&5BQD>\6W_],BC;3<G@@S4'TL4+#)21T6)
M0V(2IV-2Q==).5?=7<[I*:(UL^!G$.]_.#@.2%/ZI3D?7K_$U]69/@RN^#6:
M-F18'QV99Y47+>)IE* &*KJ)DI0%%#:J5O[8@X$E?N72K-;+>R6^_[T@^[K7
M\Z27#@,YD^8)I#B4%S\8<(\#<S)SX*O$JMSF13HB[1FSZV/M@#>O?GWS\Y68
M <%W<19I$XKO0QC0MQ!%^B\>H[<B6=%#VHC8Z6EU#?VB,Q*B12JM$%S+ &LN
M\"'_T]L/(>[S_H\WO+PD%-X-#X._><O;.PJNO#T7JX@$,2U2H@5Z9G3H6$ W
M$I/)#&^60[G!7&@,QQ:KN4DPW26DX&W=;Y/2/*^E18*YB%LC:#<-8X'0<3&+
MA\DX0<^%/P_^=OCAT+?7W$W@\<PKBU*UQS!ZZ1>1B,TSXH]$>QRX6R;_EAUM
M.E/4F[BX?A=W[IR=VR=O:'I'([:6C D:_TE*#)*( L60_S^(R76XH0V0Z>NW
M5D:R>)$.KL@6:C);!+G-0-9^, T36;35.NM8SQ(Q/<5Q^X#''0;OZ%?1@,Q3
MNJ$9#21VPQ&U#BBTQ:/S9(J)(J'$C;7!"ZHPI_F"?UT@MC*#=V^$V?N96,AS
MKC;64\L3J]#7!&*96QEW$B=C23!)P[B88V=S/2U]0D_1"6 ]A-=_@"GE=V*O
M*4N7/*9D#O_%;74X0=Q215QFJ3S-1G=OCI7'RLYXTUP+/B9WYLXXP!X<D5#0
MXIRQX/)F)NU]0XH<&A&]@D0H8# 5?#:QP-@YV*Y'%40((:T?'V3JK+>V8V6X
M9Q>'E_W+AZ^4/#X\[=WOMD]0,$N#[?<?I:RS*TC<KX+$8*M:Q.=4TM35@G6U
M8 ^ P>33=U$*:T=N<S+.(/Q"H.$.,;V[$*'^22\\/ML"(M35 G22O1^2?7X>
M'O5Z.R;9#VN1[<!YHEX? P.2["8N[SA36B"9>PBM/ F/3]=3[7\Y-;@%V'4/
M9[9_?A;V>\=??&[O:PON]PX=)UF4#;?>H1O-QKX(V-E1>'E\=K]6 D]@W'P6
MMGU_EZG7#X^.[MF%ZC'TPWJ(_'/Q&"WI)&L2SB344CJKUN8AYF?/[>L'F8+=
MWJ7]X_"R?[)^ES[03GE(7?NY0UKE3G9"_S4(/7H1'=W11.XIA?[Y\NAO%<5\
MBKSH8?!J46@N?Z/4IL)J%(;[[<7QX;&%M#!>9Q6$^-OSPTL?!M1 /N"P_O;D
M\+R*]VJB%&H@XI>5G/Y5>TZ?'G]VV//O[-BT]5T$7/!M?_L!"%3 /IG10!XN
MXC8N&(!7DBR01^,DP)8BN$H'&E$<%<-) W8CT)V6@H7W_B]>>;]X;0L=@)G(
MI.8%^QT(9GIZQH!JI=<6*,Q,45D.(_X<T'%;"7COLB;@)[W-!%RDIW?B7;U"
M?.Z _6PDSW?(F%ON%FDSS/(08JR]N;CD =/\04\'\P+P%A4[$9)H= - I8Q&
M&>2G>$']8F1A^T,(T@@T]6&P$EH6JL0!B18-@5I*O@YIO>\9LFGD\FG.D9>;
M#'$[%$VU'@P_(_VX2!D8J35AMC*$M^8TFIO&!8R4-CNUO;?!G)Q%@)S):2S7
M7!=Z&^O;WG'U%*O\G 9#LJC55' Y9W(>//34-$KE=F)J3JNJ;Y.9V44$Z4/L
MSG51RQW9G6U#?+C="0RYE3_ZFY'\I]5SU._6\>5PZK8T"^CI#ZV \]+ RQ/%
MT8N=:W"OWX*YWPY=A+FM&DV*$O*9G'%_XLPSYI?;"].(1NX75F!HM*./@]<?
M_OCCX=?I#E4A[]?W8.E?]OWV'Q7[\\)4+I 6*\08V@^S8ZV&^$?,!B+9;FI<
MB:WHF8=BSF8970,!8&M4H-'7>54\0S)KX>W31BO0(0GF*7Y*!Y[8;[Y)&-?]
M1*W+U(M%6MG#":MU"+BL8JQ"#X1:(15_LDA_5$GPV<6#G&%OX5K:0E(?VK19
M#X,W8PPY'PC$?-V->"NBCDN56#[7H[=A!]_:&99)I8M+6O=D3&_ #E[#3#:+
MX/F;M;I8.Q[\,UN0&3U?V.+6$<JST)I*RQVX=@4UNX#,1W2/!;D!6]\(B/@L
MGYN5F9'9G6C)@5\0JTYQ;F>$)"*+"YK;JR$Z,=&]TR5/RBTI'C;O65O(E)>+
M 4J$&&'O3?]8]]X*252IV=0G^/KJ;B^ZNML=&$M7=]MRZK!&^JR"+*Y#'$N0
M>R4APCR_CED?L=* AADF,U:N1K,JO4A8^;+6!I 'X7]O&M+5(CTK"X_HYV1M
M2 \[C_6 5"S=:I@N1J)ZE[[RTUK# ZT''+96=;$R)>L74[/@XQLZTR=^\"-!
MDAX5T@_^D!XF3?.<;6-/#NE82-/8ESHK+;,UOZ_\AH<AM6"PV:=X%9PI>4%C
MI#F4-[RS. ;R>@SM+#F& R25?NR?MTJP?)1P\=F/![CHB60:5$/]LQ=/Y^[5
MINL8N9QO_L+>UI"$(!1)BLLR5$= !8%#?;3$HV)QC3-_F-_$Q1*7Q];0JI3L
MJ43#EYJ;<$:+56;*3)M&T8M. !Y9 !;#(2T\%Q97$PRE*WP+FQJK6ZG'7BG>
MC>&*XEDOB$''54(C4>^CVV*[L7!*1D1.#^\G, ;I*M(*P61A90G; 9[L;$;&
M@.PSN%]D;-#_S ]BU*8.33TJ#)$T)8-I(1:!!%4U.B9;>AP;)ZGET@/C2P[3
M*)E^MG1THK!*%#9SYR6*0/^>QB,R)A&*9*^<3-EF<M$/<78+]Z46+L69:'(6
MOD>P+OG;+<>75ZGU9M^B7V5OF7BXXV7P^"/2:)'1GL(1*1&I:5[$JT],ST'A
M>PX623HZH--7Z%A2.I%9@;H')-FXB,IYL1@*\9#P7KS^6R<57THJ\AK128E@
M0** 7W."^LYSU9J%3SJ.;NA/YFV)BRE6?0PRD2A-NV5[I&53;V2\2-,E$DID
M%L58&ES&S&+Q=3($(2/Y'W=2,7=V[ .NDXF>L\>?1DN+O(%B,PF?E^_^_N;5
M0>\R8!#/-!FRF;)A+NRX&I7LMM,]ST:3T/'8 J,A1^)PTM'L:IPQE(,O2^:(
MQB @,_>^XI"HLT$Y\QT/)QF]W'6R/T3H:Q?Q;V08I&)>@RR*%3Y9=D5H$I0T
M).2NH'<J":A&9+B2R9/\?.S8@@2I9I@4(Q@* [IFKLEUA$GG2\<+BZSF8.[2
M_(R8\P^KT-.%=#HE>!I]*(O'7F)1H.C%@0ME.;.<+)IT@626=P?Z1U9&0TF-
M!?^(@U'.Z3RF"4:8=AN2*WT2@X6:,:/#X&,SZ0AL990@[NT=SAI"-G/F T/,
M='%VCT'D.+)YRGP8$NNE6R08)\G,A>O5R&/DPB1/1_2]Q*8'= ],CH'],E$9
M[  %1925S +X-\4HC)586I?3Y7M!/!QC9>0UHQ&X,F-DOVFAAYHN51!+D[-3
MQW88O*K(@A@EAMPRU''<Y.F-GS>0)YKQ(6I+/Z>/V5+EP$&!0.^\2(9S$T?P
M3N%Y]"D.;%)!12.T?JBP!;*<N17#_&,XGR11T\@@E'CF*!ZF' "AJ0:<Y;-8
MT79'CP@V0(18=H'=ZZOLS=8MC"E:L8F5,14M51A)H? !+#_O4V:QI)&1))+"
MN8G2!1NRCH&3X52> @]-ML;XLC2>.)I*!D#@XYI>XF&U.47T,7U/VUA/#3:B
M9<NP_&%P4"2TLSS3.@\6%DX!Y, B,Y\WM$!U+MV^KZE'.N?BC)4LT,V GY#9
M3K,[9$6GMKQ.UL"FLCC:PJ9,*/L";T[OR*<D?@0-'5<\0A]LXEAEUZ"9[0RY
M==![>$G+EKFUBO$V7Z2JO6\Q.:)55MPG1YJ1%$';GMJP,<'%!HT)GF+?M0.O
MWHW'!X,HY</VPR2F*;CR]LS]S,Z=4BPXC).1/8W),'"%"V20)_D(.#[:KYD]
MMF[M^:TT]NE2?RN0)#=C)<^8KV5"Z8 Q9@9ER51K)!H[%%S-Q2*]O^VW6\(#
M] 1T!&+A[P8T(%',S^ X^H>V>*B2E3OC0*-1&0@N<2Y!;< $&2Q*V/JFK.3]
M.TG4UI.W!HV'R:M!P_+B.LJ,%L1ORP7)S[(%0,:/H(-GE!?R%#^E;$^@<KX8
M&7BZF%4T)3?)T&!,17%J/MF"&6:+8I9S@Q:IB!EZ*YV[E>;39XBM($3AL-%H
MB\ 3 ,IV0=M!C'_$(IB[=D8[K@AN"QC#&?88B-/5!99W>0[6S-;5?UB86.J-
MLKR*8.3:>VM_K%P(9?=-YB*@KJ9-E-#;*(M$17'3IO,79? J*8>+LC30F2LR
M%Y9EPI;TSV(8T#->PM^Q\)KWBFR@2[PN5UJT=)5E"^YS,Z.3VS+6]XX._FHC
MR4N229V%5_'0QQ+U!%9][V/WLG?7L7OQ9/V WM!RZVL>RG^;__\_0':3P<_V
M%J::/DC-WUBI-"_9!2#[=S&GY61SY7U2?GH&V^4?ROG])W0.&Y5JCA7T?GYF
MSVR&2J6I@(MK_0ZJ$#4MXVR3.&WG,]H>&8<"C/-^__#$HORY6/&\=WYX83YB
M5P!!#5I&('.' /8*J,<5#]"-I'3)GBU,2/\1 '%Z&/R$:Z"&,K::?6P>;WK2
MU!Q=J;GO@B>3IRQE;F%JUR8W*:LS23?(@,"](3\AU.@7:/;9WY;:"6\1L*=5
MP0><XL.[\."KRU/#K@_B8;0HQ3'H@,062'Q9G8L.2-P!B9]6+_M:"0K:J2Q4
M$TSHF#^ E]^N'T7_K  5%QP,_J>MV_ U$.LE46WPW,=D/.)Y",C$"-VI^JIJ
M&%M0 ^H%:U%Z8R2WST:+!?-CWBV O3+.25W;H&6:W\HPR#Q&NYWFCR0<HF[B
M($[1703-@9(I OYX#=QK06:<&$%'P2""<37+D\PG5*J]A00K)&R,XM*8Z\5C
MB79JZX=QE)AYU4E9\TK/P9I6\X <IWP[&X'FGNZ3J1L_Q"FH,Z]&@W'SC%7M
M^VUI/E24.MD62<3K^7H!Q)<&H[DQ1Y9+D&O4\CS;6T/#=)[$CU/ &IS]W!BI
M$>I&28YV![&NJ)]N\,(5\>@ZUMYYZ^: 9^]SC*<TD: W=O6=LR$.#FT1%>S[
M6_LG^V#MGZRT]CEPDFL@X \4AHY@W#^#O2HZW_B:H6M3)@8@*CL\)4P'2H;/
M4@4JP-G)Q^3Y:E,V]_W8>J3Z?1C$'**7J)W),)F""A?=X]1-(98K][31=NJT
M29J>ZO](SDOT+=AC%-;-?76L$R;JPBS?S"[?8?"3L(-DHB%T@-[[WGT/?965
MI3:?.6O<FQ,9K9&K#=IX4)R\&O'95GB3)-V"D!2(REPR$5%)M^,(*7L%TLF+
MCV%.^A^]N/N9(5_9>^''4T',@^AIT#N.#GJGW\52A]X['>E?KBG=:Z/EKH;(
MJ<4DTM4GV9)2\XZ,0QMJ_T!/PR,8(R<+>4;L04EBT&]NX[(AG +E=Q.1<[=4
M=ZE@H3/IQ3EW\^/T$)T.T\26-]7? 4Y8 7-U!'GG89<EU_4OIK#)_@WV(E#@
M\.T5S9?87E$NUNT:G^FW'UZ_M"$ACDWS??!VR)S>+1N:(I6MCM@$9X*BN;:P
M;?_1%YO6[68T&@X7TX68#B:"MD  56T)_-K79@[#B&\^2WLA7AL7)<Y_^B_>
M&K<M:>[(1T;:SJ2,2?X9T$QW4VJA" V7>%71SYN6LV0SPO58LC/GMIFQQLV[
ML#!=9R0W)K?.*(7VK8B8)"T*;>!@0D_F5GAV!7DS<3 0X@B\AQ(M2'NO5JV
MO<8=^31*2@9MSK8136'I^OYZPR4;B 1>G ].J$#R: W^N1A=2R_ S.I;C;P"
MX'HP(!T^3N9B(&*:@&0 ##DO2P8]K-+ENTBB<E<O+B^$[%G!IL*AD!0ZOVZ
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MH>*K1O:=]H:"#N=3N/75M78-CTZD60DZVT"KHR5K@GY$.K-HH::]31@22:[
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M<U/K4LO;,X]B05[;/H+FB2R\2%NM*$P+,B]1'FE6L4*K#7!\Q<%_1V35%<N
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M#(/@$\,4[+40K71+^:B[UH&6.>=<\4SF$NN@+[5,$CCE EW9%92%G^%BAL.
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M,JD#!EY-C"'#4LXG38KIK$N6I:IV5O&,NZJ8[=*(LBC;HRBXN9*&F*NE"N0
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MQZSQ[AS8FM(5OUG &HS&=*&,J%SMY2-1ZM+(6#"M/I>Z;NX@5]_5M>V*870
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MY;;,<9(] DLV--!83SK!WI6KNV98FLZ#(:H2BM+@(Y76#-?6+_5/M1<DU4/
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M^O8P )]9&[K#Z/<*M?6&%N*JL^:V1F_=WGJR6LG/#(%:?>\SRS?F,)WGUPP
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MF08W=*LN0#X3[W1:W$TH#Z*TL.\?(_HH*DPTR&]-MT3ZGJ(MP"\J:4DD/[.
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MG;R$378N'QKL^=J%F?M@$UFRPCJY_-HG$$46V8E/V!U3\ITHXN/TEQV4T!U
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MV)4WG/DWKDI$YT80'BG4&453NL!OKIWH6$3LO*@[1N(*+671?9?B9 EED"3
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MZH2P@MQRKB!Z-K*P 09B2E;5\[N&LQ +HS$K,+<+3CJ#V>1L6F7@XGDAA_+
MFQH>E2<:V4J5]X2>*7P-_DYR_\DBL(RJSJ?6;+U*2^YXSWGH^#EO"Z2YLT9Y
M/'KQLD!X'&996A/($>'ZB)'C>D[9U<M*V<"D#B_D;9;WT7G N0V3^41F\TF$
M9V/X8!O@ 17)^H!I96ZE(V1,!B]V2+WBRZ,)U8/;T'7T\MR.0BX 1,V>W]8J
MYE*/)N'?!FR82WSR;D5FWJ1&< ZPV,8\'HJL-H6WICK)9/WBUDVU.VD+#JUM
MN>5YR6I<Z1EDBE$^JZWY8K1=$U=)_O <BFK!RG!^(#SVXM6?!2%<#[ *83(Y
M<40>\J8+AS4<M9?!:8*(U_,OGOW!$G:WC2#QS2RB&ZCZKYF.<D,%+-7_9*_<
ME-_\.+__O]_36(LH [$XV-?KH>6Q/O\B=C;A.L.]4(E>;(W^G;KQA+K.&7'G
MF;=G@O^[FK= 48Z676^MF'J6IEMRQ]@4/='>TH[6JJ'X!X7P?]:[L:M.V\+,
M.'L^GXG*<QZ1SZ'K];MS/V/YJ6C_$L[$QW#W2H]\H9-A[9HGW)*P7N'-KF\C
M[BFR+ I9$FB0[<DJ,)-KO3UQ62#B4PL,*V7;@*0J-#G,C26"7@LS^($V<XJ4
MXFXA]#^6<+XKKN>+H'$6"J.KOE"&6JU&0$]&VPQGY6F5+B1A29U+,K6[&@'H
M)FI9)L)Q82G;\,+K^"MB9:HF##A:&9NX\*K4&-<S'YM&PGR9N%^9DO-8I!&M
MGKZ8LQ*%0Q'&W)$<#?-4N^JGZ-N'=7 _P)RK&I&[>/IT$*WXL0BKHRI'5RF[
M7C("W;R:CYMXB+3K$F)$M?5VYWH:#O/D<E=M:QZ5!']Z4WOF]NCD%'%76V0@
M%V\&B:1]JVVCD3W78)!,S*^;'@;M5D8F%>X*2U8HE54,*>9=S7*ZM8G4XSCW
M\:5$),'3]AQ@F2F'VZ-7%3OK/]E]PG+"BNA$PZH]A,QV/>QC1U]716%8]C,B
MKD=(2EPOV@<T.CT&6YT#:%<O7O_UNY=/GOTAN!H-%TXD.#&IJ'!>NO' $128
M.:T!F)N#P_1>5^5NN%Z7 AEQ-H)92TT30'Z+F7CSQBN6N.2@78*A0N,K.E8]
MMQR\-P;!6 HK9CT.O>C/2!)#DCP_(TD^@[&<D22V(^<R$G13B-[MG,,Q8PXR
M.#, $"=M#:L_3-RFY33)([#]:8YLN03H8L"9*E_BK]FOH*BG4B(*3KDU^51D
ME4Q(G[ ^VW(&3?T AB/_B]3Y/K+"_<U=XN"Z,>F"E,?_)FG03FD <+Z80(U_
MDLNR.'&/+K+]KN%N^TQPV:AJXK1()/'U#]K?I)G 9$Y.D"6,I/#(2]6SI-$<
MN"#"])58NQG#V6F%GD/=_\1F1DIX#J'2:&=#VP3AK(K:Q]!)HV$)2I,,($<'
M_(LI!^R, 6 %CF!RNRRHEN83..23K_L:)S]HKM9D"8<E1G\O)\,I]U[Q$<.B
MMD\T=^DH<G;&/;-4ZXR=D!6(,1'6^M(%'EM$OO7^<NQZACHYOAQG "=?0N%;
M)3!X%,=E<@E-PV:K<[I^NSRMK1,CO2S[FI/ 2M'Q#T_&%A^;C7U0R5B=+K39
M^X1YVI$<MR6 !>Z"3>8Q?ZM"0R7TH!5S2T=)G _4WAT1B/;S+CUOI2%IM/>?
MN3.P@1Z6V<6$X?GR""J=N8KMB?WXSQD:!";L_9/.Q%SR%SPH"R8[:C1Q5VA,
MF<?/S2HM)%=,+(4\AMOUPJX3V9-_&IN*Z:6>_Z:@,_P[=A KZASB7I$T7_R_
M8:(WP79]:,4-0?\SR$PKIH[B2[F01EG0"H5;2.Z9LE]]U5%VE@I))'TA> ,4
M(8@&MKIJI26R+^:>NR/!2[GW:?QE,]*2_N99(<?Z!\LR\=$O;RC-IE#PA.0U
M"L'0I8;TK8@FF573WUW]!XJ/&^R^\0"#=M-R.OP_^:9\T]&=_(HTKZBZS IH
M '^H$MC,ZQ@H3[N,^#%B#Z?#NZR.K?PS?2Q,.[_U7]R\A0\--ZJUECU/@6AA
M]H;VIB2IT%*8+&R..'\+!K"#:( "_D6:YCM@5'=']QF7$21,K%_"U657-^_#
MKB5= I2]FW;F:2(-Q^CYC;^)Y1T79D,74WD_7'>\<QVIRMQ2EBU&IX\##E4W
MUB1NIG;;E?O*>%$R[I>#4]"8V1LFP/FWL625" 4/>AP2,.'SOUM,<0/.. N?
MMY0F/.$EMZGG:,(3#T('!+$H:DH];&<6OZD_6 ^]JZ>PR9FF)(3.:8B,DHD;
M?T4'F@OQ5("HE$4^*N^DQ91%M-[L?&=)%X?I!:YAE6CR*"9X4IG7TEX9M1%H
M(/+&6KL@M9<B"S*7ZJL?\PZ:*W:!F%8%;LT0P/]87]>5=*YHKW]X]K96 2W?
MGB*@#VYD"5[">CUVGO='-%M=98+S5C3!TCADXL=S8<W)-PQO=PIAY(G-G!W:
M2?OR*:JS1V"*$LIV=N^^'JGEN,PE&O6:4\P1? .Z5R>=-E(/0=8#=S'=(5%Y
M]^L?X!@*D13UU="7;B"BR3"A[ CX^J7R+GP0<!BS(VH^4TJO>EXD;SEA3^ 7
MR(O?;7<Z_<.;>,851SUWR4+](QX^'X%H\/@P=N%'YN1"M$G-6>1<OA><_ 1L
MKF$"2W02+J<J51:PA">79*N[^>QXGALIB%"'XZ,:[8])>+0$1J!Q4<CS,!;C
MMCS>3$:F:DH*)9OZDDN:'UK]3X/"+ZP8D@0^09"F!@@ZAILZV-=+OC^1U:"G
M6-I :99C7,[7RVK3C5>,&!"8\'Q*8D5ST8Y"';VMGBC7-)VSX+HPJP\H0X3I
M0GT$/&!3A7B(")H&06A'CCV0Z&S(TPX!R#XXKHA!PS\T5;71!B2T?4X?4L0G
M@+M)4!$L>DW?I%T^/ZL1X $GG. _'JMQ<UW!<K8=3@A=XJ"CGO^QX"ZVE-#0
M/B_J*L'=SOVY:]!8S*"U>E(HOZJ5V8@+2?YG_4D5K$<R' HF$W&^J?.B.8"E
MD;L$D"O%S%H .^#3P^^R<85<-^R/A+62GNBPI/0JE@?NXQ+0 #1D73H%X??K
M06>VCU%E\AE*R:QV;;C#.L40BAH)85&XRXTRE=;]D+Y=F-3] [% '\UH:K=]
MUD*_W.[==@>"Z\H!CK.,GN7X3UZL2_U$_$/:!%;X [)I"UY!_^4H7F8-S@K2
MM0PJFFZQY^JH 4XF*#SPA#_YKP>]^,T9>O$9C.4,O8C-XXM)<;019V%!"F^=
M G8YQBKD8F3;Q)Z -$36($-?]U+NXI,>O()^3]4X\:""&W+05 E(@Z)9ZWTZ
M]37__259M8OUD-_+^OA8=*.41&I ^?I"[A7_W78VQNA[46J5W"K*9Z#M>=;G
MD<J4+S5NJBTCBWM68\M>#LCAZ@9O4Y(\PA=%6.R$"KALFE&JEM,I?R@QTLD-
M^*W.%OLJME8B_[MXW24U-?&FV(EE4?,%S/_ ]!6*W:4_64F17,YY9T\'5:=R
M[Z4FP=&$.".3J;M"._5ZNS)E*/"$T]NS;#@[,-_PI>\ >0$=%O^1/"_*#_*8
MK,ZO+0<R5.)8PY4OP/DE[/W@/\+GFG_2\BC>29 ?E_HTTX5BBOKZ9P?1MQ%'
M?W!?50-/RSK8'LHRL+NR[.74VWQ-(JIZ=[1LW8[8_[59$KEW/^#$)^434!/B
M_O6""Z6XXS9LK7K:+"=Z[=X#)C!#U0]"CAK?@$11$L"K:QR57_:L2,R/HSZ@
MQ.T.1OZWD8 4TWX"0JN$J<7?.&:;A*@8Y9)!\T5@[!=N4<SM9V]@A&A^:1<D
MQ].ZN 0 (GZ]V[NRH6.<ZN98FR3=W.[ D.IV@(8.=)6,V(R=82+8P/?7[4TC
MQ$!41>B*C)>5P?OO:?N'__\3ST7,_8. G"TX89P?A>U]W:PNQBM"HG"I];\%
M#AY.!2+_ Y$S;FPAOJ^2D@G=N5SOHR]R6/_]Q5/^?X4 B8Q#"6S+ZW:#<Z8_
M:>WEP4 ^,04>E\]*>Q@*3J6[9M$R33.XA :;%.L0E4TA!R7;Q;Q->J=#;SN2
MK^ZH=V#0&WPQV;S)4:H=:DQC_87PC,TJR5F3Y%._4S)7L.72U-3<:Q$L*JJ3
M[6X3B:6F;A!9B_UE?37R@%T'ONN ID[7JX;P!?07&=B,06<1LITT<Y4X12+G
M,C>W:>Y@RTEXDA$#+;\L2CY>Y-V&WA?(\#=M;YJDU>LMW:L5$](0=Y7W^SA7
M[E\+\[WTXZF.D[ +#&QTE9F''H$073J@6#[<9>&C2$S2(8S<OW[)CY',#+BI
MAOY.@\Q8>HV,5QB5+2O_6)&L5)8\V6 9W;@E;.5R%<)F\T0CD0-N&%6V*^C/
M*GWX=K.P*<H=!U91_$*X9Q3$N8#7C AKEP<,1]QHX=!I%]R#O:,O].S$UU6C
MA/6Q;+E'3Z0:LP>R:TX#B?Z)>X3D^%IM.$H=-,=.0K.==9QY.A?/:^1(C/B@
M*X\1(8,B(Y-EGW4]"T.Q)P1&3-*^R_;-5JK?2 K?2F84@W_MTTI^35"SCL.%
MF>\C+8SP5=,$Q!G,Z0:[ZL!TF81EP$6M_[*SRS\^-3@,W[YZDP[$"U8(+(0=
MM=9D)>+2%/81.,X@M6/P=,>Z$AO&L"/4Q[^V6Z&C$HK.=CW*4%R+IHY$!3J1
M\,Z (CT("1B@<7WLP_*5C0)!/-U5K!3<N8T220:6(31BC8BQ3C<'&B6U =38
M&P4#-O:RR?A<8&=K_Z/\E.'[VTXQL^:D\QZS,R(><XE^'3=/6_Q#C]@LW1W:
M7LI@B^Y#%38W5H&"E[8!#R>[5]AE!$]UF!\_W#PUY0: BY;6@BG,6$A='!+=
M?/LH:,#>X]7Q,=C$=Y,3KYQE^7R]I'8#JRO^B4:]K@K-4KQ\_2="4K5P-<1H
M\$'RJY3:/K>;O8%#%*J I4RK:Z#^H;)SFRY!8$&G4RJ(<=<#\[DQ&@KN2Z56
M[7#&L)?,:"/!8I8K^06US&E_>7AMD,:1CN  Z4)02'G7H$D9C"6> 8)I;&Q0
MT5*TV^T3/ Q*8W(MWY@SD;79M!T?40VB2M49BQ7CV5E8T!ZKP %<F42+I)/B
MF&S-GJ[^6K?JB1K;W N_DY0J(-])WY2[\&8BEHBLK+?8L@ZR%TI68+.K$'L#
M;+#,<\>)8VA["02"M77DK J=R.2MG,#YA^0UMM4&##FP-Y3JDJ9E1/2$5!PW
MPCLQBHPM8&PWU.I#N<&!F>J)OY/3#X,0%?!'V8JZ1S)]@.J!P?;N35*#[@B'
M#RTW>P!U.Q$%6@<G0+KQNYHX>)T7^1AL4])$P_D<*O13PNDH&T%C[K&AL*^)
M C(?U#$VC8QE_S<YGU.&*.>[M9VGCKF#:\YUCF-=[3:.B0\:3^Y4_,]MBT5+
M\QNJ@-)\-%=/"%#^/\__>W:Q^$\UF);_YPE]Z!,M'UFZY[_[4M_M_H>03==O
MGOZ6YB*WSIGW?-?-\.5YS3[=FG&"ER_D5=). W=85_.\1I]PC=)H!V[*>74^
MX>JX<,NA<;-PR]$D9CC=\VK=XVK=E!WPF;L*[/K1CVG:060=S8?4#YT7Z#X7
M*&9[LS1#GOT]+\N]6KGMV LT60K*6FQ)F"A;!IGNHCVT&/D$H>IY*>]U*=?"
MOF"1VGG^[W'^63I=*%CY.%S7AUY!5T?7")"42)87Z5\/ROM?9RCO9S"6^X+R
MGJW//\[ZC TH&AB5V#&B@:C+KT3 Q8P3I?*ZZB"-4N<;XA[7:,O94XK[Z\'"
M_!#V7[7=591B ]92Z(+11'U>I'M<I'[LP8K-BY.&+3,]^>>U^331RH&PP8/5
M?SH 5$282B@:SF[PIU@C15;T5?W+V)UMUWW.?=W\-#8183<MCG(!E'*5D_HG
MQ,W.BW5_B[6+^!CF@42U3)L)6.@V,6./H4+]E[9YLHYBJ(B-O_YA"0,F&"4!
MQ$CI2MB"V@_U50UDDZC#<%$Y1[5)J]F4CM@ ,PI].81Y+JD@X[K)"O1=B.J:
M8@X\PB"X=&$("1SUZ>IM.%N[LJ/VJX7BMS#IG("^.2"$R?-F4L,V- 5R^(%%
M="R &67SH,AC/Q++_'KLYI(NCCT?.*4-]- SY*#7R3F41\*LSN!!7<\7H82?
MO*_7[R_+]?MB@G"):![W>,*R3 FK@&TI%,8BI,!4\+-212%(:G)L>M6;,MMM
MJZK(%EOTJ 8_ BE+P1\B#XW[2%N .(H8# :4S#6CGA%[0/*'N;(JKJP\E)US
MTOK\\>_9$ =BF"+D:+TG+L*NW1EK(J%/]WLB.#((5H*Y$A&R&<J*%$"]A)5F
M.459D++KJ/MA'WO.?NT^)Z1-LK/ #;([^MW^J[?WRB05U]P^)'-E'1<$#3+K
MF;P4_Y(_SJJ);E/%<U0P8W2*:&3VM 3P=Y<9_MY7XY$+2Z9A >6V_/H*[D8C
MC))@GG%+]^A@8>9EW2[(:/^O&&VTY-)."6M_75_60*+/=-;QK2L$>@27 \6_
M>!N[W79$:R3ZB5B3N:5&S)H%NZD]33T6'$H&XN]'$.3!MC.9X0X@;$*:\G_A
M0EB7_37_>?6^)D81X#2I YCS0D3J6<@'NBK8!<!.BU55RQM40LBJ$HBN YX_
MJ5[/V*VORQZXY VS &76C+A4<#H9+<3LA%=MRT)!5?<!J.9XS()QV;."D8#=
M-Y6>)UN.U&(1%PVCRLI^]0J<2")XP_]1;\Y1Y"<Z-SGR6+#;?71"@*;-O0\/
M7V;+S1\).Z0?=M5EL(:\UX+_NQK"ZI=&DD<RA]0/[@@;*+-#_=C2OC-_6./Y
MI*N7/B\DFR2-)DCIRTK_D;H\MG@WNH;HCAMW:$/F-P6MJNSCR^/IC<LMSKA,
MY"=Q040B.72F:'<Z]SP?(]L8?P7/Q5'[T,)4%$2"U55E+S:$&K;#LQG['^ZQ
MG<:._'L4(U5'#75TM%=4 FB8$1F>0BQ!A@!,F ;C6H7=M&%$[M!5=.N)X\BW
M7A)<=$]XQ#%]<#ZAG^:$LD^[^J[17JPW;:>\JE@X4J<9&_N3-)@_^\,??H?C
M\<?OWEQ<%*?.==PJ4"3\N5J/[#NM^O5UM6<MLTH=Q:,_(Y=54X6 8N:L9"<E
M[4%SO[ OSUBM^]Y>LB6H37_/;#W2Z6A[+28AWE7KZX;(?7AW?*TTW+1]7B@@
M4K[G&].M>\R1$\@-0"D-W8[1T"6W2K14/LXEOI"^F'#,4A;I:DQR*_6'<DW,
MUV$K=WI.0#TN?9AT0N(-1+W@M%>"^4,P( TN+A=SWIZ?R/J]T2!W]88OU7[U
M=J2@L:FPW8RIP<5R6</"EBOE0C_1,X '=:2#_F0,>K%)MO(]ZG>L9II1!V+Y
MI<UVW?8'2F*=D^OWO4?*<(6U5]0\Q-$Z$EJBR36?C-/X0S_ODGS\[>BG]?$G
ML!^( ;19'UW[7J1FA?W957W:=#%)=\COQD* NP)K$OITP58?-8U@F9NV>1(]
M/;*#DU2/MYVP?E#\Z'$"'D-B[RWQZO'*86F4SR93%@!;:R,4_WD^/OLL1=O]
MT!V-3B>L#+E1N'.L@'$UAIMAAT23L@ '1Z;Z0%YR]C'\#^K3''=7Y1 OU:FS
M;L(V^AH@,DG-5K12OB3@2AZ_UGA-DGN64DRW,,3#-_7 ]+9O%TX9W>7\8O[F
MY8!"+]\PF.F-:FR)Z[I;CWMB_5A+ZR&^P;D&T3Y#@@;4ZCSZK$A#Z$!^MRTQ
ML-%+"?EJM3_(2HC/,UR/O2S<NAR4>%564>0%'L.!^3HJ)?AN\8029YIHAF%A
MHN=*LN+^%+D[]K;L*+ZK\G>>U85(#4A\&W1!P0?L01F-P24VSA-KRD LX9J_
MR($<1!A.Y=WUHPZ[L)-873+LT8[[(2.5P"W,SDZ?2)5;#\HMDP%Z<AIP>Y#4
M8(\]N@UAVT;2%F%'Q_Z5-A/+P(\*Y3$_,9FJV:2\W4[C4F>[/T$(!(LT.$R;
MJWWVQ^I- G@+SGQ7]ZTD(H01*Z,MP!%V)G [(O"8YEO<53V;*BS,$(>%'<IZ
M%Q,Q8:RCMJ6V^91G&B3>+,XM9&(5+3N%#75S39)/S"W$4[EISU+9$>3]VS/(
M^S,8RYFOV7:DN_%2JTM7!15C,L"*L_E,4@&2E:D%57-91-Q59C1=!3\ZZ&8@
M/\8J/@:GY)TGE*'=)NE#OMPVY%0C'9TZK4EE+,1AP:R75RKQ&HOP15;7(IF2
M32NZL(6K@Z'/[>CJ8=*'+27E3* ,'J[6$5DK<1#AHE_W.L1#A06/$4*CD U$
MI9==?4E\'GSK;PE'](IE#%5_1>]'D! __=^GJZ_D*Y01>?[%LR](;G<+\AVM
M0SA'@A$G#N[DO+.M13K^3G\4O*V6/T+!,EN38 .$MS*?;1,=/HR7P2@0^7#=
M@]9IDTB^JA"B^ C>NT!0HC\#:BXQ(?"/:M9E@2<6"7XR!5G[.8M60V2S:X_T
M:%*4(4Y/$<>J!F$*WE9(=4)O_BI$Q;_8SZO6VY)R\=8HSZ2@G$_*+-N=\YKL
MF-C.9CNJ,3=QVG+*)!FG_'6KO?B%M\11*#P;RC>+$+Q\A/G.3^!21'%6R"K3
MOQ ,J-E0OGK1#^;30D5Z?U@>QEGY2 1>%!!XUXW[P^K"34H;=V5"^D.Q?BK2
M-F$P-J[6G,75$BIRZQ*Q4<^,>N%_MN^%YTSUNZ,@8L'L?5$S<$XC<%'CT?2G
M\9/SLFVY!.*CL(X_5GS3A:F0U D)6#"M3/V^VM77+2FUAO-,1PUEPD&N%N>^
MQ%5T@6A'W-!P="3\]HS-4Y<IEB")J&TM5WFM>9\I\3[]!(!M)$9,7P:)9&$6
MW5B+Q:[-;6",U"UW]!A!C<=6Z^GJ+^4>,N"+/T-J"$/YGO1TB8HZ;+7\72;<
M;W7?C\JB6:Z:$;:-KGW[XNN. 7]NLRO#G@OA+\?P,1#-%(E@:,J;'T[$]!BZ
MS5TU5^1<D7%LJ0J<7A*48B,Z,=HXGG-5'9*DZ*=9%H.(=&/X1U2'B^2M]:PK
M72BX5Y-;,&_-,CX"4E]E\%$P:$0NO1'V^]30X[V-MMJ_.C.:]F&:%;,8/@2$
M;)P3&5'"XMHEP^#WJ?)T4GPQOB-V!AH1_KU%_N+:J3QNR_Y:CPK+/#X">Y.<
M5*\ _H62ZK\)2X.JK)PTS#!9_?QD)%X"0;EWR:E;(.\,FT"-O<R\W"; 0%"J
M.3++A%U(QVWC=K"B6W>)S>-4'@^41-6#IQ@^05(>3BD (SJN^FL:J-2=C[2T
MNPIR<3<D'YZR^G-JK^6+\!""0X(WC<V.DY\6FUPB:%ATSC(%=QH+JGM??!F>
M^22\]Y.69.3#7YY]Z8@_Z?>"BYG-NN)?B>K_<MQ<5<.JJ<9@!W%J8EB$.74S
M3$LTH/RRYK%)3ACFCU34P_Y*8;;X$DV?GT^_G#HE:;U/(_S5%=0=A0KTEZIK
MD:*L#K ,<!:J35J%X(O$/:VGY_^>U9@@W<XKF4])+$;+ID/LJBN<K66[W?:@
M0C_.ST4V$]$@_ESO516 IQ(I==0/2TI9D_Q3WX9@@=X+KC!OY_3GX$A-YHT"
M1]:/J/?1!Y,=+;'(:Z(3QKGX+B.J=KI8%]MM67<<#(5I?OWJ*SKEWU27'8[Y
M<R^=4:9WJ%(M._6%NVQ3E_4F#P:LM[31^;0E6^-R'-C;R;+@\EE[;R.RQK1$
MYLWD3?[K=H,5K1'G'$3DG%)!M#(LBD ?Y><#;F5"7(W^N85\3;EC>0V9$C?E
MW[/#S<O3Z02![;4G:9^ZOS[UO7=E_Y[V_=KF-N& QG:+\^\GWA&91_Y1>?OL
MU5,8&,>@K+\9B6:3I;IN;\B1$GD)*@>2!.G $N[LHXJ816[QM,G'7J%RI0/Q
M7J$U+2S>1ZE913'Y)1?I9])9)[F2(0EX-(0^<EX $/$&>.^P7UZOAY8<NS]@
MM_QA<;?D6^4_9+UR4Q-^\@U3 LM]]OW("=P_ES?!7K/#]=U>*)PN> =]JQO[
MI6YL6>K_7.VKLAGR:N'B>5!ED;BQ@D\/#_.R;C8Y([WJ@_"V[V73VUZG'%[M
M0[[X&)4B<E)1_35\NZA#Q<4S5B1"C8?WPL3O5I_9NE4&(\Z\U1=V3B^GQGA'
MB>6+?K!F/<@J0B2C _#>!Q02SS;5E<KXW5F&Y &D";Z.NJCMC$0K"VB(GX9D
M;4<6C21UYONG)-=I"5F>O370(#$/GW*C4!)W*@OC,3,&KQ&Q7*D>I\$_VN<2
MH9I'X':_@Q2!SCM-[EIDBA8DEV$3-Q#H\8EBLFKA=:_#6=T3VPFKB'%IG$+Q
M0H_6C*%5?^7T,RGC6M;B=)R".[GT@Z!,,G_"IS:Y<X_Q44ICKC0ZAI<B(Y*0
MZZ3[!2IXP1)\*.L=;;F"?:GL(_;/YHFHJ[FC/F44Y3]"QUA6BEN2TI,S/XM1
M(B.^8&_Y62^!4>4O6.X)3^Y'<1VV4#"'N%0XP@IW[MC;^"6QD[T&F5"[(( M
MJEGI0L^H4^3#/2"6P/]=>I_(81T[Z6FJ.Z&TC[[9)"M4T TQ!L^.7!MD@(Z&
M!)U?UFT4P.DY .NE#V6FLY+U4.[V6]3&+3@FYVQ28$\Y,?R@X+G:[NGJ@IP[
MSEP4<EKD,7H)\JX6VFTHL#'J"?F")\RTKQ(2*B$B'V;V1CI>BCSCOE#9%JL>
MDTXC%-!B5"L#%$U;Z:5BYG8>(XU*;@\#E#',5U@(,A2(09K6R<E()LO-7[D)
M ^*DJI](-06(\"E,HUQ-/\"O0I8+_9ZQWL RIM1@1,\YBVA'4,;OSJ",SV L
M9U"&=T4ZW$D^ C?]0'AICMXCL\"GC&^8L*:ZR64GPSWQ:LKN5=A=-&_$*6D"
M<*Z9N0\4]-\0*%@,.)JONB-[M/B?3U> *_-_U55$*_M\-DLTB<,JR7\\Z9+"
M<0HN51A8A7UPT>W979!?5J%E=7D12HL*Y26)N?2B0.OD **S$"Y%(D+SVEE1
M) M/ T!7 ;_\&Y@R1WV0H:KC6.BV[V<DUU*?#6$2"Y$YP5PN&N[FQY7<D"><
M*,1KRQ*&M+Q1)PP)=P!?UR%LZ'0I.5<TD!Q@"OWA59L@+[GDZ#SL71FV]'6F
M,UPH\)5[JG8AT!RNCUZ(VF(1.&%YK*B)$ZH^4JCEHRJK3AKK-G99)G2L,K^V
M8R]$)D;7STN@T1BN:Q2 ?2E4%:7T/[<S\1X+N;;C8<E]0W3=L(YPVU6S(6 E
MCNQ"N+#,^? ( K8W)CY]W:8("\"5($90E8,9+)Y?IS9WI5+Q9$^/')9-W%DL
MD]@^9.'1'MTI<D@BMCRMS,^RYZ/N@*J_Y#QD9\2LVZFM4LRG!.X6F5),@>'.
M!YVW>.J<,#(+;^PD=/?HR\6H- 9V<L+RV42]))_AX V0@RV'NHK::S'SB%%F
M^=ITL!PY,O#,]P\IJH;"SO4XX&IJUR/P$@U7%$1DD+%PB-P71>S#(ZH;6LFG
MJV]=RTH615MS?OZFUR7EW(9!6B_$\).!YUU$12HR+MQ[X18&.X1#3PA*3@*J
M:)W=!!:VQI2T<?K"B9DJAT7[!(:9A3W&=$EA+8Y:5'/,.A0;<^[:A4&%2,:B
MNY9>^(EII1>W18T^[+=-)HR^836#J0(, "_4BG;,]!@AT+8?2D-L#MSGQ\OU
MLBA=21<BX\EJI%$ORQ!Y/0V^:'@G75$'[I$%(#*&RJ<&IH=<> \J\UTJO<7I
M+.C%'<^ #Z;3U8X%?N:;0(4O$_G%DAI2Y[MM?"JS0,Q/AHVQA9!PVIER:O=+
M8EP#:EMMX%SF0MQ"1X!V9AZ37NTB HDMR)L9AH+6M.H>P^V65-50!04?!D-L
MIDF73DL\:* ,OU-U8A/I+%0TXP(I 1&5HG&35$8[#I0^[B5,6 W:WZZ&C9ZR
MIMI\Q8PX;K^$/W=7Y(+^6"E0"D>LRS,:,W>%'(>I+JTH:LP>F&)R(VYXC\;<
MH]5(4UO2)9E4W7I/5]^PO#P'#DTUS-C9--Z9HMYUQ5"JHP]Q=063WE4Z?XT@
MGP$YQB"%F06>"%-Q";,OUH)[LUU$A78;_&*"OF_)R@]RX&5=<.[G[C/ @^K&
MU72H/_. Y!%[C?-)*"5PX5G$H'!G1COP1)#Z/J$LVU27>MEU\91E"^M^F_1Z
MFDFT6H6T.R$ $TW%#+W8E52Z7)?H6P\[H-KH)>TW6N(,X8>!9MLY1C?S,1^(
M(?K(2M8+Z1IT3(G.Y1)PJT<R D'8N*O-BM5'2\6*.BUOMCEG1)8]R\?CVWG*
M'\?4Y?L?QBK<(24$!_*R0DH[PB%MJC^HZV2%=[4V<ETR5$O_F+*NNB7LCWWP
M41VH<IYV:NI1%G>)? LQ-N(^*H_A4>U<;@'8]3E!7_AC[#?$B&5[3O1V)XV,
MLE7W85]2*W<$YN)>: ^NJ87W>9%)\"(N[^JKMFM'ISJQ#L$ X4I7JAX=KX5-
M>],0@1T+50 PW#AO[]2-U^O3B5XO7IM9*N\1[/4+*2W-26Q+T$\(#^4(!M$3
M]71OX$Z\H)6%4'28H(L7%P5@BD;^Q?>JJL)/ ,TSY@/7]G"FLOQD="9A89J1
M6@F)[6/#?A43D^+TT"% %_)1#["116@'"CPIBB*"7T!HO:Z$AS(C#@X<8PVG
M=PT@SG#FW[KGU39/04PO@^7I-B/LPG[<!Q-XR0<S(0;A/C(B!!RM(T<[XU<O
MZ4Q_C^^1[:"^T?.ZWN.ZA@NZ;+09U%W!.7&$-L-Y/#IW$$_H.#4Q=I+GMD D
MZX PG%^OKZ1CC6(ER>TUUW0K;!Q]/,I<;1-[H,];YCY- 9;.B"[>4!;[972R
MKLH#^DV1%956</ ':W7(4P;!-* 15?#EP3[\]HO_$]:_#D-KMT]0"=*?(V^#
M4B!7[5!+LHR#Z795A17$Y<,IE!!U(!K?,+.&EAC<$+EHQ8R",3"4$IL?I,$L
MVW$0*8S(RG99&5,;&[=L6LX;\UYMV5"9+4OVF:QAO';XIHHTHN=U^E1W#A]<
MCDHM/J-3:&NE=!+G-?I4:X0"I?()F:7=LE"@6.;HV[WA?G0A6'W+!(%+H(O#
MV>>[][7EMBK7[!")^[0!>4$%(^>)6& 6/2_F?7MC;CE1[T!@CK(%EA69DQZM
MJ_TD&!<_V]1***^KQ<"$<^0T8^R_'C[UO\_XU,]@+&=EZ(=JM"1G_.0%3G$(
MH5YKH?O[JJ_*;@T) >@2<W@(O%]5Q/YD4!%I'YN"51JN71*OKO!S6"7=@"W(
M*W?R%.)WI\PV;C<JDD(,@#H"1K3:\Z<>0P;_]<#X@UB7TII3K&!9.8K+RUQM
MZ6ON@:@H<[^Z"4%SU7 'H(",]'>\Q-17W&/_0I WHO+P_(MGSTQG;JY\M9-V
M_ZLK*H0!?&(E^_!WB["-33AV@S"-\'B@/SW_/__^;\]^%RZ6*NF+Y^NO'T)X
MSE6D,)[?K%0_B?[A&)LSC0?D^1?/_TO9"US5*+S:56=<4-RU29 V\*E$$.'%
M/BP70:/?E<&M/H8!?1^\Z&KKIN3YR2G!#%2;^7=7VI;A>&",2)P,KG-QVG;C
MDK8P@1XO*P!L;99Q>3F!PQ+.C_[/_*0+K%#2.%O:6. @T-U!IQVHBK1,MP#+
M:%(6U4EY4(^H_2,X8TI=,<.^"(6L5"@_#N/@OSE+Q\03M27'"UW!0K-*WZ:G
M^!Y0AYQ!/QN*&Y?,##6"E,U#7))RLJXM-V:O?GCZ]BE9.+?IZ@;HHKR6["CF
M)0WK"__<JX]S-K_A+I$V0QDUH9,G+!QC;1"^%0K@9S1/E,<+HQ]NV)K$7H6D
M**"IM$BARYL\;;?D1%N66N-:.DK$;J.JGDL&4*R&ZW:C8*D)5NA1$&&]A7%6
M.IIY9@=B>=(UOVDG3$U^1TA'P'!=Y6WCU(VH#%63"C!=# F)$_.30$$431GR
MN23RW+9=)%K75CM64HGL'>&7GZY>-U/R$NW.-R5$Y3!A2M0,_JN\24@VT1]C
MRH+&3M#K$IC7#9'.%-R]04WY^\-@S*=%9&F;GR!!S$6&3?M]0 @\%5:I]Q+P
MDV9CF!6+*JB]](4ZX;%B05G33V)EF-I,5"3-P3!YOD#R-Q5D'!BHW5?D14VF
M6WLYJ]X.Z9,^_"3WQ5Z&_59K>!FA^3JB=+:?KMZ*96-#=1$.6==4QW[U+8/_
MP]20']"/-1-_AT,W1[S"%X_VF$I=RL9BK3 U$]U4 F<J&<X7]C&W%]' R*<)
MTU[SMHOJ:C^1$T-WTHMPU,.7F[KTY!C/?\M<*CQQN[:W\P#P%$V/<V#BO5WW
M@HWA(V>UU7 [[.MQ#YZ'"1M<)+7YVTBCJ8UWEY1@F\D</P+;EL!MZ<4X6.A=
MBCA,\+^7^X/+[DO.D4_!BU=O"Y@_)3=QW%AY+Q0?SRO0('-W@3(Q;7?5S[6I
MTX43,F"[70:#<TW8)QZ0;78ID3L^4LA+[ F/>-51<Q$#IL*R.18'="W1W8^$
MJZ"XMKA8?];-'2Y^0<S(RAMFV!BK4KL&+#IV!X"HZM'"0?&#(!.[^DNX3P%?
M$U*SWQ<T?Y1/:D<48<N46<Q/&X2Y7'6?X#[**.SH\&/)< +S,&VVC'=*/(-V
M9/[9=AT&+3Z"OEV(1T*,L:L4$?W_VOO6YK:1)-N_PIA]3/<&18N2W;*Z[TZ$
M++>GW;<?#LNSO5]! A(Q!@D. %KF_/I;>3*S*@L$];JV)&IP(_:VQR;!0CVR
M\G'R''0-!'>Y$%9F7SL4-&[E'3\];-)X>=+A% GRR;R]1CTR ?&/AI?W/[_B
M$ZY7D]#;?O/NY%O>'TT&*U<ER_7@F[,/WW(4FG\>B/1Z!E6>NLZ"<R2]ZCI\
MI@GC+I,EV<4F_'I@1GIW@M\[^Q YVUB65_Q89F'B]V-HJ%N81:ZWG%#\;)1B
ME8?)[6>2)>_^%D/JH!X)+U:_Y)6KK0P%F"G<WBLH=KN<9;(BTOX4 R<O,R $
MIS0%2IV4G[M]3P?,[5,Y4MCZ_CL4]>'0"6&#YTX9_)(WJFA)3XHX0#^9$P81
M#6(<79N>T4P69K40TB<1:D]#P[ "GAF<+U]#,9N$<)0PS4>B IK'+XIBG1<C
M85XT<7-PGIE=)*DW7NL)7 I_8'=I\(VW1 <+G0S@CMV4SS)09.K,F,4;4J/R
M+*0P#-Y_7J:45KK2R6U1MC);'3W)\)93H#\X70D8_>=R4IM0_XANI0^G/WLR
MQ\O@FXO'&[QWMWJOW;T%FWS@*>C\JWL^O"90SIE+1SSID9ZP#S,_(1BHTJO4
MF):(6M+%ZN3 :.J"Y:F2BF)@QGMA4C]E1:25)"[\D!B/W'T0$FZ2:3D>0?M3
MT,U,IQ8G421IQ)1P0S$(8<31G2JO)[V(:.,:'[K1%05\PXPL?/0"$_5')?-S
M<"11LSA=1*1JPA TCW/.P@4T3^'D_&ZVT_BY7O$))Q9>Y]+C<NH,1A,\7YKU
MWTID*!;A0VXY/KA34.,F3(-]ZE@?JD&UHB'J^UP89X8S59SN8 RIT#;[K_AT
M&O?K8H>MI&_!;X3$' GW9]L0S">.]]-<7/_N*)8;5)T-SE.%J;-[W\F?3*,B
M'XF3-M1R ]?1S(B;H!SI9;UI%G074^1%8^8CPF]G3[MZ8!S2T&&2!?$<C1RX
M4,92G4/Z!"=#,DF1+6DRKA@]YI,9#(A 7H2HP]%<\02>X#DUD]FDF8"JW"+Z
M7_2\=V7&UKA<(LAM9NIK$;=<\^=:I@/NYL\K=V>.]Y5@L/,G-2?Y)C]W<WM*
M284<O%D5)=!0H;Y8:5\^QD226$*QA#!;_KV^@@2;/L-&07F#D$>>.8]9Y]:\
M!%JC:W"/1@?J97@1[M!P'TV<(:OF8J'-,P*=,^^.VY\?YT>44AY1*8X4>QL8
M:H2@Z.LII;5'SBT/ZUQDP'DY$_MX.80<ZR!H]ERN(5]+8I;K.O?G9LM5^7N@
M23X8T^P<[/,JP."<K<CRZIJ[22UR24'YM&)>^\EF3#G"YI2Y@[F]U_W&KR@6
M'=@?B)\-B&$J.LY5V"9X+>3&IK,LA2&+]A1O/Q\5\58]V+]'W_ )7#I_Z W]
M-5S<J3 ?=CGP78I]6QX3:3ZXF$%]PWS!#:%#^2&W)N R+FP=@ST-DZ6C\03%
M5.-3V.;J?-'UE8[/8J^@] 1F#&IITJ#?A0[PA6G6FMQSJ-73<NF;[4./38>8
M 4-_6C."!3 GVDTBM2X7:[,_<R'V$5'K>BA\MRP^%$VYS?ZVGLPBBI[O0V4P
M S>F6G^MPNY-4,K:(HRJE HT!N?K]5@5CU5YV6-5'L%8>BXUOR.#FQZP%V0<
MO-4+"%3+Z^^C1R)<$'P&50(CJSVTMP+UJ0E3E*948\8-I:Y@;LO-LK#T?B(.
MC#A-4PI_RR576;?4CCNZX1-14C9MNE>TJDL/CF^&UQ\%H5Q'__ON]5??LLO]
M@ZT/7\'KYI/PFW1!2@_W]Y6+Z\G_TELNIGYCUQB2BJU.[DVF;H8>&06F&(=@
M, B^D[5%X9)2=G/AVX9W9/%N0-U\YZ4BOURN\FRAE3U5H8O6AV#H*V20.I_$
MP?4</GPM%I7S9QZAT]9$T@I0"..%R<;%0/@F)Y'Q<EI2 <JEM5-:2E':TJY*
MC R.N'9V9![,]NRD(RQ739T+^*I%*L*$P[6A> P\DIK%SUD%.R(-:<E:$XB)
MP$WQ](,%D),([*M-,_<F&Q)('22&;AZV,$B45<".>$I%U5\/[W!IY-94L*7T
M(, D0/\:TI/2P)R@@::*W<(%;D<($0@1!0A#=H5R39XQ!_<&K6?$-XR@W;!L
M5YY@F]Z,??9*",6&PN.DDT#6B;17B'"T=FM54V6?X +*S7V-Y)NT4#,1O6=Y
MR,1HL>A$0O/W% S/&;>43YGU_8N!JCS.Q/XE]ZARM,A@AAYIU8FT.N%+,>#1
MW+X=;IIBI0E).DPRV+I5;"?U.<>-[$*=91^[S/&S3>V^0#(26/^8:()FIE7L
M*2G5M!Z,QYHYOV+ FJ?E\C1E$9#\\XM*%D,E*MWAGA0K$O 40BL5$;SJ^?$T
MT"=?$X.YKT-) Q;-ZT\KMR-B6,1//YT->>)@SZGTS(VTL@P7R5RNII::'CG-
MO G($\[ CHB7FKOG,"40B5OD%2,MJ&SMMO>B)!0+KF(JB[O=-\E=%.W.?B(X
M51BL?,IUFI*LLM:)A= /HHHV;02LL<*LQ->2"KX,1OL^DU3>#:WD70^NEY0?
M3%A; ATTJ6?HR[S"E7(KXZ6G;NC.Q*&.H @=U.L%$I4;J2D]I!X@@HZ;,% W
M+9_*/$7YOD;=4H_SA%E0O9%P#Z,YR#01$CZ&@ GI:B&,TX]XS%$+6*MX&;</
MRNHC+@WZY0V8!NU?0.= (TF#,!X#M^JSVQ"]$!T:$F/DJ*@+9. YZO0*,G "
M]SY=XR!GF16"!)1 UE5S2^W?.#54D"=39]$Y:Z,\$\/!:HGTNG[/I^1I<'LZ
MLVE2SR8E51LL3LO::O*D6-"NHRO>691DZG6!!!TOE=J+Y +5,P^;4-(Y@";%
M"X2J V)3WE#8;X%BESUCS7P1RP8RA6X+4/N\8&4F3*ZYJJ,,HXI7,M,W?KMS
M[=5QGA@J7T98*@4,7WQJ>/ EW77#UE!J*4T-PQ'@XZA3>P-,[J/S-UKB65W@
M6[D.@(W?4!ACZ2J4'9UQ%7J[V/QLQE"MZY4""M:2$$"C\(T*CSME%_CF+3K@
M@U-!U4'4HV:5J3)L,RD@2:MO,\O:WU/RJY)-7)%SWB);NJE:SBJR QHE;9RV
MP^?[KY@'YK721L@)C="H]JV,.IQH_WG5;N\ONVG\;.%IY#W[H'S#5BQ);%63
MS9 @R0DM:FF/8Z('*7K!$9(2&RV8O[:()!R.'HV^G*O<$%]^:0AA1INR:LPD
M3]3I[2L>LNEA&DCF)J/_$K&*>UY>#$Y6%T2IP1)_5 LC!*S@79C\,U/79/1U
MNL(.;G1B!D\!G$J[$Z2OLBIY'1W@[6[V9*UU9H]93LXSY4!KO$O3IL$:#38B
M&_EI^@OGOB^%M<YY=^C$<=='D2,H 9J=88"FZ.1^!:#WRA9R<97)&*X=4H0
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M=1NXM-'S[V&G4W=J*-BQ=/2!E7,8/25V \/*7THXX GW6&,K?'&3Z\*82YX
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MI 3Z!:8*2-U]I@&>=.]-/\[* ND@7&%H_N6$EVZ,T)RZ&Q-[76;3LC5Z@]J
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M:\H%@$=0<1"GV,VN:G0SC$^RC, 8=6=:#J7,GF5,>]R,9Q9%3<"Z'-%>Z>:
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M_IT<=-3+LVJ(LG7=D&\:>=:<+/#77_X?4$L#!!0    ( $=B95%M*<PK8R$
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MRSEX\\-/EKFN7 ZVX;^0=]P$GYA/,$D0HB/B3"7D:*!(,&P=Q-P,ARJ'8P[
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M:?*:BQ0&.2L\HHQ"(.0)UOKQ(OR=D(=4?7@X).QOW9IY[Z(IL='6F/UHR4(
M,K1TX;9NCITP3$QIK7.1#8_S[<\2)MN0(O+:,>X\DR9562D=1,)PTWYO?N0E
MRY=G^=6(16X29@89*44^,*21T4+G6P>L-A$3JJJ4:3L([9-,'>[#N[W&UR(V
M+7?UUAW%2TS0U O)\ZHIC//1YU+DEJ' %$M$N:AME;TL/<K,#"X?V(=")>Q2
M9_Y=5^-:%QD\:)EMNXE><]Z]>'HL26ZU>_C:].Z&2LI<>+5ZJ_6K8T);[_=8
M9]VSAY*ZVDN:4N>=;A6PNZPJS+D /YIIQ+RVX,4'AK1P#I%$);?PI!M?99B]
M$U'?^>0-F+^YB'%=,FV'R%X$&S!AB%O-062ID246(P%#H]71<2VJ.'0/(AN2
MFU*&,=N32EGCE"ENMY8T;ZR"IG*-A-?Q/$Z:]CJM?$C@"AM6!C-&')(09"+N
M8Y9<>Y2,35A+'GSH=@5-YRZ'Y'64941%U1>]KQ'@?9PU"3RN=@?2VW@M-OC$
M01JLD7;@8G'-"+*6*92HLD9$%X/5%8?..V -:?VPSB!2T"QE+Q"^6UPA*+<N
MY5#*@;@^"$#''#(&''3I#::JRL'"^V$-:96O#E4*FJ5.+ ,D#DN_N+R%[@!/
M=JN%7I[J?6AZN/,WFST\CMG93D&!"T<Q-QN_SHG>?+]'$+-?!P45M9<LU37X
M<C)ION?<L9V&R^WQU;5Z7Z='T'1GF8M4MMM1FGH]A.8EF77_;='C/!W/1YKG
M:D[4(AA;87#5%)QXKB32'$<1HTF,=W.4]^VY5R"PT?!5BV^;V26&I9V\#/^]
MO+R\66L6;0"ADDXDW[,+;H;Q''DO(^6:,[P=1=XEXS[=#B%$K,^)&T%"/;.4
MB1]WX9L#P!/P*19QK8B1II0["D)[F1SB. ED!5=(4<V4M H;^>#(U+V[(<2-
M Z!)/S.4H<<F9]O[F#\W)]$WYW&V'M'?33>@C["VQ"@L 9O)]Q,:A8QS$7DN
M-=:&YTUEG7BR7[]#B!J/3)B*ABDTL'12Q1IS+C'!N!$0R7#$3"[B2!1')N?.
MHF8N<(M)(!W'F#U[+B[F3GO<0' E-%8T&0J1OC YD*/ !*N31-)B9Z2DD1EW
ML-#=<3RQB?E UMP<<8]GN'H/U(WIX1K=S6??*4YME!R%$&@>8P32X$Z LJ2A
MP7DCNOIZ!R)X8O-Y-7:5-E;%@7K]WK5O>HUW$RUGE+H8!%(*Y[NBO /]P/1E
M& F>"VJ(4X>/V=U /+')OQ:[:IBL'L$^SL9->QQF?MLGPLZF*)5&3I)<2"+O
MT9#<H!"U3Q9'*>+AX]4]'==VE*^['A$<A)>,HQ@ES!Z$>N2,4"AA</Y45#:(
M;K>Q[]7MH&?Y4HS8UTL^T"JEPJMUY_<$?2QR#\]DA"C/YN+F,B"="U2R -,$
M,2;Y(#IRY<'.!CU35V)(60O4XL7=.2/,,4X)8_ 3#,1W)!KDJ$Z(>$Y]/CIM
MMA=R._.C5R+OT>;<(_&DC$7J3;&?FP7 NLRTYQL4KJKO* )NA@8N$RIXWB"+
MD95$(.:$2RE:Z76WZ6>_?JNYJ3?T?_G48LJ3SGL[H\XE4>$Q10[\*B03Y]X+
M<*^V2V4<X)ONZGG0TVPA5G1V1WN;YDC!\PC[2(()#!&<RY<Q9Q"XX1&)1)C@
M%"(QTB,3\V0FV6/QXW#E5R3$+@_Q$B(7D@L<$LIG!F'FD!Z!+CQB+(H ^(+B
M'>^\VK/G0<^U1Z-+*=,<,:3=B/0=MUR$:)'&$CR"&"#2]TQ"X"^8T,XEWF-P
MN:?CXSPB5P V<QO182\M1289ER\(;D]Z&V0=8VUE >UPV<=E!XI!S\2E^'+8
ML]/79H^3>[Q"/3(P/PB>=]-)B-"YH^!M,^Q!5\KHX)U5]O D42<(@Y[&CT:N
M\M9ZA-62C1R0 -?366F1Q#G65P[4%+A$@266!$F$RL,SVAT #'JV/]Z05=A2
MQ]C^>KW9;?W&^IA(Q4U]]W=492/?'K+5VKQWC\])&!,001B4,,UEBT- %D>%
M'$\<NX"U2?S@I[=\8N-J^_AEHV^;V>MFZ19I.5G?]PU/FH_C\[RW]VK?M[78
M1&[!L0X@I! &&6' \<U;S8.6SNHJY;CV0CEHUZL0@VX=[:AFQGISXA7F#25<
M'Y=FQ'@1K0%XGL$?3I'V$,CIG,@,TK#$NZT][-WUH+VKPOPY@G&..P&^.K73
MKW$^GEYYA_-Y;.\]WSC&4OT@00\45:;.4EKI<23A53.!0:&9M>*T'?M\>OOE
MUUE<W;Q[B/X?;K27.O?$7%,[AQ_^Z=IT74T5/B+T8'^OXN1KG,:/RYD_M9L?
M]'C:^W=:5\?[R5Q5^YM?Z#_,]NJOLLZ[2EI3W7L.]#4M<2"4ND8JH9_CV&_-
MH+F=6_"ZEI/%#LA'M^2!H(YETQ(ZJVG=TI?'].NPKE6.<N7,PX/RIT4#\^"I
M!0 ^+A=CD'1^:UJL.B'MA:#R%'6X-HXT:>V80W,HO )^%'L=#.9H$U</'55]
MU+I,J&VATB-:LS>HR@]D49WUL&Z^=[E);Y>+Y2SVJ*2QJYE>&GP05UF9#X^M
M[VZLM/R%X^<=/91V4_;MHK3&CN**[.AWPS%M+NQD<?'!3<9?*VBS0T>E=;JO
M;'TT"_Y*_!4\E'!9F/4@M=UNI9].'D!55. >X])=;146OO2H=*N#XH/2?CT4
M5M=QAJ1;W5X53@5OPO_YX5N[EN47X_/Q8O=-\H?JLDM'A56ZMVQU-/ME>A[G
M>5?"IR_SNJJ]KZ=:NNTL75GE7I=PBK/V<9GZU3? 4_[=SOZ,B_;5E^FX5UJ_
M4,^EE=];^DK&:!^T]K-7S5FNP-S*N2[&["Y>?K>S\!D O)OZR1*ZSZO*X^GB
M-$*T$_)WX'?3>3,9A[R-Y],"_K8]-&E=.1T^K63-8T*O1H='TW]1/ET6[U[O
MYEHT;_YG":-*^YU6A+(<Z-Y=8;L=*&>?"[F;^1P,V4(Y1'DW?M_O3IL[D102
MK\>M\[=;*29JZ1OH-YK.E_\TTW8$>/-C]7BW2<!KO$UZ/9XL@6E_Q$7^Y<?U
M+_M<K5X40#$U%];%IH76>Y3R'P</ZC_^]O\!4$L#!!0    ( $=B95%RYX^D
MVTP  /5N P 5    86=I;RTR,#(P,#DS,%]D968N>&UL[;UI=ULYDB;\O7]%
M3L[7027VI4Y7SW$YG34^)S/M8V=VS?N))P $9$Y)HINDG.G^]6^ 6BQ1I'0O
M><%%4E676PMU;R">!T $$,N__^\_STZ_^X+3V7AR_K?OQ5_X]]_A>9KD\?G)
MW[[__;>?F/_^?__'O_W;O_\/QO[OWS_\_-V/DW1QAN?S[UY/$>:8O_MC//_T
MW3\SSO[U79E.SK[[YV3ZK_$78.P_%G_T>O+YZW1\\FG^G>22+_]V^M>,D#@'
MPQ3&Q'3TDD5?$DL<BH_9QVCP?YW\E4=9;):1">X]TZB >>$*"\5KHYTUFMO%
M0T_'Y__Z:_TGP@R_H\&=SQ;?_NW[3_/YY[_^\,,??_SQES_C]/0OD^G)#Y)S
M]</UI[^_^OB?]S[_AUI\6H00?EC\]N:CL_&J#])CQ0__]Y>?/Z9/> 9L?#Z;
MPWGZ]@)Z?9[?_.%M:<P/E[^DC\[&?YTM_O[G28+Y IY'A_#=VD_4[]CUQUC]
M$1.2*?&7/V?Y^__XM^^^N]0<3--T<HH?L'QW]>7O'][>EW1\/O\AC\]^N/K,
M#W!Z2A(OGC#_^AG_]OUL?/;Y%*]_]FF*9:WTUT.N0IDJSO^L3_MA:YD^D2#3
M=!&1T4_QO!)\0!E7/7U[F6^>Q3(6N#B=#RCQ_6</*N_D#,9#*OC>HP>0=O$@
M=H9G$:=#BGKGN;?DO!9R64(X&4]F?TF3LQ\6<KV>T +\'D[P<9GJ7[*ZDO*@
M^.+EW_[XUHL)X?'YN"X:/].W5T^H[^HI OXYQ_.,^?OOQOEOWX^#+^BEL=%9
MIRT:'[+/D)/,63L#>K12F,Y:H#>=SS#3%[/)Z3C7[>7O<%I7SH^?$.>SS=3S
MZ%.WTUL_H9<4:KW$$HH3$HP.D$/FEI="_P-7'/)1/_$'T_1[F-(>_PGGXP0=
M5O9-U'[W%6TQ>& X2X D3)$3*MJ322&$""HE#$6B4AZ-]AT 63NP;=#Y.*=_
MJ]TUFY1WM/,L#(+A)L2:QP^.2I=A+"%BHDXF"\51@Y;1Q!!1J.!I"9(:0:U&
M9,V+ZGBN1W0Z27?>>UK-K,G-OG *$4\7/QU=S-@)P.?1S4-)!?B6OIR-K,DN
MZ@PL<)N9MLHR3^IF*8-W+ICB.%^YJRQVE *SN-A6KM[P0T7J!SR=SZY_LL".
M<7%EJ?W/]:)<@K7YX#[@%SR_P-FK.)M/(<U'-#*+* W322#3*B@6P"I6E-(V
M<Y++I19#6Q;D[L"^\?#5]'J(5_O[A@9 ]5H&Q7D^&5"SE_#1 +[_;C+-./W;
M]WP@I'^B<=.468CT3W+B7E_,YI,SG+[Y,YU>5/_OU6R&]'_Y-_AS!,$ZC@69
MMR4R78PF_TL()JR6AAPQE5 U)$,?67?/E^T 7LV69NC<)Y38EE!7"^SYR9L_
M/]>5^)LB@#SS&,F[YS*08-PABR0-RRZ#XC992*8%;=9*=/2+R3"Z;D""UY/9
M_%WYQV229Z_.\T><?B%C:O9Q<II'WH"C2:!9,8G&6S"R&+EB$)6T)G 5P+5@
MP7J1=D^#@7";-%%Z SI\P!G2 S^16#_2BG8Z^5SGP-7@1P8X%UID!D;6&1 X
M R<,S0!'8$BKHX0VV\D#4CT54@RG^ON\D-ORXA]X3F,^)=E>Y3-2<!WO?/P%
MK\7+!C21U;)DC6-:>,V"38D%Y)[$Y)ZVN!;,>$2NI\*-(=5_GQUJB$VDKF37
M8Q[QP#,'SYG1R)EVTC'/=6+1N%QRTLZHV&KKN"W(4\%_*P7?!UP/9CJ^/4]D
MWOX\F<U&V3JEG>5,<3*<M0N91=1D/0NR;'EV$- V-1J_R?)TS,4-]=M@!WA[
M_@5G\SK$2YG>GL]Q2C\9*>,#3Q*8<U#(:^*<O"9O&7U7"IDM6F*3I7^=0$</
M_B":'G"5KR>$HVLAKE:@7R?GKV'VZ2.<XKORT\7\8HI7'O HTL ]+75DO";B
MJ;"T#4G:FH*-,FI%KG71CYUV]GOET2+>4+,-%OU?<7YK.5)&1!X#,B&=IN6(
M5J+@/#*ED*A8T"%OX@O<D>)HD=]>I_<!-ML"_ :FY[3GS-[C].,GF.+?839.
MU1T9GU[,,8]$$8K[2*B0A<&T$8*&+,DWM3H%3*Y8[UM _HA<1T^"(?5^GQ9V
M6UK\$VL@$.977\@H.<%?+ZIRWI6%J.\NYC5(IIYL+DL=M I>DKTB.9!&M 4&
M21DF,'/TRA<L31:(S<0]>A+M *7[W'+;<NM&";]!/"4_UG$E7,FL\$06CBV<
MQ< +L\%*#"ZDXIK8DG?%&) +MR*LFC-@"UVN.DG\[C)>YJ_I=#+#_+?OY],+
M_/;#"5DM?\[?G"Y>^+?O9WA2O]B4#K/I?/1^.LD7:?YN>G4>^NK/\6P4,^>V
M>LDE@V3:!\>B3(&!%M**8FE=['*!1<^_10;Z;ID(ZP08D H/!+8]0(T-L)P,
MJ-,!CYAOR7/[U/O'Q6K92:C14G3=0(#?EV;(S6!=:. WS(<!ZC[J VEY9Q0H
M$J5/PC O"KDW)48&W!>62TD:1.#1=C$8#A'Z.U&6>T&^CW(;W"M="?;+PB8:
MA6*2!Q^8CS8PS65D/LG 8M(Z^(1"ZR;A-W>DV)W%-R RDZ'4.F" RN(4X_7D
ME'XTN8S8NCJP^("G-:CK/4SG7Z]$E*J('#,RER,1VUG-8B9SLTAK+03A<EZZ
M4UYS.-3M?<>,<2NU#CB[UXKX;OX)IU>R(;D7.6%FHA3R7DN]N>19L:P!P-MH
M@*N-(;_UHB>)]::*;' !\&'R%4YO&)<XRD)+"@O!(-,8R6716C+N(7$?#,_0
M)K+LMA3'#/GV:EU[Q/_O/RSI@_S+?PT?T/QZ<O9YBI^JC?/E\C3VCF #Q37?
M?TO3\.9'!K44Y5PT2K"$4 '06OE =AF@=S*I;%U>$W?>>7A#(?5Q/DG_^C0Y
M)9+,WOS7Q7C^M0E4*U[3%*O'AK6<M2' J.1Y"<9H'45P7G#.I5">DVV$CX.U
MXH7#AZ9K(WC)G(F4$FWE7-<50+"L("6+R'T*QQ&:OCAZG-TZ>QP9FXH+03/G
M/6<Z0J)U+F66O$[120W:-XDKO2?)89SV]D#ZWEG?5KIM$)U^?VJ,,&>)7FAF
M4!6F12@L!K)<O-0&7!;18*,DB]7+T#'#O9UV&SCT"XG>SF87F'^\F!(!W^-T
M/,F7O%S\\MWG1?+.FS]QFL:TJ(YX*!:-)6/&^6HE&<<".LDR.(\^%9/;1(_V
M%_5I\*4=.@V\BS42_R><7N!J@06Y0X)[R5+R@FDKD<5H)%/>&<M]3,HV"4_O
M+>E39=- V#2(1WV5_]_%9035[+?)JYP7ZH;3]S#.;\]?P^?Q'$X7<Z%65<C5
M!">S[\KMIM5U-I[CE8=W.=(/F"8GEZ M!CWRA@S]S"5#X4.M:Y$9>$F>N0C9
M2">E;V/(M![8T5/UH)!O$7A;SX/N^(S?PH=^Q?F[4O/*DG0ZT2QC.B?)M$Z&
M^<0=<\Z@<0XS3TT,KR["'3W#!D>@02#7W:@R[0N2M4C^@*,E6)>0F3<YLV!=
MS(K;P$63H[H#C-3; O?-==H@).N^^P?19; YLB06>6/",F^38MSZ:)(*67JY
M!]=Z$$>R9.>2BO1N[FEL7D<&RA7F('*3179E^09A-X[DUN%.UKH2G?8L*@M,
M&Z3-A"/2JB&%]0Z+:',/>CCA3EM9I1OK<M_A3O>&<,FNNJM,SJOML@@"L!QD
M<=XPDSEY9"&0$0VTIP3RQFID'JU!31)J'I3J0 *B>J&]CCA;:[W!N<J23%<7
M3%V$ZA$=U3\">Y54NXV2:H#><ACV8*K?&2\@T.N5 E9JS*AVA79]CI;))$H&
M(X74JZNC'0\?UH1.[8L.?33>I%S#V=GD?&&87-T8ZQB,!J@#D^1O")T8"&.8
M,UX;\D83M"GQ<D^2W5OX R!T+\]V&_4VN%99<X1Q)9Q11O,H$_.E'K,5Y5@
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M@>!H<*!W+<MU%$P':5I6MKHKSGX*5VT.SQJ<M]!M>\1%U%9D2?Z/,=4=(M%
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ML"@<.2G:>F.Y$P;:7$X_P\NO;7BY'\0/Y?+K[3EMPW@3Y_%S_8,ZZ'HB"0$
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MQH2I0/QUAJ'/13I)!'9+)00>3Z?8>R9%$YB'U&2KA(C;L?=78D7'C8TBDS^
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MW_;W__Z0H^SJ$WRT>_74GX<I*&W"2>UB^J("I1_RA7R^K U)FZ 9@850"@B
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MLX?UD3F,-O*)*GM6;R^2IMI*FM?$YDM#^_,Q(/5TF0OA<;R9-]1Y-7G>#XK
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M.*F]NSO3ZY3?/<KMR0J\Q[]]4=!,*8=3875M)@_G<2S_+P0!E_]!#!*  XA
M3%@<$@YI1K!AMM21::8F+EHJE=U4D6F<''4,2KW-?SE CC?_!IN&0C<Y4#T8
M. @WVI_I-4*-3G![(LSHU+<'N&%4^.RM>+]>R>/OLW*4K_E-6:Z5&^%-7LI3
MB\$4Q@2'@*0Q!"B&'$A- 0*8,)YE(4<!@0;76ZU))WHG;6GTJ"+2P%Q_%F0-
M?X@5S$:Z^:EVKK?"JXGU&FJOO U^;VSC9^#>L(GC2.Z,"_$T<WKHXM/KY#@[
MR'A.#5U^=IP8V@]94;>NEZQ)8NU48'T[+^DB5[>2;<U40B'"28!!$*I>F7XD
MKV^")0!#BE,<X21,C>HS#J1C@@I;E:'=U*LSSV8?M!B#-#H7$(^L\E7!!2WD
MW=Z:6S:\KT[JU%Z(I4/549N4U]0M3?$ZHWP:#S=,5FXJ]OR,%TK^?GG@?/6W
M(E\_R3OP^_E2?C;'B\IWI([B-[BVIGW8M&WD-&!9QAC H2\ HO(2FQ(4 )]+
M739(_ P'6CW ;1$T->FYK2-VY34L>15/7LO4E;=AR]OPY;6,7="4\^*UU9/!
M8ZZ88V$\SF(92V9;"-L4T1?3-*JLMH7@OM"V-NXPZ?V9K[ <BKW#A2K@6LH3
M8_VXKLH3O.5B3N>K69P2'X=Q M(42_F,,@H(%T0N)T<Q36**,Z,@]_-33DT"
M=RCT6$VBF1S50%E/4MK%SK$L;(GU6FJ]'[I(-@1;[ >HCXY-.:8QZZB22A^%
M?5ED\*0-K^=G50+R5OQ:\BK!>"82GZ*4^:J\LFH>ZF<@0QD''(9IE*1^$,5&
MWHS>V:8F8[9>N]JY.:2)03^\0]R;%X VMI>S(A7D DABZ^8%KOR=)T!QY_;<
MG_ 5O9\G>.]W@IYZ:( [I K*J'( JZ"-LLF[A7$*42!E!0T"!I ?*FT%"<!$
M1B,6I=C'^O7<CL\Q.8%1!5J5BDP/5W0:&.Q/P*CAYK@<'->"H<*EHK .4Y-W
MJII(S<MO'T &?HS+@1K)>W$(F"5/13\"O?Z)$X^.YY7HIWW'%W'FJV[SD3_R
M;ZN[W_GBF?^2+U</Y8R0- @X)R 662J5J)2#C"<8T"RF61:&@E#N(B5YGY"I
MB4OYC@5N\I$/ED!/T1H#6,>BUC0KN<JKNUV^0CKR*1!?(R/Y@)9))B6?0FQH
M7O+)\4;.'FF">6_7JW*%ETR2_'%='^T98A&/?$ BGP+$1:!* B< )D$0,TC3
M3(@1FTV=HM-D^X_7.:JF387FU@IIWH;^YUOZKSI]HDAC&A\_?>3D^B>4)9 *
M#B(?A0 %O@\RYJ? SP*4B$ DP6;]W?=ZLK?Z[ALWZ:T]K_Z=XL+K'=>ONI2.
MSW$+F4";7)_;[J+7G$X@W>?<(DPBK^<DD=]' L\YC*UEZIR=R.V5JRJN(O?>
M#'*(2,@3P$@4 !02J3$PS%4A;>K[/N4Q-6IF;DK !*]8R,T5:P.YW:O5$""G
M>*52/(Q_I]I'[S7N4AL:)GF'VD=HZ-WI8)QA N[=X],B?^'\"R^>YRK2X)C\
MW71HJXU95>6B[M]5>.W'?/4/OE(E0NZ7\W]Q-D,^SGC@)T!$@92$D12"V$>J
M=BE.4$PQY,S(Z.2,TJF)S%^7Q8:V1GVNU2O:5<.:7N=FLM7=:NL)X4FLX8B*
M\T8AWBHPG5:AK9ZL&)*?J@I>*V_+TY5W766]VI/BSN&W*>[=$3OJN> <\_T#
MQ/V$(UOG?L'?YH_KQUJ?OQ75E\I/O&@9G?DL9C!),4B%Z@](I<Z=A1$$D")(
M_23"<6R48>&,TJF=-+=/3WFQ6B]5O0ZI0#[)<1]4G$DNU%GS*$^9^O@9WS!S
M=LT=&VALKN3T#34-M][6:E<SK$JS>"W+$[#8Z*[*)"PW9XG]/BPXNIA;L^1H
M3SBD?NV75;[DFP:V30 'Q0$+$BI A+(,((@I2*D/ 0^B( M8%""3QH_'IIB:
MX*^)'-0*^CB$&D%"%P/C6(X>I<]64=(^WOLKCQY]<L3RHGV4[]80[?WF!3IC
MUZ@[BPC-,.*J@G2  4HC C#S0\!)&J.0DR05V4"/;'>>:7I4?[;L*]U!-HD3
MP3 7(.4B!"B"/L <Q8 )AD(_)H+R:)"O\S)<W?LJW]GT0NY :J"D#@5I#.5R
MUX-G60\\QKAU_6UGDO'UKF,\'M67CGYQF.C\)#'D1<%9%85899/-$D(C+F@$
M_%25Y/=5_E8H4H""+*(HCD.6&CFGCLPQ-4UG0V)]E;WR_E__S[X?J&[5WK,B
M^*]>&%WYOJ_^O]GW'EZO'O)"V3S^ZBWS]M-Y6:KL^;SH!C%X6'4O?5I5IYT'
M_2M/O8=5NOU;3IM/ _5ID)F)DV,+J"=0+EP6QR)ENR)?ZA5I,F-O*GCM29<>
M%&S*EV/3C"IA>OC<ES%]7[74#:2R)%YOFEI<+UE3/+Z<,9%E-.44""X%#Q(B
M!EGL9T!@%$14A%$,T]GJ@B8@I^<VDDJC]?XHZB(UH*A;?V^:?US84Z)G"72N
M:<Z =7U_.]' H\9Z2[TGR6\;>3B$^L+F'78@__Y;=YS'P;AQ1\^0K]NVXSRO
M9YMV: PQ0-"_;8Z-IJI64\&P,?T@X7,$50']% < Q0F4]\8L &%&.?=#3+-0
MWWK6-]/45,N6UE:.>W_Z8QH&P5^]5IY+'5.%YK3]F91.N.15K>+V(^5^46%K
M!F*H=RTTY+LMA!U+\SXR+8D;'21ZA4OO ..)$AT^=@2'U@,#D_E5WILR^!?\
M@2_+^3._65(IF#[D9?F1KV[%'?Y6UTJ7GQ<JMDG>DJI_-PV_TSC-0AB&(!&J
M-0=A$2 XB &,$4H3*4TBPW+G%Y,T-<%3)V?2+DO>#PO)SH^J/KIDS;!"P.5K
MIG<O'7<E' NH>A%VN/%J=KP?%$,_7GD?:V$ON7+2YMT>G%:K%%Q.U;BE#*RA
M>%#OP-[(KY,/]^X;+^B\5'4#F[08*O6Y*$M"$%/,  I43&<00N#C).,P#& 6
M&<5T6J=P:J+Z9!X4WU+^>GE/APMLX+%XK64;P^-A*>^IP^?T\IY.+L(DHF=.
M$OE]1,V<P]AVWM/IB88='6^J\+_*3/P)%[=%56N0519C>615I,RXCW$0A S0
M*CF:RL,@%1D%?A(BS -(>!2:' 8:<TY-O+_I1$E>;7U*E41?E\Q[4M5X%.&&
M@ET'?CU1;1E4YS;<"L_&,20)5MZVFN3:351%)%94VQ.D!A#9%(TZTXXJ[ QP
MV!=?)H\.K"A=53WE=?^D0EYSYT]XL>G2)22_/A<9R C$ &49 BD+8T!QB%D0
M^1DE8=OO1$\8]<ZGM6-V6YVX=G,WE'ER]XBZ0.RF:F!.%O-[;&!GU,-<3_Y<
MCN-(-9IK.C?MT5I2'31*TX+$:E'EW@G'K9BLP_M!.62MAX;)E9OELQPE+U[^
MGA>_W2P_%3GES?5\X\HCL<]]&J@D[DA*EP1' /LB $$D$BCOOV&<(A-%1V/.
MJ2DZBE(P7X*GFE8S.:*#L9XTL8R<8YFRH?;*4_16O6YKBC>VP;-^:&/I8@"1
M31FC,^VHDL8 AWUY8_+HP%Y"[+_7Y:J27W?Y-6-S=3HKF39G-\LW^&F^PHM*
M:R+[5\+/_)_K>3E?M>E]M0&Q2=)37Z@#Q:202DC,&( 90P#YC(,,$P$") +$
ML8]1:&2H<TWPU.1=I<H"6VG7SI=;3WI.:1$=B][K3S=OKH[;Z+JIV*WAO>HQ
M7*5A=WBRV -I)."M-DMR3?.X795&6H&#]DMCS7NA]OM1E=K'&?<QIP#Z<080
M13' &&% 0\BPCS"+?2-[7G?PJ<GW#6T#-5F%%X5)3(,  H*R *! U39)D#IR
M?>$SQ) ?")UXUHOQ&BU@=6X!-4-%WQ"+\33ZCS9["1QCUXEV_G'L3@''.#NI
M;W\<W >@':H):7HOZ3@6'OGN&UVL5=J&ZCD@_X_=X6^S,,0,A0P#F&(?()P1
MD,G_ ;&(I*H<IS#TC5J,#*!A:N)Q)S[=M*W1H!7P49(P( +Y'T02>?*00+[(
M"62!X)1F<@6>>4'RB:Q!EQ9WJ_!Y+/SU9+)C3!V+[H9Z3XDH;Y,K\/MNKL"&
M!Z]E0D5OV6Q&-1A"N]VIS,D8N5W58)P.^U<-'^K"YJ>_R*OENJBNFN\+J<[S
M)7UYFS_B^7*6^#%BOL^!#[D *,RD%BD""E(<XP!%H?PG&]3?]/2<4SMCNETQ
M.U1[&[*]KS7A0_N3]L"OZ;NR"ZIC 3<0P^%M0\^CXJ0S:,^TK]/\\SP.)_M[
M:CPZ(%VG$7D=6\$OZ\5J_K3@;_EB+G67JA/TU@Y6MK5VWGU;J4#5?%G.PC3R
M18@C &$: @3E@J09BT'($<U4&QG&A796CP6"IB:]-I1Y=9D*@PP>&\O3+\!>
M _21U+<..U[+C]=AJ&O?+=N"9K?"VS)E*7O((KR]248VYADO%\DB*CLI2S;'
M'2!1/Q7Y\UR-\CXOJL:%=[DB1<XK_\+6='6S;+*H5%GF613$E$+& ?<#U38F
MAB!+PU2*4<AI& 4($JWN]0/FGIJ<_,Q7ZT+%0F]2'EMVRCI/4EVV5KE7XH4J
ML;'T5@]\\]T7R9"!8#5<)0T9Z@Y[Q^)R0[@G*:_;H'IWN=<0[S74>S=+KZ&_
M*AKO#FN#;'AWF']?V?##<.@]2PR''._8&,;KS@DQ< A+94^J'K;72[:IU/]A
MON0W*_XH->F$T82D4I-&$0,H@Q!@3 .0"8Y2(F" ]/)9!\P]M</@E-FMXJ#*
MC]_PX'U57'@5&R8]6@T71^,,< >YXS/@5$&4&NWK5T#[PIHH=E ?Z10P0-]A
M^93SD!F73^D9\G7+IYSG]6SY%(TA!J;BJH0(]=9M-P.B$2$I1H S(B\)"&%
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MTO Z^HHA0B=5%M-Q!F8D#6V%W99\K*,WKY_Q?*%>O_=Y\3?Y[&K&Y.L=ASP
M+ P3@((D 41(.>MS[,=,)"&D1K':K@B=G"CN-+GVBKH!'JLZ9JE8[ZIKZN!H
M;V>+K2>*I["$CD5VMP=:E\F=A%;R<KQ7FF+UJJVBFXLV2GW#;_465!Q;3!9S
MO"96T\Y<T3IN IMCQ ]2X5S/-^S@J;*ZKRDMUGQ3 $SJETW5R%F2^ P32D$<
M!*D\/K"\/J,T CSPHPBS)/6)5D5TO>FF=@@TA+8]@4!5N[?ZO6Z(6NGGN6+)
M[  X [J>&+<'I6-A7!<.:+'LD'K5UN&U)T?U0+$I#<_,.*I,T^-^7S)I/C7
M);D;?%X5J+T5OY:U3GW]F!>K^;]J=Q0*?8@A)@"%D0!(=6#$61* B-(@2F"&
M<:05]FDV[=3D355"1=D \KV<(*,&O(;0:_A#G0#J6NKLYZ)49(-; 23A]3U>
M7N<[M#L!U\#IZ@3DD9RR]L V<^$:8];KXM4?;3P7L#&'.RYB\Z?MN9#K=('Z
MOUMK8<HEZ*%4*"%+0H!\J4NF)! @$RF->.*G(C4JP:4]\]1D?<=HV_6*7>XT
M/H[[<(?QQ6B.YRSN4#U..I$Q7JZ]QL<G?W6/<2\F.M[B_@&&-;>AG+-2E3/\
M@E5MJO?KE9RLZ;E3?N124MXTIKXW>;DJ9QQ)$16A#'"F&MR(( 89PS$(_ 0A
M'])$!-RDP8WA_%,38"T'=3%2U<%&M;-1!C-1<=+>FJ^\)5^ICS>&4ZK8,6N[
M8KI6&DJMVQ5P+/0VX"OJ/46^ZO=5,^"U'%3]NM7G+1?>&_?(FS6]<;@"(ZF^
M3E;"N&G.0!S/-<XQ'7;4YCD#>=YOH#-TF&&:LAQ0>?FKQCV,LY]?I#;..FGZ
MUW0U?Z[L+[,H22",J"J*XF. $$M!"AD%<9)@^0GS(0QF*]6T7$]5UI_:Z*C9
M$.#0+B(W3V4762M'S7S9L8_@#=%FFK/!.NBISF[0=7R,*&"KH).6;.44^^'7
M&N4?._4\KL_#;*P\FR-F4WLVF'U4]=D<E7W]>< (P_OM=EN,E]VN,N4O\P67
M/R[Y;AO+?W$VR_PPH2E$((9I %"<,4 PBP%+J ]13! E6C'DEQ(R-95Z0VDI
MY=K#7)([H,7NH!71T)='PMFQQ&M;ZKZO.R@T?.SVJY+JVH87;Z\'[[]&6Q*3
M?)UQEF:L#!^'2S2HW?$EN.JT.1XT_NCMC2]!X5A;XXO&&YK8_(:K"1<W2\:_
M_1_^,L.8,13S# A$!4!<F:,S0@$1:1;P!&$::_4;.CG#U(Z8)I.WH=*KR/0D
MG:;YS?M ]A\@5N!Q?#(8(S,@S?D$]Q<G.N^/.W*J\PFV#I.=3WWQ0J_3SR\=
M4_'[@O]SS9?TI:J$':91+#=T!"!5O<AQQ %.20H2/Y*;6X@PYD;UI#3FG-J6
M[Y;2WA!J5%S<!'!#1Y,=&!V+AD$(#G<FG<?$B1NI9]K7<2"=Q^&DZTCCT0%W
MWB,6PN/>UBB3<H735"5)0X!@('_B6 #($8W]B 1":'FYC6:=FMS9-EK^W,1-
MKO+:0)[O&\CK9D.=> 3UE<%>"^UETKCUN@#?L;0Z[H,8Y!"_ %N#ZZL+C$>Z
MJ_9C;>D::HI/[YU3>[#Q+IBF_.W<)HT?'J9K=N/NU93;5,RWG*RVO[4QW%$D
M8!!$!%!UNT29'P/"A0 \Y"RB29"%>L$" ^>?VEG026(M!]9&-ET!/474(:Z.
MQ;RB;Z=^\H85(/("J& ,!P'V _&RJ;":DC"J\CH0GWU%=N@P Y3:U@;7-<%5
M\:%=W[AJW,=IW?#U,Z=\_JR(*V=^D/F,B SX4%" B!^"-, $)# A.! T"6DZ
M6_)[I?[=:>J[EQ"DM3^S>G\>D.5RK[)UW;[00-6Z:&$T5%OG.(_5P70X&Y84
M-!M(]BIM%TTPGB)G X<=Y<[*@$-DXA?E?OCT@(M'^=*MJY9T95-'#P4"A5C>
MZ$,8Q@!1%DB1AV(0"T9I2E! F);+X-Q$4U/A:E*]/5I-Y%D/J#KBR@Y4KJ71
M:2IM"9OS./3+DI[G1Q05Y[G8E00:WQ]VLWN#G^8KO'BG4NS87%TCRYNEJO'!
MV<_KU<=\]0\I;O"<S0@/DB3D"'!,5-M#'H&493Y 483C)/*SE!F5TM"=>&J"
MX)I):JL^[JO<>RI4+-ZJ+L_'_[F>/U56\OG2PY3F:U7$Z F_5!<_]0W<9 $W
M"8V&5T#MI=*[^[E8 -?BI2;9Z]+LM41[9+WR)-G>"U]YBG![USY3J&S>][3G
M'O6B9XK(_@W/^'E;5[O%(O]=F=6OE^QS4\=@V[^.I#XB F5 9+Z*AR "9$D:
MR>M=1%(D;WI!H%7O8=CT4Y-TJE*'/'665?K*,-$U<!V&7M]LH3O2G6TWJ.O*
MV]#O20:\EH-A31O-03=P63@%__OJP#$8"O,;;^^HKWS-U>'X_-U6:Q0['HQ=
M0V+C?%75B<I55=IN1BCV4R:%O_!#E>\80Y#Q (,@))!P%H4H24SR3TP),#H-
M1LA"V5!8.:0O<UZ<!7^8]\(FI%-P7VA"?K$70Q<WEVZ,LS2\JA]#%Z%SC@SM
M<0:VEWQ\6N0OG'^1HG-.^?&B:Q_SI92K*\ZJ^FKEG9(=W;\K8FH%?!MY7+5(
MOWVJ[KTSEG(1"1@#)KB\_Y.4 I+(GW#*XQ!'!"9ZX3VC4CTUY?K79;&ATZ/=
M(HV-AEW56<R?#-PFX[X%>B)Z<FOK6*X?+:FYK7)XY6UX;2MMUCQ<52)^8[[8
M\EF= FN;/NQ1E\1J>\]1"!^W2>B8:W'0:G34R0<8<#8$JO$^R2WZ(*G[)/=;
MZ >P[>O$XC @4B]/,$\ @B26:KJ?@C A?AP302A-M$TV&A-.[1QI26YJ-3\U
M1'M/\EL&Y@(=J#6L,I8!="RL-:BU9"4PP*77+J SSGB6  .N=N[^)L\YN>U3
MNGY<5T'9?RORLE2Z&%XHR?4W/%_^S*7FQ>_PMYD4)$)D"04TA!@@P2 @#*7
MCWV<1BA- J'52= J55,30%LR/47GA6&-PQ;*BKG /OR3L"%LV?(JOKR]!;OR
M2,6;)YD;S<1@AO6(=@=-PJ9DC###TM!"83CXP/8?*SF!NA[="E6ZX_TB_[V\
M)F5E'];MZM SQ(2V[(9,Y5*K2L]4E'I?6UHM)M3I0&*U,4+??.,V-]#@_*!!
M@<XS=I+F2GFG4G-\SE_P8O72?#K#?H*32$(;P#22-YF4 .Q#'U >!SCC.&-$
M_R:C/>W4U(E-$?"B)K.MHWA9DM8)R$,?0N8S"D(10" 5.@8R&C! .(K"+$Q9
M"(5I_+9=Y,</UCZR )OTQ=-E+ITLC\:%T\E[[OH0.%DE44)?'0H-Z>V?G(![
M68;BY2"_:HKB$+ OSEKLQ\PT;?'$:*^:M]C/X;G$Q3-/#SA\;Y:T4*7?W_+Z
MWYNEBI;')"^JMVX;+E\U 6E3Y^*09D2H@FQ459Y,40A2EO@@A2(EE,8D(<ST
M5!A$R41/B!W*Y0'0DN[]Z8]I& 1_->D)=,$R:9P.[E ?YZ1HZ?=^:#GXT;M9
M>KL+L.7BRJOX.)_W:&L)#,X0YTOQ?86-701'[U$Q;.3QCHV+.-\Y0BX;:9BI
M0LZ9/_+-9?&#6F75R*XJMH1C3H,( <8) RC#'! B8H!)$"10,!YF1G$1/7--
M[=96D^IMS1LML8,*+?6!K&<.L@2=>_$^##5C6Y &'C9-07W3C6H)TN![WQ"D
M\\A IU0;WOH^+][F:[(2Z\5UDR:T%5;MV8I0E,:(IR!D4:3Z;60@(UD(?(C2
M-.&1GU)HY'PRF7UJ\N5SFT'>I"+4J55;U=/0Z62T$)K.)5?P.I9!+8T[:N0V
M$4$%H;TI.)LKX52ZZ%DY"#BK'B$C L;U_ S!YL##,VB0(371VWM[.^;;-5<\
M-?7//N%BIT20B&"BHDA1*A(57X\!3I@/8$Q]P=,4,:9?),YHZLD)MXVA]> F
MW=I>GR0#)MD_9DNA<9-V!K!C\69$MZVZV4.PZJ^4;33BB+6QAW"Z6PU[T B#
MZU_GCX_YL@H[JON)WZY7Y0HOV7QY/T,TX5F*8B#"1 HDDB&0BA#)BYP(?>83
M/PRP83'LGNFF)H3:^L\5R5Y%\Y574^UUR#8NE-V'>+_<L8^C8UES*81#*FIK
M('-Y>>V^2<:NM:W!\)'"VSI/634(O<T?\7PY2PE$/HPS@#F-5*L7J"KA$D 2
M0E0>H?S'J/YV[VQ3$RD]YHV:8#MFH0;JBPQ#Y@"^GFGH'':VC$.[F(Q@'FHF
MG(*!:)=W31/1WD/#Y,D'7I:<[W:NWN1 -QE%I522_L%Q<?=[/DL0%'&2,, A
M@0!%D(',YP10'R>0H4@D 3&1,(;S3TWFR#<N-),JIH#KR1F',#J6/#7E5]Y!
M4_L-^5<J%(CPJL;.E:<X\"0+]N310.QL2BA3$D:560/QV9=B0X<9WBVOR1!3
MLG+3Y.@7OGK(V;O%_'XN;W_;>^ L"RF)&9:K@X4 *$P%2.,P!I"E+.11B##6
M#X<<0,#4)-N&X":[M&,M>FH6Z\KC#1O-#JV_,Z1GF]%2Z=B/W"Z :RN2.?5V
M>[ -P4VG]YK1N*/W7!O"];%>:X/&L5E+^K"](29QPGQ5+YJJ6($T(R##00PH
MXR%"-&09T5+;#.>=FE#;%%.T41AZ4%]/-]@YED<G"X@IPJ\N:]II .^E%<,N
MAOG[BODRQV!85>S7[)9ISJ->Q6M;O3 WZ3[T@;.U"D$^W6M 3;:D4AVN7J\[
M]9UM@Q^,PHQE(08PE5=N)-( 9#1.@<#(#Q&!$>3(Y-Y]*4%3D^PM/RI@H]/^
M9,N,V2W]XO72N[:/N0J.SXCN APF!G<6PMMER/M:L:35(,L\)]$2OE;S%B^E
M:=S<1DL('N0_VAK73H[DS5(**:FIOZN+8<T(2I$\_BC((*< H2@".$L(8# 4
MT.?<]T5X27+DWGQ3DZ:;I+QY0^>F2A@NRYS.JR"1WY4RZ"I%;W]!-%1KNS"[
M%I<G6MFU%'L-R791O"P)[P(T7[E!H#:J%R?=G<#(--MN?YA73;,[P=.Y_+I3
MCXW@J))P\UD0LCB04APD(L( A2K;&B($H*!2O$,!Y?\X<U4I"J8FU>6;!QTZ
MJRK0';BK3*&<I,-*,?%*+JLN?J_FM*J(F*[;JHO118ZKG8&&2;HJ?:RR0J@,
M9=H$S29I1% 41R!3WG<4!P1@+F*092$/T\#'.-'22'MGF9K$JHA4.B?7;4G=
M#Z*>=+H8&L<2J$:E)K J+$!M)TGT(F!3AAR?:%0YT<OKOBSH__*P_:XJ$7Z4
MRUTG=::Q$#1( 0T#N<T#H2Z>4H=)4T@HC"GEL5:_NV.#3VUW*]H\1=R@K,T=
MV/0V]E P'.]G;1R,]_$QAFUNWYWQ1]VUQSC;WZQ'OS.T;5WY<+UDZI]W_US/
MG^5M1Q[Z[_&\^"^\6/.W\Y(N\E+>?6:ASPCEA  ?,I5LQ!- :!2!E,,LB3),
M#:O5:\\\M=U=E6[V*BL2WQ)NVH).%W8] > $3-?.5X6@ZN97_= A^\I3A'L5
MY=Z6=)MMZ S1LMN'3G?RD1O1&6)RV(G.=("!V=^5DC(3%*8$T0AP'(< $8DU
M23(.4AQ%*.(LI%EHU%:H&M9(UHS0+*B6-4/N"0U,>N+#G'G'LN&ZGV/SY.@=
M!JUF/=<CCYO.O,/-09[R[E^'AYE^4EUU5#OL3_E*[N4Y7FRBOAKKP#;<2_FX
MGCB=BSEGG_F]*G6;%R^;[W_)%VP6JOR_(,H B;D *%/*0P3E/2#.>(12+/\U
MCD2U3./4=(U-2O/\_F%5>J4DT3P&U?8Z:KBL7G]U' NHC0>F85$Y9S9,>ANJ
M-[UKMGQZDE%OPZFW9;7SU)=)K+.!4^WUUWLD1]QI#DT9?/>L]*-/17Y?X,?>
M!1\4Z>QH*72"H6U//7J\M"/LCH54NYIJP*EO2,K[N1SH_E9\Y+^_+=;WUT]/
MBWF=OS>+4,!"@3& <9@!!#$$F, $)!'S8Q%E!*>^]D%OC:RIG>W;X^)Q(_B;
M#!0#V6]OU32.]5=9"]=&2EL\69+?UC'N%=GV9AM/2EM':$<PVQ_=4@;,IV*>
M%\H76S8]G:7N\#POJR:2 HN8,)I)$9MP@'S$ 68I 5R*79;X)$RR3,<:,F3R
MB=I,VFI=965C+#9-X#'[;\E3Y=NNRT*I2(=5[CTI#KT7Q>*%61Y]"Z4A9!W"
M[]JB>R*=IJ*^BA=10=(5_=Z6 8=H7YA88PGU[S^[1@,(XQ2;OC%?-\]&@]NS
MR38Z8PS,N#G:7K33&_?GE^U7FA.KZCFJK/*KEYMEN2JJU[&L?/YW#WC9M!C=
MM"C]N*[Z5 H<^%D0$T#"3%5.)5*-]S$"S$<I%6E"$TQG3UQRRKZL<+'2,[2/
M1K_)%MWGPMTN_;5M6US6!:T(OY\OE^H,RH57D^'],%\V?_[1,+MGM'<C86$8
M^5+#(#1& $F- V091X G+$4X3!*!X^;=>+=DW_V;T?(PWGO!I=+R7;T1>IZF
M2:ZQ8[6HV\N\RW6WH;E'7KRC/<_KYN8U]UZ'_;I%A;>2 #2MS\M.4W3YX]I.
MV]U76SBKJ6FC$3]N#MO8:W*0[#8Z >852YNTNY<@)'?SU8+/6,C\) TIH $+
M $H$ UD,4Q!&C''B!XQSK6[$QP:?FHVQ(DJ=(T'X _FQ35;5K(!\%+U^,7\I
M)HXEL2D<1I5$3_%]0=W0@R%'JQ)ZBIEN3="3W[FXE "EQ9JS-A=ASLN])/2
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M6[(NS98\3\88]7JE]$<;SV-ES.&.-\O\:3.Q4Q:KF3S\U57DMOC"B^<YK6O
MB2!(N(]2$"<L!,C/Y TOQ,HZF!*:"I[Y@9:'ZM0$4Q,E#8UUXE9#IYE![R24
M_:+"!D".A4)#7A<::V:S<^SWJ"?RT8YJ(G_;5TM.CCW*[C_'6;O/SWYO4"KG
M0OZ<%Y7E:9LZ^G;-E57JL\I 5+&QA5)<VA.-XCC+,$N!'"X"B(48$!+%P(]0
MB*@?9S@VB!XQ)V!J$F&'A6['QC_],0V#X*]U(J?4/IXD&YK1K8,71R=@Q2WD
MS@TN7;2WY,L;U)I[B@.O8<%K>% 6&)NJR 7XG<E#-!]WS%S$P5SOY2,.'V=@
M#X-M0-T,H30(.0Q!&JM"OW'* 5&-M'$00NX+3 ,?FA3FZXQM))9&RS1?; DT
M;$+004W/!C,0"\?RXH,& .:=  Y9M5KCOS/\N-7[#_DZJ,M_Y"N6:DA\5G7D
ME.V1YL\J2;E2=9H,Y5G&DX R!H%4.C)YSY *1^K[$1!$A E+2)PBK)_O.X@&
MD[=ZO)S=SWRU+E1^W399E^"%*BYQ8>V"WN6@D&?(QP3P&$. U)IDB$NY&@6"
MAUB*62AT4VQ'6@SW:;*;I>!+-M(Z:.E[[I =R[NV5[.C(M^[R[V& :_AX*JM
MX.$2\@OK=MB"_OLOW*&#A''ECMY!7[=TAPZ_9VMW: URJ5?N3@Y0F:2"&!+!
M4WG6LDR*^2!E\J=(*BQ9ZH<APE&0,9/8O\,IIG:;WU+H*1('A>H= 5)/A;X,
M'L?"V!"9"UR2^\R[<3UN9GDE%^,^EZ==B0??'%0VN_8,M";K)L$I2BBF288D
M7! !E,($8![$@"4,9SB+0Q%K!??VS#&U'7Z[!/>Y4L].>@/+AGZC*L='X=50
MSRX'S?&^/TZ@M8+ ?=R?*>A[]-$Q"_+VT;Y74+?WJ\/.ZW>/3XO\A?-FT./U
M+C:U*JK2%F5E%>K^7?D&/^:K?W!5.3*_7ZH4ACHUX7U>-!^I[P6S(&"9E!(I
M2$2, <K\&& *A8KO9$QJ FF4&G7V')?\J4FAOW.ER'$&L%3C\#UOBRFM<N5"
MJ#GQ:+<@3]L,6I5;JBI!&E9;&OEUT=-XIOL2.):J1^LI;6O3=,HEM666%)?R
MTY5<_*ID?\/HE5>SZHF\\#K,VE/,7F>-;"I](W,PJD+Y.JNSKZR^$A4.NEK_
MNF3SDN;KI:3SW3=Y5I?7C^JW&:'0]QE*04IY %#DAX!03@&C!">1'Z0B96U"
M@Z;W: @=6C)L-TW!^96Y;CENL<OUR470=$4Y W8ZW:Z[;'@U'U[-R$@=K\_A
M.%K7ZY.$3*?S]3FLC+I?GQULF%14\<J=,.4VR5XU]L"+3H*SRFK^E)>5))ZA
MC KH"P9HINP'5"FT$8T I7X:X,P/$39*#AY"Q-14^^O[^Z(2O)Y0K2*?JU:1
MN?"8"O'?%IM0:3[K;=D"5:;">VI8,A.E@U9.3Y*Z7@_'@O1,[8AROW:$8L/[
M=&X1C.7H)2C:%*.#Z!A5BEZ"U+X0O6@L!_FT35+55K>=P0BF,$DYB!&A4J7D
M J28,L RGM L#3,"^>R9%R2WDAY[0(#)3NV2X5!V,C:WG>QZB'N"D<^R$ +,
M$P@0@:K5NTA & D&H4@R[&N%L+I'?93SJM(>U'E4)Z2K@VGUH*Q/C?>]#2)[
M\?"J^LM.77CU06V\<KIF>N>5NY5P?%)I)!(WY'=L/R.E!)_$;;0TWT,*II.Z
M>Q(=HW3<TZ,,Z9;'"ZG>/*K@HR^KG/[VZW*^:CQ2//$3$@L$:.)S@%0?)A((
MKJP8A*<TB7 B](Z<,S--[VSIT-H87DM%LE3"YT;)?SWH:OC[["#F6!J=)M)6
M([FS*/1WACO]^(BMWL[RL-N[[?S7ARF=FS;V-\NG]:K\H#S90?-"4C\1-($0
M1 (& (F4@I13'U 88(*0W/$B-M%T>N::FEI3T>8%9DI)'Y9Z&H@EA!QO<$6E
M5Y%YY=6$2E6C!LS[6E-K,;1' Q.;JD3?=*/J#1I\[RL).H\,#>^CA;(CON7U
MOS=+%6&TE"NG<CPRAE.A"OQ!K'SZ3$2 L#0&0<@#+%#H2Z7!S+O1.]\4O1@U
M<9H9>GJHZHF,RY$:*P*PIL_[H:7T1W57[!!K,QI0 Q.[@8%]$XX<(ZC!^V&X
MH,Y#%VH8UV7)5^7ULENEOBD.Q&Y5.M^Z4+5-Y1<^YLNB_?5G7,[K8O8S/TG\
MB"04((HS5= Z!AD- L!X&H8P11!!K>[;UBF;FO:R/:#;6F!-H: -*U788I>9
MIO^#8;"RO;4UU(_&7+$1M:D+UF>X7F4+2R=:V,7$O8[.9@O3DQJ>M0D&6(CN
M?L_O'O)U*=]1.?[=P[Q8<;ZL[J7R(%&MQ9_Y)_F.-U<?)$A*4$A %/M2;&."
M 4XB"B@F4< RQFA M,/$S>:>FF ._0!Z%;'>AEI/D6M@03)$7\.JY Y3QZ+3
MC'!+UJ=A:/5:I R'',]*-8S7'<O5P"$&9:E45G!5"N+=-[F;EWC16LK+S_D+
M7FP,Y7M=OR0L-(PI F%"?8 $5.5I8@)X(N*4AT3>;:E!'LLP*J8FJKK]PAJZ
M6R>246K+P#71$%MC(.U8@+5>N:KT3,O$QH&G%/9=Y$VZM%E<#(.LY3$6Y?O*
M7KX4D3-Y3 ,''S/3Z3+^]W*A+AS,EOGSFE9!E.4G_%+=7S'W*:0H #@CJG&G
M\$%*T@@(&C":9B1.,R/;Q-D9IW9>M.1Y3S5]EUI"]P$>:@V] +;7L8AN@/QT
M!D@+9M$3X+@UC>Y/^LKFT1,8G#>1GGIP8)-@]QW'/^>+Q?N\4 _-$BR83ZF\
MBI-$7LICN789C#" *0LH1DBDL5%QAG')GYKPZR;D=?GO9N5YY,4[FKA79^@U
MI=L[0'@5$MY*0N$U6'0R^^2/50-YI9]7PY;>5X60UT!D:,D=^?73D^;3?:D<
M'PW?U?MDW@[Z59;5:DOI<3D8MRWUJZS.06OKUZ%B>/&CROW_&?_^"Y8'SAPO
MRJH[8U-<J9Q%/H21"#B@ JE2YS!1;;,3@ 5'"0Y"PH11KM/Y*:=V1DI"O<>6
M4O.:2&?PU;T>V$3-^?V@(?;*4]AMZ)62FJ\JLUQ#L]TR2GKXV"ZK=&;6T<LL
MZ:%PK.R2YI,#@RGF2[RD\^7]MOKQ]6*1_ZX"0Z4L>U-P-E^IG"2Y)=*4A#SU
M(^"+,%/M6P@@(HA!X$=!3$.B:C09A4OHSSTUV;.ALRIT02M*JZ1)PW ' _0U
M QK<8.HZ9*&E>J>&^B[(->E54J3%F 5SN*Q&)1A,/V[<@3DN!Y$% X88V&^Z
M2=/#BT]XSFZ6;_#3?(47C;\:0PII1I'$/@NDU/)30)(P CP*_3@.2)H@HTI1
MO;--3DYMB/44M>!FZ37T&O9[[H583S19 \ZQ,-K';+[!S$$PNA8H5ELG]TXX
M;O-C'=X/VA=K/33 V__KDLP7"]6U2J<-1!N*!,,D\A,"I(1A (DHDA<P@0'V
M$48))PE.0VU/_Q *IB9P6AZZK6? ;M.9*V]97S=HS8CWE!<&6=;#%TLC!,#U
M$C@671OTC5K1G!=KEA; P.WO>B%&<OD/6Q!+@0*78-@;)#!HX/$"!"[A>R<X
MX**!!NJRR]6<S1=K%<6V+1?R4;YB;_-'/%_.1.8'1 @(?!Q)=99*Q19G*LHL
M$CQB0B0LC(S4V3,33NV Z=*[4TQ'D>Q]K8DV]%6=!5U3P;4(I6L=]S(4S=5<
M36BL:KKGYAQ7V=5$X$#?U7UN>(!KIYCE+^O%:OXDY1Q?S%4I8'5IW[I(RB]/
MG,[QX@TNN8J66I;RD3M>/,[B&,(4!A"$D*< 01S4>G 0A8E(?)A0H265[)(U
M-=G5T.E1%:3#6TH].?6C>=2EA5734(A?92T<"[^]TC65'[SERNNPU76.EUZ[
M>(HS;\.:=]>W>(,".^UAK1/I:6&VT4,_[2%T+!;4XN@#:U_.2]Q4;90#*E=/
M1=>'^9+?K/AC.8-I$&8)\P'S$0(H20.0Q5D"8D2A\",2)%@KOT!WPJG)T5UZ
M:\]E$\ZN:/8JH@UUP+.@Z^F -J%T+ 8O1-&\[J0F-%9K3)Z;<]QZDIH('-2.
MU'W.4N_+]K-K]M_KNNE/T^%K>]G]!\?%+(CB,('$!ZF?0H!B) #)4 IX%O($
M$P1%HEFFXU)2M+;5J!4\6L+74F7 &^+E#>NICBTJ?RKJ!HVU<53Y/E>YIVK
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M6J68P>>H@8HF$:_55L4,HYYF*X8##1.*;^<EOK\OE)HE#\5;<3R^.*8A@;%
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M]H SF*9*HT]1 4E&<UA@JF1!599()Q*-$-B/8;EWX;9 0%L>^ / %]BD&\'
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M6@,@=RI4'(!7,-^Z+XB-^Q0(YM"^E(/8OER% 4CU^PTN X[H1 S0<]^C&#+
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MJS\-.8_V =^MGMA&/2UN>=T>[XOD4KN+VD'\LEHLU+:!'1=QG"&HD,00\X3
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M-ZH_61ZXB_K]:>!6(XV8!>ZBV7X2N-.3 RSV;[34!L\,I)_[<;L4>VGGV[Z
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MG#$$F=(_1IRDG.H?<^R4IM(WV=1LUOW)>-&PT/%YA*TCR5YP"Q]8KL2\:6)
M+;=6@]SG'N2&A)HO0N(Y\GQ^OK$#T1<U/Q&7OOS,4$ZM;_2OCT*/-5=S7EUY
M?GZJ;DEB$<5)$4<PPUP:DAT)642T^Z.BC,5$$)18N3\79YJ:Z6C8H[2T8%]<
M4,OKRK%U#N!^X^$5MM"QGZ&(#>#<NH#&U<Q;Y\8?F7_K@IK'+%R7'AC*25%=
MN=9Y6L?U3?>KQ9R_[%(ZDC3!*(I32!E!$.>Y_ILPG2CRB"0%XDS#[D92X3+]
MU Q)>U/;:.%*5^&$O)TG$@[/P!:FS2QK\DV;:L@_N]60X(]:?*M\I@$,%T.0
M\TMYX23!R!P80] Y)L48-,HPR_9N7O+%JGQ:ZS/:VPZ-7I.[:$KURRH%]0TM
M33_5NM1I]\)1JLT9(Q+F-,(F X="1F(.D521BH4LHL+)U%TIS]1L7R4JK&0%
MK;!N!O#:!;*SB"/"'CJ$5"'.NHAWFS""/X+814_X^324UXHTJN7TA-^A*?4U
M[##;JH^E=>L3DZ,P8RC23F$>0T$2"K%$'!)>($A$*@LA4QIQY<+_OC>ZD]T;
M@>Q="P<T\(ZV;A\P[3?G$<LY9&FL 6,1@BQ3&C\A24I)3#!1+EO+<,!&V"A\
M ":))()R!?.,%!JP3$*2F*Z8!4L42A5!A,Z>Y9JM@D/6G67:H-GMCX.!"+S;
M&02:#EI-3EOH1B(GD?"Y;^U/,.HN=%*WPSWE](<&TN]6Z?)RGT_@LQ:V(9]6
M29QA@1F4,C>T_KF$1<XRR(LX*3"B@J5.)O#"?%,SBKMZG:-^M]45AKDF;$0'
MCZNU._WW)?SMC(-'5 .;BT;2$U0E.W$]4N_:X>*5<_?"E..2[=KI?\2R:_G8
M,).C;=?:C/Q.UG]^7&YI3=[2Q[EV#;==*3F1&(LHA6DNA/%8,20J3B%AG"E*
MBCQC3@EM]E-/S1#5Y%8E, GY6[Z?FD>ONA_L&*;_<+- #LMA9XS"@!S8+K5"
M@U]:L?]FL-YQ*S6B!VD3ZHZ83XOE,/NHQLL=E4,[-F"$@'QP7Z3)!M:#WJD/
M\Y+3A>%JTF=,@;(\EC"B20(QB;2#Q0F"@B9I1",:(\J],\.=%&5J)J\6TKQ[
MYHL;@"WN](+8&;EQ8 YL]%P9Y+;Z&+>WUJABE1N94*X7UM&IY4Y+,SV2N5[4
M!M'-]8\XU#E\UD.OUB^[P.GN)H'D@B'3:X&02$$L)(8TS2(HHYS+C!9))IR*
MK?LFFYHUW,KJZMWUX&GKS_E!*;@'UX@)=G(&NFNQ0<2OA]8SW\@^V67-C[TP
MBV<&=EC8_)#K$YW>36#LL]S<J6_TKQE3 JN\*&"5@HM%(B$I"@151&+3GITJ
MXM9SP6+2J5F/2N:*W&TKM#[>U%%;$[]VI'*SPMW.NOA&,["5J8'<DW<__%WE
MYQK_2,OML9V# TI>&SS8S#MNRP<')(Z:0+@\._0DJ#VETC%BLO_0A+[MM6!!
M8AZG=?;KO>_-,+)'?DJ[8R_[Y*<&,JI6P<"V:2B1C.84(TB5%!"K.(9%3E.(
M!$LQ-ZE2N72YZ]\;?6IW_0W#:7,/X])=Y#1X=F_M8$@"O[2U7 'ZJ)Y4V"MG
MY]X$XW)OGM+MB$/SY(?<ZSV:$7:'YO=+\8YNY"R+LRR2.(.,H$3[JP6#+),)
M3!07F4)$RMBJMV#?)%-S31LYN_$DH$4%1E;["H^SD/:_R[Z "OQ*#\+(J:;C
M$@A7E'.<'7JT2HY+RG6+."Y^]LI>@ U]^LY%C.,TDJFD>I/&'&+]CD.6ZXV;
M%20JD,0)4_F@EH"',TWNQ5^5=6VC; 1UO+@\#ZGER=,'4*&/F]O(?"MD$&?\
M(A1!F@8>3?8ZO0//Z7RVA>#9!P;2>QU2;;M]C<\]/J%O\3$1?9!O\24DO#)3
MG9MK7'*J"QH?\5-=^ORK-//X-%_*CQOY4,XH,KW0: Y))E*]%R8II"@A,$.,
M)2I%2:'&[.>Q%6QJ6Z>G=A#@#Z,AJ%1TY(KQMN269^U76,C0Q_0QUW#LOAY'
M@$^HM<=.MI^IN\<1HIX;?!R//Z#'AQY,K=8/)GFTJF?:]E1O"+^S/"I2FF!M
MT%,$<4HX9$)FD*8J87&A_[6PHK*PF6QJ-KLC;E,<6/=B>C(MYQWZ/5S"N-^@
M^D8NL)'L@E;7L%:R B/L9>)U=_ <6F%X!'&D1A=]8'IJ@F$)2F^+BTMCC-?
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MKI[E>FG&?KM:/Z[6E3$R[0=NO\LEG\MR%]=LXC64Q3S'N83Z#PIQ',>0)5+
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MT?\^IXO?Y@M9;E9+>4]?3#QMEK$8J8P6,$(T@C@Q-]:1MBR)9+'(H\C\FWW
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MR4T+TD9VT BO7=X.O5,XH!VR]8,!_G-E[@^"H3>+WVW$\3+Z!VFZE]T_;(1
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MMF3\%0]L(SVP[FYY=3O:GV#6;1$ %003X-$=MF:3X,=U%'U:=SE^U\,;G^W
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MC",1%Q0QP6,GOBB;2:?V:G<KB[IB&W:C1O"!15I]R-LY1;[Q#&P5NE!NI0Q
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M+-S[I4F1Z6Q^\Y<3Y]-D]>DHIO%H]>07?K&<N[ <61*#4MR"I)J#(": <YQ
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MCB_=,BU&GN6H1$*_4QDTO>AU8ES#,\)!>9L-T5I7:?=XGXQA$RJ5\'."I!O
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M'3.6)6^UC%5.C6HU%AZRO?5I**RKNP;@^7@CVV",X>5,5OI4;G>+!-:0<D"
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M)1G$*(S+C#/%JK1DK9QPN)?"NW*3%_%_XY.O>WS.)I,WL_D?;AY'7//(I1>
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M,!50 58593ZTI>K VH9KYTD*C' /AHO2]I(R< YWZZ0]>@516JFZ)2$/>NV
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M,5B^W\5\.6"["_9[E.S(Y?G-Q^L"KAL2UKEM10DO@D,HDD=0.6CP27DR&&-
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MBJ#2L&84P]><\W)L#:B6[)_]:GR*K/M=8>I+2XXW0>$;#^7B)+A2!&>>+(Q
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MYOW:YYP-RJ@U"%_(7*9K [PM$GB4B1<F);IA!^;HI8\H3C4*(B\\STPHK\-
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ME0H?8W%6=E/E,]\IU;_ADRG_\=;9_P!02P,$%     @ 1V)E4?!DK%OI!P
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M>55C+HT._P902P$"% ,4    " !'8F51>DF_'Q"V @ N^1H $0
M    @ $     86=I;RTR,#(P,#DS,"YH=&U02P$"% ,4    " !'8F51TZW$
MRE83  ".XP  $0              @ $_M@( 86=I;RTR,#(P,#DS,"YX<V10
M2P$"% ,4    " !'8F51;2G,*V,A  #36 $ %0              @ '$R0(
M86=I;RTR,#(P,#DS,%]C86PN>&UL4$L! A0#%     @ 1V)E47+GCZ3;3
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M:&EB:70S,2TQ># Y>#,P>#(P+FAT;5!+ 0(4 Q0    ( $=B95'P9*Q;Z0<
M !DF   8              "  5: ! !E>&AI8FET,S$M,G@P.7@S,'@R,"YH
M=&U02P$"% ,4    " !'8F51:RM](<P$  ",$@  &               @ %U
MB 0 97AH:6)I=#,R+3%X,#EX,S!X,C N:'1M4$L! A0#%     @ 1V)E41=#
MDZCB!   CQ(  !@              ( !=XT$ &5X:&EB:70S,BTR># Y>#,P
=>#(P+FAT;5!+!08     "@ * *("  "/D@0    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
